PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kohn, KW				Kohn, KW			Functional capabilities of molecular network components controlling the mammalian G1/S cell cycle phase transition	ONCOGENE			English	Article						molecular reaction network modeling; molecular reaction diagrams; computer simulation of reaction networks; cell cycle models; G1/S phase transition; E2F; retinoblastoma protein	UBIQUITIN-PROTEASOME PATHWAY; SPINDLE-ASSEMBLY CHECKPOINT; TRANSCRIPTION FACTOR E2F-1; S-PHASE; NITROGEN-MUSTARD; DNA-SYNTHESIS; RETINOBLASTOMA PROTEIN; INCREASED EXPRESSION; MITOTIC OSCILLATOR; INHIBITS GROWTH	The molecular interactions implicated in the mammalian G1/S cell cycle phase transition comprise a highly nonlinear network which can produce seemingly paradoxical results and make intuitive interpretations unreliable, A new approach to this problem is presented, consisting of (1) a convention of unambiguous reaction diagrams, (2) a convenient computer simulation method, and (3) a quasi-evolutionary method of probing the functional capabilities of simplified components of the network, Simulations were carried out for a sequence of hypothetical primordial systems, beginning with the simplest plausibly functional system, The complexity of the system was then increased in small steps, such that functionality was added at each step, The results suggested new functional concepts: (1) Rb-family proteins could store E2F in a manner analogous to the way a condenser stores electric charge, and, upon phosphorylation, release a large wave of active E2F; (2) excessive or premature cyclin-dependent kinase activities could paradoxically impair E2F activity during the G1/S transition period, The results show how network simulations, carried out by means of the methods described, can assist in the design and interpretation of experiments probing the control of the G1/S phase transition.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kohn, KW (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA.							Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Botz J, 1996, MOL CELL BIOL, V16, P3401; CAMPISI J, 1982, P NATL ACAD SCI-BIOL, V79, P436, DOI 10.1073/pnas.79.2.436; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOU QP, 1993, CANCER RES, V53, P1493; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FINGERT HJ, 1988, CANCER RES, V48, P4375; FINGERT HJ, 1986, CANCER RES, V46, P2463; GOLDBETER A, 1991, P NATL ACAD SCI USA, V88, P9107, DOI 10.1073/pnas.88.20.9107; Goldbeter A., 1996, BIOCH OSCILLATIONS C; HAN EKH, 1995, ONCOGENE, V10, P953; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; HUTCHISON CJ, 1987, EMBO J, V6, P2003, DOI 10.1002/j.1460-2075.1987.tb02464.x; HYVER C, 1990, BIOSYSTEMS, V24, P86; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAUFFMAN S, 1975, J THEOR BIOL, V55, P47, DOI 10.1016/S0022-5193(75)80108-1; KHOLODENKO BN, 1995, TRENDS BIOCHEM SCI, V20, P52, DOI 10.1016/S0968-0004(00)88955-0; KOHN KW, 1997, COMPUTER MODELING CO; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LOCK RB, 1992, CANCER RES, V52, P1817; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NOREL R, 1991, SCIENCE, V251, P1076, DOI 10.1126/science.1825521; NOVAK B, 1993, J THEOR BIOL, V165, P101, DOI 10.1006/jtbi.1993.1179; NOVAK B, 1993, J CELL SCI, V106, P1153; NOVAK B, 1995, J THEOR BIOL, V173, P283, DOI 10.1006/jtbi.1995.0063; OBEYESEKERE MN, 1995, ONCOGENE, V11, P1199; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OConnor PM, 1997, CANCER SURV, V29, P151; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1988, UCLA S MOL CELL BIOL, V58, P157; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sgambato A, 1996, CANCER RES, V56, P1389; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; Tyson J J, 1995, Prog Cell Cycle Res, V1, P1; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; TYSON JJ, 1991, P NATL ACAD SCI USA, V88, P7328, DOI 10.1073/pnas.88.16.7328; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; ZARAKOWSKA R, 1997, J BIOL CHEM, V272, P12738	66	51	53	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1065	1075		10.1038/sj.onc.1201608	http://dx.doi.org/10.1038/sj.onc.1201608			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519880				2022-12-28	WOS:000072335900012
J	Zhang, ZC; Nechushtan, H; Jacob-Hirsch, J; Avni, D; Meyuhas, O; Razin, E				Zhang, ZC; Nechushtan, H; Jacob-Hirsch, J; Avni, D; Meyuhas, O; Razin, E			Growth-dependent and PKC-mediated translational regulation of the upstream stimulating factor-2 (USF2) mRNA in hematopoietic cells	ONCOGENE			English	Article						PKC; USF2; translational; regulation	TRANSCRIPTION FACTOR USF; PROTEIN-KINASE-C; HELIX-LOOP-HELIX; FOS-INTERACTING PROTEIN; MAST-CELL; MESSENGER-RNAS; QUIESCENT CELLS; EXPRESSION; PROLIFERATION; GENE	Upstream stimulating factor (USF2) is a basic helix-loop-helix leucine zipper transcription factor, which is found in most tissues, A critical role for USF2 in cellular proliferation has been proposed based on its importance in the regulation of various cyclins and P53 and its capability to antagonize c-myc., In this paper we report that IL-3, which is a major growth factor for mast cells, induces USF2 protein synthesis in murine mast cells (MC-9), Surprisingly, it does not significantly affect the level of USF2 mRNA in these cells at any of the time points tested, Using polysomal fractionation and RNA analysis we then demonstrated that this translational regulation is mostly the result of increased USF2 translational efficiency. Moreover, protein kinase C (PKC) inhibitors prevented both the induction of USF2 protein synthesis and the increase in USF2 translational efficiency in IL-3-activated mast cells, Two other hematopoietic cell lines were used to determine whether the translational regulation of USF2 is of a more general nature: mouse lymphosarcoma cells whose proliferation is inhibited by dexamethasone; and mouse erythroleukemia cells that differentiate upon exposure to hexamethylen bisacetamide, In both cell types, USF2 translation was repressed in the non-dividing cells, This strongly implies that USF2 is translationally repressed in quiescent hematopoietic cells, Considering the proposed role of USF in proliferation it seems that translational regulation of USF2 might have an important role in cellular growth.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Razin, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.		Avni, Dror/GRE-8325-2022; nechushtan, hovav/Z-3564-2019	Avni, Dror/0000-0002-8738-1840				AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; BARANES D, 1991, BLOOD, V78, P2354; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHAIKIN E, 1994, J BIOL CHEM, V269, P8498; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; FALVEY E, 1991, FASEB J, V5, P309, DOI 10.1096/fasebj.5.3.2001790; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GWILLIAM DJ, 1993, ACTA DIABETOL, V30, P99, DOI 10.1007/BF00578222; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; IHLE JN, 1983, J IMMUNOL, V131, P282; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEWIN I, 1993, BLOOD, V82, P3745; Lewin I, 1996, J BIOL CHEM, V271, P1514, DOI 10.1074/jbc.271.3.1514; LIN Q, 1994, J BIOL CHEM, V269, P23894; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MATHEWS MB, 1996, ORIGINS TARGETS TRAN, P1; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; Meyuhas Oded, 1996, P65; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; Nechushtan H, 1996, CRIT REV ONCOL HEMAT, V23, P131, DOI 10.1016/1040-8428(96)00200-4; Nechushtan H, 1997, BLOOD, V89, P2999, DOI 10.1182/blood.V89.8.2999; RAZIN E, 1984, J IMMUNOL, V132, P1479; RAZIN E, 1994, P NATL ACAD SCI USA, V91, P7722, DOI 10.1073/pnas.91.16.7722; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; Sambrook J., 1989, MOL CLONING; Shama Silvian, 1995, Gene Expression, V4, P241; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; West MJ, 1995, ONCOGENE, V11, P2515; YUNG YP, 1981, J IMMUNOL, V127, P794	32	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					763	769		10.1038/sj.onc.1201584	http://dx.doi.org/10.1038/sj.onc.1201584			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488040				2022-12-28	WOS:000071931800008
J	Chiariello, E; Roz, L; Albarosa, R; Magnani, I; Finocchiaro, G				Chiariello, E; Roz, L; Albarosa, R; Magnani, I; Finocchiaro, G			PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas	ONCOGENE			English	Article						glioblastoma; chromosome 10; tumor suppressor; mutation	GENE; PATHWAYS; TUMORS	A novel tumor suppressor, PTEN/MMAC1, was recently found on chromosome 10q23 and mutations of this gene mere described in about 20% of primary glioblastomas (GBM) and 60% of GBM cell lines. To define further the relevance of PTEN/MMAC1 mutations in GBM we investigated by SSCP analysis its coding sequence in 44 gliomas, including 41 GBM, and in 21 short-term cultures (15 GBM and six malignant astrocytomas). Loss of heterozygosity (LOH) at 10q23 was present in at least one marker in the vicinity of the PTEN/MMAC1 locus in 59% of the informative GBM (primary tumors and cell cultures). SSCP variant bands were found in seven primary GBM (17%) and in one short-term GBM culture and sequence analysis confirmed the presence of somatic mutations in all these cases (five missense, one splicing mutation and two small deletions). These data indicate that PTEN/MMAC1 is inactivated in a subset of GBM and suggest that the high mutation frequency previously found in GBM established cell lines reflects culture condition artifacts rather than the true mutation frequency in vivo. Other suppressors, located on chromosome 10q, may also have a critical role in glioma tumorigenesis.	Ist Nazl Neurol C Besta, Dept Biochem & Genet, Milan, Italy; Univ Milan, Dept Biol & Genet Med Sci, I-20122 Milan, Italy	IRCCS Istituto Neurologico Besta; University of Milan	Finocchiaro, G (corresponding author), Ist Nazl Neurol C Besta, Dept Biochem & Genet, Milan, Italy.		Finocchiaro, Gaetano/AAG-6791-2020; Roz, Luca/AAB-3889-2019	Roz, Luca/0000-0001-5817-7149; Finocchiaro, Gaetano/0000-0003-3583-4040				Albarosa R, 1996, AM J HUM GENET, V58, P1260; BOGLER O, 1995, GLIA, V15, P308, DOI 10.1002/glia.440150311; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; MAGNANI I, 1994, CANCER GENET CYTOGEN, V75, P77, DOI 10.1016/0165-4608(94)90157-0; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Rhei E, 1997, CANCER RES, V57, P3657; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TENAN M, 1995, INT J CANCER, V62, P115, DOI 10.1002/ijc.2910620121; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; VONDEIMLING A, 1995, GLIA, V15, P328, DOI 10.1002/glia.440150312	20	69	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					541	545		10.1038/sj.onc.1201689	http://dx.doi.org/10.1038/sj.onc.1201689			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484844				2022-12-28	WOS:000071739400013
J	Zhao, Y; Hague, S; Manek, S; Zhang, L; Bicknell, R; Rees, MCP				Zhao, Y; Hague, S; Manek, S; Zhang, L; Bicknell, R; Rees, MCP			PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium	ONCOGENE			English	Article						tamoxifen; adenomedullin; differential PCR display; endometrium; angiogenesis	BREAST-CANCER PATIENTS; GROWTH-FACTOR; POSTMENOPAUSAL WOMEN; HYPOTENSIVE PEPTIDE; CELL-PROLIFERATION; PROMOTER-CONTEXT; POTENTIAL ROLE; EXPRESSION; PREVENTION; PHEOCHROMOCYTOMA	Tamoxifen is currently the most widely used drug for the treatment of breast cancer, but there now exists considerable evidence that tamoxifen can also induce endometrial hyperplasia in pre menopausal women. We have used PCR differential display on primary human endometrial isolates in an attempt to identify genes induced by but not estrogen. Eight such tamoxifen differentially expressed bands were cloned and sequenced, one of which was found to be the peptide adrenomedullin. We have shown that adrenomedullin is a novel growth factor for endothelial cells and is angiogenic in vivo in the chick chorioallantoic membrane assay. Immunohistochemical analysis of endometrial sections have shown that while macrophages in the endometrium express adrenomedullin at a low level, endometrial macrophages of women receiving tamoxifen strongly express adrenomedullin (P=0.008). We postulate that endometrial induction of the angiogenic factor adrenomedullin by tamoxifen is part of the mechanism by which tamoxifen results in endometrial hyperplasia.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynecol, Oxford OX3 9DU, England; Univ Oxford, Inst Mol Med, Imperial Canc Res Fund, Mol Angiogenesis Grp, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Dept Histopathol, Oxford OX3 9DU, England	University of Oxford; University of Oxford; University of Oxford	Rees, MCP (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynecol, Oxford OX3 9DU, England.		zhao, yuan/E-2435-2013	Bicknell, Roy/0000-0002-0941-8919	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FA, 1990, CURRENT PROTOCOLS MO; Barakat RR, 1996, CLIN OBSTET GYNECOL, V39, P629, DOI 10.1097/00003081-199609000-00012; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BUTTA A, 1992, CANCER RES, V52, P4261; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; GAL D, 1991, GYNECOL ONCOL, V42, P120, DOI 10.1016/0090-8258(91)90330-8; HARPER MJK, 1967, J REPROD FERTIL, V13, P101; HUYNH H, 1994, CANCER RES, V54, P3115; ICHIKI Y, 1994, FEBS LETT, V338, P6, DOI 10.1016/0014-5793(94)80106-1; Ishihara T, 1997, LIFE SCI, V60, P1763, DOI 10.1016/S0024-3205(97)00136-7; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; ISMAIL SM, 1994, J CLIN PATHOL, V47, P827, DOI 10.1136/jcp.47.9.827; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jones RK, 1996, FERTIL STERIL, V66, P81, DOI 10.1016/S0015-0282(16)58391-5; JORDAN VC, 1991, ANN NY ACAD SCI, V622, P439; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; LAHTI E, 1993, OBSTET GYNECOL, V81, P660; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Macri CJ, 1996, AM J OBSTET GYNECOL, V175, P906, DOI 10.1016/S0002-9378(96)80023-8; Maniatis T., 1982, MOL CLONING; MARTINEZ A, 1995, ENDOCRINOLOGY, V136, P4099, DOI 10.1210/en.136.9.4099; Miller MJ, 1996, J BIOL CHEM, V271, P23345; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; Nephew KP, 1996, ENDOCRINOLOGY, V137, P219, DOI 10.1210/en.137.1.219; PEEK MJ, 1988, EXP PATHOL-JENA, V34, P35, DOI 10.1016/S0232-1513(88)80020-3; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; SAKAKIBARA K, 1992, AM J OBSTET GYNECOL, V166, P206, DOI 10.1016/0002-9378(92)91860-D; SARTOR BM, 1995, REPROD TOXICOL, V9, P225, DOI 10.1016/0890-6238(95)00003-S; SATOH F, 1995, J CLIN ENDOCR METAB, V80, P1750, DOI 10.1210/jc.80.5.1750; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VU N, 1984, P ANN C RES MED ED, V23, P383; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Withers DJ, 1996, FEBS LETT, V378, P83, DOI 10.1016/0014-5793(95)01427-6; ZHANG L, 1995, J CELL SCI, V108, P323	38	113	121	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					409	415		10.1038/sj.onc.1201768	http://dx.doi.org/10.1038/sj.onc.1201768			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467966				2022-12-28	WOS:000071582100013
J	Eiriksdottir, G; Barkardottir, RB; Agnarsson, BA; Johannesdottir, G; Olafsdottir, K; Egilsson, V; Ingvarsson, S				Eiriksdottir, G; Barkardottir, RB; Agnarsson, BA; Johannesdottir, G; Olafsdottir, K; Egilsson, V; Ingvarsson, S			High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers	ONCOGENE			English	Article						breast cancer; chromosome 17p13; TP53, BRCA2 carriers; LOH	P53 GENE-MUTATIONS; SUPPRESSOR GENE; CANCER PATIENTS; OVARIAN-CANCER; CARCINOMAS; LINKAGE; TP53; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PROGNOSIS	Breast tumours from BRCA1 and BRCA2 mutation carriers are genetically instable and display specific patterns of chromosomal aberrations, suggestive of distinct genetic pathways in tumour progression, The frequency of abnormalities affecting chromosome 17p and the TP53 gene was determined in 27 breast tumours from 26 female patients carrying the Icelandic BRCA2 founder mutation (999del5), Loss of heterozygosity (LOH) was detected in 23 of the 27 tumours (85%), The majority of tumours manifesting LOH had lost a large region on 17p, although a more restricted loss, including the TP53 locus was seen in a few tumours. Positive p53 immunostaining was observed in 18 of 26 tumours (69%), However, mutations in the TP53 gene were detected in only three tumours (11%), including a missense (codon 139) and a nonsense mutation (codon 306) in two tumours with moderate p53 expression and a frameshift deletion (codon 182) in a tumour with no detectable p53 expression, Positive p53 immunostaining, mainly weak, was observed in 16 of the 24 tumours (66%) without TP53 mutation, The high frequency of LOH at chromosome 17p13 suggests that one or more genes from this region are involved in the development of BRCA2-induced breast cancer. The frequent finding of weak overexpression of, presumably wild type p53 protein, suggests an alternative mechanism of TP53 involvement specific to these tumours.	Univ Iceland, Dept Pathol, IS-121 Reykjavik, Iceland; Natl Hosp Iceland, IS-121 Reykjavik, Iceland	University of Iceland; Landspitali National University Hospital	Barkardottir, RB (corresponding author), Univ Iceland, Dept Pathol, POB 1465, IS-121 Reykjavik, Iceland.		Ingvarsson, Sigurdur/E-7448-2011	Ingvarsson, Sigurdur/0000-0003-4125-1714				BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BHARGAVA V, 1994, MODERN PATHOL, V7, P361; CORNELIS RS, 1994, CANCER RES, V54, P4200; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DENG G, 1994, CANCER RES, V54, P499; EASTON DF, 1993, AM J HUM GENET, V52, P678; ELNAGGAR AK, 1995, INT J CANCER, V64, P196, DOI 10.1002/ijc.2910640309; ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P300; FISHER CJ, 1994, BRIT J CANCER, V69, P26, DOI 10.1038/bjc.1994.4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gretarsdottir S, 1996, BRIT J CANCER, V74, P555, DOI 10.1038/bjc.1996.400; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JACQUEMIER J, 1994, BRIT J CANCER, V69, P846, DOI 10.1038/bjc.1994.164; Johannesdottir G, 1996, CANCER RES, V56, P3663; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Lakhani SR, 1997, LANCET, V349, P1505; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LYNCH HT, 1990, BREAST CANCER RES TR, V15, P63, DOI 10.1007/BF01810778; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MERLO GR, 1994, CANCER GENET CYTOGEN, V76, P106, DOI 10.1016/0165-4608(94)90458-8; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAITOH S, 1994, ONCOGENE, V9, P2869; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; Sobol H, 1997, INT J ONCOL, V10, P349; Soddu S, 1996, MOL CELL BIOL, V16, P487; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Tirkkonen M, 1997, CANCER RES, V57, P1222; UMEKITA Y, 1994, JPN J CANCER RES, V85, P825, DOI 10.1111/j.1349-7006.1994.tb02954.x; VIGNAL A, 1993, METHODS MOL GENETICS, V1, P211; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; YANDELL DW, 1993, DIAGN MOL PATHOL, V2, P1	42	31	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					21	26		10.1038/sj.onc.1201509	http://dx.doi.org/10.1038/sj.onc.1201509			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467939	Green Published			2022-12-28	WOS:000071236800003
J	Komurasaki, T; Toyoda, H; Uchida, D; Morimoto, S				Komurasaki, T; Toyoda, H; Uchida, D; Morimoto, S			Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4	ONCOGENE			English	Article						epiregulin; EGF family; ErbB receptors; tyrosine phosphorylation	NEU DIFFERENTIATION FACTOR; HUMAN-BREAST CANCER; TUMOR-CELL-LINES; EGF RECEPTOR; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; NERVOUS-SYSTEM; GENE-PRODUCT; FACTOR-ALPHA; PROTEIN	Epiregulin is a member of the epidermal growth factor (EGF) family, and has certain characteristics that are different from that of EGF, including mitogenic responses and binding to EGF receptor (EGFR). Epiregulin may also have another cell surface receptor and/or induces different receptor heterodimerizations for intracellular signaling. We investigated the binding ability of epiregulin to four ErbB family receptors using four human breast carcinoma cell lines that expressed different subsets of receptors. Chemical cross-linking experiments showed that [I-125]epiregulin directly bound to each of EGFR and ErbB-4 but not to ErbB-2 and ErbB-3. Furthermore, although epiregulin stimulated tyrosine phosphorylation of all four ErbB receptors, the main intracellular signal was mediated by ErbB-4 and/or EGFR. The pattern of activation of ErbB family receptors was different from that of other EGF-related ligands. Our findings indicate that ErbB-4 and EGFR are receptors for epiregulin, and suggest that EGF-related ligands transduce signals for different biological responses by the hierarchical mechanism.			Komurasaki, T (corresponding author), TAISHO PHARMACEUT CO LTD, MED RES LABS, MOL BIOL LAB, 1-403 YOSHINO CHO, OHMIYASHI, SAITAMA 330, JAPAN.							ALIMANDI M, 1995, ONCOGENE, V10, P1813; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HANCOCK MC, 1991, CANCER RES, V51, P4575; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOMES WE, 1992, SCIENCE, V256, P1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE DC, 1995, PHARMACOL REV, V47, P51; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1992, ONCOGENE, V7, P1273; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Toyoda H, 1995, FEBS LETT, V377, P403, DOI 10.1016/0014-5793(95)01403-9; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	49	117	122	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	1997	15	23					2841	2848		10.1038/sj.onc.1201458	http://dx.doi.org/10.1038/sj.onc.1201458			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419975				2022-12-28	WOS:A1997YJ80300010
J	Nishimori, H; Shiratsuchi, T; Urano, T; Kimura, Y; Kiyono, K; Tatsumi, K; Yoshida, S; Ono, M; Kuwano, M; Nakamura, Y; Tokino, T				Nishimori, H; Shiratsuchi, T; Urano, T; Kimura, Y; Kiyono, K; Tatsumi, K; Yoshida, S; Ono, M; Kuwano, M; Nakamura, Y; Tokino, T			A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis	ONCOGENE			English	Article						BAI1; thrombospondin type 1 repeat; p53; angiogenesis	GLIOBLASTOMA CELLS; P53; EXPRESSION; PROTEIN; METASTASIS; CANCERS; SITES; DNA	The genetic alteration of p53 is associated with neovascularization during progression of glioma to its more malignant form, glioblastoma, Hence, one or more of the genes transactivated by p53 is likely to function as an angiogenesis inhibitors, We isolated a novel p53-inducible gene that encodes a 1584-amino-acid product containing five thrombospondin type 1 (TSP-type 1) repeats and is specifically expressed in the brain, A recombinant protein corresponding to the TSP-type 1 repeats of this gene product inhibited in vivo neovascularization induced by bFGF in the rat cornea, The expression of this gene, designated BAI1 (brain-specific angiogenesis inhibitor 1) was absent or significantly reduced in eight of nine glioblastoma cell lines, suggesting BAI1 plays a significant role in angiogenesis inhibition, as a mediator of p53.	UNIV TOKYO, INST MED SCI, MOL MED LAB, TOKYO, JAPAN; KYUSHU UNIV, SCH MED, DEPT BIOCHEM, FUKUOKA 812, JAPAN; OTSUKA PHARMACEUT CO LTD, FUJII MEM RES INST, TOKUSHIMA, JAPAN	University of Tokyo; Kyushu University; Otsuka Pharmaceutical			Tokino, Takashi/AAI-9887-2021; Urano, Tomohiko/AFS-9574-2022	Yoshida, Shigeo/0000-0003-1049-8909				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Furuhata T, 1996, ONCOGENE, V13, P1965; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIMURA Y, IN PRESS ONCOGENE; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; TOKINO T, 1991, AM J HUM GENET, V48, P258; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VAN MEIR EG, 1994, CANCER RES, V54, P649; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; XU Y, 1995, COMPUT APPL BIOSCI, V11, P117	28	241	260	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2145	2150		10.1038/sj.onc.1201542	http://dx.doi.org/10.1038/sj.onc.1201542			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393972				2022-12-28	WOS:A1997YD01900002
J	Wan, HS; Dawson, MI; Hong, WK; Lotan, R				Wan, HS; Dawson, MI; Hong, WK; Lotan, R			Enhancement of Calu-1 human lung carcinoma cell growth in serum-free medium by retinoids: Dependence on AP-1 activation, but not on retinoid response element activation	ONCOGENE			English	Article						retinoids; AP-1; lung cancer; nuclear receptors; growth stimulation	ACID RECEPTOR-GAMMA; PROTEIN-KINASE-C; BRONCHIAL EPITHELIAL-CELLS; BREAST-CANCER CELLS; BETA-CAROTENE; ESTROGEN-RECEPTOR; MAMMARY-CARCINOMA; NUCLEAR RECEPTORS; RIBONUCLEIC-ACID; GENE-EXPRESSION	Many lung cancer cell lines are resistant to the growth inhibitory effects of retinoids, However, some small-cell lung cancer cell lines were inhibited by all trans-retinoic acid (ATRA) in serum-free medium, We compared the responses of seven non-small cell lung cancer (NSCLC) cell lines to ATRA in serum-free medium and in medium supplemented with delipidized serum, Whereas the growth of four cell lines was inhibited more in serum-free medium, the growth of the Calu-1 cell line was stimulated by ATRA in a dose-dependent fashion with a maximum at 10(-8) M. Delipidized serum (>2.5%) but not bovine serum albumin (0.15%) suppressed growth stimulation by ATRA, Transcripts of RA receptors RAR alpha and RAR gamma but not of RAR beta were detected in Calu-1 cells, Receptor expression, the formation of a complex among receptors and a RA-responsive element (RARE), and the transcriptional activation RARE were not suppressed by serum, Natural retinoids and synthetic receptor class-or subtype-selective retinoid agonists, which activated RARs and RXRs for gene transcription from a RARE, and a RAR antagonist (CD2366), which was unable to do so, stimulated the growth of Calu-1 cells in serum-free medium but not in serum-containing medium, Both ATRA and CD2366 enhanced the transcriptional activation of an Activator Protein-1 (AP-1)-luciferase reporter construct in serum-free medium but not in delipidized serum, Transcriptional activation of the RARE by ATRA occurred both in the presence or absence of delipidized serum, These results demonstrate that retinoid-induced growth stimulation of Calu-1 cells is associated with enhanced AP-1 transactivation but not with RARE transactivation.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT THORAC HEAD & NECK MED ONCOL, HOUSTON, TX 77030 USA; SRI INT, RETINOID PROGRAM, MENLO PK, CA 94025 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; SRI International					NATIONAL CANCER INSTITUTE [U19CA068437] Funding Source: NIH RePORTER; NCI NIH HHS [U19 CA68437] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; AMOS B, 1990, METHOD ENZYMOL, V190, P217; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AVIS I, 1995, CELL GROWTH DIFFER, V6, P485; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DAWSON MI, 1983, J MED CHEM, V26, P1653, DOI 10.1021/jm00365a021; DAWSON MI, 1995, CANCER RES, V55, P4446; DAWSON MI, 1995, J MED CHEM, V38, P3368, DOI 10.1021/jm00017a021; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GITTER BD, 1991, CLIN IMMUNOL IMMUNOP, V61, P191, DOI 10.1016/S0090-1229(05)80023-6; Gottardis MM, 1996, CANCER RES, V56, P5566; Gudas Lorraine J., 1994, P443; Haq R, 1991, Biochem Biophys Res Commun, V180, P1137; Hodam JR, 1996, BBA-MOL CELL RES, V1311, P102, DOI 10.1016/0167-4889(95)00203-0; Hong WK, 1995, CLIN CANCER RES, V1, P677; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JIANG XL, 1992, INT J IMMUNOPHARMACO, V14, P195, DOI 10.1016/0192-0561(92)90031-F; KAGECHIKA H, 1989, J MED CHEM, V32, P1098, DOI 10.1021/jm00125a027; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kazmi SMI, 1996, CANCER RES, V56, P1056; KITABAYASHI I, 1994, IN VITRO CELL DEV-AN, V30A, P761; KOJIMA R, 1994, J BIOL CHEM, V269, P32700; KURIE JM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P203, DOI 10.1016/0167-4889(93)90142-C; KURLANDSKY SB, 1994, J BIOL CHEM, V269, P32821; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOTAN R, 1995, RETINOIDS ONCOLOGY, P1031; Mangelsdorf David J., 1994, P319; MOASSER MM, 1995, ONCOGENE, V10, P1537; NAPOLI JL, 1988, J BIOL CHEM, V263, P17372; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Oridate N, 1996, ONCOGENE, V12, P2019; PENG YM, 1987, J NATL CANCER I, V78, P95, DOI 10.1093/jnci/78.1.95; PFAHL M, 1994, VITAM HORM, V49, P327; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SANCHEZ JH, 1987, TOXICOL IN VITRO, V1, P183, DOI 10.1016/0887-2333(87)90019-1; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHAO ZM, 1995, ONCOGENE, V11, P493; SHARIF M, 1992, ONCOGENE, V7, P953; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Soprano DR, 1996, ONCOGENE, V12, P577; VERMA AK, 1992, J NUTR, V122, P2144, DOI 10.1093/jn/122.11.2144; WANG XD, 1991, ARCH BIOCHEM BIOPHYS, V285, P8, DOI 10.1016/0003-9861(91)90322-A; WU R, 1990, AM J RESP CELL MOL, V3, P467, DOI 10.1165/ajrcmb/3.5.467; YANG PC, 1992, AM J RESP CELL MOL, V7, P161, DOI 10.1165/ajrcmb/7.2.161; ZHANG QY, 1992, J IMMUNOL, V149, P1402; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZOU CP, 1994, CANCER RES, V54, P5479; ZYLBERKATZ E, 1986, LEUKEMIA RES, V10, P1425, DOI 10.1016/0145-2126(86)90009-3	72	16	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	1997	15	17					2109	2118		10.1038/sj.onc.1201381	http://dx.doi.org/10.1038/sj.onc.1201381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366527				2022-12-28	WOS:A1997YC28400011
J	Zauberman, A; Oren, M; Zipori, D				Zauberman, A; Oren, M; Zipori, D			Involvement of p21(WAF1/Cip1), CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition	ONCOGENE			English	Article						activin A; hepatoma; p21(WAF1/Cip1); CDK4; Rb; p53	ERYTHROID-DIFFERENTIATION FACTOR; RAT SEMINIFEROUS EPITHELIUM; CYCLIN-DEPENDENT KINASES; TGF-BETA; RETINOBLASTOMA PROTEIN; MESODERM INDUCTION; MESSENGER-RNA; DNA-SYNTHESIS; EXPRESSION; IDENTIFICATION	Cytokines are growth inhibitory in a target cell specific manner. The signaling pathways that characterize each cell type play a crucial role in determining the responsiveness to cytokine triggering. Activin A has been shown to suppress the growth of primary hepatocytes, Similarly, the human HepG2 hepatoma cell line was growth arrested by activin A as judged by lack of cell proliferation and suppression of DNA synthesis. In HepG2 cells activin A further induced accumulation of retinoblastoma protein in the hypophosphorylated form known to prevent entrance into S phase. This finding implies the involvement of cyclin dependent kinases and CDK inhibitors. Examination of HepG2 cells following addition of activin A revealed reduced expression of CDK4 and conversely, an increase in the CKI p21(WAF1/Cip1). This accumulation of p21(WAF1/Cip1) protein was partly due to increased transcriptional activity. Functional inactivation of p53, using a miniprotein that oligomerizes with p53 and abrogates DNA binding, abolished the ability of activin A to induce transcriptional activation from the p21(WAF1/Cip1) promoter. Thus, activin A, like transforming growth factor beta, seems to suppress cell growth through the downstream target Rb. However, each of these cytokines seem to operate through a distinct pathway.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ASASHIMA M, 1990, NATURWISSENSCHAFTEN, V77, P389, DOI 10.1007/BF01135742; Attisano L, 1996, MOL CELL BIOL, V16, P1066; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BHASIN S, 1989, ENDOCRINOLOGY, V124, P987, DOI 10.1210/endo-124-2-987; BROSH N, 1995, J BIOL CHEM, V270, P29594, DOI 10.1074/jbc.270.49.29594; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chun SY, 1996, ENDOCRINOLOGY, V137, P1447, DOI 10.1210/en.137.4.1447; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUJIMOTO K, 1991, BIOCHEM BIOPH RES CO, V174, P1163, DOI 10.1016/0006-291X(91)91543-L; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HASHIMOTO M, 1993, ENDOCRINOLOGY, V133, P1934, DOI 10.1210/en.133.5.1934; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KADOURI A, 1992, INT J CELL CLONING, V10, P299, DOI 10.1002/stem.5530100508; KAIPIA A, 1993, ENDOCRINOLOGY, V132, P477, DOI 10.1210/en.132.1.477; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KOSEKI T, 1995, FEBS LETT, V376, P247, DOI 10.1016/0014-5793(95)01290-7; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu QY, 1996, CANCER RES, V56, P1155; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MINE T, 1989, ENDOCRINOLOGY, V125, P586, DOI 10.1210/endo-125-2-586; Miro F, 1996, ENDOCRINOLOGY, V137, P464, DOI 10.1210/en.137.2.464; MITAKA T, 1995, CELL STRUCT FUNCT, V20, P167, DOI 10.1247/csf.20.167; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NISHIHARA T, 1993, BIOCHEM BIOPH RES CO, V197, P985, DOI 10.1006/bbrc.1993.2576; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sambrook J., 2002, MOL CLONING LAB MANU; SEHY DW, 1992, J CELL BIOCHEM, V50, P255, DOI 10.1002/jcb.240500306; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; STERNBERG D, 1995, GROWTH FACTORS, V12, P227; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727; ZIPORI D, 1986, P NATL ACAD SCI USA, V83, P4547, DOI 10.1073/pnas.83.12.4547	60	64	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1705	1711		10.1038/sj.onc.1201348	http://dx.doi.org/10.1038/sj.onc.1201348			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349504				2022-12-28	WOS:A1997XY63100010
J	Keynan, S; Asipu, A; Hooper, NM; Turner, AJ; Blair, GE				Keynan, S; Asipu, A; Hooper, NM; Turner, AJ; Blair, GE			Stable and temperature-sensitive transformation of baby rat kidney cells by SV40 suppresses expression of membrane dipeptidase	ONCOGENE			English	Article						SV40; adenoviruses; cell transformation; tumour cells; peptidases	PHOSPHATIDYLINOSITOL-ANCHORED ECTOENZYME; HUMAN RENAL DIPEPTIDASE; MOLECULAR-CLONING; MICROSOMAL DIPEPTIDASE; WILMS-TUMOR; GENE DPEP1; DNA; PURIFICATION; BINDING; 16Q24.3	Membrane dipeptidase (MDP) is a zinc metalloenzyme located in the lungs and on the brush border membranes of the kidney and intestine, The gene for MDP (also termed DPEP1) is both frequently lost in Wilm's tumours and is located on human chromosome 16q24.3, a region of the genome known to contain a tumour suppressor gene(s), We now report on the regulation of MDP gene expression in normal and transformed cells, MDP enzyme activity and mRNA was detected in primary baby rat kidney (BRK) cells maintained in culture for up to 4 weeks. In contrast all stable transformed cell lines that were tested, derived either by transformation with the DNA tumour viruses SV40 or adenovirus, or in human tumour cell lines, contained very low levels of or no detectable MDP mRNA or enzyme activity, In BRK cells transformed by the temperature-sensitive tsA58 mutant of SV40 T antigen, MDP activity was not detectable, in cell lines grown at the permissive temperature (33 degrees C) but after 5-14 days of incubation at the non-permissive temperature (39.5 degrees C), MDP protein and enzyme activity could be readily detected. Taken together, these results indicate that MDP expression is characteristic of differentiated kidney epithelial cells and is down-regulated in proliferating, transformed cells.	UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds			Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795; Hooper, Nigel/0000-0002-5811-3484	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADACHI H, 1992, BIOCHIM BIOPHYS ACTA, V1132, P311, DOI 10.1016/0167-4781(92)90167-X; ADACHI H, 1990, J BIOL CHEM, V265, P3992; AN SZ, 1994, BBA-MOL BASIS DIS, V1226, P337, DOI 10.1016/0925-4439(94)90046-9; AUSTRUY E, 1993, CANCER RES, V53, P2888; AUSTRUY E, 1993, GENOMICS, V15, P684, DOI 10.1006/geno.1993.1126; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; Fukuda S, 1996, HUM MUTAT, V7, P123, DOI 10.1002/(SICI)1098-1004(1996)7:2<123::AID-HUMU6>3.3.CO;2-V; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUENAL I, 1995, FEBS LETT, V374, P384, DOI 10.1016/0014-5793(95)01157-A; HABIB GB, 1996, J BIOL CHEM, V217, P16273; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; IGARASHI P, 1991, BIOCHEM J, V280, P71, DOI 10.1042/bj2800071; KAHAN FM, 1983, J ANTIMICROB CHEMOTH, V12, P1; KEYNAN S, 1994, FEBS LETT, V349, P50, DOI 10.1016/0014-5793(94)00637-7; Keynan S, 1996, ZINC METALLOPROTEASE, P285; KOZAK EM, 1982, J BIOL CHEM, V257, P6322; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLEWOOD GM, 1989, BIOCHEM J, V257, P361, DOI 10.1042/bj2570361; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; MAW MA, 1992, CANCER RES, V52, P3094; NAKAGAWA H, 1992, CYTOGENET CELL GENET, V59, P258, DOI 10.1159/000133263; NANUS DM, 1993, RENAL CELL CARCINOMA, P53; RACHED E, 1990, BIOCHEM J, V271, P755, DOI 10.1042/bj2710755; Sambrook J., 2002, MOL CLONING LAB MANU; SATOH S, 1993, BIOCHIM BIOPHYS ACTA, V1163, P234, DOI 10.1016/0167-4838(93)90157-M; SATOH S, 1993, BIOCHIM BIOPHYS ACTA, V1172, P181, DOI 10.1016/0167-4781(93)90289-P; SCHAFFNER W, 1980, P NATL ACAD SCI-BIOL, V77, P2163, DOI 10.1073/pnas.77.4.2163; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; van der Eb A J, 1980, Methods Enzymol, V65, P826; VERITY AN, 1993, J NEUROCHEM, V60, P577, DOI 10.1111/j.1471-4159.1993.tb03188.x; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	32	7	7	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1241	1245		10.1038/sj.onc.1201297	http://dx.doi.org/10.1038/sj.onc.1201297			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294618				2022-12-28	WOS:A1997XU99100014
J	Barker, KT; Jackson, LE; Crompton, MR				Barker, KT; Jackson, LE; Crompton, MR			BRK tyrosine kinase expression in a high proportion of human breast carcinomas	ONCOGENE			English	Article						BRK; breast tumour kinase; non-receptor protein tyrosine kinase; breast cancer	GROWTH-FACTOR RECEPTOR; PP60C-SRC PROTEIN-KINASE; MAMMARY-TUMORS; NEU PROTOONCOGENE; TRANSGENIC MICE; PROGNOSTIC VALUE; CELL-LINES; CANCER; INDUCTION; ONCOGENE	BRK is a recently described non receptor protein tyrosine kinase whose mRNA was found to be expressed in human breast tumours and breast cancer cell lines, Expression of BRK in fibroblasts and mammary epithelial cells has been shown to enhance their ability to grow anchorage independently, and mammary epithelial cells expressing BRK acquire a potentiated mitogenic response to epidermal growth factor, In order to investigate further the expression of BRK in breast cancers, we have isolated monoclonal antibodies specifically recognising the protein, Whereas BRK expression was low or undetectable in normal mammary tissue and benign lesions, approximately two-thirds of breast tumours expressed appreciable levels, and 27% of tumours over expressed BRK by fivefold or more (up to 43x), This expression pattern was mirrored in a comparison of cell lines derived either from normal mammary epithelial cells or from carcinomas, BRK expression was found to be constant throughout the cell cycle, and did not vary with cell proliferation rate, A consideration of this expression data, in conjunction with BRK's demonstrated ability to deregulate the proliferation of mammary epithelial cells, supports the hypothesis that the over expression of BRK in a high proportion of breast carcinomas is a functionally important factor in their evolution.	INST CANC RES,SECT CELL BIOL & EXPT PATHOL,SUTTON SM2 5NG,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK								BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; Bosher JM, 1996, ONCOGENE, V13, P1701; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GRIMAUX M, 1989, BREAST CANCER RES TR, V14, P77, DOI 10.1007/BF01805978; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HENNIPMAN A, 1989, CANCER RES, V49, P516; JACOBS C, 1983, CANCER RES, V43, P1696; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; KAMALATI T, 1996, MAMMARY TUMOUR CELL, P227; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NICHOLSON S, 1991, BRIT J CANCER, V63, P146, DOI 10.1038/bjc.1991.30; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; ORMEROD MG, 1994, FLOW CYTOMETRY PRACT, P122; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PATERSON MC, 1991, CANCER RES, V51, P556; ROMAIN S, 1994, BRIT J CANCER, V70, P304, DOI 10.1038/bjc.1994.297; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SAINSBURY JRC, 1987, LANCET, V1, P1398; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Taylor-Papadimitriou J., 1987, The mammary gland. Development, regulation, and function., P181; TOI M, 1989, INT J CANCER, V43, P220, DOI 10.1002/ijc.2910430208; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WHITEHEAD RH, 1983, J NATL CANCER I, V70, P649	32	128	133	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					799	805		10.1038/sj.onc.1201241	http://dx.doi.org/10.1038/sj.onc.1201241			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266966				2022-12-28	WOS:A1997XQ11700006
J	Koch, G; Tanaka, K; Masuda, T; Yamochi, W; Nonaka, H; Takai, Y				Koch, G; Tanaka, K; Masuda, T; Yamochi, W; Nonaka, H; Takai, Y			Association of the Rho family small GTP-binding proteins with Rho GDP dissociation inhibitor (Rho GDI) in Saccharomyces cerevisiae	ONCOGENE			English	Article						small GTP binding protein; Rho GDI; Rho; S-cerevisiae	GDP/GTP EXCHANGE PROTEIN; REGULATORY PROTEIN; CELL POLARITY; MOLECULAR-CLONING; ADP-RIBOSYLATION; ONCOGENE PRODUCT; BUD FORMATION; YEAST-CELLS; PURIFICATION; CYTOSOL	The small GTP-binding proteins of the Rho family, consisting of the Rho, Rac, and Cdc42 subfamilies, are implicated in various cell functions, such as cell shape change, cell motility and cytokinesis, through reorganization of actin cytoskeleton. Rho GDI is a general regulator which forms a complex with the GDP-bound inactive form of the Rho family members and inhibits their activation. We have purified Rho GDI from the yeast Saccharomyces cerevisiae, cloned its gene, and named it RD11 (Rho GD). In this study, we have further characterized Beast Rho GDI, Rho GDI was found in the cytosol by immunoblot and immunofluorescence microscopic analyses. Rho1p and Cdc42p were co-immunoprecipitated with Rho GDI from the cytosol. This immunoprecipitated Rho1p was mainly bound to GDP. In the disruption mutant of Rho GDI, which did not show any apparent phenotype, both Rho1p and Cdc42p were also present in the cytosol. These results indicate that yeast Rho GDI possesses properties similar to those of mammalian Rho GDI, and that there is a cytosolic factor which functionally substitutes for Rho GDI in yeast.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University								ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BACKLUND PS, 1993, BIOCHEM BIOPH RES CO, V196, P534, DOI 10.1006/bbrc.1993.2283; BOIVIN D, 1995, AM J PHYSIOL, V269, P180; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOURMEYSTER N, 1992, BIOCHEMISTRY-US, V31, P12863, DOI 10.1021/bi00166a022; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hirano H, 1996, MOL CELL BIOL, V16, P4396; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; IMAMURA H, 1997, IN PRESS EMBO J; ISOMURA M, 1991, ONCOGENE, V6, P119; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; Mack D, 1996, MOL CELL BIOL, V16, P4387; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; Rubin G M, 1975, Methods Cell Biol, V12, P45; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Sherman F., 1986, METHODS YEAST GENETI; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAPON M, 1997, CURR OPIN CELL BIOL, V9, P86; UEDA T, 1990, J BIOL CHEM, V265, P9373; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366	45	53	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					417	422		10.1038/sj.onc.1201194	http://dx.doi.org/10.1038/sj.onc.1201194			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242378				2022-12-28	WOS:A1997XM23800006
J	Miller, CW; Yeon, C; Aslo, A; Mendoza, S; Aytac, U; Koeffler, HP				Miller, CW; Yeon, C; Aslo, A; Mendoza, S; Aytac, U; Koeffler, HP			The p19(INK4D) Cyclin dependent kinase inhibitor gene is altered in osteosarcoma	ONCOGENE			English	Article						p19; osteosarcoma; rearrangement; mutation	CELL LUNG-CANCER; CDK6 INHIBITOR; P18 GENES; P53 GENE; RETINOBLASTOMA; PROTEIN; AMPLIFICATION; SUPPRESSION; EXPRESSION; P16(INK4)	Inhibition of cyclin dependent kinases (CDK) by cyclin dependent kinase inhibitors (CDKI) blocks cell cycle progression and inhibits cellular proliferation. The archetypical member of the INK4 CDKI family, p16(INK4A) (also called CDKN2), is a tumor suppressor frequently deleted or mutated in certain neoplasms and many cell lines. Because p19(INK4D) has strong structural and functional similarity to p16(INK4A), We have assessed its role as a tumor suppressor. This was accomplished by screening the p19(INK4D) coding region for mutations, deletions and rearrangements in sarcomas and non-small cell lung cancers. Alterations of the p19(INK4D) gene were found in samples from five of 67 (7%) patients with osteosarcomas and none were found in other types of sarcomas or in lung cancers. Five osteosarcoma samples had Southern blot patterns consistent with gene rearrangement. These samples included a primary and recurrent osteosarcoma from the same patient; both with the same rearrangement. Four samples had SSCP patterns consistent with sequence alterations, sequencing determined that three were due to silent base changes and apparently polymorphisms. Sequencing the fourth shifted band revealed a one base insertion causing a frameshift beginning with codon 27. In summary, these studies found alterations affecting the p19(INK4D) gene in a small but significant number of osteosarcomas. Presumably, abnormalities of this gene contribute to the development of cancer of bone cells.			Miller, CW (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,CEDARS SINAI RES INST,DEPT MED,DIV HEMATOL ONCOL,DAVIS 5019,LOS ANGELES,CA 90048, USA.							CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHIBA I, 1990, ONCOGENE, V5, P1603; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kawamata N, 1995, MOL CARCINOGEN, V14, P263, DOI 10.1002/mc.2940140406; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILLER CW, 1990, CANCER RES, V50, P7950; Miller CW, 1996, CANCER GENET CYTOGEN, V86, P136, DOI 10.1016/0165-4608(95)00216-2; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARK DH, IN PRESS; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RODENHUIS S, 1988, CANCER RES, V48, P5738; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; Shiohara M, 1996, LEUKEMIA, V10, P1897; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; STONE S, 1995, CANCER RES, V55, P2988; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; TAM SW, 1994, CANCER RES, V54, P5816; XU HJ, 1991, CANCER RES, V51, P2735; YAMAGUCHI T, 1992, CANCER RES, V52, P2419; YANG R, 1995, CANCER RES, V55, P2503; Zariwala M, 1996, ONCOGENE, V13, P2033	37	34	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					231	235		10.1038/sj.onc.1201185	http://dx.doi.org/10.1038/sj.onc.1201185			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244358				2022-12-28	WOS:A1997XK37200011
J	Fournes, B; Monier, R; Michiels, F; Milgrom, E; Misrahi, M; Feunteun, J				Fournes, B; Monier, R; Michiels, F; Milgrom, E; Misrahi, M; Feunteun, J			Oncogenic potential of a mutant human thyrotropin receptor expressed in FRTL-5 cells	ONCOGENE			English	Article						FRTL-5 cells; TSH receptor; Gsp; malignant transformation	HYPERFUNCTIONING THYROID ADENOMAS; SOMATIC MUTATIONS; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; GERMLINE MUTATIONS; EPITHELIAL-CELLS; FOLLICULAR CELLS; TRANSGENIC MICE; TSH RECEPTOR; GS-ALPHA; GENE	An abnormal stimulation of the cAMP pathway has been recognized as the primary event in various pathological situations that lead to goitrogenesis or thyroid tumors, Thyroid adenomas are monoclonal neoplasms that become independent of thyroid stimulating hormone (TSH) in their secretory function and growth, Mutated forms of the TSH receptor (TSHR) and the adenylyl cyclase-activating Gs alpha protein, which confer a constitutive activity on these proteins, have been observed in human adenomas, The FRTL-5 rat thyroid cell line is a permanent but untransformed line; the growth of which depends on the presence of TSH, and at least in part, on the stimulation of the cAMP pathway, In order to compare the oncogenic potential of the activated mutant Gs alpha protein and the constitutively activated TSHR, we have transfected FRTL-5 cells with an expression vector bearing either the cDNA of the Gs alpha gene carrying the A201S mutation or the cDNA of the TSH receptor carrying the M453T mutation recently identified in a case of congenital hyperthyroidism. The expression of these two cDNAs was driven by the bovine thyroglobulin gene promoter, We show that, although the expression of both the Gs alpha or TSHR mutant proteins leads to TSH-independent proliferation and to constitutive cAMP accumulation in FRTL-5 cells, only the mutant TSHR is able to induce neoplastic transformation, as demonstrated by growth in semi-solid medium and tumorigenesis in nude mice.	Inst Gustave Roussy, CNRS, URA 1967, Lab Genet Oncol, F-94805 Villejuif, France; Ctr Hosp Bicetre, INSERM, U135, F-94270 Le Kremlin Bicetre, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Feunteun, J (corresponding author), Inst Gustave Roussy, CNRS, URA 1967, Lab Genet Oncol, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; DeRoux N, 1996, J CLIN ENDOCR METAB, V81, P2023, DOI 10.1210/jc.81.6.2023; DERWAHL M, 1992, BIOCHEM BIOPH RES CO, V183, P220, DOI 10.1016/0006-291X(92)91631-Y; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; FUSCO A, 1982, CANCER RES, V42, P618; GORETZKI PE, 1992, WORLD J SURG, V16, P576, DOI 10.1007/BF02067325; HEN R, 1989, P NATL ACAD SCI USA, V86, P4785, DOI 10.1073/pnas.86.12.4785; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; Laglia G, 1996, ENDOCRINOLOGY, V137, P3170, DOI 10.1210/en.137.8.3170; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MUCA C, 1994, ONCOGENE, V9, P647; OSSENDORP FA, 1990, ENDOCRINOLOGY, V127, P419, DOI 10.1210/endo-127-1-419; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; PETER HJ, 1991, ENDOCRINOLOGY, V128, P211, DOI 10.1210/endo-128-1-211; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; RUSSO D, 1995, ONCOGENE, V11, P1907; SAJI M, 1994, SURGERY, V116, P1048; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SUAREZ HG, 1991, ONCOGENE, V6, P677; Tonacchera M, 1996, J CLIN ENDOCR METAB, V81, P547, DOI 10.1210/jc.81.2.547; TSUZAKI S, 1991, ENDOCRINOLOGY, V128, P1359, DOI 10.1210/endo-128-3-1359; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WEIGEL RJ, 1993, CANCER RES, V53, P3472; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zeiger MA, 1996, ENDOCRINOLOGY, V137, P5392, DOI 10.1210/en.137.12.5392	39	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					985	990		10.1038/sj.onc.1201626	http://dx.doi.org/10.1038/sj.onc.1201626			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519872				2022-12-28	WOS:000072335900004
J	Xie, GF; Habbersett, RC; Jia, YW; Peterson, SR; Lehnert, BE; Bradbury, EM; D'Anna, JA				Xie, GF; Habbersett, RC; Jia, YW; Peterson, SR; Lehnert, BE; Bradbury, EM; D'Anna, JA			Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints	ONCOGENE			English	Article						gamma radiation; DNA replication; flow cytometry; cyclin-dependent kinases; p53(-/-) mouse fibroblasts; ataxia telangiectasia	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; ATAXIA-TELANGIECTASIA; DNA-SYNTHESIS; RADIATION; FIBROBLASTS; ARREST; GROWTH; MICE; INHIBITION	We investigated the requirements for protein p53 and the ATM gene product in radiation-induced inhibition of DNA synthesis and regulation of the cyclin E/ and cyclin A/cyclin dependent kinases (Cdks), Wild mouse lung fibroblasts (MLFs), p53(-/-) knock-out, normal human skin fibroblasts (HSF-55), and human AT skin fibroblasts (GM02052) were used in the investigations, The absence of p53 had no significant effect on the inhibition or recovery of DNA synthesis throughout the S phase, as determined from BrdU labeling and flow cytometry, or the rapid inhibition of cyclin A/Cdks., gamma: radiation (8 Gy) inhibited DNA synthesis and progression into G2 during the first 3 h after irradiation, and the recovery of these processes occurred at similar rates in both WT and p53(-/-) MLFs., The cyclin A/Cdks were inhibited 55-70% at Ih after irradiation in both cell types, but 921(WAF1/Clp1) levels or p21 interaction with Cdk2 did not increase in the irradiated p53(-/-) MLFs., Although p53(-/-) MLFs do not exhibit prolonged arrest at a G1 checkpoint, radiation did induce a rapid 20% reduction and small super-recovery of cyclin E/Cdk2 within 1-2 h after irradiation, Similar inhibition and recovery of cyclin E/Cdk2 previously had been associated with regulation of transient G1 delay and the inhibition of initiation at an apparent G1/S checkpoint in Chinese hamster cells, In contrast, loss of the ATM gene product abrogated transient cyclin E/Cdk2 inhibition, most inhibition of DNA synthesis and all, but a 10-15% inhibition, of the cyclin A/Cdks, The results indicate that neither p53 nor p21 is required for transient inhibition of cyclin E/Cdk2 associated with the G1/S checkpoint or for inhibition of DNA synthesis at 'checkpoints' within the S phase, Conversely, the ATM gene product appears to be essential for regulation of the G1/S checkpoint and for inhibition of DNA replication the inhibition of cyclin A/Cdk2., of DNA synthesis inhibition among cell types are presented and discussed in the context of S phase checkpoints,.	Univ Calif Los Alamos Natl Lab, Div Life Sci, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	D'Anna, JA (corresponding author), Univ Calif Los Alamos Natl Lab, Div Life Sci, Los Alamos, NM 87545 USA.		Jia, Yanwei/AAX-1317-2021	Jia, Yanwei/0000-0001-5795-7450	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001315] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR01315] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; CRISSMAN HA, 1987, EXP CELL RES, V173, P256, DOI 10.1016/0014-4827(87)90350-8; CRISSMAN HA, 1993, EUR J HISTOCHEM, V37, P129; DAnna JA, 1997, RADIAT RES, V148, P260, DOI 10.2307/3579611; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gilad S, 1996, HUM MOL GENET, V5, P2033, DOI 10.1093/hmg/5.12.2033; GRAY JW, 1981, J CELL PHYSIOL, V108, P135, DOI 10.1002/jcp.1041080204; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HARVEY M, 1993, ONCOGENE, V8, P2457; HENNEQUIN C, 1994, CANCER RES, V54, P1720; Higashikubo R, 1996, CELL PROLIFERAT, V29, P43, DOI 10.1111/j.1365-2184.1996.tb00093.x; KHANNA KK, 1995, ONCOGENE, V11, P609; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Laderoute MP, 1996, ANTICANCER RES, V16, P2825; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; LEHNERT BE, 1994, AM J RESP CELL MOL, V11, P375, DOI 10.1165/ajrcmb.11.4.7917306; MICHIELI P, 1994, CANCER RES, V54, P3391; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1975, RADIAT RES, V64, P648, DOI 10.2307/3574254; Petrocelli T, 1996, ONCOGENE, V12, P1387; POVIRK LF, 1982, BIOCHEMISTRY-US, V21, P5857, DOI 10.1021/bi00266a020; SACHEZ Y, 1997, SCIENCE, V277, P1497; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALTERS RA, 1970, BIOPHYS J, V10, P556, DOI 10.1016/S0006-3495(70)86319-6; WALTERS RA, 1975, BIOCHEM BIOPH RES CO, V65, P265, DOI 10.1016/S0006-291X(75)80088-X; Wang Y, 1997, CANCER RES, V57, P1654; WATANABE I, 1974, RADIAT RES, V58, P541, DOI 10.2307/3573922; Wyllie FS, 1996, ONCOGENE, V12, P1077; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411	40	59	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					721	736		10.1038/sj.onc.1201793	http://dx.doi.org/10.1038/sj.onc.1201793			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488036				2022-12-28	WOS:000071931800004
J	Wang, L; Darling, J; Zhang, JS; Qian, CP; Hartmann, L; Conover, C; Jenkins, R; Smith, DI				Wang, L; Darling, J; Zhang, JS; Qian, CP; Hartmann, L; Conover, C; Jenkins, R; Smith, DI			Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact	ONCOGENE			English	Article						deletions; tumor cell lines; FRA3B; FHIT	3P14.2 FRAGILE SITE; VIRAL INTEGRATION; TRANSLOCATION BREAKPOINT; CARCINOMA; CANCER; GENE; REPEAT; DNA; HETEROZYGOSITY; AMPLIFICATION	FRA3B at human chromosomal band 3p14.2 is the most active common fragile site in the human genome. The molecular mechanism of fragility at this region remains unknown but does not involve expansion of a trinucleotide or minisatellite repeat as has been observed for several of the cloned rare fragile sites. Deletions and rearrangements at FRA3B have been observed in a number of distinct tumors. The recently identified putative tumor suppressor gene FHIT spans FRA3B, and various groups have reported identifying deletions in this gene in different tumors. Using a high density of PCR amplifiable markers within FRA3B searching for deletions in the FRA3B region, we have analysed 21 tumor cell lines derived from renal cell, pancreatic, and ovarian carcinomas. We found a commonly deleted region in the renal cell and ovarian carcinoma cell lines located in the middle of an HPV16 viral integration site. Despite the presence of deletions in the FRA3B region in most of the cell lines, we did not detect alterations in FHIT exons in any of the cell lines examined. Thus, deletions of 3p14.2 in these carcinoma cell lines may simply reflect instability of the FRA3B region during tumor progression.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55902 USA; Mayo Clin & Mayo Fdn, Dept Med Oncol, Rochester, MN 55902 USA	Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55902 USA.				NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Cohen S, 1997, ONCOGENE, V14, P977, DOI 10.1038/sj.onc.1200917; DRUCK T, 1995, CANCER RES, V55, P5348; Druck T, 1997, CANCER RES, V57, P504; EHLEN T, 1990, ONCOGENE, V5, P219; Fong KM, 1997, CANCER RES, V57, P2256; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Hendricks DT, 1997, CANCER RES, V57, P2112; JENKINS RB, 1993, CANCER GENET CYTOGEN, V71, P76, DOI 10.1016/0165-4608(93)90205-Z; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; KAMEL D, 1994, HISTOPATHOLOGY, V25, P339, DOI 10.1111/j.1365-2559.1994.tb01352.x; Kastury K, 1996, CANCER RES, V56, P978; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; Mao L, 1996, CANCER RES, V56, P5128; Mauillon JL, 1996, CANCER RES, V56, P5728; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Panagopoulos I, 1996, CANCER RES, V56, P4871; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; PARADEE W, 1995, GENOMICS, V27, P358, DOI 10.1006/geno.1995.1057; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; POPESCU NC, 1990, HUM GENET, V84, P383; Puget N, 1997, CANCER RES, V57, P828; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; Reiter LT, 1996, NAT GENET, V12, P288, DOI 10.1038/ng0396-288; Shridhar R, 1996, CANCER RES, V56, P4347; Shridhar V, 1997, ONCOGENE, V14, P1269, DOI 10.1038/sj.onc.1201100; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SMITH PP, 1992, GENE CHROMOSOME CANC, V5, P150, DOI 10.1002/gcc.2870050209; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUTHERLAND GR, 1985, OXFORD U MONOGRAPHS, V13; Todd S, 1997, CANCER RES, V57, P1344; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P59, DOI 10.1002/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.3.CO;2-O; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; WAGATSUMA M, 1990, J VIROL, V64, P813, DOI 10.1128/JVI.64.2.813-821.1990; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; Wang L, 1996, ONCOGENE, V12, P699; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; YAMAGISAWA K, 1996, CANCER RES, V56, P5579; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; Zimonjic DB, 1997, CANCER RES, V57, P1166	45	33	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					635	642		10.1038/sj.onc.1201576	http://dx.doi.org/10.1038/sj.onc.1201576			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482109				2022-12-28	WOS:000071816600008
J	Burger, A; Li, H; Zhang, XK; Pienkowska, M; Venanzoni, M; Vournakis, J; Papas, T; Seth, A				Burger, A; Li, H; Zhang, XK; Pienkowska, M; Venanzoni, M; Vournakis, J; Papas, T; Seth, A			Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12	ONCOGENE			English	Article						gene anatomy; breast cancer; molecular oncology; subtractive cloning; differential display; immunohistochemistry	DIFFERENTIAL DISPLAY; IDENTIFICATION; PROTEINS; BINDING	To determine which genes may be activated or inactivated during breast cancer development, we employed two cloning strategies (subtractive hybridization and differential display) using RNA samples from a human breast tumor and its matching normal breast cell line. Of 950 clones isolated, 102 cDNA inserts were analysed by DNA sequencing and database searching. We found 30 clones that were obviously unidentified, with no significant homology to any listed human gene. We focused upon one of the novel genes, Di12, that is differentially expressed as a 1.35 kb RNA in breast cancer tissues and cell-lines. and in several normal tissues. A full length cDNA of this gene was cloned, and its DIVA sequence revealed an open reading frame of 339 amino acids. Antibodies to the ten N-terminal amino acids were developed to investigate the expression of Di12 in breast cancer cell-lines and tumors. The Di12 protein was found in tissue sections of infiltrating ductal carcinomas (IDCs), but not in benign or normal breast specimens. RT-PCR analysis confirmed expression of Di12 in 80% of infiltrating ductal carcinomas (IDCs). As IDC constitutes similar to 70% of breast cancers seen clinically, the level of Di12 expression may be predictive of disease progression.	Univ Toronto, Womens Coll Hosp, Dept Pathol, Toronto, ON M5S 1B3, Canada; Univ Toronto, Womens Coll Hosp, Lab Lab Med & Pathobiol, Toronto, ON M5S 1B3, Canada; Univ Bradford, Clin Oncol Unit, Bradford BD7 1DP, W Yorkshire, England; Mem Sloan Kettering Canc Inst, New York, NY 10021 USA; Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; INRCA, Ancona, Italy	University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Bradford; Memorial Sloan Kettering Cancer Center; Medical University of South Carolina; IRCCS INRCA	Seth, A (corresponding author), Univ Toronto, Womens Coll Hosp, Dept Pathol, 76 Grenville St, Toronto, ON M5S 1B3, Canada.							ABTS H, 1991, LEUKEMIA RES, V15, P987, DOI 10.1016/0145-2126(91)90103-Z; ALLRED D, 1990, P ASCO, V9, P23; BERNS EMJJ, 1992, CANCER RES, V52, P1107; Burger AM, 1996, INT J ONCOL, V8, P395; EASTON D, 1993, CANCER SURV, V18, P95; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; IWASE H, 1994, BREAST CANC RES TREA, V33, P83; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAINSBURY JRC, 1987, LANCET, V1, P1398; SALESIOTIS AN, 1995, CANCER LETT, V91, P47, DOI 10.1016/0304-3835(95)03717-B; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SOUBEYRAN I, 1995, BREAST CANCER RES TR, V34, P119, DOI 10.1007/BF00665784; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333	20	29	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					327	333		10.1038/sj.onc.1201517	http://dx.doi.org/10.1038/sj.onc.1201517			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467958				2022-12-28	WOS:000071582100005
J	Queimado, L; Reis, A; Fonseca, I; Martins, C; Lovett, M; Soares, J; Parreira, L				Queimado, L; Reis, A; Fonseca, I; Martins, C; Lovett, M; Soares, J; Parreira, L			A refined localization of two deleted regions in chromosome 6q associated with salivary gland carcinomas	ONCOGENE			English	Article						salivary gland carcinomas; chromosome 6q; loss of heterozygosity (LOH); deletions; histological subtypes	MANGANESE SUPEROXIDE-DISMUTASE; TUMOR-SUPPRESSOR GENE; LONG ARM; BREAST-CARCINOMA; OVARIAN CANCERS; MELANOMA-CELLS; HUMAN GENOME; HETEROZYGOSITY; TUMORIGENICITY; IDENTIFICATION	Deletions within chromosome 6 (6q25 to 6qter) are the most consistent structural change observed in salivary gland carcinomas, To better define the location of these deletions we investigated loss of heterozygosity (LOH) for 23 polymorphic markers within 19 salivary gland carcinomas covering several histological subtypes, LOH was observed in 47% of tumors, confirming previous reports that such losses are frequent and occur in almost all histological subtypes of tumors, The highest frequency of LOH was found at, or distal to, D6S437, Seven tumors had allelic losses for D6S297 and/or D6S37, A second peak of loss was also observed at D6S262 and D6S32, In some tumors we observed LOH in one or the other of these two regions, In other tumors we observed loss of both regions with retention of intervening loci, These data suggest that two small deletions commonly occur, one between D6S262 and D6S32 (estimated to cover less than 1.5 Mb) and another between D6S297 and D6S446 (estimated to cover similar to 2 Mb), These results extend previous studies by sublocalizing the regions of LOH and suggest that inactivation of one or more tumor suppressor genes located in these regions may be an important step in salivary gland carcinogenesis.	Univ Texas, SW Med Ctr, McDermott Ctr, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Otorhinolaryngol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Fac Med Lisboa, Inst Histol & Embriol, Lisbon, Portugal; Inst Portugues Oncol Francisco Gentil, Dept Patol Morfol, Lisbon, Portugal; Inst Portugues Oncol Francisco Gentil, Ctr Invest Patobiol Mol, Lisbon, Portugal; Fac Med Lisboa, Inst Histol & Embriol, Lisbon, Portugal	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universidade de Lisboa; Portuguese Institute of Oncology; Portuguese Institute of Oncology; Universidade de Lisboa	Queimado, L (corresponding author), Univ Texas, SW Med Ctr, McDermott Ctr, NB10106, Dallas, TX 75235 USA.		Queimado, Lurdes/AAY-2545-2021; Fonseca, Isabel/A-7396-2008; Soares, Jorge/C-7429-2015; Queimado, Lurdes/L-7465-2013; Parreira, Leonor/S-2304-2019	Queimado, Lurdes/0000-0002-1106-4873; Fonseca, Isabel/0000-0002-1359-6494; Soares, Jorge/0000-0002-1359-6494; Queimado, Lurdes/0000-0002-1106-4873; Martins, Carmo/0000-0002-7901-7600; Parreira, Leonor/0000-0002-1970-9285				Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Bockmuhl U, 1996, CANCER RES, V56, P5325; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooke IE, 1996, MAMM GENOME, V7, P157, DOI 10.1007/s003359900040; Cooney KA, 1996, CANCER RES, V56, P4150; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1991, CANCER RES, V51, P1020; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; Hankins GR, 1996, ONCOGENE, V12, P2003; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JIN Y, 1994, BRIT J CANCER, V70, P42, DOI 10.1038/bjc.1994.247; Johns MM, 1996, CANCER RES, V56, P1151; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MORITA R, 1991, CANCER RES, V51, P5817; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NORDKVIST A, 1994, GENE CHROMOSOME CANC, V10, P115, DOI 10.1002/gcc.2870100206; Noviello C, 1996, CLIN CANCER RES, V2, P1601; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; SAFFORD SE, 1994, CANCER RES, V54, P4261; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; Sandhu AK, 1996, ONCOGENE, V12, P247; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SEIFERT G, 1990, PATHOL RES PRACT, V186, P555, DOI 10.1016/S0344-0338(11)80220-7; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Simonic I, 1996, HUM GENET, V97, P524; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; TAGUCHI T, 1993, CANCER RES, V53, P4349; Tahara H, 1996, CANCER RES, V56, P599; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WELCH DR, 1994, ONCOGENE, V9, P255	40	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					83	88		10.1038/sj.onc.1201480	http://dx.doi.org/10.1038/sj.onc.1201480			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467946				2022-12-28	WOS:000071236800010
J	Xu, HJ; Zhou, YL; Ji, W; Perng, GS; Kruzelock, R; Kong, CT; Bast, RC; Mills, GB; Li, J; Hu, SX				Xu, HJ; Zhou, YL; Ji, W; Perng, GS; Kruzelock, R; Kong, CT; Bast, RC; Mills, GB; Li, J; Hu, SX			Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition	ONCOGENE			English	Article						tumor suppressor gene; retinoblastoma (RB) gene; p53; senescence; telomerase	BREAST-CARCINOMA CELLS; REPLICATIVE SENESCENCE; HUMAN FIBROBLASTS; GENE-EXPRESSION; IMMORTAL CELLS; RB PROTEIN; P53 GENE; SUPPRESSION; APOPTOSIS; FAILURE	Normal human diploid cells senesce in vitro and in vivo after a limited number of cell divisions, This process known as cellular senescence is an underlying cause of aging and a critical barrier for development of human cancers, We demonstrate here that reexpression of functional pRB alone in RB/p53-defective tumor cells via a modified tetracycline-regulated gene expression system resulted in a stable growth arrest at the G0/G1 phase of the cell cycle, preventing tumor cells from entering S phase in response to a variety of mitogenic stimuli, These cells displayed multiple morphological changes consistent with cellular senescence and expressed a senescence-associated beta-galactosidase biomarker, Further studies indicated that telomerase activity, which was assumably essential for an extended proliferative life-span of neoplastic cells, was abrogated or repressed in the tumor cell lines after induction of pRB (but not p53) expression, Strikingly, when returned to an nonpermissive medium for pRB expression, the pRB-induced senescent tumor cells resumed DNA synthesis, attempted to divide but most died in the process, a phenomenon similar to postsenescent crisis of SV40 T-antigen-transformed human diploid fibroblasts in late passage, These observations provide direct evidence that overexpression of pRB alone in RB/p53-defective tumor cells is sufficient to reverse their immortality and cause a phenotype that is, by all generally accepted criteria, indistinguishable from replicative senescence, The results suggest that pRB may play a causal role in the intrinsic cellular senescence program.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT HEMATOL,DIV MED,THE WOODLANDS,TX 77381; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL ONCOL,DIV MED,HOUSTON,TX 77030; BEIJING INST GERIATR,DEPT BIOCHEM,BEIJING 100730,PEOPLES R CHINA; BEIJING UNION MED COLL HOSP,BEIJING 100730,PEOPLES R CHINA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Xu, HJ (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL ONCOL,4000 RES FOREST DR,THE WOODLANDS,TX 77381, USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NCI NIH HHS [CA67274] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067274] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; Berry DE, 1996, ONCOGENE, V12, P1809; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dawson D. W., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P88; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FUTREAL PA, 1991, ONCOGENE, V6, P1109; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, BIOTECHNIQUES, V19, P213; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Li J, 1996, ONCOGENE, V13, P2379; LINSKENS MHK, 1995, SCIENCE, V267, P17, DOI 10.1126/science.7848496; LU YM, 1994, ONCOGENE, V9, P1015; Lu YM, 1996, J IMMUNOL, V156, P2495; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1985, J CELL PHYSL, V125, P35; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; WANG E, 1995, CANCER RES, V55, P2284; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XU HJ, 1994, P NATL ACAD SCI USA, V91, P9837, DOI 10.1073/pnas.91.21.9837; XU HJ, 1991, ONCOGENE, V6, P1139; XU HJ, 1997, GENE THERAPY ADV PHA, V40, P233; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	37	132	139	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2589	2596		10.1038/sj.onc.1201446	http://dx.doi.org/10.1038/sj.onc.1201446			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399646				2022-12-28	WOS:A1997YG73200008
J	Monaco, L; SassoneCorsi, P				Monaco, L; SassoneCorsi, P			Cross-talk in signal transduction: Ras-dependent induction of cAMP-responsive transcriptional repressor ICER by nerve growth factor	ONCOGENE			English	Article						transcription factors; cyclic AMP; CREM; nerve growth factor; Ras; c-fos	INDUCED NEURONAL DIFFERENTIATION; LONG-TERM DESENSITIZATION; PROTO-ONCOGENE FOS; PC12 CELLS; TYROSINE PHOSPHORYLATION; MAP KINASE; CYCLIC-AMP; CREM GENE; NEURITE OUTGROWTH; EXPRESSION	The CREM gene encodes both activators and repressors of cAMP-induced transcription. By virtue of an alternative, intronic promoter within the gene, the ICER (Inducible cAMP Early Repressor) isoform is generated. ICER acts as a dominant negative regulator and is cAMP-inducible in various neuroendocrine cells and tissues. ICER negatively autoregulates its own expression, and appears to participate in the molecular events governing oscillatory hormonal regulations. Here we report that ICER is inducible with nerve growth factor (NGF). This is the first example of cAMP-independent induction of ICER expression. Importantly, induction by NGF occurs via a subset of the CREs present in the ICER promoter which were previously shown to direct cAMP-inducibility. ICER induction correlates with a NGF-mediated phosphorylation of CREB. Both CREB phosphorylation and ICER inducibility require an intact Ras-dependent signalling pathway. We show that increased ICER levels result in the attenuation of c-fos expression. The activation of a powerful repressor of cAMP-responsive transcription by NGF, whose transduction signalling is cAMP-independent, constitutes a notable example of nuclear cross-talk and thus is likely to have relevant physiological implications.	INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Monaco, Lucia/A-4031-2010					BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUKUDA M, 1995, ONCOGENE, V11, P239; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNIPPER M, 1993, FEBS LETT, V324, P147, DOI 10.1016/0014-5793(93)81382-A; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LALLI E, 1994, J BIOL CHEM, V269, P17356; Lamas M, 1997, MOL ENDOCRINOL, V11, P1415, DOI 10.1210/me.11.10.1415; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHUBERT D, 1980, BRAIN RES, V190, P67, DOI 10.1016/0006-8993(80)91160-9; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	46	42	42	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2493	2500		10.1038/sj.onc.1201636	http://dx.doi.org/10.1038/sj.onc.1201636			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395245				2022-12-28	WOS:A1997YE96300011
J	Sokolowski, M; Zhao, CP; Tan, W; Schwartz, S				Sokolowski, M; Zhao, CP; Tan, W; Schwartz, S			AU-rich mRNA instability elements on human papillomavirus type 1 late mRNAs and c-fos mRNAs interact with the same cellular factors	ONCOGENE			English	Article						HPV-1; c-fos; RNA stability; hnRNPC	HUMAN-IMMUNODEFICIENCY-VIRUS; MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; OPEN READING FRAME; REV GENE-PRODUCT; 3'-UNTRANSLATED REGION; BINDING PROTEINS; DNA-REPLICATION; NUCLEAR; SEQUENCE	Expression levels of human papillomavirus type 1 late genes are determined in part by an AU-rich inhibitory sequence in the 3' untranslated region on the late mRNAs. Fine mapping of the AU rich inhibitory sequence revealed that it mapped to a 57 nucleotide sequence, consisting of an AU-rich region containing two AUUUA motifs and a U-rich region containing three UUUUU motifs. An internal deletion showed that the U-rich region was required for inhibition, Point mutations in the AUUUA- and UUUUU-motifs inactivated the inhibitory sequence. Analysis of the stability of mRNAs containing the AU-rich sequence in sense or anti-sense orientation showed that mRNAs containing the AU-rich sequence in sense orientation had reduced half life. Analysis of RNA-protein interactions revealed that binding to the inhibitory sequence of three poly(U) binding proteins (38, 44 and 46 kDa) correlated with inhibition and that the same proteins bind to the AU-rich mRNA instability element in the 3' untranslated region on the human c-fos mRNA. We speculate that the human papillomavirus late mRNAs, produced from several hundred copies of the virus genome present in infected cells, compete with the c-fos mRNAs for destabilizing cellular factors and that this may lead to elevated Fos protein levels in human papillomavirus infected cells.	KAROLINSKA INST, MICROBIOL & TUMORBIOL CTR, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet				Sokolowski, Marcus/0000-0003-3931-1810				BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CHEN CM, 1991, J BIOL CHEM, V266, P7754; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOU ZF, 1994, NUCLEIC ACIDS RES, V22, P2525, DOI 10.1093/nar/22.13.2525; CHOW LT, 1994, INTERVIROLOGY, V37, P150, DOI 10.1159/000150373; DANOS O, 1982, EMBO J, V1, P231, DOI 10.1002/j.1460-2075.1982.tb01152.x; DietrichGoetz W, 1997, P NATL ACAD SCI USA, V94, P163, DOI 10.1073/pnas.94.1.163; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; ENG AM, 1985, J CUTAN PATHOL, V12, P46, DOI 10.1111/j.1600-0560.1985.tb00429.x; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISHER C, 1991, DEVELOPMENT, V111, P253; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; FURTH PA, 1994, MOL CELL BIOL, V14, P5278, DOI 10.1128/MCB.14.8.5278; FURTH PA, 1991, J VIROL, V65, P5806, DOI 10.1128/JVI.65.11.5806-5812.1991; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; GRUSSENDORF EI, 1979, ARCH DERMATOL RES, V264, P55, DOI 10.1007/BF00417279; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HOWLEY P M, 1990, P1625; HOWLEY PM, 1991, FUNDAMENTAL VIROLOGY, V2, P743; JENSON AB, 1980, J NATL CANCER I, V64, P495; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KENNEDY IM, 1991, J VIROL, V65, P2093, DOI 10.1128/JVI.65.4.2093-2097.1991; KENNEDY IM, 1990, J VIROL, V64, P1825, DOI 10.1128/JVI.64.4.1825-1829.1990; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; LAMBERT PF, 1991, J VIROL, V65, P3417, DOI 10.1128/JVI.65.7.3417-3420.1991; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; NAKAMAKI T, 1995, J CELL PHYSIOL, V165, P484, DOI 10.1002/jcp.1041650306; RAYMOND V, 1989, ONCOGENE RES, V4, P861; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUTHER U, 1989, ONCOGENE, V4, P861; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STAKNIS D, 1994, MOL CELL BIOL, V14, P2994, DOI 10.1128/MCB.14.5.2994; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; TAN W, 1995, J VIROL, V69, P2932, DOI 10.1128/JVI.69.5.2932-2945.1995; TAN W, 1995, J VIROL, V69, P5607, DOI 10.1128/JVI.69.9.5607-5620.1995; TUREK LP, 1994, ADV VIRUS RES, V44, P305, DOI 10.1016/S0065-3527(08)60332-2; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WENNBORG A, 1995, P NATL ACAD SCI USA, V92, P7322, DOI 10.1073/pnas.92.16.7322; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292; Zhao CP, 1996, J VIROL, V70, P3659, DOI 10.1128/JVI.70.6.3659-3667.1996; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	57	50	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2303	2319		10.1038/sj.onc.1201415	http://dx.doi.org/10.1038/sj.onc.1201415			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393875	Bronze			2022-12-28	WOS:A1997YE15700005
J	LeBrun, DP; Matthews, BP; Feldman, BJ; Cleary, ML				LeBrun, DP; Matthews, BP; Feldman, BJ; Cleary, ML			The chimeric oncoproteins E2A-PBX1 and E2A-HLF are concentrated within spherical nuclear domains	ONCOGENE			English	Article						leukemia; E2A-PBX1; E2A-HLF; transcription factors; translocations	ACUTE LYMPHOBLASTIC-LEUKEMIA; COOPERATIVE DNA-BINDING; PRE-B; TRANSCRIPTIONAL ACTIVATOR; HOMEODOMAIN PROTEIN; PBX1 HOMEODOMAIN; MESSENGER-RNA; HOX PROTEINS; E2A GENE; FUSION	Oncogenic mutation of nuclear transcription factors often is associated with altered patterns of subcellular localization that may be of functional importance, The leukemogenic transcription factor gene E2A-PBX1 is created through fusion of the genes E2A and PBX1 as a result of t(1;19) in acute lymphoblastic leukemia, We evaluated subcellular localization patterns of E2A-PBX1 protein in transfected cells using immunofluorescence. Full-length E2A-PBX1 was exclusively nuclear and was concentrated in spherical domains denoted chimeric-E2A oncoprotein domains (CODs), In contrast, nuclear fluorescence for wild-type E2A or PBX1 proteins was diffuse, Enhanced concentrations of RNA polymerase II within many CODs and the requirement for an E2A-encoded activation domain suggested transcriptional relevance, However, in situ co-detection of nascent transcripts labeled with bromouridine failed to confirm altered transcriptional activity in relation to CODs, CODs also failed to co-localize with other proteins known to occupy functional nuclear compartments, including the transcription factor PML, the spliceosome-associated protein SC-35 and the adenovirus replication factor DBP, or with foci of DNA replication, Co-transfection of Hoxb7, a homeodomain protein capable of enhancing DNA binding by PBX1, impaired COD formation, suggesting that CODs contain E2A-PBX1 protein not associated with DNA, We conclude that, as a 'gain of function' phenomenon requiring protein elements from both E2A and PBX1, COD formation may be relevant to the biology of E2A-PBX1 in leukemogenesis.	STANFORD UNIV,MED CTR,DEPT PATHOL,EXPT ONCOL LAB,STANFORD,CA 94305	Stanford University	LeBrun, DP (corresponding author), QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA.				NCI NIH HHS [CA42971] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BERENDES P, 1995, LEUKEMIA, V9, P1321; BOROWITZ M, 1992, NEOPLASTIC HEMATOPAT, P1295; BRIDGE E, 1995, J VIROL, V69, P281, DOI 10.1128/JVI.69.1.281-290.1995; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARROLL AJ, 1984, BLOOD, V63, P721; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CLEARY ML, 1992, CANCER SURV, V15, P89; CRIST WM, 1990, BLOOD, V76, P117; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FORNEROD M, 1995, ONCOGENE, V10, P1739; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, BLOOD, V83, P2970, DOI 10.1182/blood.V83.10.2970.2970; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; Inukai T., 1996, Blood, V88, p552A; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; PUI CH, 1990, BLOOD, V76, P1449; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; REUTER R, 1984, EXP CELL RES, V154, P548, DOI 10.1016/0014-4827(84)90179-4; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1984, BIOL CELL, V51, P109, DOI 10.1111/j.1768-322X.1984.tb00289.x; SPECTOR DL, 1987, ONCOGENE, V1, P5; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; TISCHLER AS, 1992, J HISTOCHEM CYTOCHEM, V40, P1043, DOI 10.1177/40.7.1351491; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VERHEIJEN R, 1986, J CELL SCI, V86, P173; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247	51	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2059	2067		10.1038/sj.onc.1201367	http://dx.doi.org/10.1038/sj.onc.1201367			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366523				2022-12-28	WOS:A1997YC28400007
J	Tahara, H; Tokutake, Y; Maeda, S; Kataoka, H; Watanabe, T; Satoh, M; Matsumoto, T; Sugawara, M; Ide, T; Goto, M; Furuichi, Y; Sugimoto, M				Tahara, H; Tokutake, Y; Maeda, S; Kataoka, H; Watanabe, T; Satoh, M; Matsumoto, T; Sugawara, M; Ide, T; Goto, M; Furuichi, Y; Sugimoto, M			Abnormal telomere dynamics of B-lymphoblastoid cell strains from Werner's syndrome patients transformed by Epstein-Barr virus	ONCOGENE			English	Article						Werner's syndrome; B-lymphoblastoid cells; telomere; telomerase; EBT	LINES; LYMPHOCYTES; ELONGATION	The characteristics of B-lymphoblastoid cell strains transformed by Epstein-Barr virus (EBV) from normal individuals and Werner's syndrome (WRN) patients were compared, We continuously passaged cell strains from 28 WRN patients and 20 normal individuals for about 2 years corresponding to over 160 population doubling levels (PDLs), First, the WRN mutation significantly suppressed the immortalization: all the 28 cell strains from WRN patients, as well as 15 out of 20 cell strains from normal individuals, died out before 160 PDLs mostly without developing a significant telomerase activity, The remaining five cell strains from normal individuals became moderately/strongly telomerase-positive and, three of them were apparently immortalized with an infinitively proliferating activity, Second, the monitoring of the telomere length of both normal and WRN cell strains during;the culture period suggests that the WRN gene mutation causes abnormal dynamics of the telomere: (1) a significant proportion of WRN cell strains showed drastic shortening or lengthening of telomere lengths during cell passages compared with normal cell strains, and (2) WRN cell strains terminated their life-span at a wide range of telomere length (between 3.5 and 18.5 Kbp), whereas normal cell strains terminated within a narrow telomere length range (between 5.5 and 9 Kbp), The chromosomal aberration characteristic of WRN cells, including translocation was confirmed in our experiment, We discussed the correlation between the chromosomal instability, abnormal telomere dynamics and inability of immortalization of the WRN B-lymphobloastoid cell strains.	AGENE,RES INST,KAMAKURA,KANAGAWA 247,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT CELLULAR & MOL BIOL,MINAMI KU,HIROSHIMA 734,JAPAN; TOKYO METROPOLITAN OTSUKA HOSP,DEPT RHEUMATOL,TOSHIMA KU,TOKYO 170,JAPAN	Hiroshima University								Avilion AA, 1996, CANCER RES, V56, P645; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; BRYAN TM, 1997, IN PRESS EUR J CAN; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P175; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GOSDEN J, 1994, HUM MOL GENET, V3, P931, DOI 10.1093/hmg/3.6.931; Goto M, 1997, HUM GENET, V99, P191, DOI 10.1007/s004390050336; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; GOTO M, 1981, CLIN GENET, V19, P8; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIROSE M, 1997, IN PRESS J CANC RES; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MARTIN GM, 1970, LAB INVEST, V23, P86; Matsumoto T, 1997, HUM GENET, V100, P123, DOI 10.1007/s004390050477; MILLER G, 1990, VIROLOGY, P1921; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Norrback KF, 1996, BLOOD, V88, P222; Oshima J, 1996, HUM MOL GENET, V5, P1909, DOI 10.1093/hmg/5.12.1909; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; RUNGER TM, 1994, J INVEST DERMATOL, V102, P45, DOI 10.1111/1523-1747.ep12371730; SALK D, 1985, ADV EXP MED BIOL, V190, P541; SALK D, 1985, ADV EXP MED BIOL, P305; SCHELLENBERG GD, 1992, LANCET, V339, P1002, DOI 10.1016/0140-6736(92)91590-5; Schulz VP, 1996, HUM GENET, V97, P750; Strahl C, 1996, MOL CELL BIOL, V16, P53; Sugihara S, 1996, HUM GENET, V97, P1; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	36	115	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1911	1920		10.1038/sj.onc.1201377	http://dx.doi.org/10.1038/sj.onc.1201377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365237				2022-12-28	WOS:A1997YA87200005
J	Hahn, SL; Criqui, P; Wasylyk, B				Hahn, SL; Criqui, P; Wasylyk, B			Modulation of ETS-1 transcriptional activity by huUBC9, a ubiquitin-conjugating enzyme	ONCOGENE			English	Article						transcription activation; ubiquitination; physical interactions; UBC9; Hus5; pointed domain	DNA-BINDING; GENE FAMILY; SECONDARY STRUCTURE; T-CELLS; KAPPA-B; C-JUN; V-ETS; PROTEIN; DOMAIN; PROMOTER	Ets transcription factors have Ets DNA binding domains, that have a winged helix-turn-helix structure. ETS-1, the founding member of the family, is regulated by the Ras and Ca2+ signaling pathways and is implicated in various physiological processes leading to cell growth, differentiation and apoptosis. We have identified ETS-1 interacting factors with a yeast two-hybrid screen. The majority of the positive clones turned out to encode the human homologue of the yeast ubiquitin-conjugating enzymes UBC9 and Hus5. In two different yeast assays, ETS-1 interacted with HuUBC9. In an in vitro GST 'pull-down' assay, ETS-1 and several other Ets family members complexed with huUBC9. Interestingly, in mammalian cells, coexpression of huUBC9 resulted in a substantial increase in the transcriptional activity of ETS-1. Coexpressed huUBC9 did not affect the ETS-1 protein level, and moreover, a point mutation at Cys93, an amino acid known to be essential for ubiquitination, did not abolish the stimulation of the ETS-1 transcriptional activity. Our results indicate that the modulation of ETS-1 activity by huUBC9 results from processes other than ubiquitination and ETS-1 stabilization.	ULP,INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ALKHODAIRY F, 1995, J CELL SCI, V108, P475; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BELLACOSA A, 1994, J VIROL, V68, P2320, DOI 10.1128/JVI.68.4.2320-2330.1994; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COFFER P, 1994, ONCOGENE, V9, P911; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FISHER RJ, 1994, PROTEIN SCI, V3, P257; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN SL, 1994, ONCOGENE, V9, P2499; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; LEPRINCE D, 1983, NATURE, V306, P295; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rose MD., 1990, METHODS YEAST GENETI; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1997, IN PRESS RG LANDES C; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	48	40	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1489	1495		10.1038/sj.onc.1201301	http://dx.doi.org/10.1038/sj.onc.1201301			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333025				2022-12-28	WOS:A1997XW41100013
J	Dong, JA; Naito, M; Tsuruo, T				Dong, JA; Naito, M; Tsuruo, T			c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis in human monocytic leukemia U937 cells	ONCOGENE			English	Article						c-myc; TNF-alpha; Fas; antitumor agents; CPP32; apoptosis	AGENT-INDUCED APOPTOSIS; ANTICANCER DRUGS; INDUCTION; BCL-2; RESISTANCE; EXPRESSION; GENE; FAS; CYTOTOXICITY; HOMOLOG	Human monocytic leukemia U937 cells readily undergo apoptosis when they are treated with TNF-alpha, anti-Fas antibody and anticancer drugs such as etoposide and Ara-C, To study the mechanism of apoptosis, we developed a novel apoptosis-resistant variant, UC, from U937 cells, The UC cells showed resistance to apoptosis induced by TNF-alpha, anti-Fas antibody, etoposide and Ara-C, Somatic cell hybridization between U937 and UC showed that apoptosis-resistance to TNF-alpha in UC was genetically recessive and resistance to etoposide was dominant, suggesting that UC has at least two different mutations functionally involved in apoptosis, Mechanistic analysis revealed that UC cells expressed reduced amounts of c-Myc, Transfection of the c-myc gene into UC cells restored the sensitivity of the cells to undergo apoptosis induced by TNF-alpha and anti-Fas, which attributes apoptosis-resistance in this circumstance to the reduced expression of c-Myc, On the other hand, c-myc transfection into UC cells could not restore their sensitivity to etoposide- and Ara-C-induced apoptosis, arguing against the role of c-myc in chemotherapy-induced apoptosis, However, treating the parental U937 cells with antisense oligonucleotides designed to reduce c-Myc expression rendered the cells resistant to etoposide-induced as well as to TNF-alpha-induced apoptosis, These results indicate that the reduced expression of c-Myc in UC is strongly associated with the resistance to etoposide-induced apoptosis, Our finding that c-myc transfection into UC could not restore the sensitivity to etoposide-induced apoptosis, suggests UC could have a second mutation that confers resistance to etoposide-induced apoptosis in a genetically dominant manner, Taken together, our present results indicate that c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research								AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Baker SJ, 1996, ONCOGENE, V12, P1; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chen ZH, 1996, CANCER RES, V56, P5224; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FUJITA M, 1995, ONCOGENE, V11, P15; FUJITA N, 1993, CANCER RES, V53, P5022; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; Mikami K, 1996, CANCER RES, V56, P2823; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; Noguchi K, 1996, ONCOGENE, V13, P39; NOGUCHI K, 1995, CELL GROWTH DIFFER, V6, P1271; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WOOD AC, 1995, BRIT J CANCER, V71, P937, DOI 10.1038/bjc.1995.181; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONEHARA S, 1989, J EXP MED, V169, P1749	33	41	45	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					639	647		10.1038/sj.onc.1201237	http://dx.doi.org/10.1038/sj.onc.1201237			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264404				2022-12-28	WOS:A1997XP68300003
J	Munoz, R; Klingenberg, O; Wiedlocha, A; Rapak, A; Falnes, PO; Olsnes, S				Munoz, R; Klingenberg, O; Wiedlocha, A; Rapak, A; Falnes, PO; Olsnes, S			Effect of mutation of cytoplasmic receptor domain and of genistein on transport of acidic fibroblast growth factor into cells	ONCOGENE			English	Article						acidic fibroblast growth factor; receptor mutant; genistein; farnesylation	NUCLEAR TRANSLOCATION SEQUENCE; TYROSINE KINASE-ACTIVITY; FACTOR-I; SIGNAL-TRANSDUCTION; DIPHTHERIA-TOXIN; BALB/C 3T3; PRELAMIN-A; FGF; INTERNALIZATION; LOCALIZATION	Acidic fibroblast growth factor (aFGF) binds to specific transmembrane receptors and is partly transported to a nuclear location, To study this transport we made a kinase-negative mutant of FGF receptor 4 as well as one where the major part of the cytoplasmic receptor domain was deleted, and expressed them in U2OSDr1 cells that lack functional FGF receptors. All receptors mediated endocytic uptake of aFGF. Translocation of the growth factor across cellular membranes was assayed using aFGF with a C-terminal CAAX-motif, which signals addition of a farnesyl group onto the protein once in the cytosol. CAAX-tagged aFGF was farnesylated when incubated with cells containing wild-type or kinase-negative receptors. It was not farnesylated in cells expressing the,deleted receptor, or when the incubation was in the presence of genistein, aFGF incubated with cells transfected with wild-type or kinase-negative receptors, but not with the deleted receptor, was partly recovered from the nuclear fraction in the absence, but not in the presence of genistein. The data indicate that the cytoplasmic receptor domain, but not the active kinase, is required for transport of the growth factor into cells, and that genistein inhibits the process.	NORWEGIAN RADIUM HOSP,INST CANC RES,N-0310 OSLO,NORWAY	University of Oslo			Falnes, Pål Ø./AAA-4581-2020; Rapak, Andrzej/ABE-6262-2021	Rapak, Andrzej/0000-0003-4897-0287; Falnes, Pal/0000-0001-8114-6025; Munoz, Raquel/0000-0001-9861-0349				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAO Y, 1993, J CELL SCI, V104, P77; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DUNN WA, 1980, J BIOL CHEM, V255, P5971; FALLON RJ, 1994, J BIOL CHEM, V269, P11011; FALNES PO, 1995, BIOCHEMISTRY-US, V34, P11152, DOI 10.1021/bi00035a021; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HILL T, 1990, SCIENCE, V248, P1661; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1992, J BIOL CHEM, V267, P5676; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; KOROMA BM, 1994, BIOCHEM PHARMACOL, V48, P809, DOI 10.1016/0006-2952(94)90060-4; LANDGREN E, 1995, ONCOGENE, V10, P2027; LINASSIER C, 1990, BIOCHEM PHARMACOL, V39, P187, DOI 10.1016/0006-2952(90)90664-7; LOMAZE C, 1993, MOL BIOL CELL, V4, P715; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; RIESE J, 1995, MECH DEVELOP, V49, P13, DOI 10.1016/0925-4773(94)00296-Y; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SINENSKY M, 1994, J CELL SCI, V107, P61; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; TROWBRIDGE IS, 1991, CURR OPIN CELL BIOL, V3, P634; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; Vera JC, 1996, J BIOL CHEM, V271, P8719, DOI 10.1074/jbc.271.15.8719; Wiedlocha A, 1995, J BIOL CHEM, V270, P30680, DOI 10.1074/jbc.270.51.30680; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611	53	31	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					525	536		10.1038/sj.onc.1201226	http://dx.doi.org/10.1038/sj.onc.1201226			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247306	Green Published			2022-12-28	WOS:A1997XN25500004
J	Bessard, ACH; Garay, E; Lacronique, V; Legros, Y; Demarquay, C; Houque, A; Portefaix, JM; Granier, C; Soussi, T				Bessard, ACH; Garay, E; Lacronique, V; Legros, Y; Demarquay, C; Houque, A; Portefaix, JM; Granier, C; Soussi, T			Regulation of the specific DNA binding activity of Xenopus laevis p53: evidence for conserved regulation through the carboxy-terminus of the protein	ONCOGENE			English	Article						p53; xenopus; manoclonal antibodies; transactivation	TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; MONOCLONAL-ANTIBODIES; STRUCTURAL ASPECTS; GENE EVOLUTION; MURINE P53; CYCLIN-G; MUTANT; TRANSACTIVATION; MUTATIONS	Recombinant human p53 isolated either from E. coli or from insect cells is poorly active for binding to DNA but it can be dramatically stimulated by phosphorylation, antibody binding to the carboxy-terminal negative regulatory domain, short peptides derived from this negative regulatory domain or short single strands of DNA. We report here that Xenopus p53 has a very similar behavior. Using a new set of monoclonal antibodies directed either to the amino- or the carboxy-terminus of Xenopus p53, we demonstrate that the frog protein can be activated by specific carboxy-terminus monoclonal antibodies in order to bind to human p53 DNA response element. In addition, we report that such activation of both humans and frogs protein can also be achieved by small peptides derived from the carboxy-terminus of both p53. Although, the sequence of this region is not conserved in the various p53 species, the presence of conserved basic residues indicates that such activation is charge-dependent. This is confirmed by the finding that small poly-lysine peptides can activate both human and Xenopus p53. In vivo expression of Xenopus p53 indicates that this protein is able to transactivate a wide variety of human p53 response elements as long as the experiments are performed at 32 degrees C since activity at 37 degrees C, a temperature well above the natural temperature of Xenopus, is lost. Finally, we demonstrate that human mdm2 is able to down regulate the transcriptional activity of Xenopus p53.	Inst Genet Mol, INSERM, U301, F-75010 Paris, France; UFR Pharm, CNRS, UMR 9921, F-34060 Montpellier 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Soussi, T (corresponding author), Inst Curie, CNRS, UMR 218, Pavillon Trouillet Rossignol,26 Rue Ulm, F-75231 Paris 05, France.		GRANIER, Claude/A-8841-2008; Penard-Lacronique, Virginie/E-5729-2016; Penard-Lacronique, Virginie/R-1938-2019	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; soussi, thierry/0000-0001-8184-3293				ABARZUA P, 1995, CANCER RES, V55, P3490; Beroud C, 1997, NUCLEIC ACIDS RES, V25, P138, DOI 10.1093/nar/25.1.138; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lane DP, 1996, ONCOGENE, V12, P2461; LEGROS Y, 1993, B CANCER, V80, P102; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1994, ONCOGENE, V9, P3689; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; MIYASHITA T, 1995, CELL, V80, P293; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; RIDGWAY PJ, 1994, J VIROL, V68, P7178, DOI 10.1128/JVI.68.11.7178-7187.1994; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shaw P, 1996, ONCOGENE, V12, P921; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SOUSSI T, 1987, ONCOGENE, V1, P71; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; WAGNER P, 1991, ONCOGENE, V6, P1539; WANG Y, 1995, ONCOGENE, V10, P779; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	45	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					883	890		10.1038/sj.onc.1201598	http://dx.doi.org/10.1038/sj.onc.1201598			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484779				2022-12-28	WOS:000072053200007
J	Greco, A; Fusetti, L; Miranda, C; Villa, R; Zanotti, S; Pagliardini, S; Pierotti, MA				Greco, A; Fusetti, L; Miranda, C; Villa, R; Zanotti, S; Pagliardini, S; Pierotti, MA			Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene	ONCOGENE			English	Article						TRK oncogenes; coiled-coil domain; oncogenic transformation	RECEPTOR TYROSINE KINASE; PROTEIN; OLIGOMERIZATION; DIMERIZATION; LEUKEMIA; CELLS; TEL	The thyroid TRK-T3 oncogene results from the fusion of the tyrosine kinase (TK) domain of NTRK1 (one of the receptors for the Nerve Growth Factor) on chromosome 1 to sequences of a novel gene, TFG, on chromosome 3., The 68 kDa TRK-T3 fusion oncoprotein displays a constitutive tyrosine kinase activity resulting in its capability to transform mouse NIH3T3 cells, The TFG portion of TRK-T3 contains a coiled-coil domain most likely responsible for the constitutive, ligand-independent activation of the receptor tyrosine kinase activity. We have previously shown that TRK-T3 oncoprotein forms, in vivo, complexes of three or four molecules. By mean of different experimental approaches, we show here that TRK-T3 activity depends on oligomers formation, In addition, the analysis of different TRK-T3 mutants indicates that the TFG coiled-coil domain and its N-terminal region are both required for the activation and the fully transforming activity of the TRK-T3 oncoprotein, although, most likely, they play a role in different steps of the transforming process, The deletion of the coiled-coil domain abrogates the oligomers formation leading to a constitutive activation; the deletion of the N-terminal region, although not affecting phosphorylation and complexes formation, abrogates transformation, thus suggesting a role in cellular localization and/or interaction with substrata.	Ist Nazl Tumori, Div Expt Oncol A, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Greco, A (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Via Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349; Zanotti, Simona/0000-0003-4520-4966; Villa, Riccardo/0000-0001-8385-800X				BONGARZONE I, 1989, ONCOGENE, V4, P1457; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GRECO A, 1995, MOL CELL BIOL, V15, P6118; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MENCINGER M, 1997, ONCOGENE, V41, P327; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Tong Q, 1997, J BIOL CHEM, V272, P9043	21	63	65	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					809	816		10.1038/sj.onc.1201596	http://dx.doi.org/10.1038/sj.onc.1201596			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488046				2022-12-28	WOS:000071931800014
J	Bellanger, JM; Lazaro, JB; Diriong, S; Fernandez, A; Lamb, N; Debant, A				Bellanger, JM; Lazaro, JB; Diriong, S; Fernandez, A; Lamb, N; Debant, A			The two guanine nucleotide exchange factor domains of Trio link the Rac1 and the RhoA pathways in vivo	ONCOGENE			English	Article						Trio; GDP/GTP exchange factor; actin; MAP kinases	ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; CDC42 GTPASES; ACTIVATION; KINASE; RAS; ONCOGENE; TRANSFORMATION; FAMILY	Trio contains two functional guanine nucleotide exchange factors (GEF) domains for the Rho-like GTPases and a serine/threonine kinase domain. In vitro, GEF domain 1(GEFD1) is specifically active on Rac1, while GEF domain 2 (GEFD2) targets RhoA. To determine whether Trio could activate Rad and RhoA in vivo, we measured the effect of Trio on Mitogen Activated Protein Kinase (MAPK) pathways and cytoskeletal rearrangments events mediated by the two GTPases. We show that: (i) the GEFD1 domain of Trio triggers the MAPK pathway leading to Jun kinase (JNK) activation and the production of membrane ruffles; (ii) co-expression of the TrioGEFD1 domain with a dominant-negative form of Rac blocked JNK induction, whereas a dominant-negative form of Cdc42 did not; (iii) a deletion mutant of TrioGEFD1 lacking a region important for exchange activity could not stimulate JNK activity; (iv) in contrast, the TrioGEFD2 domain does not stimulate JNK activity and induces the formation of stress fibers, as does activated RhoA; (v) furthermore, co-expression of both GEF domains induces simultaneously the formation of ruffles and stress fibers. Trio, therefore represents a unique member of the Rho-GEFs family possessing two functional domains of distinct specificities, that allow it to link Rho and Rac signaling pathway in vivo.	CNRS, CRBM, ERS155, F-34033 Montpellier 01, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Debant, A (corresponding author), CNRS, CRBM, ERS155, 1919 Route Mende,BP5051, F-34033 Montpellier 01, France.		Bellanger, Jean-Michel/D-1579-2017; Bellanger, Jean-Michel/S-2103-2019	Bellanger, Jean-Michel/0000-0001-9289-2349				BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CERIONE RA, 1996, CURR OPIN CELL BIOL, V6, P216; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Lamb NJC, 1997, METHOD ENZYMOL, V283, P72; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Leung T, 1996, MOL CELL BIOL, V16, P5313; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1996, J MOL MED-JMM, V74, P563, DOI 10.1007/s001090050060; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TOMINAGA T, 1993, J CELL BIOL, V120, P1523; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHENG Y, 1996, J BIOL CHEM, V271, P33269	32	111	112	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					147	152		10.1038/sj.onc.1201532	http://dx.doi.org/10.1038/sj.onc.1201532			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464532				2022-12-28	WOS:000071427100001
J	Edelson, MI; Lau, CC; Colitti, CV; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC				Edelson, MI; Lau, CC; Colitti, CV; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC			A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors	ONCOGENE			English	Article						ovary; cancer; borderline; loss of heterozygosity; chromosome Xq	ANDROGEN-RECEPTOR GENE; HUMAN PROSTATE-CANCER; TERM FOLLOW-UP; X-CHROMOSOME; LINKAGE MAP; MALIGNANCY; MUTATION; CARCINOMAS; HETEROZYGOSITY; PROGRESSION	We have used polymerase chain reaction (PCR) amplification of tandem repeats to study the pattern of allelic loss on chromosome X11.2-q12 in borderline and invasive epithelial ovarian tumors, Using eight microsatellite markers spanning Xq11.2-q12, 41 borderline and 65 invasive ovarian tumors, together with their corresponding normal tissues, were analysed, The highest percentage of loss of heterozygosity (LOH) was observed at the DXS1194 locus in borderline tumors (four of 16 informative cases, 25%) and at the androgen receptor (AR) locus in invasive epithelial ovarian tumors (18 of 47 informative cases, 38%), X chromosome activation studies performed in cases with LOH at the AR locus showed that the allelic loss at the AR locus is not confined to the inactive allele, A one centimorgan region including the AR locus and flanked by the primers DXS1161 and PGK1P1 was identified as the smallest common loss region in both borderline and invasive epithelial ovarian tumors.	Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol, Lab Gynecol Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Texas Childrens Hosp, Div Hematol Oncol, Houston, TX 77030 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Baylor College of Medicine	Mok, SC (corresponding author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol, Lab Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.				NCI NIH HHS [R01CA63381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BARAKAT RR, 1994, OBSTET GYN CLIN N AM, V21, P93; BELL DA, 1994, CANCER, V73, P1859, DOI 10.1002/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO;2-L; BOSTWICK DG, 1986, CANCER, V58, P2052, DOI 10.1002/1097-0142(19861101)58:9<2052::AID-CNCR2820580916>3.0.CO;2-5; CASEY AC, 1993, GYNECOL ONCOL, V50, P316, DOI 10.1006/gyno.1993.1218; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; DODSON MK, 1993, CANCER RES, V53, P4456; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KIM TM, 1994, CANCER RES, V54, P605; LEAKE JF, 1992, CURR OPIN OBSTET GYN, V4, P81; LEAKE JF, 1992, GYNECOL ONCOL, V47, P150, DOI 10.1016/0090-8258(92)90099-5; LOBACCARO JM, 1993, HUM MOL GENET, V2, P1799, DOI 10.1093/hmg/2.11.1799; MOK SCH, 1993, CANCER RES, V53, P1489; NELSON DL, 1995, CYTOGENET CELL GENET, V71, P308; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SCHOENBERG MP, 1994, P ANN M AM ASS CANC, V35, pA1653; SCULLY RE, 1982, B CANCER, V69, P228; Tangir J, 1996, CANCER RES, V56, P2501; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tilley WD, 1996, CLIN CANCER RES, V2, P277; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WEEKS DE, 1995, GENOMICS, V26, P39, DOI 10.1016/0888-7543(95)80080-6; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549	28	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					197	202		10.1038/sj.onc.1201479	http://dx.doi.org/10.1038/sj.onc.1201479			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464537				2022-12-28	WOS:000071427100006
J	Asakura, T; Sasaki, T; Nagano, F; Satoh, A; Obaishi, H; Nishioka, H; Imamura, H; Hotta, K; Tanaka, K; Nakanishi, H; Takai, Y				Asakura, T; Sasaki, T; Nagano, F; Satoh, A; Obaishi, H; Nishioka, H; Imamura, H; Hotta, K; Tanaka, K; Nakanishi, H; Takai, Y			Isolation and characterization of a novel actin filament-binding protein from Saccharomyces cerevisiae	ONCOGENE			English	Article						F-actin; F-actin-binding protein; yeast; ABP140	YEAST SACCHAROMYCES; MEMBRANE INTERACTIONS; CELL-ADHESION; BUD FORMATION; F-ACTIN; CYTOSKELETON; RHO; GTP; MORPHOGENESIS; GENE	We purified a novel actin filament (F-actin)-binding protein from the soluble fraction of Saccharomyces cerevisiae by successive column chromatographies by use of the I-125-labeled F-actin blot overlay method. The purified protein showed a minimum M-r of about 140 kDa on SDS-polyacrylamide gel electrophoresis and we named it ABP140. A search with the partial amino acid sequences of ABP140 against the Saccharomyces Genome Database revealed that the open reading frame of the ABP140 gene (ABP140) corresponded to YOR239W fused with YOR240W by the +1 translational frame shift. The encoded protein consisted of 628 amino acids with a calculated M-r of 71,484. The recombinant protein interacted with F-actin and showed the activity to crosslink F-actin into a bundle. Indirect immunofluorescence study demonstrated that ABP140 was colocalized with both cortical actin patches and cytoplasmic actin cables in intact cells. However, elimination of ABP140 by gene disruption did not show a deleterious effect on cell growth or affect the organization of F-actin. These results indicate that ABP140 is not required for cell growth but may be involved in the reorganization of F-actin in the budding yeast.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 565, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 65122, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.			Nakanishi, Hiroyuki/0000-0002-9765-0266				ADAMS AEM, 1989, SCIENCE, V243, P231, DOI 10.1126/science.2643162; ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; CHIA CP, 1991, CELL MOTIL CYTOSKEL, V18, P164, DOI 10.1002/cm.970180303; COOPER JA, 1982, METHOD ENZYMOL, V85, P182; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gips Sanford J., 1994, Seminars in Cell Biology, V5, P201, DOI 10.1006/scel.1994.1025; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; Madden K, 1992, Trends Cell Biol, V2, P22, DOI 10.1016/0962-8924(92)90140-I; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SHEMATEK EM, 1980, J BIOL CHEM, V255, P895; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKAISHI K, 1997, IN PRESS J CELL BIOL; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; WELCH MD, 1994, CURR OPIN CELL BIOL, V6, P110, DOI 10.1016/0955-0674(94)90124-4; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Zahner JE, 1996, MOL CELL BIOL, V16, P1857	50	85	92	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					121	130		10.1038/sj.onc.1201487	http://dx.doi.org/10.1038/sj.onc.1201487			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467951				2022-12-28	WOS:000071236800015
J	Bartunek, P; Karafiat, V; Dvorakova, M; Zahorova, V; Mandikova, S; Zenke, M; Dvorak, M				Bartunek, P; Karafiat, V; Dvorakova, M; Zahorova, V; Mandikova, S; Zenke, M; Dvorak, M			The Myb leucine zipper is essential for leukemogenicity of the v-Myb protein	ONCOGENE			English	Article						v-myb; leukemia; leucine zipper; protein-protein interaction	MYELOMONOCYTIC GROWTH-FACTOR; C-MYB; TRANSCRIPTIONAL ACTIVATION; MYELOID CELLS; CELLULAR PROGENITOR; MAMMALIAN-CELLS; DNA-BINDING; NF-M; TRANSFORMATION; ONCOGENE	The AMV v-Myb oncoprotein causes oncogenic transformation of myelomonocytic cells in vivo and in vitro, Its transforming capacity is strictly dependent upon the N-terminal DNA binding domain, the central transactivation region, and on the C-terminal domain containing a putative leucine zipper motif, Here we show that the v-Myb(L3.4A) mutant, in which Leu(325) and Leu(332) of the leucine zipper have been replaced by alanines, failed to induce leukemia in virus infected chicken, This demonstrates that the leucine zipper domain is indispensable for v-myb induced leukemogenesis in vivo, v-Myb(L3,3A) was, however, still able to transform myelomonocytic cells from chicken bone marrow in vitro. Yet, while v-myb(L3,4) transformed cells were impaired in growth at 37 degrees C, they failed to grow at 42 degrees C, the physiological body temperature of avian species, This might explain the loss of v-Myb(L3,4A) leukemogenic potential in vivo, We also demonstrate that the v-Myb leucine zipper domain interacts in vitro with two host cell proteins, p26 and p28, This interaction is compromised in v-Myb(L3,4A) indicating that binding of v-Myb to p26 and p28 might be important for the leukemogenic potential of v-Myb.	ACAD SCI CZECH REPUBL,INST MOL GENET,CR-16637 PRAGUE 6,CZECH REPUBLIC; MAX DELBRUCK CTR MOL MED,D-13125 BERLIN,GERMANY	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Bartunek, Petr/J-3897-2014; Dvorak, Michal/G-5861-2014; Škopová, Václava/F-4992-2017; Dvořák, Michal/I-9939-2014	Bartunek, Petr/0000-0002-6202-7650; Škopová, Václava/0000-0002-6560-4177; 				Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; BEUG H, 1995, METHOD ENZYMOL, V254, P41; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CORBEL C, 1992, EXP CELL RES, V203, P91, DOI 10.1016/0014-4827(92)90043-8; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; EBNETH A, 1994, FEBS LETT, V337, P265, DOI 10.1016/0014-5793(94)80205-X; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FAVIER D, 1994, ONCOGENE, V9, P305; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FOOS G, 1993, ONCOGENE, V8, P1775; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Gonda TJ, 1996, CURR TOP MICROBIOL, V211, P99; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HLOZANEK I, 1968, Veterinarni Medicina (Prague), V13, P489; HURST HC, 1995, PROTEIN PROFILE, V2, P105; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KASPERS B, 1993, VET IMMUNOL IMMUNOP, V36, P333, DOI 10.1016/0165-2427(93)90029-4; KAUFMAN J, 1990, J IMMUNOL, V144, P2258; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Lipsick JS, 1996, ONCOGENE, V13, P223; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; OLSON WC, 1994, CELL IMMUNOL, V154, P328, DOI 10.1006/cimm.1994.1081; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P129; STERNECK E, 1992, MOL CELL BIOL, V12, P1728, DOI 10.1128/MCB.12.4.1728; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Vainio O, 1996, J CELL BIOL, V135, P1655, DOI 10.1083/jcb.135.6.1655; VRANOVSKY K, 1992, GENE, V117, P233; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	45	26	26	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2939	2949		10.1038/sj.onc.1201457	http://dx.doi.org/10.1038/sj.onc.1201457			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416837				2022-12-28	WOS:A1997YK37700006
J	Hu, JF; Cheng, ZQ; Chisari, FV; Vu, TH; Hoffman, AR; Campbell, TC				Hu, JF; Cheng, ZQ; Chisari, FV; Vu, TH; Hoffman, AR; Campbell, TC			Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by low protein diet	ONCOGENE			English	Article						hepatitis B virus; dietary protein; IGF2; IGF1; HGF; gene expression	GROWTH-FACTOR-II; PRIMARY HEPATOCELLULAR-CARCINOMA; LARGE ENVELOPE POLYPEPTIDE; INSITU HYBRIDIZATION; PARTIAL-HEPATECTOMY; INTEGRATION SITE; CARRIER STATE; RISK-FACTORS; EXPRESSION; MICE	Persistent infection with hepatitis B virus (HBV) is one of the primary risk factors for human hepatocellular carcinoma (HCC). In a human ecological study, we have shown that, in addition to HBV, animal food consumption also significantly contributes to the variance of HCC. To test the interacting effect of HBV and animal food consumption on the development of HCC, we investigated HBV expression in HBV transgenic mice fed three levels of casein diet. HBV expression in transgenic animals was substantially inhibited when dietary casein was reduced from the traditional level of 22% to the level of 6%. Northern analysis revealed that suppression of HBV was derived from both the; upstream albumin promoter and the internal HBV promoter. Immunochemical staining of liver sections indicated that only a few hepatocytes around the central vein expressed viral surface antigen (HBsAg) in the 6% casein animals, whereas virtually all hepatocytes stained positively for HBsAg in the 22% dietary casein animals. Serum HBsAg concentrations at 4 months were increased by 1.6-, 2.1-, and 5.1-fold over baseline for animals fed the 6%, 14%, and 22% casein diets, respectively. Correspondingly, liver injury was much less severe in animals fed 6% casein diet than in those fed 14% and 22% casein diets. These results demonstrate that a low casein diet is a potent suppresser of HBV transgene and HBV-induced liver injury, suggesting that diet management may be a practical means to aid in the control HBV infection.	VET ADM MED CTR, GRECC, PALO ALTO, CA 94304 USA; STANFORD UNIV, DEPT MED, DIV ENDOCRINOL, PALO ALTO, CA 94304 USA; Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA; CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; Scripps Research Institute; Cornell University	Hu, JF (corresponding author), VET ADM MED CTR, MED SERV, PALO ALTO, CA 94304 USA.		Hu, Jifan/Q-3003-2019; Chisari, Francis V/A-3086-2008	HU, Jifan/0000-0002-2174-0361; Chisari, Francis/0000-0002-4832-1044	NCI NIH HHS [R01-CA34205] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034205] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BEASLEY RP, 1981, LANCET, V2, P1129; BOSCH FX, 1988, IARC SCI PUBLICATION, V89; CAMPBELL TC, 1990, CANCER RES, V50, P6882; CHANG MH, 1991, HEPATOLOGY, V13, P316, DOI 10.1016/0270-9139(91)92446-F; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; CLEMMONS DR, 1991, ANNU REV NUTR, V11, P393, DOI 10.1146/annurev.nu.11.070191.002141; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DIBISCEGLIE AM, 1987, PRINCIPLES PRACT ONC, V1, P1; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; Hu JF, 1996, J BIOL CHEM, V271, P18253, DOI 10.1074/jbc.271.30.18253; *INT AG RES CANC, 1988, IARC MON EV CARC RIS, P416; *INT AG RES CANC, 1987, IARC MON EV CARC RIS, P83; Kew MC, 1996, CLIN LAB MED, V16, P395, DOI 10.1016/S0272-2712(18)30276-2; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; LONDON WT, 1981, HUM PATHOL, V12, P1085, DOI 10.1016/S0046-8177(81)80329-2; LUTWICK LI, 1979, LANCET, V1, P755; Maier JAM, 1996, INT J CANCER, V65, P168, DOI 10.1002/(SICI)1097-0215(19960117)65:2<168::AID-IJC7>3.0.CO;2-X; MAITER D, 1988, J ENDOCRINOL, V118, P113, DOI 10.1677/joe.0.1180113; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PASQUINELLI C, 1994, TRANSGENICS, V1, P451; POPPER H, 1987, HEPATOLOGY, V7, P764, DOI 10.1002/hep.1840070425; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROGLER CE, 1985, SCIENCE, V230, P319, DOI 10.1126/science.2996131; SALLIE R, 1994, GASTROENTEROL CLIN N, V23, P567; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; STRAUS DS, 1990, ENDOCRINOLOGY, V127, P1849, DOI 10.1210/endo-127-4-1849; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; Szmuness W, 1978, Prog Med Virol, V24, P40; TANAKA K, 1995, CANCER CAUSE CONTROL, V6, P91, DOI 10.1007/BF00052768; TANAKA T, 1986, HUM PATHOL, V17, P202; VATANASAPT V, 1995, CANCER EPIDEM BIOMAR, V4, P475; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987; YANG DY, 1991, CARCINOGENESIS, V12, P1893, DOI 10.1093/carcin/12.10.1893; YOUNGMAN LD, 1992, CARCINOGENESIS, V13, P1607, DOI 10.1093/carcin/13.9.1607; YOUNGMAN LD, 1992, CANCER LETT, V66, P165, DOI 10.1016/0304-3835(92)90229-O; YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K	47	19	19	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2795	2801		10.1038/sj.onc.1201444	http://dx.doi.org/10.1038/sj.onc.1201444			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419970				2022-12-28	WOS:A1997YJ80300005
J	Bustelo, XR; Crespo, P; LopezBarahona, M; Gutkind, JS; Barbacid, M				Bustelo, XR; Crespo, P; LopezBarahona, M; Gutkind, JS; Barbacid, M			Cbl-b, a member of the Sli-1/c-Cbl protein family, inhibits Vav-mediated c-Jun N-terminal kinase activation	ONCOGENE			English	Article						Cbl family; Vav; tyrosine phosphorylation; JNK activation	PROTOONCOGENE PRODUCT; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; STEEL FACTOR; SH2 DOMAIN; T-CELLS; BINDING; RECEPTORS; P95(VAV)	We have used the yeast two-hybrid system to identify proteins that interact with Vav, a GDP/GTP exchange factor for the Rac-1 GTPase that plays an important role in cell signaling and oncogenic transformation, This experimental approach resulted in the isolation of Cbl-b, a signal transduction molecule highly related to the mammalian c-cbl proto-oncogene product and to the C. elegans Sli-1 protein, a negative regulator of the EGF-receptor-like Let23 protein, The interaction between Vav and Cbl-b requires the entire SH3-SH2-SH3 carboxy-terminal domain of Vav and a long stretch of proline-rich sequences present in the central region of Cbl-b. Stimulation of quiescent rodent fibroblasts with either epidermal or platelet-derived growth factors induces an increased affinity of Vav for Cbl-b and results in the subsequent formation of a Vav-dependent trimeric complex with the ligand-stimulated tyrosine kinase receptors. During this process, Vav, but not Cbl-b, becomes highly phosphorylated on tyrosine residues, Overexpression of Cbl-b inhibits the signal transduction pathway of Vav that leads to the stimulation of c-Jun N-terminal kinase. By contrast, expression of truncated Cbl-b proteins and of missense mutants analogous to those found in inactive Sli-1 proteins have no detectable effect on Vav activity, These results indicate that Vav and Cbl-b act coordinately in the first steps of tyrosine protein kinase receptor-mediated signaling and suggest that members of the Sli-l/Cbl family are also negative regulators of signal transduction in mammalian cells.	SUNY STONY BROOK,SCH MED,DEPT PATHOL,STONY BROOK,NY 11794; SUNY STONY BROOK,UNIV HOSP,STONY BROOK,NY 11794; NIDR,CELLULAR DEV & ONCOL LAB,NIH,BETHESDA,MD 20892	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Bustelo, XR (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL ONCOL,POB 4000,PRINCETON,NJ 08543, USA.		Gutkind, J. Silvio/J-1201-2016; Bustelo, Xose R./AAD-2081-2022; Gutkind, J. Silvio/A-1053-2009; Bustelo, Xose R./A-9526-2010; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Crespo, Piero/0000-0003-2825-7783				ALAI M, 1992, J BIOL CHEM, V267, P18021; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; BUTELO XR, 1996, CRIT REV ONCOGEN, V7, P65; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRESPO P, 1996, ONCOGENE, V13, P355; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FISHER KD, 1995, NATURE, V374, P474; Hobert O, 1996, ONCOGENE, V12, P1577; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KEANE MM, 1995, ONCOGENE, V10, P2367; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; MACHIDE M, 1995, ONCOGENE, V11, P619; Marengere LEM, 1997, J IMMUNOL, V159, P70; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Romero F, 1996, MOL CELL BIOL, V16, P37; Schuebel KE, 1996, ONCOGENE, V13, P363; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	37	73	77	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2511	2520		10.1038/sj.onc.1201430	http://dx.doi.org/10.1038/sj.onc.1201430			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399639				2022-12-28	WOS:A1997YG73200001
J	Walsh, AB; Dhanasekaran, M; BarSagi, D; Kumar, CC				Walsh, AB; Dhanasekaran, M; BarSagi, D; Kumar, CC			SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway	ONCOGENE			English	Article						RAS; RAC; membrane ruffles; signaling pathways	SIGNAL-TRANSDUCTION; FARNESYLTRANSFERASE INHIBITORS; ACTIN POLYMERIZATION; KINASE; ACTIVATION; PROTEINS; GROWTH; FARNESYLATION; ONCOGENES; INDUCTION	RAS interacts with multiple targets in the cell and controls at least two signaling pathways, one regulating extracellular signal-regulated kinase (ERK) activation and the other controlling membrane ruffling formation. These two pathways appear to act synergistically to cause: transformation. SCH 51344 is a pyrazolo-quinoline derivative identified based on its ability to derepress transformation sensitive alpha-actin promoter in RAS-transformed cells, Previous studies have shown that SCH 51344 is a potent inhibitor of RAS-transformation, However, SCH 51344 had very little effect on the activities of proteins in the ERI( pathway, suggesting that it inhibits RAS-transformation by a novel mechanism. In this study, we show that SCH 51344 specifically blocks membrane ruffling induced by activated forms of H-RAS, II-RAS, N-RAS and RAG. Treatment of fibroblast cells with this compound had very little effect on RAS-mediated activation of ERK and JUN kinase activities. SCH 51344 was effective in inhibiting the anchorage-independent growth of Rat-2 fibroblast cells transformed by the three forms of oncogenic RAS and RBC V12, These results indicate that SCH 51344 inhibits a critical component of the membrane ruffling pathway downstream from RAC and suggest that targeting this pathway may be an effective approach to inhibit transformation by RAS and other oncogenes.	SCHERING PLOUGH CORP,RES INST,DEPT TUMOR BIOL,KENILWORTH,NJ 07033; SUNY STONY BROOK,DEPT MICROBIOL & MOL GENET,STONY BROOK,NY 11794; SUNY STONY BROOK,GRAD PROGRAM PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; TEMPLE UNIV,SCH MED,FELS INST CANC RES,PHILADELPHIA,PA 19140	Merck & Company; Schering Plough Corporation; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA 55360] Funding Source: Medline; NIGMS NIH HHS [GM 49897] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA055360, R01CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; BOS JL, 1989, CANCER RES, V49, P4682; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX LR, 1991, CANCER RES, V51, P4810; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; ITOH O, 1989, CANCER RES, V49, P996; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KUMAR CC, 1995, CANCER RES, V55, P5106; KUMAR CC, 1992, CANCER RES, V52, P6877; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; QUI RG, 1995, NATURE, V374, P457; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459	35	19	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2553	2560		10.1038/sj.onc.1201424	http://dx.doi.org/10.1038/sj.onc.1201424			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399643				2022-12-28	WOS:A1997YG73200005
J	Sherman, L; Xu, HM; Geist, RT; SaporitoIrwin, S; Howells, N; Ponta, H; Herrlich, P; Gutmann, DH				Sherman, L; Xu, HM; Geist, RT; SaporitoIrwin, S; Howells, N; Ponta, H; Herrlich, P; Gutmann, DH			Interdomain binding mediates tumor growth suppression by the NF2 gene product	ONCOGENE			English	Article						merlin; negative growth regulator; tumor suppressor gene; schwannomin; schwannoma; ERM proteins	NEUROFIBROMATOSIS TYPE-2 GENE; TERMINAL DOMAIN; CELL LINES; MUTATIONS; MEMBRANE; RADIXIN; MERLIN; EXPRESSION; LOCALIZES; ISOFORMS	The neurofibromatosis 2 (NF2) tumor suppressor gene encodes an intracellular membrane-associated protein, called merlin (or schwannomin), that belongs to the band 4.1 family of cytoskeleton-associated proteins, Inactivating NF2 mutations occur in several sporadic tumor types and have been linked to the NF2 disease, whose hallmark is the development of bilateral Schwann cell tumors (schwannomas) of the eighth cranial nerve, Two major alternatively spliced NI;2 variants are expressed in normal tissues:'NF2-17 lacking exon 16 and 'NF2-16' that contains exon 16 and encodes a merlin protein truncated at the C-terminus, We report that overexpression of NF2-17 in rat schwannoma cells inhibits their growth in vitro and in vivo, while NF2-16 fails to influence schwannoma growth, Tumor growth inhibition by merlin depends on an interdomain association occurring either in cis or in hans between the N- and C-termini, This association does not occur in the truncated NF2-16 protein nor in a mutant NF2-17 protein lacking C-terminal sequences, These data indicate that merlin has a unique mechanism of tumor suppression, inhibiting cell proliferation via self-association.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; FORSCHUNGSZENTRUM KARLSRUHE,INST GENET,D-76021 KARLSRUHE,GERMANY	Washington University (WUSTL); Helmholtz Association; Karlsruhe Institute of Technology				Gutmann, David/0000-0002-3127-5045				BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BIJISMA E, 1995, HUM GENET, V96, P1; DENBAKKER MA, 1995, ONCOGENE, V10, P757; EVANS DGR, 1995, J MED GENET, V32, P470, DOI 10.1136/jmg.32.6.470; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GUTMANN DH, 1995, HUM MOL GENET, V4, P471, DOI 10.1093/hmg/4.3.471; Gutmann DH, 1995, INT J DEV BIOL, V39, P895; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; HAASE VH, 1994, HUM MOL GENET, V3, P407, DOI 10.1093/hmg/3.3.407; HARA T, 1994, CANCER RES, V54, P330; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MACCOLLIN M, 1994, AM J HUM GENET, V55, P314; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Parry DM, 1996, AM J HUM GENET, V59, P529; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.3.CO;2-2; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; Sherman L, 1995, J NEURO-ONCOL, V26, P171, DOI 10.1007/BF01052620; SHORT MP, 1994, NEUROFIBROMATOSES PA, P414; SWAFFIELD JC, 1996, CURRENT PROTOCOLS MO, pCH20; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TOMOZAWA Y, 1978, P NATL ACAD SCI USA, V75, P6305, DOI 10.1073/pnas.75.12.6305; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G	30	187	189	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2505	2509		10.1038/sj.onc.1201418	http://dx.doi.org/10.1038/sj.onc.1201418			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395247				2022-12-28	WOS:A1997YE96300013
J	Hazzalin, CA; Cuenda, A; Cano, E; Cohen, P; Mahadevan, LC				Hazzalin, CA; Cuenda, A; Cano, E; Cohen, P; Mahadevan, LC			Effects of the inhibition of p38/RK MAP kinase on induction of five fos and jun genes by diverse stimuli	ONCOGENE			English	Article						MAP kinases; p38/RK; fos, jun; SB 203580	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; C-JUN; TRANSCRIPTIONAL ACTIVATION; OKADAIC ACID; HISTONE H3; PHOSPHORYLATION; STRESS; DOMAIN; IDENTIFICATION	The ERK, JNK/SAPK and p38/RK MAP kinase subtypes are differentially activated by physiological, pharmacological and stress stimuli; all three subtypes are implicated in immediate-early (IF) gene induction by these agents, Here, we have asked whether inhibition of a single MAP kinase subtype under these conditions would generally alter induction of several IF genes in a similar way or whether this would differentially up-and down-regulate particular IF genes, an issue which bears on the question of whether individual MAP kinases ape strictly targeted to specific IE genes, or whether they might catalyse phosphorylation events that affect several IF genes in the same way, SB 203580, an inhibitor of p38/RK, has been used to analyse the role of this kinase in the induction of five IF genes (c-fos, fosB, c-jun, junB and junD) under diverse conditions of stimulation, Bn C3H 10T1/2 cells, p38/RK and its downstream kinase MAPKAP K-2 are activated by all stimuli used with the exception of TPA, The specificity of SB 203580 as a p38/RK inhibitor in these cells is demonstrated; it does not affect ERKs or JNK/SAPKs but does result in a small increase in the activity of the upstream kinase MKK6, the principal p38/RK activator in these cells. We find that inhibition of p38/RK under these conditions produces general effects on all five IE genes as a group in three ways, First, induction of all five genes in response to okadaic acid or tumour necrosis factor-alpha (TNF-alpha) is not significantly altered by SB 203580, Second, in cells stimulated with anisomycin or U.V. radiation, SB 203580 potently inhibits all of the induced IE genes. Finally, SB 203580 enhances induction of all five IE genes in EGF-treated cells; these enhanced mRNA levels are not due to stabilisation of labile mRNA transcripts, The significance of these results to current thinking on the relationship between distinct MAP kinase subtypes and specific IF genes is discussed.	UNIV LONDON KINGS COLL,NUCL SIGNALLING LAB,DEV BIOL RES CTR,RANDALL INST,LONDON WC2B 5RL,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,MRC PROTEIN PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of London; King's College London; University of Dundee			Cano, Eva/A-2049-2010	Cano, Eva/0000-0003-2750-6135				ALESSI DR, 1995, P NATL ACAD SCI USA, V92, P7686; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BAYAERT R, 1996, EMBO J, V15, P1914; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CANO E, 1995, J CELL SCI, V108, P3599; Cano E, 1996, ONCOGENE, V12, P805; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CUENDA A, 1996, EMBO J, V15, P4293; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOZA YN, 1995, FEBS LETT, V364, P233; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; PRICE MA, 1996, IN PRESS EMBO J; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; YAN MH, 1994, NATURE, V372, P798; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	60	89	93	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2321	2331		10.1038/sj.onc.1201403	http://dx.doi.org/10.1038/sj.onc.1201403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393876				2022-12-28	WOS:A1997YE15700006
J	Jares, P; Fernandez, PL; Nadal, A; Cazorla, M; Hernandez, L; Pinyol, M; Hernandez, S; Traserra, J; Cardesa, A; Campo, E				Jares, P; Fernandez, PL; Nadal, A; Cazorla, M; Hernandez, L; Pinyol, M; Hernandez, S; Traserra, J; Cardesa, A; Campo, E			p16(MTS1/CDK4I) mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx	ONCOGENE			English	Article						p16(MTS1/CDK4I); LOH 9p21-23; larynx; squamous cell carcinoma	KINASE-4 INHIBITOR GENE; CYCLIN D1 FUNCTION; HUMAN CANCERS; SOMATIC MUTATIONS; NONSMALL CELL; GEL-ELECTROPHORESIS; ALTERED EXPRESSION; PRIMARY TUMORS; LUNG CANCERS; CDKN2 GENE	We have examined the presence of p16(MTS1/CDK4I) gene deletions, mutations and methylation status, and 9p21-23 deletions in a series of 46 squamous cell carcinomas of the larynx and paired normal mucosa previously characterized for cyclin D1 gene amplification and overexpression. pRb expression was also examined by immunohistochemistry. p16(MTS1/CDK4I) mutations were found in 10/46 (22%) carcinomas and hypermethylation in 2/31 (7%). Loss of heterozygosity at 9p21-23 was found in 24 out of 42 (57%) carcinomas examined. All p16(MTS1/CDK4I) mutated cases and the two hypermethylated carcinomas showed 9p21-23 loss of heterozygosity. The loss of heterozygosity correlated with advanced local invasion (P = 0.0045), lymph node metastases (P = 0.0326), stage IV of the tumors (P = 0.0058), and existence of cyclin D1 amplification/overexpression (P < 0.03). Only one out of 37 carcinomas was negative for pRb expression. No alterations in p16 gene or 9p21-23 loss of heterozygosity were detected in this case. These findings indicate that p16(MTS1/CDK4I) is frequently inactivated by gene mutation, hypermethylation, and allelic deletions in a significant subset of squamous cell carcinomas of larynx. Since 9p21-233 loss of heterozygosity was more frequently detected than p16(MTS1/CDK4I) mutations, and mutated carcinomas invariably had loss of heterozygosity, allelic losses probably precede the p16(MTS1/CDK4I) mutations. Their association with cyclin D1 deregulation in advanced carcinomas could indicate a possible cooperative effect in the progression of these neoplasms.	UNIV BARCELONA,HOSP CLIN & PROV BARCELONA,DEPT ANAT PATHOL,E-08007 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN & PROV BARCELONA,DEPT OTOLARYNGOL,E-08007 BARCELONA,SPAIN; UNIV LLEIDA,DEPT BASIC MED SCI,LLEIDA,SPAIN; HOSP CASA MATERNITAT,BARCELONA,SPAIN	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; Universitat de Lleida			Hernandez-Llodra, S/H-6863-2014; Hernandez, Luis/D-4684-2018; Jares, Pedro/T-3778-2019; Fernandez, Pedro L/H-2594-2017; Campo, Elias/AAC-5593-2019	Hernandez-Llodra, S/0000-0003-3963-3756; Hernandez, Luis/0000-0002-4854-3069; Campo, Elias/0000-0001-9850-9793; JARES, PEDRO/0000-0002-8401-579X; Fernandez, Pedro Luis/0000-0002-8618-4597				American Joint Committee on Cancer, 1992, MAN STAG CANC; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; DOLCETTI R, 1992, INT J CANCER, V52, P178, DOI 10.1002/ijc.2910520204; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; GERADTS J, 1994, INT J CANCER, V58, P161, DOI 10.1002/ijc.2910580203; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HERMAN JG, 1995, CANCER RES, V55, P4525; Jares P, 1996, AM J PATHOL, V148, P1591; JARES P, 1994, CANCER RES, V54, P4813; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kwiatkowski David J., 1993, Cytogenetics and Cell Genetics, V64, P93, DOI 10.1159/000133566; LO KW, 1995, CANCER RES, V55, P2039; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, CANCER RES, V55, P4818; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MICHALIDES R, 1995, CANCER RES, V55, P975; MORI T, 1994, CANCER RES, V54, P3396; NADAL A, 1995, J PATHOL, V175, P181, DOI 10.1002/path.1711750205; NAWROZ H, 1994, CANCER RES, V54, P1152; NEVILLE EM, 1995, ONCOGENE, V11, P581; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379; Pinyol M, 1997, BLOOD, V89, P272, DOI 10.1182/blood.V89.1.272.272_272_280; POLLOCK PM, 1995, ONCOGENE, V11, P663; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; PUIG S, 1995, AM J HUM GENET, V57, P395; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHIMIZU T, 1995, INT J CANCER, V63, P616, DOI 10.1002/ijc.2910630503; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAM SW, 1994, ONCOGENE, V9, P2663; TUYNS AJ, 1988, INT J CANCER, V41, P483, DOI 10.1002/ijc.2910410403; Ueki K, 1996, CANCER RES, V56, P150; VANDERRIET P, 1994, CANCER RES, V54, P1156; VANDYKE DL, 1994, GENE CHROMOSOME CANC, V9, P192, DOI 10.1002/gcc.2870090308; Yang R, 1996, BIOCHEM BIOPH RES CO, V218, P254, DOI 10.1006/bbrc.1996.0045; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737	50	47	48	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1445	1453		10.1038/sj.onc.1201309	http://dx.doi.org/10.1038/sj.onc.1201309			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333020				2022-12-28	WOS:A1997XW41100008
J	Kogerman, P; Sy, MS; Culp, LA				Kogerman, P; Sy, MS; Culp, LA			Counter-selection for over-expressed human CD44s in primary tumors versus lung metastases in a mouse fibrosarcoma model	ONCOGENE			English	Article						CD44; metastasis; nude mice; 3T3; sis	SPLICE VARIANTS; 3T3 CELLS; PROGRESSION; DEGRADATION; ONCOGENE; CANCER; GROWTH; HYALURONAN; CARCINOMAS; ISOFORMS	Human CD44 standard isoform cDNA (hCD44s) was transfected into sis-transformed Balb/c 3T3 cells and into ras-revertant IIIA4 cells (both tumorigenic but nonmetastatic). Transfectants were injected subcutaneously into athymic nude mice to elucidate the functional role of hCD44s over-expression in progression and metastasis. The transfectants (but not parental cells) vr ere capable of lung micrometastasis and of binding exogenously-added hyaluronan. hCD44s protein expression was conserved in lung micrometastases suggesting that it may have been necessary for their formation. In contrast, no hCD44s protein was detected in large subcutaneous (s.c.) tumors but normal levels of murine CD44 were detected. A second round of tumor development, using these two tumor cell classes, demonstrated that hCD44s-nonexpressing s.c. tumor cells re-expressed it in lung micrometastases. Conversely, hCD44s-expressing lung micrometastatic cells, when injected into a second group of mice, downregulated hCD44s expression in order to grow sizable s.c. tumors. S.c. tumor cells still contained the hCD44s gene but its expression was inhibited by epigenetic mechanisms, one of which was shown to be methylation of the hCD44s gene. These studies demonstrate (a) opposing selective pressures on CD44s over-expression for s.c. tumor growth and for metastatic spread to the lung and (b) further credence for the significance of CD44 for metastatic spread of fibrosarcomas. Therefore, CD44s may he a critical component of the metastatic phenotype induced by specific oncogenes.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PATHOL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University			Kogerman, Priit/B-6333-2008		NCI NIH HHS [CA27755, CA60469] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA060469, R01CA027755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CULTY M, 1994, J CELL PHYSIOL, V160, P275, DOI 10.1002/jcp.1041600209; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; FIDLER IJ, 1994, CANCER METAST REV, V13, P209, DOI 10.1007/BF00689637; FOX SB, 1994, CANCER RES, V54, P4539; GOROWSKI JJ, 1995, J BIOL CHEM, V270, P26940; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUO YJ, 1994, CANCER RES, V54, P1561; GUO YJ, 1993, CELL IMMUNOL, V152, P186, DOI 10.1006/cimm.1993.1278; HEIDER KH, 1993, CANCER RES, V53, P4197; HOUCHENS DP, 1978, P S USE ATHYMIC NUDE, P267; Jackson PA, 1995, J CLIN PATHOL, V48, P1098, DOI 10.1136/jcp.48.12.1098; Kogerman P, 1996, CLIN EXP METASTAS, V14, P73, DOI 10.1007/BF00157688; Kogerman P, 1996, J CELL PHYSIOL, V169, P341, DOI 10.1002/(SICI)1097-4652(199611)169:2<341::AID-JCP13>3.3.CO;2-M; Kogerman P, 1997, INT J ONCOL, V10, P553; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LEWIN DI, 1996, J NIH RES, V8, P24; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; NICOLSON GL, 1993, EXP CELL RES, V204, P171, DOI 10.1006/excr.1993.1022; RADINSKY R, 1992, In Vivo (Attiki), V6, P325; RADINSKY R, 1987, P NATL ACAD SCI USA, V84, P5143, DOI 10.1073/pnas.84.15.5143; RADINSKY R, 1991, INT J CANCER, V48, P148; RUDY W, 1993, CANCER RES, V53, P1262; Sambrook J., 2002, MOL CLONING LAB MANU; Sinn Hans-Peter, 1995, Breast Cancer Research and Treatment, V36, P307, DOI 10.1007/BF00713402; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; Weiss L, 1990, Adv Cancer Res, V54, P159, DOI 10.1016/S0065-230X(08)60811-8; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; WIELENGA VJM, 1993, CANCER RES, V53, P4754	31	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1407	1416		10.1038/sj.onc.1201306	http://dx.doi.org/10.1038/sj.onc.1201306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333016				2022-12-28	WOS:A1997XW41100004
J	Schreiber, M; Poirier, C; Franchi, A; Kurzbauer, R; Guenet, JL; Carle, GF; Wagner, EF				Schreiber, M; Poirier, C; Franchi, A; Kurzbauer, R; Guenet, JL; Carle, GF; Wagner, EF			Structure and chromosomal assignment of the mouse fra-1 gene, and its exclusion as a candidate gene for oc (osteosclerosis)	ONCOGENE			English	Article						AP-1 target gene; Fos gene family; Fos11 genomic locus; fra-1; MMU 19; osteosclerosis (oc)	TRANSCRIPTION FACTOR AP-1; FOS-TRANSGENIC MICE; LACKING C-FOS; REGULATORY FUNCTION; CELL-PROLIFERATION; MAP; TRANSFORMATION; EXPRESSION; REGION; BONE	We have determined the genomic structure of the mouse fra-1 gene, which consists of four exons and three introns at positions also found in the other members of the fos gene family, Fra-1 is expressed rather highly in the brain and testes of adult mice, and at low levels in most other tissues, Absence of c-Fos leads to significantly reduced serum stimulation of fra-1 expression in gene targeted mouse fibroblasts, demonstrating that mitogen induction of fra-1 is partially mediated by c-Fos/AP-1. A polymorphic (CA)(n) microsatellite marker was found in intron 2 of fra-1 and used to map the gene to the centromeric region of mouse chromosome 19, Since fra-1 maps to the same genomic region as oc (osteosclerosis), an autosomal recessive disorder leading to the bone remodelling disease osteopetrosis, we tested it as a candidate gene for oc, The segregation of fra-1 in two different crosses of mice carrying oc and an allelism test between oc and a targeted disruption of fra-1 demonstrate that fra-1 and oc are two distinct genes rather than oc being a mutant allele of fra-1.	RES INST MOL PATHOL, A-1030 VIENNA, AUSTRIA; INST PASTEUR, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE; UNIV NICE, FAC MED, LAB ETUD GENOME MURIN, CNRS, UMR 6549, F-06107 NICE 2, FRANCE	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Martin, Schreiber/F-2175-2013; Carle, Georges/GWC-5240-2022	Martin, Schreiber/0000-0003-1102-7789; Wagner, Erwin F/0000-0001-7872-0196; Carle, Georges/0000-0002-3901-1052				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BROOKES S, 1992, GENE CHROMOSOME CANC, V4, P290, DOI 10.1002/gcc.2870040404; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1993, ONCOGENE, V8, P443; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; DEUSTACHIO P, 1984, J EXP MED, V160, P827, DOI 10.1084/jem.160.3.827; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FOLETTA VC, 1994, ONCOGENE, V9, P3305; GACK S, 1994, J BIOL CHEM, V269, P10363; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GROSKOPF JC, 1994, MOL CELL BIOL, V14, P6013, DOI 10.1128/MCB.14.9.6013; HSU JC, 1993, CANCER RES, V53, P3789; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MARKS SC, 1985, J HERED, V76, P171, DOI 10.1093/oxfordjournals.jhered.a110059; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; SCHREIBER M, 1996, THESIS VIENNA; Silver L. M., 1995, MOUSE GENETICS; SINKE RJ, 1993, GENOMICS, V18, P165, DOI 10.1006/geno.1993.1447; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TANIGAMI A, 1992, GENOMICS, V13, P16, DOI 10.1016/0888-7543(92)90195-X; UDAGAWA N, 1992, BIOCHEM BIOPH RES CO, V184, P67, DOI 10.1016/0006-291X(92)91158-M; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WISDOM R, 1993, MOL CELL BIOL, V13, P2635, DOI 10.1128/MCB.13.5.2635; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	40	36	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1171	1178		10.1038/sj.onc.1201460	http://dx.doi.org/10.1038/sj.onc.1201460			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294610				2022-12-28	WOS:A1997XU99100006
J	Flajolet, M; Gegonne, A; Ghysdael, J; Tiollais, P; Buendia, MA; Fourel, G				Flajolet, M; Gegonne, A; Ghysdael, J; Tiollais, P; Buendia, MA; Fourel, G			Cellular and viral trans-acting factors modulate N-myc2 promoter activity in woodchuck liver tumors	ONCOGENE			English	Article						N-myc2; woodchucks; IL-6	INTERLEUKIN-6 RESPONSE ELEMENT; HEPATITIS-VIRUS; HEPADNAVIRUS INSERTION; MYC; EXPRESSION; ACTIVATION; PROTEIN; FAMILY; CELLS; GENE	Activation of the N-myc2 oncogene by integration of woodchuck hepatitis virus (WHV) DNA is a central event in woodchuck liver oncogenesis, In this study, we have evaluated the influence of several cellular and viral tr ans-acting factors and mediators of inflammation on N-myc2 promoter activity in hepatoma cell lines, Ets oncoproteins, including Ets1, Ets2 and PEA3 efficiently activated a chimeric N-myc2 promoter/luciferase reporter gene, By electrophoretic mobility shift assays, we show that Ets1 and Ets2 proteins can efficiently bind two consensus Ets sites located within a 59 bp sequence upstream of the N-myc2 transcription start site, Site-directed mutagenesis of these Ets-binding motifs abolished transactivation of the N-myc2 promoter by Ets proteins, Addition of interleukin-6 (IL-6) induced a weak but reproducible activation of the N-myc2 promoter, while IL-1 was ineffective, We further show that the N-myc2 promoter can be transactivated by the hepadnavirus X protein, and that distal promoter sequences are required for both IL-6 and X responsiveness, Similar effects of these factors were observed in the context of the N-myc2 promoter activated by WHV cis-regulatory elements, In view of the high-level expression of the N-myc2 oncogene in most woodchuck liver tumors, the Ets oncoproteins, inflammation-associated cytokine IL-6 and the viral X transactivator might play important roles in hepadnavirus-associated tumorigenesis.	CTR UNIV ORSAY, CNRS URA 1443, F-91405 ORSAY, FRANCE	UDICE-French Research Universities; Universite Paris Saclay	Flajolet, M (corresponding author), INST PASTEUR, INSERM U163, UNITE RECOMBINAISON & EXPRESS GENET, F-75724 PARIS, FRANCE.		GHYSDAEL, Jacques/F-3377-2013					BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FLAJOLET M, 1997, IN PRESS VIRAL HEPAT; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; Fourel G, 1996, J VIROL, V70, P8571, DOI 10.1128/JVI.70.12.8571-8583.1996; FOUREL G, 1994, LIVER GENE EXPRESSIO, P297; GIRONES R, 1989, P NATL ACAD SCI USA, V86, P1846, DOI 10.1073/pnas.86.6.1846; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; POLI V, 1994, LIVER GENE EXPRESSIO, P131; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; STEMMER WPC, 1992, BIOTECHNIQUES, V13, P214; TOSHKOV I, 1990, J CANCER RES CLIN, V116, P581, DOI 10.1007/BF01637078; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; Ueda K, 1996, J VIROL, V70, P4714, DOI 10.1128/JVI.70.7.4714-4723.1996; Ueda K, 1996, VIROLOGY, V217, P413, DOI 10.1006/viro.1996.0133; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang BS, 1996, MOL CELL BIOL, V16, P538; YANG D, 1993, CANCER RES, V53, P2020; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	41	13	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1103	1110		10.1038/sj.onc.1201257	http://dx.doi.org/10.1038/sj.onc.1201257			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285565				2022-12-28	WOS:A1997XT16100012
J	Narducci, MG; Virgilio, L; Engiles, JB; Buchberg, AM; Billips, L; Facchiano, A; Croce, CM; Russo, G; Rothstein, JL				Narducci, MG; Virgilio, L; Engiles, JB; Buchberg, AM; Billips, L; Facchiano, A; Croce, CM; Russo, G; Rothstein, JL			The murine Tcl1 oncogene: embryonic and lymphoid cell expression	ONCOGENE			English	Article						ATM; ataxia-telangiectasia; TCL1; chronic lymphocytic leukemia; MTCP1; T-PLL	T-PROLYMPHOCYTIC LEUKEMIA; ATAXIA-TELANGIECTASIA; MOLECULAR ANALYSIS; CHROMOSOME; GENE; TRANSLOCATIONS; LOCUS; BREAKPOINT; RECEPTOR; PATIENT	In human leukemias and lymphomas nonrandom chromosomal rearrangements cause changes in cell growth and/or survival in such a way as to promote malignancy, The detailed study of the biochemical and genetic pathways altered in human cancer requires the identification or development of models to allow the study and manipulation of cancer gene function, Recently, the breakpoint gene TCL1, involved in chromosome translocations observed mostly in mature T-cell proliferations and chronic lymphocytic leukemias (CLL), was isolated and characterized, and showed to be part of a new gene family of proteins involved in these tumors, The murine Tcl1 gene, is similar in sequence to the murine and human MTCP1 gene also involved in T cell leukemias, The murine Tcl1 gene was shown to reside on mouse chromosome 12 in a region syntenic to human chromosome 14, Furthermore, we show that the murine Tcl1 gene is expressed early in mouse embryonic development and demonstrates expression in fetal hematopoietic organs as well as in immature T and B cells, Characterization of the murine Tcl1 gene will help in developing a mouse model of CLL and would provide the best opportunity to study and decipher the role of TCL1 in malignant transformation.	THOMAS JEFFERSON MED COL,KIMMEL CANC INST,DEPT MICROBIOL IMMUNOL,PHILADELPHIA,PA 19107; IRCCS,IST DERMOPAT IMMACOLATA,I-00167 ROME,ITALY; THOMAS JEFFERSON MED COL,KIMMEL CANC INST,DEPT OTOLARYNGOL HEAD & NECK SURG,PHILADELPHIA,PA 19107; UNIV ALABAMA,HOWARD HUGHES MED INST,BIRMINGHAM,AL 35294	Jefferson University; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Jefferson University; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham			Engiles, Julie/K-1916-2015; Facchiano, Antonio/K-5984-2016; Facchiano, Antonio/J-4744-2012; Young, Richard A/F-6495-2012; Russo, Giandomenico/K-9566-2016; Narducci, Maria Grazia/L-3093-2018	Engiles, Julie/0000-0001-9057-2093; Facchiano, Antonio/0000-0002-4243-2392; Facchiano, Antonio/0000-0002-4243-2392; Young, Richard A/0000-0001-8855-8647; Russo, Giandomenico/0000-0002-7718-9687; Narducci, Maria Grazia/0000-0002-9066-186X; Narducci, Maria Grazia/0000-0002-8877-4611; Buchberg, Arthur/0000-0002-0543-5631	NCI NIH HHS [CA-56336, CA-39869, CA-21124] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA021124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAER R, 1987, P NATL ACAD SCI USA, V84, P9069, DOI 10.1073/pnas.84.24.9069; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BERTNESS VL, 1990, CANCER GENET CYTOGEN, V44, P47, DOI 10.1016/0165-4608(90)90196-H; BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; BRUNNING RD, 1991, BLOOD, V78, P3111; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CIMINO G, 1991, CANCER RES, V51, P6712; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; CROCE CM, 1991, ORIGINS OF HUMAN CANCER, P527; DIETRICH W, 1992, GENETICS, V131, P423; Freeman SJ, 1990, POSTIMPLANTATION MAM, P249; FU TB, 1994, CANCER RES, V54, P6297; Green MC., 1989, GENETIC VARIANTS STR, P12; HEIM S, 1987, CANC CYTOGENETICS; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; ISOBE M, 1985, SCIENCE, V228, P580, DOI 10.1126/science.3983641; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Madani A, 1996, BLOOD, V87, P1923; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; NADEAU JH, 1992, MAMM GENOME, V3, P480, DOI 10.1007/BF00778825; NAGASAKA M, 1983, BLOOD, V61, P1174; NARDUCCI MG, 1995, BLOOD, V86, P2358, DOI 10.1182/blood.V86.6.2358.bloodjournal8662358; ROTHSTEIN JL, 1993, METHOD ENZYMOL, V225, P587; ROTHSTEIN JL, 1992, GENE DEV, V6, P1190, DOI 10.1101/gad.6.7.1190; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; Sambrook J., 2002, MOL CLONING LAB MANU; SAVAGE PD, 1988, CYTOGENET CELL GENET, V49, P289, DOI 10.1159/000132680; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; STAATS J, 1981, MOUSE BIOCH RES, P177; STERN MH, 1993, ONCOGENE, V8, P2475; TAYLOR AM, 1992, ATAXIA TELANGIECTASI, P53; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P925; WEI S, 1990, CANCER GENET CYTOGEN, V46, P1, DOI 10.1016/0165-4608(90)90002-R; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WOLF FW, 1994, J BIOL CHEM, V269, P3633	42	32	34	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					919	926		10.1038/sj.onc.1201246	http://dx.doi.org/10.1038/sj.onc.1201246			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285687				2022-12-28	WOS:A1997XR76700005
J	Ogris, E; Gibson, DM; Pallas, DC				Ogris, E; Gibson, DM; Pallas, DC			Protein phosphatase 2A subunit assembly: the catalytic subunit carboxy terminus is important for binding cellular B subunit but not polyomavirus middle tumor antigen	ONCOGENE			English	Article						phosphatase; PP2A; polyomavirus middle tumor antigen	SMALL-T-ANTIGEN; A-SUBUNIT; TYROSINE PHOSPHORYLATION; REGULATORY SUBUNITS; DNA-REPLICATION; TYPE-2A; IDENTIFICATION; KINASE; GROWTH; FORMS	The carboxy terminus of protein phosphatase 2A (PP2A) catalytic subunit is highly conserved. Seven out of the last nine residues, including two potential in vivo phosphorylation sites, threonine 304 and tyrosine 307, are completely invariant in all known PP2As, Mutational analysis of the carboxy terminus in vivo was facilitated by efficient immunoprecipitation of trimeric PP2A holoenzyme via an epitope-tagged catalytic subunit, The results indicate that the catalytic submit carboxy terminus is important for complex formation with the PP2A 55 kDa regulatory B subunit, but not with polyomavirus oncogene, middle tumor antigen (MT), a viral B-type regulatory subunit, Replacing catalytic subunit threonine 304 or tyrosine 307 with a negatively charged amino acid abolished binding of the B subunit to the dimeric enzyme core and altered substrate specificity, Certain other amino acid substitutions of different size and/or charge also abolished or greatly reduced B subunit binding, Substitution of alanine at position 304 or phenylalanine at position 307 did not dramatically reduce B subunit binding or phosphatase activity in vitro, yet the latter substitutions are not found in naturally occurring PP2As, Thus, the wild-type residues are important for a yet unknown function in vivo, Additionally, deleting the carboxy terminal nine amino acids inhibited binding of the B subunit to the dimeric enzyme core, indicating a requirement for one or more of these amino acids for complex formation, MT interaction with the dimeric PP2A enzyme core was not inhibited by any of these mutations, Finally, unlike B subunit, MT does not activate the phosphatase activity of the PP2A heterodimer towards cdc2-phosphorylated histone HI.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Ogris, Egon/0000-0001-5950-9264	NCI NIH HHS [CA57327, R01 CA057327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CAYLA X, 1993, EUR J BIOCHEM, V214, P281, DOI 10.1111/j.1432-1033.1993.tb17922.x; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; FAVRE B, 1994, J BIOL CHEM, V269, P16311; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Harlow E., 1988, ANTIBODIES LAB MANUA; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1993, J BIOL CHEM, V268, P19192; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; Sambrook J., 2002, MOL CLONING LAB MANU; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; UEMURA T, 1993, GENE DEV, V7, P429, DOI 10.1101/gad.7.3.429; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; USUI H, 1988, J BIOL CHEM, V263, P3752; XIE HY, 1994, J BIOL CHEM, V269, P1981	45	109	111	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					911	917		10.1038/sj.onc.1201259	http://dx.doi.org/10.1038/sj.onc.1201259			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285686				2022-12-28	WOS:A1997XR76700004
J	Zong, WX; Farrell, M; Bash, J; Gelinas, C				Zong, WX; Farrell, M; Bash, J; Gelinas, C			v-Rel prevents apoptosis in transformed lymphoid cells and blocks TNF alpha-induced cell death	ONCOGENE			English	Article						v-Rel; apoptosis; cell transformation; tetracycline-regulation	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; RECEPTOR FUSION PROTEIN; CHICKEN SPLEEN-CELLS; RETICULOENDOTHELIOSIS VIRUS; ESTROGEN-RECEPTOR; MAMMALIAN-CELLS; GENE-EXPRESSION; FAMILY; DNA	The v-Rel oncoprotein belongs to the Rel/NF-kappa B family of transcription factors, It transforms chicken lymphoid cells in vitro and induces fatal lymphomas in vivo, In this study, we used a tetracycline-regulated system to characterize the role of v-Rel in cell transformation. We show that the continued expression of v-Rel is necessary to maintain the viability of transformed lymphoid cells and enables primary spleen cells to escape apoptosis in vitro culture. In agreement with a possible role for v-Rel in the inhibition of programmed cell death, its inducible expression in HeLa cells prevented TNF alpha-induced apoptosis, While the repression of v-Rel was accompanied by the rapid degradation of I kappa B alpha, changes in the steady-state levels of the apoptosis inhibitors Bcl-2 and Bcl-X-L were only observed following the onset of cell death in transformed lymphoid cells. This suggests that the anti-apoptotic activity of v-Rel may affect other apoptosis inhibitors or other factors in the death pathway, Together, these findings demonstrate that v-Rel blocks apoptosis and suggest that this activity may be an important component of its transforming function.	UNIV MED & DENT NEW JERSEY,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,GRAD PROGRAM BIOCHEM & MOL BIOL,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,GRAD PROGRAM MICROBIOL & MOL GENET,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CANC INST NEW JERSEY,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey					NCI NIH HHS [CA54999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054999, R01CA054999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERNARD HU, 1985, EXP CELL RES, V158, P237, DOI 10.1016/0014-4827(85)90446-X; BHAT GV, 1990, ONCOGENE, V5, P625; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; Gilmore TD, 1996, ONCOGENE, V13, P1367; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; Houldsworth J, 1996, BLOOD, V87, P25; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LU D, 1991, ONCOGENE, V6, P1235; LUQUE I, 1997, IN PRESS SEMIN CANC, V8; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RUBIN BY, 1988, CANCER RES, V48, P6006; SACHDEV S, 1997, IN PRESS ONCOGENE, V14; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1996, ONCOGENE, V13, P891; WHITE DW, 1995, ONCOGENE, V10, P857; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733	54	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					971	980		10.1038/sj.onc.1201266	http://dx.doi.org/10.1038/sj.onc.1201266			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285692				2022-12-28	WOS:A1997XR76700010
J	Kim, E; Albrechtsen, N; Deppert, W				Kim, E; Albrechtsen, N; Deppert, W			DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53	ONCOGENE			English	Article						p53 DNA binding; DNA conformation; p53 conformation; p53 consensus sequence	WILD-TYPE; GENE-EXPRESSION; PROTEIN; TRANSCRIPTION; NUCLEI; IDENTIFICATION; ENHANCER; ELEMENT; DOMAIN; CELLS	Sequence-specific transactivation of target genes is one of the most important molecular properties of the tumor suppressor p53. Binding of p53 to its target DNAs is tightly regulated, with modifications in the carboxyterminal regulatory domain of the p53 protein playing an important role. In this study we examined the possible influence of DNA structure on sequence-specific DNA binding by p53, by analysing its binding to p53 consensus elements adopting different conformations. We found that p53 has the ability to bind to consensus elements which are present in a double-helical form, as well as to consensus elements which are located within alternative non-B-DNA structures. The ability of a consensus element to adopt either one of these conformations is dependent on its sequence symmetry, and is strongly influenced by its sequence environment. Our data suggest a model according to which the conformational status of the target DNA is an important determinant for sequence-specific DNA binding by p53. Modifications in the carboxy-terminal regulatory region of p53 possibly determine the preference of p53 for a given DNA conformation.	UNIV HAMBURG,HEINRICH PETTE INST EXPT VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg			Holst, Jens/AAA-8022-2022					Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DAYN A, 1992, NUCLEIC ACIDS RES, V20, P5991, DOI 10.1093/nar/20.22.5991; DELIC J, 1991, BIOCHEM BIOPH RES CO, V181, P818, DOI 10.1016/0006-291X(91)91263-C; Deppert W, 1996, J CELL BIOCHEM, V62, P172, DOI 10.1002/(SICI)1097-4644(199608)62:2<172::AID-JCB5>3.0.CO;2-P; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P185; DROGE P, 1994, BIOESSAYS, V16, P91, DOI 10.1002/bies.950160205; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Flaman JM, 1996, ONCOGENE, V12, P813; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HANKE JH, 1995, J MOL BIOL, V246, P63, DOI 10.1006/jmbi.1994.0066; Hecker D, 1996, ONCOGENE, V12, P953; HERBERT AG, 1993, P NATL ACAD SCI USA, V90, P3339, DOI 10.1073/pnas.90.8.3339; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEITH IR, 1993, BIOCHEM BIOPH RES CO, V196, P601, DOI 10.1006/bbrc.1993.2292; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MAYFIELD C, 1994, NUCLEIC ACIDS RES, V22, P1909, DOI 10.1093/nar/22.10.1909; MCCLELLAN JA, 1990, P NATL ACAD SCI USA, V87, P8373, DOI 10.1073/pnas.87.21.8373; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MIYASHITA T, 1995, CELL, V80, P293; Muller BF, 1996, ONCOGENE, V12, P1941; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; PEARSON CE, 1995, EMBO J, V14, P1571, DOI 10.1002/j.1460-2075.1995.tb07143.x; PRIVES C, 1994, COLD SPRING HARB SYM, V59, P207, DOI 10.1101/SQB.1994.059.01.025; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SOLARO P, 1995, EUR J BIOCHEM, V230, P926, DOI 10.1111/j.1432-1033.1995.tb20638.x; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; SPIRO C, 1995, J BIOL CHEM, V270, P27702, DOI 10.1074/jbc.270.46.27702; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WANG Y, 1995, ONCOGENE, V10, P779; WARD GK, 1991, EXP CELL RES, V195, P92, DOI 10.1016/0014-4827(91)90503-M; WARD GK, 1990, EXP CELL RES, V188, P235, DOI 10.1016/0014-4827(90)90165-7; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1996, CANCER RES, V56, P158; WEISSKER S, 1992, ONCOGENE, V7, P155; WITTIG B, 1989, J CELL BIOL, V108, P755, DOI 10.1083/jcb.108.3.755; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhao JQ, 1996, ONCOGENE, V13, P293	70	54	55	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					857	869		10.1038/sj.onc.1201412	http://dx.doi.org/10.1038/sj.onc.1201412			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266973				2022-12-28	WOS:A1997XQ11700013
J	Finkenzeller, G; Sparacio, A; Technau, A; Marme, D; Siemeister, G				Finkenzeller, G; Sparacio, A; Technau, A; Marme, D; Siemeister, G			Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression	ONCOGENE			English	Article						PDGF; promoter; Sp1; tumor angiogenesis; VEGF	SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; TRANSCRIPTIONAL ACTIVATION; TUMOR ANGIOGENESIS; PERMEABILITY FACTOR; MESSENGER-RNA; BINDING; INDUCTION; HYPOXIA; INVIVO	Stimulation of NIH3T3 cells with platelet-derived growth factor (PDGF)-BB enhances expression of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen and a key mediator of tumor angiogenesis. Here, we identified cis-acting VEGF promoter elements and trans-acting factors which are involved in PDGF-stimulated VEGF expression. By 5'-deletion and transient transfection analysis, a G + C-rich region at -85 to -50 of the human VEGF promoter was shown to be necessary and sufficient for both PDGF inducible and basal expression. The region contains three potential recognition sites for Spl transcription factors, which overlap with two Egr-1 sites. Mutations that abolish the ability of Spl to interact with the VEGF promoter element also abrogate expression induced by PDGF. Mutations of the potential Egr-1 binding sites did not affect PDGF responsiveness. Gel shift and antibody supershift analyses showed that Spl and Sp3 interact constitutively with the VEGF promoter element. Our data strongly suggest that enhanced VEGF gene expression in PDGF-induced NIH3T3 cells is mediated by Spl and/or Sp3 transcription factors bound to the -85 to -50 promoter region of the VEGF gene.	TUMOR BIOL CTR, INST MOL MED, D-79106 FREIBURG, GERMANY					, Gerhard/0000-0002-4712-0531				ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BASHEERUDDIN K, 1995, ARTERIOSCL THROM VAS, V15, P1248, DOI 10.1161/01.ATV.15.8.1248; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARSH GR, 1990, J NEURO-ONCOL, V8, P1; HECHT A, 1990, THESIS HEIDELBERG GE; HERMANSON M, 1992, CANCER RES, V52, P3213; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Janknecht R, 1996, ONCOGENE, V12, P1961; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KIESER A, 1994, ONCOGENE, V9, P963; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; Liang YX, 1996, ONCOGENE, V13, P863; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAJELLO B, 1995, ONCOGENE, V10, P1841; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAK J, 1995, CANCER RES, V55, P4575; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Siemeister G, 1996, CANCER RES, V56, P2299; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WEINDEL K, 1994, NEUROSURGERY, V35, P439, DOI 10.1227/00006123-199409000-00012	55	183	185	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	1997	15	6					669	676		10.1038/sj.onc.1201219	http://dx.doi.org/10.1038/sj.onc.1201219			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264407				2022-12-28	WOS:A1997XP68300006
J	Miyake, H; Hanada, N; Nakamura, H; Kagawa, S; Fujiwara, T; Hara, I; Eto, H; Gohji, K; Arakawa, S; Kamidono, S; Saya, H				Miyake, H; Hanada, N; Nakamura, H; Kagawa, S; Fujiwara, T; Hara, I; Eto, H; Gohji, K; Arakawa, S; Kamidono, S; Saya, H			Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer	ONCOGENE			English	Article						Bcl-2; cisplatin; adenoviral-mediated p53 gene transfer; apoptosis; bladder cancer	WILD-TYPE P53; IN-VIVO; LUNG-CANCER; P53-DEPENDENT APOPTOSIS; RECOMBINANT ADENOVIRUS; DNA-BINDING; CARCINOMA; EXPRESSION; THERAPY; RESISTANCE	To investigate the effects of the expression of Bcl-2 protein in bladder cancer on the apoptosis induced by cisplatin or adenoviral-mediated p53 gene (Ad5CMV-p53) transfer, we transfected the bcl-2 gene into KoTCC-1, a human bladder cancer cell line that does not express the Bcl-2 protein. The Bcl-2-transfected KoTCC-1 (KoTCC-1/B) exhibited significantly higher resistance to both cisplatin and Ad5CMV-p53 transfer than did either the parental KoTCC-1 (KoTCC-1/P) or the vector-only transfected cell line (KoTCC-1/C). The flow cytometric analysis of the propidium iodide-stained nuclei and DNA fragmentation analysis after cisplatin or Ad5CMV-p53 treatment revealed DNA degradation in both KoTCC-1/P and KoTCC-1/C, whereas KoTCC1/B showed a marked inhibition of DNA degradation. Following the treatment with cisplatin or Ad5CMV-p53, the accumulation of p53 protein was highly detectable for a long period in KoTCC-1/B compared to that in KoTTC-1/P and KoTCC-1/C. Furthermore, the cisplatin and Ad5CMV-p53 treatments each reduced the volume of the subcutaneous tumors established in nude mice formed by KoTCC-1/P or KoTCC-1/C; in contrast, their reductive effects on the tumors formed by KoTCC-1/B were significantly suppressed. The intraperitoneal tumor cell implantation model revealed that the prognoses of mice injected with KoTCC-1/B were significantly inferior to those of the mice injected with either KoTCC-1/P or KoTCC-1/C after treatment with cisplatin or Ad5CMV-p53. These findings suggest that the expression of Bcl-2 in bladder cancer cells interferes with the therapeutic effects of cisplatin and Ad5CMV-p53 through the inhibition of the apoptotic pathway.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 860, Japan; Kobe Univ, Sch Med, Dept Urol, Kobe, Hyogo 650, Japan; Okayama Univ, Sch Med, Dept Surg 1, Okayama 700, Japan	Kumamoto University; Kobe University; Okayama University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 860, Japan.		Kagawa, Shunsuke/B-2189-2011; Saya, Hideyuki/J-4325-2013	Kagawa, Shunsuke/0000-0002-3610-8211				ARMSTRONG DK, 1992, CANCER RES, V52, P3418; Bilim V, 1996, J NATL CANCER I, V88, P686, DOI 10.1093/jnci/88.10.686-a; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU G, 1994, J BIOL CHEM, V269, P787; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUJIWARA T, 1994, CANCER RES, V54, P2287; Gallo O, 1996, CLIN CANCER RES, V2, P261; GomezManzano C, 1996, CANCER RES, V56, P694; Graham FL, 1991, METHOD MOL BIOL, P109; Hamada K, 1996, CANCER RES, V56, P3047; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KIM YH, 1992, J IMMUNOL, V149, P17; King ED, 1996, J UROLOGY, V155, P316, DOI 10.1016/S0022-5347(01)66652-7; KYO E, 1993, INT J ONCOL, V3, P265; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIU TJ, 1995, CANCER RES, V55, P3117; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Miyake H, 1997, J UROLOGY, V157, P2351, DOI 10.1016/S0022-5347(01)64779-7; Mujoo K, 1996, ONCOGENE, V12, P1617; Murphy Andrew J. M., 1992, Methods (Orlando), V4, P111, DOI 10.1016/1046-2023(92)90044-9; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; PARK JG, 1987, CANCER RES, V47, P5875; Parker S. L., 1996, CA CANC J CLIN, V65, P5; RAFFO AJ, 1995, CANCER RES, V55, P4438; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; ROUSCULP MD, 1992, HUM GENE THER, V3, P471, DOI 10.1089/hum.1992.3.5-471; STERNBERG CN, 1993, CANCER, V72, P1975, DOI 10.1002/1097-0142(19930915)72:6<1975::AID-CNCR2820720631>3.0.CO;2-I; THRASHER JB, 1993, J UROLOGY, V149, P957, DOI 10.1016/S0022-5347(17)36270-5; Tomita Y, 1996, INT J CANCER, V66, P322, DOI 10.1002/(SICI)1097-0215(19960503)66:3<322::AID-IJC9>3.0.CO;2-0; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG YS, 1993, ONCOGENE, V8, P3427; WELSH MJ, 1994, HUM GENE THER, V5, P209, DOI 10.1089/hum.1994.5.2-209; Werthman PE, 1996, J UROLOGY, V155, P753, DOI 10.1016/S0022-5347(01)66515-7; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	44	112	113	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					933	943		10.1038/sj.onc.1201602	http://dx.doi.org/10.1038/sj.onc.1201602			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484785				2022-12-28	WOS:000072053200013
J	Ronai, Z; Yang, YM; Fuchs, SY; Adler, V; Sardana, M; Herlyn, M				Ronai, Z; Yang, YM; Fuchs, SY; Adler, V; Sardana, M; Herlyn, M			ATF2 confers radiation resistance to human melanoma cells	ONCOGENE			English	Article						ATF2; melanoma; radiation resistance; UV	JUN-NH2-TERMINAL KINASE ACTIVATION; ELEMENT-BINDING PROTEIN; TRANSCRIPTION FACTOR-II; ULTRAVIOLET-IRRADIATION; EXPRESSION; JUN; MEDIATE; FAMILY; CREB; IDENTIFICATION	We have previously identifed a U.V.-response element (URE; TGACAACA) and its bound proteins, members of the AP1 and ATF transcription factor families, in melanoma cells, Using a mutant form of cylic AMP response element binding (CREB), we found that CREB-associated-URE-bound proteins conferred characteristic melanoma phenotypes, including radiation resistance (Oncogene 12:2223, 1996). In the present study,ve sought to determine which of the CREB-associated proteins confers radiation resistance on human melanoma cells, To this end we purified and identified via microsequencing ATF2 as a major URE-boundand CREB-associated protein in MeWo cells - a late stage human melanoma cell line, To determine the contribution of ATF2 to radiation resistance, MeWo cells mere transfected with ATF2 cDNA lacking the trans-activation domain (ATF2(Delta 1-195)). MeWo cells that stably express ATF2(Delta 1-195) showed weaker transcriptional activities and an altered pattern of homo/ hetero dimers. ATF2(Delta 1-195) clones exhibited up to tenfold lower resistance to irradiation by either U.V. or X-rays. The degree of resistance to radiation in the ATF2(Delta 1-195) expressing clones could be increased upon transient transfection with ATF2(wt), but not with phosphorylation-defective mutant ATF2(69,71). Similarly, transfection of ATF2(wt) to WM3211, an early stage human melanoma cells line, increased resistance to radiation, Finally, changes elicited through ATF2(Delta 1-195) also led to reduced drug resistance, as shown for MMC, araC and cis-platinum. Our results suggest that ATF2 is a regulator of radiation and drug resistance in melanomas, and that tumor targeted ATF2 modulators may be useful sensitizers in the treatment of tumors of this type.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Merck Sharp & Dohme, W Point, NY USA; Wistar Inst, Mol & Cellular Biol Program, W Point, NY USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, Box 1130,1 Gustave Levy Pl, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA51995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051995, R01CA051995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; CHATTON B, 1994, ONCOGENE, V9, P375; Dhar V, 1996, CELL GROWTH DIFFER, V7, P841; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; GRINJORGENSEN CM, 1992, CUTANEOUS MELANOMA, P27; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERLYN M, 1992, CUTANEOUS MELANOMA, P82; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KIM SJ, 1992, NATURE, V358, P31; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; KRASILNIKOV M, UNPUB; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Loganzo Frank Jr., 1994, Molecular and Cellular Differentiation, V2, P23; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; MAEKAWA T, 1991, ONCOGENE, V6, P627; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; RONAI ZA, 1990, CANCER RES, V50, P5374; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P1815, DOI 10.1093/nar/20.7.1815; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P4305, DOI 10.1093/nar/20.16.4305; SCHMID P, 1995, CARCINOGENESIS, V16, P1499, DOI 10.1093/carcin/16.7.1499; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; *WHO, 1994, ENV HLTH CRIT, P15; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; YANG YM, 1995, MOL CARCINOGEN, V14, P111, DOI 10.1002/mc.2940140207; YANG YM, 1993, MOL CARCINOGEN, V7, P36, DOI 10.1002/mc.2940070107; YANG YM, 1993, CELL GROWTH DIFFER, V4, P595; Yang YM, 1996, ONCOGENE, V12, P2223; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	37	68	70	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					523	531		10.1038/sj.onc.1201566	http://dx.doi.org/10.1038/sj.onc.1201566			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484842				2022-12-28	WOS:000071739400011
J	Wang, XY; Smith, DI; Frederick, L; James, CD				Wang, XY; Smith, DI; Frederick, L; James, CD			Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences	ONCOGENE			English	Article						EST; amplicon; EGFR; glioblastoma	EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; DEAD BOX GENE; INDEPENDENT AMPLIFICATION; AMPLIFIED REGIONS; MALIGNANT GLIOMAS; CARCINOMA-CELLS; PROTO-ONCOGENE; N-MYC; COAMPLIFICATION	In this study we have examined the epidermal growth factor receptor gene (EGFR) region for the amplification of novel expressed sequences in 28 glioblastoma tumors and two cell lines with EGFR gene amplification. Southern analysis with expressed sequence tag (EST) probes revealed instances of amplification for 11 of 13 loci investigated. Northern blot analysis with the same probes indicated that three ESTs identified transcripts that are over-expressed in cell lines having corresponding sequence amplification. The determination of increased dosage and transcript levels for multiple expressed sequences raises the possibility that there are genes in addition to EGFR whose elevated expression contribute to the biologic behavior of tumors with amplification of this region.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA	Mayo Clinic	James, CD (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA.		James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X	NATIONAL CANCER INSTITUTE [R01CA055728, R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55728, CA-48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Bieche I, 1996, CANCER RES, V56, P3886; Bringuier PP, 1996, ONCOGENE, V12, P1747; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; ELKAHLOUN AG, 1996, CANCER, V17, P205; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; George RE, 1996, ONCOGENE, V12, P1583; HALEY J, 1987, ONCOGENE RES, V1, P375; JAMES CD, 1988, CANCER RES, V48, P5546; KAWASAKI K, 1988, JPN J CANCER RES, V79, P1174, DOI 10.1111/j.1349-7006.1988.tb01542.x; MANOHAR CF, 1995, GENE CHROMOSOME CANC, V14, P196, DOI 10.1002/gcc.2870140307; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; Reifenberger G, 1996, CANCER RES, V56, P5141; Reiter JL, 1996, GENOMICS, V32, P97, DOI 10.1006/geno.1996.0081; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TANIGAMI A, 1992, GENOMICS, V13, P21, DOI 10.1016/0888-7543(92)90196-Y; Tanner MM, 1996, CANCER RES, V56, P3441; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	23	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					191	195		10.1038/sj.onc.1201476	http://dx.doi.org/10.1038/sj.onc.1201476			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464536				2022-12-28	WOS:000071427100005
J	Matsuda, T; Sasaki, M; Kato, H; Yamada, H; Cohen, M; Barrett, JC; Oshimura, M; Wake, N				Matsuda, T; Sasaki, M; Kato, H; Yamada, H; Cohen, M; Barrett, JC; Oshimura, M; Wake, N			Human chromosome 7 carries a putative tumor suppressor gene(s) involved in choriocarcinoma	ONCOGENE			English	Article						tumor suppressor gene; choriocarcinoma; chromosome 7; homozygous deletion	HUMAN ENDOGENOUS RETROVIRUS; PRIMARY BREAST-CANCER; CARCINOMA CELL-LINE; HYDATIDIFORM MOLE; SQUAMOUS-CELL; MESSENGER-RNAS; TUMORIGENIC EXPRESSION; PANCREATIC-CARCINOMA; HOMOZYGOUS DELETIONS; FREQUENT LOSS	Choriocarcinoma developed from a complete hydatidiform mole has an unique genetic feature that involves monoallelic contribution from the paternal genome, To the chromosome carrying putative tumor gene(s), microcell-hybrids were isolated following fusion of choriocarcinoma cells with microcells from mouse A9 cells containing a single human chromosome (1, 2, 6, 7, 9 or 11), Microcell-hybrids with the introduction of chromosome 7 were suppressed or modulated for tumorigenicity and exhibited altered in vitro growth properties, Introduction of chromosomes 1, 2, 6, 9 or 11 had no effect, Tumorigenic revertants isolated from microcell-hybrids with the introduced chromosome 7 contains reduced numbers of chromosome 7, These findings suggest that chromosome 7 contains a putative tumor suppressor gene(s) for choriocarcinoma, Alterations in tumorigenic phenotypes seen in microcell-hybrids were not associated with the presence of either ERV3 or H-plk locus located on the introduced chromosome 7, indicating the putative tumor suppressor gene(s) is outside of ERV3 and H-plk gene loci, Furthermore, we obtained evidence to define a critical region on chromosome 7 (7p12-7q11.23) that was frequently lost in surgically removed choriocarcinoma tissues and cell lines, Using a panel of microsatellite markers, biallelic deletions were observed, which strongly suggests the presence of a tumor suppressor gene(s) within this critical region.	KYUSHU UNIV,MED INST BIOREGULAT,DEPT REPROD PHYSIOL & ENDOCRINOL,BEPPU,OITA 874,JAPAN; TOTTORI UNIV,FAC MED,SCH LIFE SCI,DEPT MOL & CELL GENET,YONAGO,TOTTORI 683,JAPAN; ABBOTT LABS,DEPT CORP MOL BIOL,ABBOTT PK,IL 60064; NIEHS,MOL CARCINOGENESIS LAB,NIH,RES TRIANGLE PK,NC 27709	Kyushu University; Tottori University; Abbott Laboratories; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								Achille A, 1996, CANCER RES, V56, P3808; [Anonymous], 1982, MOL CLONING LAB MANU; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; BELLEFROID EJ, 1992, GENOMICS, V14, P780, DOI 10.1016/S0888-7543(05)80185-5; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BOYD MT, 1993, VIROLOGY, V196, P905, DOI 10.1006/viro.1993.1556; CAVANEE WK, 1983, NATURE, V305, P779; CHERIF D, 1989, HUM GENET, V81, P358, DOI 10.1007/BF00283691; COHEN M, 1988, J CELL BIOCHEM, V36, P121, DOI 10.1002/jcb.240360203; CONWAY K, 1992, CANCER RES, V52, P6487; Decker HJH, 1996, HUM GENET, V97, P770; JACOBS PA, 1980, NATURE, V286, P714, DOI 10.1038/286714a0; KAJII T, 1977, NATURE, V268, P633, DOI 10.1038/268633a0; Kastury K, 1996, CANCER RES, V56, P978; KATO N, 1990, MOL CELL BIOL, V10, P4401, DOI 10.1128/MCB.10.8.4401; KATO N, 1987, J VIROL, V61, P2182, DOI 10.1128/JVI.61.7.2182-2191.1987; KATO N, 1988, INT J CANCER, V41, P380, DOI 10.1002/ijc.2910410310; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; MARTIN MA, 1981, P NATL ACAD SCI USA, V78, P4896; NOZAWA S, 1987, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V39, P889; OCONNELL C, 1984, VIROLOGY, V138, P225, DOI 10.1016/0042-6822(84)90347-7; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OHAMA K, 1981, NATURE, V292, P551, DOI 10.1038/292551a0; Ohnishi H, 1996, LEUKEMIA, V10, P1104; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PARK WW, 1971, CHORIOCARCINOMA STUD, P55; PATTILLO RA, 1971, IN VITRO CELL DEV B, V6, P398; PATTILLO RA, 1968, CANCER RES, V28, P1231; PATTILLO RA, 1981, AM J OBSTET GYNECOL, V141, P104; PORTEOUS DJ, 1989, GENOMICS, V5, P680, DOI 10.1016/0888-7543(89)90108-0; Roche J, 1996, ONCOGENE, V12, P1289; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCABLE H, 1989, P NATL ACAD SCI USA, V86, P7480; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; SPEICHER MR, 1995, CANCER RES, V55, P1010; SREEKANTAIAH C, 1993, AM J PATHOL, V142, P293; STANBRIDGE EJ, 1988, CANC SURVEYS, V29, P317; SUGIURA M, 1988, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V40, P1447; SURTI U, 1979, HUM GENET, V51, P153, DOI 10.1007/BF00287169; Suzumori K, 1983, Asia Oceania J Obstet Gynaecol, V9, P309; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TSUI LC, 1995, CYTOGENET CELL GENET, V71, P1, DOI 10.1159/000134055; VENABLES PJW, 1995, VIROLOGY, V211, P589, DOI 10.1006/viro.1995.1442; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAKE N, 1978, J NATL CANCER I, V60, P51, DOI 10.1093/jnci/60.1.51; WAKE N, 1978, P JPN ACAD B-PHYS, V54, P533, DOI 10.2183/pjab.54.533; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YAMADA H, 1990, ONCOGENE, V5, P1141; YAMASHITA K, 1979, AM J OBSTET GYNECOL, V135, P597, DOI 10.1016/S0002-9378(16)32983-0; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	59	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2773	2781		10.1038/sj.onc.1201461	http://dx.doi.org/10.1038/sj.onc.1201461			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419968				2022-12-28	WOS:A1997YJ80300003
J	Dietrich, C; Wallenfang, K; Oesch, F; Wieser, R				Dietrich, C; Wallenfang, K; Oesch, F; Wieser, R			Differences in the mechanisms of growth control in contact-inhibited and serum-deprived human fibroblasts	ONCOGENE			English	Article						cyclin-dependent kinase regulation; contact-inhibition; serum-deprivation	CYCLIN-DEPENDENT KINASES; PLASMA-MEMBRANE GLYCOPROTEINS; HUMAN-DIPLOID FIBROBLASTS; CELL-CYCLE; G1 PHASE; RETINOBLASTOMA PROTEIN; P27(KIP1); ARREST; PHOSPHORYLATION; EXPRESSION	In the present work we studied mechanisms of growth control in contact-inhibited and serum-deprived human diploid fibroblasts. The observation that the effects on [H-3]thymidine incorporation and reduction of retinoblastoma gene product-phosphorylation were additive when contact-inhibition and serum-deprivation were combined led us to the conclusion that the underlying mechanisms might be different. Both contact-inhibition and serum-deprivation led to a strong decrease of cdk4-kinase-activity and cdk2-phosphorylation at Thr 160, while the total amounts of cdk4 and cdk2 remained constant. In contact-inhibited cells, we revealed a strong protein accumulation of the cdk2-inhibitor p27 and a slight, but significant increase of the cdk4-inhibitor p16. In serum-deprived cells, the protein levels in p27 and p16 remained low. In contrast, we detected a rapid decrease of cyclin D1 and cyclin D3 which did not occur in contact-inhibited cells. These results indicate that serum-deprivation and contact-inhibition have different mechanisms although they affect the same pathway cyclin D-cdk4, pRB, cyclin E-cdk2.	UNIV MAINZ,INST TOXICOL,D-55131 MAINZ,GERMANY	Johannes Gutenberg University of Mainz			Oesch, Franz/AAA-8746-2020					APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUSTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORETON K, 1995, FEBS LETT, V372, P33, DOI 10.1016/0014-5793(95)00941-2; MORETON K, 1995, BIOCHEM SOC T, V23, pS446, DOI 10.1042/bst023446s; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	37	59	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2743	2747		10.1038/sj.onc.1201439	http://dx.doi.org/10.1038/sj.onc.1201439			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9401001				2022-12-28	WOS:A1997YH46800012
J	VarmehZiaie, S; Okan, I; Wang, YS; Magnusson, KP; Warthoe, P; Strauss, M; Wiman, KG				VarmehZiaie, S; Okan, I; Wang, YS; Magnusson, KP; Warthoe, P; Strauss, M; Wiman, KG			Wig-1, a new p53-induced gene encoding a zinc finger protein	ONCOGENE			English	Article						p53; differential display; zinc finger protein	WILD-TYPE P53; DIFFERENTIAL DISPLAY; MESSENGER-RNA; APOPTOSIS; EXPRESSION; ARREST; CELLS; BAX; IDENTIFICATION; ACTIVATION	Wild type p53 expressed from a temperature-sensitive (ts p53) construct induces both G1 cell cycle arrest and apoptosis in the p53-negative J3D mouse T lymphoma line (Wang et al., 1995). Using differential display analysis, we have identified one new p53-induced gene, wig-1 (for mild type p53-induced gene 1), whose 7.6 kb and 2.2 kb transcripts are upregulated in ts p53-transfected J3D cells following induction of wild type p53 expression by temperature shift to 32 degrees C. The wig-1 transcripts were also induced in irradiated NIH3T3 and p21(-/-) fibroblasts but not in irradiated p53(-/-) fibroblasts. Whole body gamma irradiation caused induction of both wig-1 transcripts in mouse brain, testis, kidney, spleen and lung. A basal wig-1 expression was detected in brain, testis and kidney. The WIG-1 protein contains three zinc finger motifs and a putative nuclear localization signal.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN,DENMARK	Karolinska Institutet; Danish Cancer Society			Magnusson, Kristinn P Pétur/X-4907-2019; Magnusson, Kristinn/A-6479-2011; Wiman, Klas/AAB-8399-2021	Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Magnusson, Kristinn/0000-0003-4528-6826; Wiman, Klas/0000-0002-7113-524X; Warthoe, peterwarthoe@gmail.com/0000-0003-3840-5460				BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUNT T, 1985, NATURE, V316, P580, DOI 10.1038/316580a0; ISRAELI D, 1997, IN PRESS EMBO J; KASTAN MB, 1991, CANCER RES, V51, P6304; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; MacCallum DE, 1996, ONCOGENE, V13, P2575; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MIYASHITA T, 1995, CELL, V80, P293; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PIENTENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sambrook J., 2002, MOL CLONING LAB MANU; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	25	54	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2699	2704		10.1038/sj.onc.1201454	http://dx.doi.org/10.1038/sj.onc.1201454			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400996				2022-12-28	WOS:A1997YH46800007
J	Chen, SL; Zhang, XK; Halverson, DO; Byeon, MK; Schweinfest, CW; Ferris, DK; Bhat, NK				Chen, SL; Zhang, XK; Halverson, DO; Byeon, MK; Schweinfest, CW; Ferris, DK; Bhat, NK			Characterization of human N8 protein	ONCOGENE			English	Article						leucine zipper protein; homodimerization; phosphorylation; cytoplasmic protein; epithelial cells	DNA-BINDING DOMAIN; LEUCINE ZIPPER; DIMERIZATION; EXPRESSION; SEQUENCE; COMPLEX; FAMILY; GENES; MYC; MAX	We have shown before that the N8 mRNA is expressed at higher levels in lung tumor and lung tumor-derived cell lines than normal lung cells. In this paper, we have characterized the N8 protein, and studied its properties. The N8 gene encodes a major 24 kDa protein and its expression correlates well with the N8 mRNA expression pattern observed in different cell lines. N8 protein is capable of forming a homodimer or multimeter in vitro. It is a phosphorylated cytoplasmic protein and phosphorylation occurs mainly at serine residues, N8 protein is expressed at higher levels in epithelial cells than in mesenchymal cells, Ns protein expression is induced in a fibroblast cell line expressing adenoviral Ela protein, which acquired epithelial-like characteristics. Furthermore, ectopic expression of N8 protein in NIH3T3 cells converts them into a spheroid form. These spheroids also have some of the characteristic features of epithelial cells. Taken together, these results suggest that the N8 protein may be associated with the development or maintenance of epithelial cell phenotype.	NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,FREDERICK,MD 21702; NCI,MOL ONCOL LAB,FREDERICK,MD 21702; MED UNIV S CAROLINA,HOLLINGS CANC CTR,CTR MOL & STRUCT BIOL,CHARLESTON,SC 29425	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Medical University of South Carolina								ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BHAT NK, 1992, HYBRIDOMA, V11, P277, DOI 10.1089/hyb.1992.11.277; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BYRNE JA, 1995, CANCER RES, V55, P2896; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Chen SL, 1996, ONCOGENE, V12, P741; Coligan JKA, 1991, CURRENT PROTOCOLS IM; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872	15	23	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2577	2588		10.1038/sj.onc.1201437	http://dx.doi.org/10.1038/sj.onc.1201437			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399645				2022-12-28	WOS:A1997YG73200007
J	Sun, Q; Tang, SC; Pater, MM; Pater, A				Sun, Q; Tang, SC; Pater, MM; Pater, A			Different HPV16 E6/E7 oncogene expression patterns in epithelia reconstructed from HPV16-immortalized human endocervical cells and genital keratinocytes	ONCOGENE			English	Article						human papillomavirus type 16; E6/E7 oncogene expression; metaplasia; stratified squamous epithelium; endocervical cells; keratinocytes	HUMAN PAPILLOMAVIRUS TYPE-16; CERVICAL-CARCINOMA CELLS; EARLY GENE-EXPRESSION; CYTOKERATIN-EXPRESSION; RETINOIC ACID; SHORT ARM; E7 GENES; DNA; GROWTH; INVITRO	Human papillomavirus type 16 (HPV16) E6/E7 oncogenes immortalize two types of human genital epithelial cells in vitro, endocervical cells and ectocervical or foreskin keratinocytes. Epithelia reconstructed in in vivo nude mouse implants or in vitro organotypic raft cultures from immortalized endocervical cells form higher grade dysplasia than those from keratinocytes, Here, we compared viral E6/E7 mRNA expression in immortalized cell lines of the three cell types using implants, rafts and in situ hybridization assays, Endocervical cells expressed E6/E7 throughout their reconstructed epithelia. In contrast, oncogenes were limited to basal cells for keratinocyte lower grade dysplasias, To study the role of the HPV16 promoter/enhancer in this repression in the upper layers of keratinocyte epithelia, new cell lines were established by immortalization with E6/E7 controlled by the SV40 promoter, The oncogenes were shown to be controlled from the SV40 elements after immortalization, Nevertheless, E6/E7 in the two cell types had the same cell-specific expression pattern as that controlled from the homologous HPV16 promoter, In addition, naturally occurring premalignant lesions having integrated HPV16 DNA expressed E6/E7 extensively in the high-grade dysplastic region of undifferentiated metaplasia, On the other hand, oncogene expression was restricted to lower layers in the lower grade dysplastic region of more mature differentiation, Our data suggest that keratinocytes have an inherent HPV16 promoter-nonspecific mechanism of repression, Apparently this mechanism, which can be acquired during maturation, is initially nonfunctional in in vitro and in vivo epithelia derived from metaplastic endocervical cells.	MEM UNIV NEWFOUNDLAND, FAC MED, DIV BASIC MED SCI, St John, NF A1B 3V6, CANADA	Memorial University Newfoundland								AVERETTE HE, 1970, AM J OBSTET GYNECOL, V108, P8, DOI 10.1016/0002-9378(70)90195-X; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BELAGULI NS, 1992, J VIROL, V66, P2724, DOI 10.1128/JVI.66.5.2724-2730.1992; BLANTON RA, 1991, AM J PATHOL, V138, P673; BOSCH FX, 1990, J VIROL, V64, P4743, DOI 10.1128/JVI.64.10.4743-4754.1990; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOUKAMP P, 1990, DIFFERENTIATION, V44, P150, DOI 10.1111/j.1432-0436.1990.tb00548.x; BOURGHARDT E, 1986, VIRAL ETIOLOGY CERVI, P81; BRAUN L, 1992, MOL CARCINOGEN, V6, P100, DOI 10.1002/mc.2940060205; BRAUN L, 1990, CANCER RES, V50, P7324; COOPER K, 1991, J CLIN PATHOL, V44, P406, DOI 10.1136/jcp.44.5.406; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; DURST M, 1991, J VIROL, V65, P796; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FU YS, 1989, PATHOLOGY UTERINE CE, P28; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1986, LANCET, V2, P489; JENSON AB, 1990, PAPILLOMAVIRUSES HUM, P11; Kessis TD, 1996, ONCOGENE, V13, P427; KNAPP AC, 1989, CELL, V59, P67, DOI 10.1016/0092-8674(89)90870-2; LECHNER MS, 1991, VIROLOGY, V185, P563, DOI 10.1016/0042-6822(91)90526-H; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MUNGER K, 1989, J VIROL, V63, P4417; NUOVO GJ, 1991, AM J PATHOL, V139, P847; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PATER MM, 1988, J MED VIROL, V26, P185, DOI 10.1002/jmv.1890260210; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; RADER JS, 1990, ONCOGENE, V5, P571; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; ROSL F, 1991, EMBO J, V10, P1337, DOI 10.1002/j.1460-2075.1991.tb07653.x; Sarma D, 1996, INT J CANCER, V65, P345, DOI 10.1002/(SICI)1097-0215(19960126)65:3<345::AID-IJC12>3.3.CO;2-L; SCHELLHAS HF, 1969, AM J OBSTET GYNECOL, V104, P617, DOI 10.1016/0002-9378(69)90595-X; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHINDOH M, 1995, OBSTET GYNECOL, V85, P721, DOI 10.1016/0029-7844(95)00043-Q; SMITS HL, 1988, J VIROL, V62, P4538, DOI 10.1128/JVI.62.12.4538-4543.1988; SMITS HL, 1991, VIROLOGY, V182, P870, DOI 10.1016/0042-6822(91)90632-L; SMITS PHM, 1993, J GEN VIROL, V74, P121, DOI 10.1099/0022-1317-74-1-121; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; SUN Q, 1992, CANCER RES, V52, P4254; SUN Q, 1993, INT J CANCER, V54, P656, DOI 10.1002/ijc.2910540422; TSUTSUMI K, 1992, AM J PATHOL, V140, P255; TURYK ME, 1989, IN VITRO CELL DEV B, V25, P544, DOI 10.1007/BF02623567; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WOODWORTH CD, 1988, CANCER RES, V48, P4620; WOODWORTH CD, 1990, J VIROL, V64, P4767, DOI 10.1128/JVI.64.10.4767-4775.1990; Yang XL, 1996, INT J CANCER, V65, P338, DOI 10.1002/(SICI)1097-0215(19960126)65:3<338::AID-IJC11>3.0.CO;2-6; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	53	10	13	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	1997	15	20					2399	2408		10.1038/sj.onc.1201425	http://dx.doi.org/10.1038/sj.onc.1201425			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395236				2022-12-28	WOS:A1997YE96300002
J	Gao, SJ; Boshoff, C; Jayachandra, S; Weiss, RA; Chang, Y; Moore, PS				Gao, SJ; Boshoff, C; Jayachandra, S; Weiss, RA; Chang, Y; Moore, PS			KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway	ONCOGENE			English	Article						Kaposi's sarcoma-associated herpesvirus; interferon; oncogenesis; p21; lymphoma	KAPOSIS-SARCOMA; DNA-SEQUENCES; REGULATED EXPRESSION; CELL-GROWTH; BETA-GENE; HERPESVIRUS; TRANSCRIPTION; ALPHA; PROTEINS; IRF-1	Kaposi's sarcoma-associated herpesvirus (KSHV) is a gammaherpesvirus linked to the development of Kaposi's sarcoma and a rare B cell lymphoma, primary effusion lymphoma, The KSHV gene ORF K9 encodes vIRF which is a protein with low but significant homology to members of the interferon (IFN) regulatory factor (IRF) family responsible for regulating intracellular interferon signal transduction (Moore PS, Boshoff C, Weiss RA and Chang Y. (1996), Science, 274, 1739-1744), vIRF inhibits IPN-beta signal transduction as measured using an IFN-responsive ISG54 reporter construct co-transfected with ORI; K9 into HeLa and 293 cells, vIRF also suppresses genes under IFN regulatory control as shown by inhibition of the IFN-beta inducibility of p21(WAF1/CIP1), however, no direct DNA-binding or protein-protein interactions characteristic for IRF repressor proteins were identified, Stable transfectant NIH3T3 clones expressing vIRF grew in soft agar and at low serum concentrations, lost contact inhibition and formed tumors after injection into nude mice indicating that vIRF has the properties of a viral oncogene, Since vIRF is primarily expressed in KSHV-infected B cells, not KS spindle cells, this study suggests that vIRF is a transforming oncogene active in B cell neoplasias that may provide a unique immune escape mechanism for infected cells, This data is consistent with tumor suppressor pathways serving a dual function as host cell antiviral pathways.	COLUMBIA UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Columbia University; Columbia University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Gao, Shou-Jiang/B-8641-2012; Moore, Patrick S./F-3960-2011; Chang, Yuan/F-4146-2011; Moore, Patrick/GVR-8294-2022	Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041; Gao, Shou-Jiang/0000-0001-6194-1742	NATIONAL CANCER INSTITUTE [R01CA067391] Funding Source: NIH RePORTER; NCI NIH HHS [CA67391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLUYSSEN HAR, 1994, EUR J BIOCHEM, V220, P395, DOI 10.1111/j.1432-1033.1994.tb18636.x; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, INFECT AGENT DIS, V5, P215; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Foreman KE, 1997, NEW ENGL J MED, V336, P163, DOI 10.1056/NEJM199701163360302; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; JansenDurr P, 1996, TRENDS GENET, V12, P270, DOI 10.1016/0168-9525(96)81455-7; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MOORE PS, 1997, IN PRESS J NCI; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Neil JC, 1997, TRENDS MICROBIOL, V5, P115, DOI 10.1016/S0966-842X(96)10083-4; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Offermann MK, 1996, TRENDS MICROBIOL, V4, P383, DOI 10.1016/0966-842X(96)10060-3; OLSEN SJ, 1997, IN PRESS MOL IMMUNOL; RABKIN CS, 1995, CLIN CANCER RES, V1, P257; Rabkin CS, 1997, NEW ENGL J MED, V336, P988, DOI 10.1056/NEJM199704033361403; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; REICH N, 1988, J VIROL, V62, P114, DOI 10.1128/JVI.62.1.114-119.1988; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Strathdee S A, 1996, AIDS, V10 Suppl A, pS51, DOI 10.1097/00002030-199601001-00008; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Wold William S. M., 1994, Trends in Microbiology, V2, P437, DOI 10.1016/0966-842X(94)90801-X; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	52	292	302	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1979	1985		10.1038/sj.onc.1201571	http://dx.doi.org/10.1038/sj.onc.1201571			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365244				2022-12-28	WOS:A1997YA87200012
J	Whitaker, LL; Hansen, MF				Whitaker, LL; Hansen, MF			Induction of apoptosis in Mv1Lu cells by expression of competitive RB1 mutants	ONCOGENE			English	Article						dominant-negative; growth suppression domain; tumor suppressor	RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; HUMAN LYMPHOID NEOPLASMS; LARGE T-ANTIGEN; SUSCEPTIBILITY GENE; HUMAN CANCER; FUNCTIONAL INTERACTIONS; PROTEIN; BINDING; MUTATIONS	The Retinoblastoma tumor suppressor gene (RB1) plays a role in a variety of human cancers, Experimental analyses have indicated that the protein product of the RB1 gene (pRb) plays a role in cell cycle regulation. pRb function is dependent on its ability to bind to cellular factors, which is facilitated by multiple protein binding domains within pRb. Mutations within these domains which eliminate the ability of pRb to bind its targets result in loss of function. Although loss of pRb function may lead to uncontrolled cellular proliferation, tumorigenesis is not the only response to pRb inactivation. Examination of various tissues from RB1-nullizygous mouse embryos showed problems in differentiation and induction of apoptosis, suggesting that the ultimate response to the loss of pRb is influenced by cellular context. It has previously been demonstrated in RB1-negative Saos-2 cells that co-expression of the C-terminal domain of pRb with wildtype pRb resulted in escape from G1 arrest and continued cell cycling. In this paper we demonstrate that in RB1-positive Mv1Lu cells, expression of the A/B pocket region or the N-terminus (when combined with a nuclear localization signal), but not the C-terminal domain, is able to competitively disrupt the function of the endogenous pRb, and that the result of this disruption is apoptosis.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [T32CA009299, R01CA050331] Funding Source: NIH RePORTER; NCI NIH HHS [CA09299, CA50331] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA HG, 1991, BLOOD, V78, P3259; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ANTELMAN D, 1995, ONCOGENE, V10, P697; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANERJEE A, 1992, CANCER RES, V52, P6297; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN YC, 1990, BLOOD, V76, P2060; CHITTENDEN T, 1991, COLD SPRING HARB SYM, V56, P187; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FATTAEY AR, 1993, ONCOGENE, V8, P3149; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fung Y K, 1992, Cancer Treat Res, V61, P59; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GALLIE BL, 1994, NEW ENGL J MED, V330, P786, DOI 10.1056/NEJM199403173301112; GINSBERG AM, 1992, LEUKEMIA LYMPHOMA, V7, P359, DOI 10.3109/10428199209049791; GINSBERG AM, 1991, BLOOD, V77, P833; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; ISHIKAWA J, 1991, CANCER RES, V51, P5736; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KATO J, 1993, GENE DEV, V7, P331; KATO MV, 1994, HUM MUTAT, V3, P44, DOI 10.1002/humu.1380030108; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KLOSS K, 1991, AM J MED GENET, V39, P196, DOI 10.1002/ajmg.1320390215; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MELING GI, 1991, BRIT J CANCER, V64, P475, DOI 10.1038/bjc.1991.334; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MURAKAMI Y, 1991, ONCOGENE, V6, P37; NAKAMURA T, 1991, JPN J CLIN ONCOL, V21, P325; NEVINS JR, 1991, COLD SPRING HARB SYM, V56, P157; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; REISSMANN PT, 1989, ONCOGENE, V4, P839; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; SHEN WJ, 1995, J BIOL CHEM, V270, P20525, DOI 10.1074/jbc.270.35.20525; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TANG A, 1989, ONCOGENE, V4, P401; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UZVOLGYI E, 1991, CELL GROWTH DIFFER, V2, P297; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEIDE R, 1991, BRIT J HAEMATOL, V78, P500, DOI 10.1111/j.1365-2141.1991.tb04479.x; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1992, Semin Immunol, V4, P389; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XU HJ, 1991, CANCER RES, V51, P4481; Yamaguchi T, 1996, ANTICANCER RES, V16, P2009; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588	79	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1069	1077		10.1038/sj.onc.1201277	http://dx.doi.org/10.1038/sj.onc.1201277			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285561				2022-12-28	WOS:A1997XT16100008
J	Garton, AJ; Burnham, MR; Bouton, AH; Tonks, NK				Garton, AJ; Burnham, MR; Bouton, AH; Tonks, NK			Association of PTP-PEST with the SH3 domain of p130(cas); a novel mechanism of protein tyrosine phosphatase substrate recognition	ONCOGENE			English	Article						p130(cas); SH3 domain; PTP-PEST; tyrosine phosphorylation; PTP	FOCAL ADHESION KINASE; SWISS 3T3 CELLS; V-CRK ONCOGENE; GROWTH-FACTOR; STRUCTURAL BASIS; RECEPTOR-BETA; CROSS-TALK; PHOSPHORYLATION; PHOSPHOTYROSINE; PAXILLIN	The protein tyrosine phosphatase PTP-PEST displays remarkable substrate specificity, in vitro and in vivo for p130(cas) a signalling intermediate implicated in mitogenic signalling, cell-adhesion induced signalling, and in transformation by a variety of oncogenes. We have identified a high affinity interaction between the SH3 domain of p130(cas) and a proline-rich sequence ((PPPKPPR)-P-335) within the C-terminal segment of PTP-PEST. Mutation of proline 337 within this sequence to alanine significantly impairs the ability of PTP-PEST to recognise tyrosine phosphorylated p130(cas) as a substrate, without qualitatively affecting the selectivity of the interaction. Thus the highly specific nature of the interaction between PTP-PEST and p130(cas) appears to result from a combination of two distinct substrate recognition mechanisms; the catalytic domain of PTP-PEST contributes specificity to the interaction with p130(cas), whereas the SH3 domain-mediated association of p130(cas) and PTP-PEST dramatically increases the efficiency of the interaction. Furthermore, our results indicate that one important function of the p130(cas) SH3 domain is to associate with PTP-PEST and thereby facilitate the dephosphorylation of p130(cas), resulting in the termination of tyrosine phosphorylation-dependent signalling events downstream of p130(cas).	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	Cold Spring Harbor Laboratory; University of Virginia; University of Virginia					NCI NIH HHS [CA 53840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Burnham MR, 1996, ONCOGENE, V12, P2467; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RANKIN S, 1994, J BIOL CHEM, V269, P704; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SCHNEIDER C, 1992, J BIOL CHEM, V267, P10766; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; YANG Q, 1993, J BIOL CHEM, V268, P6622; YANG Q, 1993, J BIOL CHEM, V268, P17650; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	142	146	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	1997	15	8					877	885		10.1038/sj.onc.1201279	http://dx.doi.org/10.1038/sj.onc.1201279			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285683				2022-12-28	WOS:A1997XR76700001
J	Scimeca, JC; Servant, MJ; Dyer, JO; Meloche, S				Scimeca, JC; Servant, MJ; Dyer, JO; Meloche, S			Essential role of calcium in the regulation of MAP kinase phosphatase-1 expression	ONCOGENE			English	Article						phosphatase; MAP kinase; gene expression; calcium	ACTIVATED PROTEIN-KINASE; DUAL-SPECIFICITY PHOSPHATASE; IMMEDIATE-EARLY GENE; SMOOTH-MUSCLE CELLS; TYROSINE-PHOSPHATASE; HEAT-SHOCK; IN-VIVO; MITOGEN; PHOSPHORYLATION; TRANSCRIPTION	Mitogen-activated protein (MAP) kinase phosphatase-l (MKP-1) is a dual-specificity protein phosphatase encoded by an immediate-early gene responsive to growth factors and stress. The MKP-1 protein selectively inactivates MAP kinases in vitro by dephosphorylation of the regulatory Thr and Tyr residues. Little is known on the mechanisms that regulate MKP-1 gene expression. Here, we demonstrate that Ca2+ is both necessary and sufficient for the induction of MKP-1 gene expression. Treatment of Rat1 fibroblasts with the Ca2+ chelating agent BAPTA completely suppressed serum-induced MKP-1 expression in a dose- and time-dependent manner. The inhibitory effect of BAPTA was observed at the level of the protein and the mRNA. Importantly, Ca2+ chelation blocked the induction of MKP-1 expression in response to all stimuli tested and in different cell types. Increasing the intracellular concentration of Ca2+ with the ionophore A23187 was sufficient to induce MKP-1 mRNA and protein expression in rat fibroblasts. We also provide evidence that activation of MAP kinases is not an absolute requirement for induction of the MKP-1 gene. Exposure of rat fibroblasts to A23187 induced MKP-1 expression without activating the JNK and p38 MAP kinase pathways. Also, inhibition of the ERK pathway with the selective MEK inhibitor PD98059 did not interfere with serum-stimulated MKP-1 mRNA expression. These results will help define the regulatory mechanisms that govern MKP-1 gene transcription in target cells.	HOP HOTEL DIEU,CTR RECH,MONTREAL,PQ H2W 1T8,CANADA; UNIV MONTREAL,DEPT PHARMACOL,MONTREAL,PQ H2W 1T8,CANADA	Universite de Montreal; Universite de Montreal			; Scimeca, Jean-Claude/P-3830-2016	Dyer, Joseph-Omer/0000-0002-7570-9941; Scimeca, Jean-Claude/0000-0003-3773-6110				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEJONGE PC, 1983, BIOCHIM BIOPHYS ACTA, V722, P219, DOI 10.1016/0005-2728(83)90177-9; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1993, J BIOL CHEM, V268, P26037; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; FUKUDA M, 1995, ONCOGENE, V11, P239; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HAMBLETON J, 1995, J EXP MED, V182, P147, DOI 10.1084/jem.182.1.147; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MILLAR JBA, 1995, GENE DEV, V9, P2217; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	76	52	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					717	725		10.1038/sj.onc.1201231	http://dx.doi.org/10.1038/sj.onc.1201231			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264412	Bronze			2022-12-28	WOS:A1997XP68300011
J	Weinberg, WC; Montano, NE; Deng, C				Weinberg, WC; Montano, NE; Deng, C			Loss of p21(CIP1/WAF1) does not recapitulate accelerated malignant conversion caused by p53 loss in experimental skin carcinogenesis	ONCOGENE			English	Article						p53; p21(CIP1/WAF1); epidermal carcinogenesis	P53-MEDIATED G(1) ARREST; HARVEY SARCOMA-VIRUS; P53-INDEPENDENT PATHWAY; PRIMARY KERATINOCYTES; GENE DOSAGE; EXPRESSION; P21; PROGRESSION; INHIBITOR; WAF1/CIP1	The p21(CIP1/WAF1) protein is considered a downstream effector of tumor suppression by p53, We have previously demonstrated that p53 null keratinocytes have lower basal p21(CIP1/WAF1) mRNA levels and that tumors derived from these cells following transduction with the v-ras(Ha) oncogene grow faster than wildtype keratinocytes and rapidly progress to undifferentiated carcinomas (Cancer Res 54: 5584-5592, 1994), In this study, primary keratinocytes differing in p21(CIP1/WAF1) gene dose were transduced with v-ras(Ha) encoding retrovirus and grafted to nude mouse hosts to test whether the p53 null phenotype is mediated through p21(CIP1/WAF1). Resulting tumors from all genotypes were well differentiated papillomas; focal carcinomas were observed in 43, 30 and 44% of papillomas derived from +/+, +/- and -/- keratinocytes, respectively, p21(CIP1/WAF1) deficient keratinocytes expressing v-ras(Ha) do not display the degree of increased growth observed in p53 deficient tumors irt vivo or the decreased responsiveness to negative growth regulation by Ca2+ in vitro. These results suggest that p21(CIP1/WAF1) does not regulate the differentiated phenotype or malignant progression of v-ras(Ha) initiated keratinocytes and that additional functions of the p53 protein other than transcriptional regulation Of the p21(CIP1/WAF1) gene are required for p53 mediated tumor suppression.	NIDDKD,BIOCHEM & METAB LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Weinberg, WC (corresponding author), NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,NIH,BETHESDA,MD 20892, USA.		Weinberg, Wendy/A-8920-2009; deng, chuxia/N-6713-2016					Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAE IS, 1995, CANCER RES, V55, P2387; BRISSETTE JL, 1993, MOL CARCINOGEN, V7, P21, DOI 10.1002/mc.2940070105; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CONWAY K, 1992, CANCER RES, V52, P6487; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doglioni C, 1996, J PATHOL, V179, P248, DOI 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIU M, 1995, ONCOGENE, V10, P1955; Matsushita K, 1996, INT J CANCER, V69, P259, DOI 10.1002/(SICI)1097-0215(19960822)69:4<259::AID-IJC3>3.3.CO;2-D; MICHIELI P, 1994, CANCER RES, V54, P3391; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Reiners JJ, 1997, CARCINOGENESIS, V18, P593, DOI 10.1093/carcin/18.3.593; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; TENNENBAUM T, 1993, CANCER RES, V53, P4803; WALDMAN T, 1995, CANCER RES, V55, P5187; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINBERG WC, 1994, CANCER RES, V54, P5584; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng YX, 1996, ONCOGENE, V12, P1557	33	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					685	690		10.1038/sj.onc.1201230	http://dx.doi.org/10.1038/sj.onc.1201230			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264409				2022-12-28	WOS:A1997XP68300008
J	Wang, HC; Shao, NS; Ding, QM; Cui, JQ; Reddy, ESP; Rao, VN				Wang, HC; Shao, NS; Ding, QM; Cui, JQ; Reddy, ESP; Rao, VN			BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases	ONCOGENE			English	Article						BRCA1a; BRCA1b; zinc finger; cyclins; CDKs; E2F	OVARIAN-CANCER INCIDENCE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; BREAST-CANCER; GENE-PRODUCT; EXPRESSION; LOCALIZATION; SEQUENCE; BINDING; CELL	BRCA1, a familial breast and ovarian canter susceptibility gene encodes nuclear phosphoproteins that function as tumor suppressors in human breast cancer cells, Previously, we have shown that overexpression of a BRCA1 splice variant BRCA1a accelerates apoptosis in human breast cancer cells, In an attempt to determine whether the subcellular localization of BRCA1 is cell cycle regulated, we have studied the subcellular distribution of BRCA1 in asynchronous and growth arrested normal, breast and ovarian cancer cells using different BRCA1 antibodies by immunofluorescence and immunohistochemical staining, Upon serum starvation of NIH3T3, some breast and ovarian cancer cells, most of the BRCA1 protein redistributed to the nucleus revealing a new type of regulation that may modulate the activity of BRCA1 gene, We have also characterized two new variant BRCA1 proteins (BRCA1a/p110 and BRCA1b/p100) which are phosphoproteins containing phosphotyrosine, Immunofluorescence and Western blotting analysis indicate cytoplasmic and nuclear localization of BRCA1a and BRCA1b proteins. To elucidate the biological function of BRCA1, we created a bacterial fusion protein of glutathione-transferase (GST) and BRCA1 zinc finger domain and detected two cellular proteins with molecular weights of approximately 32 and 65 kD, one of which contains phosphotyrosine designated p32 and p65 BRCA1 interacting proteins (BIP) that specifically interact with BRCA1, Western blot analysis of BIP with cyclins/CDKs and E2F antisera indicated association with cdc2, cdk2, cdk4, cyclin B, cyclin D, cyclin A and E2F-4 but not with cdk3, cdk5, cdk6, E2F-1, E2F-2, E2F-3, E2F-5 and cyclin E, Furthermore, we have also demonstrated a direct interaction of in vitro translated BRCA1a and BRCA1b proteins with recombinant cyclin A, cyclin B1, cyclin D1, cdc2, cdk2 and E2F fusion proteins in vitro, Taken together these results seem to suggest that BRCA1 could be an important negative regulator of cell cycle that functions through interaction with E2F transcriptional factors and phosphorylation by cyclins/cdk complexes with the zinc ring finger functioning as a major protein-protein interaction domain, If the interactions we observe in vitro is also seen in vivo then it may be possible that lack or impaired binding of the disrupted BRCA1 proteins to E2F, cyclins/CDKs in patients with mutations in the zinc finger domain could deprive the cell of an important mechanism for braking cell proliferation leading to the development of breast and ovarian cancers.	ALLEGHENY UNIV HLTH SCI, DEPT HUMAN GENET, DIV CANC GENET, PHILADELPHIA, PA 19102 USA	Drexel University					NCI NIH HHS [CA 57322, CA 51083, CA 50507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, P01CA050507, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; EASTON DF, 1995, AM J HUM GENET, V56, P265; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FORD D, 1995, AM J HUM GENET, V57, P1457; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Rao VN, 1996, ONCOGENE, V12, P523; RAO VN, 1993, CANCER RES, V53, P3449; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Shao NS, 1996, ONCOGENE, V13, P1; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SINGH H, 1989, BIOTECHNIQUES, V7, P252; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; WU CJ, 1996, NAT GENET, V14, P430	42	101	114	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	1997	15	2					143	157		10.1038/sj.onc.1201252	http://dx.doi.org/10.1038/sj.onc.1201252			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244350				2022-12-28	WOS:A1997XK37200003
J	Carneiro, C; Alvarez, CV; Zalvide, J; Vidal, A; Dominguez, F				Carneiro, C; Alvarez, CV; Zalvide, J; Vidal, A; Dominguez, F			TGF-beta 1 actions on FRTL-5 cells provide a model for the physiological regulation of thyroid growth	ONCOGENE			English	Article						apoptosis; cell cycle; cyclin; thyroid; TGF-beta 1; p27	ALPHA MESSENGER-RNA; FACTOR-BETA; TGF-BETA; C-MYC; TRANSFORMING GROWTH-FACTOR-BETA-1; PROTHYMOSIN-ALPHA; CYCLE ARREST; RETINOBLASTOMA PROTEIN; EPITHELIAL-CELLS; EXPRESSION	Little is known about the TGF-beta 1 mechanism that promotes thyroid cell growth arrest, We assessed TGF-beta 1 effects on Fisher rat thyroid cell line (FRTL-5), This allowed us to study TGF-beta 1 action on thyroid cells in various physiological situations such as actively proliferating cells, resting cells stimulated to proliferate by the action of various mitogens, and resting cells, TGF-beta 1 arrested proliferating FRTL-5 cells, increasing c-myc mRNA levels and reducing p27-free cyclin D1 protein levels, without affecting either the cellular content of p27 or the cyclin D1-p27 complexes, Moreover, TGF-beta 1 treatment reduced the activity of cyclin E-CDK2 complexes and, consequently, pRB was found to be hypophosphorylated. TGF-beta 1 prevented resting cells to enter in the cell cycle when stimulated with growing medium (newborn calf serum plus a mixture of five hormones) but not when TSH (thyroid stimulating hormone) plus IGF-1 (Insulin-like growth factor I) were used as mitogens, Both stimuli increased the levels of cyclins D1, D3 and E but TGF-beta 1 had a greater effect in decreasing these cyclin levels in growing-medium stimulated cells than in TSH + IGF-1. This suggests that for FRTL-5 cells, the content of these cyclins must exceed a threshold to progress through the cell cycle, TGF-beta 1 induced apoptosis in quiescent cells, accompanied by a reduction in p27 protein levels and an increase in c-myc expression, Interestingly, TGF-beta 1-induced variations in prothymosin alpha and c-myc mRNA levels were not correlated, TGF-beta 1 always promoted an increase of p15 mRNA levels, In summary, our results point to the fact that TGF-beta 1 could play a physiological role in the control of thyroid growth through the modification of cell cycle regulatory proteins.	Dept Fisiol, Lab Neurociencia Ramon Dominguez, Santiago De Compostela, Spain; Unidad Med Mol, Santiago De Compostela, Spain		Alvarez, CV (corresponding author), Dept Fisiol, Lab Neurociencia Ramon Dominguez, Santiago De Compostela, Spain.		Zalvide, Juan/ABG-4050-2020; Alvarez, Clara V/AAN-4173-2020; Vidal, Anxo/B-5010-2015	Vidal, Anxo/0000-0002-0866-4202; Alvarez, Clara V/0000-0003-1500-4058; Zalvide, Juan/0000-0001-7645-156X				ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; ALVAREZ CV, 1993, J MOL ENDOCRINOL, V11, P249, DOI 10.1677/jme.0.0110249; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BATES S, 1994, ONCOGENE, V9, P1633; BLAYDES JP, 1995, ONCOGENE, V10, P307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GOODALL GJ, 1986, P NATL ACAD SCI USA, V83, P8926, DOI 10.1073/pnas.83.23.8926; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KHOSLA S, 1994, ENDOCRINOLOGY, V135, P1887, DOI 10.1210/en.135.5.1887; KO TC, 1995, ONCOGENE, V10, P177; KRIEGLSTEIN K, 1995, EMBO J, V14, P736, DOI 10.1002/j.1460-2075.1995.tb07052.x; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOGAN A, 1994, J ENDOCRINOL, V141, P45, DOI 10.1677/joe.0.1410045; MACHWATE M, 1995, MOL ENDOCRINOL, V9, P187, DOI 10.1210/me.9.2.187; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P1385, DOI 10.1210/endo-123-3-1385; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; Packham G, 1996, ONCOGENE, V13, P461; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PANG XP, 1992, ENDOCRINOLOGY, V131, P45, DOI 10.1210/en.131.1.45; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK C, 1995, BIOCHIM BIOPHYS ACTA, V1242, P185; RAVITZ MJ, 1995, CANCER RES, V55, P1413; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Saltis J, 1996, MOL CELL ENDOCRINOL, V116, P227, DOI 10.1016/0303-7207(95)03721-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOTO JL, 1995, ENDOCRINOLOGY, V136, P3863, DOI 10.1210/en.136.9.3863; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; TRAUTH BC, 1997, GUIDE CELL PROLIFERA; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; ZALVIDE JB, 1992, J BIOL CHEM, V267, P8692	43	60	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	1998	16	11					1455	1465		10.1038/sj.onc.1201662	http://dx.doi.org/10.1038/sj.onc.1201662			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525744				2022-12-28	WOS:000072572400009
J	Lu, YJ; Yamagishi, N; Yagi, T; Takebe, H				Lu, YJ; Yamagishi, N; Yagi, T; Takebe, H			Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells	ONCOGENE			English	Article						adriamycin; apoptosis; CDK; p21; X-ray	CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; HUMAN CANCER-CELLS; TUMOR SUPPRESSION; DNA-REPLICATION; P21; P53; IDENTIFICATION; GENE; PCNA	Human colorectal tumor cell lines were established which express wildtype p21 or p21 with a mutation at codon 46 (Cys) or 140 (Gly) on IPTG treatment (LacSwitch). The IPTG-induced windtype p21 bound to CDK2 and PCNA and inhibited CDK activity in the cells and reduced cell growth rate; whereas, both IPTG-induced mutated p21 proteins neither bound to CDK2 nor affected the CDK activity but did bind to PCNA, and they did not affect the cell growth rate, Wildtype p21 suppressed apoptosis and enhanced survival of X-ray-irradiated or adriamycin-treated cells; but, mutated p21 neither suppressed apoptosis nor affected cell survival, When cells were treated with mimosine, a p53-independent p21-inducer, or butyrolactone I, a specific inhibitor of CDK, cellular endogenous p21 was induced and X-ray or adriamycin-induced apoptosis was blocked, These results suggest that CDK-binding or CDK-inhibitory activity of p21 is required to prevent apoptosis, i.,e.,, CDK is required for apoptosis in human tumor cells.	Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 60601, Japan	Kyoto University	Lu, YJ (corresponding author), Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Yoshida-konoe-cho, Kyoto 60601, Japan.							Adams PD, 1996, MOL CELL BIOL, V16, P6623; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Balbin M, 1996, J BIOL CHEM, V271, P15782, DOI 10.1074/jbc.271.26.15782; BHATIA K, 1995, CANCER RES, V55, P1431; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHEN YQ, 1995, CANCER RES, V55, P4536; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GOUBIN F, 1995, ONCOGENE, V10, P2281; HARPER JW, 1993, CELL, V75, P805; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI YJ, 1995, ONCOGENE, V10, P599; LU YJ, 1996, CARCINOGENESIS, V17, P2243; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; McDonald E, 1996, CANCER RES, V56, P2250; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEEPER DS, 1994, BBA-REV CANCER, V1198, P215, DOI 10.1016/0304-419X(94)90015-9; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393	38	84	87	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					705	712		10.1038/sj.onc.1201585	http://dx.doi.org/10.1038/sj.onc.1201585			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488034				2022-12-28	WOS:000071931800002
J	Gazzeri, S; Gouyer, V; Vourc'h, C; Brambilla, C; Brambilla, E				Gazzeri, S; Gouyer, V; Vourc'h, C; Brambilla, C; Brambilla, E			Mechanisms of p16(INK4A) inactivation in non small-cell lung cancers	ONCOGENE			English	Article						p16(INK4A); lung cancer; protein expression; mutation methylation; homozygous deletion	KINASE-4 INHIBITOR GENE; TUMOR-SUPPRESSOR GENE; RB PROTEIN; SOMATIC MUTATIONS; CYCLE INHIBITION; P18 GENES; IN-VITRO; EXPRESSION; CARCINOMA; GROWTH	The cyclin-dependent kinase inhibitor p16 (p16(INK4A)/CDKN2/MTS1) is a potent inhibitor of the cyclin D-dependent phosphorylation of the retinoblastoma gene (Rb) product, the inactivation of which induces loss of Rb-dependent G1 arrest through inappropriate phosphorylation of the Rb protein. To analyse the role of po16(INK4A) as a tumor suppressor in the genesis of non small cell lung cancers (NSCLC) and correlate loss of p16(INK4A) protein expression to genetic or epigenetic mechanisms, we have performed a comprehensive study of p16 status in a series of 43 NSCLC. To this end, we have investigated p16(INK4A) protein expression with immunohistochemistry, deletions of the gene by FISH, and determined the methylation status of exon 1 alpha using a PCR-based methylation assay. Finally, possible mutations were studied by SSCP and subsequent sequencing, Twenty one of the 43 (49%) NSCLC studied exhibited an absence of p16(INK4A) nuclear staining. Of these, three (14%) had frameshift or missense mutations, seven (33%) displayed methylation of exon1 alpha and 10 (48%) displayed homozygous deletions, In total, 95% of the tumors with p16(INK4A) negative staining carried one of these three alternative genetic or epigenetic alterations. Furthermore, a high degree of chromosome 9 polysomy was found (58%) in those tumors with p16(INK4A) inactivation. Taken together these results suggest that deregulation of the p16 gene locus is a frequently occurring event in NSCLC through distinct mechanisms including rare point mutations, promotor methylation and frequent homozygous deletions. Furthermore, our data show that immunohistochemistry is a rapid and an accurate technique for screening of p16(INK4A) gene inactivation events that result in loss of protein expression.	Inst Albert Bonniot, Grp Rech Canc Poumon, F-38706 La Tronche, France; Inst Albert Bonniot, INSERM, U309, DYOGEN, F-38706 La Tronche, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, Grp Rech Canc Poumon, F-38706 La Tronche, France.		Vourc'h, Claire/AAE-3119-2022; gazzeri, sylvie/U-4669-2019; VOURC'H, Claire/L-9319-2013; Brambilla, Elisabeth MP/L-8796-2013; Gouyer, Valérie/R-4984-2018; gazzeri, sylvie/M-1961-2013; VOURC'H, Claire/AAG-8576-2021	gazzeri, sylvie/0000-0001-5817-1839; VOURC'H, Claire/0000-0002-7276-9359; Gouyer, Valérie/0000-0002-4223-7060; gazzeri, sylvie/0000-0001-5817-1839; VOURC'H, Claire/0000-0002-7276-9359				ARAP W, 1995, CANCER RES, V55, P1351; BRAMBILLA E, 1992, HUM PATHOL, V23, P993, DOI 10.1016/0046-8177(92)90260-A; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164; DURO D, 1995, ONCOGENE, V11, P21; GERADTS J, 1995, CANCER RES, V55, P6006; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GOUYER V, 1994, INT J CANCER, V58, P818, DOI 10.1002/ijc.2910580612; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Hittelman WN, 1996, J CELL BIOCHEM, P57; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JIN X, 1995, CANCER RES, V55, P3520; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kratzke RA, 1996, CANCER RES, V56, P3415; LI Y, 1994, CANCER RES, V54, P6078; Liggett WH, 1996, CANCER RES, V56, P4119; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; Marchetti A, 1997, J PATHOL, V181, P178, DOI 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Packenham JP, 1995, CLIN CANCER RES, V1, P687; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; QUESNEL B, 1995, BRIT J CANCER, V72, P351, DOI 10.1038/bjc.1995.337; Reed AL, 1996, CANCER RES, V56, P3630; ROCCHI M, 1991, GENOMICS, V9, P517, DOI 10.1016/0888-7543(91)90419-F; Rusin MR, 1996, INT J CANCER, V65, P734, DOI 10.1002/(SICI)1097-0215(19960315)65:6<734::AID-IJC4>3.0.CO;2-#; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; STONE S, 1995, CANCER RES, V55, P2988; TAM SW, 1994, CANCER RES, V54, P5816; *WHO CLASS, 1981, HIST TYP LUNG TUM; Wiest JS, 1997, CANCER RES, V57, P1	46	154	161	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	1998	16	4					497	504		10.1038/sj.onc.1201559	http://dx.doi.org/10.1038/sj.onc.1201559			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484839				2022-12-28	WOS:000071739400008
J	Pitkanen, K; Haapajarvi, T; Laiho, M				Pitkanen, K; Haapajarvi, T; Laiho, M			UVC-induction of p53 activation and accumulation is dependent on cell cycle and pathways involving protein synthesis and phosphorylation	ONCOGENE			English	Article						transcriptional regulation; DNA damage; post-transcriptional modification; staurosporine	TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; DNA-BINDING FUNCTION; CASEIN KINASE-II; DAMAGING AGENTS; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; POTENT INHIBITOR; MAMMALIAN-CELLS	Transcriptional activation and stabilization of p53 is a major response of mammalian cells to U.V.-light induced genetic damages, and possibly responsible for cell damage control. We have studied here by gel mobility shift and immunoblotting assays the activation and accumulation of p53 by U.V.C. and its dependency on cell cycle, protein synthesis and protein phosphorylation. In G(0)/G(1) synchronized cells U.V.C.-induced p53 DNA-binding activity, but not its accumulation, whereas both events took place in G(1)/S and S-phase cells. The kinetics of p53 activation by U.V.C. were slow requiring at least 1 h and slowly increasing thereafter with full activation observed at 6 h. Treatment of cells with cycloheximide (CHX) prevented the activation of p53 in all phases of the cell cycle and its accumulation in G(1)/S and S. However, removing CHX-block allowed full activation and accumulation of p53 with fast kinetics even if 4 h had lapsed since the initial U.V.C. insult. This suggests that the protein synthesis-dependent signal initiating p53 activation by U.V.C. remains continuous in the cells, The requirement of protein phosphorylation as mediator of p53 activation by U.V.C. was studied by using chemical protein kinase inhibitors. Of the tested inhibitors, only staurosporine, a known inhibitor of protein kinase C (PKC) and various other kinases, inhibited both p53 activation and accumulation, whereas specific PKC inhibitors, tyrosine kinase inhibitors and a serine/threonine kinase inhibitor did not. PKC-mediation of the p53 U.V.-response was further ruled out by the reactivity of the activated p53 to C-terminal antibody PAb 421. Kinetic studies shelved that staurosporine-mediated inhibition of p53 function is an early event in cell damage response, Thus dual, kinetically different events, de novo protein synthesis and staurosporine-inhibited protein phosphorylation are required for p53 activation and accumulation in all phases of the cell cycle, Notably, in the absence of U.V.-induced accumulation in G(0)/G(1) cells, p53 activation is still subject to inhibition of protein synthesis.	Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland	University of Helsinki	Laiho, M (corresponding author), Univ Helsinki, Dept Virol, Haartman Inst, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							ADDISON C, 1990, ONCOGENE, V5, P423; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAKALKIN, 1994, P NATL ACAD SCI US, V1, P413; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Bond J, 1996, ONCOGENE, V13, P2097; BRUNO S, 1992, CANCER RES, V52, P470; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; DEFFIE A, 1995, MOL CELL BIOL, V15, P3926; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRITSCHE M, 1993, ONCOGENE, V8, P307; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lane DP, 1996, ONCOGENE, V12, P2461; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MIYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PRICE BD, 1993, ONCOGENE, V8, P3055; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1995, ONCOGENE, V10, P1053; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TARUNINA M, 1993, ONCOGENE, V8, P3165; TISHLER RB, 1993, CANCER RES, V53, P2212; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	75	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					459	469		10.1038/sj.onc.1201528	http://dx.doi.org/10.1038/sj.onc.1201528			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484835	Bronze			2022-12-28	WOS:000071739400004
J	Landgren, E; Schiller, P; Cao, YH; Claesson-Welsh, L				Landgren, E; Schiller, P; Cao, YH; Claesson-Welsh, L			Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1	ONCOGENE			English	Article						VEGF; PLGF; endothelial cells; migration; proliferation	TYROSINE KINASE; SIGNAL-TRANSDUCTION; IN-VIVO; VASCULAR ENDOTHELIUM; RECEPTOR; VEGF; ANGIOGENESIS; BINDING; FLK-1; KDR	Vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) are structurally related growth factors for endothelial cells. VEGF binds to the related receptor tyrosine kinases Fit 1 and KDR/Flk 1 with high affinity, whereas PlGF binds only to Fit 1. Ligand-stimulated KDR is known to transduce signals for cellular activity such as proliferation and migration, whereas weak or no responses have been recorded for Fit 1. We examined VEGF and PIGF for their capacity to stimulate signal transduction in porcine aortic endothelial cells expressing Fit 1 or KDR. VEGF had essentially no effect on Fit 1 expressing cells, but induced DNA synthesis and migration of KDR expressing cells. PlGF on the other hand induced DNA synthesis but not migration of the Fit 1 cells. In agreement, MAP kinase, examined as a marker for DNA synthesis, was activated both by VEGF-stimulation of the KDR cells and by PlGF-stimulation of the Fit 1 cells. In contrast, phospholipase C-gamma (PLC-gamma), was tyrosine phosphorylated only in VEGF stimulated KDR cells, and not in the PlGF-stimulated Fit 1 cells, which is in agreement with a role for PLC-gamma in cellular migration. We furthermore examined induction of protein levels of plasminogen activator (PA), which was evident in the PlGF-stimulated Fit 1 cells, but not in the VEGF-stimulated KDR cells. These data show that Fit 1 is able to mediate an array-of biological signals when appropriately stimulated and that the pattern of responses of PlGF-stimulation of Fit 1 is distinct from the pattern of responses to VEGF-stimulation of KDR.	Biomed Ctr, Dept Med & Physiol Chem, S-75123 Uppsala, Sweden; Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden	Karolinska Institutet	Claesson-Welsh, L (corresponding author), Biomed Ctr, Dept Med & Physiol Chem, Box 575, S-75123 Uppsala, Sweden.			Claesson-Welsh, Lena/0000-0003-4275-2000; Schiller, Petter/0000-0002-1790-3711				AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; Landgren E, 1996, EXP CELL RES, V223, P405, DOI 10.1006/excr.1996.0095; MAGLIONE D, 1993, ONCOGENE, V8, P925; Maniatis T., 1982, MOL CLONING LAB MANU; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; OBERG C, 1994, GROWTH FACTORS, V10, P115, DOI 10.3109/08977199409010985; PARK JE, 1994, J BIOL CHEM, V269, P25646; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TESSLER S, 1994, J BIOL CHEM, V269, P12456; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WENNSTROM S, 1994, ONCOGENE, V9, P651; WILKIE AOM, 1995, CURR BIOL, V5, P500	39	143	145	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					359	367		10.1038/sj.onc.1201545	http://dx.doi.org/10.1038/sj.onc.1201545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467961	Bronze			2022-12-28	WOS:000071582100008
J	Gloushankova, N; Ossovskaya, V; Vasiliev, J; Chumakov, P; Kopnin, B				Gloushankova, N; Ossovskaya, V; Vasiliev, J; Chumakov, P; Kopnin, B			Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes	ONCOGENE			English	Article						p53; ras; morphological transformation	P-GLYCOPROTEIN FUNCTION; TATA-BINDING PROTEIN; MAP KINASE KINASE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; WILD-TYPE; FUNCTION MUTATIONS; TUMOR-ANTIGEN; DOMAINS; GENE	p53 plays an important role in restriction of abnormal cell proliferation, Loss of this safeguard function induced by p53 mutations seems to be a key mechanism in oncogenesis, It cannot be excluded however, that in addition to elimination of p53-dependent checkpoints and/or apoptosis p53 mutations may cause additional effects that contribute to oncogenic transformation. In order to analyse the effects of 7 wild-type (wt) and mutant p53 on expression of res-induced morphological transformation we used the method of computer-assisted morphometry, The following parameters were determined: a) the area covered by the spread cells; b) dispersion and c) elongation of cell contours, The last two indices characterise cell shape, Elongation indicates the degree of bipolarity of cell contour and dispersion the degree of its multipolarity. Transformation of Rat1 and mouse 10(3) fibroblasts by N-rasasp12 oncocgene, was accompanied by dramatic decrease of cell area and increase of dispersion and elongation. IAR-2 discoid epitheliocytes expressing exogenous res oncogene transformed into polarised cells with decreased cell area, Fluorescent microscopic examination of actin cytoskeleton stained with rhodamine-phalloidin had shown that res-induced transformation of IAR-2 cells is characterised by disappearance of circumferential actin bundle and straight fibers, Neither did we reveal actin stress-fibers in the ras-transformed Rat1 cells, Transduction of p53 cDNAs caused no significant changes in morphometric parameters of non-transformed parental Rat1, IAR-2 and 10(3) cells, but some of the p53 mutants modified cell shape of ras-transformed cells, p53-His273, unlike other tested p53 mutants (Tyr141, His194, Trp248), induced partial reversion of morphological transformation in both Rat1 fibroblasts and IAR-2 epitheliocytes. Its expression led to increase of average cell area, decrease of dispersion and elongation indices, and re-appearance of actin bundles, Exogenous wild-type p53 also caused some reversion of transformed phenotype of Rat/ras cells, but its effect was weaker than that of the p53-His273. In contrast, another p53 mutant p53-His175 was able to enhance ras-induced morphological transformation in p53-deficient murine 10(3) fibroblasts that is consistent with possible involvement of some gain of function activity of mutant p53 in modulation of cell shape, Possible pathways that might be responsible for p53-induced changes of cell morphology are discussed.	RUSSIAN ACAD SCI,ENGELHARDT INST MOL BIOL,MOSCOW,RUSSIA; RUSSIAN ACAD SCI,CANC RES CTR,INST CANCEROGENESIS,MOSCOW,RUSSIA	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Russian Academy of Sciences			Chumakov, Peter M/E-7731-2014; Kopnin, Boris/R-8240-2019; Gloushankova, Natalya/S-2577-2019	Kopnin, Boris/0000-0003-3100-2212; Gloushankova, Natalya/0000-0002-2044-2063; Chumakov, Peter/0000-0002-8078-2908				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BROWN AF, 1989, CELL BIOL INT REP, V13, P357, DOI 10.1016/0309-1651(89)90162-8; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dunn G. A., 1986, J CELL SCI, V108, P1659; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FUKASAWA K, 1995, ONCOGENE, V11, P1447; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSIAO M, 1994, AM J PATHOL, V145, P702; JENKINS JR, 1984, NATURE, V312, P851; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOPNIN BP, 1995, ONCOL RES, V7, P299; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACHESKY LM, 1996, TRENDS CELL BIOL, V6, P394; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MONTESANO R, 1975, INT J CANCER, V16, P550, DOI 10.1002/ijc.2910160405; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OKAZAKI K, 1995, ONCOGENE, V10, P1149; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARK DJ, 1994, ONCOGENE, V9, P1899; PERREM K, 1995, ONCOGENE, V11, P1299; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ransone Lynn J., 1993, Gene Expression, V3, P37; SCHENENBERGER CA, 1991, J CELL BIOL, V112, P873; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, CANCER RES, V51, P5232; STROMSKAYA TP, 1995, FEBS LETT, V368, P373, DOI 10.1016/0014-5793(95)00662-S; Thomas M, 1996, ONCOGENE, V13, P265; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZAICHUK TA, 1993, P RUSSIAN ACAD SCI, V330, P386; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	52	28	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2985	2989		10.1038/sj.onc.1201483	http://dx.doi.org/10.1038/sj.onc.1201483			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416842				2022-12-28	WOS:A1997YK37700011
J	Barboule, N; Chadebech, P; Baldin, V; Vidal, S; Valette, A				Barboule, N; Chadebech, P; Baldin, V; Vidal, S; Valette, A			Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line	ONCOGENE			English	Article						p21; paclitaxel; p34(cdc2) activity; mitotic exit	CYCLIN-DEPENDENT KINASES; HUMAN OVARIAN-CARCINOMA; TAXOL-INDUCED APOPTOSIS; LEUKEMIA-CELLS; GROWTH ARREST; DNA-DAMAGE; EXPRESSION; ACTIVATION; P53; DIFFERENTIATION	It has been shown recently that expression of p21 is enhanced by paclitaxel, This cytotoxic compound induces mitotic spindle damage resulting in blockade of the mitotic cell cycle associated or not with apoptotic cell death, In the present study, we showed that, in MCF-7 cells, paclitaxel induced accumulation of p21 in cells with a G2/M DNA content, corresponding to cells either in abnormal mitosis or in an interphase-like state (decondensed chromatin) with multiple nuclei, In MCF-7 cells, the increase in p21 was subsequent to the mitotic arrest and was associated with the exit from abnormal mitosis leading to formation of cells with micronuclei. In this cell line, we noted a relationship between the elevation of p21 expression and the inhibition of p34(cdc2) activity, High levels of p21 protein were also found to be associated with inactive p34(cdc2)/cyclin B protein complex after treatment with paclitaxel, Treatment with p21 antisense oligonucleotide partially blocked induction of p21 expression by paclitaxel and significantly reduced survival of MCF-7 cells exposed to this agent, In NIH-OVCAR-3 cells, which are deficient in basal and paclitaxel-induced p21 expression, paclitaxel led to a prolonged activation of p34(cdc2) and a delayed mitotic exit associated with apoptotic cell death, These observations suggest that p21 is not required for the mitotic arrest in response to paclitaxel, but argue in favor of a role for this inhibitor in facilitating the exit from abnormal mitosis, This effectively enhances cell survival after paclitaxel-induced spindle-damage.	IPBS,CNRS,F-31077 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			CHADEBECH, Philippe/ABB-4423-2020; BALDIN, Véronique/Y-8397-2019	BALDIN, Véronique/0000-0001-8523-0494; CHADEBECH, Philippe/0000-0003-0757-4309				ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; BARBOULE N, 1995, INT J CANCER, V63, P611, DOI 10.1002/ijc.2910630502; BHALLA K, 1993, LEUKEMIA, V7, P563; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Chen J, 1996, ONCOGENE, V13, P1395; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P421; Debernardis D, 1997, CANCER RES, V57, P870; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1996, MOL CELL BIOL, V16, P762; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; JIANG HP, 1994, ONCOGENE, V9, P3397; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; LI Y, 1994, ONCOGENE, V9, P2261; LIEBMANN JE, 1993, BRIT J CANCER, V68, P1104, DOI 10.1038/bjc.1993.488; LONG BH, 1994, CANCER RES, V54, P4355; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAZARS P, 1995, FEBS LETT, V362, P295, DOI 10.1016/0014-5793(95)00247-7; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; ROWINSKY EK, 1988, CANCER RES, V48, P4093; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TANG C, 1994, LEUKEMIA, V8, P1960; TISHLER RB, 1995, CANCER RES, V55, P6021; TRIELLI MO, 1996, J CELL BIOL, V3, P689; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359	45	86	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2867	2875		10.1038/sj.onc.1201469	http://dx.doi.org/10.1038/sj.onc.1201469			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419978				2022-12-28	WOS:A1997YJ80300013
J	Guha, A; Feldkamp, MM; Lau, N; Boss, G; Pawson, A				Guha, A; Feldkamp, MM; Lau, N; Boss, G; Pawson, A			Proliferation of human malignant astrocytomas is dependent on Ras activation	ONCOGENE			English	Article						astrocytomas; ras; receptor tyrosine kinases; farnesyl transferase inhibitors	EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE-C; NUCLEOTIDE EXCHANGE FACTOR; RECEPTOR TYROSINE KINASES; HUMAN GLIOBLASTOMA CELLS; FARNESYLTRANSFERASE INHIBITORS BLOCK; MITOGENIC SIGNAL TRANSDUCTION; GRB2 ADAPTER PROTEIN; FACTOR BETA-RECEPTOR; HUMAN-BRAIN TUMORS	Overexpression and activation of receptor tyrosine kinases, such as platelet derived growth factor receptors (PDGFRs) and epidermal growth factor receptor (EGFR), leads to proliferation of human malignant astrocytoma cells. Although oncogenic mutations affecting Pas are not prevalent in human malignant astrocytomas, we have investigated whether levels of activated Ras.GTP might be elevated in these tumors secondary to the mitogenic signals originating from activated receptor tyrosine kinases. In support of this hypothesis high levels of Ras.GTP, similar to those found in oncogenic Pas transformed fibroblasts, were present in four established human malignant astrocytoma cell lines which express PDGFRs and EGFR, and 20 operative malignant astrocytoma specimens. Stimulation of PDGFR's and EGFR's induced tyrosine phosphorylation of the Shc adaptor protein and its association with Grb2, suggesting a mechanism by which Pas may be activated in human malignant astrocytoma cells. Furthermore, blocking Pas activation by expression of the Ha-Ras-Asn17 dominant-negative mutant, or by farnesyl transferase inhibitors, decreased in vitro proliferation of the human astrocytoma cell lines. These results support the hypothesis that proliferative signals from receptor tyrosine kinases expressed by human malignant astrocytoma cells utilize the Pas mitogenic pathway. Pharmacological inhibitors of the Ras pathway may therefore be of therapeutic value in these presently terminal tumors.	UNIV TORONTO,TORONTO HOSP,DIV NEUROSURG & SURG ONCOL,TORONTO,ON,CANADA; UNIV TORONTO,ONTARIO CANC INST,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON,CANADA; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of California System; University of California San Diego	Guha, A (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOL BIOL & CANC,600 UNIV AVE,TORONTO,ON M5G 1X5,CANADA.		Pawson, Tony J/E-4578-2013	Boss, Gerry/0000-0002-9758-8714				AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BASU T, 1994, ONCOGENE, V9, P3483; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BENZIL DL, 1992, CANCER RES, V52, P2951; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOS JL, 1989, CANCER RES, V49, P4682; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GLICK RP, 1992, J NEUROSURG, V77, P445, DOI 10.3171/jns.1992.77.3.0445; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guha A, 1996, ONCOGENE, V12, P507; GUHA A, 1995, J NEUROL NEUROSUR PS, V58, P711, DOI 10.1136/jnnp.58.6.711; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERMANSON M, 1992, CANCER RES, V52, P3213; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JOHN J, 1993, J BIOL CHEM, V268, P923; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KLEIHUES P, 1991, HISTOLOGICAL TYPING; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOVALENKO M, 1994, CANCER RES, V54, P6106; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MANNE V, 1995, ONCOGENE, V10, P1763; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MISRAPRESS A, 1992, GLIA, V6, P188, DOI 10.1002/glia.440060306; MORRISON RS, 1991, J BIOL CHEM, V266, P728; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUROYA K, 1992, ONCOGENE, V7, P277; NAGASU T, 1995, CANCER RES, V55, P5310; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISTER M, 1991, J BIOL CHEM, V266, P16755; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OLSON JJ, 1995, NEUROSURGERY, V36, P740, DOI 10.1227/00006123-199504000-00015; PAULUS W, 1990, ACTA NEUROPATHOL, V79, P418, DOI 10.1007/BF00308718; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; POLLACK IF, 1990, J NEUROSURG, V73, P98, DOI 10.3171/jns.1990.73.1.0098; PRISELL P, 1987, ACTA NEUROCHIR, V89, P48, DOI 10.1007/BF01406667; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RAK J, 1995, CANCER RES, V55, P4575; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROSAKISADCOCK M, 1992, NATURE, V360, P689; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SANDBERGNORDQVIST AC, 1993, CANCER RES, V53, P2475; Satoh T, 1992, Semin Cancer Biol, V3, P169; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STECK PA, 1988, CANCER RES, V48, P5433; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WINDEL K, 1994, NEUROSURGERY, V35, P439; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAN N, 1995, CANCER RES, V55, P3569; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	98	260	267	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2755	2765		10.1038/sj.onc.1201455	http://dx.doi.org/10.1038/sj.onc.1201455			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419966				2022-12-28	WOS:A1997YJ80300001
J	Miyaki, M; Nishio, J; Konishi, M; KikuchiYanoshita, R; Tanaka, K; Muraoka, M; Nagato, M; Chong, JM; Koike, M; Terada, T; Kawahara, Y; Fukutome, A; Tomiyama, J; Chuganji, Y; Momoi, M; Utsunomiya, J				Miyaki, M; Nishio, J; Konishi, M; KikuchiYanoshita, R; Tanaka, K; Muraoka, M; Nagato, M; Chong, JM; Koike, M; Terada, T; Kawahara, Y; Fukutome, A; Tomiyama, J; Chuganji, Y; Momoi, M; Utsunomiya, J			Drastic genetic instability of tumors and normal tissues in Turcot syndrome	ONCOGENE			English	Article						Turcot syndrome; genetic instability; colon tumor; brain tumor; RER in normal tissue	NONPOLYPOSIS COLON-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; MISMATCH REPAIR DEFICIENCY; COLORECTAL-CANCER; GERM-LINE; MUTATIONS; HOMOLOG; HMLH1; MSH2	Turcot syndrome is characterized by an association of malignant brain tumors and colon cancer developing in the patient's teens, Since the mechanism of carcinogenesis in Turcot syndrome is still unclear, we analysed genetic changes in tumors from a Turcot patient with no family history of the condition, All tumors, including one astrocytoma, three colon carcinomas, and two colon adenomas, exhibited severe replication error (RER), and all colon tumors showed somatic mutations at repeated regions of TGF beta RII, E2F-4, hMSH3, and/or hMSH6 genes, Somatic APC mutations were detected in three of three colon carcinomas, and somatic p53 mutations were detected in the astrocytoma and two of three colon carcinomas, both of which showed two mutations without allele loss, We also found that normal colon mucosa, normal skin fibroblasts and normal brain tissue from this patient showed respective high frequencies of RER, in contrast to usual HNPCC patients in which RER was very rare in normal tissues, These results suggest that extreme DNA instability in normal tissues causes the early development of multiple cancer in Turcot syndrome, A missense mutation (GAG to AAG) at codon 705 of hPMS2 gene was detected in one allele of this patient, which was inherited from his mother without tumors, Additional unknown germline mutation may contribute to the genetic instability in normal tissues.	TOKYO METROPOLITAN KOMAGOME HOSP,DEPT PATHOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN BOKUTOU HOSP,DEPT PATHOL,SUMIDA KU,TOKYO 130,JAPAN; TOKYO METROPOLITAN BOKUTOU HOSP,DEPT SURG,SUMIDA KU,TOKYO 130,JAPAN; TOKYO METROPOLITAN BOKUTOU HOSP,DEPT INTERNAL MED,SUMIDA KU,TOKYO 130,JAPAN; HYOGO MED UNIV,DEPT SURG 2,NISHINOMIYA,HYOGO 663,JAPAN; TOKYO MED & DENT UNIV,DEPT INTERNAL MED 1,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Hyogo College of Medicine; University of Hyogo; Tokyo Medical & Dental University (TMDU)	Miyaki, M (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; ITOH H, 1985, DIS COLON RECTUM, V28, P399, DOI 10.1007/BF02560221; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARCOWITZ S, 1995, SCIENCE, V268, P1336; MIYAKI M, 1995, J MOL MED-JMM, V73, P515; MIYAKI M, 1994, CANCER RES, V54, P3011; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NICOLAIDES NC, 1995, GENOMICS, V29, P329, DOI 10.1006/geno.1995.9997; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; ROCHLITZ CF, 1993, BRIT J CANCER, V68, P519, DOI 10.1038/bjc.1993.379; TURCOT J, 1959, Dis Colon Rectum, V2, P465, DOI 10.1007/BF02616938; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544	26	66	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2877	2881		10.1038/sj.onc.1201668	http://dx.doi.org/10.1038/sj.onc.1201668			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419979				2022-12-28	WOS:A1997YJ80300014
J	Kiyokawa, N; Karunagaran, D; Lee, EK; Xie, YM; Yan, DH; Hung, MC				Kiyokawa, N; Karunagaran, D; Lee, EK; Xie, YM; Yan, DH; Hung, MC			Involvement of cdc2-mediated phosphorylation in the cell cycle-dependent regulation of p185(neu)	ONCOGENE			English	Article						cdc2; cell cycle; p185(neu); phosphoamino acid analysis; peptide mapping; serine/threonine kinases	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; NEU ONCOGENE; POINT MUTATION; PROTEIN-KINASE; TRANSMEMBRANE DOMAIN; MOLECULAR-CLONING; EGF RECEPTOR; GENE-PRODUCT; CDC2 KINASE	We previously reported cell cycle-dependent negative regulation of p185(neu) (decreased tyrosine phosphorylation and kinase activity, with electrophoretic mobility retarded by serine/threonine phosphorylation) in M phase and the escape of mutation-activated p185(neu*) from this regulation. Our present results showed that retardation of electrophoretic mobility occurs independently of the cells' transformed status. We found that normal p185(neu) lost its ability to dimerize in the M phase. We demonstrated a physical association between cdc2 (a serine/threonine kinase, active in NI phase) and p185(neu). We showed that the carboxy terminal portion of p185(neu) is phosphorylated in vitro by cdc2. Many phosphopeptides (at least three phosphoserine residues) unique to the M phase were identified, and the in vivo and irt vitro phosphopeptide patterns were superimposable. In contrast, mutation-activated p185(neu*) dimerized in the M phase with no changes in electrophoretic mobility, failed to associate with cdc2 and no unique phosphoserine residues could be identified in the M phase (data not shown), consistent with the escape of p185(neu*) from cell cycle-dependent regulation. Our results suggest that this escape is an intrinsic property of the mutation-activated p185(neu*) independent of its ability to transform cells. Our results also suggest the involvement of serine/threonine kinases such as cdc2 in the cell cycle-dependent negative regulation of p185(neu).	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Karunagaran, Devarajan/A-8148-2010; Hung, Mien-Chie/ABD-5911-2021	Karunagaran, Devarajan/0000-0001-9331-8947; Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [CA60856, CA58880, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO HN, 1991, ONCOGENE, V6, P705; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; COCHET C, 1984, J BIOL CHEM, V259, P2553; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; FEINMESSER RL, 1986, ONCOGENE, V12, P2725; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATIN A, 1994, ONCOGENE, V9, P1333; MORRISON P, 1993, J BIOL CHEM, V268, P15536; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	49	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2633	2641		10.1038/sj.onc.1201442	http://dx.doi.org/10.1038/sj.onc.1201442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400990				2022-12-28	WOS:A1997YH46800001
J	Bobak, D; Moorman, J; Guanzon, A; Gilmer, L; Hahn, C				Bobak, D; Moorman, J; Guanzon, A; Gilmer, L; Hahn, C			Inactivation of the small GTPase Rho disrupts cellular attachment and induces adhesion-dependent and adhesion-independent apoptosis	ONCOGENE			English	Article						Rho; apoptosis; exoenzyme C3; adhesion	BINDING PROTEIN-RHO; DIFFICILE TOXIN-A; ADP-RIBOSYLTRANSFERASE; CLOSTRIDIUM-BOTULINUM; TRANSIENT EXPRESSION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; FOCAL ADHESIONS; SINDBIS VIRUS; GENE-PRODUCT	Rho small GTPases regulate a variety of cellular signaling pathways involved in cell growth and transformation, In this study, we examined potential roles for Rho in adhesion-dependent and -independent pathways regulating apoptosis, Rho GTPases are specifically inactivated by exoenzyme C3 (C3) of Clostridium botulinum. Using a novel Sindbis virus-based gene expression system, we created a double subgenomic recombinant (dsSIN:C3) capable of expressing active C3 in intact cells, Infection of L929 fibroblasts with dsSIN:C3 caused essentially complete ADP-ribosylation of intracellular Rho within 1 h, dsSIN:C3-infected cells also became rounded within 1-2 h and detached by 5 h post-infection, Infection of L929 in suspension with dsSIN:C3 disrupted the ability for normal cellular attachment and spreading, Infection of primary cell explants of chicken embryo fibroblasts (CEF) and rat aortic smooth muscle cells (RSM) with dsSIN:C3 caused cytoskeletal effects similar to those seen in L929, We also observed that C3 markedly decreased the basal phosphorylation state of focal adhesion kinase (FAK), Most intriguingly, we found that dsSIN-based expression of C3 or loss of function mutants of Rho could each induce apoptosis and, in RSM, this effect was observed to be adhesion-independent. Rho GTPases, therefore, appear to regulate signal pathways that are required for cell survival and growth that are separate from, but likely overlap with, Rho-dependent pathways involved in cellular adhesion.	UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia	Bobak, D (corresponding author), UNIV VIRGINIA,SCH MED,DEPT MED,CHARLOTTESVILLE,VA 22908, USA.				NIGMS NIH HHS [GM54572] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKTORIES K, 1994, MOL CELL BIOCHEM, V138, P167, DOI 10.1007/BF00928459; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BATES RC, 1995, CANCER METAST REV, V14, P191, DOI 10.1007/BF00690291; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEHAR S, 1995, CANCER METAST REV, V14, P165; DILLON ST, 1995, INFECT IMMUN, V63, P1421, DOI 10.1128/IAI.63.4.1421-1426.1995; Esteve P, 1995, ONCOGENE, V11, P2657; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Harlow E., 1989, ANTIBODIES LAB MANUA; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JIMENEZ B, 1995, ONCOGENE, V10, P811; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1992, BIOCHEM BIOPH RES CO, V183, P931, DOI 10.1016/S0006-291X(05)80279-7; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; LANG P, 1992, J BIOL CHEM, V267, P11677; Lebowitz PF, 1997, CANCER RES, V57, P708; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Malik RK, 1996, BBA-REV CANCER, V1287, P73, DOI 10.1016/0304-419X(96)00008-X; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Moorman JP, 1996, J IMMUNOL, V156, P4146; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PERONA R, 1993, ONCOGENE, V8, P1285; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PIERCE JS, 1973, J VIROL, V13, P1030; POPOFF M, 1990, NUCLEIC ACIDS RES, V18, P1291, DOI 10.1093/nar/18.5.1291; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Ruoslahti E, 1997, SCIENCE, V276, P1345, DOI 10.1126/science.276.5317.1345; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; SUGAI M, 1992, J BIOL CHEM, V267, P2600; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; THORNE J, 1997, UNPUB; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	67	67	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2179	2189		10.1038/sj.onc.1201396	http://dx.doi.org/10.1038/sj.onc.1201396			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393976				2022-12-28	WOS:A1997YD01900006
J	Lane, TF; Philip, L				Lane, TF; Philip, L			Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice	ONCOGENE			English	Article						Wnt10b; FGF-3/int-2; oncogene; mammary adenocarcinoma; neoplasm	WNT GENE FAMILY; TRANSGENIC MICE; TUMOR VIRUS; PROVIRAL INSERTION; EPITHELIAL-CELLS; BREAST-CANCER; EXPRESSION; GROWTH; TUMORIGENESIS; ONCOGENE	Wnt-10b is expressed during the formation of the mammary rudiment in mouse embryos and its expression continues through puberty when the mammary ductal pattern is established under control of ovarian steroids, Recently, viral activation of the Wnt-10b locus has linked its overexpression to mammary tumor formation, suggesting a role for Wnt-10b in patterning and growth-regulation of the mammary gland, To test this notion, we created lines of transgenic mice that express elevated levels of Wnt-10b under the control of the MMTV promoter/enhancer. Overexpression of this gene resulted in profound developmental alterations in the mammary gland, including expanded glandular development and the precocious appearance of alveoli in virgin females, Moreover, transgenic male mice also exhibited dramatic mammary development involving highly branched mammary ducts and gynecomastia. Aberrant expression of Wnt-10b in the mammary rudiments of males evidently bypasses the normal requirement for ovarian hormonal control in stimulating mammary ductal growth and the repressive effects of androgens, In addition to these developmental effects, transgenic mice of both sexes were highly susceptible to the development of mammary adenocarcinomas, Such tumors arose in a solitary manner indicating that Wnt-10b is a proto-oncogene which provides a necessary, but insufficient signal for oncogenesis, Relevant to this, there was no evidence of amplified expression of FGF mRNAs in these tumors though the Fgf's are a class of genes often implicated as collaborators in Wilt-mediated tumor formation, Indeed, co-expression of MMTV-Wnt-10b and MMTV-FGF-3/int-2 resulted in sterile offspring with highly disorganized mammary epithelium, demonstrating a potent interaction between their respective developmental pathways, These results suggest that Wnt-10b, or other Wilt genes expressed early in mammary development, play a role in regulating sexual dimorphism and show potent transforming activity when overexpressed.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Lane, Timothy F./0000-0002-0210-970X				Amundadottir LT, 1996, ONCOGENE, V13, P757; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; BRADBURY JM, 1994, ONCOGENE, V9, P2579; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; CHOOI KF, 1994, CANCER RES, V54, P6434; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; DU SJ, 1995, MOL CELL BIOL, V15, P2625; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; Dunn T, 1959, PHYSIOPATHOLOGY CANC, P38; FAUKLIN LV, 1960, J NATL CANCER I, V24, P953; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Hardiman G, 1996, GENE, V172, P199, DOI 10.1016/0378-1119(96)00109-6; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MEDINA D, 1982, TRANSGENES MOUSE BIO; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NANDI S, 1958, J NATL CANCER I, V21, P1039; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; TZENG YJ, 1993, ONCOGENE, V8, P1965; Wang JW, 1996, ONCOGENE, V13, P1537; Wang YS, 1996, J BIOL CHEM, V271, P4468; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	42	120	127	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2133	2144		10.1038/sj.onc.1201593	http://dx.doi.org/10.1038/sj.onc.1201593			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393971				2022-12-28	WOS:A1997YD01900001
J	Sivak, LE; Tai, KF; Smith, RS; Dillon, PA; Brodeur, GM; Carroll, WL				Sivak, LE; Tai, KF; Smith, RS; Dillon, PA; Brodeur, GM; Carroll, WL			Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines	ONCOGENE			English	Article						N-myc promoter; neuroblastoma; autoregulation	HUMAN C-MYC; GENE AMPLIFICATION; MAMMALIAN-CELLS; NEURO-BLASTOMA; NEGATIVE AUTOREGULATION; DIFFERENTIAL EXPRESSION; REGULATORY ELEMENTS; BURKITT-LYMPHOMA; TRANSGENIC MICE; CYCLIN D1	Amplification of the N-myc gene is a significant adverse prognostic factor in neuroblastoma, a common childhood tumor, In non-transformed cells, myc expression is controlled through an autoregulatory circuit, through which elevated Myc protein levels lead to down-regulation of myc transcription, The precise mechanism of myc gene autoregulation is unknown, Loss of c-myc autoregulation has been documented in transformed cells from a number of different lineages, but N-myc autoregulation has not yet been investigated, In neuroblastoma, the increased N-Myc protein produced by amplified tumors mould be expected to silence N-myc transcription if the autoregulatory loop were intact, To determine whether N-myc autoregulation is operative in human neuroblastoma, and to localize cis-acting elements which mediate N-myc autosuppression, we transfected a series of N-myc 5' promoter constructs into a panel of human neuroblastoma cell lines carrying one or multiple copies of N-myc, The transfected promoter was equally amplified lines, Significant promoter activity in the presence of abundant Myc protein in amplified neuroblastoma Lines indicates that autoregulation is disabled in this subset of tumors, To investigate,whether single-copy lines produce insufficient N-Myc protein to trigger autosuppression yet retain an intact autoregulatory circuit, we transfected neuroblastoma lines with 5' promoter constructs in the presence of a c- or N-myc expression vector, Overexpression of c- or N-Myc resulted in diminution of activity of both the transfected promoter and the endogenous N-myc gene in single-copy, but not amplified lines, Using a series of 5' promoter-deletion minigenes, we localized a cis-acting element required for autoregulation close to the transcription start sites, While the precise mechanism of autosuppression remains unknown, we demonstrated that Myc is incapable of silencing the adenovirus major late promoter (AdMLP) in neuroblastoma cells, indicating that Myc suppression of its own promoter and the AdMLP involve distinct components, These studies provide the first systematic investigation of autoregulation in neuroblastoma, and indicate that single-copy neuroblastoma lines produce insufficient N-Myc protein to activate downstream effector(s) of autosuppression; the autoregulatory circuit is otherwise intact, Amplified lines, in contrast, have lost autoregulation.	UNIV UTAH, SCH MED, ECCLES INST HUMAN GENET, HUNTSMAN CANC INST, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT PATHOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT PEDIAT, SALT LAKE CITY, UT 84112 USA; JOHNS HOPKINS UNIV, DIV PEDIAT SURG, BALTIMORE, MD USA; CHILDRENS HOSP PHILADELPHIA, DIV PEDIAT HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Johns Hopkins University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia					NCI NIH HHS [5T32CA09602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1986, NATURE, V321, P702; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BARTRAM CR, 1987, EUR J PEDIATR, V146, P162, DOI 10.1007/BF02343225; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BERTLING W, 1987, J BIOCHEM BIOPH METH, V14, P223, DOI 10.1016/0165-022X(87)90011-X; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BUCKLE RS, 1996, ONCOGENE, V10; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CROUCH DH, 1990, ONCOGENE, V5, P683; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Goldman SC, 1996, AM J PATHOL, V148, P1381; GRADY EF, 1987, CANCER RES, V47, P2931; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HILLER S, 1991, ONCOGENE, V6, P969; JAKOBVITS A, 1985, NATURE, V318, P1188; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MA A, 1991, MOL CELL BIOL, V11, P440, DOI 10.1128/MCB.11.1.440; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NEPVEU A, 1987, ONCOGENE, V1, P243; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SLAVC I, 1990, CANCER RES, V50, P1459; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; VERSTEEG R, 1990, MOL CELL BIOL, V10, P5416, DOI 10.1128/MCB.10.10.5416; VOGAN K, 1993, CANCER RES, V53, P5269; WADA RK, 1992, ONCOGENE, V7, P711; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WANG YS, 1992, ONCOGENE, V7, P1241; WOODRUFF KA, 1995, ONCOGENE, V10, P1335; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	65	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	1997	15	16					1937	1946		10.1038/sj.onc.1201363	http://dx.doi.org/10.1038/sj.onc.1201363			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365240				2022-12-28	WOS:A1997YA87200008
J	Takada, S; Kaneniwa, N; Tsuchida, N; Koike, K				Takada, S; Kaneniwa, N; Tsuchida, N; Koike, K			Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells	ONCOGENE			English	Article						hepatitis B virus; X gene transfection; X protein; p53 tumor suppressor gene; p53 protein; nuclear localization	HUMAN HEPATOCELLULAR-CARCINOMA; LONG TERMINAL REPEAT; WILD-TYPE; DNA-BINDING; TRANSACTIVATION FUNCTION; TRANSCRIPTIONAL ACTIVITY; CELLULAR PROTEINS; EXPRESSION SYSTEM; TRANS-ACTIVATION; VIRAL ENHANCERS	It has been suggested that hepatitis B virus (HBV) X gene activates X gene expression by disrupting the function of p53 tumor suppressor gene (Takada et al., 1996). To find out their connection, effect of X protein expression on the nuclear localization of p53 protein in human hepatoma cells was examined by the immunofluorescent double-staining technique. The location of transiently-expressed p53 protein was examined in X gene-transfected cells, where X protein was detected in the cytoplasm. The nuclear location of transiently-expressed p53 protein was changed to the cytoplasm by X protein co-expression. Endogenous p53 protein was also observed in the cytoplasm by X protein expression. The transcriptional activation domain of X protein and the carboxy-terminal region of p53 protein were found mutually responsible for the cytoplasmic retention of p53 in X gene-transfected cells. Therefore, the cytoplasmic retention of p53 protein may be closely correlated to the function of X protein expressed in transfected cells.	JAPANESE FDN CANC RES,INST CANC,DEPT GENE RES,TOSHIMA KU,TOKYO 170,JAPAN; TOKYO MED & DENT UNIV,DEPT MOL & CELLULAR ONCOL,BUNKYO KU,TOKYO 113,JAPAN	Japanese Foundation for Cancer Research; Tokyo Medical & Dental University (TMDU)								ARII M, 1992, ONCOGENE, V7, P397; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FAKTOR O, 1990, ONCOGENE, V5, P867; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOBAYASHI M, 1984, GENE, V30, P227; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NATOLI G, 1994, ONCOGENE, V9, P2837; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAKOTOMAHANINA CK, 1994, ONCOGENE, V9, P2613; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SAKAI E, 1992, ONCOGENE, V7, P927; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; TAKADA S, 1994, ONCOGENE, V9, P341; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; Takada S, 1996, VIROLOGY, V216, P80, DOI 10.1006/viro.1996.0036; TAKADA S, 1994, VIRAL HEPATITIS LIVE, P753; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	52	76	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1895	1901		10.1038/sj.onc.1201369	http://dx.doi.org/10.1038/sj.onc.1201369			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365235				2022-12-28	WOS:A1997YA87200003
J	Michael, D; Beer, DG; Wilke, CW; Miller, DE; Glover, TW				Michael, D; Beer, DG; Wilke, CW; Miller, DE; Glover, TW			Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas	ONCOGENE			English	Article						Barrett's esophagus; fragile sites; FRA3B; gene deletion; human chromosome 3	RENAL-CELL CARCINOMA; TUMOR-SUPPRESSOR LOCUS; COMMON FRAGILE SITES; LUNG-CANCER; SHORT ARM; 3P14.2; GENE; DNA; BREAKAGE; LINES	The FHIT gene, which spans the common fragile site FRA3B, has been shown to produce aberrant transcripts in a variety of tumor types, Homozygous deletions within the FHIT locus have been detected only in tumor-derived cell lines and LOH has been described in numerous primary tumors, Based on these findings and its location on 3p, FHIT has been proposed as a tumor suppressor gene, To further study the relationship of FRA3B to the findings regarding the FHIT gene and to determine the extent of FHIT mRNA alterations in early stages of tumor development, the status of the FHIT gene was evaluated in the premalignant condition of Barrett's esophagus and associated esophageal adenocarcinomas, FHIT expression was investigated by RT-PCR in normal esophageal, Barrett's metaplasia and adenocarcinoma tissues from 15 patients, Alterations of FHIT transcripts were observed in 12/14 (86%) of Barrett's metaplasia and in 14/15 (93%) of the adenocarcinomas from the same patients, Characterization of the altered transcripts revealed FHIT mRNA lacking one or more exons, with deletion of exons 5-7 being most frequent, Analysis of genomic DNA from 20 patients showed homozygous deletions involving exon 5 of FHIT in 4/20 (20%) esophageal adenocarcinomas, and 7/20 (35%) tumors demonstrated hemizygous loss, Genomic deletions also involved the BE758-6 locus, indicating that a large region is deleted. Fluorescence ill situ hybridization (FISH) analysis demonstrated that this region of deletion is localized within FRA3B, Our results extend the range of tumor types in which altered FHIT transcripts have been demonstrated and show that these alterations can be seen in the premalignant stage of esophageal tumor development, These results indicate that the fragility and recombination-prone nature of FRA3B is related to tumor-specific chromosomal instability affecting the FHIT gene in esophageal adenocarcinoma development.	UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT SURG,THORAC SURG SECT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [CA 71606, CA 43222] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071606, R01CA043222] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BIRNBOIM HC, 1982, SCIENCE, V215, P1247, DOI 10.1126/science.6276978; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIERICK HA, 1995, GENOMICS, V28, P462, DOI 10.1006/geno.1995.1175; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Druck T, 1997, CANCER RES, V57, P504; Gantz I, 1996, CYTOGENET CELL GENET, V74, P286, DOI 10.1159/000134436; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, AM J HUM GENET, V43, P265; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gustashaw KM., 1991, ACT CYTOGENETICS LAB, V2; JONES MH, 1992, ONCOGENE, V7, P1631; Kastury K, 1996, CANCER RES, V56, P978; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151; NAWROZ H, 1994, CANCER RES, V54, P1152; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Negrini M, 1996, CANCER RES, V56, P3173; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; SATO T, 1991, CANCER RES, V51, P5794; Shridhar R, 1996, CANCER RES, V56, P4347; SOZZI G, 1996, CELL, V85, P7; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; Thiagalingam S, 1996, CANCER RES, V56, P2936; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; WANG ND, 1993, GENOMICS, V17, P341, DOI 10.1006/geno.1993.1330; WEITBERG AB, 1983, NEW ENGL J MED, V308, P26, DOI 10.1056/NEJM198301063080107; WEITZMAN SA, 1985, SCIENCE, V227, P1231, DOI 10.1126/science.3975611; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Yanagisawa K, 1996, CANCER RES, V56, P5579; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZEIGER MA, 1994, GENE CHROMOSOME CANC, V11, P15, DOI 10.1002/gcc.2870110104	42	105	114	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1653	1659						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349498				2022-12-28	WOS:A1997XY63100004
J	Chalk, JG; Barr, FG; Mitchell, CD				Chalk, JG; Barr, FG; Mitchell, CD			Translin recognition site sequences flank chromosome translocation breakpoints in alveolar rhabdomyosarcoma cell lines	ONCOGENE			English	Article							PAX3-FKHR FUSION PROTEIN; GENE; PAX3; HYBRID; DIFFERENTIATION; REARRANGEMENT; CLUSTER; REGION	Alveolar rhabdomyosarcoma is characterized by a t(2;13)(q35;q14) chromosome translocation, which leads to the fusion of the PAX3 and the FKHR genes, The resulting fusion gene encodes a chimeric protein which has aberrant transcriptional activity, We report the molecular definition of the genomic breakpoints on both derivative chromosomes in one case and the derivative chromosome 13 breakpoints in two other cases, The DNA sequences adjacent to the breakpoints on the derivative chromosome 13 are remarkable for their resemblance to recognition sequences for the protein translin. Gel shift analyses confirm that these sequences bind translin, These findings suggest that translin may not only be important in the genesis of chromosomal translocations in lymphoid malignancy, but also in translocations found in solid tumours.	UNIV OXFORD, JOHN RADCLIFFE HOSP, DEPT PAEDIAT, OXFORD OX3 9DU, ENGLAND; UNIV PENN, DIV PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DIV LAB MED, PHILADELPHIA, PA 19104 USA	University of Oxford; University of Pennsylvania; University of Pennsylvania					NATIONAL CANCER INSTITUTE [R29CA061935] Funding Source: NIH RePORTER; NCI NIH HHS [CA61935] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; CHEN SJ, 1989, ONCOGENE, V4, P195; COWELL JK, 1989, CYTOGENET CELL GENET, V52, P1, DOI 10.1159/000132827; DAVIS RJ, 1995, HUM MOL GENET, V4, P2355, DOI 10.1093/hmg/4.12.2355; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; MACINA RA, 1995, GENOMICS, V26, P1, DOI 10.1016/0888-7543(95)80076-X; MITCHELL CD, 1991, ONCOGENE, V6, P89; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SHAN Z, 1992, HUM GENET, V90, P435; SORENSEN PHB, 1995, CANCER RES, V55, P1385	18	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1199	1205		10.1038/sj.onc.1201285	http://dx.doi.org/10.1038/sj.onc.1201285			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294613				2022-12-28	WOS:A1997XU99100009
J	SchmidtUllrich, RK; Mikkelsen, RB; Dent, P; Todd, DG; Valerie, K; Kavanagh, BD; Contessa, JN; Rorrer, WK; Chen, PB				SchmidtUllrich, RK; Mikkelsen, RB; Dent, P; Todd, DG; Valerie, K; Kavanagh, BD; Contessa, JN; Rorrer, WK; Chen, PB			Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation	ONCOGENE			English	Article						ionizing radiation; epidermal growth factor receptor; calcium; phospholipase C; mitogen-activated protein kinase; cell proliferation	EPIDERMAL-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASES; FACTOR RECEPTOR; IONIZING-RADIATION; BREAST-CANCER; MCF-7 CELLS; IN-VITRO; INHIBITION; APOPTOSIS; STRESS	Accelerated cellular repopulation has been described as a response of tumors to fractionated irradiation in both normal tissue and tumor systems, To identify the mechanisms by which cells enhance their proliferative rate in response to clinically used doses of ionizing radiation (IR) we have studied human mammary and squamous carcinoma cells which are autocrine growth regulated by the epidermal growth factor receptor (EGFR) and its ligands, transforming growth factor-alpha and EGF, Both EGF and IR induced EGFR autophosphorylation, comparable levels of phospholipase C gamma activation as measured by inositol-1,4,5-triphosphate production, and as a consequence oscillations in cytosolic [Ca2+]. Activities of Raf-l and mitogen-activated protein kinase (MAPK) were also stimulated by EGF and IR by Ca2+-dependent mechanisms. All these responses to EGF and IR were dependent upon activation of EGFR as judged by the use of the specific inhibitor of EGFR autophosphorylation, tyrphostin AG1478. Importantly, IR-induced proliferation of A431 cells was also inhibited by AG1478. This is the first report which demonstrates a link between IR-induced activation of proliferative signal transduction pathways and enhanced proliferation, We propose that accelerated repopulation of tumors whose growth is regulated by EGFR is initiated by an IR-induced EGFR activation mechanism that mimics the effects of growth factors.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL TOXICOL,RICHMOND,VA 23298	Virginia Commonwealth University	SchmidtUllrich, RK (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT RADIAT ONCOL,POB 980058,RICHMOND,VA 23298, USA.		Valerie, Kristoffer/AAL-8299-2021		NATIONAL CANCER INSTITUTE [R01CA065896] Funding Source: NIH RePORTER; NCI NIH HHS [CA65896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; CARMICHAEL J, 1987, CANCER RES, V47, P943; CHAJRY N, 1994, BIOCHEM BIOPH RES CO, V203, P984, DOI 10.1006/bbrc.1994.2279; DENEKAMP J, 1973, BRIT J RADIOL, V46, P381, DOI 10.1259/0007-1285-46-545-381; DENT P, 1995, MOL CELL BIOL, V15, P4125; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FAN Z, 1994, J BIOL CHEM, V269, P27595; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; FUKS Z, 1993, RADIAT ONCOL INVEST, V1, P81; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HERNANDEZSOTOMAYOR SMT, 1993, BIOCHEM J, V293, P507, DOI 10.1042/bj2930507; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kavanagh BD, 1995, CLIN CANCER RES, V1, P1557; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIANG M, 1992, MOL PHARMACOL, V42, P743; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; SCHMIDTULLRICH RK, 1994, INT J RADIAT ONCOL, V29, P813, DOI 10.1016/0360-3016(94)90570-3; SCHMIDTULLRICH RK, 1996, RADIAT RES, V145, P79; SCHMIDTULLRICH RK, 1992, INT J RADIAT BIOL, V61, P141; STEVENSON MA, 1994, CANCER RES, V54, P12; TODD DG, 1994, CANCER RES, V54, P5224; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WITHERS HR, 1995, INT J RADIAT ONCOL, V33, P549, DOI 10.1016/0360-3016(95)00228-Q; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; YANG LJ, 1993, J BIOL CHEM, V268, P3739; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	36	375	388	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1191	1197		10.1038/sj.onc.1201275	http://dx.doi.org/10.1038/sj.onc.1201275			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294612				2022-12-28	WOS:A1997XU99100008
J	Ueno, NT; Yu, DH; Hung, MC				Ueno, NT; Yu, DH; Hung, MC			Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A	ONCOGENE			English	Article						HER-2/neu; E1A; paclitaxel; breast neoplasms; gene therapy	GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; GENE-PRODUCTS; EGF RECEPTOR; PROGNOSTIC-SIGNIFICANCE; EXPRESSION; METASTASIS; P53; TRANSFORMATION; C-ERBB-2	Breast cancer cells that overexpress HER-2/neu are more resistant to chemotherapeutic agents such as paclitaxel (Taxol) and docetaxel (Taxotere) than those that do not overexpress HER-2/neu. In previous work, we showed that the adenovirus type 5 E1A can repress HER-2/neu expression at the transcriptional level, Here we first demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse fibroblasts expressing different levels of HER-2/neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel. To further test whether E1A can sensitize HER-2/neu-overexpressing human breast cancer cells to paclitaxel through E1A-mediated HER-2/neu repression, an adenoviral vector was used to transfer the E1A gene into two human breast cancer cell lines, MDA-MB-453 and MDA-MB-361, that overexpress HER-2/neu. After E1A delivery, we observed that HER-2/neu expression level was reduced, and cells mere treated with paclitaxel. Cell proliferation assays showed a synergistic growth inhibition effect of E1A and paclitaxel, The synergistic effect was also confirmed by soft agar colony-formation assay, Breast cancer cell lines that express low levels of HER-2/neu, MDA-MB-435 and MDA-MB-231 cells showed no synergistic growth inhibition effect when treated on the same protocols, Thus, we concluded that the adenovirus type 5 E1A gene can sensitize paclitaxel-resistant HER-2/neu-overexpressing breast cancer cells to the drug by repressing HER-2/neu expression. This in turn may have important implications for the development of a novel therapy that combines chemotherapy and gene therapy.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,SECT BLOOD & MARROW TRANSPLANTAT,DEPT HEMATOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BREAST CANC BAS RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [CA58880, CA60856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880, R01CA060856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMANDI M, 1995, ONCOGENE, V10, P1813; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Chang JY, 1996, ONCOGENE, V13, P1405; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; FRISCH SM, 1995, CANCER RES, V55, P5551; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HATA Y, 1994, ONCOL RES, V6, P19; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MATIN A, 1990, ONCOGENE, V5, P111; MCCANN AH, 1991, CANCER RES, V51, P3296; MILLER SJ, 1995, ONCOL REP, V2, P497; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1994, J NATL CANCER I, V86, P1018, DOI 10.1093/jnci/86.13.1018; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Ullrich Axel, 1989, SCIENCE, V244, P707, DOI DOI 10.1126/SCIENCE.2470152; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WEBB JL, 1963, ENZYMES METABOL INH, V1, P507; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1991, ONCOGENE, V6, P343; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1994, CELL GROWTH DIFFER, V5, P431; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; Yu DH, 1996, ONCOGENE, V13, P1359; Zhang LS, 1996, ONCOGENE, V12, P571; ZHANG YJ, 1995, ONCOGENE, V10, P1947	52	92	102	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					953	960		10.1038/sj.onc.1201250	http://dx.doi.org/10.1038/sj.onc.1201250			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285690				2022-12-28	WOS:A1997XR76700008
J	Huang, CC; Papas, TS; Bhat, NK				Huang, CC; Papas, TS; Bhat, NK			A variant form of ETS1 induces apoptosis in human colon cancer cells	ONCOGENE			English	Article						oncogene; tumor suppressor gene; colon cancer; ETS1 protein; epithelial cancer	TRANSCRIPTION FACTORS; EXPRESSION; GENES; ISOFORMS; PROTEINS; BINDING; FAMILY	We have previously shown that the human ETS1 protein (pS1-ETS1), when ectopically expressed in colon cancer cell lines, is able to reduce its tumorigenicity without affecting its growth properties, To understand the mechanism of tumor reduction, we have expressed two different forms of ETS1 in colon cancer cell lines, Data presented in this paper indicate that the naturally occurring spliced variant protein, p42-ETS1, lacking the region encoded by ETS1 exon VII, represses the tumorigenicity, while p51-ETS1 reduces the tumorigenicity, Repression of tumorigenicity mediated by p42-ETS1 appears to be caused by its ability to induce apoptosis in epithelial cancer cells, This work can have profound medical significance in that it may open up new insights into the potential role of the p42-ETS1 in the induction of apoptosis in epithelial cell cancers and may provide a rationale for its use for potential gene therapy experiments to initiate cell death in cancer cells.	NCI,FREDERICK CANC RES & DEV CTR,SAIC,RECOMBINANT DNA LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Huang, CC (corresponding author), MED UNIV S CAROLINA,HOLLINGS CANC CTR,CTR MOL & STRUCT BIOL,CHARLESTON,SC 29425, USA.							BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; Bhat NK, 1996, INT J ONCOL, V8, P841; BHAT NK, 1994, CHALLENGES MODERN ME, V5, P63; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; JORCYK CL, 1991, ONCOGENE, V6, P523; KOIZUMI S, 1990, ONCOGENE, V5, P675; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROMANOSPICA V, 1994, INT J ONCOL, V4, P521; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2726; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; SUZUKI H, 1993, INT J ONCOL, V3, P56; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	20	39	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					851	856		10.1038/sj.onc.1201408	http://dx.doi.org/10.1038/sj.onc.1201408			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266972				2022-12-28	WOS:A1997XQ11700012
J	Rizos, H; Becker, TM; Holland, EA; Kefford, RF; Mann, GJ				Rizos, H; Becker, TM; Holland, EA; Kefford, RF; Mann, GJ			Differential expression of p16(INK4a) and p16 beta transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations	ONCOGENE			English	Article						p16(INK4a); p16 beta; hereditary melanoma	TUMOR-SUPPRESSOR GENE; KINASE-4 INHIBITOR GENE; HOMOZYGOUS DELETIONS; HUMAN CANCERS; P16 GENE; METHYLATION; P16/CDKN2; LOCUS; HYPERMETHYLATION; INACTIVATION	Mutations in the CDKN2A (p16(INK4a)) tumour suppressor gene on chromosome 9p21 are associated with inherited predisposition to melanoma, yet some 9p-linking hereditary melanoma families show no mutations in this gene. Splicing of CDKN2A exons 2 and 3 to an alternative first exon produces a transcript (p16 beta) encoding a protein with cell cycle regulatory properties. We have analysed allele-specific expression levels of both the p16(INK4a) and p16 beta transcripts in B-lymphoblastoid cells from 18 members of hereditary melanoma kindreds including four unrelated control individuals. In 15 of the 18 individuals examined, steady-state levels of each transcript either originated equally from each parental chromosome, or one parental chromosome was dominant for both transcripts. However, in three affected members of two 9p-linking hereditary melanoma kindreds, without exonic CDKN2A mutations, this pattern of coordinate expression was disrupted. In these individuals there was underexpression of the p16 beta transcript, relative to the p16(INK4a) transcript, from the chromosome segregating with disease susceptibility, Loss of coordinate expression of the p16(INK4a) and p16 beta transcripts may be an alternative genetic basis for melanoma susceptibility in certain 9p-linking kindreds.			Rizos, H (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,WESTMEAD INST CANC RES,WESTMEAD,NSW 2145,AUSTRALIA.		Rizos, Helen/AAE-5010-2020; Mann, Graham J/G-4758-2014	Rizos, Helen/0000-0002-2094-9198; Mann, Graham J/0000-0003-1301-405X; Becker, Therese/0000-0002-5636-9902; Kefford, Richard/0000-0001-9251-9229				Borg A, 1996, CANCER RES, V56, P2497; Brown DW, 1996, P NATL ACAD SCI USA, V93, P1418, DOI 10.1073/pnas.93.4.1418; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; COLOMBO P, 1992, P NATL ACAD SCI USA, V89, P6358, DOI 10.1073/pnas.89.14.6358; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GLENDENING JM, 1995, CANCER RES, V55, P5531; GODECKE A, 1991, NUCLEIC ACIDS RES, V19, P5351, DOI 10.1093/nar/19.19.5351; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Hara E, 1996, MOL CELL BIOL, V16, P859; HERMAN JG, 1995, CANCER RES, V55, P4525; HOFFMEYER S, 1995, HUM MOL GENET, V4, P1267, DOI 10.1093/hmg/4.8.1267; Holland EA, 1995, ONCOGENE, V11, P2289; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; IGAKI H, 1995, CANCER RES, V55, P3421; JONES BK, 1995, MOL CELL BIOL, V15, P7010; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEFFORD RF, 1991, CANCER GENET CYTOGEN, V51, P45, DOI 10.1016/0165-4608(91)90007-H; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; LI Y, 1994, CANCER RES, V54, P6078; Liggett WH, 1996, CANCER RES, V56, P4119; LIU L, 1995, ONCOGENE, V11, P405; LUBBERT M, 1992, BRIT J HAEMATOL, V81, P370, DOI 10.1111/j.1365-2141.1992.tb08241.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OTTERSON GA, 1995, ONCOGENE, V11, P1211; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SAKAI T, 1991, AM J HUM GENET, V48, P880; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STONE S, 1995, CANCER RES, V55, P2988; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; YEAGER T, 1995, CANCER RES, V55, P493	46	27	27	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					515	523		10.1038/sj.onc.1201217	http://dx.doi.org/10.1038/sj.onc.1201217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247305				2022-12-28	WOS:A1997XN25500003
J	ElAshry, D; Miller, DL; Kharbanda, S; Lippman, ME; Kern, FG				ElAshry, D; Miller, DL; Kharbanda, S; Lippman, ME; Kern, FG			Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis	ONCOGENE			English	Article						breast cancer; apoptosis; Raf-1 kinase; estrogen-independence	HUMAN MAMMARY TISSUES; PROTEIN-KINASE; MCF-7 CELLS; IN-VITRO; MAP KINASE; SIGNAL-TRANSDUCTION; DEPLETED CONDITIONS; PROGNOSTIC FACTORS; FACTOR SECRETION; RECEPTOR	Overexpression of many growth factor receptors, as well as growth factors, has been shown to confer varying degrees of estrogen-independent growth on estrogen receptor (ER) positive breast cancer cells. The protooncogene Raf-1 is a key intermediate in the signal transduction pathway of many of these growth factor receptors, and when constitutively activated in fibroblasts is transforming. To examine the effects of Raf-1 kinase activity on the estrogen-dependent growth of human breast cancer cells, ER+ MCF-7 breast cancer cells were stably transfected with an expression construct directing the expression of an amino-truncated protein having constitutive kinase activity. Expression of constitutively activated Raf in MCF-7 cells is incompatible with growth in the presence of estrogen; that is, cells down-regulate expression of the transfected Raf. Constitutive Raf activity does allow for growth of the cells in the absence of estrogen, suggesting that activation of growth factor signaling pathways through Raf may confer a selective advantage for growth of breast cancer cells under estrogen-deprived conditions. In addition, the high levels of Raf activity induce apoptosis in cells grown under either condition. This is a novel activity for Raf, and may occur because the levels of the constitutive Raf are extremely high in these cells.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20007	Georgetown University; Georgetown University	ElAshry, D (corresponding author), GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007, USA.				NCI NIH HHS [CA50376, 2P30-CA-51008, CA71465] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA071465, P30CA051008, R01CA050376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1992, CELL GROWTH DIFFER, V3, P731; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRACEY TS, 1995, ONCOGENE, V10, P2391; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK GM, 1988, SEMIN ONCOL, V15, P20; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DESOMBRE ER, 1986, CANCER RES, V46, P4256; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; HEERDT BG, 1994, CANCER RES, V54, P3288; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMAL S, 1995, ONCOGENE, V10, P2095; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KASID A, 1987, CANCER RES, V47, P5733; KNIGHT WA, 1977, CANCER RES, V37, P4669; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYPRIANOU N, 1991, CANCER RES, V51, P162; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIPPMAN ME, 1989, J STEROID BIOCHEM, V34, P107, DOI 10.1016/0022-4731(89)90071-X; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MCGUIRE WL, 1990, J NATL CANCER I, V82, P1006, DOI 10.1093/jnci/82.12.1006; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OHUCHI N, 1986, CANCER RES, V46, P2511; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SOMMERS CL, 1990, CANCER RES, V50, P67; STRANGE R, 1992, DEVELOPMENT, V115, P49; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOR A, 1986, LAB INVEST, V55, P603; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WANG HG, 1994, ONCOGENE, V9, P2751; WANG TTY, 1995, CANCER RES, V55, P2487; WARRI AM, 1993, JNCI-J NATL CANCER I, V85, P1412, DOI 10.1093/jnci/85.17.1412; WHITE E, 1994, COLD SPRING HARB SYM, V59, P395, DOI 10.1101/SQB.1994.059.01.044; WILSON JW, 1995, INT J CANCER, V61, P502, DOI 10.1002/ijc.2910610413; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	62	84	86	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					423	435		10.1038/sj.onc.1201198	http://dx.doi.org/10.1038/sj.onc.1201198			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242379				2022-12-28	WOS:A1997XM23800007
J	Voz, ML; Astrom, AK; Kas, K; Mark, J; Stenman, G; Van de Ven, WJM				Voz, ML; Astrom, AK; Kas, K; Mark, J; Stenman, G; Van de Ven, WJM			The recurrent translocation t(5;8)(p13;q12) in pleomorphic adenomas results in upregulation of PLAG1 gene expression under control of the LIFR promoter	ONCOGENE			English	Article						PLAG1; LIFR; chromosome translocation; pleomorphic adenoma	LEUKEMIA INHIBITORY FACTOR; CYTOKINE RECEPTOR SUPERFAMILY; TUMORS	We have previously shown that the PLAG1 gene on chromosome 8q12 is consistently rearranged in pleomorphic adenomas of the salivary glands with t(3;8)(p21;q12) translocations, The t(3;8) results in promoter swapping between the PLAG1 gene, which encodes a novel zinc finger protein, and the constitutively expressed gene for beta-catenin (CTNNB1), a protein with roles in cell-cell adhesion and the WG/WNT signalling pathway, In order to assess the importance of other translocation partner genes of PLAG1, and their possible relationship to CTNNB1, we have characterized a second recurrent translocation, i.e. the t(5;8)(p13;q12), This translocation leads to ectopic expression of a chimeric transcript consisting of sequences from the ubiquitously expressed gene for the leukemia inhibitory factor receptor (LIFR) and PLAG1, As for the t(3;8), the fusions occurred in the 5'-noncoding regions of both genes, exchanging regulatory control elements while preserving the coding sequences. The results of the current as well as previous studies indicate that ectopic expression of PLAG1 under the control of promoters of distinct translocation partner genes is a general pathogenetic mechanism for pleomorphic adenomas with 8q12 aberrations.	Catholic Univ Louvain, Ctr Human Genet, Oncol Mol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Gothenburg Univ, Sahlgrens Hosp, Dept Pathol, Canc Genet Lab, SE-41345 Gothenburg, Sweden; Cent Hosp, Dept Pathol, SE-54185 Skovde, Sweden	Universite Catholique Louvain; Sahlgrenska University Hospital; University of Gothenburg	Van de Ven, WJM (corresponding author), Catholic Univ Louvain, Ctr Human Genet, Oncol Mol Lab, Herestr 49, B-3000 Louvain, Belgium.							ASHAR HR, 1995, CELL, V82, P57; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BULLERDIEK J, 1993, CANCER GENET CYTOGEN, V65, P27, DOI 10.1016/0165-4608(93)90054-P; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; Eaton S, 1996, TRENDS CELL BIOL, V6, P287, DOI 10.1016/0962-8924(96)20026-1; GEARING DP, 1993, GENOMICS, V18, P148, DOI 10.1006/geno.1993.1441; GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; Ilyas M, 1997, J PATHOL, V182, P128; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Owczarek CM, 1996, J BIOL CHEM, V271, P5495, DOI 10.1074/jbc.271.10.5495; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Roijer E, 1996, GENE CHROMOSOME CANC, V17, P166; Sambrook J., 2002, MOL CLONING LAB MANU; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SCHOENMAKERS EFPM, 1995, GENOMICS, V29, P665, DOI 10.1006/geno.1995.9952; SCHOENMAKERS EFPM, 1994, GENOMICS, V20, P210, DOI 10.1006/geno.1994.1155; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Tomida M, 1996, J BIOCHEM-TOKYO, V120, P201; [No title captured]	22	123	127	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1409	1416		10.1038/sj.onc.1201660	http://dx.doi.org/10.1038/sj.onc.1201660			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525740				2022-12-28	WOS:000072572400005
J	Wicking, C; Evans, T; Henk, B; Hayward, N; Simms, LA; Chenevix-Trench, G; Pietsch, T; Wainwright, B				Wicking, C; Evans, T; Henk, B; Hayward, N; Simms, LA; Chenevix-Trench, G; Pietsch, T; Wainwright, B			No evidence for the H133Y mutation in SONIC HEDGEHOG in a collection of common tumour types	ONCOGENE			English	Article						Hedgehog; patched; mutation	SUPPRESSOR GENE; HUMAN HOMOLOG; CARCINOMA; RECEPTOR; ENCODES	The homologue of the Drosophila segment polarity gene patched is mutated in the cancer predisposition syndrome naevoid basal cell carcinoma syndrome (NBCCS), as well as in several types of tumour associated with the disorder, It was recently reported that a single recurrent mutation in the SONIC HEDGEHOG gene, which encodes the PATCHED ligand, was found in one of 43 basal cell carcinomas (BCCs), one of 14 medulloblastomas and one of six breast carcinomas analysed (Ore ef al., 1997), We have searched extensively for this same mutation in a large collection of BCCs, medulloblastomas and carcinomas of the breast, ovary and colorectum and have failed to detect the mutation in any sample analysed.	Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; Queensland Inst Med Res, Queensland Canc Fund Res Unit, Joint Expt Oncol Programme, Herston, Qld 4029, Australia; Glaxo Gastroenterol Lab, Bancroft Ctr, Herston, Qld 4029, Australia	University of Queensland; University of Bonn; QIMR Berghofer Medical Research Institute	Wainwright, B (corresponding author), Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia.		hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020; Chenevix-Trench, Georgia/AAV-2014-2020; Wicking, Carol/J-1814-2014	hayward, nicholas k/0000-0003-4760-1033; Chenevix-Trench, Georgia/0000-0002-1878-2587; Evans, Timothy/0000-0001-7962-6863; Wicking, Carol/0000-0002-7225-3803; Wainwright, Brandon/0000-0003-0406-2092				Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pietsch T, 1997, CANCER RES, V57, P2085; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Xie JW, 1997, CANCER RES, V57, P2369	11	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1091	1093		10.1038/sj.onc.1201644	http://dx.doi.org/10.1038/sj.onc.1201644			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519883				2022-12-28	WOS:000072335900015
J	Watabe, M; Ito, K; Masuda, Y; Nakajo, S; Nakaya, K				Watabe, M; Ito, K; Masuda, Y; Nakajo, S; Nakaya, K			Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells	ONCOGENE			English	Article						apoptosis; AP-1; JNK; leukemia cells; MAP kinase	MAP KINASE KINASE; PROTEIN-KINASES; JUN; PHOSPHORYLATION; MEK1; TRANSFORMATION; FIBROBLASTS; DOMAIN; FAMILY; AGENTS	In a previous study, we demonstrated that bufalin caused apoptosis in human leukemia U937 cells by the anomalous activation of mitogen-activated protein kinase (MAPK) via a signaling pathway that included Ras, Raf-1 and MAPK kinase-l, We report here the effect of bufalin on c-Jun N-terminal protein kinase (JNK), a member of the MAPK family, and on the signaling pathway downstream of MAPKs in U937 cells, When U937 cells were treated with 10(-8) M bufalin, the activity of JNK1 was markedly elevated 3 h after the start of treatment and remained so for 9 h, This activation of JNK and the induction of apoptosis by bufalin were suppressed by expression of antisense mRNA for MAPK kinase-l, c-Jun was translocated from the cytoplasm to the nucleus after treatment of U937 cells with bufalin. The transcriptional activity of AP-1 was transiently enhanced by the treatment with bufalin and this activation was suppressed by the expression of antisense mRNA for MAPK kinase-l, Both curcumin (1,7-bis[4-hydroxy-3-methoxy-phenyl]-1,6-heptadiene-3,5-dione), an inhibitor of the biosynthesis of AP-1, and the expression of dominant negative c-Jun inhibited the activation of AP-1 and the induction of apoptosis by. bufalin, Expression of a constitutively active mutant form of MAPK kinase-l induced the activation of AP-1 and subsequent apoptosis in U937 cells. These results suggest that the activation of AP-1 via a MAPK cascade that includes JNK is required for the induction of apoptosis by bufalin in U937 cells,.	Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, Tokyo 142, Japan	Showa University	Nakaya, K (corresponding author), Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.							BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BRUNET A, 1994, ONCOGENE, V9, P3379; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Franklin CC, 1995, ONCOGENE, V11, P2365; GOTOH Y, 1994, ONCOGENE, V9, P1891; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu R, 1996, CANCER RES, V56, P2954; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	29	112	123	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					779	787		10.1038/sj.onc.1201592	http://dx.doi.org/10.1038/sj.onc.1201592			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488042				2022-12-28	WOS:000071931800010
J	Schwachtgen, JL; Janel, N; Barek, L; Duterque-Coquillaud, M; Ghysdael, J; Meyer, D; Kerbiriou-Nabias, D				Schwachtgen, JL; Janel, N; Barek, L; Duterque-Coquillaud, M; Ghysdael, J; Meyer, D; Kerbiriou-Nabias, D			Ets transcription factors bind and transactivate the core promoter of the von Willebrand factor gene	ONCOGENE			English	Article						Ets family of proteins; gene regulation; von Willebrand factor; endothelial cells	HUMAN-ENDOTHELIAL-CELLS; HUMAN VONWILLEBRAND-FACTOR; DNA-BINDING; ACTIVATION PROPERTIES; VASCULAR ENDOTHELIUM; 5'-FLANKING REGION; INITIATION SITE; IIB GENE; EXPRESSION; PROTEIN	von Willebrand factor (VWF) gene expression is restricted to endothelial cells and megakaryocytes. Previous results demonstrated that basal transcription of the human vWF gene is mediated through a promoter located between base pairs -89 and +19 (cap site: +1) which is functional in endothelial and non endothelial cells, Two DNA repeats TTTCCTTT correlating,vith inverted consensus binding sites for the Ets family of transcription factors are present in the -56/-36 sequence, In order to analyse whether these DNA elements are involved in transcription, human umbilical vein endothelial cells (HUVEC), bovine calf pulmonary endothelial cell line (CPAE), HeLa and COS cells mere transfected with constructs containing deletions of the -89/+19 fragment, linked to the chloramphenicol acetyl transferase (CAT) reporter gene, The -60/+19 region exhibits significant promoter activity in HUVEC and CPAE cells only, The -42/+19 fragment is not active, Mutations of the -60/+19 promoter fragment in the 5' (-56/-49) Ets binding site abolish transcription in endothelial cells whereas mutations in the 3' (-43/ -36) site does not, The -60/-33 fragment forms three complexes with proteins from HUVEC nuclear extracts in electrophoretic mobility shift assay which are dependent on the presence of the 5' Ets binding site, Binding of recombinant Ets-1 protein to the -60/-33 fragment gives a complex which also depends on the 5' site, The -60/+19 VWF gene core promoter is transactivated in HeLa cells by cotransfecting with Ets-1 or Erg (Ets-related gene) expression plasmids, In contrast to the wild type construct, transcription of the 5' site mutants is not increased by these expressed proteins, The results indicate that the promoter activity of the -60/+19 region of the vWF gene depends on transcription factors of the Ets family of which several members like Ets-1, Ets-2 and Erg are expressed in endothelium. Cotransfection of Ets-1 and Erg expression plasmids is sufficient to induce the -60/+19 vWF promoter activity in HeLa cells.	Hop Bicetre, Unite Rech Hemostase & Thrombose, INSERM U 143, F-94275 Le Kremlin Bicetre, France; Inst Biol Lille, CNRS, UMR 319, F-59021 Lille, France; Inst Curie, Ctr Univ, CNRS, UMR 146, F-91405 Orsay, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Kerbiriou-Nabias, D (corresponding author), Hop Bicetre, Unite Rech Hemostase & Thrombose, INSERM U 143, F-94275 Le Kremlin Bicetre, France.		GHYSDAEL, Jacques/F-3377-2013	Janel, Nathalie/0000-0002-4746-8941; Duterque-Coquillaud, Martine/0000-0003-3943-5629				AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; ASSOULINE Z, 1988, BIOCHEM BIOPH RES CO, V153, P1159, DOI 10.1016/S0006-291X(88)81349-4; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BAHNAK BR, 1989, J CELL PHYSIOL, V138, P305, DOI 10.1002/jcp.1041380212; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BONTHRON D, 1988, EUR J BIOCHEM, V171, P51, DOI 10.1111/j.1432-1033.1988.tb13757.x; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; Buttice G, 1996, ONCOGENE, V13, P2297; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; COLLINS CJ, 1987, P NATL ACAD SCI USA, V84, P4393, DOI 10.1073/pnas.84.13.4393; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DEGROOT PG, 1987, ARTERIOSCLEROSIS, V7, P605, DOI 10.1161/01.ATV.7.6.605; DEGUINE V, 1995, BLOOD COAGUL FIBRIN, V6, P42, DOI 10.1097/00001721-199502000-00007; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; FERREIRA V, 1993, BIOCHEM J, V293, P641, DOI 10.1042/bj2930641; FISHER RJ, 1992, J BIOL CHEM, V269, P17957; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GEBRANEYOUNES J, 1991, AM J PATHOL, V139, P1471; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEGONNE A, 1992, NEW BIOL, V4, P512; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HOSHI H, 1984, P NATL ACAD SCI-BIOL, V81, P6413, DOI 10.1073/pnas.81.20.6413; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; JAFFE EA, 1974, P NATL ACAD SCI USA, V71, P1906, DOI 10.1073/pnas.71.5.1906; Jahroudi N, 1996, J BIOL CHEM, V271, P21413, DOI 10.1074/jbc.271.35.21413; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; Janel N, 1995, GENE, V167, P291, DOI 10.1016/0378-1119(95)00696-6; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; LEMARCHANDEL V, 1993, MOL CELL BIOL, P668; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MARTIN F, 1993, J BIOL CHEM, V268, P21606; NACHMAN RL, 1975, J EXP MED, V141, P101; PAGE C, 1992, AM J PATHOL, V141, P673; PRASAD DDK, 1994, ONCOGENE, V9, P669; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REDDY ESP, 1991, ONCOGENE, V6, P2285; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; ROUET P, 1992, BIOTECHNIQUES, V13, P700; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; SADLER JE, 1994, THROMB HAEMOSTASIS, V71, P520; SADLER JE, 1991, J BIOL CHEM, V266, P22777; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SCHWACHTGEN JL, 1994, BIOTECHNIQUES, V17, P882; SCHWACHTGEN JL, 1996, J VASC RES S1, V33, P90; Shore P, 1996, MOL CELL BIOL, V16, P3338; SPORN LA, 1985, J CLIN INVEST, V76, P1102, DOI 10.1172/JCI112064; TYMMS MJ, 1994, MOL REPROD DEV, V39, P208, DOI 10.1002/mrd.1080390214; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VONDERAHE D, 1993, NUCLEIC ACIDS RES, V21, P5636, DOI 10.1093/nar/21.24.5636; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WERNERT N, 1992, AM J PATHOL, V140, P119; WERNERT N, 1994, CANCER RES, P5683	63	75	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3091	3102		10.1038/sj.onc.1201502	http://dx.doi.org/10.1038/sj.onc.1201502			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444957				2022-12-28	WOS:000070968000009
J	McCracken, S; Kim, CS; Xu, Y; Minden, M; Miyamoto, NG				McCracken, S; Kim, CS; Xu, Y; Minden, M; Miyamoto, NG			An alternative pathway for expression of p56(lck) from type I promoter transcripts in colon carcinoma	ONCOGENE			English	Article						lck; colon cancer; transcription	T-CELL DEVELOPMENT; PP60C-SRC PROTEIN-KINASE; THYMOCYTE DEVELOPMENT; LCK TRANSCRIPTS; GENE-EXPRESSION; HMG DOMAIN; BINDING; ACTIVATION; RECEPTOR; P56LCK	The lymphoid-specific protein tyrosine kinase, p56(lck) which is essential for both T cell development and function, is aberrantly expressed in colon and small lung carcinoma lines, In this paper, we demonstrate p56(lck) is also expressed in colon tumour biopsies due predominantly or exclusively to the use of the lck type I promoter, In T leukaemia lines, the lck type I promoter requires binding sites for both Ets- and Myb-related transcription factors, In contrast, in colon tumour lines the activation of the lck type I promoter requires the Ets but not the Myb binding site, In these lines, a consensus binding site for HMG-related transcription factors, AACAAAG, is required for efficient lck type I promoter activity, Sox-4 is a candidate transcription factor for binding and activating the lck type I promoter in colon carcinoma cells. Go-expression of Ets-1 and Sox-4, but neither protein alone, was sufficient to activate the lck type I promoter in HeLa cells which do not normally express lck transcripts, These results suggest that aberrant expression of p56(lck) from the lck type I promoter in colon carcinoma arises from transcriptional activation mediated by Ets-and HMG-related transcription factors.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DIV CELLULAR & MOL BIOL,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; PRINCESS MARGARET HOSP,AMGEN RES INST,TORONTO,ON M5G 2M9,CANADA; BERLEX BIOSCI,DEPT IMMUNOL,RICHMOND,CA 94804	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre								ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GROETTRUP M, 1993, IMMUNOL TODAY, V14, P610, DOI 10.1016/0167-5699(93)90201-U; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LEUNG S, 1993, ONCOGENE, V8, P989; LEUNG S, 1991, J CELL PHYSIOL, V148, P344, DOI 10.1002/jcp.1041480304; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; PARK JS, 1993, ONCOGENE, V8, P2627; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TOMITA N, 1992, CANCER RES, V52, P6840; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840	34	40	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2929	2937		10.1038/sj.onc.1201474	http://dx.doi.org/10.1038/sj.onc.1201474			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416836				2022-12-28	WOS:A1997YK37700005
J	Bellosta, P; Zhang, Q; Goff, SP; Basilico, C				Bellosta, P; Zhang, Q; Goff, SP; Basilico, C			Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation	ONCOGENE			English	Article						programmed cell death; gene knock-out; TWF; c-myc	PROGRAMMED CELL-DEATH; ARREST-SPECIFIC GENE-6; AXL; PROTEINS; LIGAND; GAS6; FIBROBLASTS; ACTIVATION; EXPRESSION; CLONING	ARK (AXL) is the prototype of a distinctive family of receptor tyrosine kinases which contain in their extracellular domains features reminiscent of cell adhesion molecules, ARK is capable of homophilic binding, which results in a degree of receptor activation, but can also be activated by a heterophilic ligand, Gas6, a member of the family of vitamin K dependent proteins that is preferentially expressed in quiescent cells, Since a number of tissues and cell lines express both ARK and Gas6, we studied the effect of endogenous and exogenous Gas6 on the phenotype of ARK expressing cells, Here we show that constitutive expression of Gas6 in an NIH3T3 cell line that does not spontaneously express this protein does not result in cell transformation or uncontrolled growth, but protects from apoptosis induced by serum deprivation. Recombinant exogenous Gas6 was also capable of protecting cells from apoptosis at concentrations that did not result in significant induction of DNA synthesis, Activation of ARK phosphorylation and a weak but significant induction of MAP kinase activity accompanied the increased survival of cells treated with Gas6. The antiapoptotic effect of ARK signaling was confirmed by studies using fibroblasts from ARK knock-out mice, that showed that the absence of ARK resulted in higher levels of serum deprivation-induced apoptosis, that could not be rescued by the addition of Gas6, Interestingly ARK signaling protects from apoptosis induced by serum deprivation, myc overexpression, or by TNF alpha but not from u.v. irradiation or Staurosporine. These results suggest that a major function of Gas6-ARK signaling is that of increasing cell survival under conditions which do not allow cell proliferation.	NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT BIOCHEM, NEW YORK, NY 10032 USA	New York University; New York University; Columbia University			Goff, Stephen P/K-6337-2014; Bellosta, Paola/AAA-3413-2020	Goff, Stephen P/0000-0003-0693-5547; Bellosta, Paola/0000-0003-1913-5661	NATIONAL CANCER INSTITUTE [R35CA042568] Funding Source: NIH RePORTER; NCI NIH HHS [CA42568] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; CHINNAIYAN AM, 1996, J BIOL CHEM, V271, P30022; Costa M, 1996, J CELL PHYSIOL, V168, P737, DOI 10.1002/(SICI)1097-4652(199609)168:3<737::AID-JCP27>3.0.CO;2-U; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FUJIMOTO J, 1994, ONCOGENE, V9, P693; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1995, ONCOGENE, V10, P2349; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; LAI C, 1994, ONCOGENE, V9, P2567; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LING L, 1995, MOL CELL BIOL, V15, P6582; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OHASHI K, 1994, ONCOGENE, V9, P699; PESCIGNO J, 1992, ONCOGENE, V6, P1909; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; RESCIGNO J, 1991, ONCOGENE, V6, P1909; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang QK, 1996, J VIROL, V70, P8089, DOI 10.1128/JVI.70.11.8089-8097.1996	50	122	138	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2387	2397		10.1038/sj.onc.1201419	http://dx.doi.org/10.1038/sj.onc.1201419			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395235	Green Published			2022-12-28	WOS:A1997YE96300001
J	Cortez, D; Reuther, G; Pendergast, AM				Cortez, D; Reuther, G; Pendergast, AM			The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells	ONCOGENE			English	Article						Bcr-Abl; tyrosine kinase; cell cycle; mitogenesis	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC GRANULOCYTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PHILADELPHIA-CHROMOSOME; POSITIVE LEUKEMIAS; MAMMALIAN-CELLS; MAP KINASES; TRANSFORMATION; APOPTOSIS	Bcr-Abl is a constitutively active tyrosine kinase that is expressed in Philadelphia chromosome (Ph-1)-positive human leukemias. Bcr-Abl has been shown to inhibit apoptosis and cause anchorage independent growth. However, its ability to activate mitogenic signaling pathways is controversial. Here we show that Bcr-Abl signaling prevents down-regulation of cyclin-dependent kinase activity and cell cycle arrest after growth factor deprivation of hematopoietic progenitor cells, Using an inducible system to regulate Bcr-Abl expression, we also demonstrate that Bcr-Abl expression is sufficient to induce G1-to-S phase transition, DNA synthesis, and activation of cyclin-dependent kinases in cells that were arrested in G(0) by growth factor deprivation, Furthermore, Bcr-Abl activates Pas, Erk, and Jnk pathways as a primary consequence of expression. These data show that Bcr-Abl is one of a select group of oncogenes that is capable of both inhibiting apoptosis and deregulating cell proliferation. The combination of these activities is likely to be important for the progression of CML.	DUKE UNIV, MED CTR, DEPT PHARMACOL & CANC BIOL, DURHAM, NC 27710 USA	Duke University			Reuther, Gary/AFR-2892-2022	Pendergast, Ann Marie/0000-0002-1250-6880	NCI NIH HHS [CA61033] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061033] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; ATHENS JW, 1965, J CLIN INVEST, V44, P765, DOI 10.1172/JCI105189; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; CARLESSO N, 1994, ONCOGENE, V9, P149; CHERVENICK PA, 1968, SER HAEMATOL, V1, P24; CLARK SS, 1989, ANNU REV MED, V40, P113; CLARKSON B, 1993, LEUKEMIA, V7, P1683; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; GALBRAITH PR, 1972, BRIT J HAEMATOL, V22, P135, DOI 10.1111/j.1365-2141.1972.tb08795.x; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOTO T, 1982, BLOOD, V59, P793; GROFFEN J, 1993, LEUKEMIA LYMPHOMA, V11, P19, DOI 10.3109/10428199309047857; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kortenjann M, 1995, CRIT REV ONCOGENESIS, V6, P99; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANEUVILLE P, 1994, CANCER RES, V54, P1360; MANDANAS RA, 1993, BLOOD, V82, P1838; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; OGAWA M, 1970, CANCER-AM CANCER SOC, V25, P1031, DOI 10.1002/1097-0142(197005)25:5<1031::AID-CNCR2820250507>3.0.CO;2-N; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RIBEIRO RC, 1987, BLOOD, V70, P948; Roger R, 1996, BLOOD, V87, P1113, DOI 10.1182/blood.V87.3.1113.bloodjournal8731113; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCOTT JL, 1971, BLOOD-J HEMATOL, V38, P162, DOI 10.1182/blood.V38.2.162.162; SMETSERS TFCM, 1994, LEUKEMIA, V8, P129; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRIFE A, 1988, SEMIN HEMATOL, V25, P1; STRYCKMANS PA, 1977, CLIN HAEMATOL, V6, P21; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TSAI LH, 1993, ONCOGENE, V8, P1593; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; VONCKEN JW, 1992, CANCER RES, V52, P4534; WADA H, 1995, CANCER RES, V55, P3192; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	65	161	167	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2333	2342		10.1038/sj.onc.1201400	http://dx.doi.org/10.1038/sj.onc.1201400			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393877				2022-12-28	WOS:A1997YE15700007
J	Beer, HD; Florence, C; Dammeier, J; McGuire, L; Werner, S; Duan, DR				Beer, HD; Florence, C; Dammeier, J; McGuire, L; Werner, S; Duan, DR			Mouse fibroblast growth factor 10: cDNA cloning, protein characterization, and regulation of mRNA expression	ONCOGENE			English	Article						keratinocyte growth factor; secretion; wound repair; heparin; growth factor; regulation	LARGE INDUCTION; FACTOR FAMILY; FGF FAMILY; KERATINOCYTE; RECEPTOR; KGF; CELLS; GENE; DIFFERENTIATION; MORPHOGENESIS	Fibroblast growth factor 7 (FGF-7) or keratinocyte growth factor (KGF), is a potent and specific mitogen for epithelial cells, We have recently identified a novel human FGF-7 homologue, named FGF-10. To study the expression of this new FGF family member and its regulation in wound repair, we cloned the mouse FGF-10 (mFGF-10) cDNA, The encoded protein is 92% identical to human FGF-10 and 91% identical to rat FGF-10, When expressed in mammalian 293 cells, the mFGF-10 protein was glycosylated but remained cell- or extracellular matrix-associated. Upon addition of heparin, mFGF-10 protein was released into the media, mRNA encoding mFGF-10 was relatively abundant in lung, skin, brain and heart, In the skin, both FGF-7 and mFGF-10 were expressed in the dermal, but not the epidermal compartment, In contrast to FGF-7, mFGF-10 expression was not induced during cutaneous wound repair, In cultured fibroblasts, expression of mFGF-10 was strongly repressed by transforming growth factor beta and tumor necrosis factor alpha, whereas epidermal growth factor and interleukin-1 beta had no effect, These results demonstrate a differential regulation of mFGF-10 and FGF-7 expression in vitro and during the wound healing process.	HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	GlaxoSmithKline; Human Genome Sciences Inc; Max Planck Society				Werner, Sabine/0000-0001-7397-8710; Beer, Hans-Dietmar/0000-0002-8085-713X; Dammeier, Johanna/0000-0002-6040-2779				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P597; BROOKES S, 1989, ONCOGENE, V4, P429; CHEDID M, 1994, J BIOL CHEM, V269, P19753; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; JIMENEZ PA, 1997, UNPUB; Kiefer P, 1996, ONCOGENE, V12, P1503; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PIERCE GF, 1994, J EXP MED, V179, P831, DOI 10.1084/jem.179.3.831; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Sambrook J., 2002, MOL CLONING LAB MANU; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; UENO H, 1993, J BIOL CHEM, V268, P22814; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Wu LC, 1996, ARCH SURG-CHICAGO, V131, P660; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	34	107	110	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2211	2218		10.1038/sj.onc.1201383	http://dx.doi.org/10.1038/sj.onc.1201383			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393979				2022-12-28	WOS:A1997YD01900009
J	Kroll, M; Conconi, M; Desterro, MJP; Marin, A; Thomas, D; Friguet, B; Hay, RT; Virelizier, JL; ArenzanaSeisdedos, F; Rodriguez, MS				Kroll, M; Conconi, M; Desterro, MJP; Marin, A; Thomas, D; Friguet, B; Hay, RT; Virelizier, JL; ArenzanaSeisdedos, F; Rodriguez, MS			The carboxy-terminus of I kappa B alpha determines susceptibility to degradation by the catalytic core of the proteasome	ONCOGENE			English	Article						I kappa B alpha; carboxy-terminus; NF-kappa B; 20S proteasome	CASEIN KINASE-II; SIGNAL-INDUCED DEGRADATION; CONSTITUTIVE PHOSPHORYLATION; INDUCIBLE DEGRADATION; TRANSCRIPTION FACTORS; PROTEIN-DEGRADATION; INDUCED APOPTOSIS; PRECURSOR P105; DNA-BINDING; ACTIVATION	The Rel/NF-kappa B family of transcription factors controls the expression of a wide variety of genes that are implicated in immune and inflammatory responses and cellular proliferation. Disregulation of NF-kappa B is associated with cellular transformation and the maintenance of a high anti-apoptotic threshold in transformed cells. NF-kappa B activity is in turn regulated by its sequestration in the cytoplasm by the inhibitor I kappa B. I kappa B alpha, the most abundant and well-characterized member of the I kappa B multiprotein family, is rapidly degraded in response to multiple physiologic stimuli. In the present study we show that not only the amino-terminus, but also the carboxy-terminus of I kappa B alpha contain transferable signals that must be simultaneously present in an unrelated protein to render it susceptible to activation-induced, proteasome-mediated degradation. We show here that I kappa B alpha amino-terminal modifications occur independently of the carboxy-terminus. Moreover, we present evidence indicating a critical role far the carboxy-terminal region in facilitating proteolysis by the catalytic core of the proteasome. When incubated with 20S proteasome extracted from rat liver, I kappa B alpha was quickly degraded while a deletion mutant lacking the carboxy-terminus was resistant to proteolysis. Likewise, chimeric proteins of beta-galactosidase with the I kappa B alpha carboxy-terminus were degraded in vitro independently of the presence of the I kappa B alpha amino-terminus, whereas chimeric proteins lacking the I kappa B alpha carboxy-terminus were stable. Our results identify the carboxy-terminus of I kappa B alpha as a domain critical for degradation through interaction with an as yet unidentified component of the proteasome.	INST PASTEUR,UNITE IMMUNOL VIRALE,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE BIOCHIM CELLULAIRE,F-75724 PARIS 15,FRANCE; UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AL,FIFE,SCOTLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of St Andrews			Hay, Ronald/S-3233-2019; Arenzana-Seisdedos, Fernando/E-5835-2016; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024; Desterro, Joana/0000-0002-6359-7233; Friguet, Bertrand/0000-0001-8085-1961				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Aoki T, 1996, ONCOGENE, V12, P1159; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FEHRENTZ JA, 1985, INT J PEPT PROT RES, V26, P236; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; Lin RT, 1996, MOL CELL BIOL, V16, P1401; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rodriguez MS, 1996, ONCOGENE, V12, P2425; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; ROGERS SW, 1986, BIOMED BIOCHIM ACTA, V45, P1611; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1996, MOL CELL BIOL, V16, P1058; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	66	32	33	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1841	1850		10.1038/sj.onc.1201560	http://dx.doi.org/10.1038/sj.onc.1201560			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362451				2022-12-28	WOS:A1997XZ72500011
J	Chen, G; Shu, JY; Stacey, DW				Chen, G; Shu, JY; Stacey, DW			Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide	ONCOGENE			English	Article						oncogene; apoptosis; SAPK; cell cycle; etoposide	SIGNAL-TRANSDUCTION PATHWAYS; CYCLIN-DEPENDENT KINASES; PROGRAMMED CELL-DEATH; PROTEIN-KINASES; C-MYC; INTERCALATING AGENTS; ANTICANCER AGENTS; GAMMA-RADIATION; JNK ACTIVATION; CANCER-THERAPY	The exact mechanisms for the selective toxicity of chemotherapeutic drugs against tumor cells are not fully understood, We designed a series of experiments to test the possibility that the positive proliferative signal initiated by oncogenes might change the sensitivity for apoptosis induction by the anticancer drug etoposide (VP16), an inhibitor of topoisomerase IT (Topo II), Treatment with VP16 induced significantly increased apoptosis in NIH3T3 cells transformed by oncogenic src, ras or raf, compared with the normal 3T3 cells, Apopototic changes involved nuclear DNA fragmentation, morphological alterations and decreased viability, Furthermore it was shown that stress-activated protein kinase (SAPK) was activated much more strongly in all three transformed lines compared to untransformed cells by VP16 treatment, while slight activation of extracellular signal-regulated kinase (ERK1) was observed in all four cell lines, In addition, the transformed cells displayed arrest in mid-S-phase following the treatment, whereas NIH3T3 cells were primarily arrested in late S and G(2)/M phase. Finally, the cyclin-dependent kinase inhibitor p21 WAF1 was induced in all four cell lines, although induction of p53 was not detected in any of these cell lines. Taken together our results demonstrated that oncogenic transformation can sensitize the cells to apoptosis induction, stress kinase activation and cell cycle arrest in response to VP16 treatment, These results may have important implications for understanding the selective toxicity of anti-cancer drugs in tumor cells.	CLEVELAND CLIN FDN,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NIGMS NIH HHS [GM52271] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELANI CP, 1994, CANCER CHEMOTH PHARM, V34, pS118, DOI 10.1007/BF00684875; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chresta CM, 1996, CANCER RES, V56, P1834; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7274; GLISSON B, 1986, CANCER RES, V46, P1939; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; Hitomi M, 1996, J BIOL CHEM, V271, P9376, DOI 10.1074/jbc.271.16.9376; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LIU YO, 1994, BIOCHEM PHARMACOL, V48, P1265; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOCK RB, 1994, CANCER RES, V54, P4933; Lock RB, 1996, CANCER RES, V56, P4006; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Shu JY, 1996, ONCOGENE, V13, P2421; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TEODORO JG, 1995, ONCOGENE, V11, P467; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	55	56	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1643	1651		10.1038/sj.onc.1201347	http://dx.doi.org/10.1038/sj.onc.1201347			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349497				2022-12-28	WOS:A1997XY63100003
J	Madden, SL; Galella, EA; Zhu, JS; Bertelsen, AH; Beaudry, GA				Madden, SL; Galella, EA; Zhu, JS; Bertelsen, AH; Beaudry, GA			SAGE transcript profiles for p53-dependent growth regulation	ONCOGENE			English	Article						SAGE; p53; transcription	MESSENGER-RNA; DIFFERENTIAL DISPLAY; GENE-EXPRESSION; P53 MUTANTS; CELL-CYCLE; APOPTOSIS; IDENTIFICATION; PROTEIN; OSTEOPONTIN; ACTIVATION	Serial analysis of gene expression (SAGE) allows for a quantitative, representative, and comprehensive profile of gene expression, We have utilized SAGE technology to contrast the differential gene expression profile in rat embryo fibroblast cells producing temperature-sensitive p53 tumor suppressor protein at permissive or nonpermissive temperatures, Analysis of similar to 15 000 genes revealed that the expression of 14 genes (P<0.001, greater than or equal to 0.03% abundance) was dependent on functional p53 protein, whereas the expression of three genes was significantly higher in cells producing non-functional p53 protein, Those genes whose expression was increased by functional p53 include RAS, U6 snRNA, cyclin G, EGR-1, and several novel genes, The expression of actin, tubulin, and HSP70 genes was elevated at the nonpermissive temperature for p53 function, Interestingly, the expression of several genes was dependent on a non-temperature-sensitive mutant p53 suggesting altered transcription profiles dependent on specific p53 mutant proteins. These results demonstrate the utility of SAGE for rapidly and reproducibly evaluating global transcriptional responses within different cell populations.			Madden, SL (corresponding author), PHARMAGEN INC,DEPT CELLULAR & MOL BIOL,4 PEARL COURT,ALLENDALE,NJ 07401, USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AMBARTSUMIAN N, 1995, GENE, V159, P125, DOI 10.1016/0378-1119(94)00778-Q; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Arai T, 1996, INT J RADIAT BIOL, V69, P547, DOI 10.1080/095530096145553; Bains W, 1996, NAT BIOTECHNOL, V14, P711, DOI 10.1038/nbt0696-711; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BERTIOLI DJ, 1995, NUCLEIC ACIDS RES, V23, P4520, DOI 10.1093/nar/23.21.4520; CALLARD D, 1994, BIOTECHNIQUES, V16, P1096; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHAMBERS AF, 1995, ANN NY ACAD SCI, V760, P101, DOI 10.1111/j.1749-6632.1995.tb44623.x; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; HARPER JW, 1993, CELL, V75, P805; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; Madden SL, 1996, CANCER RES, V56, P5384; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Oates AJ, 1996, ONCOGENE, V13, P97; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wright PS, 1996, EXP CELL RES, V222, P54, DOI 10.1006/excr.1996.0007; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	37	148	162	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1079	1085		10.1038/sj.onc.1201091	http://dx.doi.org/10.1038/sj.onc.1201091			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285562				2022-12-28	WOS:A1997XT16100009
J	vandenBerghe, N; Cool, RH; Horn, G; Wittinghofer, A				vandenBerghe, N; Cool, RH; Horn, G; Wittinghofer, A			Biochemical characterization of C3G: an exchange factor that discriminates between Rap1 and Rap2 and is not inhibited by Rap1A(S17N)	ONCOGENE			English	Article						Rap; C3G; small G proteins; nucleotide exchange factor; Rap1A(S17N)	GUANINE-NUCLEOTIDE EXCHANGE; GTPASE-ACTIVATING PROTEIN; TUMOR-SUPPRESSOR ACTIVITY; RAS-RELATED GENE; SACCHAROMYCES-CEREVISIAE; WILD-TYPE; BINDING; MUTANTS; SITE; IDENTIFICATION	A catalytically active fragment of the Rap-specific guanine-nucleotide exchange factor C3G was expressed in E coli. It was purified and its interaction with GTP-binding proteins was investigated using fluorescence spectroscopy, C3G stimulates GDP dissociation from Rap1, but not from Rap2, neither from Bud1, which is believed to be the yeast homologue of Rap1 nor from all other proteins of the human Ras-subfamily, Like the corresponding fragment from CDC25(Mm), the increase in the GDP dissociation rate is linear with increasing concentration of Rap1A.GDP up to 100 mu M, indicating an apparent K-M higher than 100 mu M. Unlike the Ras-CDC25(Mm) system, the Rap1A(S17N) mutant does not inhibit the C3G-activated guanine nucleotide dissociation from wild-type Rap1A in vitro. These data suggest that Rap1A(S17N) is unlikely to titrate away C3G in vivo, the proposed mechanism by which S17N-mutants exert their dominant negative effects.	MAX PLANCK INST MOL PHYSIOL,D-44139 DORTMUND,GERMANY	Max Planck Society				Cool, Robbert/0000-0002-9845-2202				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH G, 1993, GTPASES BIOL 1, V108, P377; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARNERO A, 1995, BIOCHEM BIOPH RES CO, V216, P748, DOI 10.1006/bbrc.1995.2685; ECCLESTON JF, 1988, NATO ASI A, V165, P87; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HANEY SA, 1994, J BIOL CHEM, V269, P16541; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HOLDEN JL, 1991, J BIOL CHEM, V266, P16992; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; JOHN J, 1993, J BIOL CHEM, V268, P923; JOHN J, 1988, NATO ASI A, V165, P209; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; LEROSEY I, 1991, J BIOL CHEM, V466, P4315; MALY FE, 1994, J BIOL CHEM, V269, P18743; MCCABE PC, 1992, MOL CELL BIOL, V12, P4084, DOI 10.1128/MCB.12.9.4084; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PIZON V, 1988, ONCOGENE, V3, P210; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SATO KY, 1994, CANCER RES, V54, P552; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TANAKA X, 1994, P NATL ACAD SCI USA, V91, P3442; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	44	89	91	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					845	850		10.1038/sj.onc.1201407	http://dx.doi.org/10.1038/sj.onc.1201407			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266971				2022-12-28	WOS:A1997XQ11700011
J	DeYoung, KL; Ray, ME; Su, YA; Anzick, SL; Johnstone, RW; Trapani, JA; Meltzer, PS; Trent, JM				DeYoung, KL; Ray, ME; Su, YA; Anzick, SL; Johnstone, RW; Trapani, JA; Meltzer, PS; Trent, JM			Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma	ONCOGENE			English	Article						interferon-inducible; melanoma; tumorigenicity	HUMAN-MALIGNANT MELANOMA; CHROMOSOME-6; IDENTIFICATION; CLUSTER; CELLS	Chromosome 6-mediated suppression of tumorigenicity in malignant melanoma cell lines provides a model system to identify genes associated with the reversion of the tumorigenic phenotype. Using subtractive cDNA selection, we recently identified a series of novel genes which are differentially expressed in association with chromosome 6-mediated suppression. We now report the molecular characterization of a novel gene termed AIM2 for (Absent In Melanoma), which represents a 1485 bp cDNA. An open reading frame of 1032 base pairs, corresponding to 344 amino acid residues, is predicted. The predicted protein shares a conserved sequence domain of approximately 200 amino acids with known interferon-inducible genes of both human and mouse. We demonstrate that the AIM2 gene encodes a transcript of approximately 2 kb which is expressed in spleen, small intestine, and peripheral blood leukocytes. In addition, we have localized AIM2 to the long arm of human chromosome 1 (band q22) in a highly conserved region which also contains the known interferon-inducible genes IFI16 and MNDA. We have also demonstrated that, like IFI16 and MNDA, AIM2 is induced in HL60 cells by interferon gamma. Our findings support the existence of a family of genes in this region similar to the well-characterized mouse Ifi200 gene family.	NATL HUMAN GENOME RES INST,CANC GENET LAB,NIH,BETHESDA,MD 20892; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; AUSTIN HOSP,AUSTIN RES INST,HEIDELBERG,VIC 3084,AUSTRALIA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Michigan System; University of Michigan; Austin Research Institute; Florey Institute of Neuroscience & Mental Health			Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Trapani, Joseph/0000-0003-0983-1532				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRIGGS RC, 1994, BLOOD, V83, P2153; BURDE S, 1996, IN PRESS CYTOMETRY; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; DAWSON MJ, 1995, IMMUNOGENETICS, V41, P40, DOI 10.1007/BF00188431; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; KINGSTON RE, 1991, CURRENT PROTOCOL S14, V1; KRAEHN GM, 1995, CANCER-AM CANCER SOC, V75, P1228, DOI 10.1002/1097-0142(19950315)75:6<1228::AID-CNCR2820750604>3.0.CO;2-T; MILLIKIN D, 1991, CANCER RES, V51, P5449; PETERS J, 1989, MOUSE NEWS LETT, V84, P52; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Ray ME, 1996, ONCOGENE, V12, P2527; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; Seldin MF, 1988, GENOMICS, V2, P48, DOI 10.1016/0888-7543(88)90108-5; SKOLNICK MH, 1994, EUR J CANCER, V30A, P1991, DOI 10.1016/0959-8049(94)00392-I; TANNENBAUM CS, 1993, J LEUKOCYTE BIOL, V53, P563, DOI 10.1002/jlb.53.5.563; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; YOU J, 1995, BIOCHEM BIOPH RES CO, V208, P476, DOI 10.1006/bbrc.1995.1363	23	193	213	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					453	457		10.1038/sj.onc.1201206	http://dx.doi.org/10.1038/sj.onc.1201206			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242382				2022-12-28	WOS:A1997XM23800010
J	Levresse, V; Moritz, S; Renier, A; Kheuang, L; Galateau-Salle, F; Mege, JP; Piedbois, P; Salmons, B; Guenzburg, W; Jaurand, MC				Levresse, V; Moritz, S; Renier, A; Kheuang, L; Galateau-Salle, F; Mege, JP; Piedbois, P; Salmons, B; Guenzburg, W; Jaurand, MC			Effect of simian virus large T antigen expression on cell cycle control and apoptosis in rat pleural mesothelial cells exposed to DNA damaging agents	ONCOGENE			English	Article						apoptosis; cell cycle; TSV40; p53; asbestos; gamma radiations	MALIGNANT MESOTHELIOMA; ASBESTOS FIBERS; CROCIDOLITE ASBESTOS; IONIZING-RADIATION; INDUCE APOPTOSIS; G(2) ARREST; P53 PROTEIN; FIBROBLASTS; CHECKPOINT; MECHANISMS	Cell cycle progression and apoptosis are controlled by regulatory proteins, including p53, of which functional alterations are linked to carcinogenesis. Recently, malignant mesothelioma (MM), a primary tumour related to asbestos exposure, alternatively to post therapeutic radiations, has proven to be an important problem in oncogenesis. The p53 protein does not seem mutated or deleted in MM but a possible inactivation by binding to other proteins [mdm2; SV40 large T antigen (Tag)] has been suggested, The present work investigated cell cycle regulation in normal rat pleural mesothelial cells (RPMC) and in RPMC expressing Tag (RPMC-TSV40), under exposure to asbestos and radiations, In RPMC, these agents induced activation of cell cycle checkpoints located at G1/S and G2/M and/or mitosis but a lack of control at G1/S was found in RPMC-TSV40, A loss of G2/M control may account for the formation of micronuclei observed after exposure of RPMC-TSV40 to radiations, In RPMC-TSV40 the enhancement of abnormal mitoses and apoptosis after asbesto exposure, in comparison with RPMC, suggests a loss of mitotic control and a p53-independent mechanism of apoptosis, Thus Tag expression in mesothelial cells might have both adverse and beneficial effects by impairing the control of DNA integrity and enhancing apoptosis respectively.	Fac Med, INSERM, U139, F-94010 Creteil, France; CHRU, Dept Pathol, F-14033 Caen, France; Hop Henri Mondor, Unite Radiophys & Radioprotect, F-94010 Creteil, France; Bavarian Nord Res Inst, D-85758 Oberschleissheim, Germany; Univ Vet Sci, Inst Virol, A-1210 Vienna, Austria	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHU de Caen NORMANDIE; Universite de Caen Normandie; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Bavarian Nordic; University of Veterinary Medicine Vienna	Jaurand, MC (corresponding author), Fac Med, INSERM, U139, IM3,8 Rue Gen Sarrail, F-94010 Creteil, France.		Salle, Francoise BJ Galateau/J-1530-2015; Salmons, Brian/E-3001-2010; JAURAND, MARIE-CLAUDE/S-3538-2017	Salle, Francoise BJ Galateau/0000-0003-3642-0165; Salmons, Brian/0000-0002-9490-9447; JAURAND, MARIE-CLAUDE/0000-0002-0915-6728				Abend M, 1996, CELL PROLIFERAT, V29, P101; AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; BAE IS, 1995, CANCER RES, V55, P2387; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BASES R, 1994, INT J RADIAT BIOL, V65, P591, DOI 10.1080/09553009414550681; BeruBe KA, 1996, AM J RESP CELL MOL, V15, P141, DOI 10.1165/ajrcmb.15.1.8679218; BOYLAN AM, 1992, J CLIN INVEST, V89, P1257, DOI 10.1172/JCI115710; Broaddus VC, 1996, J CLIN INVEST, V98, P2050, DOI 10.1172/JCI119010; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Cavazza A, 1996, CANCER, V77, P1379, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1379::AID-CNCR24>3.3.CO;2-5; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; Churg A, 1996, AM J RESP CRIT CARE, V154, P1124, DOI 10.1164/ajrccm.154.4.8887617; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DEPPERT W, 1989, ONCOGENE, V4, P1103; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Goi K, 1997, CANCER RES, V57, P1895; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAWN MT, 1995, CANCER RES, V55, P3721; HESTERBERG TW, 1985, CARCINOGENESIS, V6, P473, DOI 10.1093/carcin/6.3.473; INOUE H, 1992, VIROLOGY, V187, P343, DOI 10.1016/0042-6822(92)90325-J; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JAURAND MC, 1981, IN VITRO CELL DEV B, V17, P98; Jensen CG, 1996, CARCINOGENESIS, V17, P2013, DOI 10.1093/carcin/17.9.2013; JIANG D, 1993, ONCOGENE, V8, P2805; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KE Y, 1989, AM J PATHOL, V134, P979; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1985, PROC R SOC SER B-BIO, V226, P25, DOI 10.1098/rspb.1985.0077; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lenahan MK, 1996, ONCOGENE, V12, P1847; LEVRESSE V, IN PRESS AM J RESP C; LIU VF, 1995, STEM CELLS, V13, P117; MacFarlane M, 1996, MOL PHARMACOL, V50, P900; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; Maizel JV, 1971, METHOD VIROL, V5, P179; METCALF RA, 1992, CANCER RES, V52, P2610; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIYASHITA T, 1994, CANCER RES, V54, P3131; Mor O, 1997, AM J RESP CELL MOL, V16, P9, DOI 10.1165/ajrcmb.16.1.8998073; PATEROUR MJ, 1985, CARCINOGENESIS, V6, P523, DOI 10.1093/carcin/6.4.523; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; Pepper C, 1996, THORAX, V51, P1074, DOI 10.1136/thx.51.11.1074; RAMAEL M, 1992, J PATHOL, V168, P371, DOI 10.1002/path.1711680406; Segers K, 1995, VIRCHOWS ARCH, V427, P431, DOI 10.1007/BF00199393; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strickler HD, 1996, CANCER EPIDEM BIOMAR, V5, P473; TAUCHI H, 1994, INT J RADIAT BIOL, V65, P449, DOI 10.1080/09553009414550521; WAGNER JC, 1986, THORAX, V41, P161, DOI 10.1136/thx.41.3.161; WALKER C, 1992, AM J IND MED, V21, P253, DOI 10.1002/ajim.4700210214; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; WANG NS, 1987, AM J PATHOL, V126, P343; WOODS C, 1994, ONCOGENE, V9, P2943; ZHENG DQ, 1994, ONCOGENE, V9, P3345	60	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	1998	16	8					1041	1053		10.1038/sj.onc.1201627	http://dx.doi.org/10.1038/sj.onc.1201627			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519878				2022-12-28	WOS:000072335900010
J	Fahraeus, R; Lain, S; Ball, KL; Lane, DP				Fahraeus, R; Lain, S; Ball, KL; Lane, DP			Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule	ONCOGENE			English	Article						p16(INK4a); cyclin dependent kinases 4 and 6; cell cycle; peptide delivery; tumour suppressor	PROVIRUS INSERTIONAL MUTAGENESIS; RETINOBLASTOMA GENE-PRODUCT; REPLICATIVE SENESCENCE; TRANSCRIPTION FACTOR; PRB PHOSPHORYLATION; CDK INHIBITORS; HUMAN HEAD; WILD-TYPE; CELL; PROTEIN	We have previously shown that a 20 amino acid peptide derived from the third ankyrin-like repeat of the p16(CDKN2/INK4a) (p16) tumour suppressor protein (residues 84-103 of the human p16 protein) can bind to cdk4 and cdk6 and inhibit cdk4-cyclin D1 kinase activity in vitro as well as block cell cycle progression through G1. Substitution of two valine residues corresponding to amino acids 95 and 96 (V95A and V96A) of the p16 peptide reduces the binding to cdk4 and cdk6 and increases its IC0.5 for kinase inhibition approximately threefold when linked to the Antennapedia homeodomain carrier sequence. The same mutations increase the IC0.5 approximately fivefold in the p16 protein. Substitution of aspartic acid 92 by alanine instead increases the binding of the peptide to cdk4 and cdk6 and the kinase inhibitory activity. The p16 peptide blocks S-phase entry in nonsynchronized human HaCaT cells by approximately 90% at a 24 mu M concentration. The V95A and V96A double substitution minimizes the cell cycle inhibitory capacity of the peptide whereas the D92A substitution increases its capacity to block cell cycle progression. A deletion series of the p16 derived peptide shows that a 10 residue peptide still retains cdk4-cyclin D1 kinase and cell cycle inhibitory activity. The p16 peptide inhibited S-phase entry in five cell lines tested, varying between 47-75%, but had only a limited (11%) inhibitory effect in the pRb negative Saos-2 cells at a concentration of 24 mu M. Like the full length p16 protein, the p16 peptide does not inhibit cyclin E dependent cdk2 kinase activity in vitro. These data suggest that acute inhibition of CDK-cyclin D activity by a peptide derived from the INK4 family mill stop cells in late G1 in a pRb dependent fashion.	Univ Dundee, Dept Biochem, CRC, Cell Transformat Grp, Dundee DD1 4HN, Scotland	University of Dundee	Fahraeus, R (corresponding author), Univ Dundee, Dept Biochem, CRC, Cell Transformat Grp, Dundee DD1 4HN, Scotland.		Lane, David P/C-4920-2008; fahraeus, robin/K-8726-2014; Lain, Sonia/B-6980-2014	Lain, Sonia/0000-0001-9693-5246; Lane, David/0000-0003-0551-3545; , robin/0000-0003-0402-8492				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BALL K, 1997, CURR BIOL, V7, P81; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN F, 1995, MOL CELL BIOL, V15, P2681; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; EINHORN S, 1994, BLOOD, V84, P297; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNA Z, 1993, ONCOGENE, V8, P1661; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HERBERT J, 1994, BLOOD, V84, P4038; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Ichimura K, 1996, ONCOGENE, V13, P1065; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KATHIB ZA, 1993, CANCER RES, V53, P5535; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAMMIE GA, 1991, ONCOGENE, V6, P439; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Loughran O, 1996, ONCOGENE, V13, P561; LOUGHRAN O, 1994, CANCER RES, V54, P5045; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OTTERSON GA, 1995, ONCOGENE, V11, P1211; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Parry D, 1996, MOL CELL BIOL, V16, P3844; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1995, ONCOGENE, V11, P635; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Reifenberger G, 1996, CANCER RES, V56, P5141; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1973, CELL, V73, P1056; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; TREMBLAY PJ, 1992, J VIROL, V66, P1344, DOI 10.1128/JVI.66.3.1344-1353.1992; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577	61	76	79	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					587	596		10.1038/sj.onc.1201580	http://dx.doi.org/10.1038/sj.onc.1201580			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482104				2022-12-28	WOS:000071816600003
J	Martinez, JD; Craven, MT; Pennington, ME				Martinez, JD; Craven, MT; Pennington, ME			Selective binding of different p53 response elements by p53 containing complexes	ONCOGENE			English	Article						p53; DNA binding; EMSA	TRANSFORMATION; MUTATIONS; SUPPRESSION; MUTANT; GENE	The p53 tumor suppressor protein binds two copies of a ten base pair motif that is degenerate in eight out of ten bases and conforms to the sequence, 5'PuPuPuC(A/T)(T/A)GPyPyPy-3'. As a consequence of this high degree of degeneracy, p53 response elements show a great deal of variation and it has been speculated that the variation aids in the selective activation of p53 responsive genes by specific stimuli. Here, we examined the DNA binding characteristics of several different p53 protein complexes present in nuclear extracts prepared from a cell line expressing the murine temperature sensitive p53 protein, p53(val135). Interestingly, the complexes exhibited a distinct preference for binding to some p53 response elements and not others, A critical determinant of this specificity was the sequence at the center of the ten base pair motif and alteration of a single base within this region mas sufficient to alter the set of complexes that associated with the oligonucleotide, In addition, thermal denaturation experiments demonstrated that some complexes could bind DIVA even though the p53(val135) protein had a mutant conformation, Our results are consistent with the hypothesis that p53 can distinguish between various response elements and suggest that this selectivity is manifested, in part, by the sequence of the motif and conformation of the p53 protein.	Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85724 USA	University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85724 USA.				NCI NIH HHS [CA64842, CA-23074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064842, P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Park DJ, 1996, MOL CARCINOGEN, V16, P101, DOI 10.1002/(SICI)1098-2744(199606)16:2<101::AID-MC6>3.0.CO;2-L; Smith ML, 1996, AM J PATHOL, V148, P1019; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	19	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					453	458		10.1038/sj.onc.1201565	http://dx.doi.org/10.1038/sj.onc.1201565			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484834				2022-12-28	WOS:000071739400003
J	Thompson, DA; Belinsky, G; Chang, THT; Jones, DL; Schlegel, R; Munger, K				Thompson, DA; Belinsky, G; Chang, THT; Jones, DL; Schlegel, R; Munger, K			The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints	ONCOGENE			English	Article						viral oncoproteins; mitosis; checkpoint; human papillomavirus; cyclin-dependent kinases; p53 tumor suppressor	INDUCED PREMATURE MITOSIS; CELL-CYCLE CHECKPOINTS; LARGE T-ANTIGEN; GROWTH ARREST; GENE-EXPRESSION; DNA-DAMAGE; MUTATIONAL ANALYSIS; IONIZING-RADIATION; HUMAN FIBROBLASTS; EPITHELIAL-CELLS	The E6 and E7 proteins of the high risk human papillomaviruses (HPVs) are consistently expressed in HPV-positive cervical carcinomas, We investigated the ability of HPV-16 E6 and E7 to disrupt mitotic checkpoints in normal diploid human cells, Acute expression of HPV-16 E6, but not HPV-16 E7, decreased the fidelity of multiple checkpoints controlling entry into and exit from mitosis, After irradiation, nearly 50% of cells containing HPV-16 E6 readily entered mitosis as opposed to less than 10% of control cells, Consistent with this, asynchronous populations of cells expressing HPV-16 E6 had increased cdc2-associated histone Hi kinase activity relative to control populations, In addition, HPV-16 E6 increased sensitivity to chemically-induced S-phase premature mitosis and decreased mitotic spindle assembly checkpoint function relative to control populations, HPV-16 E6 mutants with a reduced ability to target p53 for degradation were unable to abrogate mitotic checkpoints, suggesting a possible mechanism by which HPV-16 E6 disrupts mitotic checkpoints, Expression of a mutant p53 gene yielded an intermediate phenotype relative to HPV-16 E6, generating moderate increases in sensitivity to chemically-induced S-phase PCC and mitotic spindle disruption and a heightened propensity to enter mitosis after irradiation.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Mol & Cellular Toxicol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Thompson, David/0000-0003-2372-7766; Munger, Karl/0000-0003-3288-9935	NATIONAL CANCER INSTITUTE [R01CA066980] Funding Source: NIH RePORTER; NCI NIH HHS [CA 66980] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CLARKE PR, 1995, J CELL SCI, V108, P1217; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Di Leonardo A, 1997, CANCER RES, V57, P1013; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; KATAYOSE D, 1995, BIOCHEM BIOPH RES CO, V215, P446, DOI 10.1006/bbrc.1995.2485; KAUFMANN WK, 1995, CANCER RES, V55, P7; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUNGER K, 1993, BIOCHIM BIOPHYS ACTA, V1155, P111, DOI 10.1016/0304-419X(93)90025-8; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; OSHIMA J, 1993, ONCOGENE, V8, P2987; PAULES RS, 1995, CANCER RES, V55, P1763; Pines J, 1996, BIOCHEM SOC T, V24, P15, DOI 10.1042/bst0240015; POWELL SN, 1995, CANCER RES, V55, P1643; Russell KJ, 1996, INT J RADIAT ONCOL, V36, P1099, DOI 10.1016/S0360-3016(96)00432-4; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STEINBECK RG, 1995, ACTA ONCOL, V34, P171, DOI 10.3109/02841869509093952; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; STEINMANN KE, 1994, ONCOGENE, V9, P387; STEWART N, 1995, ONCOGENE, V10, P109; Stoppler MC, 1996, J VIROL, V70, P6987; TAM SW, 1995, J CELL BIOCHEM, V59, P339, DOI 10.1002/jcb.240590306; TSANG NM, 1995, ONCOGENE, V10, P2403; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	56	94	97	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3025	3035		10.1038/sj.onc.1201495	http://dx.doi.org/10.1038/sj.onc.1201495			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444951				2022-12-28	WOS:000070968000003
J	Qi, XM; Simonson, M; Distelhorst, CW				Qi, XM; Simonson, M; Distelhorst, CW			Bcl-2 inhibits c-fos induction by calcium	ONCOGENE			English	Article						Bcl-2; calcium; c-fos; thapsigargin	PROGRAMMED CELL-DEATH; GENE-EXPRESSION; APOPTOSIS; THAPSIGARGIN; PROTEIN; FAMILY; CA2+; BCL-X(L); PATHWAY; NUCLEAR	Transient elevation of cytosolic Ca2+ induces the expression of a variety of genes involved in cell growth and transformation, including the early response gene c-fos. Previously, we reported that Bcl-2 inhibits the transient elevation of cytosolic Ca2+ induced by thapsigargin (TG), a selective inhibitor of the endoplasmic reticulum-associated Ca2+-ATPase. Therefore, to determine if the effect of Bcl-2 on cytosolic Ca2+ elevation modulates Ca2+ signaling, we investigated the induction of c-fos by TG in WEHI7.2 mouse lymphoma cells, control transfectants (WEHI7.2-neo), and transfectants that stably express a high level of Bcl-2 (W.Hb12 and W.Hb15). TG induced 20-fold elevation of c-fos mRNA in WEHI7.2 and WEHI7.2-neo cells, but c-fos mRNA induction by TG was only fivefold in W.Hb12 and W.Hb15 cells, In contrast, phorbol 12-myristate acetate induced marked c-fos mRNA elevation in both WEHI7.2 and W.Hb12 cells, indicating that the inhibitory effect of Bcl-2 is selective for induction of c-fos by Ca2+. To measure c-fos promoter activity, WEHI7.2 and W.Hb12 cells were transiently transfected with a c-fos promoter-luciferase reporter plasmid, TG induced c-fos promoter activity in WEHI7.2 cells, but not in W.Hb12 cells. In WEHI7.2 cells, the signal for c-fos induction by TG was cytosolic Ca2+ elevation, as the increase in both c-fos mRNA level and promoter activity were prevented by lowering extracellular Ca2+ concentration, a condition that inhibits cytosolic Ca2+ elevation by reducing the TG-mobilizable Ca2+ pool, In summary, the findings indicate that Bcl-2 regulates Ca2+ signaling.	CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NCI NIH HHS [R01 CA42755-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; CURRAN T, 1987, ONCOGENE, V2, P79; FLOMERFELT FA, 1994, J CELL BIOL, V127, P1729, DOI 10.1083/jcb.127.6.1729; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; Marin MC, 1996, ONCOGENE, V12, P2259; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Preston GA, 1996, MOL CELL BIOL, V16, P211; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WERLEN G, 1993, J BIOL CHEM, V268, P16596; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	32	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2849	2853		10.1038/sj.onc.1201463	http://dx.doi.org/10.1038/sj.onc.1201463			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419976				2022-12-28	WOS:A1997YJ80300011
J	Sweetser, DA; Kapur, RP; Froelick, GJ; Kafer, KE; Palmiter, RD				Sweetser, DA; Kapur, RP; Froelick, GJ; Kafer, KE; Palmiter, RD			Oncogenesis and altered differentiation induced by activated Ras in neuroblasts of transgenic mice	ONCOGENE			English	Article						Ras; sympathetic nervous system; neuroblastoma	NERVE GROWTH-FACTOR; LACKING GDNF; SYMPATHETIC NEUROBLASTS; ENTERIC NEURONS; NEURAL CREST; CELLS; EXPRESSION; SURVIVAL; ABNORMALITIES; NEUROTROPHINS	Sympathetic neurons, enteric neurons and adrenal chromaffin cells all derive from the neural crest. During development these cells migrate, proliferate, survive and differentiate in a highly controlled fashion influenced by local signals encountered during their migration. Aberrations of these processes are responsible for a variety of developmental defects and malignancies, Many of the environmental signals influencing these precursor cells activate receptor tyrosine kinases that can signal, at least in part, via Ras pathways, To assess the extent to which Ras can alter neuroblast cell number and fate in vivo, we expressed activated H-Ras in transgenic mice using the dopamine-beta-hydroxylase promoter, which directs expression to these cells prior to and after their differentiation. Ganglioneuromas and occasional neuroblastomas formed in the adrenal gland and preaortic sympathetic ganglia. Curiously, neurons of the superior cervical ganglia and the gut were largely unaffected despite demonstrated expression of activated Ras. The sensitivity of preaortic sympathetic neurons and adrenal chromaffin cells to the effects of oncogenes such as Ras may explain the predilection of neuroblastomas in humans to these sites. The ability to analyse neuroblastoma development in these mice may shed light on the molecular basis of certain types of human neuroblastoma.	UNIV WASHINGTON,DIV MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DIV PEDIAT HEMATOL & ONCOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Sweetser, DA (corresponding author), UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT BIOCHEM,BOX 357370,SEATTLE,WA 98195, USA.		Sweetser, David/ABB-9347-2021	Sweetser, David/0000-0002-1621-3284	NCI NIH HHS [T32CA09351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT F, 1990, CRIT REV ONCOGENESIS, V2, P75; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BAETGE G, 1990, DEV BIOL, V141, P353, DOI 10.1016/0012-1606(90)90391-U; BALJET B, 1975, STAIN TECHNOL, V50, P31, DOI 10.3109/10520297509117028; BARSAGI D, 1989, ANTICANCER RES, V9, P1427; BESSHO F, 1991, J PEDIATR-US, V119, P237, DOI 10.1016/S0022-3476(05)80733-4; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BRADLEY A, 1987, PRODUCTION ANAL CHIM; BRANDS JHG, 1986, EUR J BIOCHEM, V155, P137; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRODEUR GM, 1995, METABOLIC MOL BASES, P697; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; BURCHILL SA, 1995, EUR J CANCER, V31A, P476, DOI 10.1016/0959-8049(95)00054-M; BURCHILL SA, 1995, J NEUROL SCI, V133, P3, DOI 10.1016/0022-510X(95)00163-V; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Davies Alun M., 1994, Progress in Growth Factor Research, V5, P263, DOI 10.1016/0955-2235(94)90010-8; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; DICICCOBLOOM E, 1993, NEURON, V11, P1011; Durbec PL, 1996, DEVELOPMENT, V122, P349; EVANS MI, 1978, CLIN CHEM, V24, P567; FOREMAN PJ, 1992, J NEUROSCI RES, V31, P52, DOI 10.1002/jnr.490310108; GAESE F, 1994, DEVELOPMENT, V120, P1613; GOODMAN SN, 1991, AM J DIS CHILD, V145, P1415, DOI 10.1001/archpedi.1991.02160120083024; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; IKEDA Y, 1981, J PEDIATR SURG, V16, P636, DOI 10.1016/0022-3468(81)90019-1; IRELAND CM, 1989, CANCER RES, V49, P5530; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KAPUR RP, 1991, NEURON, V7, P717, DOI 10.1016/0896-6273(91)90275-5; Le Douarin N.M., 1982, NEURAL CREST; Lee T, 1996, DEVELOPMENT, V122, P409; LO L, 1996, NEURON, V15, P527; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; POLUHA W, 1995, ONCOGENE, V10, P185; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; Silos-Santiago Inmaculada, 1995, Current Opinion in Neurobiology, V5, P42, DOI 10.1016/0959-4388(95)80085-9; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; TANAKA T, 1988, CANCER RES, V48, P1030; TEITELMAN G, 1981, DEV BIOL, V86, P348, DOI 10.1016/0012-1606(81)90192-5; TURKEL SB, 1974, AM J PATHOL, V76, P225; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0	48	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2783	2794		10.1038/sj.onc.1201452	http://dx.doi.org/10.1038/sj.onc.1201452			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419969				2022-12-28	WOS:A1997YJ80300004
J	Geley, S; Hartmann, BL; Hattmannstorfer, R; Loffler, M; Ausserlechner, MJ; Bernhard, D; Sgonc, R; StrasserWozak, EMC; Ebner, M; Auer, B; Kofler, R				Geley, S; Hartmann, BL; Hattmannstorfer, R; Loffler, M; Ausserlechner, MJ; Bernhard, D; Sgonc, R; StrasserWozak, EMC; Ebner, M; Auer, B; Kofler, R			p53-induced apoptosis in the human T-ALL cell line CCRF-CEM	ONCOGENE			English	Article						p53; apoptosis; CCRF-CEM; human leukemia; caspase; chemotherapy	GLUCOCORTICOID-INDUCED APOPTOSIS; WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; PROTEASE INHIBITORS; ICE/CED-3 PROTEASE; BREAST-CANCER; DNA-BINDING; DEATH; GENE; RESISTANCE	The tumor suppressor p53 has been implicated in apoptosis induction and is mutated in human T-ALL CCRF-CEM cells. To investigate possible consequences of wild-type p53 loss, we reconstituted CEM-C7H2, a subclone of CCRF-CEM, with a temperature-sensitive p53 allele (p53ts). Stably transfected lines expressed high levels of p53ts and shift to the permissive temperature (32 degrees C) caused rapid induction of p53-regulated genes, such as p21(CIP1/WAF1), mdm-2 and bax. This was followed by extensive apoptosis within 24 h to 36 h, supporting the notion that mutational p53 inactivation contributed to the malignant phenotype. p53-dependent apoptosis was preceded by digestion of poly(ADP-ribose) polymerase, a typical target of interleukin-1 beta-converting enzyme (ICE)-like proteases/caspases, and was markedly resistant to the ICE/caspase-1 and FLICE/caspase-8 inhibitor acetyl-Tyr-Val-Afa-Asp.chloromethylketone (YVAD), but sensitive to the CPP32/caspase-3 inhibitor benzyloxycarbonyl-Asp-Glu-Val-Asp.fluoromethylketone (DEVD) and benzyloxycarbonyl-Val-Ala-Asp.fluoromethylketone (zVAD), a caspase inhibitor with broader specificity. This indicated an essential involvement of caspases, but argued against a significant role of ICE/caspase-1 or FLICE/caspase-8. Actinomycin D or cycloheximide prevented cell death, suggesting that, in this system, p53-induced apoptosis depends upon macromolecule biosynthesis. Introduction of functional p53 into CEM cells enhanced their sensitivity to the DNA-damaging agent doxorubicin, but not to the tubulin-active compound vincristine. Thus, mutational p53 inactivation in ALL might entail relative resistance to DNA-damaging, but not to tubulin-destabilizing, chemotherapy.	UNIV INNSBRUCK, INST GEN & EXPT PATHOL, DIV MOL PATHOPHYSIOL, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck; University of Innsbruck				Bernhard, David/0000-0002-2383-6607; Ausserlechner, Michael/0000-0002-1015-2302				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Anthoney DA, 1996, CANCER RES, V56, P1374; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; Chandler JM, 1997, BIOCHEM J, V322, P19, DOI 10.1042/bj3220019; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1996, CANCER RES, V56, P5033; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALDAR S, 1994, CANCER RES, V54, P2095; Haupt Y, 1996, Behring Inst Mitt, P32; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUIDA K, 1995, SCIENCE, V267, P200; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NORMAN MR, 1977, CANCER RES, V37, P3785; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PARK DJ, 1994, ONCOGENE, V9, P1899; Perego P, 1996, CANCER RES, V56, P556; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; PROKOCIMER M, 1994, BLOOD, V84, P2391; ROLLEY N, 1995, ONCOGENE, V11, P763; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Thomas A, 1996, ONCOGENE, V12, P1055; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1994, COLD SPRING HARB SYM, V59, P395, DOI 10.1101/SQB.1994.059.01.044; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	72	36	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2429	2437		10.1038/sj.onc.1201399	http://dx.doi.org/10.1038/sj.onc.1201399			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395239				2022-12-28	WOS:A1997YE96300005
J	Zhang, LR; Kharbanda, S; Chen, D; Bullocks, J; Miller, DL; Ding, IYF; Hanfelt, J; McLeskey, SW; Kern, FG				Zhang, LR; Kharbanda, S; Chen, D; Bullocks, J; Miller, DL; Ding, IYF; Hanfelt, J; McLeskey, SW; Kern, FG			MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice	ONCOGENE			English	Article						estrogen independence; antiestrogen resistance; angiogenesis; metastasis; fibroblast growth factors	FIBROBLAST GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCAN; ESTROGEN-DEPLETED CONDITIONS; HUMAN MAMMARY-GLAND; CANCER-CELLS; FACTOR-I; EPITHELIAL-CELLS; FACTOR RECEPTORS; FACTOR FAMILY; CONSTITUTIVE ACTIVATION	FGF-1 is expressed in a high proportion of breast tumors, While overexpression of FGF-4 in the MCF-7 breast carcinoma cell line confers the ability to form spontaneously metastasizing tumors in ovariectomized nude mice without estrogen supplementation and in mice that receive tamoxifen pellets, the response of a cell to individual FGFs can be controlled at multiple levels, and the significance of FGF-1 expression in human breast tumors is uncertain, To study the role of FGF-1, MCF-7 human breast cancer carcinoma cells, previously transfected with bacterial beta-galactosidase, were retransfected with FGF-1 expression vectors, FGF-1 transfectants formed large, vascularized tumors in ovariectomized nude mice without estrogen supplementation as web as in mice that received tamoxifen pellets, Lymphatic and pulmonary micrometastases were detected as deposits of X-gal-stained cells as early as 17 days after cell inoculation whereas no metastases were detected in estrogen-supplemented mice bearing similar-sized control tumors, When compared with controls, both clonal and polyclonal populations of FGF-1 overexpressing cells exhibited increased anchorage-independent growth and decreased population doubling times in estrogen-depleted or 4-hydroxytamoxifen containing medium, These results suggest that FGF signaling may be important in the transition of breast cancer cells from hormone-dependent to hormone-independent and from nonmetastatic to metastatic.	GEORGETOWN UNIV, MED CTR, SCH NURSING, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT PHARMACOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT MED, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT BIOCHEM & MOL BIOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University; Georgetown University; Georgetown University					NCI NIH HHS [P50CA53185, R01-CA50376, R29-CA6614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1991, ONCOGENE, V6, P659; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BANSAL GS, 1995, BRIT J CANCER, V72, P1420, DOI 10.1038/bjc.1995.524; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BLAM SB, 1988, ONCOGENE, V3, P129; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; BROWN KJ, 1995, J CELL BIOCHEM, V58, P6, DOI 10.1002/jcb.240580103; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DALY RJ, 1991, CELL GROWTH DIFFER, V2, P457; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DING IY, 1992, P ANN M AM ASS CANC, V33, pA1610; ENGEL LW, 1978, CANCER RES, V38, P4327; Fenig E, 1997, CLIN CANCER RES, V3, P135; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GLOVER JF, 1988, CANCER RES, V48, P3693; GOMM JJ, 1991, CANCER RES, V51, P4685; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; IMAGAWA W, 1994, BIOCHEM BIOPH RES CO, V204, P1165, DOI 10.1006/bbrc.1994.2585; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KE YQ, 1993, J CELL SCI, V106, P135; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; KUREBAYASHI J, 1993, CANCER RES, V53, P2178; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEHTOLA L, 1992, INT J CANCER, V50, P598, DOI 10.1002/ijc.2910500419; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; MCLESKEY SW, 1993, CANCER RES, V53, P2168; McLeskey SW, 1996, BRIT J CANCER, V73, P1053, DOI 10.1038/bjc.1996.204; MCLESKEY SW, 1994, CANCER RES, V54, P523; McLeskey SW, 1996, BREAST CANCER RES TR, V39, P103, DOI 10.1007/BF01806082; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; NOEL A, 1992, BIOCHEM PHARMACOL, V43, P1263, DOI 10.1016/0006-2952(92)90501-9; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SMITH J, 1994, EUR J CANCER, V30A, P496, DOI 10.1016/0959-8049(94)90426-X; SOMMERS CL, 1990, CANCER RES, V50, P67; SPIRITO P, 1991, CIRCULATION, V84, P322, DOI 10.1161/01.CIR.84.1.322; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STRYDOM DJ, 1986, BIOCHEMISTRY-US, V25, P945, DOI 10.1021/bi00353a001; TAKAHASHI K, 1989, INT J CANCER, V43, P870, DOI 10.1002/ijc.2910430522; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; TOI M, 1994, JPN J CANCER RES, V85, P1045, DOI 10.1111/j.1349-7006.1994.tb02904.x; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; VISSCHER DW, 1995, MODERN PATHOL, V8, P665; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	88	51	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	1997	15	17					2093	2108		10.1038/sj.onc.1201386	http://dx.doi.org/10.1038/sj.onc.1201386			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366526				2022-12-28	WOS:A1997YC28400010
J	Carpentier, A; Balitrand, N; RochetteEgly, C; Shroot, B; Degos, L; Chomienne, C				Carpentier, A; Balitrand, N; RochetteEgly, C; Shroot, B; Degos, L; Chomienne, C			Distinct sensitivity of neuroblastoma cells for retinoid receptor agonists: evidence for functional receptor heterodimers	ONCOGENE			English	Article						neuroblastoma; retinoic acid; retinoid receptor agonist; retinoic acid receptor	INDUCED GRANULOCYTIC DIFFERENTIATION; NEURO-BLASTOMA CELLS; BINDING PROTEIN-II; RAR-ALPHA; ACID RECEPTORS; 13-CIS-RETINOIC ACID; CHILDRENS-CANCER; RXR HETERODIMERS; WILD-TYPE; PHASE-I	Retinoic acid (RA) plays a major role in embryogenesis of the nervous system and has been reported to induce differentiation in neuroblastoma cell lines. To identify RA signaling pathways involved in such differentiation processes, two RA-sensitive neuroblastoma cell lines (LA-N-5 and SH-SY5Y) were extensively studied. Northern blot experiments determined that of the three RAR mRNAs, only RAR alpha was significantly expressed, with respectively weak or undetectable levels of RAR gamma and RAR beta. RXRs (alpha and beta) receptors were weakly expressed, Western blotting analysis confirmed the constitutive expression of RAR alpha and absence of RAR beta and weak levels of RXR alpha. Treatment with all-trans-RA up-regulated RAR alpha and induced a drastic increase of RAR beta (both at the RNA and protein level). To further characterize the function of RAR alpha, RAR beta and RXR alpha in NB cells, nuclear extracts from LA-N-5 cells were analysed by EMSA studies. Three specific retarded complexes were observed which were significantly decreased or shifted in the presence of monoclonal antibodies to RAR alpha, RAR beta and RXR alpha. RA treatment dramatically induced a DR5-binding RXR alpha-RAR beta heterodimer. Treatment with combinations of RAR alpha or RAR beta agonists with a RXR alpha agonist or with a RAR alpha agonist alone, induced neurite-outgrowth supporting the probability that both RXR alpha-RAR alpha or RXR alpha-RAR beta heterodimers are involved in RA-mediated differentiation of NB cells. The availability of novel synthetic RA-specific receptor ligands should provide the possibility of tissue specific therapeutic regimes.	UNIV PARIS 07, HOP ST LOUIS,CNRS,EP 107,INST HEMATOL, LAB BIOL CELLULAIRE HEMATOPOIET, F-75475 PARIS 10, FRANCE; IGBMC, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; CIRD, GALDERMA, F-06902 SOPHIA ANTIPOLIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Galderma R&D SNC				CHOMIENNE, Christine/0000-0001-5513-5752; Carpentier, Antoine/0000-0003-2926-0060				BERARD J, 1994, EMBO J, V13, P5570, DOI 10.1002/j.1460-2075.1994.tb06894.x; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Calabresse C, 1995, LEUKEMIA, V9, P2049; CARNEY DN, 1988, SEMIN ONCOL, V15, P199; CASTLE VP, 1992, J CLIN INVEST, V90, P1857, DOI 10.1172/JCI116062; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DE LUCA LM, 1991, FASEB J, V5, P2924; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FINKLESTEIN JZ, 1992, MED PEDIATR ONCOL, V20, P307, DOI 10.1002/mpo.2950200407; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Gudas Lorraine J., 1994, P443; HIGUCHI T, 1991, CANCER RES, V51, P3958; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEROY P, 1991, P NATL ACAD SCI USA, V87, P4804; Li C, 1994, Prog Clin Biol Res, V385, P221; LOVAT PE, 1993, NEUROSCI LETT, V162, P109, DOI 10.1016/0304-3940(93)90572-3; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Manohar CF, 1996, TUMOR BIOL, V17, P34, DOI 10.1159/000217965; MARSHALL GM, 1995, ONCOGENE, V11, P485; MARSHALL GM, 1994, ANTICANCER RES, V14, P437; NERVI C, 1990, CELL GROWTH DIFFER, V1, P535; PLUM LA, 1995, ARCH BIOCHEM BIOPHYS, V319, P457, DOI 10.1006/abbi.1995.1317; REDFERN CPF, 1994, BIOCHEM J, V304, P147, DOI 10.1042/bj3040147; REES JL, 1989, BIOCHEM J, V259, P917, DOI 10.1042/bj2590917; Reynolds CP, 1994, ADV NEUROBLASTOMA RE, V4, P237; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; ROSOLEN A, 1992, EUR CYTOKINE NETW, V2, P81; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROUSSELOT P, 1994, ONCOGENE, V9, P545; ROY DY, 1995, MOL CELL BIOL, V15, P6481; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SIDELL N, 1982, J NATL CANCER I, V68, P589; SMITH MA, 1992, J CLIN ONCOL, V10, P1666, DOI 10.1200/JCO.1992.10.11.1666; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; VILLABLANCA JG, 1995, J CLIN ONCOL, V13, P894, DOI 10.1200/JCO.1995.13.4.894; WUARIN L, 1994, INT J CANCER, V56, P840, DOI 10.1002/ijc.2910560615	51	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	1997	15	15					1805	1813		10.1038/sj.onc.1201335	http://dx.doi.org/10.1038/sj.onc.1201335			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362447				2022-12-28	WOS:A1997XZ72500007
J	Ishino, M; Ohba, T; Inazawa, J; Sasaki, H; Ariyama, Y; Sasaki, T				Ishino, M; Ohba, T; Inazawa, J; Sasaki, H; Ariyama, Y; Sasaki, T			Identification of an Efs isoform that lacks the SH3 domain and chromosomal mapping of human Efs	ONCOGENE			English	Article						Efs; Src homology; FAK; tyrosine phosphorylation; chromosomal mapping	PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; BINDING; SRC; GRB2; CRK; HYBRIDIZATION; EXPRESSION; P130(CAS); PEPTIDES	Efs was originally found by expression cloning of a mouse embryo cDNA library through its Fyn-SH3 binding capacity (Ishino et al., Oncogene 11, 2331-2338, 1995), Efs has characteristic regions important in intracellular signal transduction; these are an SH3 domain, a cluster of putative ligands for SH2 domains and proline-rich sequences with SH3-binding consensus, In this paper, we report cDNA cloning of human Efs and a variant of it from a hippocampal cDNA library, The human Efs gene was mapped to chromosome 14q11.2-q12 by fluorescence in situ hybridization. We identified two forms of human Efs, designated hEfs1 and hEfs2, hEfs1 represents the human counterpart of original mouse embryo Efs (mEfs1), hEfs2, the newly identified form, is identical to hEfs1, except for its lack of the SH3 domain, hEfs1 and mEfs1 are 80% identical in their amino acid sequences and 100% identical within the SH3 domain. Reverse transcription polymerase chain reaction analysis of adult mouse tissue RNA indicated expression of Efs2 and of Efs1 in various tissues, Evidence suggesting the presence of the Efs2 protein in human tissue was obtained by immunoprecipitation followed by immunoblotting with two different anti-Efs antibodies. Possible functions of Efs2 are discussed.	SAPPORO MED UNIV, CANC RES INST, DEPT BIOCHEM, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT HYG, KAMIGYO KU, KYOTO 602, JAPAN	Sapporo Medical University; Kyoto Prefectural University of Medicine								AKASHI M, 1994, BLOOD, V83, P3182; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; Ishino M, 1995, ONCOGENE, V11, P2331; Law SF, 1996, MOL CELL BIOL, V16, P3327; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1741	1745		10.1038/sj.onc.1201346	http://dx.doi.org/10.1038/sj.onc.1201346			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349509				2022-12-28	WOS:A1997XY63100015
J	McWhirter, JR; Wang, JYJ				McWhirter, JR; Wang, JYJ			Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein	ONCOGENE			English	Article						actin filaments; ALL CML; Dbl-homology; tyrosine kinase	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW STROMA; TYROSINE KINASE; C-ABL; PHILADELPHIA-CHROMOSOME; HEMATOPOIETIC PROGENITORS; COILED-COIL; BINDING; PROTEIN	In Philadelphia chromosome (Phl)-positive human leukemia, the c-Abl tyrosine kinase is activated by fusion to sequences encoded by the breakpoint cluster region (bcr) gene, Two major types of Bcr-Abl fusion proteins have been found in human leukemia, Fusion of the N-terminal 426 amino acids of Bcr generates p190(Bcr-Abl) which is mostly found in acute lymphocytic leukemia (ALL), whereas fusion of the N-terminal 902 or 927 amino acids of Bcr generates p210(Bcr-Abl) mostly found with chronic myelogenous leukemia (CML). Previous studies have demonstrated that both the Bcr and the Abl functional domains contribute to the oncogenic activity of Bcr-Abl proteins, Present in both p190 and p210 is the N-terminal coiled-coil of Bcr (aa 1-63), which is shown here to be functionally replaceable with the leucine zipper of the yeast transcription factor GCN4, The ZIP-Bcr-Abl protein transforms Rat-1/myc cells, is autophosphorylated on tyrosine and localized predominantly to actin filaments, Thus, formation of homo-oligomers through either Bcr or GCN4 coiled-coil can activate the tyrosine kinase and F-actin binding functions of Abl, We also found that a Bcr-Abl fusion containing only Bcr amino acids (1-191) can efficiently transform Rat-1/myc cells. Fusion of additional Bcr sequences (aa 192-923) did not affect the transformation of Rat-1/myc cells but progressively reduced the disruptive effect on the actin cytoskeleton, In particular, the Dbl homology domain present in p210(Bcr-Abl) but not in p190(Bcr-Abl) contributes to the stabilization of actin fibers, The modulatory effect of Bcr sequences on actin structure may underlie the apparent pathogenic variations between the different Bcr-Abl fusion proteins.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [CA43054, R37 CA043054, R01 CA043054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATIA R, 1995, J CLIN INVEST, V96, P931, DOI 10.1172/JCI118141; BHATIA R, 1994, J CLIN INVEST, V94, P384, DOI 10.1172/JCI117333; CAMPBELL ML, 1990, ONCOGENE, V5, P773; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DOWDING C, 1991, BLOOD, V78, P499; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOJI T, 1995, J BIOL CHEM, V279, P27880; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1995, MOL CELL BIOL, V15, P835; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Melo JV, 1996, LEUKEMIA, V10, P751; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; vanRhee F, 1996, BLOOD, V87, P5213, DOI 10.1182/blood.V87.12.5213.bloodjournal87125213; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; VERFAILLIE CM, 1992, BLOOD, V79, P2821; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; WilsonRawls J, 1996, CANCER RES, V56, P3426	48	41	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1625	1634		10.1038/sj.onc.1201342	http://dx.doi.org/10.1038/sj.onc.1201342			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349495				2022-12-28	WOS:A1997XY63100001
J	Schmale, H; Bamberger, C				Schmale, H; Bamberger, C			A novel protein with strong homology to the tumor suppressor p53	ONCOGENE			English	Article						keratinocyte; taste bud; differentiation; gene evolution	CRYSTAL-STRUCTURE; CELLS; EXPRESSION; SEQUENCE; ONCOPROTEIN; ANTIGEN; DOMAIN	The p53 tumor important genes apoptosis. Mice deficient for p53 show a high incidence of cancer but are developmentally normal suggesting that compensatory mechanisms exist in embryogenesis and differentiation. The new KET protein is the first mammalian protein with strong homology to p53 in all evolutionary conserved regions. This conservation makes a functional redundancy of the two proteins in cell-cycle control possible. KET is expressed during embryonic development and in certain adult tissues. Among all of the known p53 proteins of different species KET is most closely related to that found in squid. The relationship between KET and the invertebrate p53 protein sheds light on the evolutionary origin of p53. KET appears to be an ancestral p53-related protein in vertebrates,vith a possible role in development and differentiation while the ubiquitously expressed p53 protein attained its general role as 'guardian of the genome' during evolution.			Schmale, H (corresponding author), UNIV HAMBURG,HOSP EPPENDORF,INST ZELLBIOCHEM & KLIN NEUROBIOL,MARTINISTR 52,D-20246 HAMBURG,GERMANY.		Bamberger, Casimir/E-7356-2011; Bamberger, Tom Casimir/D-1292-2014	Bamberger, Tom Casimir/0000-0002-3830-4486				BEIDLER LM, 1965, J CELL BIOL, V27, P263, DOI 10.1083/jcb.27.2.263; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHMALE H, 1995, EXPT CELL BIOL TASTE, P147; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STONE LM, 1995, P NATL ACAD SCI USA, V92, P1916, DOI 10.1073/pnas.92.6.1916; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; VONGAUDECKER B, 1991, ANAT EMBRYOL, V183, P1; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	24	246	266	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1363	1367		10.1038/sj.onc.1201500	http://dx.doi.org/10.1038/sj.onc.1201500			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315105				2022-12-28	WOS:A1997XV84500015
J	Sheikh, MS; Carrier, F; Johnson, AC; Ogdon, SE; Fornace, AJ				Sheikh, MS; Carrier, F; Johnson, AC; Ogdon, SE; Fornace, AJ			Identification of an additional p53-responsive site in the human epidermal growth factor receptor gene promotor	ONCOGENE			English	Article						p53; EGF-R promotor; transactivation	TUMOR-SUPPRESSOR PROTEIN; HUMAN BREAST-CARCINOMA; DNA-BINDING FUNCTION; WILD-TYPE P53; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS; CELLS; EXPRESSION; RADIATION; ACTIVATION	Exogenously introduced wild-type and mutant p53 have recently been reported to enhance the human epidermal growth factor receptor (EGF-R) gene promoter activity in p53-deficient Saos2 osteosarcoma cells. A p53 binding site residing at position -265/-239 in the EGF-R proximal promoter has also been identified. We investigated the p53 regulation of EGF-R core promoter activity in human cell lines with varying endogenour p53 status. Wild-type and mutant p53(Ala143) enhanced the EGF-R core promotor activity in cells that were either p53-deficient or contained wild-type or mutant endogenous p53. Upon further characterization of the various deletion fragments of the EGF-R promoter, we identified a wild-type p53 responsive 62 bp region residing at position -167/-105. The -167/-105 segment was responsive only to wild-type p53 but not to mutant p53(Ala143) Or p53(His273). The -167/-105 segment of the EGF-R promotor contains one perfect and several imperfect consensus p53-binding half sites; indeed in gel shift experiments the 62 bp -167/-105 segment as well as the oligonucleotides corresponding to two p53 consensus half-sites within the 62 bp fragment, exhibited binding to p53-containing protein complexes. Thus, we have identified an additional wild-type p53 responsive site in the human EGF-R promoter. This site containing consensus p53-binding sequences resides at position -167/-105 and is proximal to recently identified p53 binding element located at position -265/-239 in the EGF-R promotor.	NCI, MOL BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sheikh, MS (corresponding author), NCI, MOL PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA.		Carrier, France/C-3063-2008; Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Carrier, France/0000-0002-5517-5284				ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY C, 1993, NAT GENET, V4, P42; FISCELLA M, 1994, ONCOGENE, V9, P3249; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Hollander M. C., 1995, DNA REPAIR MECH IMPA, P221; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; JOHNSON GL, 1994, SCIENCE, V266, P1719; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYASHITA T, 1995, CELL, V80, P293; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANTON JB, 1986, CANCER RES, V46, P4701; SCHMIDTULLRICH RK, 1994, INT J RADIAT ONCOL, V29, P813, DOI 10.1016/0360-3016(94)90570-3; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; STOSCHECK CM, 1986, CANCER RES, V46, P1030; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WARMUTH I, 1994, CANCER RES, V54, P374; WEINMANN R, 1992, P NATL ACAD SCI USA, V89, P12028; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHAN QM, 1994, ONCOGENE, V9, P3743	56	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1095	1101		10.1038/sj.onc.1201264	http://dx.doi.org/10.1038/sj.onc.1201264			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285564				2022-12-28	WOS:A1997XT16100011
J	Magae, J; Illenye, S; Tejima, T; Chang, YC; Mitsui, Y; Tanaka, K; Omura, S; Heintz, NH				Magae, J; Illenye, S; Tejima, T; Chang, YC; Mitsui, Y; Tanaka, K; Omura, S; Heintz, NH			Transcriptional squelching by ectopic expression of E2F-1 and p53 is alleviated by proteasome inhibitors MG-132 and lactacystin	ONCOGENE			English	Article						E2F/DP; transcription; p53	RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; TATA-BINDING PROTEIN; S-PHASE ENTRY; IN-VIVO; CELL-CYCLE; ACTIVATING MUTATIONS; APOPTOSIS; FAMILY; REPRESSION	The transcription factors p53 and E2F-1 play important roles in the control of cell cycle progression. In transient transfection experiments, expression of E2F-1, other E2F family members, or p53 squelched transcription from cotransfected plasmids in a dose-dependent manner, Although the proteasome inhibitors MG-132 and lactacystin markedly increased the level of expression of E2F-1 and p53, these inhibitors completely alleviated squelching by both proteins, Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1 MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107, The protease inhibitors ALLN and ALLM did not influence expression of E2F-1 or p53, nor did they alleviate squelching by either transcription factor, Because MG-132 and lactacycstin are highly specific inhibitors of the proteasome protease, our results suggest that the proteasome influences post-translational processes involved in proper folding and cytoplasmic clearing of E2F-1 and p53.	UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405; NATL INST BIOSCI & HUMAN TECHNOL,TSUKUBA,IBARAKI 305,JAPAN; TOKYO METROPOLITAN INST MED SCI,BUNKYO KU,TOKYO 113,JAPAN; KITASATO INST,MINATO KU,TOKYO 108,JAPAN	University of Vermont; National Institute of Advanced Industrial Science & Technology (AIST); Tokyo Metropolitan Institute of Medical Science								ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATAOKA T, 1992, J ANTIBIOT, V45, P1618, DOI 10.7164/antibiotics.45.1618; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Magae J, 1996, J CELL SCI, V109, P1717; Maki CG, 1996, CANCER RES, V56, P2649; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MILBRANDT JD, 1981, P NATL ACAD SCI-BIOL, V78, P6043, DOI 10.1073/pnas.78.10.6043; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHULL S, 1991, J BIOL CHEM, V266, P24398; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOO JT, 1992, J ANTIBIOT, V45, P1108, DOI 10.7164/antibiotics.45.1108; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	70	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					759	769		10.1038/sj.onc.1201251	http://dx.doi.org/10.1038/sj.onc.1201251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266962				2022-12-28	WOS:A1997XQ11700002
J	Tanaka, Y; Watanabe, T; Chiba, N; Niki, M; Kuroiwa, Y; Nishihira, T; Satomi, S; Ito, Y; Satake, M				Tanaka, Y; Watanabe, T; Chiba, N; Niki, M; Kuroiwa, Y; Nishihira, T; Satomi, S; Ito, Y; Satake, M			The protooncogene product, PEBP2 beta/CBF beta, is mainly located in the cytoplasm and has an affinity with cytoskeletal structures	ONCOGENE			English	Article						PEBP2 beta/CBF beta; proto-oncogene; acute myeloid leukemia; transcription factor; cytoskeleton; immunocytochemistry	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; NF-KAPPA-B; TRANSCRIPTION FACTOR; DNA-BINDING; E-CADHERIN; AML1 GENE; FUSION TRANSCRIPT; PROTEIN; RUNT	The Pebp62/Cbfb gene encodes the non-DNA binding beta subunit of the heterodimeric transcription factor, PEBP2/CBF, and has been implicated in a subtype of human acute myeloid leukemia, as well as being indispensable for the development of definitive hematopoiesis in the murine fetal liver, By examining a subcellular localization of the PEBP2 beta/CBF beta protein in tissue culture cells, we could reveal an additional aspect of the protein other than to be a subunit of a transcription factor, Immunoblot and immunocytochemical staining showed that PEBP2 beta/CBF beta was mostly present in the cytoplasm, This PEBP2 beta/CBF beta was free from its DNA-binding partner, the cc subunit of PEBP2/CBF, as judged by the electrophoretic mobility shift assays, Furthermore, a significant amount of PEBP2 beta 1/CBF beta was retained in the cytoskeleton preparation after detergent extraction of the cells and was found by double immunofluorescence to colocalize with the F-actin on stress fibers and the vinculin in membrane processes, Thus, the present study extends PEBP2 beta/CBF beta to be a cytoskeleton-affinitive as well as nuclear protein, The implications of these results are discussed.	TOHOKU UNIV,SCH MED,INST DEV AGING & CANC,DEPT MOL IMMUNOL,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; TOHOKU UNIV,SCH MED,DEPT SURG 2,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; HITACHI LTD,CHEM,PHARMACEUT RES LABS,HITACHI,IBARAKI 317,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 60601,JAPAN	Tohoku University; Tohoku University; Hitachi Limited; Kyoto University								ABERLE H, 1994, J CELL SCI, V107, P3655; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; ERICKSON P, 1992, BLOOD, V80, P1825; Geiger B, 1989, CURR OPIN CELL BIOL, V1, P103, DOI 10.1016/S0955-0674(89)80045-6; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NIKI M, 1997, IN PRESS P NATL ACAD; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PRATT WB, 1993, J BIOL CHEM, V268, P21455; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SALGIA R, 1995, ONCOGENE, V11, P1149; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89	39	34	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					677	683		10.1038/sj.onc.1201235	http://dx.doi.org/10.1038/sj.onc.1201235			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264408				2022-12-28	WOS:A1997XP68300007
J	Fitz, LJ; Morris, JC; Towler, P; Long, A; Burgess, P; Greco, R; Wang, J; Gassaway, R; Nickbarg, E; Kovacic, S; Ciarletta, A; Giannotti, J; Finnerty, H; Zollner, R; Beier, DR; Leak, LV; Turner, KJ; Wood, CR				Fitz, LJ; Morris, JC; Towler, P; Long, A; Burgess, P; Greco, R; Wang, J; Gassaway, R; Nickbarg, E; Kovacic, S; Ciarletta, A; Giannotti, J; Finnerty, H; Zollner, R; Beier, DR; Leak, LV; Turner, KJ; Wood, CR			Characterization of murine Flt4 ligand VEGF-C	ONCOGENE			English	Article						Flt41; Flt4 ligand; VEGF-C; BIAcore	LYMPHATIC ENDOTHELIUM; GENE	Flt4 is a receptor protein tyrosine kinase that is expressed in the adult lymphatic endothelium and high endothelial venules. We have used a BIAcore assay to identify rodent and human cell conditioned media containing the ligand of Flt4 (Flt4-L). Receptor-based affinity chromatography was used to purify this growth factor, followed by amino acid sequencing and molecular cloning of the murine cDNA, the orthologue of human vascular endothelial growth factor-C and vascular endothelial growth factor related protein. The murine flt4-L gene was localized to chromosome 8 and demonstrated to be widely expressed. Flt4-L was found to have a hydrophobic signal sequence and a pro-peptidelike sequence that is removed to generate the mature N-terminus. In addition, the C-terminal region of Flt4-L has four repeats of a cysteine-rich motif that is presumably also proteolytically processed to generate the 21 000 M-r polypeptide subunit of the Flt4-L homodimer. Recombinant Flt4-L activated Flt4 as judged by induction of tyrosyl phosphorylation, and induced mitogenesis in vitro of lymphatic endothelial cells.	GENET INST INC,CAMBRIDGE,MA 02140; BRIGHAM & WOMENS HOSP,DIV GENET,BOSTON,MA 02115; HOWARD UNIV,COLL MED,DEPT ANAT,WASHINGTON,DC 20059	Harvard University; Brigham & Women's Hospital; Howard University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029028] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000951] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG00951] Funding Source: Medline; NICHD NIH HHS [HD 29028] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEIER DR, 1993, MAMM GENOME, V4, P627, DOI 10.1007/BF00360898; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; FAN YS, 1992, CYTOGENET CELL GENET, V60, P29, DOI 10.1159/000133288; FINNERTY H, 1993, ONCOGENE, V8, P2293; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; LEAK LV, 1994, IN VITRO CELL DEV-AN, V30A, P512, DOI 10.1007/BF02631324; LEAK LV, 1993, ANAT RECORD, V236, P641, DOI 10.1002/ar.1092360408; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; MANLEY DF, 1991, MAMM GENOME, V4, P303; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; [No title captured]	13	40	46	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					613	618		10.1038/sj.onc.1201191	http://dx.doi.org/10.1038/sj.onc.1201191			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247316				2022-12-28	WOS:A1997XN25500014
J	Zindy, F; Quelle, DE; Roussel, MF; Sherr, CJ				Zindy, F; Quelle, DE; Roussel, MF; Sherr, CJ			Expression of the p16(INK4a) tumor suppressor versus other INK4 family members during mouse development and aging	ONCOGENE			English	Article						cell cycle; p16(INK4a); p15(INK4b); p18(INK4c); p19(INK4d); p19(ARF)	CELL-CYCLE ARREST; FUNCTIONAL RETINOBLASTOMA PROTEIN; D-CDK COMPLEXES; GROWTH SUPPRESSION; DEPENDENT KINASES; GENE-PRODUCT; TGF-BETA; INHIBITION; P16; DIFFERENTIATION	Four INK4 proteins can prevent cell proliferation by specifically inhibiting cyclin D-dependent kinases. Both p18(INK4c) and p19(INK4d) were widely expressed during mouse embryogenesis, but p16(INK4a) and p15(INK4b) were not readily detected prenatally. Although p15(INK4b), p18(INK4c) and p19(INK4d) were demonstrated in many tissues by 4 weeks after birth, p16(INK4a) protein expression was restricted to the lung and spleen of older mice, with increased, more widespread mRNA expression during aging. Transcripts encoding the INK4a alternative reading frame product p19(ARF) were not detected before birth but were ubiquitous postnatally. Expression of p16(INK4a) and p15(INK4b) was induced when mouse embryos were disrupted and cultured as mouse embryo 'fibroblasts' (MEFs). The levels of p16(INK4a) and p18(INK4c), but not p15(INK4b) or p19(INK4d), further increased as MEFs approached senescence. Following crisis and establishment, three of four independently-derived cell lines became polyploid and expressed higher levels of functional p16(INK4a). I, contrast, one MEF line that sustained bi-allelic deletions of INK4a initially remained diploid. Therefore, loss of p16(INK4a) and other events predisposing to polyploidy may represent alternative processes contributing to cell immortalization. Whereas p18(INK4a) and p19(INK4d) may regulate pre- and postnatal development, p16(INK4a) more likely plays a checkpoint function during cell senescence that underscores its selective role as a tumor suppressor.	ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital			Sherr, Charles J/N-8074-2018; Roussel, Martine F/F-1469-2016	Sherr, Charles J/0000-0002-5516-6206; Roussel, Martine F/0000-0002-1740-8139; Quelle, Dawn/0000-0001-8776-0122	NCI NIH HHS [P01 CA-76907] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACACHI M, 1997, IN PRESS BLOOD; BATES S, 1994, ONCOGENE, V9, P1633; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hirai H, 1996, MOL CELL BIOL, V16, P6457; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Lukas J, 1996, MOL CELL BIOL, V16, P6917; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Noble JR, 1996, ONCOGENE, V13, P1259; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Parry D, 1996, MOL CELL BIOL, V16, P3844; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; QUELLE DE, 1995, ONCOGENE, V11, P635; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; REYMOND A, 1995, ONCOGENE, V11, P1173; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WICK ST, 1995, ONCOGENE, V11, P2013	49	448	457	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					203	211		10.1038/sj.onc.1201178	http://dx.doi.org/10.1038/sj.onc.1201178			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244355				2022-12-28	WOS:A1997XK37200008
J	Philips, A; Huet, X; Plet, A; Le Cam, L; Vie, A; Blanchard, JM				Philips, A; Huet, X; Plet, A; Le Cam, L; Vie, A; Blanchard, JM			The retinoblastoma protein is essential for cyclin A repression in quiescent cells	ONCOGENE			English	Article						cyclin A; transcription; pocket proteins	A GENE-TRANSCRIPTION; DNA-REPLICATION; ADENOVIRUS E1A; EXPRESSION; P107; E2F; RB; FIBROBLASTS; CDK2; P130	Cyclin A is a positive regulatory component of kinases required for the progression through S phase and for the transition between the G2 and M phases of the cell division cycle. Previous studies have demonstrated that the promoter of its gene is under transcriptional repression in quiescent cells. Whereas the DNA sequences mediating this effect have been clearly delineated, the nature of the proteins acting in trans is still debated, Indirect observations suggest the involvement of proteins related to the retinoblastoma tumor suppressor protein (pRb), However, the precise role of these proteins has been difficult to assess, since most experiments designed to analyse their function have been carried out in transformed cell lines, Nevertheless, a current model has emerged whereby the role of the p130 protein would be restricted to resting and early G1 cells and p107, absent in quiescent cells, would be involved later in the control of the G1/S transition, whilst pRb mould be effective throughout the cell cycle, We show here that cyclin A transcriptional inhibition is relieved in primary fibroblasts from pRb(-/-) embryos and not in fibroblasts from p130(-/-), p107(-/-) or even p130(-/-)/p107(-/-) double mutant embryos, This suggests a unique role for pRb in controlling the extinction of specific genes in GO, providing thus the first example of non-overlapping functions achieved by the different pocket proteins.	Inst Mol Genet, CNRS, UMR 5535, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Blanchard, JM (corresponding author), Inst Mol Genet, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.		PHILIPS, Alexandre/AAB-6047-2020; Le Cam, Laurent/O-1408-2016	LE CAM, Laurent/0000-0003-0325-878X				BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BUCHOU T, 1993, ONCOGENE, V8, P1765; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FOTEDAR R, 1991, COLD SH Q B, V56, P325; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HEICHMAN KA, 1994, CELL, V79, P556; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERBER B, 1994, ONCOGENE, V9, P1295; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Huet X, 1996, MOL CELL BIOL, V16, P3789; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAYOL X, 1993, ONCOGENE, V8, P2561; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PAGANO M, 1992, EMBO J, V88, P1039; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	47	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1373	1381		10.1038/sj.onc.1201655	http://dx.doi.org/10.1038/sj.onc.1201655			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525736				2022-12-28	WOS:000072572400001
J	Takaoka, A; Hinoda, Y; Satoh, S; Adachi, Y; Itoh, F; Adachi, M; Imai, K				Takaoka, A; Hinoda, Y; Satoh, S; Adachi, Y; Itoh, F; Adachi, M; Imai, K			Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene	ONCOGENE			English	Article						colon cancer; KAI1 gene; invasion; metastasis	SPAN-TRANSMEMBRANE PROTEIN; PROSTATE-CANCER; TUMOR-CELLS; COLORECTAL-CARCINOMA; DECREASED EXPRESSION; SYNCYTIUM FORMATION; COLORIMETRIC ASSAY; MOLECULAR-CLONING; BASEMENT-MEMBRANE; LIVER METASTASES	KA11 is a potential metastatic suppressor gene for prostate cancer, We found by Northern blot analysis that six of ten (60%) gastric and colon cancer cell lines exhibited undetectable or very low expression level of KA11 mRNA. The effects of KA11 on the adhesion, motility and invasiveness of colon cancer cells was therefore investigated by using two kinds of stable transfectants, i.e., antisense transfectants of BM314 cells whose KA11 mRNA expression was suppressed by transfer of antisense KA11 cDNA and sense transfectants of DLD-1 cells with the enhanced KA11 mRNA by sense cDNA transfer. The following results were obtained: (1) KA11 gene expression had no significant effect on in vitro cell growth rate of colon cancer BM314 and DLD-1 cells; (2) Cell aggregation assay showed that KA11 enhanced the Ca++-independent aggregatability of those colon cancer cells; (3) It was revealed by cell motility and invasion assays that KA11 suppressed both the motility and in vitro invasiveness of those cells and (4) Furthermore, both the binding to fibronectin and the migration on fibronectin-coated plates of those cells were inhibited by KA11 expression, These suggest that reduced KA11 gene expression may contribute to the invasiveness and metastatic ability of colon cancer cells.	Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 060, Japan	Sapporo Medical University	Hinoda, Y (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 060, Japan.							Adachi M, 1996, CANCER RES, V56, P1751; ALBINI A, 1987, CANCER RES, V47, P3239; ALBRECHTBUEHLER G, 1977, CELL, V11, P359; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; AZORSA DO, 1991, BLOOD, V78, P280; BARNES R, 1990, AM J PATHOL, V139, P254; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BURK RR, 1973, P NATL ACAD SCI USA, V70, P369, DOI 10.1073/pnas.70.2.369; Chintala SK, 1996, CANCER LETT, V103, P201, DOI 10.1016/0304-3835(96)04215-2; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; FURUKAWA T, 1993, J SURG ONCOL, V53, P10, DOI 10.1002/jso.2930530105; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GIL ML, 1992, J IMMUNOL, V148, P2826; Guo XZ, 1996, CANCER RES, V56, P4876; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; HOTTA H, 1988, CANCER RES, V48, P2955; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IMAI T, 1992, J IMMUNOL, V149, P2879; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; Jass JR, 1989, WHO INT HISTOLOGICAL, V2nd; KONDOH M, 1993, MELANOMA RES, V3, P241; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; LEBELBINAY S, 1995, J LEUKOCYTE BIOL, V57, P956, DOI 10.1002/jlb.57.6.956; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIOTTA LA, 1991, CANCER RES, V51, pS5054; MARX J, 1995, SCIENCE, V268, P799, DOI 10.1126/science.7754364; *MIN HLTH WELF, 1996, STAT INF DEP VIT STA, P52; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYEROFF LL, 1993, J NATL CANCER I, V85, P147, DOI 10.1093/jnci/85.2.147; OHE Y, 1994, JPN J CANCER RES, V85, P400, DOI 10.1111/j.1349-7006.1994.tb02373.x; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PARISH CR, 1992, INT J CANCER, V52, P378, DOI 10.1002/ijc.2910520309; REPESH LA, 1989, INVAS METAST, V9, P192; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SATO Y, 1986, AM J PATHOL, V125, P431; SCHALEPFER DD, 1994, NATURE, V372, P786; SEEHAFER JG, 1991, BIOCHEM BIOPH RES CO, V179, P401, DOI 10.1016/0006-291X(91)91384-O; STRAUS AH, 1989, EXP CELL RES, V183, P126, DOI 10.1016/0014-4827(89)90423-0; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; UEDA T, 1991, CELL, V66, P107; WANG LM, 1993, CANCER RES, V53, P717; WHITE K, 1993, J COLL STUDENT DEV, V34, P289; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; WU CY, 1993, J BIOL CHEM, V268, P21883	62	100	109	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1443	1453		10.1038/sj.onc.1201648	http://dx.doi.org/10.1038/sj.onc.1201648			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525743				2022-12-28	WOS:000072572400008
J	Erhardt, JA; Pittman, RN				Erhardt, JA; Pittman, RN			p21(WAF1) induces permanent growth arrest and enhances differentiation, but does not alter apoptosis in PC12 cells	ONCOGENE			English	Article						p21(WAF1); PC12; NGF; apoptosis; differentiation; proliferation	CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; IN-VIVO; TERMINAL DIFFERENTIATION; SYMPATHETIC NEURONS; TUMOR SUPPRESSION; HUMAN FIBROBLASTS; PROTEIN-KINASES; G(1) ARREST; P21	p21(WAF1) cyclin-dependent kinase inhibitor has been implicated in the control of proliferation, differentiation, and death in, various cell lines, To further examine p21 regulation of the transitions between these cellular processes, an inducible p21 vector (lac operon system) was transfected into the rat pheochromocytoma (PC12) neural cell line, Induction of p21 led to permanent growth arrest, as evidenced by cell counts, FACS analysis, and thymidine incorporation, This arrest was maintained, even after removal of the inducing signal (IPTG). Northern analysis revealed that endogenous p21 mRNA increased following IPTG removal, which may be responsible for the continued growth arrest despite the decrease in ectopic p21 expression, p21 overexpression did not directly lead to a differentiated phenotype; however, differentiation in response to nerve growth factor (NGF) was greatly accelerated. To examine effects on cell, death, and specifically test the hypothesis that apoptosis caused by withdrawal of trophic support results from inappropriate entry into cell cycle, serum was removed from proliferating and p21-arrested PC12 cells, The rate of apoptotic death was not affected by p21, nor was it effective in altering the extent of death following other apoptotic stimuli.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Erhardt, JA (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.				AHRQ HHS [HS32465] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ATTARDI D, 1996, EMBO J, V15, P3696; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Buchkovich K, 1994, MOL BIOL CELL, V5, P1226; Chen J, 1996, ONCOGENE, V13, P1395; CHEN YQ, 1995, CANCER RES, V55, P4536; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FERRARI G, 1995, J NEUROSCI, V15, P2857; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Givol I, 1995, ONCOGENE, V11, P2609; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GRANA X, 1995, ONCOGENE, V11, P211; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUO K, 1995, MOL CELL BIOL, V15, P3823; GUPTA M, 1987, BRAIN RES BULL, V18, P555, DOI 10.1016/0361-9230(87)90119-5; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HUPPI K, 1994, ONCOGENE, V9, P3017; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; Mills JC, 1997, EXP CELL RES, V231, P337, DOI 10.1006/excr.1997.3474; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Poluha W, 1996, MOL CELL BIOL, V16, P1335; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; STEIN GS, 1994, CELL BIOL LAB HDB, P282; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Teng KK, 1994, CELL BIOL LAB HDB, P218; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanGrunsven LA, 1996, ONCOGENE, V12, P855; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Woodgett JR, 1996, CANCER SURV, V27, P127; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAN GZ, 1995, J NEUROSCI, V15, P6200; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG BW, 1996, CURR BIOL, V6, P606	67	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					443	451		10.1038/sj.onc.1201577	http://dx.doi.org/10.1038/sj.onc.1201577			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484833				2022-12-28	WOS:000071739400002
J	Sekiguchi, T; Hunter, T				Sekiguchi, T; Hunter, T			Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHKZ1 cells	ONCOGENE			English	Article						cell cycle; PCNA; tetracycline	DEPENDENT-KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; P53-MEDIATED G(1) ARREST; DNA-REPLICATION; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; HUMAN FIBROBLASTS; PHASE-TRANSITION; NUCLEAR ANTIGEN; BINDING DOMAINS	p21(cip1/waf1/sdil) is universal cyclin-Cdk kinase inhibitor that has two functional domains; one binds and inhibits cyclin-Cdk activity and the other binds PCNA and thereby inhibits elongation by DNA polymerase. When transiently expressed in hamster BHK21 cells we found that human p21 was able to cause cell cycle arrest in G1 phase; this arrest was counteracted by coexpression of E2F-1 or SV40 large T antigen. To study the effect of p21 overexpression in vivo, BHK21 cell clones inducibly expressing human p21 (Tet-p21) driven by the tetracycline (Tet)-repressible promoter were established. The maximum induced p21 levels in the absence of Tet were estimated to be ten times that of endogenous hamster p21. As p21 levels rose following removal of Tet, p21-associated histone H1 kinase activity was increased and concomitantly cell growth and DNA synthesis were reduced. Tet-p21 BHK21 cells became arrested in G1 phase and lost colony forming ability irreversibly 2-4 days after removal of Tet. The induction of cyclin E- and cyclin A-associated kinase activities was diminished when G0-synchronized Tet-p21 BHK21 cells mere serum stimulated in the absence of Tet. Increased binding of p21 to PCNA and cyclin D1-Cdk4 was detected in induced cells. Overexpression of p21 led to cell death in BHK21 cells at 39.5 degrees C within 4 days.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, CA14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen IT, 1996, ONCOGENE, V12, P595; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CRISTOFALO VJ, 1989, EXP GERONTOL, V24, P367, DOI 10.1016/0531-5565(89)90044-2; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar R, 1996, ONCOGENE, V12, P2155; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOUBIN F, 1995, ONCOGENE, V10, P2281; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kobayashi T, 1995, ONCOGENE, V11, P2311; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1987, EXP CELL RES, V169, P395, DOI 10.1016/0014-4827(87)90200-X; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; Sekiguchi T, 1996, GENES CELLS, V1, P687, DOI 10.1046/j.1365-2443.1996.00259.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Tsao YP, 1995, BIOCHEM J, V312, P693, DOI 10.1042/bj3120693; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	71	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					369	380		10.1038/sj.onc.1201539	http://dx.doi.org/10.1038/sj.onc.1201539			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467962				2022-12-28	WOS:000071582100009
J	Jackson, P; Mastrangelo, I; Reed, M; Tegtmeyer, P; Yardley, G; Barrett, J				Jackson, P; Mastrangelo, I; Reed, M; Tegtmeyer, P; Yardley, G; Barrett, J			Synergistic transcriptional activation of the MCK promoter by p53: tetramers link separated DNA response elements by DNA looping	ONCOGENE			English	Article						p53; MCK; transcription; DNA looping	TATA-BINDING PROTEIN; GENE; IDENTIFICATION; ENHANCER; SEQUENCE; DOMAINS; MUTANT; SITES; TRANSACTIVATION; SUPPRESSION	The WAF1, Cyclin G and muscle creatine kinase (MCK) genes, all contain multiple copies of the consensus p53-binding element within their regulatory regions, We examined the role of these elements in transactivation of the muscle creatine kinase (MCK) gene by p53, The MCK promoter possesses distal (-3182 to -3133) and proximal (-177 to -81) p53-binding elements within which residues -3182 to -3151 (distal) and -176 to -149 (proximal) show homology to the consensus p53-binding site, Using promoter deletion studies, we find that both proximal and distal elements are required for high level, synergistic transcriptional activation in vivo. Electron microscopy indicates that p53-p53 interactions link proximal and distal p53-binding elements and cause looping out of intervening DNA, suggesting that this DNA sequence may be dispensable for synergy, This idea was confirmed by progressive deletion of the DNA between p53-binding elements, Synergism persisted with spacing reduced to only 150 bp, Tetramerization-deficient p53 mutants were defective for transcriptional activation but still capable of synergy, Our results provide evidence for a model by which high level transcriptional activation of promoters with multiple p53 response elements is achieved.	Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; SUNY Stony Brook, Med Ctr, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Jackson, P (corresponding author), Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia.				NCI NIH HHS [CA-18808, CA-28148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018808, R37CA018808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BURATOWSKI S, 1995, SCIENCE, V270, P1773, DOI 10.1126/science.270.5243.1773; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; JACKSON P, 1995, GENE EXPRESSION, V5, P19; JACKSON P, 1993, ONCOGENE, V8, P589; Jackson P, 1997, FEBS LETT, V406, P271, DOI 10.1016/S0014-5793(97)00283-4; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAYR GA, 1995, CANCER RES, V55, P2410; Momand J, 1997, J CELL BIOCHEM, V64, P343; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; Reed Michael, 1993, Gene Expression, V3, P95; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YUAN JN, 1993, BIOCHEM BIOPH RES CO, V192, P662; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	47	30	30	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					283	292		10.1038/sj.onc.1201491	http://dx.doi.org/10.1038/sj.onc.1201491			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464547				2022-12-28	WOS:000071427100016
J	Wagner, P; Fuchs, A; Gotz, C; Nastainczyk, W; Montenarh, M				Wagner, P; Fuchs, A; Gotz, C; Nastainczyk, W; Montenarh, M			Fine mapping and regulation of the association of p53 with p34(cdc2)	ONCOGENE			English	Article						p53; growth suppressor protein; protein kinase p34(cdc2)	CASEIN KINASE-II; CELL-CYCLE CONTROL; TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; FISSION YEAST; DNA-BINDING; TMS1 PROTEIN; PHOSPHORYLATION SITES; GROWTH ARREST; MUTANT	In vivo p53 is multiply phosphorylated by different protein kinases suggesting a central role for phosphorylation in modulating p53 function. In addition, p53 was found to be associated with two protein kinases, p34(cdc2) and protein kinase CK2. Here we report the precise mapping of the interaction sites of p53-p34(cdc2) complexes. The p34(cdc2) binding site on human p53 maps to one distinct C-terminal site LQIRGRERFE (aa 330-339) close to the corresponding phosphorylation site at serine 315. In order to test whether phosphorylation of p53 might influence the binding of p53 to p34(cdc2) phosphorylation mutants of the C-terminus of p53, which mimick permanent phosphorylation, were tested on their ability to bind to p34(cdc2) in vitro. Substitution of serine 315 (the p34(cdc2) phosphorylation site) with aspartic acid had only little effect on complex formation whereas an exchange of serine 392 (the protein kinase CK2 phosphorylation site) to aspartic acid resulted in a significant reduced relative binding affinity of p53 to p34(cdc2). The same result was obtained when the C-terminus of p53 was phosphorylated by purified protein kinase CK2 prior to examination of complex formation. In addition, the specificity of the complex formation has been checked by competition experiments with full length p53 proteins and the influence of cyclin B on complex formation was examined.	Univ Saarlandes, D-66421 Homburg, Germany	Saarland University	Wagner, P (corresponding author), Univ Saarlandes, Bldg 44, D-66421 Homburg, Germany.		Montenarh, Mathias/AAB-6689-2020					APPEL K, 1995, ONCOGENE, V11, P1971; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DAMICO D, 1992, ONCOGENE, V7, P339; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1994, ONCOGENE, V9, P3249; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARLOW E, 1981, J VIROL, V398, P61; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hecker D, 1996, ONCOGENE, V12, P953; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; KASTAN MB, 1993, ADV EXP MED BIOL, V339, P291; KRAISS S, 1990, ONCOGENE, V5, P845; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LIU FS, 1994, OBSTET GYNECOL, V83, P118; LORENZ A, 1992, INT J ONCOL, V1, P571; MEEK DW, 1992, BIOCHEM J, V287, P1; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NISHIDA N, 1993, CANCER RES, V53, P368; SCHNEIDER E, 1995, HYBRIDOMA, V14, P329, DOI 10.1089/hyb.1995.14.329; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; STURZBECHER HW, 1990, ONCOGENE, V5, P795; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; WAGNER P, 1991, ONCOGENE, V6, P1539; Wagner P, 1995, FEBS LETT, V377, P155, DOI 10.1016/0014-5793(95)01329-6; WAGNER P, 1994, HYBRIDOMA, V13, P527, DOI 10.1089/hyb.1994.13.527; WAGNER P, 1995, INT J ONCOL, V7, P171; WAGNER P, 1994, INT J ONCOL, V4, P987; WAGNER P, 1994, INT J ONCOL, V4, P491; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0	49	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					105	111		10.1038/sj.onc.1201510	http://dx.doi.org/10.1038/sj.onc.1201510			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467949				2022-12-28	WOS:000071236800013
J	Waltz, SE; Toms, CLV; McDowell, SA; Clay, LA; Muraoka, RS; Air, EL; Sun, WY; Thomas, MB; Degen, SJF				Waltz, SE; Toms, CLV; McDowell, SA; Clay, LA; Muraoka, RS; Air, EL; Sun, WY; Thomas, MB; Degen, SJF			Characterization of the mouse Ron/Stk receptor tyrosine kinase gene	ONCOGENE			English	Article						Ron; Stk; hepatocyte growth factor-like protein receptor	MACROPHAGE-STIMULATING PROTEIN; HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; MOLECULAR-CLONING; CONSTITUTIVE ACTIVATION; MET; EXPRESSION; RON; MSP; STK	In an effort to understand the mechanisms governing the regulation of the mouse Ron receptor gene, a mouse genomic library was screened and overlapping clones coding for the Ron gene and flanking DNA were identified, Continuous DNA sequence was obtained for approximately 16.4 kilobases, The gene, from the initiator methionine to the polyadenylation site, is contained within 13 244 basepairs and contains 19 exons, Primer extension analyses were performed to determine the transcription start site of the mouse Ron transcript, Multiple transcription start sites were found which also appear to be used in transfected reporter constructs containing Ron 5' flanking DNA, To determine the location of sites which may be critical for the function of the Ron gene promoter, a series of chimeric genes containing serial deletions of the Ron gene promoter fused to the coding sequences for the chloramphenicol acetyl-transferase gene were constructed, Transient transfection analyses of these hybrid genes into various cell lines demonstrated that two regions of the Ron gene promoter, encompassing nucleotides -585 to -465 and from -465 to -285, are important for expression of this transcript in CMT-93 cells, Further analysis of the Ron promoter utilizing gel mobility shift analyses suggests that regions encompassing nucleotides -585 to -508 and nucleotides -375 to -285 appear to bind specific proteins which may be involved in the negative and positive regulation, respectively, of the mouse Ron gene.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45221 USA; Univ Cincinnati, Grad Program Dev Biol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Degen, SJF (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45221 USA.		Toms, Christy/L-4472-2013	Toms, Christy/0000-0003-4305-6357; Waltz, Susan/0000-0003-3572-4642	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009466] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07382] Funding Source: Medline; NIDDK NIH HHS [DK47003, DK09466] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERKNER KL, 1985, NUCLEIC ACIDS RES, V13, P841, DOI 10.1093/nar/13.3.841; BEZERRA JA, 1993, PROTEIN SCI, V2, P666; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Collesi C, 1996, MOL CELL BIOL, V16, P5518; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CORRELL PH, 1997, GENES FUNCTION, V1, P1; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DEGEN SJF, 1991, BIOCHEMISTRY-US, V30, P9781, DOI 10.1021/bi00104a030; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P6165, DOI 10.1021/bi00393a033; DEGEN SJF, 1992, GENOMICS, V13, P1368, DOI 10.1016/0888-7543(92)90073-2; DELGATTO F, 1995, BBA-GENE STRUCT EXPR, V1263, P93, DOI 10.1016/0167-4781(95)00082-R; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; Gambarotta G, 1996, ONCOGENE, V13, P1911; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HAN S, 1993, HEPATOCYTE GROWTH FA, P81; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; KRAYEV AS, 1982, NUCLEIC ACIDS RES, V10, P7461, DOI 10.1093/nar/10.23.7461; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QUANTIN B, 1995, DEV DYNAM, V204, P383, DOI 10.1002/aja.1002040405; RONSIN C, 1993, ONCOGENE, V8, P1195; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SHIMAMOTO A, 1993, FEBS LETT, V333, P61, DOI 10.1016/0014-5793(93)80375-5; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKEEL A, 1994, J IMMUNOL, V152, P4618; Waltz SE, 1996, J BIOL CHEM, V271, P9024, DOI 10.1074/jbc.271.15.9024; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; ZHEN Z, 1994, ONCOGENE, V9, P1691	44	30	33	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					27	42		10.1038/sj.onc.1201508	http://dx.doi.org/10.1038/sj.onc.1201508			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467940				2022-12-28	WOS:000071236800004
J	Suzuki, J; Kaziro, Y; Koide, H				Suzuki, J; Kaziro, Y; Koide, H			An activated mutant of R-Ras inhibits cell death caused by cytokine deprivation in BaF3 cells in the presence of IGF-I	ONCOGENE			English	Article						R-Ras; apoptosis; PI3K; MAPK; IGF-I; Ras	GROWTH-FACTOR; HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL-3 KINASE; SIGNAL-TRANSDUCTION; PROTO-ONCOGENES; H-RAS; APOPTOSIS; EXPRESSION; RECEPTOR; IDENTIFICATION	R-Ras belongs to a family of low molecular weight GTP-binding proteins and exhibits 55% amino acid identity to H-Ras. It has been demonstrated that H-Ras inhibits cell death caused by interleukin-3 (IL-3) withdrawal in BaF3 cells (Kinoshita rt al. (1995b); Terada et al. (1995)). In the present study, we examined whether R-Ras also rescues BaF3 cells from the factor-deprived cell death, To do this, several BaF3 transfectants were established, in which expression of wild-type as well as mutant R-Ras was regulated by an inducible promoter. Using these transfectants, we found that expression of an activated R-Ras mutant, R-Ras (Q87L), suppressed the death of IL-3-deprived BaF3 cells. On the other hand, expression of the wild-type and the dominant-negative mutant of R-Ras showed no inhibitory effect on cell death, indicating that R-Ras.GTP abrogated cell death caused by deprivation of IL-3, Furthermore, it was found that IGF-I in serum was required for the anti-apoptotic activity of R-Ras, Suppression of cell death by R-Ras(Q87L) was inhibited by wortmannin, LY294002 (phosphatidylinositol 3-kinase (PI3K) inhibitors), or PD98059 (inhibitor for MEK, a specific activator of mitogen-activated protein kinase (MAPK)), In addition, we have shown that, in HEK293 cells, R-Ras and IGF-I could activate MAPK synergistically. Also, PI3K activity was co-immunoprecipitated with an activated mutant of R-Ras. These results suggest that R-Ras in collaboration with IGF-I suppressed apoptotic cell death of BaF3 caused by IL-3 deprivation, presumably by modulating the activitites of MAPK and PI3K.	TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL, MIDORI KU, YOKOHAMA, KANAGAWA 227, JAPAN	Tokyo Institute of Technology			Koide, Hiroshi/E-9000-2011	Koide, Hiroshi/0000-0001-5916-3179				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; Cormier F, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104811; COX AD, 1994, ONCOGENE, V9, P3281; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Minshall C, 1996, J IMMUNOL, V156, P939; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; REY I, 1994, ONCOGENE, V9, P685; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	45	30	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1689	1697		10.1038/sj.onc.1201333	http://dx.doi.org/10.1038/sj.onc.1201333			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349502				2022-12-28	WOS:A1997XY63100008
J	FitzerAttas, CJ; Do, MS; Feigelson, S; Vadai, E; Feldman, M; Eisenbach, L				FitzerAttas, CJ; Do, MS; Feigelson, S; Vadai, E; Feldman, M; Eisenbach, L			Modification of PDGF alpha receptor expression or function alters the metastatic phenotype of 3LL cells	ONCOGENE			English	Article						3LL cells; dominant negative; paracrine loop; PDGF alpha receptors; tumor metastases	GROWTH-FACTOR PDGF; LUNG-CARCINOMA CELLS; BETA-RECEPTOR; TUMOR-CELLS; DIFFERENTIAL EXPRESSION; SIGNAL TRANSDUCTION; NEGATIVE MUTATIONS; CANCER METASTASIS; PROTEIN PRODUCTS; TYROSINE KINASES	Functional PDGF alpha receptors are selectively expressed on highly lung-metastasizing clones of the 3LL Lewis lung carcinoma, but not on low-mestastatic clones. The highly metastatic clones are also growth induced in vitro by PDGF and lung conditioned medium. To investigate whether modification of PDGF alpha receptor expression or function can affect metastatic capability, we transfected cells of a low-metastatic 3LL clone with a full length PDGF alpha receptor gene and cells of a highly-metastatic clone with a truncated kinase domain PDGF alpha receptor gene. Introduction of the full length PDGF alpha receptor conferred upon low-metastatic cells the ability to grow in vitro in the presence of PDGF-AA and to colonize the lung in experimental and spontaneous metastases assays. Conversely, introduction of a truncated version of the PDGF alpha receptor into highly metastatic cells reduced their metastatic load to control levels. Accordingly, their responses to PDGF-AA, including growth stimulation and receptor autophosphorylation, were reduced. These results demonstrate that PDGF alpha receptor expression and function can control the capacity of tumor cells to generate metastases in the lung. The response of this receptor to lung-derived PDGF-like factors may define a paracrine mode of metastatic cell growth in the target organ.	WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Fitzer-Attas, Cheryl/0000-0002-8709-1384; Eisenbach, Lea R/0000-0002-4816-1968				ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; DEBAETSELIER P, 1980, NATURE, V288, P179; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DO MS, 1992, ONCOGENE, V7, P1567; EISENBACH L, 1983, INT J CANCER, V32, P113, DOI 10.1002/ijc.2910320118; EISENBACH L, 1984, INT J CANCER, V34, P567, DOI 10.1002/ijc.2910340421; FIDLER IJ, 1989, CYTOMETRY, V10, P673, DOI 10.1002/cyto.990100602; FIDLER IJ, 1990, CANCER RES, V50, P6130; FITZERATTAS C, 1993, INT J CANCER, V53, P315, DOI 10.1002/ijc.2910530224; FITZERATTAS CJ, 1993, THESIS WEIZMANN I SC; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; Hall A, 1996, DEVELOPMENT, V122, P4085; HARSH GR, 1990, J NEURO-ONCOL, V8, P1; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART IR, 1981, CANCER RES, V41, P1281; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; HENRIKSEN R, 1993, CANCER RES, V53, P4550; HERMANSON M, 1992, CANCER RES, V52, P3213; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; KEMP PR, 1993, FEBS LETT, V336, P119, DOI 10.1016/0014-5793(93)81623-8; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LEVEEN P, 1990, INT J CANCER, V46, P1066, DOI 10.1002/ijc.2910460620; LIU M, 1995, AM J PHYSIOL, V269, P178; MALIK R, 1991, CANCER RES, V51, P5626; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MAXWELL M, 1990, INT J CANCER, V46, P16, DOI 10.1002/ijc.2910460106; MORNEX JF, 1986, J CLIN INVEST, V78, P61, DOI 10.1172/JCI112574; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; PLAKSIN D, 1988, P NATL ACAD SCI USA, V85, P4463, DOI 10.1073/pnas.85.12.4463; PONTEN F, 1994, J INVEST DERMATOL, V102, P304, DOI 10.1111/1523-1747.ep12371787; PORGADOR A, 1993, J IMMUNOL, V150, P1458; RADINSKY R, 1992, In Vivo (Attiki), V6, P325; RUSCIANO D, 1992, BIOESSAYS, V14, P185, DOI 10.1002/bies.950140309; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHAMAH SM, 1995, METHOD ENZYMOL, V254, P565; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SMITS A, 1992, AM J PATHOL, V140, P639; SOUZA P, 1995, DEVELOPMENT, V121, P2559; STRAWN LM, 1994, J BIOL CHEM, V269, P21215; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; TARIN D, 1984, CANCER RES, V44, P3584; UENO H, 1993, J BIOL CHEM, V268, P22814; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; Van Furth R, 1980, MONONUCLEAR PHAGOCYT; VIGNAUD JM, 1994, CANCER RES, V54, P5455; WANG JL, 1990, INT J CANCER, V46, P772, DOI 10.1002/ijc.2910460504; WESTERMARK B, 1993, ACTA ONCOL, V32, P101, DOI 10.3109/02841869309083897; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	58	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1545	1554		10.1038/sj.onc.1201321	http://dx.doi.org/10.1038/sj.onc.1201321			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380406				2022-12-28	WOS:A1997XX36900005
J	Wu, GF; Fan, RS; Li, WH; Ko, TC; Brattain, MG				Wu, GF; Fan, RS; Li, WH; Ko, TC; Brattain, MG			Modulation of cell cycle control by vitamin D-3 and its analogue, EB1089, in human breast cancer cells	ONCOGENE			English	Article						breast cancer; vitamin D-3; EB1089; p21(WAF-1)/(CIP-1); inactivation of Cdk2 activity	DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; DNA-REPLICATION; MCF-7 CELLS; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; CDK INHIBITOR; P21; P27(KIP1); PHASE	Examination of a panel of ER positive breast cancer cell lines showed that they were differentially growth inhibited by vitamin D-3 and its analogue EB1089. EB1089 treatment of the breast cancer cell lines MCF-7 E, BT20, T47D, and ZR75 demonstrated a correlation between a reduction in Cdk2 kinase activity towards phosphorylation of histone H1 and a decrease in DNA synthesis, while no modulation of Cdk2 activity was observed in the vitamin D-3 and EB1089 resistant cell line MCF-7 L. This was accompanied by a time dependent decrease in the percentage of S phase cells in the responsive lines. Characterization of the expression levels of Cdk2 and its related cell cycle proteins in MCF-7 E cells showed that after EB1089 treatment, there was a concentration and time dependent up-regulation of p21 as well as a decrease in cyclin A proteins. Paradoxically, cyclin E levels were increased as a function of treatment. Analysis of cyclin-Cdk2-Cdki complex formation showed that in EB1089 treated MCF-7 E cells, Cdk2, cyclin A and cyclin E immunoprecipitates contained an increased abundance of p21. In contrast to MCF-7 E cells, increases in both p21 and p27 as well as their complex formation with Cdk2 were observed in BT20 and ZR75 cells. These findings indicate that up-regulation of p21 as well as p27 in some cell types mag account for the inactivation of Cdk2 activity and a G(1) block of the cell cycle following EB1089 treatment.	MED COLL OHIO,DEPT BIOCHEM & MOL BIOL,TOLEDO,OH 43699; UNIV TEXAS,MED BRANCH,DEPT SURG,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [CA72001, CA50457, CA38173] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA038173, R01CA038173, R01CA050457, R01CA072001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE J, 1991, ENDOCRINOLOGY, V129, P832, DOI 10.1210/endo-129-2-832; ABE J, 1986, CANCER RES, V46, P6316; BERGER U, 1987, CANCER RES, V47, P6793; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Brattain MG, 1996, J MAMMARY GLAND BIOL, V1, P365, DOI 10.1007/BF02017392; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHOUVET C, 1986, J STEROID BIOCHEM, V24, P373, DOI 10.1016/0022-4731(86)90085-3; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EISMAN JA, 1986, CANCER RES, V46, P5406; EISMAN JA, 1989, J CELL PHYSIOL, V138, P611, DOI 10.1002/jcp.1041380323; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P815; ELSTNER E, 1995, CANCER RES, V55, P2822; FELDMAN D, 1980, J CLIN ENDOCR METAB, V51, P1463, DOI 10.1210/jcem-51-6-1463; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar R, 1996, ONCOGENE, V12, P2155; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gorospe M, 1996, CANCER RES, V56, P475; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAZARS P, 1995, FEBS LETT, V362, P295, DOI 10.1016/0014-5793(95)00247-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RIGBY WFC, 1985, J IMMUNOL, V135, P2279; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang QM, 1996, CANCER RES, V56, P264; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	55	95	96	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1555	1563		10.1038/sj.onc.1201329	http://dx.doi.org/10.1038/sj.onc.1201329			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380407				2022-12-28	WOS:A1997XX36900006
J	Mirkovic, N; Voehringer, DW; Story, MD; McConkey, DJ; McDonnell, TJ; Meyn, RE				Mirkovic, N; Voehringer, DW; Story, MD; McConkey, DJ; McDonnell, TJ; Meyn, RE			Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols	ONCOGENE			English	Article						apoptosis; lymphoma; Bcl-2; radiation; thiols; antioxidants	DNA FRAGMENTATION; BCL-2 PROTECTION; REDOX REGULATION; LYMPHOMA-CELLS; MURINE TUMORS; DEATH; GLUTATHIONE; OXYGEN; P53; GENE	The mechanism by which Bcl-2 oncogene expression inhibits radiation-induced apoptosis has been investigated in two mouse lymphoma cell lines: line LY-as is radiation sensitive, displays substantial radiaton-induced apoptosis. and expresses low levels of Bcl-2; line LY-ar is radiation-resistant, displays a low apoptosis propensity, and expresses 30-fold higher amount of Bcl-2 protein than does the sensitive line. We observed that upon incubation in cystine/methionine-free (C/M-) medium, radiation-induced apoptosis in the LY-ar cells was restored to levels comparable to that seen in the LY-as cells. Intracellular glutathione (GSH) concentrations in LY-ar cells incubated in C/M- medium plummeted to 50% of control values within 2 h. LY-ar cells treated with diethyl maleate (DEM) or diamide, agents that deplete cellular thiols, had increased susceptibility to radiation-induced apoptosis in a manner similar to C/M- medium. These results are consistent with the general idea that Bcl-2 expression blocks apoptosis through an antioxidant pathway that involves cellular thiols. That Bcl-2-expressing tumor cells can be sensitized by exogeneous agents that modify cellular thiols offers strategies for overcoming such resistance.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT EXPT RADIAT ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Story, Michael/AAX-2864-2021	Story, Michael/0000-0001-6522-4169	NCI NIH HHS [P01-CA-06294, R01-CA-69003, R01-CA-62597] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062597, P01CA006294, R01CA069003] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFY G, 1993, J BIOL CHEM, V268, P6511; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dynlacht JR, 1996, CYTOMETRY, V24, P348, DOI 10.1002/(SICI)1097-0320(19960801)24:4<348::AID-CYTO6>3.0.CO;2-B; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; FAN SJ, 1994, CANCER RES, V54, P5824; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; Herrmann JL, 1996, BIOCHEM SOC T, V24, P1059, DOI 10.1042/bst0241059; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JONES DP, 1995, IMMUNOL LETT, V45, P205, DOI 10.1016/0165-2478(95)00004-O; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KROMER G, 1997, IMMUNOL TODAY, V18, P44; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; MARIN MC, 1994, ONCOGENE, V9, P3107; Marin MC, 1996, ONCOGENE, V12, P2259; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEISTER A, 1994, CANCER RES, V54, pS1969; MEYN RE, 1995, ANTI-CANCER DRUG, V6, P443, DOI 10.1097/00001813-199506000-00013; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; MUSCHEL RJ, 1995, CANCER RES, V55, P995; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SATO N, 1995, J IMMUNOL, V154, P3194; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shimizu S, 1996, ONCOGENE, V13, P21; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; STORY MD, 1993, CANCER CHEMOTH PHARM, V32, P129, DOI 10.1007/BF00685615; STORY MD, 1994, INT J RADIAT BIOL, V66, P659; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUZUKAKE K, 1982, BIOCHEM PHARMACOL, V31, P121; Voehringer DW, 1997, INT J RADIAT BIOL, V71, P237, DOI 10.1080/095530097144102; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WALTON MI, 1993, CANCER RES, V53, P1853; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	55	202	205	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1461	1470		10.1038/sj.onc.1201310	http://dx.doi.org/10.1038/sj.onc.1201310			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333022				2022-12-28	WOS:A1997XW41100010
J	Mizuno, T; Kyoizumi, S; Suzuki, T; Iwamoto, KS; Seyama, T				Mizuno, T; Kyoizumi, S; Suzuki, T; Iwamoto, KS; Seyama, T			Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis	ONCOGENE			English	Article						thyroid; radiation; RET oncogene; H4-RET; scid mice	SEVERE COMBINED IMMUNODEFICIENCY; POTENTIALLY LETHAL DAMAGE; DOUBLE-STRAND BREAKS; CARCINOMA CELL-LINE; RET PROTO-ONCOGENE; SCID MICE; PHILADELPHIA-CHROMOSOME; HUMAN-FIBROBLASTS; IN-VIVO; HUMAN SKIN	Ionizing radiation is a well-known risk factor of cancer development, but the mechanism of radiation induced carcinogenesis is not clear. Chromosomal rearrangements induced by radiation most likely are one of the principal genetic alterations resulting in malignant transformation. The chimeric BCR-ABL associated with chronic myelogenous leukemia (CML) and H4-RET oncogenes associated with thyroid papillary carcinoma are the result of a translocation and inversion, respectively. In vitro studies showed these genes were induced by high-doses of X-irradiation in cell lines. Studies also show that therapeutic external X-ray doses as high as 60 Gy for treatment of various childhood cancers including Hodgkin's disease significantly increase the risk of thyroid cancer. Therefore, we examined the induction and persistence of these chimeric genes in human thyroid tissues transplanted in scid mice after 50 Gy exposure as a function of time for 2 months to elucidate the early events of thyroid carcinogenesis. The H4-RET genes were detected on day 2 and throughout the 2 month period. On the other hand, BCR-ABL genes were detected on day 2 and were undetectable subsequently. These results suggest that ionizing radiation causes various oncogene activations, but cells with only specific gene alteration uniquely associated with thyroid carcinogenesis are selectively retained demonstrating one of the early events in the beginnings of radiation carcinogenesis in human thyroid tissues.	RADIAT EFFECTS RES FDN,DEPT RADIOBIOL,HIROSHIMA 732,JAPAN	Radiation Effects Research Foundation - Japan								AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; BEDFORD JS, 1991, INT J RADIAT ONCOL, V21, P1457, DOI 10.1016/0360-3016(91)90320-4; BROWN JM, 1993, ENVIRON MOL MUTAGEN, V22, P218, DOI 10.1002/em.2850220407; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CORNFORTH MN, 1987, RADIAT RES, V111, P385, DOI 10.2307/3576926; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANCOCK SL, 1995, INT J RADIAT ONCOL, V31, P1165, DOI 10.1016/0360-3016(95)00019-U; HILL LL, 1991, CANCER RES, V51, P4937; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ITO T, 1993, JPN J CANCER RES, V84, P105, DOI 10.1111/j.1349-7006.1993.tb02840.x; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P259; ITO T, 1995, CANCER LETT, V88, P113, DOI 10.1016/0304-3835(94)03622-P; Klugbauer S, 1995, ONCOGENE, V11, P2459; KYOIZUMI S, 1994, RADIAT RES, V137, P76, DOI 10.2307/3578793; Lobrich M, 1995, P NATL ACAD SCI USA, V92, P12050, DOI 10.1073/pnas.92.26.12050; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; METTLER FA, 1995, MED EFFECTS IONIZING, P214; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Preston DL, 1994, RADIAT RES, V137, P68; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Soballe PW, 1996, CANCER RES, V56, P757; TAKIZAWA Y, 1995, ARCH DERMATOL RES, V287, P237, DOI 10.1007/BF01105072; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; TERAOKA S, 1994, INT J ONCOL, V5, P501; THOMPSON DE, 1994, RAD RES S, V137, P17; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0	35	67	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1455	1460		10.1038/sj.onc.1201313	http://dx.doi.org/10.1038/sj.onc.1201313			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333021				2022-12-28	WOS:A1997XW41100009
J	Koera, K; Nakamura, K; Nakao, K; Miyoshi, J; Toyoshima, K; Hatta, T; Otani, H; Aiba, A; Katsuki, M				Koera, K; Nakamura, K; Nakao, K; Miyoshi, J; Toyoshima, K; Hatta, T; Otani, H; Aiba, A; Katsuki, M			K-ras is essential for the development of the mouse embryo	ONCOGENE			English	Article						K-ras; ras genes; gene targeting	N-MYC GENE; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; MICE LACKING; RXR-ALPHA; PROTEIN; DEFECTS; CELLS; HEART	ras genes encode members of the small GTP-binding proteins, Ras protein is highly conserved in various species from yeast to humans and plays a key role in signal transduction, Ras is related to cell proliferation and differentiation, While, in addition, mutations in the ras genes are implicated in a variety of tumors, However, the physiological functions and specific roles of each ras gene, H-ras, K-ras and N-ras, are still not fully understood, To clarify the role of the K-Ras in vivo, we generated K-ras mutant mice by gene targeting, In contrast to the findings that H-Ras-deficient mice and N-Ras-deficient mice are born and grow normally, the K-Ras-deficient embryos die progressively between embryonic day 12.5 and term, At embryonic day 15.5, their ventricular walls are extremely thin, Besides, at embryonic day 11.5, they demonstrate increased cell death of motoneurons in the medulla and the cervical spinal cord, Our results thus indicate K-Ras to be essential for normal development in mice and residual Ras composed of H-Ras and N-Ras cannot compensate for the loss of K-Ras function in the mutant mice.	UNIV TOKYO,INST MED SCI,DEPT DNA BIOL & EMBRYO ENGN,TOKYO 108,JAPAN; OSAKA MED CTR CANC & CARDIOVASC DIS,OSAKA 537,JAPAN; SHIMANE MED UNIV,DEPT ANAT,IZUMO,SHIMANE 693,JAPAN	University of Tokyo; Osaka Medical Center for Cancer & Cardiovascular Diseases; Shimane University				Aiba, Atsu/0000-0002-8192-0778; zhong wei, he gui/0000-0002-3066-3564				BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KIRSTEN WH, 1967, J NATL CANCER I, V39, P311; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOENS CB, 1993, DEVELOPMENT, V119, P485; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SAKAI N, 1994, EXP CELL RES, V215, P131, DOI 10.1006/excr.1994.1324; SATOH T, 1992, J BIOL CHEM, V267, P24149; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; Shorey ML, 1909, J EXP ZOOL, V7, P25, DOI 10.1002/jez.1400070103; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	56	278	282	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1151	1159		10.1038/sj.onc.1201284	http://dx.doi.org/10.1038/sj.onc.1201284			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294608				2022-12-28	WOS:A1997XU99100004
J	Chi, KD; McPhee, RA; Wagner, AS; Dietz, JJ; Pantazis, P; Goustin, AS				Chi, KD; McPhee, RA; Wagner, AS; Dietz, JJ; Pantazis, P; Goustin, AS			Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-I-infected T-cells results in a novel tyrosine kinase product with transforming activity	ONCOGENE			English	Article						receptor tyrosine kinase; PDGF; insertional mutagenesis; HTLV-I; long terminal repeat; T-lymphocyte	VIRUS TYPE-I; DIFFERENT SIGNALING PATHWAYS; BOVINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL TRANSLOCATION; NUCLEOTIDE-SEQUENCE; HUMAN RETROVIRUS; RNA EXPRESSION	We have previously shown that noninfected human T-cell lines express the canonical 5.7 kb mRNA coding for the type beta platelet-derived growth factor-receptor (PDGF beta-receptor), whereas HTLV-I-infected T-cell lines express a novel PDGF beta-receptor mRNA of 3.8 kb, In this report, we have extended those studies to molecularly characterize the 3.8 kb PDGF beta-receptor mRNA and show that it has resulted from integration of an apparently undeleted HTLV-I provirus into the PDGF beta-receptor gene in an orientation enabling expression of a truncated PDGF beta-receptor mRNA using the 3' HTLV-I long terminal repeat as a promoter, Further, NIH3T3 cells transfected with a plasmid containing the truncated PDGF beta-receptor ORF plasmid generate colonies in soft agar with more cells per colony than untransfected cells, or cells transfected with the Tax 1 or PDGF-B (c-sis) plasmids, These results indicate that the truncated PDGF beta-receptor protein acquires transforming capability and that HTLV-I-induced truncation of PDGF beta-receptor may correlate with HTLV-I-associated neoplasia of human T-cells.	WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,DETROIT,MI 48201; STEHLIN FDN CANC RES,HOUSTON,TX 77003	Wayne State University; Wayne State University			Goustin, Anton Scott/A-2136-2011	Goustin, Anton Scott/0000-0002-4483-5101	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027444] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD27444] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARYA SK, 1984, SCIENCE, V223, P1086, DOI 10.1126/science.6320374; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEPPER JM, 1984, J IMMUNOL, V133, P1691; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Goustin AS, 1990, GROWTH FACTORS, V2, P189, DOI 10.3109/08977199009071505; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3425; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KETTMANN R, 1982, P NATL ACAD SCI-BIOL, V79, P2465, DOI 10.1073/pnas.79.8.2465; KORBER B, 1991, J VIROL, V65, P5471, DOI 10.1128/JVI.65.10.5471-5476.1991; Kubota S, 1996, ONCOGENE, V12, P1441; MARKHAM PD, 1983, INT J CANCER, V31, P413, DOI 10.1002/ijc.2910310404; MARRIOTT SJ, 1992, ONCOGENE, V7, P1749; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; OHSHIMA K, 1991, CANCER RES, V51, P4639; PANTAZIS P, 1990, EUR J HAEMATOL, V45, P127; PANTAZIS P, 1987, ONCOGENE, V1, P285; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; RAO VN, 1993, ONCOGENE, V8, P2167; RATNER L, 1985, J VIROL, V54, P781, DOI 10.1128/JVI.54.3.781-790.1985; REITZ MS, 1981, P NATL ACAD SCI-BIOL, V78, P1887, DOI 10.1073/pnas.78.3.1887; SAGGIORO D, 1990, CANCER RES, V50, P4968; SAKURAI H, 1992, LEUKEMIA RES, V16, P941, DOI 10.1016/0145-2126(92)90040-E; SALAHUDDIN SZ, 1984, SCIENCE, V223, P703, DOI 10.1126/science.6320367; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SEIGEL LJ, 1986, VIROLOGY, V154, P67, DOI 10.1016/0042-6822(86)90430-7; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHIMOTOHNO K, 1984, P NATL ACAD SCI-BIOL, V81, P6657, DOI 10.1073/pnas.81.21.6657; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; UMADOME H, 1988, J CLIN INVEST, V81, P52, DOI 10.1172/JCI113309; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDENBROEKE A, 1988, P NATL ACAD SCI USA, V85, P9263, DOI 10.1073/pnas.85.23.9263; WATANABE T, 1984, VIROLOGY, V133, P238, DOI 10.1016/0042-6822(84)90446-X	48	10	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1051	1057		10.1038/sj.onc.1201267	http://dx.doi.org/10.1038/sj.onc.1201267			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285559				2022-12-28	WOS:A1997XT16100006
J	Nitta, M; Okamura, H; Aizawa, S; Yamaizumi, M				Nitta, M; Okamura, H; Aizawa, S; Yamaizumi, M			Heat shock induces transient p53-dependent cell cycle arrest at G1/S	ONCOGENE			English	Article						p53; heat shock; cell cycle arrest	NUCLEAR ACCUMULATION; P53 PROTEIN; DNA-DAMAGE; DEPENDENT KINASES; HUMAN FIBROBLASTS; TUMOR-ANTIGEN; UV; DEGRADATION; REPLICATION; CHECKPOINT	Heat shock (43 degrees C, 45 min) induced transient nuclear accumulation of p53 in primary human fibroblasts without any clonogenically toxic effects, The accumulation of p53 reached a maximal level 3 similar to 5 h after heat shock, and returned to the basal level within 12 h. Following the increase in p53 level, cell cycle arrest at G1/S was observed in normal fibroblasts, whereas neither nuclear accumulation of p53 nor cell cycle arrest were observed in HeLa cells. By comparing cell cycle patterns of heat-treated mouse cells with different genotypes at the p53 locus (+/+, +/-, -/-), the observed cell cycle arrest at G1/S was demonstrated to be p53-dependent, Cell cycle arrest in normal human fibroblasts continued for nearly 24 h, resulting in a one day delay of cell growth compared with non-treated cells, Following enhancement of the p53 level, the amount of p21/WAF1/CIP1 increased, and the high level of p21 was sustained for almost one day in a cell cycle-independent manner, suggesting the involvement of p21 in the inhibition of cell cycle progression by heat shock.	KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,KUMAMOTO 862,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT OBSTET & GYNECOL,KUMAMOTO 862,JAPAN	Kumamoto University; Kumamoto University								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Brown CR, 1996, J BIOL CHEM, V271, P833, DOI 10.1074/jbc.271.2.833; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MINISINI MP, 1994, MUTAT RES-DNA REPAIR, V315, P169, DOI 10.1016/0921-8777(94)90016-7; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shivji KK, 1992, CELL, V69, P367, DOI DOI 10.1016/0092-8674(92)90416-A; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; TSUKADA T, 1993, ONCOGENE, V8, P3313; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	32	78	81	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					561	568		10.1038/sj.onc.1201210	http://dx.doi.org/10.1038/sj.onc.1201210			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247309				2022-12-28	WOS:A1997XN25500007
J	Sun, JZ; Qian, YM; Hamilton, AD; Sebti, SM				Sun, JZ; Qian, YM; Hamilton, AD; Sebti, SM			Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts	ONCOGENE			English	Article						Ras; farnesyltransferase; geranylgeranyltransferase; prenylation and antitumor efficacy	FARNESYL-PROTEIN TRANSFERASE; PEPTIDOMIMETIC INHIBITORS; MEMBRANE ASSOCIATION; SELECTIVE-INHIBITION; WHOLE CELLS; TRANSFORMATION; CANCER; CAAX; BLOCKS; GERANYLGERANYLATION	The ability of Ras oncoproteins to cause malignant transformation requires their post-translational modifications by prenyl groups, Because K-Ras can be both farnesylated and geranylgeranylated it is not known whether both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for suppressing human tumor growth in whole animals, In this paper we report that oncogenic Ras processing. MAP kinase activation and growth in nude mice are inhibited by the farnesyltransferase inhibitor FTI-276 in H- and N-Ras transformed NIH3T3 cells; whereas in K-B-Ras transformed NIH3T3 cells both FTI-276 and the geranylgeranyltransferase I inhibitor GGTI-297 are required for inhibition, Furthermore, human lung A-549 and Calu-1 carcinoma cell lines were found to co-express H-, N- and K-Ras, In Calu-1 cells, the processing of H- and N-Ras is inhibited greatly by FTI-276 but only partially by GGTI-297 whereas K-Ras processing inhibition requires both FTI-276 and GGTI-297, In contrast, in A-549 cells the processing of H- and N-Ras is inhibited only by FTI-276 and K-Ras processing is resistant to co-treatment with FTI-276 and GGTI-297, Yet, the growth in nude mice of A-549 and Calu-1 xenografts, both of which express K-Ras mutations, is inhibited by FTI-276 (80% inhibition) and GGTI-297 (60%). Furthermore, FTI-276 inhibits tumor growth of NIH3T3 cells transformed by a form of oncogenic H-Ras that is exclusively geranylgeranylated and whose processing is resistant to this inhibitor, Taken together, the results demonstrate that both FTase and GGTase I inhibitors are required for inhibition of K-Ras processing but that each alone is sufficient to suppress human tumor growth in nude mice.	Univ S Florida, H Lee Moffitt Canc Ctr, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ Pittsburgh, Sch Arts & Sci, Dept Chem, Pittsburgh, PA 15261 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sebti, SM (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Drug Discovery Program, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; BOS JL, 1989, CANCER RES, V49, P4682; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRAHAM SL, 1994, J MED CHEM, V37, P725, DOI 10.1021/jm00032a004; Hamilton A., 1995, DRUG NEWS PERSPECT, V8, P138; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; LEBOWITZ PF, 1997, IN PRESS J BIOL CHEM; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Miquel K, 1997, CANCER RES, V57, P1846; NAGASU T, 1995, CANCER RES, V55, P5310; NIGAM M, 1993, J BIOL CHEM, V268, P20695; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; QIAN Y, 1994, BIOL CHEM, V269, P12410; QIAN YM, 1994, BIOORG MED CHEM LETT, V4, P2579, DOI 10.1016/S0960-894X(01)80287-0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SATLER I, 1996, REGULATION RAS SIGNA, P95; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SUN JZ, 1995, CANCER RES, V55, P4243; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459	45	207	217	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1467	1473		10.1038/sj.onc.1201656	http://dx.doi.org/10.1038/sj.onc.1201656			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525745				2022-12-28	WOS:000072572400010
J	Queva, C; Hurlin, PJ; Foley, KP; Eisenman, RN				Queva, C; Hurlin, PJ; Foley, KP; Eisenman, RN			Sequential expression of the MAD family of transcriptional repressors during differentiation and development	ONCOGENE			English	Article						differentiation; Mad family; Max; Myc; transcriptional repression	C-MYC PROTEIN; DNA-BINDING PROTEIN; N-MYC; EMBRYONIC LETHALITY; EPIDERMAL DIFFERENTIATION; RAS COTRANSFORMATION; TARGETED DISRUPTION; CELL-PROLIFERATION; ONCOGENIC ACTIVITY; NEOPLASTIC-CELLS	Members of the Myc proto-oncogene family encode transcription factors that function in multiple aspects of cell behavior, including proliferation, differentiation, transformation and apoptosis, Recent studies have shown that MYC activities are modulated by a network of nuclear bHLH-Zip proteins, The MAX protein is at the center of this network in that it associates with MYC as well as with the family of MAD proteins: MAD1, MXI1, MAD3 and MAD4, Whereas MYC-MAX complexes activate transcription, MAD-MAX complexes repress transcription through identical E-box binding sites, MAD proteins therefore act as antagonists of MYC, Here we report the expression patterns of the Mad gene family in the adult and developing mouse, High level of Mad gene expression in the adult is limited to tissues that display constant renewal of differentiated cell populations, In embryos, Marl transcripts are widely distributed with expression peaking during organogenesis at the onset of differentiation. A detailed analysis of their pattern of expression during chrondrocyte and neuronal differentiation in vivo, and during neuronal differentiation of P19 cells in vitro, shows that Mad family genes are sequentially induced, Mad3 transcripts and proteins are detected in proliferating cells prior to differentiation. Mxi1 and Mad4 transcripts are most abundant in cells that have further advanced along the differentiation pathway, whereas Mad1 is primarily expressed late in differentiation, Taken together, our data suggest that the different members of the MAD protein family exert their functions at distinct steps during the transition between proliferation and differentiation.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Eisenman, RN (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,Mailstop A2-025,POB 19024, Seattle, WA 98109 USA.		Foley, Kevin/ABC-1041-2020		NATIONAL CANCER INSTITUTE [R01CA057138] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA57138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Bellomo D, 1996, DEV DYNAM, V205, P471, DOI 10.1002/(SICI)1097-0177(199604)205:4<471::AID-AJA10>3.0.CO;2-4; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; CERNI C, 1995, ONCOGENE, V11, P587; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CRAIG RW, 1993, CELL GROWTH DIFFER, V4, P349; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; FINN CA, 1967, J ENDOCRINOL, V39, P593, DOI 10.1677/joe.0.0390593; FOLEY KP, IN PRESS EMBO J; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hurlin PJ, 1997, CURR TOP MICROBIOL, V224, P115; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; HURLIN PJ, 1994, COLD SPRING HARBOR S; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRANENBURG O, 1995, ONCOGENE, V10, P87; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MOENS CB, 1993, DEVELOPMENT, V119, P485; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MUKHERJEE B, 1992, GENE DEV, V7, P2110; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	67	108	119	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	1998	16	8					967	977		10.1038/sj.onc.1201611	http://dx.doi.org/10.1038/sj.onc.1201611			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519870				2022-12-28	WOS:000072335900002
J	Tamada, M; Hu, CD; Kariya, K; Okada, T; Kataoka, T				Tamada, M; Hu, CD; Kariya, K; Okada, T; Kataoka, T			Membrane recruitment of Raf-1 is not the only function of Ras in Raf-1 activation	ONCOGENE			English	Article						Ras; Raf-1; membrane translocation	PLASMA-MEMBRANE; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; HA-RAS; P21; PHOSPHORYLATION; EXPRESSION; MECHANISM; P21(RAS); DOMAINS	Pas interacts with Raf-1 and stimulates its kinase activity, which results in activation of the mitogen-activated protein (MAP) kinase cascade. It has been proposed that the main function of Ras in Raf-1 activation is to recruit Raf-1 to the plasma membrane, where a separate activation event such as phosphorylation takes place, Here, we examined the activities of various mutants of human Ha-Pas to induce membrane translocation of Raf-1 and to activate Raf-1 in vivo. Overexpression of an activator region mutant Ha-Ras(V45E) in COS7 cells induced membrane translocation of Raf-1 as effectively as wild-type Ha-Ras. However, the activity of this mutant to activate Raf-1 and extracellular signal-regulated kinase-2 (ERK2) was attenuated by approximately 70% compared to that of wild-type Ha-Pas. The decrease in the specific activity was further demonstrated by measuring the activity of the Ha-Ras(V45E)-associated Raf-1 purified from the membrane fraction. These results imply that the association of Pas with Raf-1 has another important consequence, presumably dependent on the interaction between its activator region and Raf-1, than the simple recruitment of Raf-1 to the plasma membrane.	KOBE UNIV,SCH MED,DEPT PHYSIOL 2,CHUO KU,KOBE,HYOGO 650,JAPAN	Kobe University								Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1995, MOL CELL BIOL, V15, P4125; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mineo C, 1997, J BIOL CHEM, V272, P10345; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; Shinkai M, 1996, BIOCHEM BIOPH RES CO, V223, P729, DOI 10.1006/bbrc.1996.0964; SHIROUZU M, 1994, ONCOGENE, V9, P2153; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	36	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2959	2964		10.1038/sj.onc.1201582	http://dx.doi.org/10.1038/sj.onc.1201582			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416839				2022-12-28	WOS:A1997YK37700008
J	Grasso, AW; Wen, DZ; Miller, CM; Rhim, JS; Pretlow, TG; Kung, HJ				Grasso, AW; Wen, DZ; Miller, CM; Rhim, JS; Pretlow, TG; Kung, HJ			ErbB kinases and NDF signaling in human prostate cancer cells	ONCOGENE			English	Article						ErbB3; receptor tyrosine kinase; tyrosine phosphorylation; prostate cancer	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; MAMMARY EPITHELIAL-CELLS; PHOSPHOLIPASE C-GAMMA; FACTOR RECEPTOR FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; TUMOR-CELLS; MAP KINASE	Prostate carcinoma (PCA) is the most commonly diagnosed malignancy in American men. Our knowledge of PCA growth regulation lags behind that of other cancers, such as breast and colon carcinomas. Among receptor tyrosine kinases, the ErbB family is most frequently implicated in neoplasia. We report here the expression of ErbB family kinases and their ligands in PCA cell lines and a xenograft. While ErbB1/EGFR, ErbB2/NEU, and ErbB3 were always observed in a distinct pattern, ErbB4 was not observed. Interestingly, while TGF-alpha was expressed in the majority of PCA lines, the ligand Neu Differentiation Factor/Heregulin (NDF) was expressed only in an immortalized, non-transformed prostate epithelial line. Concomitantly, there was a significant difference in biological response to these ligands, NDF inhibited LNCaP growth and induced an epithelial-like morphological change, in contrast to TGF-alpha, which accelerated cell growth. We also performed the first comprehensive analysis of NDF signaling in a prostate line, LNCaP stimulated with NDF demonstrated crosstalk between ErbB3 and ErbB2 which did not involve ErbB1. NDF also turned on several cascades, including those of PI3-K, ERK/MAPK, mHOG/p38 and JNK/SAPK, but not those of PLC gamma or the STAT family. This signaling pattern is distinct from that of TGF-alpha. The activation of mHOG by ErbB2 or ErbB3 has not been reported, and may contribute to the unusual phenotype, PI3-K activation is characterized by the formation of a striking 'activation complex' vith multiple tyrosine-phosphorylated species, including ErbB3. Our studies provide a framework in which to dissect the growth and differentiation signals of prostate cancer cells.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106; AMGEN INC,THOUSAND OAKS,CA 91320; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PATHOL,CLEVELAND,OH 44106; NCI,BIOCHEM PHYSIOL LAB,FREDERICK,MD 21702	Case Western Reserve University; Amgen; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [CA39207, CA57179] Funding Source: Medline; NIDDK NIH HHS [DK52659] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA057179, R01CA057179, R37CA039207, R01CA039207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Bacus SS, 1996, ONCOGENE, V12, P2535; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GAMETT DC, 1995, J BIOL CHEM, V270, P19022, DOI 10.1074/jbc.270.32.19022; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KAUFMANNZEH A, 1997, NATURE, V385, P5442; KIM HH, 1994, J BIOL CHEM, V269, P24747; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kitanaka A, 1996, BLOOD, V88, P590, DOI 10.1182/blood.V88.2.590.bloodjournal882590; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kubota Y, 1996, LEUKEMIA, V10, P720; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE MS, 1994, INT J ONCOL, V4, P821; Lyne JC, 1997, CANCER J SCI AM, V3, P21; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OWENS RB, 1976, J NATL CANCER I, V56, P843, DOI 10.1093/jnci/56.4.843; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRIGENT SA, 1992, ONCOGENE, V7, P1273; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sen J, 1996, J IMMUNOL, V156, P4535; SEPPLORENZINO L, 1996, ONCOGENE, V11, P1679; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TOMIYAMA K, 1995, BIOCHEM BIOPH RES CO, V212, P263, DOI 10.1006/bbrc.1995.1965; Trachtenberg JT, 1996, NATURE, V379, P174, DOI 10.1038/379174a0; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; Yao R, 1996, ONCOGENE, V13, P343; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	87	123	132	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2705	2716		10.1038/sj.onc.1201447	http://dx.doi.org/10.1038/sj.onc.1201447			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400997				2022-12-28	WOS:A1997YH46800008
J	Hess, RD; Brandner, G				Hess, RD; Brandner, G			DNA-damage-inducible p53 activity in SV40-transformed cells	ONCOGENE			English	Article						p53 function; SV40 transformation; large SV40 tumour antigen; DNA damage response; SV40 T antigen; p21WAF1	LARGE-T-ANTIGEN; WILD-TYPE P53; NUCLEAR ACCUMULATION; CANCER CELLS; PROTEIN; FIBROBLASTS; EXPRESSION; APOPTOSIS; INDUCTION; AGENTS	The biological state of the tumour suppressor proteins Rb and p53 is altered in papillomavirus-and SV40-transformed cells, due to interaction with the DNA tumour virus oncogene proteins E6/E7 and the tumour (T) antigen, Thus, the DNA damage response function of p53, a crucial feature of the tumour suppressor p53, might be considered as inactive, To investigate this subject, C57SV and VLM, two SV40-transformed murine cell lines enharboring constitutively high nuclear p53 and SV40 large T antigen levels, were treated with mitomycin C, Mitomycin C is known for its activity to elicit DNA damage, followed by nuclear accumulation of biologically active p53, Surprisingly, the nuclear p53 level significantly increased in mitomycin-C-treated C57SV cells and to a lesser degree in VLM cells. In addition, expression of p21WAF1 protein was induced in C57SV and VLM cells, This indicates a possible DNA-damage-elicited p53 activation, Finally, nuclear extracts of mitomycin-C-treated C57SV and VLM cells, but not of untreated cells, exhibited PAb421-enhanced specific DNA-binding activity of p53, as proven by gel shift analysis, Thus, DNA damage induced essential biological functions typical for wild-type p53 in the SV40-transformed cell lines examined so far.			Hess, RD (corresponding author), UNIV FREIBURG,INST MED MIKROBIOL & HYG,DEPT VIROL,POB 820,D-79008 FREIBURG,GERMANY.							ALBERTS B, 1994, MOL BIOL CELL, P1284; BUTZ K, 1995, ONCOGENE, V10, P927; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Delia D, 1996, NAT MED, V2, P724, DOI 10.1038/nm0796-724; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; FRITSCHE M, 1993, ONCOGENE, V8, P307; FRITSCHE M, 1991, J CANCER RES CLIN, V117, P30; GOLDBERG YP, 1992, J CELL BIOCHEM, V49, P74, DOI 10.1002/jcb.240490113; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HESS R, 1994, TOXICOL LETT, V72, P43, DOI 10.1016/0378-4274(94)90008-6; JANSON W, 1997, IN PRESS ONCOGENE; JOHN B, 1995, THESIS FREIBURG GERM; KASTAN MB, 1991, CANCER RES, V51, P6304; KNOBLICH J, 1993, THESIS FREIBURG GERM; KNOWLES BB, 1979, J IMMUNOL, V122, P1798; Lenahan MK, 1996, ONCOGENE, V12, P1847; LONG SB, 1995, ANTICANCER RES, V15, P1375; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Mukhopadhyay T, 1996, INT J ONCOL, V9, P405; Plaumann B, 1996, ONCOGENE, V13, P1605; SCHOEFFEL A, 1988, VIROLOGY, V166, P245, DOI 10.1016/0042-6822(88)90166-3; SIEGEL J, 1995, ONCOGENE, V11, P1363; Spitkovsky D, 1996, ONCOGENE, V13, P1027; TAHARA H, 1995, ONCOGENE, V10, P835; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wu GS, 1996, CLIN CANCER RES, V2, P623; ZARLING JM, 1973, J NATL CANCER I, V50, P137, DOI 10.1093/jnci/50.1.137; Zeng YX, 1996, ONCOGENE, V12, P1557	28	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2501	2504		10.1038/sj.onc.1201404	http://dx.doi.org/10.1038/sj.onc.1201404			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395246				2022-12-28	WOS:A1997YE96300012
J	Arap, W; Knudsen, E; Sewell, DA; Sidransky, D; Wang, JYJ; Huang, HJS; Cavenee, WK				Arap, W; Knudsen, E; Sewell, DA; Sidransky, D; Wang, JYJ; Huang, HJS; Cavenee, WK			Functional analysis of wild-type and malignant glioma derived CDKN2A beta alleles: Evidence for an RB-independent growth suppressive pathway	ONCOGENE			English	Article						CDKN2A; p16(INK4a); p16 beta; RB; tumor suppressor gene; malignant glioma	GENE; MUTATIONS; P16; DELETIONS; TRANSCRIPT; CANCER; LOCUS	The tumor suppressor gene CDKN2A (p16/MTS1/ 1NK4A), which encodes the cyclin-dependent kinase inhibitor p16(INK4a), is a target of 9p21 deletions during the malignant progression of human gliomas, This gene also encodes a second protein product (human p16 beta, murine p19(ARF)), which originates from an unrelated exon of CDKN2A (exon 1 beta) spliced onto exon 2 in an alternate reading frame, Cell cycle arrest by p16 beta is caused by an as yet unidentified pathway, In order to test the candidacy of p16 beta as a glioma suppressor, we replaced p16(INK4a), p15(INK4b) and p16 beta wild-type as well as a series of seven glioma-derived p16 beta alleles (R87H, A112V, R120H, A121V, G125R, A128A and A128V), into glioma cell lines that had either CDKN2A(-)/RB+ (U-87MG and U-251MG) or CDKN2A(+)/RB- (LN-319) endogenous backgrounds and demonstrated that p16 beta can act as a functional glioma cell growth suppressor, Moreover, p16 beta, but not p16(INK4a) or p15(INK4b) inhibited the growth of RE-negative LN-319 cells, indicating that p16 beta likely exerts its effects through an RB-independent pathway, In vitro and in vivo assays of pRB phosphorylation were consistent with this interpretation, Since none of the glioma-derived p16 beta mutations inactivated their growth suppressive activities, it appears that mutations in CDKN2A exon 2 (which is shared in the coding sequences of p16(INK4a) and p16 beta) likely exclusively target p16(INK4a).	UNIV CALIF SAN DIEGO,LUDWIG INST CANC RES,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; STANFORD UNIV,CANC BIOL PROGRAM,STANFORD,CA 94305; JOHNS HOPKINS UNIV,DEPT OTOLARYNGOL HEAD & NECK SURG,HEAD & NECK CANC RES DIV,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT ONCOL,BALTIMORE,MD 21205	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Stanford University; Johns Hopkins University; Johns Hopkins University					NCI NIH HHS [R01 CA058320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; ARAP W, 1995, CANCER RES, V55, P1351; DURO D, 1995, ONCOGENE, V11, P21; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; JAMES CD, 1993, CANCER RES, V53, P3674; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kyritsis AP, 1996, ONCOGENE, V12, P63; Liggett WH, 1996, CANCER RES, V56, P4119; Louis David N., 1997, P2013; LUCAS J, 1997, GENE DEV, V11, P1479; MAO L, 1995, CANCER RES, V55, P2995; MOULTON T, 1995, AM J PATHOL, V146, P613; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, CANCER RES, V52, P2523; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sewell D. A., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P80; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shores C., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P277; STONE S, 1995, CANCER RES, V55, P2988; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9	28	34	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2013	2020		10.1038/sj.onc.1201389	http://dx.doi.org/10.1038/sj.onc.1201389			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366518				2022-12-28	WOS:A1997YC28400002
J	McGregor, JM; Berkhout, RJM; Rozycka, M; terSchegget, J; Bavinck, JNB; Brooks, L; Crook, T				McGregor, JM; Berkhout, RJM; Rozycka, M; terSchegget, J; Bavinck, JNB; Brooks, L; Crook, T			p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status	ONCOGENE			English	Article						non-melanoma skin; transplantation; p53 gene; human papillomavirus	RENAL-TRANSPLANTATION; DNA; GENE; RECIPIENTS; ASSOCIATION; INSERTIONS; CARCINOMA; DELETIONS; CELLS; RISK	Mutations in p53 were detected in 11/23 (48%) of non melanoma skin cancers in renal allograft recipients and in 5/8 (63%) of sporadic tumours from immune competent patients, 9/12 (75%) of mutations in transplant patients and all 5 mutations in non transplant tumours were consistent with damage caused by ultraviolet (u,v,) irradiation, DNA sequences, predominantly of the epidermodysplasia verruciformis (EV) subgroup, were detected in 9/23 (39%) of transplant tumours and in 2/8 (25%) of eight non-transplant tumours, There was no relationship between HPV status and p53 mutation, HPV DNA being present in 5/16 (31%) of tumours with p53 mutation and 6/15 (40%) of tumours lacking p53 mutation, These data are consistent with an important role for sunlight in the development of post-transplant skin cancer, and with limited functional data suggesting that E6 proteins of the cutaneous and EV-related papillomaviruses do not target p53 for ubiquitin-mediated degradation.	INST CANC RES,HADDOW LABS,SECT CELL BIOL & EXPT PATHOL,SUTTON SM2 5NG,SURREY,ENGLAND; ST THOMAS HOSP,ST JOHNS INST DERMATOL,DEPT PHOTOBIOL,LONDON SE1 7EH,ENGLAND; UNIV AMSTERDAM,ACAD MED CTR,DEPT VIROL,NL-1105 AZ AMSTERDAM,NETHERLANDS; KATHOLIEKE UNIV LEUVEN HOSP,DEPT DERMATOL,LEIDEN,NETHERLANDS; LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1,ENGLAND	University of London; Institute of Cancer Research - UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Amsterdam; Academic Medical Center Amsterdam; University of London; London School of Hygiene & Tropical Medicine								BAVINCK JNB, 1993, BRIT J DERMATOL, V129, P242, DOI 10.1111/j.1365-2133.1993.tb11841.x; BERKHOUT RJM, 1995, J CLIN MICROBIOL, V33, P690, DOI 10.1128/JCM.33.3.690-695.1995; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; BLUM HF, 1948, J NATL CANCER I, V9, P247; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CHENG KC, 1992, J BIOL CHEM, V267, P166; DOLL R, 1970, BRIT MED J, V4, P420, DOI 10.1136/bmj.4.5732.420; Greenblatt MS, 1996, CANCER RES, V56, P2130; HARTEVELT MM, 1990, TRANSPLANTATION, V49, P506, DOI 10.1097/00007890-199003000-00006; IARC, 1995, IARC MONOGRAPHS EVAL, V64; IFTNER T, 1988, J VIROL, V62, P3655, DOI 10.1128/JVI.62.10.3655-3661.1988; JEGO N, 1993, ONCOGENE, V8, P209; KELLY GE, 1987, BRIT J DERMATOL, V117, P429, DOI 10.1111/j.1365-2133.1987.tb04922.x; KIYONO T, 1989, VIROLOGY, V173, P551, DOI 10.1016/0042-6822(89)90567-9; LENNARD L, 1985, BRIT J DERMATOL, V113, P723, DOI 10.1111/j.1365-2133.1985.tb02408.x; Lewandowsky F, 1922, ARCH DERMATOL SYPH-G, V141, P193, DOI 10.1007/BF01938833; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; MCGREGOR JM, 1995, LANCET, V346, P964, DOI 10.1016/S0140-6736(95)91584-2; McGregor JM, 1996, CANCER SURV, V26, P219; MORRIS JDH, 1995, LANCET, V346, P754, DOI 10.1016/S0140-6736(95)91510-9; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; PIETTE J, 1991, J PHOTOCH PHOTOBIO B, V11, P241, DOI 10.1016/1011-1344(91)80030-L; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; STEGER G, 1992, ARCH VIROL, V125, P355, DOI 10.1007/BF01309654; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	28	82	83	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1737	1740		10.1038/sj.onc.1201339	http://dx.doi.org/10.1038/sj.onc.1201339			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349508	Green Published			2022-12-28	WOS:A1997XY63100014
J	Midgley, CA; Lane, DP				Midgley, CA; Lane, DP			p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding	ONCOGENE			English	Article						p53 tumour suppressor protein; Mdm2 tumour suppressor protein; protein stability; DNA damage	WILD-TYPE P53; LI-FRAUMENI SYNDROME; C-TERMINAL DOMAIN; TRANSFORMED-CELLS; SUPPRESSOR PROTEIN; BREAST-CANCER; DNA-BINDING; SV40-TRANSFORMED CELLS; IONIZING-RADIATION; IN-VITRO	The tumour suppressor protein p53 is expressed at very low levels in normal cells but accumulates in response to DNA damaging agents such as u.v. irradiation. This increase is accompanied by transcriptional upregulation of the expression of a number of proteins including Mdm2 which can in turn inhibit p53 dependent transcriptional activation, creating a feedback loop resulting in down-regulation of p53 activity. Mutant p53 proteins are however frequently detected at constitutively high levels in many tumours and tumour cell lines, indeed this phenomenon has been used in several studies to diagnose p53 mutation in patient tumours. We show here that expression of mouse mutant p53 in tumour cell lines of this type results in high levels of both the endogenous p53 protein and the exogenously expressed mutant mouse protein, whereas the human tumour line MCF7 does not exhibit high levels of either endogenous human or exogenously expressed mouse mutant p53 unless stabilisation is induced by DNA damage, This suggests that the stability of mutant p53 is not intrinsic to mutant p53 protein structure but may vary in different cell backgrounds. We present evidence that p53 protein stability in tumour cell lines is determined by association with the Mdm2 tumour suppressor protein, and that p53 mutants which are unable to bind Mdm2 are stable in MCF7 cells, We propose that tumour lines which express high levels of transcriptionally inactive mutant p53 are unable to induce the expression of the Mdm2 protein which would normally provide a feedback mechanism down-regulating p53 protein levels in the absence of DNA damage signals, MCF7 cells however express a transcriptionally active p53 and retain the feedback regulation of p53 protein levels by Mdm2.	UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CANC RES CAMPAIGN,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1991, ONCOGENE, V6, P1699; BENNETT WP, 1993, CANCER RES, V53, P4817; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FISCELLA M, 1993, ONCOGENE, V8, P1519; FRITSCHE M, 1993, ONCOGENE, V8, P307; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall AR, 1997, ONCOGENE, V14, P1371, DOI 10.1038/sj.onc.1200962; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lane DP, 1996, ONCOGENE, V12, P2461; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOMAX ME, 1997, ONCOGENE, V14, P1868; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARTIN HM, 1992, INT J CANCER, V50, P859, DOI 10.1002/ijc.2910500604; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MOLINARI M, 1995, ONCOGENE, V10, P1849; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; REIHSAUS E, 1990, ONCOGENE, V5, P137; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sambrook J., MOL CLONING LAB MANU; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1991, J CELL PHYSIOL, V148, P391, DOI 10.1002/jcp.1041480309; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TOMINAGA O, 1993, ONCOGENE, V8, P2653; Varley JM, 1996, ONCOGENE, V12, P2437; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	66	267	271	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1179	1189		10.1038/sj.onc.1201459	http://dx.doi.org/10.1038/sj.onc.1201459			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294611				2022-12-28	WOS:A1997XU99100007
J	Chin, K; Kurashima, Y; Ogura, T; Tajiri, H; Yoshida, S; Esumi, H				Chin, K; Kurashima, Y; Ogura, T; Tajiri, H; Yoshida, S; Esumi, H			Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells	ONCOGENE			English	Article						vascular endothelial growth factor; nitric oxide; gene expression	HUMAN ERYTHROPOIETIN GENE; FACTOR EXPRESSION; TRANSCRIPTIONAL ACTIVATION; PERMEABILITY FACTOR; HYPOXIC INDUCTION; IN-VIVO; ENHANCER; ANGIOGENESIS; SIMILARITIES; PROMOTER	We evaluated the effect of nitric oxide (NO) on vascular endothelial growth factor (VEGF) gene expression in human A-172 glioblastoma cells and human HepG2 hepatocellular carcinoma cells, The mRNA level of VEGF increased in response to S-Nitroso-N-acetyl-D,L-penicillamine (SNAP) in both cell lines, and increased in mRNA level well coincided with VEGF protein production in A-172 cells. SNAP at 0.5 mM induced maximal stimulation of 4.4 and 3.7 kb VEGF mRNA expression after 6 h about 11 and 8 fold increase, respectively above control level. Similar VEGF mRNA accumulation was observed also with NOR3, another chemical NO generator. To evaluate the effect of SNAP on VEGF mRNA stability, half-lives of VEGF mRNA were measured in A-172 cells cultured with or without 0.5 mM SNAP and treated with actinomycin D (25 mu g/ml). Half-life for VEGF mRNA was found to be prolonged about 2.4 fold by SNAP, VEGF expression induced by SNAP was inhibited by guanylate cyclase inhibitors, methylene blue (10 mu M) and LY-83583 (1 mu M), and by the protein synthesis inhibitor, cycloheximide (25 mu g/ml). These results suggest that induction of VEGF gene expression by NO is mediated through guanylate cyclase activity and requires on-going protein synthesis.	NATL CANC CTR, RES INST E, INVEST TREATMENT DIV, KASHIWA, CHIBA, JAPAN; NATL CANC CTR HOSP E, DIV INTERNAL MED, KASHIWA, CHIBA, JAPAN	National Cancer Center - Japan; National Cancer Center - Japan								ADAIR TH, 1990, AM J PHYSIOL, V259, pR393, DOI 10.1152/ajpregu.1990.259.3.R393; BECK I, 1991, J BIOL CHEM, V266, P15563; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KONTUREK SJ, 1993, EUR J PHARMACOL, V239, P215, DOI 10.1016/0014-2999(93)90997-V; KRANTZ SB, 1991, BLOOD, V77, P419; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINCHENKO A, 1994, LAB INVEST, V71, P374; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; OHIGASHI T, 1993, J CLIN INVEST, V92, P1587, DOI 10.1172/JCI116740; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; POHL U, 1989, AM J PHYSIOL, V256, pH1595, DOI 10.1152/ajpheart.1989.256.6.H1595; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; ZICHE M, 1993, BIOCHEM BIOPH RES CO, V192, P1198, DOI 10.1006/bbrc.1993.1543	36	152	168	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	1997	15	4					437	442		10.1038/sj.onc.1201201	http://dx.doi.org/10.1038/sj.onc.1201201			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242380				2022-12-28	WOS:A1997XM23800008
J	Ziv, Y; BarShira, A; Pecker, I; Russell, P; Jorgensen, TJ; Tsarfati, I; Shiloh, Y				Ziv, Y; BarShira, A; Pecker, I; Russell, P; Jorgensen, TJ; Tsarfati, I; Shiloh, Y			Recombinant ATM protein complements the cellular A-T phenotype	ONCOGENE			English	Article						ataxia-telangiectasia; ATM; FLAG epitope; radiosensitivity; cell cycle checkpoints; mutations	ATAXIA-TELANGIECTASIA GENE; EPSTEIN-BARR VIRUS; PEPTIDE ELUTION; KINASE; PURIFICATION; EXPRESSION; CELLS; FIBROBLASTS; ACTIVATION; RADIATION	Ataxia-telangiectasia (A-T) is an autosomal recessive disorder characterized by neurodegeneration, immunodeficiency, cancer predisposition, genome instability and radiation sensitivity, The cellular phenotype of A-T points to defects in signal transduction pathways involved in activation of cell cycle checkpoints by free radical damage, and other pathways that mediate the transmission of specific mitogenic stimuli, The product of the responsible gene, ATM, belongs to a family of large proteins that contribute to maintaining genome stability and cell cycle progression in various organisms, A recombinant vector that stably expresses a full-length ATM protein is a valuable tool for its functional analysis, We constructed and cloned a recombinant, full-length open reading frame of ATM using a combination of vectors and hosts that overcame an inherent instability of this sequence, Recombinant ATM was stably expressed in insect cells using a baculovirus vector, albeit at a low level, and in human A-T cells using an episomal expression vector, An amino-terminal FLAG epitope added to the protein allowed highly specific detection of the recombinant molecule by immunoblotting, immunoprecipitation and immunostaining, and its isolation using immunoaffinity, Similar to endogenous ATM, the recombinant protein is located mainly in the nucleus, with low levels in the cytoplasm, Ectopic expression of ATM in A-T cells restored normal sensitivity to ionizing radiation and the radiomimetic drug neocarzinostatin, and a normal pattern of post-irradiation DNA synthesis, which represents an S-phase checkpoint. These observations indicate that the recombinant, epitope-tagged protein is functional, Introduction into this molecule of a known A-T missense mutation, Glu2904Gly, resulted in apparent instability of the protein and inability to complement the A-T phenotype, These findings indicate that the physiological defects characteristic of A-T cells result from the absence of the ATM protein, and that this deficiency can be corrected by ectopic expression of this protein.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 RAMAT AVIV,ISRAEL; GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,DEPT RADIAT MED,WASHINGTON,DC 20007	Tel Aviv University; Sackler Faculty of Medicine; Georgetown University	Ziv, Y (corresponding author), TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 RAMAT AVIV,ISRAEL.			Tsarfaty, Ilan/0000-0002-5230-7093	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31763] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALNABULSI I, 1994, CANCER RES, V54, P5614; ARTUSO M, 1995, ONCOGENE, V11, P1427; Baumer A, 1996, HUM GENET, V98, P246, DOI 10.1007/s004390050202; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; CHIANG CM, 1993, PEPTIDE RES, V6, P62; DENT P, 1995, MOL CELL BIOL, V15, P4125; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Gilad S, 1996, HUM MOL GENET, V5, P2033, DOI 10.1093/hmg/5.12.2033; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GILAD S, 1997, IN PRESS HUM MUTAT; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JORGENSEN TJ, 1995, RADIAT RES, V143, P219, DOI 10.2307/3579160; Jung M, 1997, CANCER RES, V57, P24; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KHANNA KK, 1997, IN PRESS J BIOL CHEM; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LIU F, 1995, MOL CELL BIOL, V15, P3479; Luckow Verne A., 1993, Current Opinion in Biotechnology, V4, P564, DOI 10.1016/0958-1669(93)90078-B; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; ROTMAN G, 1909, IN PRSS CANC SURVEYS; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SHILOH Y, 1982, CANCER RES, V42, P2247; Shiloh Y, 1996, J CLIN IMMUNOL, V16, P254, DOI 10.1007/BF01541389; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; TAYLOR AMR, 1994, INT J RADIAT BIOL, V65, P65, DOI 10.1080/09553009414550091; Telatar M, 1996, AM J HUM GENET, V59, P40; WATTERS D, 1997, IN PRESS ONCOGENE; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; Wright J, 1996, AM J HUM GENET, V59, P839; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZIV Y, 1989, CANCER RES, V49, P2495; ZIV Y, 1995, SOMAT CELL MOLEC GEN, V21, P99, DOI 10.1007/BF02255785	47	226	229	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					159	167		10.1038/sj.onc.1201319	http://dx.doi.org/10.1038/sj.onc.1201319			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244351				2022-12-28	WOS:A1997XK37200004
J	Li, BL; Murphy, KL; Laucirica, R; Kittrell, F; Medina, D; Rosen, JM				Li, BL; Murphy, KL; Laucirica, R; Kittrell, F; Medina, D; Rosen, JM			A transgenic mouse model for mammary carcinogenesis	ONCOGENE			English	Article						transgenic mouse model; mutant p53; carcinogenesis	MUTANT P53; FUNCTION MUTATIONS; CANCER PATIENTS; RAS ONCOGENES; BREAST-CANCER; CELL-CYCLE; MICE; TUMORS; GENE; TUMORIGENESIS	Missense mutations in the p53 tumor suppressor occur frequently in human breast cancer and influence both the prognosis and response to chemotherapy, Amino acid 175 (equivalent to murine 172) is the second most common site of missense mutations in p53 in human breast cancer, Over 95% of these mutations are arginine-to-histidine (R-H) substitutions resulting in a gain-of-function, and not merely a dominant-negative phenotype, Transgenic mice expressing a p53 172(R-H) construct targeted to the mammary gland by means of a whey acidic protein (WAP) promoter were characterized as a model system in order to determine the specific effects of this mutation on mammary tumorigenesis. Although transgene expression alone had no apparent effect on normal mammary development, transgenic mice treated with the chemical carcinogen dimethylbenz(a)anthracene developed tumors with much shorter latency than did control littermates and had a greater tumor burden, Tumors arising in transgenic mice did not exhibit either decreased apoptosis or increased cell proliferation relative to tumors arising in nontransgenic littermates, but did display increased genomic instability, Large pleiomorphic nuclei were visible in many tumors from transgenic mice, and DNA flow analysis confirmed the presence of significant aneuploid cell populations, Since these transgenic mice develop very few spontaneous tumors, while accelerating carcinogen-and oncogene-mediated tumorigenesis, this mouse model will, therefore, be useful in the investigation of early events in mammary tumorigenesis, It may also be used as a preclinical model to test newly developed chemotherapeutic strategies.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Hughes Inst, Roseville, MN 55113 USA	Baylor College of Medicine; Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Mieszkowska, Magdalena/O-6753-2017		NCI NIH HHS [CA16303] Funding Source: Medline; NIGMS NIH HHS [GM08231] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA016303, R01CA016303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Donehower LA, 1996, BBA-REV CANCER, V1242, P171, DOI 10.1016/0304-419X(95)00013-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIMENEZCONTI IB, 1992, MOL CARCINOGEN, V5, P259, DOI 10.1002/mc.2940050405; GOH HS, 1995, CANCER RES, V55, P5217; GUZMAN RC, 1992, CANCER RES, V52, P5732; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HEDLEY DW, 1985, CYTOMETRY, V6, P327, DOI 10.1002/cyto.990060409; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIAO M, 1994, AM J PATHOL, V145, P702; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUMAR R, 1990, ONCOGENE, V5, P1271; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; LI BL, 1995, MOL CARCINOGEN, V14, P75, DOI 10.1002/mc.2940140203; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; LIN JY, 1995, ONCOGENE, V10, P2387; NAKAZAWA H, 1992, ONCOGENE, V7, P2295; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PROSSER J, 1990, ONCOGENE, V5, P1573; SHANKEY TV, 1993, CYTOMETRY, V14, P472, DOI 10.1002/cyto.990140503; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; ZHANG R, 1990, CANCER RES, V50, P4286	46	73	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	1998	16	8					997	1007		10.1038/sj.onc.1201621	http://dx.doi.org/10.1038/sj.onc.1201621			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519874				2022-12-28	WOS:000072335900006
J	Byrne, JA; Nourse, CR; Basset, P; Gunning, P				Byrne, JA; Nourse, CR; Basset, P; Gunning, P			Identification of homo- and heteromeric interactions between members of the breast carcinoma-associated D52 protein family using the yeast two-hybrid system	ONCOGENE			English	Article						D52-like proteins; coiled-coil domain; yeast two-hybrid system; in vitro translation; GST pull-down assay	EXPRESSION; SEQUENCE; ALIGNMENT; CLONING	The hD52 gene was originally identified through its elevated expression level in human breast carcinoma. Cloning of D52 homologues from other species has indicated that D52 may play roles in calcium-mediated signal transduction and cell proliferation. Two human homologues of hD52, hD53 and hD54, have also been identified, demonstrating the existence of a novel gene/protein family. Since D52-like protein sequences are all predicted to contain a coiled-coil domain, we used the yeast two-hybrid system and glutathione S-transferase pull-down assays to investigate whether homo- and/or heteromeric interactions occur between D52-like proteins. Analyses of yeast strains co-transfected with paired D52-like constructs indicated that D52-like fusion proteins interact in homo- and heteromeric fashions through their predicted coiled-coil domains. Similarly, extensive two-hybrid screenings of a human breast carcinoma expression library identified hD53 and hD52 as potential interactors for both hD52 and hD53 baits. Thus, D52-like proteins appear to exert and/or regulate their activities through specific interactions with other D52-like proteins, which in turn may be intrinsic to potential roles of these molecules in controlling cell proliferation.	Childrens Med Res Inst, Cell Biol Unit, Westmead, NSW 2145, Australia; Univ Sydney, Dept Paediat & Child Hlth, Westmead, NSW 2145, Australia; CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France; New Childrens Hosp, Oncol Res Unit, Westmead, NSW 2145, Australia	Children's Medical Research Institute - Australia; University of Sydney; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Sydney	Byrne, JA (corresponding author), Childrens Med Res Inst, Cell Biol Unit, Westmead, NSW 2145, Australia.		Gunning, Peter W/E-9058-2010	Byrne, Jennifer Anne/0000-0002-8923-0587; Gunning, Peter/0000-0003-0833-3128				ALLEN JB, 1995, TRENDS BIOCHEM SCI, V20, P511, DOI 10.1016/S0968-0004(00)89119-7; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V3; BYRNE JA, 1995, CANCER RES, V55, P2896; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Chen SL, 1996, ONCOGENE, V12, P741; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Parente JA, 1996, J BIOL CHEM, V271, P20096, DOI 10.1074/jbc.271.33.20096; Proux V, 1996, J BIOL CHEM, V271, P30790, DOI 10.1074/jbc.271.48.30790; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	17	67	74	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					873	881		10.1038/sj.onc.1201604	http://dx.doi.org/10.1038/sj.onc.1201604			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484778				2022-12-28	WOS:000072053200006
J	Guerrero, C; Fernandez-Medarde, A; Rojas, JM; de Mora, JF; Esteban, LM; Santos, E				Guerrero, C; Fernandez-Medarde, A; Rojas, JM; de Mora, JF; Esteban, LM; Santos, E			Transformation suppressor activity of C3G is independent of its CDC25-homology domain	ONCOGENE			English	Article						malignant transformation; focus formation; C3G; Ras; Raf; Sis	GUANINE-NUCLEOTIDE EXCHANGE; DEPENDENT ACTIVATION; RAS P21; H-RAS; R-RAS; CEREVISIAE CDC25; POINT MUTATIONS; SEVENLESS GENE; SH3 DOMAIN; PH DOMAIN	The guanine nucleotide releasing protein C3G was initially identified as a Crk SH3-binding protein and recently shown to exhibit exchange activity on Rap1 proteins. Overexpression in NIH3T3 cells of a full-length C3G cDNA isolated from human placenta markedly reduced the focus forming activity of cotransfected, malignantly activated, ras oncogenes (5-7-fold). C3G also had a reverting effect on sis-mediated transformation, decreasing the number of c-sis-induced foci by a factor of 5-10-fold. The observed inhibitory effect of C3G on focus-forming activity of Ras and Sis was always higher than that observed with Rap1A, a known target of C3G. The inhibition of focus formation observed in the presence of C3G was not due to toxic effects on cell viability, since transfected C3G cells exhibited the same survival and growth rates as untransfected NIH3T3 cells or cells transfected with plasmid vector alone. Surprisingly, as opposed to Rap1A, which has no effect on Raf-1 oncogene-mediated transformation, C3G also reduced dramatically (6-8-fold) the number of v-raf-induced foci in transfected NIH3T3 cells. The inhibitory effect on Raf-induced transformation suggests that C3G has other functional targets in addition to Rap1. A C3G mutant (C3G Delta Cat) lacking the catalytic domain (CDC25-H) but retaining the rest of the N-terminal sequences, including the Crk-binding domain, exhibited similar ability than full length C3G to inhibit focus formation. In contrast, a C3G mutant (C3G Cat), containing the catalytic domain only but lacking the rest of the N-terminal sequences, did not have any inhibitory effect on transformation mediated by the oncogenes tested. The C3G-derived gene products overexpressed in our transfected cell lines localized to the cytoplasm and did not change the basal MAPK or JNK activity of those cell lines nor their ability to activate the kinases in response to agonists. Our results suggest that the N-terminal region of C3G, and not its catalytic domain, may be responsible for the inhibitory effects observed.	NCI, Cellular & Mol Biol Lab, DBS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Santos, E (corresponding author), NCI, Cellular & Mol Biol Lab, DBS, NIH, Bldg 37, Bethesda, MD 20892 USA.		Rojas, José M/D-3718-2018; Rojas, José M./AAA-3354-2021; Guerrero, Carmen/F-1776-2010; Fernández-Medarde, Alberto/B-3839-2017; de Mora, Jaime Font/H-6304-2015; de Mora, Jaime Font/AAK-7591-2021	Rojas, José M/0000-0002-5383-3482; Rojas, José M./0000-0002-7547-2825; Guerrero, Carmen/0000-0002-8747-6831; Fernández-Medarde, Alberto/0000-0002-1230-5501; de Mora, Jaime Font/0000-0002-6816-2095; de Mora, Jaime Font/0000-0002-6816-2095				BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN LP, 1993, DEV GENET, V14, P339, DOI 10.1002/dvg.1020140503; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1994, ONCOGENE, V9, P685; CUADRADO A, 1993, ONCOGENE, V8, P2443; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; Fam NP, 1997, GENOMICS, V39, P118, DOI 10.1006/geno.1996.4484; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FELLER SM, 1995, ONCOGENE, V10, P1465; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; Guerrero C, 1996, ONCOGENE, V12, P1097; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; JACQUET E, 1992, J BIOL CHEM, V267, P24181; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAEZ R, 1994, ONCOGENE, V9, P2977; SAKODA T, 1992, ONCOGENE, V7, P1705; SCHELESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	53	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					613	624		10.1038/sj.onc.1201569	http://dx.doi.org/10.1038/sj.onc.1201569			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482107				2022-12-28	WOS:000071816600006
J	Bednarek, AK; Chu, YL; Aldaz, CM				Bednarek, AK; Chu, YL; Aldaz, CM			Constitutive telomerase activity in cells with tissue-renewing potential from estrogen-regulated rat tissues	ONCOGENE			English	Article						telomerase; stem cells; estrogen; proliferation	IMMORTAL CELLS; DIFFERENTIATION; CANCER; LINES; PROGRESSION; PROSTATE; SKIN	To investigate the role of telomerase in estrogen-regulated rodent tissues, we assayed the activity levels of this enzyme and measured cell proliferation and indicators of cellularity in vagina, mammary gland, and uterus from virgin, pregnant, ovariectomized, and ovariectomized estradiol-treated rats. No association was observed between telomerase activity and increased cell proliferation. Telomerase activity was significantly higher (P=0.003) in vagina obtained from ovariectomized rats (very low proliferation) than in vagina from ovariectomized and estradiol-treated rats (high proliferation, high differentiation). The high telomerase levels observed in vagina from ovariectomized rats indicates that the same epithelial compartment (i.e., basal layer) that has the potential to reconstitute the epithelium also contains the cells that express telomerase. The lower telomerase activity in the keratinized (differentiated) vagina was probably due to dilution of the number of telomerase-producing cells by the terminally differentiated non-telomerase-producing cells. Similar results were observed in uterus from ovariectomized ver sus ovariectomized and estradiol-treated rats. Telomerase activity was highest in uterus from pregnant rats. Telomerase levels in samples from total mammary gland fat pads varied considerably between groups and appeared to be representative of the amount of epithelium present in the sample. Interestingly, when mammary gland samples from the same animals were obtained from pure epithelial organoid preparations, no differences in telomerase activity could be distinguished between animals or groups. Overall these data suggest that telomerase activity, particularly in rat vagina and uterus, appears to be associated with a cell subpopulation showing proliferative and tissue reconstitution potential and not directly associated with proliferation status per se.	Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Aldaz, CM (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Res, Sci Pk, Smithville, TX 78957 USA.		Bednarek, Andrzej K./S-9664-2016; Aldaz, C. Marcelo/E-7868-2011	Bednarek, Andrzej K./0000-0002-4570-4154; Aldaz, C. Marcelo/0000-0002-2453-2939	NATIONAL CANCER INSTITUTE [R01CA059967] Funding Source: NIH RePORTER; NCI NIH HHS [CA59967] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanell J, 1996, CANCER RES, V56, P1503; ALDAZ CM, 1992, CANCER RES, V52, P4791; BEDNAREK A, 1995, CANCER RES, V55, P4566; Bestilny LJ, 1996, CANCER RES, V56, P3796; CHADENEAU C, 1995, ONCOGENE, V11, P893; CHADENEAU C, 1995, CANCER RES, V55, P2533; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Holt SE, 1996, MOL CELL BIOL, V16, P2932; HORVAT B, 1995, EXP CELL RES, V199, P234; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 1997, CANCER RES, V57, P610; Meeker AK, 1996, ENDOCRINOLOGY, V137, P5743, DOI 10.1210/en.137.12.5743; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Sommerfeld HJ, 1996, CANCER RES, V56, P218; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yasumoto S, 1996, ONCOGENE, V13, P433	19	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					381	385		10.1038/sj.onc.1201553	http://dx.doi.org/10.1038/sj.onc.1201553			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467963				2022-12-28	WOS:000071582100010
J	Kon, H; Sonoda, Y; Kumabe, T; Yoshimoto, T; Sekiya, T; Murakami, Y				Kon, H; Sonoda, Y; Kumabe, T; Yoshimoto, T; Sekiya, T; Murakami, Y			Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome 10 in human gliomas	ONCOGENE			English	Article						glioma; tumor suppressor gene; chromosome 10p; loss of heterozygosity; chromosome transfer	CANCER CELL-LINE; GLIOBLASTOMA-MULTIFORME; MALIGNANT PHENOTYPE; BRAIN-TUMORS; HETEROZYGOSITY; DELETION; AMPLIFICATION; ASTROCYTOMA; PROGRESSION; REGION	Loss of heterozygosity (LOH) observed at polymorphic loci on both arms of chromosome 10 in many human gliomas suggests the presence of multiple tumor suppressor genes on this chromosome. Recently, the PTEN/MMAC1 gene on 10q23 was isolated as one of these putative glioma suppressors. To determine the subchromosomal localization of others, we analysed 79 gliomas for LOH using 30 polymorphic microsatellite markers on the short arm and 10 markers on the long arm of chromosome 10. Twenty tumors showed LOH at all the loci examined, while 17 others showed LOH at loci on a portion of chromosome 10. Deletion mapping of the latters demonstrated that two distinct regions, encompassing genetic distances of 5.6 cM on 10p15 and 5.5 cM on 10p14, were lost frequently. Introduction of chromosomal fragments 10p14-p15, which included the entire region on 10p15 and a portion of that on 10p14 assigned by deletion mapping, into the human glioblastoma cell line T98G through microcell-mediated chromosome transfer markedly suppressed colony forming ability in soft agar compared with parental T98G cells. The combined results of structural and functional analyses strongly suggest that aberrations of the tumor suppressor gene(s) within chromosomal region 10p14-p15 are involved in development of human gliomas.	Natl Canc Ctr, Res Inst, Div Oncogene, Chuo Ku, Tokyo 104, Japan; Tohoku Univ, Sch Med, Dept Neurosurg, Aoba Ku, Sendai, Miyagi 980, Japan	National Cancer Center - Japan; Tohoku University	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Div Oncogene, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 104, Japan.			Sonoda, Yukihiko/0000-0001-7651-1374				Albarosa R, 1996, AM J HUM GENET, V58, P1260; BERGERHEIM U, 1989, CANCER RES, V49, P1390; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; DOWDY SF, 1987, SCIENCE, V236, P175; FOURNIER REK, 1981, P NATL ACAD SCI-BIOL, V78, P6349, DOI 10.1073/pnas.78.10.6349; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRANT R, 1995, NEUROLOGY, V45, P929, DOI 10.1212/WNL.45.5.929; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HE J, 1994, GENE CHROMOSOME CANC, V11, P91, DOI 10.1002/gcc.2870110205; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HUNTER SB, 1995, J NEUROPATH EXP NEUR, V54, P57, DOI 10.1097/00005072-199501000-00007; IITTMANN M, 1996, CANCER RES, V56, P2143; IZUMOTO S, 1995, CANCER LETT, V97, P241, DOI 10.1016/0304-3835(95)03981-2; JAMES CD, 1988, CANCER RES, V48, P5546; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; Kimmelman AC, 1996, GENOMICS, V34, P250, DOI 10.1006/geno.1996.0277; Kleihues P., 1993, WHO INT HISTOLOGICAL, V2nd ed.; Konig JJ, 1996, HUM PATHOL, V27, P720, DOI 10.1016/S0046-8177(96)90404-9; KUMABE T, 1992, ONCOGENE, V7, P627; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; Murakami YS, 1996, CANCER RES, V56, P2157; MURAKAMI YS, 1995, CANCER RES, V55, P3389; PERHOUSE MA, 1993, CANCER RES, V53, P5043; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REMPEL SA, 1993, CANCER RES, V53, P2386; SONODA Y, 1995, CANCER RES, V55, P2166; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; SONODA Y, 1995, ONCOGENE, V11, P2145; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	43	55	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					257	263		10.1038/sj.onc.1201488	http://dx.doi.org/10.1038/sj.onc.1201488			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464544				2022-12-28	WOS:000071427100013
J	deAnta, JM; Jassem, E; Rosell, R; MartinezRoca, M; Jassem, J; MartinezLopez, E; Monzo, M; SanchezHernandez, JJ; Moreno, I; SanchezCespedes, M				deAnta, JM; Jassem, E; Rosell, R; MartinezRoca, M; Jassem, J; MartinezLopez, E; Monzo, M; SanchezHernandez, JJ; Moreno, I; SanchezCespedes, M			TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis	ONCOGENE			English	Article						NSCLC; TP53 null mutations; prognosis; TP53 mutational profile	TUMOR-SUPPRESSOR GENE; P53 GENE; K-RAS; BREAST-CANCER; CARCINOMAS; EXPRESSION; PROTEIN; DNA; ACCUMULATION; SURVIVAL	Inactivation of TP53 tumor suppressor gene is the most frequent molecular alteration in NSCLC, involving up to 60% of cases, Furthermore, TP53 mutational spectrum is related to the type of mutagen exposure, as well as racial and/or diet differences, Nearly 95% of TP53 perturbations affect codons included within exons 5-8 which encode for almost the entire DNA-binding domain, In this study we addressed the possible prognostic value of the molecular alterations identified in exons 5-8 of the TP53 gene in DNAs from 151 paraffin-embedded NSCLC sections corresponding to 59 Spanish and 92 Polish stage I-IIIA resected patients, PCR/single-strand conformation polymorphism (SSCP) analysis revealed that the occurrence of TP53 exon 5-8 mutations was 17/59 (29%) in the Spanish cohort and 17/92 (18%) in the Polish group, However, when DNA sequencing analysis was performed, these frequencies were reduced because of the presence of SSCP-false positive, intronic and silent mutations and polymorphisms, Fifteen of the 59 Spanish NSCLC tumors (25%) harbored TP53 mutations affecting exons 5-8 coding sequences, whereas only 12 of 92 Polish neoplasms (13%) contained alterations in the central hydrophobic region of p53, Our results indicate that the occurrence of TP53 mutations affecting exon 5-8 coding sequences in some European NSCLC populations may be lower than previously reported, and that the TP53 mutational patterns of these cohorts differ somewhat, The Spanish NSCLC patients contained missense mutations (9/59, 15%) and a relatively high percentage of null mutations (5/59, 8%) while the Polish patients mostly harbored missense mutations (9/92, 10%) and only one tumor contained a null type (1/92, 1%), Moreover, most TP53 missense mutations in the Spanish group were located outside the conserved regions, whereas the same mutations in the Polish group affected conserved amino acids, Furthermore, the Polish patients harbored a high percentage of G-->A transitions (most of them at non-CpG sites), while G-->T transversions were predominant in the Spanish group, Our findings suggest that there may be different racial or exogenous factors in these two populations which may help to explain both the distinct TP53 mutational pattern and the lower frequency obtained in the Polish group, The presence of missense mutations did not confer a worse clinical outcome in these subsets of NSCLC patients, However, patients whose tumors contained null TP53 gene mutations had a 5 month median disease-free survival time in contrast with 42 months in those patients without mutations (P=0.008), These findings suggest that loss of p53 function may enhance tumor progression in NSCLC patients independently of whether dominant negative TP53 missense mutations are present.	UNIV AUTONOMA BARCELONA,HOSP GERMANS TRIAS & PUJOL,MED ONCOL SERV,BADALONA 08916,BARCELONA,SPAIN; UNIV AUTONOMA BARCELONA,HOSP GERMANS TRIAS & PUJOL,LAB MOL BIOL CANC,BADALONA 08916,BARCELONA,SPAIN; GDANSK SCH MED,DEPT RADIOTHERAPY & ONCOL,PL-80211 GDANSK,POLAND; UNIV AUTONOMA MADRID,DEPT PREVENT MED STAT,MADRID 28029,SPAIN	Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Fahrenheit Universities; Medical University Gdansk; Autonomous University of Madrid			Sanchez-Cespedes, Montse/H-8485-2012; de Anta, Josep M/K-8993-2014	Sanchez-Cespedes, Montse/0000-0002-6045-5627; de Anta, Josep M/0000-0003-3499-8297; MONZO, MARIANO/0000-0003-2322-4851; Jassem, Ewa/0000-0003-4239-4776				Bonfill X, 1996, INT J CANCER, V65, P751, DOI 10.1002/(SICI)1097-0215(19960315)65:6<751::AID-IJC7>3.0.CO;2-Y; CARBONE DP, 1994, CHEST, V106, pS377, DOI 10.1378/chest.106.6.377S; Casey G, 1996, ONCOGENE, V13, P1971; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, P1; DIX B, 1994, BRIT J CANCER, V70, P585, DOI 10.1038/bjc.1994.355; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARIS CC, 1996, J NCI, V88, P1442; Harpole DH, 1995, CLIN CANCER RES, V1, P659; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARTMANN A, 1995, ONCOGENE, V10, P681; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; HUANG C, 1997, P ASCO, V16, pA457; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Law JC, 1995, CLIN CANCER RES, V1, P763; LEE JS, 1995, J CLIN ONCOL, V13, P1893, DOI 10.1200/JCO.1995.13.8.1893; LEE LN, 1994, AM J RESP CRIT CARE, V150, P1667, DOI 10.1164/ajrccm.150.6.7952630; Liloglou T, 1997, BRIT J CANCER, V75, P1119, DOI 10.1038/bjc.1997.193; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; MILLER CW, 1992, CANCER RES, V52, P1695; MITSUDOMI T, 1993, JNCI-J NATL CANCER I, V85, P2018, DOI 10.1093/jnci/85.24.2018; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; NAVONE NM, 1993, J NCI, V85, P1687; Nishio M, 1996, J CLIN ONCOL, V14, P497, DOI 10.1200/JCO.1996.14.2.497; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PASSLICK B, 1995, J THORAC CARDIOV SUR, V109, P1205, DOI 10.1016/S0022-5223(95)70204-0; QUINLAN DC, 1992, CANCER RES, V52, P4828; REID TM, 1992, CANCER RES, V52, P1082; RIDANPAA M, 1994, INT J ONCOL, V5, P1109; ROSELL R, 1993, ONCOGENE, V8, P2407; Rosell R, 1996, CLIN CANCER RES, V2, P1083; RYBERG D, 1994, CANCER RES, V54, P1551; SAITOH S, 1994, ONCOGENE, V9, P2869; SHIAO YH, 1995, CANCER RES, V55, P1485; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; TAKAGI Y, 1995, CANCER RES, V55, P5354; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TAKESHIMA Y, 1993, LANCET, V342, P1520, DOI 10.1016/S0140-6736(05)80087-X; TAYLOR JA, 1996, CANCER RES, V55, P294; THORLACIUS S, 1993, CANCER RES, V53, P1637; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	48	39	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2951	2958		10.1038/sj.onc.1201475	http://dx.doi.org/10.1038/sj.onc.1201475			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416838				2022-12-28	WOS:A1997YK37700007
J	Kimmelman, A; Tolkacheva, T; Lorenzi, MV; Osada, M; Chan, AML				Kimmelman, A; Tolkacheva, T; Lorenzi, MV; Osada, M; Chan, AML			Identification and characterization of R-ras3: a novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution	ONCOGENE			English	Article						Ras; TC21; R-ras; G-protein; transformation; MAPK	NUCLEOTIDE DISSOCIATION STIMULATOR; GTPASE-ACTIVATING PROTEIN; NIH 3T3 CELLS; R-RAS; ONCOGENIC RAS; MALIGNANT TRANSFORMATION; SIGNALING PATHWAY; K-RAS; H-RAS; KINASE	Members of the Ras subfamily of GTP-binding proteins, including Ras (H-, K-, and N-), TC21, and R-ras have been shown to display transforming activity, and activating lesions have been detected in human tumors. We have identified an additional member of the Ras gene family which shows significant sequence similarity to the human TC21 gene. This novel human ras-related gene, R-rad, encodes for a protein of 209 amino acids, and shows similar to 60-75% sequence identity in the N-terminal catalytic domain with members of the Ras subfamily of GTP-binding proteins. An activating mutation corresponding to the leucine 61 oncogenic lesion of the ras oncogenes when introduced into R-ras3, activates its transforming potential. R-ras3 weakly stimulates the mitogen-activated protein kinase (MAPK) activity, but this effect is greatly potentiated by the co-expression of c-raf-l. By the yeast two-hybrid system, R-rad interacts only weakly with known Ras effecters, such as Raf and RalGDS, but not with RglII. In addition, R-ras3 displays modest stimulatory effects on trans-activation from different nuclear response elements which bind transcription factors, such as SRF, ETS/TCF, Jun/Fos, and NF-kappa B/Rel. Interestingly, Northern blot analysis of total RNA isolated from various tissues revealed that the 3.8 kilobasepair (kb) transcript of R-rad is highly restricted to the brain and heart. The close evolutionary conservation between R-rad and Ras family members, in contrast to the significant differences in its biological activities and the pattern of tissue expression, raise the possibility that R-rad may control novel cellular functions previously not described for other GTP-binding proteins.	CUNY MT SINAI SCH MED,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029; NCI,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464	NCI NIH HHS [CA66654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BOS JL, 1989, CANCER RES, V49, P4682; CHAN AML, 1994, P NATL ACAD SCI USA, V82, P2394; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GALANG CK, 1994, ONCOGENE, V9, P2913; GOLEMIS EA, 1997, GENE CLONING ANAL CU, V4, P11; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GOTOH T, 1997, BIOL CHEM, V272, P18602; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HATTORI S, 1992, ONCOGENE, V7, P481; HUANG Y, 1995, ONCOGENE, V11, P1255; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Li WQ, 1996, ONCOGENE, V13, P731; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAEZ R, 1994, ONCOGENE, V9, P2977; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	54	72	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2675	2685		10.1038/sj.onc.1201674	http://dx.doi.org/10.1038/sj.onc.1201674			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400994				2022-12-28	WOS:A1997YH46800005
J	Smilenov, LB; Morgan, SE; Mellado, W; Sawant, SG; Kastan, MB; Pandita, TK				Smilenov, LB; Morgan, SE; Mellado, W; Sawant, SG; Kastan, MB; Pandita, TK			Influence of ATM function on telomere metabolism	ONCOGENE			English	Article						telomeric associations; telomere length; telomerase activity; A-T; LZ; PI-3 kinase domain	CHROMOSOME END ASSOCIATIONS; ATAXIA-TELANGIECTASIA GENE; IMMORTAL CELLS; CANCER; LENGTH; SSCP	The ATM gene product, which is defective in the cancer-prone disorder ataxia telangiectasia, has been implicated in mitogenic signal transduction, chromosome condensation, meiotic recombination and cell cycle control. The ATM gene has homology with the TEL1 gene of yeast, mutations of which lead to shortened telomeres. To test the hypothesis that the ATM gene product is involved in telomere metabolism, we examined telomeric associations (TA), telomere length, and telomerase activity in human cells expressing either dominant-negative or complementing fragments of the ATM gene. The phenotype of RKO colorectal tumor cells expressing ATM fragments containing a leucine zipper (LZ) motif mimics that of ataxia telangiectasia (A-T) cells. These transfected RKO cells relative to transfected controls had a higher frequency of cells with TA and shortened telomeres, but no detectable change in telomerase activity. In addition, the percentage of cells with TA after gamma irradiation was higher in the transfected RKO cells with dominant negative activity of the ATM gene, compared to control cells. SV40 transformed fibroblasts derived from an A-T patient and transfected with a complementing carboxyl terminal kinase region of the ATM gene had a reduced frequency of cells with TA, with no effect on the telomere length or telomerase activity. The present studies using isogenic cells with manipulated ATM function demonstrate a role for the ATM gene product in telomere metabolism.	COLUMBIA UNIV, COLL PHYS & SURG, CTR RADIOL RES, NEW YORK, NY 10032 USA; JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21205 USA	Columbia University; Johns Hopkins University; Johns Hopkins Medicine			Pandita, Tej K/AAM-9188-2020		NATIONAL CANCER INSTITUTE [R01CA071387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NCI NIH HHS [CA71387] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BRIDGES BA, 1982, CELLULAR MOL LINK CA; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; Cenci G, 1997, GENE DEV, V11, P863, DOI 10.1101/gad.11.7.863; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FANG G, 1995, TELOMERES, P69; Freyer GA, 1996, MUTAT RES-FUND MOL M, V357, P237, DOI 10.1016/0027-5107(96)00130-3; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, pS13, DOI 10.1080/09553009414551811; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIRK KE, 1997, NATURE, V275, P1478; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; McClintock B, 1941, GENETICS, V26, P234; MEHLE C, 1994, CANCER RES, V54, P236; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Muller H.J., 1938, COLLECTING NET, V13, P181; OLOVNIKOV AM, 1992, IZV AN SSSR BIOL+, P641; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1994, CYTOGENET CELL GENET, V67, P94, DOI 10.1159/000133807; Pandita TK, 1996, ONCOGENE, V13, P1423; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; PANDITA TK, 1993, 53 COLD SPRING HARB, P173; PATHAK S, 1988, CYTOGENET CELL GENET, V47, P227, DOI 10.1159/000132555; PRICE C M, 1992, Current Opinion in Cell Biology, V4, P379, DOI 10.1016/0955-0674(92)90002-T; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	47	80	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	1997	15	22					2659	2665		10.1038/sj.onc.1201449	http://dx.doi.org/10.1038/sj.onc.1201449			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400992				2022-12-28	WOS:A1997YH46800003
J	Coffer, PJ; vanPuijenbroek, A; Burgering, BMT; KlopdeJonge, M; Koenderman, L; Bos, JL; Kruijer, W				Coffer, PJ; vanPuijenbroek, A; Burgering, BMT; KlopdeJonge, M; Koenderman, L; Bos, JL; Kruijer, W			Insulin activates Stat3 independently of p21ras-ERK and PI-3K signal transduction	ONCOGENE			English	Article						insulin; STAT; Ras; ERK; PI-3K	EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; C-FOS EXPRESSION; PROTEIN-KINASE CASCADE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; SERINE PHOSPHORYLATION; TYROSINE PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; CYTOKINE RECEPTORS	The binding of insulin to its receptor initiates multiple signal transduction pathways regulating such diverse processes as proliferation, differentiation, glucose transport, and glycogen metabolism, The STAT-family of transcription factors has been demonstrated to play a critical role in gene induction by a variety of hemopoietic cytokines and hormones, Furthermore, constitutive activation of STATs is observed in transformed cells, Here we describe activation of a transcriptional complex binding to a consensus STAT-transcriptional element in response to insulin challenge, This complex is induced rapidly after tyrosine autophosphorylation of the insulin receptor, and is sustained for several hours, Supershift analysis of the insulin-induced complex reveals that it specifically contains the transcription factor Stat3, DAN binding of this complex is inhibited by pre-incubation with tyrosine, but not serine/threonine protein kinase inhibitors, whereas transcriptional activation is inhibited by both, Utilising a dominant negative mutant of p21ras we demonstrate that both insulin-induced Stat3 DNA-binding and also transactivation do not require p21ras, Furthermore, although previous studies have suggested a role for MAP kinases (ERKs) and PI-3K in STAT activation, utilising the specific MEK inhibitor PD098059 and the PI-3K inhibitor wortmannin, we demonstrate that activation of ERKs or PI-3K are not required for insulin induced Stat3 phosphorylation or transactivation.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS; UNIV UTRECHT,PHYSIOL CHEM LAB,NL-3584 CG UTRECHT,NETHERLANDS; UNIV GRONINGEN,CTR BIOL,DEPT GENET,NL-9750 AA HAREN,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; University of Groningen	Coffer, PJ (corresponding author), UNIV UTRECHT HOSP,DEPT PULM DIS,G03-550,HEIDELBERGLAAN 100,NL-3584 CX UTRECHT,NETHERLANDS.		Coffer, Paul J/A-5769-2009; Koenderman, Leo/AAE-7870-2020; Coffer, Paul/AAF-7970-2020	Koenderman, Leo/0000-0002-5636-6453; 				ALLESSI DR, 1995, J BIOL CHEM, V270, P27489; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BURGERING BMT, 1993, BIOCHEM SOC T, V21, P888, DOI 10.1042/bst0210888; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CAMPOS SP, 1992, MOL CELL BIOL, V12, P1789, DOI 10.1128/MCB.12.4.1789; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COFFER P, 1995, ONCOGENE, V10, P985; COFFER PJ, 1995, ONCOGENE, V11, P561; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; COFFER PJ, 1993, ONCOGENE, V9, P911; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DERIJARD B, 1994, CELL, V76, P727; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P221; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALANG CK, 1994, ONCOGENE, V9, P2913; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HEIDENREICH KA, 1993, J BIOL CHEM, V268, P14663; HILL CS, 1996, EMBO J, V15, P5037; HORN F, 1994, ANN NY ACAD SCI, V73, P308; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JHUN BH, 1995, BIOCHEMISTRY-US, V34, P7996, DOI 10.1021/bi00025a005; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEE J, 1994, AM J PHYSIOL, V266, P319; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; OLSON AL, 1994, ENDOCRINOLOGY, V134, P271, DOI 10.1210/en.134.1.271; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1992, J CELL BIOCHEM, V48, P12, DOI 10.1002/jcb.240480104; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SETH A, 1992, J BIOL CHEM, V267, P24796; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, ONCOGENE, V13, P247; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WATLING D, 1993, NATURE, V366, P114; WeberNordt RM, 1996, BLOOD, V88, P809; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	83	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2529	2539		10.1038/sj.onc.1201429	http://dx.doi.org/10.1038/sj.onc.1201429			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399641				2022-12-28	WOS:A1997YG73200003
J	DellaValle, V; Duro, D; Bernard, O; Larsen, CJ				DellaValle, V; Duro, D; Bernard, O; Larsen, CJ			The human protein p19(ARF) is not detected in hemopoietic human cell lines that abundantly express the alternative beta transcript of the p16(INK4a)/MTS1 gene	ONCOGENE			English	Article						p16(INK4a); MTS1; CDKN2; p19(ARF)	ACUTE LYMPHOBLASTIC-LEUKEMIA; P16(INK4)/MTS1 GENE; UNRELATED PROTEINS; FAMILIAL MELANOMA; P16; SENESCENCE; DELETIONS; IMMORTALIZATION; INACTIVATION; P15(INK4B)	The p16/MTS1/CDKN2 gene on human chromosome band 9p21 encodes two unrelated proteins: p16(INK4a), a inhibitor of the cyclin D-dependent kinases and CDK6, and the structurally unrelated p19(ARF) protein that arrests cell growth in G(1)/S and also in G(2)/M. By use of polyclonal antibodies, the human p19(ARF) (hp19(ARF)) protein has been identified in the nucleus of various cells including normal cultured fibroblasts. The level of this protein did not fluctuate throughout the cell cycle and was more elevated in fibroblasts with limited or arrested growth, suggesting that p19(ARF) accumulated in presenescent or senescent cells. Interestingly, hp19(ARF) was not detected in several hemopoietic tumor cell lines (mainly of B-type lymphoid origin) that expressed abundant amounts of the p16 beta transcript. This finding indicates that in certain tumors, the expression of hp19(ARF) RNA and protein may be uncoupled, Furthermore, it suggests that disruption of a translational mechanism may be involved in the inactivation of hp19(ARF).	INST GENET MOL,INSERM,U301,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Bernard, Olivier A./E-5721-2016	Bernard, Olivier/0000-0002-0463-9747				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P995; COLEMAN A, 1994, CANCER RES, V54, P344; COLIGAN JE, 1995, CURRENT PROTOCOLS PR, V1; DURO D, 1995, ONCOGENE, V11, P21; Duro D, 1996, CANCER RES, V56, P848; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Flores JF, 1996, CANCER RES, V56, P5023; Hara E, 1996, MOL CELL BIOL, V16, P859; Hui AM, 1996, HEPATOLOGY, V24, P575, DOI 10.1002/hep.510240319; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Larsen CJ, 1996, ONCOGENE, V12, P2041; Liggett WH, 1996, CANCER RES, V56, P4119; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAO L, 1995, CANCER RES, V55, P2995; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; Parry D, 1996, MOL CELL BIOL, V16, P3844; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Reznikoff CA, 1996, CANCER RES, V56, P2886; Sambrook J., 1989, MOL CLONING; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; STONE S, 1995, CANCER RES, V55, P2988; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; WICK ST, 1995, ONCOGENE, V11, P2013; ZHOU M, 1995, LEUKEMIA, V9, P1159	29	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2475	2481		10.1038/sj.onc.1201417	http://dx.doi.org/10.1038/sj.onc.1201417			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395243				2022-12-28	WOS:A1997YE96300009
J	Joh, T; Yamamoto, K; Kagami, Y; Kakuda, H; Sato, T; Yamamoto, T; Takahashi, T; Ueda, R; Kaibuchi, K; Seto, M				Joh, T; Yamamoto, K; Kagami, Y; Kakuda, H; Sato, T; Yamamoto, T; Takahashi, T; Ueda, R; Kaibuchi, K; Seto, M			Chimeric MLL products with a Ras binding cytoplasmic protein AF6 involved in t(6;11) (q27;q23) leukemia localize in the nucleus	ONCOGENE			English	Article						translocation; 11q23; MLL; AF6; leukemogenesis	11Q23 CHROMOSOMAL TRANSLOCATIONS; ACUTE MYELOID LEUKEMIAS; PROLINE-RICH PROTEIN; DROSOPHILA-TRITHORAX; ALL-1 GENE; CLONING; ABNORMALITIES; EXPRESSION; REARRANGEMENT; HOMOLOG	In infantile leukemias and therapy-related leukemias, the MLL gene is frequently found to be disrupted and fused to various translocation partner genes, such as AF4/FEL, LTG9/AF9 and LTG19/ENL as a result of 11q23 translocations, We previously showed that the N-terminal portion common to various chimeric MLL products, as well as to MLL-LTG9 and MLL-LTG19, localizes in the nuclei, and therefore suggested that it might play an important role in leukemogenesis, In the present study, MLL-AF6 chimeric products found in the t(6;11) (q27;q23) translocation were analysed since AF6, a Ras-binding protein, exhibits a different subcellular localization from that of LTG9/AF9 and LTG19/ENL, Immunofluorescence staining data and cell fractionation analyses demonstrated that MLL-AF6 chimeric products localize in the nuclei despite the fact that AF6 itself localizes in the cytoplasm, confirming the importance of the nuclear localization of chimeric MLL products, The region in the N-terminal portion of MLL responsible for this nuclear localization was examined and found to be a region containing AT-hook motifs.	AICHI CANC CTR,RES INST,LAB CHEMOTHERAPY,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,NAGOYA,AICHI 464,JAPAN; CHIBA UNIV,SCH MED,DEPT PEDIAT,CHIBA 260,JAPAN; NAGOYA CITY UNIV,SCH MED,DEPT INTERNAL MED 2,NAGOYA,AICHI 464,JAPAN; NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Chiba University; Nagoya City University; Nara Institute of Science & Technology								AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; BERNARD OA, 1994, ONCOGENE, V9, P1039; BIRKETT CR, 1985, FEBS LETT, V187, P211, DOI 10.1016/0014-5793(85)81244-8; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; Connelly MA, 1996, GENE, V175, P271, DOI 10.1016/0378-1119(96)00135-7; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; IIDA S, 1993, ONCOGENE, V8, P3085; Joh T, 1996, ONCOGENE, V13, P1945; Kakuda H, 1996, BRIT J HAEMATOL, V95, P306, DOI 10.1046/j.1365-2141.1996.d01-1909.x; KANEKO Y, 1986, BLOOD, V67, P484; KURIYAMA M, 1996, J BIOL CHEM, V271, P606; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PRASAD R, 1993, CANCER RES, V53, P5624; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Teraoka H, 1996, FEBS LETT, V393, P1, DOI 10.1016/0014-5793(96)00842-3; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TSE W, 1995, BLOOD, V85, P650, DOI 10.1182/blood.V85.3.650.bloodjournal853650; YAMAMOTO K, 1994, BLOOD, V83, P2912, DOI 10.1182/blood.V83.10.2912.2912; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	36	35	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1681	1687		10.1038/sj.onc.1201332	http://dx.doi.org/10.1038/sj.onc.1201332			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349501				2022-12-28	WOS:A1997XY63100007
J	Mitchell, PJ; Barker, KT; Shipley, J; Crompton, MR				Mitchell, PJ; Barker, KT; Shipley, J; Crompton, MR			Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk	ONCOGENE			English	Article						brk; genomic structure; alternate splicing; SH3; chromosome 19q; protein tyrosine kinase	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN BREAST-CANCER; C-SRC; PROTEIN-KINASE; LINKED AGAMMAGLOBULINEMIA; TRANSCRIPTION FACTOR; DNA; PP60C-SRC; PHOSPHORYLATION; ACTIVATION	The brk gene encodes a non-receptor protein tyrosine kinase that consists of single SH3, SH2 and catalytic domains. Although BRK shows strongest sequence similarity to members of the SRC family of PTKs, there are several key structural and regulatory differences that place it on its own amongst non-receptor PTKs. In this study we have isolated genomic DNA clones corresponding to the human brk locus and used these to determine the intron-exon structure of the brk gene. The genomic structure of brk consists of 8 exons, whose boundaries are distinct from other non-receptor PTK family members, again indicating a structural and functional divergence. Alternate splicing of the primary brk transcript generates a distinct mRNA which encodes a truncated protein consisting of an SH3 domain and a novel C-terminal proline rich sequence. Using an antiserum raised to the SH3 domain, we have demonstrated that the product of this alternate brk transcript is expressed in the human breast tumour cell line T-47D. We have previously reported that expression of a tumour derived brk cDNA in mouse embryonic fibroblasts and human mammary epithelial cells supports anchorage independent growth, and in the latter potentiates the mitogenic response to epidermal growth factor. The protein encoded by the genomic sequence derived from normal human tissue is identical to that encoded by the tumour derived cDNA, and therefore the altered growth regulation is not associated with mutations within brk. In addition, we have identified a 5' genomic region that has promoter activity. The brk gene has been assigned to chromosome 19q 13.3-13.4 using fluorescence in situ hybridisation (FISH).			Mitchell, PJ (corresponding author), INST CANC RES, HADDOW LABS, SECT CELL BIOL & EXPT PATHOL, 15 COTSWOLD RD, SUTTON SM2 5NG, SURREY, ENGLAND.		Mitchell, Philip J/F-6393-2013	Shipley, Janet/0000-0001-6748-8678	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; BARKER KT, 1997, IN PRESS ONCOGENE; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOKE M P, 1989, New Biologist, V1, P66; DAVIDSON D, 1994, MOL CELL BIOL, V14, P4554, DOI 10.1128/MCB.14.7.4554; DAVIDSON D, 1994, J BIOL CHEM, V269, P10956; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; HENNIPMAN A, 1989, CANCER RES, V49, P516; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Ohta Y, 1996, ONCOGENE, V12, P937; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; OKADA M, 1991, J BIOL CHEM, V266, P24249; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; RIED T, 1995, CANCER RES, V55, P5415; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIPLEY JM, 1993, CYTOGENET CELL GENET, V64, P233, DOI 10.1159/000133585; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	48	39	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	1997	15	12					1497	1502		10.1038/sj.onc.1201292	http://dx.doi.org/10.1038/sj.onc.1201292			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333026				2022-12-28	WOS:A1997XW41100014
J	Chattopadhyay, P; Rathore, A; Mathur, M; Sarkar, C; Mahapatra, AK; Sinha, S				Chattopadhyay, P; Rathore, A; Mathur, M; Sarkar, C; Mahapatra, AK; Sinha, S			Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours	ONCOGENE			English	Article						glioma, genetics; chromosomes, human, pair 17; gene, suppressor, tumour	POLYMERASE CHAIN-REACTION; SUPPRESSOR GENE; MUTATIONS; CHROMOSOME-17; PATHWAYS; GLIOMAS; TUMORS	Amongst the human astrocytic tumours, the commonest of primary brain tumours, the clinical outcome of astrocytoma (AS) is significantly better than anaplastic astrocytoma (AA) and glioblastoma multiforme (GEM), Often, low grade tumours can progress to or recur with a more malignant phenotype, Recent loss of heterozygosity (LOH) reports suspect the involvement of a suppressor gene, different from p53, in the region of the human chromosome, However, the effect of LOH of 17p13.3 region on tumour histology at presentation and prognosis is as yet undefined, As a first step to define the role of this putative oncogene in astrocytic tumour progression, we correlated the LOH of a locus, D17S379, in 17p13.3 region and the p53 locus in 17p13.1 region with the histopathology of astrocytic tumours by PCR based microsatellite and restriction fragment length polymorphism of DNA extracted from microdissected paraffin sections of 45 astrocytic tumours of different histopathological grades, LOH of D17S379 was significantly associated (P=0.02) with AA and GBM (high grade malignancy), while no such preferential association was found with LOH of p53. There were no mutations in the exons 5 to 9 of p53 gene in the five tumours with LOH of D17S379 but not of p53 region, In a case of AA with a heterogenous microscopic appearance, heterozygosity of D17S379 was lost only in the area with a more malignant histology while both areas had no LOH or mutation of p53, A locus at the 17p13.3 region, independent of the p53 locus, is involved in a large subset of astrocytic tumours during transformation into a more malignant phenotype, and thus may be a link in the chain of genetic events occurring in astrocytic tumour progression.	ALL INDIA INST MED SCI,DEPT BIOCHEM,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT PATHOL,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT NEUROSURG,NEW DELHI 110029,INDIA	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi								CARROZZO R, 1993, HUM MOL GENET, V2, P615, DOI 10.1093/hmg/2.5.615; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULTS D, 1992, CANCER RES, V52, P674; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAHN M, 1993, CLIN CHEM, V39, P549; Hermanson M, 1996, CANCER RES, V56, P164; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LARGEY JS, 1993, CANCER, V71, P1933, DOI 10.1002/1097-0142(19930315)71:6<1933::AID-CNCR2820710602>3.0.CO;2-D; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; SAXENA A, 1992, CANCER RES, V52, P6716; Schultz DC, 1996, CANCER RES, V56, P1997; SHAPIRO WR, 1986, SEMIN ONCOL, V13, P38; SHAW EG, 1989, INT J RADIAT ONCOL, V16, P663, DOI 10.1016/0360-3016(89)90482-3; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570	16	45	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					871	874		10.1038/sj.onc.1201238	http://dx.doi.org/10.1038/sj.onc.1201238			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266974				2022-12-28	WOS:A1997XQ11700014
J	Bauer, A; Ulrich, E; Andersson, M; Beug, H; vonLindern, M				Bauer, A; Ulrich, E; Andersson, M; Beug, H; vonLindern, M			Mechanism of transformation by v-ErbA: Substitution for steroid hormone receptor function in self renewal induction	ONCOGENE			English	Article						leukemogenesis; receptor tyrosine kinases; steroid hormone receptors; thyroid hormone receptor; v-ErbA	AVIAN ERYTHROBLASTOSIS VIRUS; RETINOIC ACID RECEPTORS; GROWTH-FACTOR RECEPTOR; DNA-SEQUENCE SPECIFICITY; THYROID-HORMONE; ESTROGEN-RECEPTOR; C-ERBA; ERYTHROID-DIFFERENTIATION; RESPONSE ELEMENT; BINDING DOMAIN	V-ErbA, a mutated thyroid hormone receptor (TR) alpha cooperates with tyrosine kinase oncoproteins to induce fatal erythroleukemia in chicks, In vitro, v-ErbA employs a similar cooperation to induce sustained proliferation and arrest differentiation of committed erythroid progenitors, V-ErbA has been proposed to function as a dominant-negative c-ErbA/TR alpha, since it lacks an AF-2 transactivation domain and cannot be activated by hormone but retains the capacity to bind corepressors, v-ErbA fails to heterodimerize with the RXR, exhibits an altered DNA binding specificity and fails to suppress the action of coexpressed TR alpha/c-ErbA in erythroblasts, In this paper, we identify a novel mechanism by which v-ErbA contributes to leukemogenesis, Recently, the glucocorticoid receptor (GR) was identified as a key regulator of proliferation and differentiation in normal erythroid progenitors, For this, the GR required to cooperate with endogenous receptor tyrosine kinases (c-Kit) and with the estrogen receptor (ER). Here, we demonstrate that v-ErbA can substitute for the ligand-activated GR and ER, inducing proliferation and arresting differentiation in the presence of specific GR and ER antagonists, Like the GR, v-ErbA required to cooperate with c-Kit for both proliferation induction and differentiation arrest, being devoid of biological activity in the absence of an active c-Kit, In self-renewing erythroblasts, v-ErbA not only repressed known v-ErbA target genes but also maintained high expression of c-myb, These biological activities of v-ErbA depended on distinct mutations in the DNA-binding domain, Additionally, v-ErbA acted as a partial, weak repressor of c-ErbA/TR alpha function in normal erythroblasts, It could be converted into a truly dominant-negative receptor by restoring its ability to heterodimerize with RXR.	VIENNA BIOCTR,INST MOL PATHOL,A-1030 VIENNA,AUSTRIA; KAROLINSKA INST,MED NOBEL INST,DEPT MOL & CELL BIOL,DEV BIOL LAB,S-17177 STOCKHOLM,SWEDEN	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Karolinska Institutet			Andersson Lendahl, Monika/ABE-5981-2021; von Lindern, Marieke/AAH-2350-2020	Andersson Lendahl, Monika/0000-0002-5690-8515				AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; BEUG H, 1995, METHOD ENZYMOL, V254, P41; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P284; BIGLER J, 1994, MOL CELL BIOL, V14, P7621, DOI 10.1128/MCB.14.11.7621; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CASINI T, 1995, ONCOGENE, V11, P1019; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROWE AJ, 1991, J VIROL, V65, P6173; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HAYMAN MJ, 1992, CANCER SURV, V15, P53; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MADER S, 1993, J BIOL CHEM, V268, P591; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NAGL SB, 1995, MOL ENDOCRINOL, V9, P1522, DOI 10.1210/me.9.11.1522; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; NIBBS RJB, 1993, MOL CELL BIOL, V13, P5582, DOI 10.1128/MCB.13.9.5582; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SANDE S, 1994, MOL ENDOCRINOL, V8, P1455, DOI 10.1210/me.8.11.1455; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; SELMI S, 1991, J BIOL CHEM, V266, P11589; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; SMITMCBRIDE Z, 1994, MOL ENDOCRINOL, V8, P819, DOI 10.1210/me.8.7.819; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; Wahlstrom GM, 1996, ONCOGENE, V13, P843; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; WINBERGER C, 1986, NATURE, V324, P641; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZILLIACUS J, 1992, J BIOL CHEM, V267, P24941; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	82	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					701	715		10.1038/sj.onc.1201208	http://dx.doi.org/10.1038/sj.onc.1201208			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264411	Bronze			2022-12-28	WOS:A1997XP68300010
J	Uhrbom, L; Nister, M; Westermark, B				Uhrbom, L; Nister, M; Westermark, B			Induction of senescence in human malignant glioma cells by p16(INK4A)	ONCOGENE			English	Article						senescence; glioma cells; CDKN2; p16(INK4A); CDK6; pRb phosphorylation	WILD-TYPE P53; RETINOBLASTOMA-PROTEIN; CYCLIN-D; CELLULAR-TRANSFORMATION; GENE; EXPRESSION; INHIBITION; APOPTOSIS; CDK4; IDENTIFICATION	p16(INK4A) is a G1-specific cell cycle inhibitor which maps to human chromosome 9p21, a region frequently mutated or deleted in cancer cell lines and primary tumors. In glioblastomas the frequency of homozygous deletions is 40-70% making it one of the most common mutations in this tumor type. We have analysed the significance of the loss of this gene in gliomas by introducing the cDNA for p16(INK4A) into the human glioma cell line U-1242 MG which has a deleted CDKN2 locus. We used the tetracycline repressable vector system and obtained two stably transfected clones that expressed p16(INK4A) upon induction. p16(INK4A) expression caused a G1 arrest and enlargement of the cells similar to that of senescent cells. When staining for Senescence-Associated beta-galactosidase activity, described to be specific for senescent cells, we could show that the enlarged cells specifically gave a positive staining reaction. This senescence phenotype was dependent on the continuous expression of p16(INK4A) since it was reversed upon reintroduction of tetracycline suppression. Thus, the induced expression of p16(INK4A) in these glioma cells reverted their immortal phenotype and caused an immediate cellular senescence.	UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital				Westermark, Bengt/0000-0001-7153-5545				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ARAP W, 1995, CANCER RES, V55, P1351; BATES S, 1994, ONCOGENE, V9, P1633; BONGCAMRUDLOFF E, 1991, CANCER RES, V51, P1553; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DREYLING MH, 1995, CANCER RES, V55, P984; Fueyo J, 1996, ONCOGENE, V12, P103; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hara E, 1996, MOL CELL BIOL, V16, P859; HAUPT Y, 1995, ONCOGENE, V10, P1563; HE J, 1995, CANCER RES, V55, P4833; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; HEDRUM A, 1994, BIOTECHNIQUES, V17, P122; HEDRUM A, 1994, BIOTECHNIQUES, V17, P126; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOGAN DAH, 1995, EMBO J, V14, P461; Loughran O, 1996, ONCOGENE, V13, P561; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LUBITZ W, 1980, INT J CANCER, V25, P53, DOI 10.1002/ijc.2910250107; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; Reznikoff CA, 1996, CANCER RES, V56, P2886; ROUACH EY, 1991, NATURE, V352, P345; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SONODA Y, 1995, ONCOGENE, V11, P2145; STEIN GH, 1982, P NATL ACAD SCI-BIOL, V79, P5287, DOI 10.1073/pnas.79.17.5287; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu Q, 1996, INT J CANCER, V65, P840, DOI 10.1002/(SICI)1097-0215(19960315)65:6<840::AID-IJC22>3.0.CO;2-6; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	53	117	122	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					505	514		10.1038/sj.onc.1201227	http://dx.doi.org/10.1038/sj.onc.1201227			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247304				2022-12-28	WOS:A1997XN25500002
J	Amarante-Mendes, GP; McGahon, AJ; Nishioka, WK; Afar, DEH; Witte, ON; Green, DR				Amarante-Mendes, GP; McGahon, AJ; Nishioka, WK; Afar, DEH; Witte, ON; Green, DR			Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-x(L)	ONCOGENE			English	Article						Bcr-Abl; Bcl-x; Bcl-2; apoptosis; transformation; tyrosine kinase; HL-60	CHRONIC MYELOGENOUS LEUKEMIA; POSITIVE HUMAN LEUKEMIAS; CELL-DEATH; TYROSINE KINASE; PHOSPHATIDYLINOSITOL-3 KINASE; GROWTH-FACTOR; K562 CELLS; BCL-2; ONCOGENE; TRANSFORMATION	Bcr-Abl is the molecule responsible for both the transformation phenotype and the resistance to chemotherapeutic drugs found in chronic myelogenous leukemia (CML) cells, Wild-type HL-60, a transformed pro-myelocytic cell line, is very susceptible to apoptosis-inducing agents, We show here that expression of Bcr-Abl in HL-60 cells rendered them extremely resistant to apoptosis induced by a wide variety of agents, The anti-apoptotic effect of Bcr-Abl was found to be independent of the phase of the cell cycle, Treatment with antisense oligonucleotides directed to bcr decreased the expression of the ectopic bcr-abl and restored susceptibility to apoptosis, Double mutations affecting the autophosphorylation site and the phosphotyrosine-binding motif (FLVRES) have been previously shown to impair the transforming activity of Bcr-Abl in fibroblasts and hematopoietic cells, however HL-60 cells expressing this double mutant molecule exhibited the same level of resistance to apoptosis as those expressing the wild-type Bcr-Abl. Interestingly, wild type and mutant Bcr-Abl induced in HL-60 cells a dramatic down regulation of Bcl-2 and increased the levels of Bcl-x(L). The level of Bar did not change in response to the presence of Bcr-Abl, Antisense oligonucleotides targeted to bcl-x downregulated the expression of Bcl-x(L) and increased the susceptibility of HL-60.Bcr-Abl cells to staurosporine. Importantly, HL-60 cells overexpressing Bcl-x(L) showed higher expression of Bcl-x(L) but lower resistance to apoptosis when compared to HL-60.Bcr-Abl cells. The results described here show that Bcr-Abl is a powerful mammalian anti-apoptotic molecule and can act independently of Bcl-2, Bcl-x(L), however, seems to participate in part in Bcr-Abl-mediated resistance to apoptosis in HL-60 cells.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Microbiol & Mol Genet, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90024 USA	La Jolla Institute for Immunology; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Amarante-Mendes, GP (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508900 Sao Paulo, Brazil.		Mendes, Gustavo P Amarante/C-8187-2012; Green, Douglas R/N-8083-2018	Mendes, Gustavo P Amarante/0000-0002-7851-6205; Green, Douglas R/0000-0002-7332-1417				ADAMS JM, 1992, CANCER SURV, V15, P119; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AmaranteMendes GP, 1997, CELL DEATH DIFFER, V4, P548, DOI 10.1038/sj.cdd.4400276; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRESCIANI F, 1974, CANCER RES, V34, P2405; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARLESSO N, 1994, ONCOGENE, V9, P149; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; GARCIA IS, 1995, P NATL ACAD SCI USA, V92, P5287; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; ITOH N, 1993, J IMMUNOL, V151, P621; KOEFFLER HP, 1981, NEW ENGL J MED, V304, P1201, DOI 10.1056/NEJM198105143042004; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; MARTIAT P, 1993, BLOOD, V81, P502; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MEMON SA, 1995, J IMMUNOL, V155, P4644; Minshall C, 1996, J IMMUNOL, V156, P939; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Ray S, 1996, CELL GROWTH DIFFER, V7, P1617; SAKAI N, 1994, EXP CELL RES, V215, P131, DOI 10.1006/excr.1994.1324; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRIFE A, 1988, SEMIN HEMATOL, V25, P37; STRYCKMANS P, 1976, CANCER RES, V36, P3034; SZCYLIK C, 1991, SCIENCE, V253, P562; WANG ZH, 1995, J IMMUNOL, V155, P3722; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	44	190	201	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1383	1390		10.1038/sj.onc.1201664	http://dx.doi.org/10.1038/sj.onc.1201664			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525737				2022-12-28	WOS:000072572400002
J	Hsu, CY; Yung, BYM				Hsu, CY; Yung, BYM			Down-regulation of nucleophosmin/B23 during retinoic acid-induced differentiation of human promyelocytic leukemia HL-60 cells	ONCOGENE			English	Article						nucleophosmin/B23; retinoic acid; HL-60 differentiation	NUCLEOLAR PHOSPHOPROTEIN B23; NUCLEAR MATRIX PROTEIN; HELA-CELLS; RNA-SYNTHESIS; TRANSCRIPTIONAL REGULATION; ACTINOMYCIN-D; NUMATRIN B23; TUMOR-CELLS; C-MYC; GROWTH	Human promyelocytic leukemia HL-60 cells were induced to undergo granulocytic differentiation by treatment with retinoic acid (RA, 10 mu M, 1-5 days). The steady-state level of nucleophosmin/B23 mRNA decreased during the RA-induced differentiation. There was also decrease in the level of total cellular nucleophosmin/B23 protein during the RA-induced differentiation. Stabilization and nuclear run-on assays indicate that the decrease in nucleophosmin/B23 mRNA in RA-treated HL-60 cells was transcriptionally regulated. Unlike c-myc mRNA, there was virtually no decline of nucleophosmin/B23 mRNA during the growth arrest by serum-starvation. The decrease in nucleophosmin/B23 mRNA expression in HL-60 cells subsequent to retinoic acid treatment can thus be attributed to cellular differentiation rather than the growth arrest induced by RA. Nucleophosmin/B23 antisense oligomer treatment significantly potentiated RA-induced cellular differentiation. Results of this study suggest that nucleophosmin/B23 is one of the key elements in the down-regulation of nucleolar function for cellular differentiation.	Chang Gung Med & Engn Coll, Dept Pharmacol, Canc Biochem Lab, Tao Yuan 333, Taiwan; Natl Yang Ming Univ, Grad Inst Pharmacol, Taipei, Taiwan	National Yang Ming Chiao Tung University	Yung, BYM (corresponding author), Chang Gung Med & Engn Coll, Dept Pharmacol, Canc Biochem Lab, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.			Yung, Benjamin Yat Ming/0000-0003-0093-3196				ADACHI Y, 1993, J BIOL CHEM, V268, P13930; BECKMANN R, 1992, EUR J BIOCHEM, V210, P45, DOI 10.1111/j.1432-1033.1992.tb17388.x; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREITMAN TR, 1980, EXP CELL RES, V126, P494, DOI 10.1016/0014-4827(80)90296-7; CHAN PK, 1989, CANCER RES, V49, P3271; CHAN PK, 1992, EXP CELL RES, V203, P174, DOI 10.1016/0014-4827(92)90053-B; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Cho SK, 1996, J BIOL CHEM, V271, P3238, DOI 10.1074/jbc.271.6.3238; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOU YH, 1995, BIOCHEM BIOPH RES CO, V217, P313, DOI 10.1006/bbrc.1995.2779; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FONAGY A, 1992, CANCER RES, V52, P5250; GROSSO LE, 1985, CANCER RES, V45, P847; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITINGER N, 1993, J CELL BIOCHEM, V52, P153, DOI 10.1002/jcb.240520207; LI XZ, 1989, BIOCHEM BIOPH RES CO, V163, P72, DOI 10.1016/0006-291X(89)92100-1; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; PATTERSON SD, 1995, J BIOL CHEM, V270, P9429, DOI 10.1074/jbc.270.16.9429; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; TSIFTSOGLOU AS, 1985, INT J CELL CLONING, V3, P349, DOI 10.1002/stem.5530030602; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; WU MH, 1995, BIOCHEM J, V305, P987, DOI 10.1042/bj3050987; YonedaKato N, 1996, ONCOGENE, V12, P265; YUNG BY, 1990, CANCER RES, V50, P5987; YUNG BYM, 1990, INT J CANCER, V46, P272, DOI 10.1002/ijc.2910460222; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; YUNG BYM, 1986, CANCER RES, V46, P922; YUNG BYM, 1992, INT J CANCER, V52, P317, DOI 10.1002/ijc.2910520227	43	57	57	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					915	923		10.1038/sj.onc.1201615	http://dx.doi.org/10.1038/sj.onc.1201615			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484783				2022-12-28	WOS:000072053200011
J	Svedberg, H; Chylicki, K; Baldetorp, B; Rauscher, FJ; Gullberg, U				Svedberg, H; Chylicki, K; Baldetorp, B; Rauscher, FJ; Gullberg, U			Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program	ONCOGENE			English	Article						WT1; leukemia; differentiation; hematopoiesis; U937	ZINC FINGER PROTEIN; I RECEPTOR GENE; SUPPRESSOR GENE; RETINOIC ACID; MYELOID-LEUKEMIA; ADHESION MOLECULES; PROMOTER ACTIVITY; FLOW-CYTOMETRY; U-937 CELLS; PRODUCT	The Wilms tumor gene, WT1, encodes a zinc-finger DNA binding protein which is thought to function as a tissue specific transcription factor, regulating cell growth and differentiation, High expression of WT1 has been detected in a range of acute leukemias. To elucidate a role for WT1 in leukemogenesis, we transfected the monoblastic cell line U937, which lacks detectable levels of endogenous WT1, with two isoforms of WT1, We showed that, in contrast to U937 control cells, cells constitutively expressing either of the isoforms, WT1(-KTS) or WT1(+KTS), did not respond to differentiation induction by retinoic acid or vitamin D3, as judged by the capacity to reduce nitro blue tetrazolium and morphology. Although U937 cells expressing WT1 were hampered in their ability to differentiate on incubation with retinoic acid and vitamin D3, the induced G1/G0-accumulation was similar to differentiating control cells treated with inducers, Furthermore, distinct effects on the maturation process were indicated by downregulation of the myeloid cell surface makers CD13 and CD15, while the upregulation of CD14 and CD11c on WT1 transfected cells was similar to control cells upon incubation with retinoic acid and vitamin D3, Taken together our results demonstrate that a constitutive expression of WT1 in the leukemic cell line U937 leads to impairment of differentiation responses, indicating that a high expression of WT1 can contribute to the differentiation block of acute leukemia.	Lund Univ, Dept Hematol, S-22185 Lund, Sweden; Lund Univ, Dept Oncol, S-22185 Lund, Sweden; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	Lund University; Lund University; The Wistar Institute	Gullberg, U (corresponding author), Lund Univ, Dept Hematol, S-22185 Lund, Sweden.		Baldetorp, Bo/HDM-9924-2022					Algar EM, 1996, ONCOGENE, V12, P1005; Baird PN, 1997, EXP HEMATOL, V25, P312; BALDETORP B, 1989, CYTOMETRY, V10, P695, DOI 10.1002/cyto.990100605; BALDETORP B, 1992, CYTOMETRY, V13, P577, DOI 10.1002/cyto.990130605; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARLOS TM, 1994, BLOOD, V84, P2068; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; Ehinger M, 1996, BLOOD, V87, P1064, DOI 10.1182/blood.V87.3.1064.bloodjournal8731064; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FRAIZER GC, 1995, BLOOD, V86, P4704, DOI 10.1182/blood.V86.12.4704.bloodjournal86124704; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOODYER P, 1995, ONCOGENE, V10, P1125; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Hewitt SM, 1996, J BIOL CHEM, V271, P8588, DOI 10.1074/jbc.271.15.8588; HEWITT SM, 1995, CANCER RES, V55, P5386; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kudoh T, 1996, ONCOGENE, V13, P1431; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; LUO XN, 1995, ONCOGENE, V11, P743; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MIWA H, 1992, LEUKEMIA, V6, P405; MORRIS JF, 1991, ONCOGENE, V6, P2339; OBERG F, 1993, J IMMUNOL, V150, P3487; Olsson I, 1996, EUR J HAEMATOL, V57, P1; OLSSON I, 1983, CANCER RES, V43, P5862; OLSSON IL, 1982, CANCER RES, V42, P3924; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Patmasiriwat P, 1996, LEUKEMIA, V10, P1127; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SEKIYA M, 1994, BLOOD, V83, P1876; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; STOCKS SC, 1990, BIOCHEM J, V268, P275, DOI 10.1042/bj2680275; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878	55	71	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	1998	16	7					925	932		10.1038/sj.onc.1201613	http://dx.doi.org/10.1038/sj.onc.1201613			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484784				2022-12-28	WOS:000072053200012
J	Hemminki, A; Hoglund, P; Pukkala, E; Salovaara, R; Jarvinen, H; Norio, R; Aaltonen, LA				Hemminki, A; Hoglund, P; Pukkala, E; Salovaara, R; Jarvinen, H; Norio, R; Aaltonen, LA			Intestinal cancer in patients with a germline mutation in the down-regulated in adenoma (DRA) gene	ONCOGENE			English	Article						DRA; CLD; cancer; neoplasia; tumor suppressor	CONGENITAL CHLORIDE DIARRHEA; LINKAGE DISEQUILIBRIUM; CYSTIC-FIBROSIS; MUCOSA; COLON; GROWTH; CARCINOMA; ENCODES	A recent study has revealed that germline mutations of the down-regulated in adenoma (DRA) gene are a likely cause of a recessive intestinal absorption defect, congenital chloride diarrhea, This finding was in accordance with previous works showing that DRA encodes a sodium independent transporter for sulfate and oxalate, Although DRA was originally reported as a candidate tumor suppressor, these studies have questioned the relevance of DRA in cancer. To evaluate whether further studies on the role of DRA in tumorigenesis are still of interest, we examined whether individuals carrying germline DRA mutations have an excess of intestinal cancer, Cancer status of 229 members of 36 Finnish congenital chloride diarrhea families (44 homozygous patients, 70 heterozygous parents, and 115 grandparents at 50% risk of being a DRA mutation carrier) was checked at the Finnish Cancer Registry and the risk of intestinal cancer was found slightly elevated (standardized incidence ratio 3.4, 95% confidence interval 1.4-7.0, P<0.05). While this result does not unambiguously demonstrate an increased intestinal cancer risk in DRA mutation carriers, it should promote further studies to determine the possible role of DRA in cancer.	Univ Helsinki, Dept Med Genet, Helsinki 00014, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, Helsinki 00014, Finland; Finnish Canc Registry, Helsinki 00171, Finland; Univ Helsinki, Cent Hosp, Dept Surg 2, Helsinki 00250, Finland; Family Fed Finland, Dept Med Genet, Helsinki 00101, Finland	University of Helsinki; University of Helsinki; Finnish Cancer Registry; University of Helsinki; Helsinki University Central Hospital; Family Federation of Finland	Aaltonen, LA (corresponding author), Univ Helsinki, Dept Med Genet, Haartmaninkatu 3,POB 21, Helsinki 00014, Finland.		Aaltonen, Lauri/A-5375-2010	Aaltonen, Lauri/0000-0001-6839-4286	NATIONAL CANCER INSTITUTE [U01CA067941, R01CA067941] Funding Source: NIH RePORTER; NCI NIH HHS [CA67941] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham EH, 1996, NAT MED, V2, P593, DOI 10.1038/nm0596-593; FILIPE MI, 1974, CANCER-AM CANCER SOC, V34, P282, DOI 10.1002/1097-0142(197408)34:2<282::AID-CNCR2820340211>3.0.CO;2-W; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HOGLUND P, 1995, AM J HUM GENET, V57, P95; HOGLUND P, 1994, AM J HUM GENET, V55, P747; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; KYLLONEN LEJ, 1987, ANN CHIR GYNAECOL FE, V76, P185; LAPIS K, 1990, Tokai Journal of Experimental and Clinical Medicine, V15, P155; Mckusick V.A., 1994, MENDELIAN INHERITANC; NAKAMURA N, 1981, CANCER RES, V41, P278; NEGLIA JP, 1995, NEW ENGL J MED, V332, P494, DOI 10.1056/NEJM199502233320803; NORIO R, 1971, Clinical Genetics, V2, P182; PUKKALA E, 1992, USE RECORD LINKAGE S, P125; PUKKALA E, 1987, CANC SOC FINLAND PUB, V37; ROBINSON J, 1984, J CELL BIOL, V98, P946, DOI 10.1083/jcb.98.3.946; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SHAMSUDDIN AKM, 1981, J NATL CANCER I, V66, P413; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; TAGUCHI T, 1994, GENOMICS, V20, P146, DOI 10.1006/geno.1994.1148; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; VONDIPPE P, 1982, J BIOL CHEM, V257, P4381; YAMORI T, 1987, CANCER RES, V47, P2741	24	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					681	684		10.1038/sj.onc.1201538	http://dx.doi.org/10.1038/sj.onc.1201538			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482116				2022-12-28	WOS:000071816600015
J	Ahmed, M; Dusanter-Fourt, I; Bernard, M; Mayeux, P; Hawley, RG; Bennardo, T; Novault, S; Bonnet, ML; Gisselbrecht, S; Varet, B; Turhan, AG				Ahmed, M; Dusanter-Fourt, I; Bernard, M; Mayeux, P; Hawley, RG; Bennardo, T; Novault, S; Bonnet, ML; Gisselbrecht, S; Varet, B; Turhan, AG			BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line	ONCOGENE			English	Article						BCR-ABL; apoptosis; EpoR	DNA-BINDING ACTIVITY; CHRONIC MYELOGENOUS LEUKEMIA; FACTOR-DEPENDENT CELLS; TYROSINE KINASE; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; POSITIVE CELLS; SH2 DOMAIN; TRANSFORMATION	The interleukin-3 dependent murine Ba/F3 cell line has been widely used as an experimental model of cell transformation by BCR-ABL oncogenes as assessed by induction of growth-factor-independence and inhibition of apoptosis in vitro. The signaling pathways used by BCR-ABL oncogenes to exert these effects are unknown, To gain insights into this phenomenon, we have introduced the p190- and p210-encoding BCR-ABL oncogenes as well as the constitutively activated oncogenic murine erythropoietin receptor (cEpoR) into Ba/F3 and compared the behavior of individual clones in response to apoptotic stimuli, Both p210 and p190 BCR-ABL vectors induced IL-3-independent growth and the same result was obtained with the cEpo-R vector, Individual clones of Ba/F3 cells expressing BCR-ABL exhibited significant resistance to apoptosis induced by either etoposide, serum deprivation or growth-factor withdrawal. In contrast, Ba/F3 cells expressing the constitutively active cEpoR behaved like parental Ba/F3 cells undergoing apoptosis when similarly treated with etoposide or upon serum deprivation, Bc12 and Bas levels were similar in all BCR-ABL and cEpoR-transfected clones, However, in band-shift assays, nuclear extracts from growth-factor-independent Ba/F3 clones expressing cEpoR had no detectable STAT activity as opposed to the constitutive STAT activation detected in all Ba/F3 clones expressing p210 or p190 BCR-ABL. Our results indicate that although both constitutively activated cEpoR and BCR-ABL oncogenes induce growth-factor independence in Ba/F3 cells, only BCR-ABL is able to protect cells from etoposide and serum-deprivation-induced apoptosis and induce a strong constitutive activation of STAT factors, suggesting a role for these molecules in the anti-apoptotic activity of BCR-ABL.	Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Hop Necker Enfants Malad, CNRS, URA 1461, F-75743 Paris, France; Hop Necker Enfants Malad, Serv Hematol Adulte, F-75743 Paris, France; Hop Cochin, ICGM, INSERM, U363, F-75674 Paris, France; Toronto Hosp, Oncol Gene Therapy Program, Toronto, ON M5G 2M1, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Turhan, AG (corresponding author), Inst Gustave Roussy, INSERM, U362, PR-1 Rue Camille Desmoulins, F-94805 Villejuif, France.		Dusanter-Fourt, Isabelle/P-4558-2017	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; TURHAN, Ali/0000-0002-4861-0137; Hawley, Robert/0000-0003-3512-5818				BEDI A, 1994, BLOOD, V83, P2038; Bright JJ, 1997, J IMMUNOL, V159, P175; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; EAVES CJ, 1987, CHRONIC MYELOID LEUK, V1, P931; Esteve P, 1995, ONCOGENE, V11, P2657; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HAWLEY RG, 1994, GENE THER, V1, P136; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; ISSAAD C, 1994, BLOOD, V84, P3447; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANEUVILLE P, 1994, CANCER RES, V54, P1360; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OFarrell AM, 1996, BLOOD, V87, P3655, DOI 10.1182/blood.V87.9.3655.bloodjournal8793655; OKUDA K, 1994, J BIOL CHEM, V269, P24602; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; SIRARD C, 1994, BLOOD, V83, P1575; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	48	23	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					489	496		10.1038/sj.onc.1201556	http://dx.doi.org/10.1038/sj.onc.1201556			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484838				2022-12-28	WOS:000071739400007
J	Kato, K; Ueoka, Y; Kato, K; Hachiya, T; Nishida, J; Wake, N				Kato, K; Ueoka, Y; Kato, K; Hachiya, T; Nishida, J; Wake, N			Contribution of enhanced transcriptional activation by ER to [(12)Val] K-Ras mediated NIH3T3 cell transformation	ONCOGENE			English	Article						Ras; transformation; ER; PR	STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; PROTEIN; PHOSPHORYLATION; STIMULATION; BINDING; REGION; KINASE; GROWTH	We investigated the biological significance of estrogen receptors (ER) in NM3T3 cell transformation by the [(12)Val] K-Ras mutant, This mutant enhanced the steady state level of ER, Cells expressing mutant K-Ras (K12V cell) were tumorigenic, To determine the role of ER accumulation in Ras-transformed cells, we developed cells (KwtER cells) that overexpressed both wild-type (wt) K-Ras and ER, and found these cells were also tumorigenic. E-2 stimulated the transcriptional activity by ER dominantly in K12V cells, However, only partial activation of ER by E-2 was seen in KwtER cells, In the presence of 10% serum in media, the activation of ER appeared only in transformed KtwER and K12V cells, suggesting that two independently transmitted signals, the E-2-ER binding and the ER-AF1 activation, are necessary for ER activation and that the dominant activation of ER might be involved in Ras-mediated cell transformation, Co-expression of progesterone receptor (PR) with mutant K-Ras led to suppression of tumorigenicity and inhibition of the activation of ER, The antisense oligomers complementary to the ER suppressed proliferation and transformed phenotypes of K12V cells, These observations support the importance of ER in aas-mediated cell transformation.	Kyushu Univ, Med Inst Bioregulat, Dept Reprod Physiol & Endocrinol, Beppu, Oita 874, Japan	Kyushu University	Wake, N (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Reprod Physiol & Endocrinol, 4546 Tsurumihara, Beppu, Oita 874, Japan.							ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CICATIELLO L, 1992, J STEROID BIOCHEM, V41, P523, DOI 10.1016/0960-0760(92)90377-U; COEZY E, 1982, CANCER RES, V42, P317; DUBIK D, 1987, CANCER RES, V47, P6517; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; PETRANGELI E, 1994, J STEROID BIOCHEM, V49, P327, DOI 10.1016/0960-0760(94)90275-5; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOJEK AB, 1993, CELL, V74, P205; WALMER DK, 1995, CANCER RES, V55, P1168; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	20	21	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3037	3046		10.1038/sj.onc.1201497	http://dx.doi.org/10.1038/sj.onc.1201497			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444952				2022-12-28	WOS:000070968000004
J	Sattler, M; Salgia, R; Shrikhande, G; Verma, S; Choi, JL; Rohrschneider, LR; Griffin, JD				Sattler, M; Salgia, R; Shrikhande, G; Verma, S; Choi, JL; Rohrschneider, LR; Griffin, JD			The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors	ONCOGENE			English	Article						BCR/ABL; SHIP; SHP-2; CBL	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; MULTIPLE CYTOKINES; RECEPTOR; ACTIVATION; BINDING; KINASE; SHC; PHOSPHORYLATION; P210(BCR/ABL); GRB2	We report here that interleukin-3 (IL-3) and erythropoietin (EPO) induce formation of a complex composed of two SH2-containing phosphatases, the tyrosine phosphatase SHP-2 and the SH2 containing inositol 5-phosphatase (SHIP), Both SHP-2 and SHIP are known to be involved in growth factor signal transduction, but their potential interaction in the same pathway is novel, SHIP has previously been shown to associate with SHC, and potentially to be involved in regulating apoptosis, In contrast, in some model systems, SHP-2 has been demonstrated to positively regulate cell growth, Both phosphatases in the complex were tyrosine phosphorylated, and the amount of SHIP coprecipitating with SHP-2 was inversely related to the amount of SHIP coprecipitating with SHC, In hematopoietic cells transformed by the BCR/ABL oncogene, this phosphatase complex was found to be constitutively present with both components heavily tyrosine phosphorylated, Also, other proteins were detected in the complex, including BCR/ABL itself and c-CBL, However, transformation by BCR/ABL was associated with a reduced SHIP protein expression, which could further affect the accumulation of various inositol polyphosphates in these leukemic cells, These data suggest that the function of SHIP and SHP-2 in normal cells are linked and that BCR/ABL alters the function of this signaling complex.	CHILDRENS HOSP,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,DPET ADULT ONCOL,BOSTON,MA 02115; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98125	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Center					NCI NIH HHS [CA01730] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BEDI A, 1994, BLOOD, V83, P2038; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P10998; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; Salgia R, 1996, EXP HEMATOL, V24, P310; Sattler M, 1996, ONCOGENE, V12, P839; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217	22	65	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2379	2384		10.1038/sj.onc.1201422	http://dx.doi.org/10.1038/sj.onc.1201422			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393882				2022-12-28	WOS:A1997YE15700012
J	Chretien, S; Duprez, V; Maouche, L; Gisselbrecht, S; Mayeux, P; Lacombe, C				Chretien, S; Duprez, V; Maouche, L; Gisselbrecht, S; Mayeux, P; Lacombe, C			Abnormal erythropoietin (Epo) gene expression in the murine erythroleukemia IW32 cells results from a rearrangement between the G-protein beta 2 subunit gene and the Epo gene	ONCOGENE			English	Article						friend erythroleukemia; Epo rearrangement; G-protein beta 2 subunit	TRANSGENIC MICE; STAT5 ACTIVATION; LEUKEMIA-VIRUS; PYRUVATE-KINASE; RECEPTOR; IDENTIFICATION; SITE; DIFFERENTIATION; TUMORIGENICITY; TRANSCRIPTION	Abnormal production of erythropoietin (Epo) has been described in several human and murine erythroleukemia, The murine IW32 cell line is derived from an F-MuLV-induced erythroleukemia. An autocrine Epo production due to the rearrangement of one Epo allele has been previously described (Beru ed al., 1989), However, the exact mechanism leading to the transcriptional activation of the abnormal Epo gene was unknown, In this study, we show that this deregulated expression results from a deletion within chromosome 5, The Epo gene in the abnormal allele is under the control of the G-protein beta 2 subunit gene promoter and the expressed mRNA results from the fusion of the non coding exon 1 of the G-protein beta 2 subunit gene to a truncated Epo exon I gene, This resulting abnormal cDNA allows the expression of a normal Epo protein.	INST NATL TRANSFUS SANGUINE,F-75015 PARIS,FRANCE; HOP HENRI MONDOR,INSERM U91,F-94000 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Chretien, S (corresponding author), UNIV PARIS 05,HOP COCHIN,IGGM,INSERM U363,27 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE.		maouche, leila/E-3887-2017; Chretien, Stany/M-5166-2018					BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERU N, 1989, DNA-J MOLEC CELL BIO, V8, P253, DOI 10.1089/dna.1.1989.8.253; CHIREUX MA, 1995, J NEUROSCI RES, V40, P427, DOI 10.1002/jnr.490400402; CHOPPIN J, 1984, BLOOD, V64, P341; CHOPPIN J, 1985, EXP HEMATOL, V13, P610; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; DREYFUS F, 1990, LEUKEMIA, V4, P590; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; HANKINS WD, 1986, BLOOD, V68, P263; HERMINE O, 1991, BLOOD, V78, P2253; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; Howard JC, 1996, ONCOGENE, V12, P1405; Kozak CA, 1996, MAMM GENOME, V6, pS97; LACOMBE C, 1988, BLOOD, V72, P1440; LACOMBE C, 1987, MOL CELLULAR ASPECTS, P61; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MAXWELL PH, 1993, KIDNEY INT, V44, P1149, DOI 10.1038/ki.1993.362; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MITJAVILA MT, 1991, J CLIN INVEST, V77, P461; MOREAUGACHELIN F, 1988, NATURE, V331, P227; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; SELS FT, 1992, ONCOGENE, V7, P643; SEMENZA GL, 1990, MOL CELL BIOL, V10, P930, DOI 10.1128/MCB.10.3.930; SEMENZA GL, 1989, P NATL ACAD SCI USA, V86, P2301, DOI 10.1073/pnas.86.7.2301; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; SHIBUYA T, 1982, CELL, V31, P483, DOI 10.1016/0092-8674(82)90141-6; StageMarroquin B, 1996, EXP HEMATOL, V24, P1322; TAMBOURIN P, 1983, P NATL ACAD SCI-BIOL, V80, P6269, DOI 10.1073/pnas.80.20.6269; VILLEVAL JL, 1992, LEUKEMIA, V6, P107; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	40	2	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1995	1999		10.1038/sj.onc.1201364	http://dx.doi.org/10.1038/sj.onc.1201364			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365246				2022-12-28	WOS:A1997YA87200014
J	PaasinenSohns, A; Holtta, E				PaasinenSohns, A; Holtta, E			Cells transformed by ODC, c-Ha-ras and v-src exhibit MAP kinase Erk-independent constitutive phosphorylation of Sos, Raf and c-Jun activation domain, and reduced PDGF receptor expression	ONCOGENE			English	Article						transformation; ODC; Ras; Src; MAP kinase; c-Jun phosphorylation	NUCLEOTIDE EXCHANGE FACTOR; NIH 3T3 CELLS; ORNITHINE DECARBOXYLASE ACTIVITY; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; TYROSINE KINASE; ONCOGENIC TRANSFORMATION; PHOSPHOTYROSINE PHOSPHATASE; TRANSCRIPTIONAL ACTIVITY	While it is known that the constitutive activity of a variety of signal transduction molecules leads to cell transformation, a key unresolved question is whether these wirings converge to a common intermediate(s) that dictates transformation, In this study, we investigated whether NIH3T3 and Rat-1 cells transformed by human ornithine decarboxylase (ODC), c-Ha-ras(Val12) and temperature-sensitive v-src oncogene display common alteration(s) in the components that relay PDGF-mediated signals in normal fibroblasts. The ras- and ODC-transformed cells did not show constitutively elevated tyrosine phosphorylation of the phospholipase Cy-l (PLC gamma-1), RasGTPase-activating protein (GAP), phosphotyrosine phosphatase Syp, She proteins, and phosphatidylinositol 3-kinase (PI3-K) or activation of the MAP kinase (Erk1 and Erk2), p70 S6 kinase or the Janus protein tyrosine kinase (JAK) and signal transducer and activator of transcription (STAT) protein-1 pathways. Instead, the Ras nucleotide exchange factor Sos-1 and Raf-l kinase exhibited constitutive phosphorylations, as deduced from their electrophoretic mobility shifts in polyacrylamide gels, Hence a kinase distinct from Erk1 and Erk2, previously known to feedback phosphorylate Sos-1 and Raf-l, is responsible for the phosphorylation of these molecules in the transformants. We also demonstrate that the ras- and ODC-transformed cells exhibit loss of both the PDGF alpha- and beta-receptors, while the v-Src-transformants show a predominant reduction in the beta-receptors. Moreover, all the transformed cell lines were found to display a constitutive increase in phosphorylation of c-Jun on serines 63 and 73, which appears to be governed by an as yet unknown kinase.	UNIV HELSINKI,HAARTMAN INST,DEPT PATHOL,FIN-00014 HELSINKI,FINLAND	University of Helsinki								Alessandrini A, 1996, J BIOL CHEM, V271, P31612, DOI 10.1074/jbc.271.49.31612; ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; AUVINEN M, 1997, IN PRESS CANC RES, V57; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BARONDELAGE S, 1994, J BIOL CHEM, V15, P18686; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BAZENET CE, 1993, ONCOGENE, V9, P517; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GAZDAR AF, 1976, NATURE, V262, P696, DOI 10.1038/262696a0; Greulich H, 1996, ONCOGENE, V12, P1689; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; HOLTTA E, 1994, BIOCHEM SOC T, V22, P853; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEHTOLA L, 1991, CELL REGUL, V2, P651, DOI 10.1091/mbc.2.8.651; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OKAZAKI K, 1995, ONCOGENE, V10, P1149; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEGG AE, 1988, CANCER RES, V48, P759; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; RAKE JB, 1991, J BIOL CHEM, V266, P5348; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TOMASKA L, 1993, BIOCHEM J, V293, P215, DOI 10.1042/bj2930215; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VAZRIL C, 1995, MOL CELL BIOL, V15, P1244; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	89	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1953	1966		10.1038/sj.onc.1201366	http://dx.doi.org/10.1038/sj.onc.1201366			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365242				2022-12-28	WOS:A1997YA87200010
J	Visconti, R; Cerutti, J; Battista, S; Fedele, M; Trapasso, F; Zeki, K; Miano, MP; deNigris, F; Casalino, L; Curcio, F; Santoro, M; Fusco, A				Visconti, R; Cerutti, J; Battista, S; Fedele, M; Trapasso, F; Zeki, K; Miano, MP; deNigris, F; Casalino, L; Curcio, F; Santoro, M; Fusco, A			Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF kappa B p65 protein expression	ONCOGENE			English	Article						NF kappa B; p65-p50; thyroid; carcinomas; antisense; oncogenes	C-MYC; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTION ACTIVATOR; INHIBITS PROLIFERATION; MESSENGER-RNA; DNA-BINDING; REL FAMILY; SUBUNIT; DIFFERENTIATION; TRANSFORMATION	We have investigated the role of the NF kappa B complex in the process of thyroid carcinogenesis by analysing thyroid carcinoma cell lines, A significant increase in p65 NF kappa B mRNA and protein expression, compared to normal thyroid cultures or tissue, was found in all of the cancer cell lines, Conversely, only a modest increase in the p50 NF kappa B mRNA and protein was found in most, but not all carcinoma cell lines, The block of p65 protein synthesis with specific antisense oligonucleotides greatly reduced the ability of two undifferentiated carcinoma cell lines to form colonies in agar and reduced their growth rate, On the other hand, no effect was observed in the same cell lines when treated with p50 specific antisense oligonucleotides. These inhibitory effects seem to be mediated by the suppression of c-myc gene expression, since treatment with antisense oligonucleotides for p65 gene interfered negatively with c-myc gene expression, Our results indicate that activation of the NF kappa B complex by overexpression of p65 plays a critical role in the process of thyroid cell transformation.	UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,CNR,I-80131 NAPLES,ITALY; IST NAZL TUMORI,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT INTERNAL MED 1,YAHATONISHI KU,KITAKYUSHU,FUKUOKA 807,JAPAN; CNR,IST INT GENET & BIOFIS,I-80125 NAPLES,ITALY; UNIV UDINE,DIPARTIMENTO PATOL & MED SPERIMENTALE & CLIN,I-33100 UDINE,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; University of Occupational & Environmental Health - Japan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Udine			Casalino, Laura/C-1506-2015; Fedele, Monica/C-1417-2015; Cerutti, Janete/D-3513-2014; Miano, Maria Giuseppina/AAX-8437-2020; Giuseppina, Miano Maria/B-9169-2015; Curcio, Francesco/K-4669-2014; Battista, Sabrina/AAY-2981-2020; Visconti, Roberta/C-5299-2009; Miano, Maria Giuseppina/E-9056-2011	Casalino, Laura/0000-0002-2557-0443; Fedele, Monica/0000-0002-9171-1312; Miano, Maria Giuseppina/0000-0003-1396-9673; Battista, Sabrina/0000-0001-5899-9759; Miano, Maria Giuseppina/0000-0003-1396-9673; CURCIO, Francesco/0000-0002-9070-4807; de nigris, filomena/0000-0002-2322-1557; Visconti, Roberta/0000-0001-7613-3801; Cerutti, Janete/0000-0003-0156-8274; Fusco, Alfredo/0000-0003-3332-5197				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P409; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; Cerutti J, 1996, CLIN CANCER RES, V2, P119; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HARLOW E, 1989, IMMUNOBLOTTING LAB M; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; ZEKI K, 1993, J CLIN ENDOCR METAB, V76, P127, DOI 10.1210/jc.76.1.127	44	154	157	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1987	1994		10.1038/sj.onc.1201373	http://dx.doi.org/10.1038/sj.onc.1201373			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365245				2022-12-28	WOS:A1997YA87200013
J	Tang, JP; Feng, GS; Li, W				Tang, JP; Feng, GS; Li, W			Induced direct binding of the adapter protein Nck to the GTPase-activating protein-associated protein p62 by epidermal growth factor	ONCOGENE			English	Article						src-homology domains; adapters; receptor tyrosine kinases; signal transduction	RECEPTOR TYROSINE KINASES; ALDRICH SYNDROME PROTEIN; SRC HOMOLOGY-3 DOMAINS; SH3 DOMAINS; ACTIN POLYMERIZATION; MOLECULAR-CLONING; PHOSPHORYLATION; RAS; GAP; CELLS	The SH3-SH3-SH3-SH2 adapter protein Nck links receptor tyrosine kinases, such as EGF and PDGF receptors, to downstream signaling pathways, among which p21(cdc42/rac)-activated kinase cascade, Sos-activated Ras signaling and the human Wiskott-Aldrich Syndrome protein (WASp)-mediated actin cytoskeleton changes, have been implicated. In EGF stimulated cells, Nck coimmunoprecipitates with a number of phosphotyrosine proteins including the EGF receptor (Li et al., 1992 Mol. Cell. Biol. 12: 5824-2833). To identify the phosphotyrosine protein(s) that directly interacts with Nck and to distinguish it from indirectly associated proteins, preexisting phosphoytrosine protein complexes in the cell lysate were dissociated by heat and SDS prior to the test for binding to Nck. We found that Nck does not directly bind to EGF receptor, instead it binds via its SH2 domain to a 62 kDa phosphotyrosine protein. We present evidence demonstrating that the Nck-bound p62 is related to the previously identified GTPase-activating protein (GAP)-associated phosphotyrosine protein p62. (1) The Nck-bound and the GAP-bound p62 proteins comigrate with each other in SDS-PAGE. (2) SH2 domains from Nck and GAP compete for binding to p62 in vitro. (3) Purified GST-Nck-SH2 binds directly to the GAP-associated p62, Under these conditions, SH2 domains from PLC gamma, PI-3 kinase, SHC, and Grb2 did not bind p62. (4) Tryptic phosphopeptide maps of the Nck- and the GAP-associated p62 proteins are identical. However, Nck and GAP do not co-immunoprecipitate with each other and apparently bind to different pools of p62. This study suggests that the GAS-associated p62 acts as an SH2 domain docking protein and mediates the interaction between Nck and EGF receptor in response to EGF stimulation.	UNIV CHICAGO,BEN MAY INST CANC RES,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	University of Chicago; University of Chicago; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute					NATIONAL CANCER INSTITUTE [R01CA065567] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA65567-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1995, METHOD ENZYMOL, V255, P179; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1991, J BIOL CHEM, V266, P6808; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NEET K, 1995, MOL CELL BIOL, V15, P4908; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rockow S, 1996, ONCOGENE, V12, P2351; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	47	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1823	1832		10.1038/sj.onc.1201351	http://dx.doi.org/10.1038/sj.onc.1201351			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362449				2022-12-28	WOS:A1997XZ72500009
J	Gutmann, DH; SaporitoIrwin, S; DeClue, JE; Wienecke, R; Guha, A				Gutmann, DH; SaporitoIrwin, S; DeClue, JE; Wienecke, R; Guha, A			Alterations in the rap1 signaling pathway are common in human gliomas	ONCOGENE			English	Article						astrocytomas; tumor suppressor gene; tuberous sclerosis complex 2; tuberin	CELL-LINES; GENE; AMPLIFICATION; TUMORS; PRODUCT; TUBERIN; CDK4; OVEREXPRESSION; NEUROBLASTOMA; EXPRESSION	Several inherited predisposition to cancer syndromes are associated with the development of nervous system tumors. Tuberous sclerosis complex (TSC) is an autosomal dominant disorder in which affected individuals are at risk for developing astrocytomas. One of the genes responsible for this disorder is TSC2, located on chromosome 16p, and encoding a 180 kDa protein (tuberin) that functions in part as a negative regulator of rap1. Previous studies from our laboratory demonstrated that 30% of sporadic astrocytomas have reduced or absent tuberin expression, In addition to loss of tuberin in sporadic astrocytomas, aberrant rap1 mediated signaling may also result from overexpression of rap1. In this study, we test the hypothesis that alterations in the rap1 signaling pathway are frequently observed in certain subsets of gliomas compared to other tumors of the nervous system. Analysis of sporadic astrocytomas and ependymomas demonstrated either increased rap1 or reduced/absent tuberin protein expression in 50-60% of different cohorts of these gliomas, compared to 30-33% of sporadic schwannomas and meningiomas and none of eight oligodendrocyte tumors. These results suggest that alterations in the rap1 signaling pathway are important in the development of certain sporadic human gliomas.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; UNIV TORONTO,MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV NEUROSURG,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,TORONTO HOSP,TORONTO,ON M5T 2S8,CANADA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Gutmann, DH (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL,BOX 8111,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.			Gutmann, David/0000-0002-3127-5045				CHENG YT, 1995, MOL CARCINOGEN, V13, P173, DOI 10.1002/mc.2940130307; Geist RT, 1996, NEUROBIOL DIS, V3, P111, DOI 10.1006/nbdi.1996.0011; Gutmann DH, 1996, ONCOGENE, V12, P2121; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; HEWETT SJ, 1995, NEUROREPORT, V6, P1505; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; KHATIB ZA, 1993, CANCER RES, V53, P5535; KRAUS J, 1996, J NEUROPATH EXPER NE, V54, P91; LOUIS DN, 1995, TRENDS GENET, V11, P111; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; OLSON JJ, 1995, NEUROSURGERY, V36, P740, DOI 10.1227/00006123-199504000-00015; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; ROY NV, 1995, CANC GENET CYTOGENET, V82, P151; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; Wienecke R, 1996, ONCOGENE, V13, P913; Wienecke R, 1997, AM J PATHOL, V150, P43; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WIENECKE R, 1997, IN PRESS ANN NEUROLO; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	22	36	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1611	1616		10.1038/sj.onc.1201314	http://dx.doi.org/10.1038/sj.onc.1201314			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380414				2022-12-28	WOS:A1997XX36900013
J	Hirsch, T; Marchetti, P; Susin, SA; Dallaporta, B; Zamzami, N; Marzo, I; Geuskens, M; Kroemer, G				Hirsch, T; Marchetti, P; Susin, SA; Dallaporta, B; Zamzami, N; Marzo, I; Geuskens, M; Kroemer, G			The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death	ONCOGENE			English	Article						mitochondrial transmembrane potential; permeability transition; programmed cell death; proteases	CULTURED-HEPATOCYTES; CYCLOSPORINE-A; ICE INHIBITORS; BCL-2; INDUCTION; 1-METHYL-4-PHENYLPYRIDINIUM; IDENTIFICATION; DEPOLARIZATION; PROTECTION; GENERATION	Mitochondrial alterations including permeability transition (PT) constitute critical events of the apoptotic cascade and are under the control of Bcl-2 related gene products, Here we show that induction of PT is sufficient to activate CPP32-like proteases with DEVDase activity and the associated cleavage of the nuclear DEVDase substrate poly(ADP-ribose) polymerase (PARP). Thus, direct intervention on mitochondria using a ligand of the mitochondrial benzodiazepin receptor or a protonophore causes DEVDase activation. In addition, the DEVDase activation triggered by conventional apoptosis inducers (glucocorticoids or topoisomerase inhibitors) is prevented by inhibitors of PT. The protease inhibitor N-benzyloxycabonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD.fmk) completely prevents the activation of DEVDase and PARP cleavage, as well as the manifestation of nuclear apoptosis (chromatin condensation, DNA fragmentation, hypoploidy). In addition, Z-VAD.fmk delays the manifestation of apoptosis-associated changes in cellular redox potentials (hypergeneration of superoxide anion, oxidation of compounds of the inner mitochondrial membrane, depletion of non-oxidized glutathione), as well as the exposure of phosphatidylserine residues in the outer plasma membrane leaflet. Although Z-VAD.fmk retards cytolysis, it is incapable of preventing disruption of the plasma membrane during protracted cell culture (12-24 h), even in conditions in which it completely blocks nuclear apoptosis (chromatin condensation and DNA fragmentation). Electron microscopic analysis confirms that cells treated with PT inducers alone undergo apoptosis, whereas cells kept in identical conditions in the presence of Z-VAD.fmk die from necrosis. These observations are compatible with the hypothesis that PT would be a rate limiting step in both the apoptotic and the necrotic modes of cell death. In contrast, it would be the availability of apoptogenic proteases that would determine the choice between the two death modalities.	CNRS,UNITE PROPRE RECH 420,F-94801 VILLEJUIF,FRANCE; FREE UNIV BRUSSELS,DEPT MOL BIOL,B-1640 RHODE ST GENESE,BELGIUM	Centre National de la Recherche Scientifique (CNRS)			Susin, Santos A/Q-6754-2017; Kroemer, Guido/AAY-9859-2020; Marzo, Isabel/E-6918-2016; KROEMER, Guido/B-4263-2013	Susin, Santos A/0000-0002-3366-1628; Marzo, Isabel/0000-0002-2315-9079; KROEMER, Guido/0000-0002-9334-4405; MARCHETTI, Philippe/0000-0002-4663-6800				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ARORA AS, 1977, HEPATOLOGY, V25, P958; BERNARDI P, 1996, J BIOENERG BIOMEMBR, V28, P129; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fiskum G., 1996, Molecular Biology of the Cell, V7, p33A; ITOH G, 1995, AM J PATHOL, V146, P1325; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KROEMER G, 1995, ADV IMMUNOL, V58, P211, DOI 10.1016/S0065-2776(08)60621-5; Kroemer Guido, 1997, P1111; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marchetti P, 1996, CANCER RES, V56, P2033; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marchetti P., 1996, APOPTOSIS, V1, P119; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOTERA P, 1997, IN PRESS CELL DEATH; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; NIEMINEN AL, 1997, AM J PHYSIOL-CELL PH, V41, pC1286; OSBORNE BA, 1994, IMMUNOL REV, V142, P301, DOI 10.1111/j.1600-065X.1994.tb00894.x; Packer MA, 1996, BIOCHEM PHARMACOL, V51, P267, DOI 10.1016/0006-2952(95)02165-5; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sasaki H, 1996, TRANSPLANT P, V28, P1908; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schinder AF, 1996, J NEUROSCI, V16, P6125; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2045; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SNYDER JW, 1992, BIOCHEM PHARMACOL, V44, P833, DOI 10.1016/0006-2952(92)90425-I; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Trost LC, 1996, J PHARMACOL EXP THER, V278, P1000; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zha HB, 1996, MOL CELL BIOL, V16, P6494	58	423	434	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1573	1581		10.1038/sj.onc.1201324	http://dx.doi.org/10.1038/sj.onc.1201324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380409				2022-12-28	WOS:A1997XX36900008
J	Visser, M; Sijmons, C; Bras, J; Arceci, RJ; Godfried, M; Valentijn, LJ; Voute, PA; Baas, F				Visser, M; Sijmons, C; Bras, J; Arceci, RJ; Godfried, M; Valentijn, LJ; Voute, PA; Baas, F			Allelotype of pediatric rhabdomyosarcoma	ONCOGENE			English	Article						RMS; Rhabdomyosarcoma; alleotype; TSG, Tumor Suppressor Gene; LOH, loss of heterozygosity; SRD	TUMOR ALVEOLAR RHABDOMYOSARCOMA; BECKWITH-WIEDEMANN SYNDROME; DEPENDENT KINASE INHIBITOR; HUMAN P57(KIP2) GENE; GROWTH-FACTOR-II; WILMS-TUMORS; HEPATOCELLULAR-CARCINOMA; SUPPRESSOR GENE; ALLELIC LOSS; HETEROZYGOSITY	An allelotype covering all autosomes was constructed for the embryonal form of childhood rhabdomyosarcoma (ERMS) in order to identify regions encompassing tumorsuppressor genes (TSG) involved in ERMS. Thusfar most studies were focussed on chromosome 11p15.5,which frequently shows loss of heterozygozity (LOH) in embryonal tumors like RMS and Wilms' tumor (WT). In this study we show that, besides LOH of chromosome 11p15.5 (72%), LOH of chromosome 16q was present in 54% of the tumors analysed. Delineation of these two regions shows that the smallest region of overlap (SRO) for chromosome 11 was between D11S988 and D11S922. This region, estimated to be 7 cM and 3-5 Mb, is also the location of the putative Wilms' tumor WT2 TSG. It contains several genes including IGF2 and potential tumorsuppressor genes like H19 and p57(kip2), which might contribute to the carcinogenesis of RMS. Analysis of chromosome 16q LOH defined the SRO between D16S752 and D16S413. LOH of chromosome 16 is also found in other tumors, including WT. Our data suggest that genes involved in the development of RMS and WT may not only be similar for chromosome 11 but also for chromosome 16.	ACAD MED CTR,DEPT PEDIAT ONCOL,NL-1100 DE AMSTERDAM,NETHERLANDS; ACAD MED CTR,NEUROZINTUIGEN LAB,NL-1100 DE AMSTERDAM,NETHERLANDS; ACAD MED CTR,DEPT PATHOL,NL-1100 DE AMSTERDAM,NETHERLANDS; CHILDRENS HOSP,MED CTR,DEPT PEDIAT,DIV HEMATOL & ONCOL,CINCINNATI,OH 45229; CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation			Baas, Frank/F-9574-2010	Baas, Frank/0000-0003-3912-5428				AGAMANOLIS DP, 1986, HUM PATHOL, V17, P778, DOI 10.1016/S0046-8177(86)80198-8; AUSTRUY E, 1995, GENE CHROMOSOME CANC, V14, P285, DOI 10.1002/gcc.2870140407; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAVIS RJ, 1994, CANCER RES, V54, P2869; FUJIMORI M, 1991, CANCER RES, V51, P89; GAIGER AM, 1981, NATL CANCER I MONOGR, V56, P19; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GRUNDY PE, 1994, CANCER RES, V54, P2331; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; KNOWLES MA, 1994, CANCER RES, V54, P531; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MAW MA, 1992, CANCER RES, V52, P3094; NEWSHAM I, 1994, GENOMICS, V19, P433, DOI 10.1006/geno.1994.1091; NEWSHAM I, 1995, GENE CHROMOSOME CANC, V12, P1, DOI 10.1002/gcc.2870120102; Orlow I, 1996, CANCER RES, V56, P1219; PAPPO AS, 1995, J CLIN ONCOL, V13, P2123, DOI 10.1200/JCO.1995.13.8.2123; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Reid LH, 1996, HUM MOL GENET, V5, P239, DOI 10.1093/hmg/5.2.239; Reid LH, 1996, CANCER RES, V56, P1214; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; TSUDA H, 1994, CANCER RES, V54, P513; Visser M, 1996, P NATL ACAD SCI USA, V93, P9172, DOI 10.1073/pnas.93.17.9172; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WeberHall SR, 1996, CANCER RES, V56, P3220; WINQVIST R, 1993, CANCER RES, V53, P4486; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	41	82	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1309	1314		10.1038/sj.onc.1201302	http://dx.doi.org/10.1038/sj.onc.1201302			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315099				2022-12-28	WOS:A1997XV84500009
J	Allen, JD; Verhoeven, E; Domen, J; vanderValk, M; Berns, A				Allen, JD; Verhoeven, E; Domen, J; vanderValk, M; Berns, A			Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc	ONCOGENE			English	Article						lymphomagenesis; leukemogenesis; transgenic mice; X-inactivation; oncogene; pim-2	E-MU-MYC; MURINE LEUKEMIA-VIRUS; PUTATIVE ONCOGENE PIM-1; T-CELL LYMPHOMAS; MESSENGER-RNA; BONE-MARROW; B-CELLS; N-MYC; MICE; ACTIVATION	Evidence from proviral tagging experiments has suggested that pim-2 is similar in oncogenic behavior to its well characterized relative pim-1. While expression in tissues differs, both genes expressed in mitogenically stimulated hematopoietic cells and their transcription is induced in response to the same cytokines, Expression of a pim-2 transgene in lymphoid cells predisposed mice to T-cell lymphomas like those promoted by pim-1 transgenes, Moreover, strong collaboration with an E mu-myc transgene was manifested as pre-B cell leukemia in neonate bi-transgenic animals, Remarkably, this collaboration was attenuated but not prevented by X-inactivation of one of the transgenes. The addition of pim-2 to the fold increases the prominence of the pim proto-oncogene family in tumorigenesis.	NETHERLANDS CANC INST,DIV MOL GENET,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute								ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; ALLEN JD, 1995, J IMMUNOL, V154, P1531; ANSON R, 1989, P NATL ACAD SCI USA, V86, P8857; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BUCKLEY AR, 1995, ENDOCRINOLOGY, V136, P5252, DOI 10.1210/en.136.12.5252; CUYPERS HT, 1984, CELL, V37, P141; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; DOMEN J, 1993, LEUKEMIA, pS108; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HARRISON PTC, 1984, LAB ANIM, V18, P325, DOI 10.1258/002367784780865324; Hogan B, 1994, MANIPULATING MOUSE E; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; LILLY M, 1992, ONCOGENE, V7, P727; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; RENAULD JC, 1994, ONCOGENE, V9, P1327; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SNODGRASS HR, 1985, NATURE, V313, P592, DOI 10.1038/313592a0; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WINGETT D, 1991, J IMMUNOL, V147, P3653; YIP SM, 1995, BLOOD, V85, P3494	33	136	147	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1133	1141		10.1038/sj.onc.1201288	http://dx.doi.org/10.1038/sj.onc.1201288			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294606				2022-12-28	WOS:A1997XU99100002
J	Komatsu, M; Li, HO; Tsutsui, H; Itakura, K; Matsumura, M; Yokoyama, KK				Komatsu, M; Li, HO; Tsutsui, H; Itakura, K; Matsumura, M; Yokoyama, KK			MAZ, a Myc-associated zinc finger protein, is essential for the ME1a1-mediated expression of the c-myc gene during neuroectodermal differentiation of P19 cells	ONCOGENE			English	Article						MAZ; c-myc; ME1a1 site; gene expression	ERYTHROLEUKEMIA-CELLS; PROMOTER ACTIVITY; RETINOIC ACID; TRANSCRIPTION; LINE; COMMITMENT; SITE; E1A; PROLIFERATION; SEQUENCES	To investigate whether MAZ (Myc-associated zinc finger protein) affects the expression of the c-myc gene during the retinoic acid-induced (RA-induced) neuroectodermal differentiation of P19 embryonal carcinoma (EC) cells, we introduced a CAT reporter construct, human c-myc promoter/CAT (pMyc2CAT), and a mutant CAT derivative that lacked an ME1a1 site (pMyc1CAT) into P19EC cells tp monitor the promoter activity of the c-myc gene, The expression of CAT in pMyc2CAT-transformed cells declined fivefold after 24 h in the presence of RA, returned to the normal level within 48 h, and decreased again to below 20% of the normal level after 96 h. By contrast, the expression of CAT in pMyc1CAT-transformed cells did not return to the normal level after 48 h in the presence of RA, In addition, an electrophoretic mobility shift assay (EMSA) with ME1a1 DNA as probe demonstrated that the kinetics of the DNA-binding activity of MAZ were closely correlated with the changes in the expression of CAT from the c-myc promoter/CAT gene during the differentiation of P19EC cells, Taken together, these results suggest that MAZ plays a key role in the transient increase in the expression of the c-myc gene after 48 h of exposure to RA during the neuroectodermal differentiation of P19EC cells.	RIKEN, TSUKUBA LIFE SCI CTR, TSUKUBA, IBARAKI 305, JAPAN; CITY HOPE NATL MED CTR, BECKMAN RES INST, DEPT MOL GENET, DUARTE, CA 91010 USA; UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN	RIKEN; City of Hope; Beckman Research Institute of City of Hope; University of Tsukuba			Komatsu, Masaaki/B-8321-2011	Komatsu, Masaaki/0000-0001-7672-7722				ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASSELIN C, 1989, ONCOGENE, V4, P549; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOSSONE SA, 1992, P NATL SCI US, V89, P11498; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HALL DJ, 1990, ONCOGENE, V5, P47; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; Kawasaki H, 1996, NUCLEIC ACIDS RES, V24, P3010, DOI 10.1093/nar/24.15.3010; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MOBERG KH, 1992, ONCOGENE, V7, P411; MOBERG KH, 1991, J CELL PHYSIOL, V148, P75, DOI 10.1002/jcp.1041480110; Parks CL, 1996, J BIOL CHEM, V271, P4417; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PYRC J, 1994, INT J ONCOL, V5, P1085; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; Sambrook D.J., 1989, MOL CLONING LAB MANU; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STARNAUD R, 1988, ONCOGENE, V3, P553; Tsutsui H, 1996, BIOCHEM BIOPH RES CO, V226, P801, DOI 10.1006/bbrc.1996.1432; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Ye JP, 1996, MOL CELL BIOL, V16, P157; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	41	32	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1123	1131		10.1038/sj.onc.1201283	http://dx.doi.org/10.1038/sj.onc.1201283			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294605				2022-12-28	WOS:A1997XU99100001
J	Lorenzi, MV; Castagnino, P; Chen, Q; Chedid, M; Miki, T				Lorenzi, MV; Castagnino, P; Chen, Q; Chedid, M; Miki, T			Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations	ONCOGENE			English	Article						FGFs; cell transformation; phosphotyrosine; receptor tyrosine kinases; MAP kinases	FMS PROTO-ONCOGENE; TRANSFORMED PHENOTYPE; KINASE-ACTIVITY; POINT MUTATION; K-SAM; EXPRESSION; FGF; DOMAIN; CELLS; CLONING	To assess the effect(s) of the C-terminal domain on FGFR2 function, we engineered a series of mutant FGFR2 cDNAs encoding deletions in the C-terminus of the receptor and compared their growth properties in NIH3T3 fibroblasts, In contrast to FGFR2-WT, receptors with C-terminal truncations induced ligand-independent transformation of NIH3T3 cells and transfectants expressing these mutant receptors efficiently formed colonies in semisolid medium. Introduction of point mutations (Y to F) into the C-terminus of FGFR2 at positions 813, 784 or 780 revealed that these mutant receptors also displayed activities similar to that of C-terminally truncated receptors. C-terminally altered FGF receptors did not show an increase in the basal level of receptor phosphorylation compared to that of FGFR2-WT suggesting that elevated receptor phosphorylation does not underlie the transforming activity of these receptors. Interestingly, expression of transforming FGFR2 derivatives, unlike H-Ras transformed cells, did not result in the activation of the mitogen-activated protein kinases (MAPKs), p42/ERK2 and p44/ERK1, indicating that this pathway is not constitutively active in FGFR2-transformed cells, Finally, we report the overexpression of FGFR2 mRNA and protein in several human tumor cell lines suggesting activation of the receptor in these tumors.			Lorenzi, MV (corresponding author), NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892, USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOU JZ, 1993, PROTEIN SCI, V2, P86; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; ITOH H, 1994, CANCER RES, V54, P3237; KALIMAN P, 1993, BIOCHEMISTRY-US, V32, P9539, DOI 10.1021/bi00088a004; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; LORENZI MV, 1995, ONCOGENE, V10, P2051; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOR O, 1993, CANCER GENET CYTOGEN, V65, P111, DOI 10.1016/0165-4608(93)90217-A; PANG L, 1994, J BIOL CHEM, V269, P10604; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RON D, 1993, J BIOL CHEM, V268, P5388; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SHAOUL E, 1995, ONCOGENE, V10, P1554; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILKIE AOM, 1995, CURR BIOL, V5, P500; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAN GC, 1993, BIOCHEM BIOPH RES CO, V194, P512, DOI 10.1006/bbrc.1993.1849; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	45	22	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					817	826		10.1038/sj.onc.1201242	http://dx.doi.org/10.1038/sj.onc.1201242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266968				2022-12-28	WOS:A1997XQ11700008
J	Palmero, I; McConnell, B; Parry, D; Brookes, S; Hara, E; Bates, S; Jat, P; Peters, G				Palmero, I; McConnell, B; Parry, D; Brookes, S; Hara, E; Bates, S; Jat, P; Peters, G			Accumulation of p(16INK4a) in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status	ONCOGENE			English	Article						CDKN2a; tumor suppressor; retinoblastoma protein; SV40 T-antigen; replicative lifespan; Cdk inhibitor	TUMOR-SUPPRESSOR GENE; CYCLIN-DEPENDENT KINASES; D-CDK COMPLEXES; CELL-LINES; P16(INK4) EXPRESSION; GROWTH SUPPRESSION; LUNG CANCERS; PROTEIN; INHIBITION; P16	Viral transformation of mouse and human fibroblasts has very different effects on the composition of cyclin-dependent kinase (Cdk) complexes. In human cells transformed by the large T-antigen of simian virus 40 (SV40 T-Ag) and human tumour cell lines that lack a functional retinoblastoma gene product (pRb) no cyclin D1-Cdk4 complexes can be detected because all the available Cdk4 is associated with the Cdk-inhibitor p16(INK4a). In contrast, SV40-transformed mouse cells and fibroblasts from Rb1-nullizygous mouse embryos contain normal levels of cyclin D1-Cdk4 complexes. To investigate this species difference, we have compared the biochemical properties and expression of mouse p16(INK4a) with that of its human counterpart. There is a marked increase in p16 RNA and protein levels as primary embryo fibroblasts approach their finite lifespan in culture, but mouse p16 expression does not appear to be influenced by the status of pRb. Transformed or spontaneously immortalized mouse cells therefore do not achieve the very high levels of p16 characteristic of pRb-negative human cell lines. We suggest that these differences may be related to the different frequencies with which mouse and human cells can be immortalized in culture.	IMPERIAL CANC RES FUND,MOL ONCOL LAB,LONDON WC2A 3PX,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research			Palmero, Ignacio/B-4346-2013					AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hara E, 1996, MOL CELL BIOL, V16, P859; HEGI ME, 1994, CANCER RES, V54, P6257; HERZOG CR, 1994, CANCER RES, V54, P4007; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; Jiang P, 1995, J MOL EVOL, V41, P795; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNAPEK DF, 1995, CANCER RES, V55, P1607; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LI Y, 1994, CANCER RES, V54, P6078; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Loughran O, 1996, ONCOGENE, V13, P561; LOUGHRAN O, 1994, CANCER RES, V54, P5045; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Noble JR, 1996, ONCOGENE, V13, P1259; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PALMERO I, 1993, ONCOGENE, V8, P1049; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Reznikoff CA, 1996, CANCER RES, V56, P2886; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; TAM SW, 1994, ONCOGENE, V9, P2663; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; WASHIMI O, 1995, CANCER RES, V55, P514; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996	52	91	94	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					495	503		10.1038/sj.onc.1201212	http://dx.doi.org/10.1038/sj.onc.1201212			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247303				2022-12-28	WOS:A1997XN25500001
J	Klugbauer, S; Demidchik, EP; Lengfelder, E; Rabes, HM				Klugbauer, S; Demidchik, EP; Lengfelder, E; Rabes, HM			Molecular analysis of new subtypes of ELE/RET rearrangements, their reciprocal transcripts and breakpoints in papillary thyroid carcinomas of children after Chernobyl	ONCOGENE			English	Article						RET oncogene; RT-PCR; reciprocal transcript; breakpoint; Chernobyl	RET PROTOONCOGENE; RET/PTC ONCOGENE; REACTOR ACCIDENT; ACTIVATION; CANCER; GENES; FORM	A high prevalence of RET rearrangements is found in papillary thyroid carcinomas (PTC) of children from Belarus after the Chernobyl reactor accident. The ELE/RET rearrangement (PTC3) is prevailing. Aberrant types of ELE/RET rearrangement have been found with a truncated ELE1 gene: As compared with the common form (PTC3r1) one aberrant type is shorter by one 144 bp exon (PTC3r2) (three cases); in the second atypic form (PTC3r3) the ELE1 part is 18 bp shorter than in PTC3r1. In agreement with the observation that the oncogenic RET is generated by a paracentric inversion at chromosome 10, we found not only ELE/RET, but also RET/ELE transcripts in these tumors. Sequencing of the breakpoint regions at the genomic DNA level revealed DNA modifications that might be relevant for illegitimate recombination after DNA doublestrand breaks. The high prevalence of ELE/RET rearrangements and various subtypes appears to be typical for radiation-induced thyroid carcinomas of children after the Chernobyl reactor accident.	Univ Munich, Inst Pathol, D-80337 Munich, Germany; Med High Sch Minsk, Chair Oncol, Minsk, BELARUS; Univ Munich, Inst Radiat Biol, Munich, Germany	University of Munich; University of Munich	Rabes, HM (corresponding author), Univ Munich, Inst Pathol, Thalkirchner Str 36, D-80337 Munich, Germany.							BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BONGARZONE I, 1997, IN PRESS GENOMICS; Fugazzola L, 1996, ONCOGENE, V13, P1093; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1996, ONCOGENE, V13, P1099; Klugbauer S, 1995, ONCOGENE, V11, P2459; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; Nikiforov YE, 1997, CANCER RES, V57, P1690; RABES HM, 1997, IN PRESS VERH DTSCH; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; TSUZUKI T, 1995, ONCOGENE, V10, P191	16	58	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	1998	16	5					671	675		10.1038/sj.onc.1201526	http://dx.doi.org/10.1038/sj.onc.1201526			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482114				2022-12-28	WOS:000071816600013
J	Colitti, CV; Rodabaugh, KJ; Welch, WR; Berkowitz, RS; Mok, SC				Colitti, CV; Rodabaugh, KJ; Welch, WR; Berkowitz, RS; Mok, SC			A novel 4 cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas	ONCOGENE			English	Article						ovary; cancer; loss of heterozygosity; chromosome 6	HUMAN BORDERLINE; BREAST-CANCER; FREQUENT LOSS; ALLELE LOSS; LONG ARM; HETEROZYGOSITY; 6Q; TUMORS; ALLELOTYPE; REGION	Detailed deletion mapping of chromosome 6q has shown that the highest percentage of loss of heterozygosity (LOH) is located at 6q25-q27 and suggested that an ovarian cancer associated tumor suppressor gene may reside in this region. To further define the smallest region of common loss, we used 12 tandem repeat markers spanning a region no more than 18 cM, located between 6q25.1 and 6q26, to examine allelic loss in 54 fresh and paraffin embedded invasive ovarian epithelial tumor tissues. Loss of heterozygosity was observed more frequently at the loci defined by marker D6S473 (14 of 32 informative cases, 44%) and marker D6S448 (17 of 40 informative cases, 43%). Detailed mapping of chromosome 6q25-q26 in these tumor samples identified a 4 cM minimal region of LOH between markers D6S473 and D6S448 (6q25.1-q25.2). Loss of heterozygosity at DGS473 correlated significantly both with serous versus non-serous ovarian tumors (P=0.040) and with high grade versus low grade specimens (P=0.023). The results suggest that a 4 chi deletion unit located at 6q25.1-q25.2 may contain the putative tumor suppressor gene which may play a role in the development and progression of human invasive epithelial ovarian carcinomas (IEOC).	Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mok, SC (corresponding author), Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA069291, R01CA069453, R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA69453, R01CA63381, R01CA69291] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CLIBY W, 1993, CANCER RES, V53, P2393; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooke IE, 1996, MAMM GENOME, V7, P157, DOI 10.1007/s003359900040; DEVILEE P, 1991, ONCOGENE, V6, P1705; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; EHLEN T, 1990, ONCOGENE, V5, P219; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; IWASE H, 1995, BRIT J CANCER, V71, P448, DOI 10.1038/bjc.1995.91; LEARY JA, 1993, INT J GYNECOL CANCER, V3, P293, DOI 10.1046/j.1525-1438.1993.03050293.x; LEE JH, 1990, CANCER RES, V50, P2724; Lee WC, 1996, CANCER RES, V56, P4297; MERLO A, 1994, CANCER RES, V54, P2322; MILLIKIN D, 1991, CANCER RES, V51, P5449; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SAITO S, 1992, CANCER RES, V52, P5815; SATO T, 1991, CANCER RES, V51, P5118; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; VOLZ A, 1994, GENOMICS, V21, P464, DOI 10.1006/geno.1994.1302; Wertheim I, 1996, ONCOGENE, V12, P2147; ZHENG JP, 1991, CANCER RES, V51, P4045	28	39	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					555	559		10.1038/sj.onc.1201523	http://dx.doi.org/10.1038/sj.onc.1201523			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484846				2022-12-28	WOS:000071739400015
J	Rampalli, AM; Gao, CY; Chauthaiwale, VM; Zelenka, PS				Rampalli, AM; Gao, CY; Chauthaiwale, VM; Zelenka, PS			pRb and p107 regulate E2F activity during lens fiber cell differentiation	ONCOGENE			English	Article						differentiation; cell cycle; tumor suppressors; lens; E2F; transcription factors	TRANSCRIPTION FACTOR E2F; B-MYB TRANSCRIPTION; RETINOBLASTOMA PROTEIN; CYCLE REGULATION; IN-VIVO; TRANSGENIC MICE; FACTOR DRTF1/E2F; GENE FAMILY; MOUSE LENS; EXPRESSION	During growth arrest and differentiation, activity of the E2F family of transcription factors is inhibited by interactions with pRb and the related proteins, p107 and p130. To determine which members of the E2F and pRb families may contribute to growth arrest as lens epithelial cells differentiate into fiber cells, we examined the expression of individual E2F species and characterized the E2F protein complexes formed in rat lens epithelia and fibers. RT/PCR detected all five known members of the E2F family in lens epithelial cells, but only E2F-1, E2F-3, and E2F-5 in fiber cells. Proteins extracted from lens epithelia of newborn rats formed at least two specific complexes with an E2F consensus oligonucleotide. Proteins from lens fiber cells formed three specific complexes, one of which comigrated with an epithelial cell complex. Incubation of epithelial and fiber cell extracts with an antibody specific for p107 demonstrated that two fiber cell complexes and one epithelial cell complex contained p107. Although the remaining fiber cell complex did not react with antibodies to pRb or p130 in this assay, a strong reaction with pRb antibody was observed when the electromobility shifted complexes were subsequently immunoblotted (shift/Western assay). Immunocytochemistry confirmed that pRb protein is present in the nuclei of both epithelial cells and fiber cells. Immunoblotting of whole cell extracts with pRb antibody showed multiple, phosphorylated forms of pRb in the epithelial cells, but predominantly hypophosphorylated pRb in the fiber cells. None of the complexes formed with E2F were recognized exclusively by the p130 antibody, although the previously identified p107 complexes reacted weakly. The absence of p130/E2F complexes was correlated with the presence of multiple ubiquitinated forms of p130, especially in the fiber cells. Thus, although p130/E2F complexes are implicated in the terminal differentiation of many cell types, in differentiating lens fiber cells pRb and p107 seem to be the primary regulators of E2F activity.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Zelenka, PS (corresponding author), NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA.							ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BASSNETT S, 1992, DEV DYNAM, V194, P85, DOI 10.1002/aja.1001940202; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CORBEIL HB, 1995, ONCOGENE, V11, P909; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRIDOVICHKEIL JL, 1993, CELL GROWTH DIFFER, V4, P679; Fromm L, 1996, ONCOGENE, V12, P69; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GAO CY, 1995, DEV BIOL, V169, P185, DOI 10.1006/dbio.1995.1136; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEIBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERZINGER T, 1995, ONCOGENE, V10, P2079; HEY HY, 1997, IN PRESS DEV DYNAM; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1994, ONCOGENE, V9, P3397; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KUWABARA T, 1974, INVEST OPHTH VISUAL, V13, P973; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PEARSON BE, 1991, MOL CELL BIOL, V11, P2181; PERSONS BJ, 1970, EXP EYE RES, V9, P144, DOI 10.1016/S0014-4835(70)80069-0; PIATIGORSKY J, 1992, ADV DEV BIOCH, V1, P211; RINAUDO JAS, 1992, EXP CELL RES, V199, P147, DOI 10.1016/0014-4827(92)90472-K; Sambrook J., 2002, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VRENSEN GFJM, 1991, EXP EYE RES, V52, P647, DOI 10.1016/0014-4835(91)90017-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wells JM, 1997, J BIOL CHEM, V272, P4483, DOI 10.1074/jbc.272.7.4483; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; ZHANG YH, 1995, ONCOGENE, V10, P2085; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	73	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					399	408		10.1038/sj.onc.1201546	http://dx.doi.org/10.1038/sj.onc.1201546			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467965				2022-12-28	WOS:000071582100012
J	Stoneley, M; Paulin, FEM; Le Quesne, JPC; Chappell, SA; Willis, AE				Stoneley, M; Paulin, FEM; Le Quesne, JPC; Chappell, SA; Willis, AE			C-Myc 5 ' untranslated region contains an internal ribosome entry segment	ONCOGENE			English	Article						internal ribosome entry segment (IRES); c-myc 5 ' UTR; internal initiation; translation	MESSENGER-RNA; TRANSLATIONAL CONTROL; BURKITT-LYMPHOMA; PROMOTER USAGE; INITIATION; GENE; CELLS; ONCOGENE; TRANSLOCATION; EFFICIENCY	Translation in eukaryotic cells is generally initiated by ribosome scanning from the 5' end of the capped mRNA. However, initiation of translation may also occur by a mechanism which is independent of the cap structure and in this case ribosomes are directed to the start codon by an internal ribosome entry segment (IRES). Picornaviruses represent the paradigm for this mechanism, but only a few examples exist which show that this mechanism is used by eukaryotic cells. In this report we show data which demonstrate that the 5' UTR of the proto-oncogene c-myc contains an IRES. When a dicistronic reporter vector, with c-myc 5' UTR inserted between the two cistrons, was transfected into both HepG2 and HeLa cells, the translation of the downstream cistron was increased by 50-fold, demonstrating that translational regulation of c-myc is mediated through cap-independent mechanisms. This is the first example of a proto-oncogene regulated in this manner and suggests that aberrant translational regulation of c-myc is likely to play a role in tumorigenesis.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Le Quesne, John/0000-0003-3552-7446; Willis, Anne/0000-0002-1470-8531				AUSUBEL RM, 1987, CURRENT PROTOCOLS MO; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BORMAN A, 1992, VIROLOGY, V188, P685, DOI 10.1016/0042-6822(92)90523-R; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; BUTNICK NZ, 1985, MOL CELL BIOL, V5, P3009, DOI 10.1128/MCB.5.11.3009; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; GRAY NK, 1994, MOL BIOL REP, V19, P195, DOI 10.1007/BF00986961; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; Jackson RJ, 1995, RNA, V1, P985; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; NILSEN TW, 1984, MOL CELL BIOL, V4, P2235, DOI 10.1128/MCB.4.10.2235; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; Paulin FEM, 1996, ONCOGENE, V13, P505; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; West MJ, 1995, ONCOGENE, V11, P2515; WINNEPENNINCKX B, 1995, BIOTECHNIQUES, V18, P1060; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; ZUKER M, 1989, METHOD ENZYMOL, P262	30	281	300	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					423	428		10.1038/sj.onc.1201763	http://dx.doi.org/10.1038/sj.onc.1201763			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467968				2022-12-28	WOS:000071582100015
J	Wiggan, O; Taniguchi-Sidle, A; Hamel, PA				Wiggan, O; Taniguchi-Sidle, A; Hamel, PA			Interaction of the pRB-family proteins with factors containing paired-like homeodomains	ONCOGENE			English	Article						mhox; paired-like homeodomain; PGX-3; pRB	EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTOR E2F; C-MET RECEPTOR; RETINOBLASTOMA PROTEIN; TYROSINE KINASE; DNA-BINDING; HUMAN PAPILLOMAVIRUSES; TERMINAL SEQUENCES; CRYSTAL-STRUCTURE; GENE-EXPRESSION	The specific loss of pRB or p107 together with p130 disrupts the normal development of only a very limited spectrum of tissues. These developmental defects have been attributed primarily to deregulation of E2F activity and consequent uncontrolled proliferation. We hypothesized, however, that the tissue-specific nature of these defects may also reflect deregulation of pRB-family associated factors that are specifically involved in determining cell fate. We report here that the pRB-family members interact with transcription factors which contain paired-like homeodomains such as MHox, Chx10 and Pax-3. The interaction between the pRB-family and the paired-like homeodomain proteins was initially identified in a yeast two-hybrid screen where the N-terminal portion of p130 was used to isolate interacting factors from an embryonic mouse library. This interaction was confirmed by in vitro binding and co-immunoprecipitation assays. We show further that coexpression of Pax-3 dependent pRB, p107 or p130 with Pax-3 causes repression of activated transcription from the c-met promoter. These data demonstrate that the pRB-family proteins can modulate the activity of factors which specifically control cell fate and/or differentiation as well as controlling cell cycle regulators.	Univ Toronto, Dept Pathol, Toronto, ON M5S 1A8, Canada	University of Toronto	Hamel, PA (corresponding author), Univ Toronto, Dept Pathol, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.							BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BUCK V, 1995, ONCOGENE, V11, P31; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CORBEIL HB, 1995, ONCOGENE, V11, P909; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; Daston G, 1996, DEVELOPMENT, V122, P1017; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWLEY PM, 1991, COLD SPRING HARB SYM, V56, P149; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; HUNT T, 1989, NATURE, V342, P483, DOI 10.1038/342483a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; PRUITT SC, 1992, DEVELOPMENT, V116, P573; Rao MV, 1996, MOL CELL BIOL, V16, P3909; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHERR C, 1996, 12 ANN M ONC FRED MA; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; SLACK RS, 1993, ONCOGENE, V8, P1585; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Yang XM, 1996, DEVELOPMENT, V122, P2163; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZHAO GQ, 1993, P NATL ACAD SCI USA, V90, P8633, DOI 10.1073/pnas.90.18.8633	85	69	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					227	236		10.1038/sj.onc.1201534	http://dx.doi.org/10.1038/sj.onc.1201534			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464541	Green Published			2022-12-28	WOS:000071427100010
J	Dahia, PLM; Aguiar, RCT; Honegger, J; Fahlbush, R; Jordan, S; Lowe, DG; Lu, X; Clayton, R; Besser, GM; Grossman, AB				Dahia, PLM; Aguiar, RCT; Honegger, J; Fahlbush, R; Jordan, S; Lowe, DG; Lu, X; Clayton, R; Besser, GM; Grossman, AB			Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours	ONCOGENE			English	Article						Cushing's disease; ACTH-tumour; p27-kip1; mutation; carcinoid; cell cycle inhibitor; pituitary tumour	DEPENDENT KINASE INHIBITOR; HUMAN PITUITARY-TUMORS; GROWTH-FACTOR-BETA; RETINOBLASTOMA GENE; P27(KIP1) GENE; CDK INHIBITOR; MICE LACKING; CELL-CYCLE; P27; G1	The molecular mechanisms leading to Cushing's disease are unclear, Inhibitors of cyclin-cyclin dependent kinase (CDK) complexes are regulators of the cell cycle and may function as tumour suppressor genes, many of which have been involved in the pathogenesis of several human malignancies, A member of this family, the p27/kip1 gene, maps to chromosome 12p13 and encodes an inhibitor of several cyclin-CDK complexes; these control the progression of the cell cycle from G1 to S-phase, Complete lack of p27/kip1 function, as occurs in the p27/kip1 'knockout' mouse, produces a complex phenotype associated with the development of pituitary tumours, specifically those of the intermediate lobe corticotrophs, We therefore investigated whether structural and functional abnormalities of the p27/kip1 gene and loss at the chromosome 12p13 region were present in human corticotrophin (ACTH)-secreting pituitary tumours, We studied 21 pituitary tumours, of which 20 were ACTH-secreting (two of these had biochemical and histological features of 'intermediate-lobe' tumours and one was malignant) while the remaining tumour was a prolactinoma; three ectopic secretors of ACTH (two bronchial and one thymic carcinoid); and a non-secretory thymic carcinoid, The whole coding region of the p27/kip1 gene was screened for mutations by PGR-SSCP analysis and/or direct sequencing, while tumour mRNA expression was analysed by means of a semi-quantitative duplex PGR, Three polymorphic microsatellite markers of the 12p13 region were used to assess loss of heterozygosity (LOH) in 12 samples, Finally, tumour p27/kip1 protein expression was assessed by immunohistochemistry using a monoclonal antibody in 12 samples suitable for analysis, No sequence abnormalities were found in any of the samples other than a previously-described polymorphism, No LOH was observed in the tumours analysed, p27/kip1 mRNA expression was similar in tumour samples in comparison with normal pituitaries, Seven of the eight corticotroph tumours analysed by immunohistochemistry stained positive for p27/kip1, including the intermediate lobe, The only malignant pituitary tumour in the original series showed an absence of staining for p27/kip1, In addition, the three carcinoid tumours studied were negative on immunohistochemistry. Of a further three malignant pituitary tumours assessed, two (including a prolactinoma) were essentially negative, while the third was moderately positive, We conclude that mutations of the p27/kip1 gene, deletions of the 12p13 area or changes in expression, are not a general feature of corticotroph tumours, even those with intermediate lobe characteristics, However, other mechanisms of p27/kip1 inactivation, such as an abnormality at the post-translational level, may be related to more aggressive histological subtypes of ACTH-secreting and possibly other pituitary tumours.	St Bartholomews Hosp, Dept Endocrinol, London, England; St Bartholomews Hosp, Dept Pathol, London, England; Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA; Univ Erlangen Nurnberg, Neurochirurg Klin, D-8520 Erlangen, Germany; St Marys Hosp, Ludwig Inst Canc Res, London, England; Univ Keele, Postgrad Med Sch, Dept Med, Stoke On Trent, Staffs, England	University of London; Queen Mary University London; University of London; Queen Mary University London; Harvard University; Dana-Farber Cancer Institute; University of Erlangen Nuremberg; Imperial College London; Ludwig Institute for Cancer Research; Keele University	Grossman, AB (corresponding author), St Bartholomews Hosp, Dept Endocrinol, London, England.			Lu, Xin/0000-0002-6587-1152				BATES AS, 1995, CLIN ENDOCRINOL, V42, P663, DOI 10.1111/j.1365-2265.1995.tb02697.x; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; Dahia PLM, 1996, J CLIN ENDOCR METAB, V81, P1768, DOI 10.1210/jc.81.5.1768; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; HALE AC, 1988, CLIN ENDOCRINOL, V28, P215, DOI 10.1111/j.1365-2265.1988.tb03658.x; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERMAN V, 1993, J CLIN ENDOCR METAB, V77, P50, DOI 10.1210/jc.77.1.50; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LEVY A, 1994, CLIN ENDOCRINOL, V41, P809, DOI 10.1111/j.1365-2265.1994.tb02797.x; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lloyd RV, 1997, AM J PATHOL, V150, P401; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NORTON AJ, 1994, J PATHOL, V173, P371, DOI 10.1002/path.1711730413; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Qian X, 1996, ENDOCRINOLOGY, V137, P3051, DOI 10.1210/en.137.7.3051; Ravitz MJ, 1996, J CELL PHYSIOL, V168, P510, DOI 10.1002/(SICI)1097-4652(199609)168:3<510::AID-JCP3>3.0.CO;2-S; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Spirin KS, 1996, CANCER RES, V56, P2400; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Woloschak M, 1996, INT J CANCER, V67, P16, DOI 10.1002/(SICI)1097-0215(19960703)67:1<16::AID-IJC4>3.0.CO;2-2	34	91	98	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					69	76		10.1038/sj.onc.1201516	http://dx.doi.org/10.1038/sj.onc.1201516			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467944				2022-12-28	WOS:000071236800008
J	Bardelli, A; Longati, P; Gramaglia, D; Stella, MC; Comoglio, PM				Bardelli, A; Longati, P; Gramaglia, D; Stella, MC; Comoglio, PM			Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential	ONCOGENE			English	Article						HGF/MET-receptor; Gab1; transformation	HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; MET RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; PROTEIN; ONCOGENE; GENE	Activation of the HGF receptor, encoded by the c-MET protooncogene (Met receptor), triggers motility, matrix-invasion and branching morphogenesis in epithelial cells. It has recently been shown that the Met receptor interacts with Gab-1, an IRS-like adaptor protein, via the docking site (Y(1349)VHVNATY(1356)VNV) known to bind Grb2 and multiple SH2-containing signal transducers. Here we show that Gab1 is the major phosphorylation-substrate of the Met receptor and of its oncogenic variant Tpr-Met. A series of point mutations in the docking site established a direct correlation between the ability to recruit and phosphorylate Gab1 and the transforming potential, Interestingly. the mutations of either Y-1356 or N-1358 abolished the binding of both Grb2 and Gab1 in intact cells, Furthermore, peptides designed to block either the SH2 or the SH3 domains of Grb2 interfered,vith the receptor-Gab1 interaction, These data indicate that Gab1 coupling to the Met receptor requires binding of Grb2 and correlates with the transforming potential of Tpr-Met.	Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Bardelli, A (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Candiolo, Italy.		GRAMAGLIA, DANIELA/A-6354-2012; BARDELLI, Alberto/J-9721-2018	BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328; Gramaglia, Daniela/0000-0001-6259-0059				BARDELLI A, 1997, IN PRESS BIOCH BIOPH; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; FIXMAN ED, 1995, ONCOGENE, V10, P237; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORDANO S, 1997, IN PRESS P NATL ACAD; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; NALDINI L, 1991, EMBO J, V10, P2687; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PONZETTO P, 1996, J BIOL CHEM, V271, P14119; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	24	110	120	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3103	3111		10.1038/sj.onc.1201561	http://dx.doi.org/10.1038/sj.onc.1201561			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444958				2022-12-28	WOS:000070968000010
J	Flores, JF; Pollock, PM; Walker, GJ; Glendening, JM; Lin, AHT; Palmer, JM; Walters, MK; Hayward, NK; Fountain, JW				Flores, JF; Pollock, PM; Walker, GJ; Glendening, JM; Lin, AHT; Palmer, JM; Walters, MK; Hayward, NK; Fountain, JW			Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds	ONCOGENE			English	Article						CDKN2A; CDKN2B; CDK4; melanoma; familial; mutation	CUTANEOUS MALIGNANT-MELANOMA; KINASE-4 INHIBITOR GENE; FAMMM SYNDROME FAMILIES; CELL-CYCLE ARREST; HOMOZYGOUS DELETIONS; MUTATIONAL ANALYSIS; GERMLINE MUTATIONS; SPORADIC MELANOMA; CHROMOSOME 9P; HUMAN CANCERS	Germline mutations within the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and one of its targets, the cyclin dependent kinase 4 (CDK4) gene, have been identified in a proportion of melanoma kindreds, In the case of CDK4, only one specific mutation, resulting in the substitution of a cysteine for an arginine at codon 24 (R24C), has been found to be associated with melanoma. We have previously reported the identification of germline CDKN2A mutations in 7/18 Australian melanoma kindreds and the absence of the R24C CDK4 mutation in 21 families lacking evidence of a CDKN2A mutation. The current study represents an expansion of these efforts and includes a total of 48 melanoma families from Australia. All of these families have now been screened for mutations within CDKN2A and CDK4, as well as for mutations within the CDKN2A homolog and 9p21 neighbor, the CDKN2B gene, and the alternative exon 1 (E1 beta) of CDKN2A. Families lacking CDKN2A mutations, but positive for a polymorphism(s) within this gene, were further evaluated to determine if their disease was associated with transcriptional silencing of one CDKN2A allele, Overall, CDKN2A mutations were detected in 3/30 (10%) of the new kindreds. Two of these mutations have been observed previously: a 24 bp duplication at the 5' end of the gene and a G to C transversion in exon 2 resulting in an M53I substitution. A novel G to A transition in exon 2, resulting in a D108N substitution was also detected, Combined with our previous findings, we have now detected germline CDKN2A mutations in 10/48 (21%) of our melanoma kindreds, In none of the 'CDKN2A-negative' families was melanoma found to segregate with either an untranscribed CDKN2A allele, an R24C CDK4 mutation, a CDKN2B mutation, or an E1 beta mutation. The last three observations suggest that these other cell cycle control genes (or alternative gene products) are either not involved at all, or to any great extent, in melanoma predisposition.	UNIV SO CALIF,INST MED GENET,DEPT BIOCHEM & MOL BIOL,LOS ANGELES,CA 90033; QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES UNIT,HERSTON,QLD 4029,AUSTRALIA	University of Southern California; QIMR Berghofer Medical Research Institute			hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020; Walker, Graeme J/C-2548-2012	hayward, nicholas k/0000-0003-4760-1033; Walker, Graeme J/0000-0002-9392-8769; Pollock, Pamela/0000-0001-8420-1026	NATIONAL CANCER INSTITUTE [R01CA066021] Funding Source: NIH RePORTER; NCI NIH HHS [CA66021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Borg A, 1996, CANCER RES, V56, P2497; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; Dracopoli NC, 1996, CANCER SURV, V26, P115; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Flores JF, 1996, CANCER RES, V56, P5023; FOUKES WD, 1997, MOL MED, V3, P5; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GLENDENING JM, 1995, CANCER RES, V55, P5531; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; GRUIS NA, 1995, AM J PATHOL, V146, P1199; GRUIS NA, 1993, MELANOMA RES, V3, P271; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOLLAND EA, 1994, ONCOGENE, V9, P1361; Holland EA, 1995, ONCOGENE, V11, P2289; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSHIKI K, 1994, ONCOGENE, V9, P1649; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LIU Q, 1995, ONCOGENE, V10, P1061; LUCA M, 1995, ONCOGENE, V11, P1399; LUI L, 1995, ONCOGENE, V11, P405; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MACLENNAN R, 1992, J NCI, V84, P1437; MAO L, 1995, CANCER RES, V55, P2995; NANCARROW DJ, 1993, AM J HUM GENET, V53, P96; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; Ohta M, 1996, INT J CANCER, V65, P762, DOI 10.1002/(SICI)1097-0215(19960315)65:6<762::AID-IJC9>3.0.CO;2-X; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Platz A, 1996, BRIT J CANCER, V73, P344, DOI 10.1038/bjc.1996.59; POLLOCK PM, 1995, ONCOGENE, V11, P663; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; WALKER GJ, 1994, MELANOMA RES, V4, P29, DOI 10.1097/00008390-199402000-00005; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	45	67	67	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2999	3005		10.1038/sj.onc.1201470	http://dx.doi.org/10.1038/sj.onc.1201470			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416844				2022-12-28	WOS:A1997YK37700013
J	Tymms, MJ; Ng, AYN; Thomas, RS; Schutte, BC; Zhou, JO; Eyre, HJ; Sutherland, GR; Seth, A; Rosenberg, M; Papas, T; Debouck, C; Kola, I				Tymms, MJ; Ng, AYN; Thomas, RS; Schutte, BC; Zhou, JO; Eyre, HJ; Sutherland, GR; Seth, A; Rosenberg, M; Papas, T; Debouck, C; Kola, I			A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer	ONCOGENE			English	Article						transcription factor; lung cancer; breast cancer; ETS; ELF; prostate cancer	DNA-BINDING SPECIFICITIES; TRANSCRIPTION FACTOR PU.1; HUMAN-BREAST-CANCER; T-CELLS; ONCOGENE FAMILY; MOLECULAR CHARACTERIZATION; CHROMOSOMAL TRANSLOCATION; MYELOMONOCYTIC LEUKEMIA; DIFFERENTIAL EXPRESSION; INSITU HYBRIDIZATION	The ETS family of genes are implicated in cancers such as Ewings sarcoma, acute myeloid leukemia and chronic myelomoncytic leukemia. Further, they have important functions in embryonic development. Hence, identification and characterization of members of this family are important. We identify a novel ETS family member, ELF3, and report its human and murine cDNA sequences. The mouse cDNA has an alternatively spliced transcript with an extra 60 bp inserted. Hence we present the organization of the murine Elf3 gene together with its exon/intron structure. This gene consists of 9 exons and 8 introns spanning 4.8 kb. ELF3 binds and transactivates ETS sequences and interestingly also shows the ability to bind a GGAT-Iike purine core, a preferential ETS1/ETS2 type binding site. The expression of ELF3, unlike most other ETS family members, is absent in hematopoietic cells and hematopoietic organs in humans and mice. Intriguingly, the gene is specifically expressed in cell lines of epithelial origin and in organs such as lung, stomach, intestine, kidney that have specialized epithelial cells. We localize the human gene to 1q32.2, a region that is amplified in epithelial tumors of the breast, lung and prostate. Finally, we show that ELF3 expression is increased in a lung carcinoma and adenocarcinoma, as compared to normal tissue. ELF3 is also expressed in cell lines derived from lung cancers. These results suggest that this novel ETS gene may be involved in lung tumorigenesis.	MONASH UNIV,INST REPROD & DEV,MOL GENET & DEV GRP,MELBOURNE,VIC 3168,AUSTRALIA; UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52242; WOMENS & CHILDRENS HOSP,CTR MED GENET,DEPT CYTOGENET & MOL GENET,ADELAIDE,SA 5006,AUSTRALIA; UNIV TORONTO,FAC MED,DEPT PATHOL,TORONTO,ON,CANADA; UNIV TORONTO,FAC DENT,TORONTO,ON,CANADA; WOMENS COLL HOSP,TORONTO,ON MDS 1A8,CANADA; SMITHKLINE BEECHAM PHARMACEUT,KING OF PRUSSIA,PA 19406; MED UNIV S CAROLINA,HOLLINGS ONCOL CTR,CTR MOL & STRUCT BIOL,CHARLESTON,SC 29425	Monash University; University of Iowa; Womens & Childrens Hospital Australia; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; GlaxoSmithKline; Medical University of South Carolina			Thomas, Ross/C-6434-2008; Kola, Ismail/C-5254-2013; Sutherland, Grant Robert/D-2606-2012		NICHD NIH HHS [P30-HD-27748] Funding Source: Medline; NIDCR NIH HHS [2P50-DE-09170] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE009170] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adachi J, 1996, COMPUTER SCI MONOGRA; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; BARRIOS L, 1990, CANCER GENET CYTOGEN, V49, P107, DOI 10.1016/0165-4608(90)90170-F; BELLO MJ, 1990, INT J CANCER, V45, P50, DOI 10.1002/ijc.2910450111; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BRITOBABAPULLE V, 1981, CANCER GENET CYTOGEN, V4, P215, DOI 10.1016/0165-4608(81)90015-7; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CHEN JH, 1990, ONCOGENE RES, V5, P277; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DOUGLASS EC, 1985, J NATL CANCER I, V75, P51; EYRE HJ, 1993, CYTOGENET CELL GENET, V62, P181, DOI 10.1159/000133467; FLETCHER JC, 1995, DEVELOPMENT, V121, P1411; Gambarotta G, 1996, ONCOGENE, V13, P1911; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HART AH, 1995, ONCOGENE, V10, P1423; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HROMAS R, 1994, INT J HEMATOL, V59, P257; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; IDA K, 1995, INT J CANCER, V63, P500, DOI 10.1002/ijc.2910630407; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KLEMSZ M, 1994, GENOMICS, V20, P291, DOI 10.1006/geno.1994.1169; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KUO CJ, 1991, EMBO J, V10, P2231, DOI 10.1002/j.1460-2075.1991.tb07759.x; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; LUKEIS R, 1993, GENE CHROMOSOME CANC, V8, P262, DOI 10.1002/gcc.2870080409; MAO XH, 1994, J BIOL CHEM, V269, P18216; MESNARD L, 1995, CIRC RES, V76, P687, DOI 10.1161/01.RES.76.4.687; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; OKA HH, 1993, CANCER RES, V53, P5104; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; OSHIMURA M, 1976, J NATL CANCER I, V56, P183, DOI 10.1093/jnci/56.1.183; PANDIS N, 1992, GENE CHROMOSOME CANC, V5, P235, DOI 10.1002/gcc.2870050310; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; REICHMANN A, 1984, CANCER GENET CYTOGEN, V12, P295, DOI 10.1016/0165-4608(84)90062-1; RIED T, 1995, CANCER RES, V55, P5415; SCHULZ RA, 1993, ONCOGENE, V8, P3369; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; THE SM, 1992, ONCOGENE, V7, P2471; THOMAS RS, 1995, ONCOGENE, V11, P2135; THOMAS RS, 1997, IN PRESS ONCOGENE, V14; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; Tymms M J, 1995, Methods Mol Biol, V37, P31; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WELTE T, 1994, EUR J BIOCHEM, V223, P997, DOI 10.1111/j.1432-1033.1994.tb19078.x; WERNERT N, 1992, AM J PATHOL, V140, P119; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; Wu JE, 1996, DEV DYNAM, V206, P169, DOI 10.1002/(SICI)1097-0177(199606)206:2<169::AID-AJA6>3.0.CO;2-G; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang BS, 1996, MOL CELL BIOL, V16, P538; YIP MY, 1991, CANCER GENET CYTOGEN, V51, P235, DOI 10.1016/0165-4608(91)90136-I; ZUTTER MM, 1993, AM J PATHOL, V142, P1439	97	126	135	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2449	2462		10.1038/sj.onc.1201427	http://dx.doi.org/10.1038/sj.onc.1201427			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395241				2022-12-28	WOS:A1997YE96300007
J	DuflotDancer, A; Mesnil, M; Yamasaki, H				DuflotDancer, A; Mesnil, M; Yamasaki, H			Dominant-negative abrogation of connexin-mediated cell growth control by mutant connexin genes	ONCOGENE			English	Article						gap junction; cell-cell communication; tumor suppression; Cx26	MARIE-TOOTH DISEASE; JUNCTIONAL INTERCELLULAR COMMUNICATION; TUMOR-SUPPRESSOR GENES; C6 GLIOMA-CELLS; GAP-JUNCTIONS; LIVER TUMOR; MUTATIONS; PROTEIN; CDNA; TRANSFECTION	Connexin genes exert negative growth control when transfected into various types of tumor cell lines, We previously demonstrated that connexin 26 (Cx26) suppresses in vitro and in vivo growth of HeLa cells, In this study, we have examined whether certain Cx26 mutants can abrogate cell growth control and the gap junctional intercellular communication (GJIC) capacity of such Cx26-transfected HeLa cells, For this purpose, we transfected three mutated Cx26 genes (C60F, P87L and R143W) into HeLa cells already containing the wild-type Cx26 gene, which are GJIC-competent and non-tumorigenic. Transfection of P87L and R143W mutants enhanced the tumorigenicity of the HeLa Cx26 cells in nude mice without any change in GJIC capacity, On the other hand, transfection of the C60F mutant reduced the GJIC capacity of HeLa Cx26 cells without affecting their growth in vivo. Immunostaining studies demonstrated that the Cx26 proteins were localized mainly at cell-cell contact areas in the Hel,a Cx26 cells both before and after transfection of mutated Cx26 genes, These results suggest that certain mutant Cx26 proteins exert a dominant-negative effect on Cx26-regulated growth of HeLa cells and that such effects may be independent of the effect on GJIC ability, It is proposed that wild-type and mutant Cx26 proteins produce heteromeric connexons and that such heteromeric connexons may exert different effects on growth control from those of homomeric connexons.	INT AGCY RES CANC,UNIT MULTISTAGE CARCINOGENESIS,F-69372 LYON 08,FRANCE	World Health Organization; International Agency for Research on Cancer (IARC)				Mesnil, Marc/0000-0003-4922-0365	NATIONAL CANCER INSTITUTE [R01CA040534] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-40534] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BRUZZONE R, 1994, NEURON, V13, P1253, DOI 10.1016/0896-6273(94)90063-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dahl E, 1996, J BIOL CHEM, V271, P17903, DOI 10.1074/jbc.271.30.17903; deFeijter AW, 1996, MOL CARCINOGEN, V16, P203, DOI 10.1002/(SICI)1098-2744(199608)16:4<203::AID-MC4>3.3.CO;2-F; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FAIRWEATHER N, 1994, HUM MOL GENET, V3, P29, DOI 10.1093/hmg/3.1.29; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; Krutovskikh V, 1996, CARCINOGENESIS, V17, P1761, DOI 10.1093/carcin/17.8.1761; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; MESNIL M, 1993, MOL CARCINOGEN, V7, P14, DOI 10.1002/mc.2940070103; MESNIL M, 1993, EUR J PHARM-ENVIRON, V248, P59, DOI 10.1016/0926-6917(93)90025-L; MIRONOV NM, 1994, CANCER RES, V54, P41; NAUS CCG, 1992, CANCER RES, V52, P4208; Omori Y, 1996, CARCINOGENESIS, V17, P2077, DOI 10.1093/carcin/17.9.2077; Omori Y, 1996, MOL BIOL CELL, V7, P907, DOI 10.1091/mbc.7.6.907; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; Saito T, 1997, CANCER RES, V57, P375; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SATO K, 1997, IN PRESS NEUROPATHOL; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	33	73	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2151	2158		10.1038/sj.onc.1201393	http://dx.doi.org/10.1038/sj.onc.1201393			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393973				2022-12-28	WOS:A1997YD01900003
J	Blagosklonny, MV				Blagosklonny, MV			Loss of function and p53 protein stabilization	ONCOGENE			English	Review						p53; stabilization; mutant; transactivating function	TUMOR-SUPPRESSOR PROTEIN; CANCER CELL-LINES; MUTANT P53; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; BREAST-CANCER; METABOLIC STABILIZATION; ACTIVATING MUTATIONS; DNA-BINDING; T-ANTIGEN	Wild-type (wt) p53 protein is rapidly degraded, has a short half-life and low intracellular levels. Stabilization of wt p53 protein following an appropriate stimulus (for example DNA damage) is a physiological regulation to increase function. Tn contrast, stabilization of p53 protein in the absence of a stimulus is always a hallmark of loss of function secondary to a mutation, or interaction with viral or cellular oncoproteins. It is generally accepted that stability of p53 protein depends on its intrinsic biochemical properties such as conformation or protein/protein interactions. However, I will discuss evidence that the stability of p53 is not a consequence of its intrinsic properties, but instead is determined by feedback control of its function. In the absence of an appropriate stimulus, a cell needs to keep p53 levels low, since increased levels can lead to apoptosis. To precisely regulate p53 levels, a cell must sense its level; and sensing its transactivating function, is the simplest way to sense p53. Following an appropriate stimulus (for example, DIVA damage), the cell senses a state of 'relative' p53 deficiency and adapts by reducing p53 degradation. When the state of p53 deficiency is a consequence of a mutation or interaction with viral oncoproteins, the cell does not sense p53, and again attempts to adapt by reducing p53 degradation. However, in the latter case, the increase in levels does not restore function, and the adaptation continues until degradation of p53 protein is maximally inhibited. In this case, no further inhibition of degradation is possible after DNA-damage or pharmacological inhibition of proteasomes. Thus lack of wt p53 function always results in increased p53 levels and nonregulation.			Blagosklonny, MV (corresponding author), NCI,MED BRANCH,NIH,BLDG 10,BETHESDA,MD 20892, USA.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; BRAITHWAITE A, 1989, J VIROL, V63, P1782; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEITRICH C, 1996, P NATL ACAD SCI USA, V93, P10815; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DEPPERT W, 1989, CURR TOP MICROBIOL, V144, P77; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; ELLEDGE RM, 1994, CANCER RES, V54, P3752; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; KUBBUTAT MH, 1997, MOL CELL BIOL, V17, P4680; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATHESWARAN S, 1995, GENE DEV, V96, P2143; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROLLEY N, 1995, ONCOGENE, V11, P763; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TISHLER RB, 1995, CANCER RES, V55, P6021; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOJTESEK B, 1993, J CELL SCI, V105, P607; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZHANG W, 1994, ONCOGENE, V9, P2513; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	67	125	127	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1889	1893		10.1038/sj.onc.1201374	http://dx.doi.org/10.1038/sj.onc.1201374			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365234				2022-12-28	WOS:A1997YA87200002
J	Duh, FM; Scherer, SW; Tsui, LC; Lerman, MI; Zbar, B; Schmidt, L				Duh, FM; Scherer, SW; Tsui, LC; Lerman, MI; Zbar, B; Schmidt, L			Gene structure of the human MET proto-oncogene	ONCOGENE			English	Article						MET proto-oncogene; HGF/SF receptor; renal carcinoma	RENAL-CELL CARCINOMA; TYROSINE KINASE; C-MET; GROWTH-FACTOR; HGF RECEPTOR; OVEREXPRESSION; SEQUENCE; MUTATION; LINE; KIT	By direct sequencing of cosmids using primers designed from the known cDNA sequence, we identified 19 exons in the human MET proto-oncogene, and sequenced the corresponding 5' and 3' exon-intron junctions. By homology search in the database of the Washington University Genome Sequence Center (GSC), we identified one additional exon. These 20 exons, together with a previously reported exon, bring the total exon number of MET to 21. Oligonucleotide primers were designed to amplify each exon and adjacent intronic sequences to permit examination of each exon for mutations. By restriction mapping, we assembled a 110 kb genomic contig that covered almost the entire MET protooncogene, This information is relevant for the screening of recently reported mutations of the MET gene which cause hereditary papillary renal carcinomas and for the search for additional mutations of the same gene which may play a role in the pathogenesis of common human carcinomas including carcinomas of the breast, ovary and pancreas.	NCI,INTRAMURAL RES SUPPORT PROGRAM,SAIC FREDERICK,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; NCI,IMMUNOBIOL LAB,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Tsui, Lap-chee/A-1081-2010; Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDRE C, 1992, ONCOGENE, V7, P685; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KWOK JBJ, 1993, ONCOGENE, V8, P2575; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1991, ONCOGENE, V6, P553; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZBAR B, 1994, J UROLOGY, V151, P561, DOI 10.1016/S0022-5347(17)35015-2; ZBAR B, 1995, J UROLOGY, V153, P907, DOI 10.1016/S0022-5347(01)67601-8	17	44	45	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1583	1586		10.1038/sj.onc.1201338	http://dx.doi.org/10.1038/sj.onc.1201338			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380410				2022-12-28	WOS:A1997XX36900009
J	Zimmermann, S; Rommel, C; Ziogas, A; Lovric, J; Moelling, K; Radziwill, G				Zimmermann, S; Rommel, C; Ziogas, A; Lovric, J; Moelling, K; Radziwill, G			MEK1 mediates a positive feedback an Raf-1 activity independently of Ras and Src	ONCOGENE			English	Article						feedback loop; mitogen-activated protein kinase cascade; MEK1; Raf-1 activation	PROTEIN-TYROSINE-PHOSPHATASE; MAP KINASE-KINASE; PLASMA-MEMBRANE; PHOSPHORYLATION; ACTIVATION; C-RAF-1; INSULIN; IDENTIFICATION; MUTANTS; BINDING	Growth factor stimulated receptor tyrosine kinases activate a protein kinase cascade via the serine/threonine protein kinase Raf-1, Direct upstream activators of Raf-1 are Ras and Src, This study shows that MEK1, the direct downstream effector of Raf-1, can also stimulate Raf-1 kinase activity by a positive feedback loop, Activated MEK1 mediates hyperphosphorylation of the amino terminal regulatory as well as of the carboxy terminal catalytic domain of Raf-1. The hyperphosphorylation of Raf-1 correlates with a change in the tryptic phosphopeptide pattern only at terminus of Raf-1 and an increase in activity, MEK1-mediated Raf-1 activation is inhibited by co-expression of the MAPK specific phosphatase MKP-1 indicating that the MEK1 effect is exerted through a MAPK dependent pathway. Stimulation of Raf-1 activity by MEK1 is independent of Ras, Src and tyrosine phosphorylation of Raf-1, MEK1 can however synergize with Ras and leads to further increase of the Raf-1 kinase activity, Thus, MEK1 can mediate activation of Raf-1 by a novel positive feedback mechanism which allows fast signal amplification and could prolong activation of Raf-1.	UNIV ZURICH, INST MED VIROL, CH-8028 ZURICH, SWITZERLAND	University of Zurich				Lovric, Josip/0000-0002-0338-6581				AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Alessandrini A, 1996, J BIOL CHEM, V271, P31612, DOI 10.1074/jbc.271.49.31612; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENT P, 1995, MOL CELL BIOL, V15, P4125; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Holt KH, 1996, MOL CELL BIOL, V16, P577; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; JOHN J, 1988, J BIOL CHEM, V263, P11792; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Lovric J, 1996, ONCOGENE, V12, P1109; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NEBREDA AR, 1994, TRENDS BIOCHEM SCI, V19, P1, DOI 10.1016/0968-0004(94)90163-5; NIEHOF M, 1995, BIOCHEM BIOPH RES CO, V206, P46, DOI 10.1006/bbrc.1995.1007; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; Radziwill G, 1996, BIOCHEM BIOPH RES CO, V227, P20, DOI 10.1006/bbrc.1996.1461; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUEN KL, 1995, SCIENCE, V264, P1463; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; UEKI K, 1994, J BIOL CHEM, V269, P15756; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	50	29	30	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1503	1511		10.1038/sj.onc.1201322	http://dx.doi.org/10.1038/sj.onc.1201322			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380402				2022-12-28	WOS:A1997XX36900001
J	Ziebold, U; Klempnauer, KH				Ziebold, U; Klempnauer, KH			Linking Myb to the cell cycle: cyclin-dependent phosphorylation and regulation of A-Myb activity	ONCOGENE			English	Article						A-myb; cell cycle; cyclins A and E; phosphorylation; transactivation	DNA-POLYMERASE-ALPHA; PROTEIN-KINASE; RETINOBLASTOMA PROTEIN; S-PHASE; C-MYB; V-MYB; TRANSCRIPTIONAL ACTIVATOR; MAMMALIAN FIBROBLASTS; GENE-EXPRESSION; G(1) CYCLINS	A-myb, a conserved member of the Myb proto-oncogene family, encodes a sequence-specific DNA binding protein (A-Myb) that binds to and transactivates promoters containing myb-binding sites, Previous work has suggested that the C-terminus of A-Myb functions as a regulatory domain, however, the physiological signals that control the activity of A-Myb have not yet been identified, The presence of potential phosphorylation sites for cyclin-dependent kinases in the C-terminus of A-Myb has prompted us to examine the possibility that the function of A-Myb is controlled by the cell cycle. We here show that the transactivation potential of A-Myb is repressed by the C-terminal domain and that phosphorylation of A-Myb, induced by cyclins A and E, relieves this inhibitory effect, Our work provides the first evidence that the function of A-Myb is regulated by the cell cycle machinery and that the carboxy-terminal domain of A-Myb acts as a cell cycle sensor, In addition, we show that A-myb mRNA expression is also cell cycle regulated and attains maximal levels during the late G(1)- and early S-phase, Thus, A-Myb appears to be controlled by two different mechanisms maximal A-Myb activity during the G(1)/S-transition and the S-phase of the cell cycle.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY; UNIV FREIBURG,KINDERKLIN,D-79106 FREIBURG,GERMANY	Max Planck Society; University of Freiburg			Ziebold, Ulrike/N-4487-2013					AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FOOS G, 1994, ONCOGENE, V9, P2481; FROST V, 1995, J BIOL CHEM, V270, P26698, DOI 10.1074/jbc.270.44.26698; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Golay J, 1996, BLOOD, V87, P1900; GOLAY J, 1994, ONCOGENE, V9, P2469; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAM EWF, 1992, ONCOGENE, V7, P1885; Latham KE, 1996, ONCOGENE, V13, P1161; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MASSAGUE J, 1995, CURR OPIN CELL BIOL, V7, P769, DOI 10.1016/0955-0674(95)80059-X; METTUS RV, 1994, ONCOGENE, V9, P3077; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Sitzmann J, 1996, ONCOGENE, V12, P1889; Sitzmann J, 1995, ONCOGENE, V11, P2273; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5894; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMMEL A, 1994, ONCOGENE, V9, P995; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	56	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1011	1019		10.1038/sj.onc.1201282	http://dx.doi.org/10.1038/sj.onc.1201282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285555				2022-12-28	WOS:A1997XT16100002
J	Fei, ZL; Xu, SQ; Dews, M; Baserga, R				Fei, ZL; Xu, SQ; Dews, M; Baserga, R			Co-operation of Simian virus 40 T antigen and insulin receptor substrate-1 in protection from apoptosis induced by interleukin-3 withdrawal	ONCOGENE			English	Article						T antigen; IRS-1; apoptosis	GROWTH-FACTOR-I; LARGE TUMOR-ANTIGEN; HEMATOPOIETIC-CELLS; TRANSFORMING ACTIVITY; PHOSPHORYLATION; FIBROBLASTS; EXPRESSION; IGF-1; MITOGENESIS; INHIBITION	32D cells are interleukin-3 (IL-3) dependent murine hemopoietic cells, that undergo apoptosis after IL-3 withdrawal. An overexpressed insulin-like growth factor I receptor (IGF-IR) protects these cells from apoptosis induced by IL-3 withdrawal. When 32D cells are stably transfected with plasmids expressing either IRS-1 (a major substrate of the IGF-IR) or the Simian virus 40 large T antigen, singly, they still undergo apoptosis after IL-3 withdrawal, although IRS-1 offers partial protection. The cells, however, are fully protected when they are stably transfected with both IRS-1 and SV40 T antigen. Protection from apoptosis in these cells is characterized by the stabilization of the Stat1 and Stat5 protein levels, whose synthesis is inhibited when IL-3 is withdrawn.	THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NCI NIH HHS [CM 33694] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARONICA MG, 1996, ONCOGENE, V13, P1917; ASKEW DS, 1991, ONCOGENE, V6, P1915; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1997, VITAM HORM, V53, P65, DOI 10.1016/S0083-6729(08)60704-9; BLANDINO G, 1995, ONCOGENE, V10, P731; Campos SP, 1996, J BIOL CHEM, V271, P24418, DOI 10.1074/jbc.271.40.24418; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DAmbrosio C, 1996, CANCER RES, V56, P4013; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HALDAR S, 1994, BIOCHEM CELL BIOL, V72, P455, DOI 10.1139/o94-061; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Hongo A, 1996, ONCOGENE, V12, P1231; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IHLE JN, 1995, NATURE, V377, P291; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; Jung YK, 1996, J BIOL CHEM, V271, P5112; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Lenahan MK, 1996, ONCOGENE, V12, P1847; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Morrione A, 1996, CANCER RES, V56, P3165; MYERS MG, 1994, J BIOL CHEM, V269, P28783; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Parrizas M, 1997, J BIOL CHEM, V272, P154; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; RUBIN R, 1995, LAB INVEST, V73, P311; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Singleton JR, 1996, CANCER RES, V56, P4522; Soddu S, 1996, MOL CELL BIOL, V16, P487; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; ULLRICH A, 1986, EMBO J, V5, P503; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V369, P1; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; Yenush L, 1996, MOL CELL BIOL, V16, P2509; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232; ZUMSTEIN PP, 1985, P NATL ACAD SCI USA, V82, P3169, DOI 10.1073/pnas.82.10.3169	66	47	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					961	970		10.1038/sj.onc.1201265	http://dx.doi.org/10.1038/sj.onc.1201265			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285691				2022-12-28	WOS:A1997XR76700009
J	Maier, D; Comparone, D; Taylor, E; Zhang, ZW; Gratzl, O; Van Meir, EG; Scott, RJ; Merlo, A				Maier, D; Comparone, D; Taylor, E; Zhang, ZW; Gratzl, O; Van Meir, EG; Scott, RJ; Merlo, A			New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26	ONCOGENE			English	Article						oligodendroglioma; glioblastoma suppressor gene; deletion mapping; chromosome 10q25-26	HUMAN-BRAIN-TUMORS; HUMAN GLIOMAS; GENE; HETEROZYGOSITY; RETINOBLASTOMA; MUTATIONS; ORIGIN	Loss of heterozygosity on chromosome 10 is considered to be associated with the progression of glioblastomas. Two closely related regions have recently been proposed to contain the glioblastoma suppressor locus on chromosome 10q25-26; a 1 cM region between the polymorphic (CA)(n)-repeat markers D10S587 and D10S216, and an area of 5 cM between the markers D10S221 and D10S209, To confirm and further delineate this region, we analyzed 51 glioblastomas and 11 intermediate and low-grade gliomas for loss of heterozygosity on chromosome 10, 47/62 mostly malignant gliomas displayed complete loss of chromosome 10 and nine tumors were unaltered, whereas four glioblastomas and two low-grade oligodendrogliomas had partial loss on distal 10q, With these six tumors, we constructed a deletion map with increased marker density at 10q25-26 which shows two centromeric breakpoints at the markers D10S587 and D10S216, thus only confirming the distal, but not the proximal candidate glioblastoma suppressor locus, Two out of four low-grade oligodendrogliomas displayed partial deletions on 10q25-26, This suggests that deletion on chromosome 10 is not merely a late event in the progression of glioblastomas, but could play a role earlier in the development of gliomas.	UNIV BASEL HOSP, DEPT RES, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DEPT NEUROSURG, CH-4031 BASEL, SWITZERLAND; CHU VAUDOIS, LAB TUMOR BIOL & GENET, DEPT NEUROSURG, UNIV HOSP, CH-1011 LAUSANNE, SWITZERLAND	University of Basel; University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Scott, Rodney J/B-2827-2013	Scott, Rodney J/0000-0001-7724-3404; Van Meir, Erwin G./0000-0003-2444-7707				Albarosa R, 1996, AM J HUM GENET, V58, P1260; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GYAPAY G, 1994, NAT GENET, V7, P294; JAMES CD, 1988, CANCER RES, V48, P5546; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; Kleihues P, 1993, HISTOLOGICAL TYPING; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MERLO A, 1994, CANCER RES, V54, P640; Moschonas N. K., 1996, Cytogenetics and Cell Genetics, V72, P99, DOI 10.1159/000134172; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; VENTER DJ, 1991, BRIT J CANCER, V63, P753, DOI 10.1038/bjc.1991.168; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WU JK, 1993, J NEURO-ONCOL, V15, P29, DOI 10.1007/BF01050260	23	44	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					997	1000		10.1038/sj.onc.1201209	http://dx.doi.org/10.1038/sj.onc.1201209			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285695				2022-12-28	WOS:A1997XR76700013
J	Larsson, LG; Bahram, F; Burkhardt, H; Luscher, B				Larsson, LG; Bahram, F; Burkhardt, H; Luscher, B			Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells	ONCOGENE			English	Article						cell growth control; c-Myc; Mad1; oncoprotein	CASEIN KINASE-II; C-MYC PROTEIN; TRANSCRIPTIONAL ACTIVATION; RAS COTRANSFORMATION; OPPOSITE REGULATION; ONCOGENIC ACTIVITY; REPRESSOR SIN3; MAX; MXI1; TRANSFORMATION	The bHLHZip protein Max interacts with both the Myc and Mad family proteins forming heterodimers which specifically bind certain E-box DIVA recognition sequences, thereby regulating transcription, Whereas Myc proteins actively promote cell proliferation, Mad complexes have the opposite function, Although the main regulation of this network seems to be the control of myc- and mad family gene expression, regulation at the level of DNA-binding and transactivation may also be in operation, Few studies on the DNA-binding activity of native Myc:Max or Max:Mad complexes have been reported mainly due to technical difficulties, To overcome these problems we have developed a specific and sensitive solid phase DNA-binding assay based on partial purification of native Myc, Max and Mad1 complexes by immunological methods, Using this technique we report that the DNA-binding activity of c-Myc-containing complexes is reduced during induced differentiation of U-937 monoblasts and F9 embryonic teratocarcinoma cells. In contrast, the DNA-binding of Mad1-containing complexes increases during monocytic differentiation, In general, the DNA-binding activity of c-Myc and Mad1 correlate with their expression, However, our studies of early kinetics of TPA-induced differentiation of U-937 cells as well as of late events during F9 differentiation suggest that post-translational regulation of Myc and Max DNA-binding may also occur. The solid phase DNA-binding assay may thus provide a tool to study the regulation of DNA-binding in more detail.	HANNOVER MED SCH,INST MOL BIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School	Larsson, LG (corresponding author), UNIV UPPSALA,DEPT PATHOL,LAB TUMOR BIOL,S-75185 UPPSALA,SWEDEN.		Larsson, Lars-Gunnar/D-9747-2012; Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1993, ONCOGENE, V8, P3211; CERNI C, 1995, ONCOGENE, V11, P587; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DELGADO MD, 1995, ONCOGENE, V10, P1659; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HAN T, 1980, J CLIN LAB IMMUNOL, V4, P169; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIHARA H, 1974, NATL I ANIM HEALTH Q, V14, P163; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LARSSON LG, 1994, ONCOGENE, V9, P1247; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Nilsson K., 1980, INT S NEW TRENDS HUM, P271; NISHIKORI M, 1984, CANCER GENET CYTOGEN, V12, P39, DOI 10.1016/0165-4608(84)90006-2; OBERG F, 1991, P NATL ACAD SCI USA, V88, P5567, DOI 10.1073/pnas.88.13.5567; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	52	34	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					737	748		10.1038/sj.onc.1201390	http://dx.doi.org/10.1038/sj.onc.1201390			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264414				2022-12-28	WOS:A1997XP68300013
J	Grandis, JR; Chakraborty, A; Melhem, MF; Zeng, Q; Tweardy, DJ				Grandis, JR; Chakraborty, A; Melhem, MF; Zeng, Q; Tweardy, DJ			Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells	ONCOGENE			English	Article						epidermal growth factor receptor; head and neck cancer	FACTOR-ALPHA; EGF-RECEPTOR; BREAST-CANCER; TGF-ALPHA; MONOCLONAL-ANTIBODIES; PSEUDOMONAS EXOTOXIN; TYROSINE KINASE; FUSION PROTEIN; MESSENGER-RNA; TUMOR-GROWTH	Previous reports have shown that fresh tissues and cell lines from patients with squamous cell carcinoma of the head and neck (SCCHN) overexpress transforming growth factor alpha (TGF-alpha) and its receptor, the epidermal growth factor receptor (EGFR) at both the mRNA and protein levels. Protein localization studies confirm that TGF-alpha and EGFR are produced by the same epithelial cells in tissues from head and neck cancer patients further supporting an autocrine growth pathway. Using three strategies, we examined the hypothesis that downmodulation of EGFR would reduce the proliferation of SCCHN cells. We targeted EGFR mRNA using antisense oligonucleotides and the mature EGFR protein at two sites, the ligand-binding domain and the kinase domain, and determined the effects of this targeting on SCCHN proliferation. Treatment of several SCCHN cell lines with a pair of antisense oligodeoxynucleotides directed against the translation start site and first intron-exon splice junction of the human EGFR gene resulted in decreased EGFR protein production and inhibited growth by 86% compared to a 13% reduction in cells treated with sense oligonucleotides (P=0.03). Growth inhibition was specific for carcinoma cells since the same EGFR antisense oligonucleotides had no effect on the proliferation of normal mucosa cells harvested from non-cancer patients. Two monoclonal antibodies which block ligand binding to EGFR (MAbs 425 and 528) inhibited the growth of several SCCHN cell lines by up to 97% which suggests that EGFR is participating in an autocrine pathway in SCCHN that is, at least in part, external. An EGFR-specific tyrosine kinase inhibitor (PD 153035) was found to inhibit EGFR phosphorylation in SCCHN cell lines and to reduce growth by 68% although it had no effect on the growth rate of normal mucosal epithelial cells. These experiments indicate that EGFR gene expression and function is critical for SCCHN cell growth but not for growth of normal mucosa cells and therefore may serve as a tumor-specific target for preventive and therapeutic strategies in head and neck cancer.	UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,DEPT OTOLARYNGOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,DEPT MED & MOL GENET & BIOCHEM,PITTSBURGH,PA 15213; UNIV PITTSBURGH,INST CANC,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Tweardy, David/L-3929-2019		NCI NIH HHS [1 K11 CA01760-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001760] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATLAS I, 1992, CANCER RES, V2, P3353; BASELGA J, 1994, PHARMACOL THERAPEUT, V64, P127, DOI 10.1016/0163-7258(94)90036-1; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; BASELGA J, 1994, BREAST CANCER RES TR, V29, P127, DOI 10.1007/BF00666188; CHRISTENSEN ME, 1992, EUR ARCH OTO-RHINO-L, V249, P243, DOI 10.1007/BF00714485; DERUI L, 1992, AM J CLIN ONCOL-CANC, V15, P288, DOI 10.1097/00000421-199208000-00003; DIFORE PP, 1992, CANC TREAT RES, V61, P139; DIMARCO E, 1989, ONCOGENE, V4, P831; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; EISBRUCH A, 1987, CANCER RES, V47, P3603; FAN Z, 1993, CANCER RES, V53, P4322; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Grandis JR, 1996, CANCER-AM CANCER SOC, V78, P1284, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; HALEY J, 1987, ONCOGENE RES, V1, P375; HARRIS AL, 1989, CANCER CEL, V7, P353; HEO DS, 1989, CANCER RES, V49, P5167; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; KAMEYAMA S, 1994, J CANCER RES CLIN, V120, P507, DOI 10.1007/BF01221026; KAWAMOTO T, 1991, JPN J CANCER RES, V82, P403, DOI 10.1111/j.1349-7006.1991.tb01863.x; Kelloff GJ, 1996, CANCER EPIDEM BIOMAR, V5, P657; KENNEY NJ, 1993, J CELL PHYSIOL, V156, P497, DOI 10.1002/jcp.1041560309; KIHARA A, 1994, BIOCONJUGATE CHEM, P532; LAIRD AD, 1994, CANCER RES, V54, P4224; LEMAISTRE CF, 1992, BLOOD, V82, pA444; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MAXWELL SA, 1989, CANCER RES, V49, P1130; MORISHIGE KI, 1991, CANCER RES, V51, P5322; MORONI MC, 1992, J BIOL CHEM, V267, P2714; MURTHY U, 1990, BIOCHEM BIOPH RES CO, V172, P471, DOI 10.1016/0006-291X(90)90696-K; NICHOLSON S, 1988, BRIT J CANCER, V58, P810, DOI 10.1038/bjc.1988.315; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PHILLIPS PC, 1994, CANCER RES, V54, P1008; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RIKIMARU K, 1992, HEAD NECK-J SCI SPEC, V14, P8, DOI 10.1002/hed.2880140103; RODECK U, 1987, CANCER RES, V47, P3692; SACCHI M, 1990, CANCER RES, V50, P3113; SAINSBURY JRC, 1987, LANCET, V1, P1398; SHIN DM, 1994, CANCER RES, V54, P3153; THEUER CP, 1993, J UROLOGY, V149, P1626, DOI 10.1016/S0022-5347(17)36464-9; TODD R, 1989, CARCINOGENESIS, V10, P1553, DOI 10.1093/carcin/10.8.1553; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; WEICHSELBAUM RR, 1989, HEAD NECK-J SCI SPEC, V11, P437, DOI 10.1002/hed.2880110510; YAMAMOTO T, 1986, CANCER RES, V46, P414	46	103	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					409	416		10.1038/sj.onc.1201188	http://dx.doi.org/10.1038/sj.onc.1201188			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242377				2022-12-28	WOS:A1997XM23800005
J	Thomas, J; Leverrier, Y; Marvel, J				Thomas, J; Leverrier, Y; Marvel, J			Bcl-X is the major pleiotropic anti-apoptotic gene activated by retroviral insertion mutagenesis in an IL-3 dependent bone marrow derived cell line	ONCOGENE			English	Article						apoptosis; Bcl-X; IL-3; retroviral insertion mutagenesis	ICE FAMILY PROTEASES; C-ELEGANS; HEMATOPOIETIC-CELLS; DEATH; INTEGRATION; BCL-X(L); MYC; SURVIVAL; SITES; INTERLEUKIN-3	In order to identify genes capable of inhibiting apoptosis induced by different pathways, without inducing proliferation we have performed retroviral insertion mutagenesis in the IL-3 dependent bone marrow derived Baf-3 cell line, Out of 200 mutants obtained in three separate mutagenesis experiments, four mutants were resistant to multiple apoptosis inducing pathways (including growth factor starvation, staurosporine, etoposide and cyclosporin A) and did not proliferate in the absence of IL-3, These four mutants overexpress the bcl-X gene following a retroviral insertion 5' of the translation initiation site, These results indicate that the bcl-X gene is a major pleiotropic anti-apoptotic gene in Baf-3 cells, They also suggest that the Bcl-2 family of genes might be the only one capable of inhibiting apoptosis induced by multiple pathways without inducing cell proliferation.	ENS Lyon, LBMC, CNRS UMR 49 INRA LA 913, F-69364 Lyon 07, France	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Marvel, J (corresponding author), ENS Lyon, LBMC, CNRS UMR 49 INRA LA 913, 46 Allee Italie, F-69364 Lyon 07, France.		marvel, jacqueline/H-8638-2014; LEVERRIER, Yann/M-3767-2014	marvel, jacqueline/0000-0001-6241-459X; LEVERRIER, Yann/0000-0002-4227-5446; Thomas, Joelle/0000-0002-0461-6131				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COFFIN J M, 1991, P645; COSSET FL, 1995, J VIROL, V69, P6314, DOI 10.1128/JVI.69.10.6314-6322.1995; CUYPERS HT, 1984, CELL, V37, P141; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENGELMAN A, 1994, BIOESSAYS, V16, P797, DOI 10.1002/bies.950161105; FANG W, 1994, J IMMUNOL, V153, P4388; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Gotoh A, 1997, Curr Opin Hematol, V4, P3; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LEVERRIER Y, 1996, TUMOR BIOL, P176; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Mangeney M, 1996, ONCOGENE, V13, P1441; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MARVEL J, 1994, ONCOGENE, V9, P1117; Mielke C, 1996, BIOCHEMISTRY-US, V35, P2239, DOI 10.1021/bi952393y; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nass SJ, 1996, BIOCHEM BIOPH RES CO, V227, P248, DOI 10.1006/bbrc.1996.1497; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; ROBINSON HL, 1986, J VIROL, V57, P28, DOI 10.1128/JVI.57.1.28-36.1986; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sorensen AB, 1996, J VIROL, V70, P4063; STOCKING C, 1993, GROWTH FACTORS, V8, P197, DOI 10.3109/08977199309011023; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Vairo G, 1996, ONCOGENE, V13, P1511; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	56	22	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1399	1408		10.1038/sj.onc.1201672	http://dx.doi.org/10.1038/sj.onc.1201672			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525739				2022-12-28	WOS:000072572400004
J	Laursen, NB; Kessler, R; Frohli, E; Klemenz, R				Laursen, NB; Kessler, R; Frohli, E; Klemenz, R			Effects of ras transformation on the induction of the IL-1 receptor related T1 gene in response to mitogens, anisomycin, IL-1 and TNF alpha	ONCOGENE			English	Article						anisomycin; IL-1R family; IL-1; TNF alpha; MAP kinases; SB203580; signal transduction pathway; ras oncogene	ACTIVATED PROTEIN-KINASE; MURINE ST2 GENE; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; SIGNAL-TRANSDUCTION PATHWAYS; TUMOR-NECROSIS-FACTOR; NIH 3T3 FIBROBLASTS; HEAT-SHOCK PROTEINS; MAP KINASE; INTERLEUKIN-1 RECEPTOR; C-JUN	The T1 gene gives rise to two transcripts encoding a 62 kDa membrane-bound and a 37 kDa secreted protein with similarity to the type I IL-1 receptor. It is weakly expressed in proliferating but not in resting fibroblasts and is strongly induced during the entry of quiescent cells into the cell cycle. Here we show that the T1 gene is also transcriptionally activated in response to the treatment of fibroblasts with cycloheximide and anisomycin. These protein synthesis inhibitors are known to stimulate the JNK and p38/RK signal transduction pathways. We provide evidence that anisomycin triggers T1 gene induction through the stimulation of the p38/RK MAP kinase. This observation is in line with our finding that physiological activators of the p38/RK pathway, the proinflammatory cytokines IL-1 and TNF alpha, stimulate T1 gene expression efficiently. Growth factor mediated T1 gene induction is a delayed early event, requiring ongoing protein synthesis. In contrast, anisomycin induces T1 gene expression at concentrations which block translation completely. Thus, transcriptional induction of the T1 gene via the p38/RK pathway is an immediate early event not requiring de novo protein synthesis. The T1 gene is strongly induced by various mitogens in quiescent NIH3T3 fibroblasts but not in ras transformed NIH3T3 cells. In contrast, all of the three tested agent which activate the p38/RK pathway, IL-1, TNF alpha, and anisomycin led to strong T1 gene expression in normal and ras transformed NIH3T3 cells alike. Thus, the T1 gene can be induced through the activation of at least two MAP kinase pathways: signaling through the ERK pathway can occur in normal but not in ras transformed NIH3T3 cells, whereas the signaling through the p38/RK pathway is not affected by ras transformation.	Univ Zurich Hosp, Dept Pathol, Div Canc Res, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Klemenz, R (corresponding author), Univ Zurich Hosp, Dept Pathol, Div Canc Res, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.							ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P240; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CANO E, 1995, J CELL SCI, V108, P3599; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DANESCU J, 1995, FEBS LETT, V367, P89, DOI 10.1016/0014-5793(95)00542-H; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Gachter T, 1996, J BIOL CHEM, V271, P124; Gayle MA, 1996, J BIOL CHEM, V271, P5784, DOI 10.1074/jbc.271.10.5784; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KALOUSEK MB, 1994, J BIOL CHEM, V269, P6866; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KUMAR S, 1995, J BIOL CHEM, V270, P27905, DOI 10.1074/jbc.270.46.27905; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1991, GENES INDUCED SERUM, P257; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Parnet P, 1996, J BIOL CHEM, V271, P3967; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; REIKERSTORFER A, 1995, J BIOL CHEM, V270, P17645, DOI 10.1074/jbc.270.30.17645; ROSSLER U, 1993, ONCOGENE, V8, P609; ROSSLER U, 1995, DEV BIOL, V168, P86, DOI 10.1006/dbio.1995.1063; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIMS JE, 1995, CYTOKINE, V7, P483, DOI 10.1006/cyto.1995.0066; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SYMONS JA, 1995, P NATL ACAD SCI USA, V92, P1714, DOI 10.1073/pnas.92.5.1714; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P194, DOI 10.1016/0167-4889(93)90009-E; TOMINAGA S, 1992, BIOCHIM BIOPHYS ACTA, V1171, P215, DOI 10.1016/0167-4781(92)90125-J; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1, DOI 10.1016/0167-4781(91)90029-L; TRUB T, 1994, P NATL ACAD SCI USA, V91, P3896, DOI 10.1073/pnas.91.9.3896; TSONIS PA, 1988, NUCLEIC ACIDS RES, V16, P7745, DOI 10.1093/nar/16.15.7745; WERENSKIOLD AK, 1992, EUR J BIOCHEM, V204, P1041, DOI 10.1111/j.1432-1033.1992.tb16726.x; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; YANAGISAWA K, 1992, FEBS LETT, V302, P51, DOI 10.1016/0014-5793(92)80282-L; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	69	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					575	586		10.1038/sj.onc.1201522	http://dx.doi.org/10.1038/sj.onc.1201522			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482103	Bronze			2022-12-28	WOS:000071816600002
J	Caruana, G; Cambareri, AC; Gonda, TJ; Ashman, LK				Caruana, G; Cambareri, AC; Gonda, TJ; Ashman, LK			Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement	ONCOGENE			English	Article						c-Kit; SLF; transformation; anchorage independence; receptor density	STEM-CELL FACTOR; COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR; EGF RECEPTOR; MAST-CELLS; SIGNAL-TRANSDUCTION; PROTO-ONCOGENE; NEURONAL DIFFERENTIATION; MONOCLONAL-ANTIBODIES	Ectopic expression of the normal murine receptor tyrosine kinase, c-Kit, in NIH3T3 cells induced many phenotypic changes characteristic of transformation including anchorage-independent growth, focus formation and tumorigenicity in nude mice, Although transformation was largely dependent on the presence of recombinant murine Steel Factor (SLF), the ligand to the c-Kit receptor, anchorage independent growth did occur at a low frequency in the absence of added factor, and this could not be inhibited by neutralising antibodies or by SLF anti-sense mRNA, Clones from factor-independent colonies in semi-solid agar displayed a narrow range of c-Kit surface protein levels (4.3-6.4 x 10(4) receptors/cell) which was relatively high compared with the pool from which they were derived, Analysis of a larger series of random clones derived from adherent cultures expressing different levels of c-Kit demonstrated a positive correlation between SLF-dependent, anchorage-independent growth and c-Kit protein and mRNA expression levels (respectively, R-S = 0.58, P < 0.01; and R-S = 0.53, P < 0.01) with consistent colony formation observed with clones having > 2.5 x 10(4) receptors/cell, Interestingly, two of the three clones expressing the highest levels of c-Kit protein and mRNA produced few or no colonies in the presence or absence of SLF, Sequential overexpression of human c-KIT in NIH3T3 cells using a dihydrofolate reductase (DHFR)-encoding vector and gene co-amplification through methotrexate selection, which resulted in pools expressing up to 1.5 x 10(5) receptors/cell, confirmed that high receptor densities resulted in a decrease in colony numbers, Thus, analysis of clonal and selected populations has indicated that an optimal level of c-Kit is required for transformation of NIH3T3 cells in the presence of SLF, and that some ligand-independent transformation occurs.	Inst Med & Vet Sci, Div Haematol, Leukaemia Res Unit, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Div Human Immunol, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia	Ashman, LK (corresponding author), Inst Med & Vet Sci, Div Haematol, Leukaemia Res Unit, Box 14,Rundle Mall PO, Adelaide, SA 5000, Australia.		ASHMAN, LEONIE/G-7631-2013; Gonda, Thomas J/A-3620-2012	ASHMAN, LEONIE/0000-0003-3559-3611; 				ALEXANDER WS, 1991, EMBO J, V10, P3683, DOI 10.1002/j.1460-2075.1991.tb04936.x; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ASHMAN LK, 1988, LEUKEMIA RES, V12, P923, DOI 10.1016/0145-2126(88)90020-3; AYLETT G, 1995, LEUCOCYTE TYPING V W, V2, P1917; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CARUANA G, 1993, EXP HEMATOL, V21, P761; CHOO KH, 1986, DNA-J MOLEC CELL BIO, V5, P529, DOI 10.1089/dna.1.1986.5.529; COLE SR, 1989, IMMUNOL CELL BIOL, V67, P377, DOI 10.1038/icb.1989.54; Cole SR, 1996, LEUKEMIA, V10, P288; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FERRAO P, 1997, IN PRESS BLOOD, V90; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GRAHAM FL, 1980, INTRO MACROMOLECULES, P3; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERBST R, 1995, ONCOGENE, V10, P369; HIBI K, 1991, ONCOGENE, V6, P2291; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; IRANI AMA, 1992, BLOOD, V80, P3009; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JOZAKI K, 1991, EXP HEMATOL, V19, P185; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; KERN JA, 1990, CANCER RES, V50, P5184; KISS C, 1993, LEUKEMIA, V7, P235; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LERNER NB, 1991, BLOOD, V77, P1876; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LIU E, 1992, ONCOGENE, V7, P1027; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MAYRHOFER G, 1987, IMMUNOL CELL BIOL, V65, P241, DOI 10.1038/icb.1987.27; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OCONNOR CG, 1982, J IMMUNOL METHODS, V54, P267, DOI 10.1016/0022-1759(82)90068-0; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; QUI F, 1988, EMBO J, V7, P1003; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RIEDEL H, 1987, SCIENCE, V236, P197, DOI 10.1126/science.3494307; ROSNET O, 1991, ONCOGENE, V6, P1641; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SASAKI K, 1995, BLOOD, V85, P1220, DOI 10.1182/blood.V85.5.1220.bloodjournal8551220; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Zar JH., 1999, BIOSTAT ANAL	60	24	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					179	190		10.1038/sj.onc.1201494	http://dx.doi.org/10.1038/sj.onc.1201494			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464535				2022-12-28	WOS:000071427100004
J	Carstens, RP; Eaton, JV; Krigman, HR; Walther, PJ; Garcia-Blanco, MA				Carstens, RP; Eaton, JV; Krigman, HR; Walther, PJ; Garcia-Blanco, MA			Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer	ONCOGENE			English	Article						prostate cancer; alternative splicing; androgen sensitivity; fibroblast growth factor receptors; xenograft cell lines	CARCINOMA CELL-LINE; EPITHELIAL-CELLS; EXPRESSION; GENES; ESTABLISHMENT; SPECIFICITY; CLONING; MODEL; KGF	Progression of prostate cancer from sensitive to androgen insensitive tumor been shown to be accompanied by a change in alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in a rat model of prostate cancer, This change results in loss of the FGF-R2(IIIb) isoform and predominant expression of the FGF-R2(IIIc) isoform, We sought to determine whether this change in FGF-R2 splicing is also associated with androgen insensitivity in human prostate tumors, We analysed three web characterized human prostate cancer cell lines and three metastatic prostate tumors which have been maintained as xenografts in nude mice, One of the cell lines, LNCaP, and two of the xenografts, DUKAP-1 and DUKAP-2, have been characterized as androgen sensitive, whereas two of the cell lines, DU-145 and PC-3, and one of the xenografts, DU9479, display androgen independent growth, Using an RT-PCR based assay, me demonstrated that progressive loss of the FGF-R2(111b) isoform correlated with androgen insensitivity in these human prostate cancer models. These findings lend support to the hypothesis that that loss of FGF-R2(IIIb) may be one step in a series of events which lead to progression of human prostate cancer.	Duke Univ, Med Ctr, Dept Mol Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Nephrol, Durham, NC USA; Duke Univ, Med Ctr, Dept Med, Durham, NC USA; Duke Univ, Med Ctr, Div Urol, Durham, NC USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC USA; Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Durham, NC USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Duke University	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Mol Canc Biol, Durham, NC 27710 USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BRIGATI DJ, 1988, J HISTOTECHNOL, V11, P165, DOI 10.1179/his.1988.11.3.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EPSTEIN JI, 1983, HUM PATHOL, V15, P853; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GLEAVE ME, 1992, J UROLOGY, V147, P1151, DOI 10.1016/S0022-5347(17)37506-7; GRAHAM SD, 1985, PROSTATE, V7, P369, DOI 10.1002/pros.2990070405; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; ISAACS JT, 1978, CANCER RES, V38, P4353; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAIGHN ME, 1979, INVEST UROL, V17, P16; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; MANSSON PE, 1989, CANCER RES, V49, P2485; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCKEEHAN WL, 1991, CANCER SURV, V11, P165; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	32	128	134	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3059	3065		10.1038/sj.onc.1201498	http://dx.doi.org/10.1038/sj.onc.1201498			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444954				2022-12-28	WOS:000070968000006
J	Nikiforov, MA; Kwek, SSS; Mehta, R; Artwohl, JE; Lowe, SW; Das Gupta, T; Deichman, GI; Gudkov, AV				Nikiforov, MA; Kwek, SSS; Mehta, R; Artwohl, JE; Lowe, SW; Das Gupta, T; Deichman, GI; Gudkov, AV			Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence	ONCOGENE			English	Article						p53; apoptosis; bcl-2; metastasis; anchorage dependence; circulation	PROGNOSTIC-SIGNIFICANCE; P53 MUTATIONS; BREAST-CANCER; EXPRESSION; CELLS; ASSOCIATION; CARCINOMA; TUMORS; GENE; PROGRESSION	Mutations in the p53 tumor suppressor gene are frequently associated with the metastatic stage of tumor progression, Inactivation of p53 was shown to promote metastasis under experimental conditions, To determine the p53 functions that are involved in the control of tumor metastasis, we compared properties of three types of transformed mouse fibroblasts: with intact p53, with p53-mediated apoptosis suppressed by bcl-2 and with p53 inactivated by dominant negative mutants, Although expression of bcl-2 blocked apoptosis in detached cells and increased tumor cell survival in the blood circulation, it was insufficient to affect the ability of p53 to cause cell cycle arrest in detached cells and suppress experimental metastasis. For the suppression of metastasis complete inactivation of p53 was required, We conclude that the apoptotic function of p53 is dispensable for the p53-dependent suppression of experimental metastasis that is presumably achieved by controlling anchorage dependence, These data provide a possible explanation to dramatic differences in values of bcl-2 and mutant p53 as prognostic markers in human cancer.	Univ Illinois, Dept Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL 60607 USA; Univ Illinois, Biol Resources Lab, Chicago, IL 60607 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cold Spring Harbor Laboratory; Russian Academy of Medical Sciences	Gudkov, AV (corresponding author), Univ Illinois, Dept Mol Genet MC669, 900 S Ashland Ave, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [R21CA062045, R01CA060730] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA60730, R21CA62045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAS AL, 1996, NAT MED, V2, P811; ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BERTORELLE R, 1995, AM J SURG PATHOL, V19, P463, DOI 10.1097/00000478-199504000-00008; DAMERON KM, 1994, SCIENCE, V265, P1502; DONG ZY, 1994, CANCER RES, V54, P789; Fidler I.J., 1997, CANC PRINCIPLES PRAC; FUGMANN RA, 1977, CANCER RES, V37, P496; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HAGUE A, 1994, ONCOGENE, V9, P3367; Herod JJO, 1996, CANCER RES, V56, P2178; HSIAO M, 1994, AM J PATHOL, V145, P702; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARCHETTI A, 1993, CANCER RES, V53, P2846; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Nikiforov MA, 1996, ONCOGENE, V13, P1709; NOONAN KD, 1977, J CELL PHYSIOL, V91, P201, DOI 10.1002/jcp.1040910206; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PROSS HF, 1993, NAT IMMUN, V12, P279; SIERRA A, 1995, INT J CANCER, V60, P5463; THOMPSON TC, 1995, ONCOGENE, V10, P869; TSURUO T, 1981, CANCER RES, V41, P3058; UHLMAN DL, 1994, J NATL CANCER I, V86, P1470, DOI 10.1093/jnci/86.19.1470; ULBRIGHT TM, 1994, MODERN PATHOL, V7, P64; VINDELOV LL, 1988, CYTOMETRY, V3, P323	34	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3007	3012		10.1038/sj.onc.1201723	http://dx.doi.org/10.1038/sj.onc.1201723			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444949				2022-12-28	WOS:000070968000001
J	Hogg, A; Schirm, S; Nakagoshi, H; Bartley, P; Ishii, S; Bishop, JM; Gonda, TJ				Hogg, A; Schirm, S; Nakagoshi, H; Bartley, P; Ishii, S; Bishop, JM; Gonda, TJ			Inactivation of a c-Myb/estrogen receptor fusion protein in transformed primary cells leads to granulocyte/macrophage differentiation and down regulation of c-kit but not c-myc or cdc2	ONCOGENE			English	Article						Myb; differentiation; target genes; bcl-2; apoptosis	RNA INHIBITS PROLIFERATION; MURINE HEMATOPOIETIC-CELLS; MYELOID-LEUKEMIA CELLS; HUMAN LYMPHOCYTES-T; V-MYB; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; ERYTHROID-DIFFERENTIATION; DEPENDENT TRANSFORMATION; CONSTITUTIVE EXPRESSION	Primary murine fetal hemopoietic cells were transformed with a fusion protein consisting of the ligand-binding domain of the estrogen receptor and a carboxyl-terminally truncated c-Myb protein (ERMYB), The ERMYB-transformed hemopoietic cells exhibit an immature myeloid phenotype when grown in the presence of beta-estradiol. Upon removal of beta-estradiol, the ERMYB cells display increased adherence, decreased clonogenicity and differentiate to cells exhibiting granulocyte or macrophage morphology, The expression of the c-myc, c-kit, cdc2 and bcl-2 genes, which are putatively regulated by Myb, was investigated in ERMYB cells grown in the presence or absence of beta-estradiol. Neither c-myc nor cdc2 expression was down-regulated after removal of beta-estradiol demonstrating that differentiation is not a consequence of decreased transactivation of these genes by ERMYB. While bcl-2 expression was reduced by 50% in ERMYB cells grown in the absence of beta-estradiol, there was no increase in DNA laddering, suggesting that Myb was not protecting ERMYB cells from apoptosis, In contrast, a substantial (200-fold) decrease in c-kit mRNA level was observed following differentiation of ERMYB cells, and c-kit mRNA could be partially re-induced by the re-addition of beta-estradiol. Furthermore, a reporter construct containing the c-kit promoter was activated when cotransfected with a Myb expression vector, providing further evidence of a role for Myb in the regulation of c-kit.	INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143; RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOL GENET LAB,TSUKUBA,IBARAKI 305,JAPAN	Institute Medical & Veterinary Science Australia; University of California System; University of California San Francisco; RIKEN			NAKAGOSHI, Hideki/B-2145-2011; Gonda, Thomas J/A-3620-2012; Ishii, Shunsuke/A-5271-2016	NAKAGOSHI, Hideki/0000-0003-0850-1814; Ishii, Shunsuke/0000-0002-6530-2478				ANDRE C, 1989, ONCOGENE, V4, P1047; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CATRON KM, 1992, J IMMUNOL, V148, P934; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Deng QL, 1996, NUCLEIC ACIDS RES, V24, P766, DOI 10.1093/nar/24.4.766; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Engelke U, 1997, J VIROL, V71, P3760, DOI 10.1128/JVI.71.5.3760-3766.1997; EVAN GI, 1992, CELL, V69, P19; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FERRAO P, 1995, ONCOGENE, V11, P1631; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1993, BLOOD, V82, P2813; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1985, DNA CLONING PRACTICA, P143; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAYASHI SI, 1995, DNA RES, V2, P21; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KU DH, 1993, J BIOL CHEM, V268, P2255; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; MACMILLAN EM, 1994, BLOOD, V83, P209; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; Melotti P, 1996, BLOOD, V87, P2221, DOI 10.1182/blood.V87.6.2221.bloodjournal8762221; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NEWMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEBER F, 1984, CELL, V36, P983, DOI 10.1016/0092-8674(84)90048-5; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YANAGISAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P380, DOI 10.1016/0167-4781(91)90128-9; YASUDA H, 1993, BIOCHEM BIOPH RES CO, V191, P893, DOI 10.1006/bbrc.1993.1301; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	73	56	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2885	2898		10.1038/sj.onc.1201472	http://dx.doi.org/10.1038/sj.onc.1201472			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416832				2022-12-28	WOS:A1997YK37700001
J	Pearson, A; Greenblatt, J				Pearson, A; Greenblatt, J			Modular organization of the E2F1 activation domain and its interaction with general transcription factors TBP and TFIIH	ONCOGENE			English	Review						E2F1; TBP; TFIIH; transactivation	RNA-POLYMERASE-II; TATA-BINDING PROTEIN; EUKARYOTIC DNA-REPLICATION; HYDROPHOBIC AMINO-ACIDS; C-TERMINAL DOMAIN; RETINOBLASTOMA PROTEIN; MOLECULAR-CLONING; GROWTH SUPPRESSION; TRANS-ACTIVATION; PROMOTER DNA	The transcriptional activator E2F1 regulates the expression of genes at the G1/S boundary. We have characterized interactions of the E2F1 activation domain with two general transcription factors, the TATA-box binding protein (TBP) and TFIIH. Two distinct binding sites on E2F1 were identified for TBP (amino acids 386-417 and 415-437) each of which supported activation in mammalian cells when expressed as a fusion to a heterologous DNA-binding domain. Neither of these minimal activation domains independently bound TFIIH; rather, the TFIIH binding site of E2F1 overlaps both domains. Loss of TFIIH-binding by E2F1 resulted in a 60-65% reduction in transactivation, suggesting that the E2F1/TFIIH interaction is important, but not essential, for transactivation. The retinoblastoma protein (Rb) binds directly to E2F1 and represses E2F1-mediated transactivation. We have demonstrated that recombinant Rb can compete with TBP and the p62 subunit of TFIIH for binding to immobilized E2F1. A tumorigenic form of Rb deficient in repressing E2F1-mediated transactivation is likewise deficient in displacing TBP from E2F1. We propose that competition between Rb and both TBP and TFIIH for binding to E2F1 is a mechanism by which Rb inhibits transactivation by E2F1.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5G 1L6,CANADA	University of Toronto; University of Toronto				Pearson, Angela/0000-0002-5997-2846				ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; AUERSPERG N, 1964, J NATL CANCER I, V32, P135; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Blair WS, 1996, EMBO J, V15, P1658, DOI 10.1002/j.1460-2075.1996.tb00511.x; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Blau J, 1996, MOL CELL BIOL, V16, P2044; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; GE H, 1994, J BIOL CHEM, V269, P17136; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; ING NH, 1992, J BIOL CHEM, V267, P17617; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PAN GH, 1994, J BIOL CHEM, V269, P30101; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PUGH BF, 1992, J BIOL CHEM, V267, P679; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; SOPTA M, 1985, J BIOL CHEM, V260, P353; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; TANTIN D, 1994, J BIOL CHEM, V269, P17397; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TONG X, 1995, P NATL ACAD SCI USA, V92, P3259, DOI 10.1073/pnas.92.8.3259; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WEEDA G, 1990, MOL CELL BIOL, V10, P2570, DOI 10.1128/MCB.10.6.2570; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WOONTNER M, 1989, J BIOL CHEM, V265, P8979; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZHU H, 1994, J BIOL CHEM, V269, P3489	112	48	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2643	2658		10.1038/sj.onc.1201451	http://dx.doi.org/10.1038/sj.onc.1201451			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400991				2022-12-28	WOS:A1997YH46800002
J	Liu, Y; Corcoran, M; Rasool, O; Ivanova, G; Ibbotson, R; Grander, D; Iyengar, A; Baranova, A; Kashuba, V; Merup, M; Wu, XS; Gardiner, A; Mullenbach, R; Poltaraus, A; Hultstrom, AL; Juliusson, G; Chapman, R; Tiller, M; Cotter, F; Gahrton, G; Yankovsky, N; Zabarovsky, E; Einhorn, S; Oscier, D				Liu, Y; Corcoran, M; Rasool, O; Ivanova, G; Ibbotson, R; Grander, D; Iyengar, A; Baranova, A; Kashuba, V; Merup, M; Wu, XS; Gardiner, A; Mullenbach, R; Poltaraus, A; Hultstrom, AL; Juliusson, G; Chapman, R; Tiller, M; Cotter, F; Gahrton, G; Yankovsky, N; Zabarovsky, E; Einhorn, S; Oscier, D			Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia	ONCOGENE			English	Article						chronic lymphocytic leukemia; 13q14; tumor suppressor gene	RETINOBLASTOMA GENE; LOCUS; DELETIONS; CELLS; PRODUCT; TRANSLOCATION; HYBRIDIZATION; BREAKPOINT; PROTEINS; TOOL	Previous studies have indicated the presence of a putative tumor suppressor gene on chromosome 13q14, commonly deleted in patients with B-cell chronic lymphocytic leukemia (B-CLL), We have previously defined a minimally deleted region of 130 kb centromeric to the marker D13S272, and constructed a PAC and cosmid contig encompassing this area, In the present study we have made a detailed restriction and transcriptional map of the region of interest, Using these tools we have screened a panel of 206 primary CLL clones and three cell lines. In five CLL cases we found limited deletions defining the region of interest to an area of no more than 10 kb, Two adjacent genes, termed Leu1 and Leu2 (leukemia-associated gene 1 and 2), mere mapped to the minimally deleted region, with several patients showing deletion borders within these genes, The Leu1 and Lead genes show little homology to previously published genes at the nucleotide and expected translated amino acid sequence level, Mutational analysis of the Leu1 and 2 genes in 170 CLL samples revealed no small intragenic mutations or point mutations, However, in all cases of 13q14 loss examined, the first exon of both genes, which are only 300 bp apart, were deleted, We conclude that the Leu1 and Lead genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis.	KAROLINSKA HOSP,RADIUMHEMMET,S-17176 STOCKHOLM,SWEDEN; ROYAL BOURNEMOUTH HOSP,MOL BIOL LAB,BOURNEMOUTH BH7 7DW,DORSET,ENGLAND; RUSSIAN ACAD SCI,INST GEN GENET,GENOME ANAL LAB,MOSCOW 117809,RUSSIA; KAROLINSKA INST,MOL & TUMOR BIOL CTR,S-17177 STOCKHOLM,SWEDEN; HUDDINGE HOSP,DEPT HEMATOL,S-14186 HUDDINGE,SWEDEN; HUDDINGE HOSP,DEPT MED,S-14186 HUDDINGE,SWEDEN; ICRF,MOL ONCOL UNIT,INST CHILD HLTH,LONDON,ENGLAND; RUSSIAN ACAD SCI,VA ENGELHARDT MOL BIOL INST,DEPT SEQUENCING & MAPPING HUMAN GENOME,MOSCOW 117984,RUSSIA; LINKOPING UNIV HOSP,DEPT HEMATOL,S-58185 LINKOPING,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Karolinska Institutet; University of London; University College London; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Linkoping University			Yankovsky, Nick/AAU-9657-2021; Kashuba, Vladimir/AAO-7742-2020; Liu, Yie/AAO-2092-2020; Baranova, Anna/HGB-3721-2022; , Ancha/B-4608-2012; Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir I/N-3732-2017	, Ancha/0000-0001-6810-5982; Kashuba, Vladimir I/0000-0001-9416-8282; Liebe, Roman/0000-0002-3199-5595; Yankovsky, Nikolay/0000-0002-2467-2683				ALLIKMETS RL, 1994, GENOMICS, V19, P303, DOI 10.1006/geno.1994.1062; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Batova A, 1997, CANCER RES, V57, P832; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CORCORAN MM, 1997, IN PRESS BLOOD; DIGWEED M, 1995, MOL CELL BIOL, V15, P305, DOI 10.1128/MCB.15.1.305; FISHER SG, 1994, GENOMICS, V21, P525; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8898; FU TB, 1994, CANCER RES, V54, P6297; GarciaMarco JA, 1996, BLOOD, V88, P1568; Gonzalgo ML, 1997, MUTAT RES-REV MUTAT, V386, P107, DOI 10.1016/S1383-5742(96)00047-6; HAIDAR MA, 1995, BLOOD, V86, P311, DOI 10.1182/blood.V86.1.311.bloodjournal861311; HAWTHORN LA, 1993, ONCOGENE, V8, P1415; HEISKANEN M, 1994, BIOTECHNIQUES, V17, P928; HEISKANEN M, 1994, BIOTECHNIQUES, V17, P932; Heyman M, 1996, LEUKEMIA LYMPHOMA, V23, P235, DOI 10.3109/10428199609054826; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; IMREH S, 1997, IN PRESS GENES CHROM; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kapanadze BI, 1996, GENETIKA+, V32, P331; KISHIDA T, 1995, CANCER RES, V55, P4544; LIU Y, 1992, GENE CHROMOSOME CANC, V4, P250, DOI 10.1002/gcc.2870040310; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; LIU Y, 1993, P NATL ACAD SCI USA, V90, P8697, DOI 10.1073/pnas.90.18.8697; MEEKER TC, 1989, BLOOD, V74, P1801; MERUP M, 1997, IN PRESS LEUKAEMIA; Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500; OSCIER DG, 1994, BLOOD REV, V8, P88, DOI 10.1016/S0268-960X(05)80013-X; Panayiotidis P, 1997, BRIT J HAEMATOL, V97, P844, DOI 10.1046/j.1365-2141.1997.1322949.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUELLE DE, 1995, CELL, V83, P993; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SOULIER J, 1994, ONCOGENE, V9, P3565; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WASMUTH JJ, 1991, HUMAN GENEMAPPING, V11, P261; WENDELHANSEN V, 1994, LEUKEMIA, V8, P476; WU X, 1997, IN PRESS GENES CHROM	39	150	155	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2463	2473		10.1038/sj.onc.1201643	http://dx.doi.org/10.1038/sj.onc.1201643			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395242				2022-12-28	WOS:A1997YE96300008
J	Benz, CC; OHagan, RC; Richter, B; Scott, GK; Chang, CH; Xiong, XH; Chew, K; Ljung, BM; Edgerton, S; Thor, A; Hassell, JA				Benz, CC; OHagan, RC; Richter, B; Scott, GK; Chang, CH; Xiong, XH; Chew, K; Ljung, BM; Edgerton, S; Thor, A; Hassell, JA			HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer	ONCOGENE			English	Article						breast cancer; HER2/Neu; PEA3; Ets transcription factor	EWINGS-SARCOMA TRANSLOCATION; MESSENGER-RNA; DNA-BINDING; CHROMOSOME-TRANSLOCATION; C-ERBB-2 EXPRESSION; MAMMARY-CARCINOMA; MOLECULAR-CLONING; PHORBOL-ESTER; GENE FAMILY; EWS GENE	HER2/Neu is overexpressed in 25-30% of all human breast cancers as a result of both gene amplification and enhanced transcription. Transcriptional upregulation of HER2/neu leads to a 6-8-fold increased abundance of its mRNA per gene copy and likely results from the elevated activity of transcription factors acting on the HER2/neu promoter, Here we report that transcripts of PEA3, an ETS transcription factor implicated in oncogenesis, were increased in 93% of HER2/Neu-overexpressing human breast tumor samples, Analyses to uncover the molecular basis for elevated PEA3 transcripts in HER2/Neu-positive breast tumors revealed that the HER2/Neu receptor tyrosine kinase initiated an intracellular signaling cascade resulting in increased PEA3 transcriptional activity; transcriptionally-activated PEA3 stimulated HER2/neu and PEA3 gene transcription by binding to sites in the promoters of these genes, PEA3 also activates transcription of genes encoding matrix-degrading proteinases, enzymes required for tumor cell migration and invasion, These findings implicate PEA3 in the initiation and progression of HER2/Neu positive breast cancer, and suggest that PEA3 and signaling proteins affecting its regulation are appropriate therapeutic targets.	MCMASTER UNIV, INST MOL BIOL & BIOTECHNOL, CANC RES GRP, HAMILTON, ON L8S 4K1, CANADA; UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DIV MOL CYTOMETRY, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV VERMONT, DEPT PATHOL, BURLINGTON, VT 05405 USA	McMaster University					NATIONAL CANCER INSTITUTE [P01CA044768, R01CA036773, P50CA058207] Funding Source: NIH RePORTER; NCI NIH HHS [CA44768, CA58207, CA36773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENZ CC, 1995, GENE, V159, P3, DOI 10.1016/0378-1119(95)00147-X; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; DANKORT DL, 1996, MAMMARY TUMOR CELL C, P71; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IGLEHART JD, 1990, CANCER RES, V50, P6701; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; KING CR, 1989, CANCER RES, V49, P4185; KOHN EC, 1995, CANCER RES, V55, P1856; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIU E, 1992, ONCOGENE, V7, P1027; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MATRISIAN LM, 1994, ANN NY ACAD SCI, V91, P10129; MONTE D, 1994, ONCOGENE, V9, P1397; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OHagan RC, 1996, ONCOGENE, V13, P1323; PARKES HC, 1990, BRIT J CANCER, V61, P39, DOI 10.1038/bjc.1990.9; PASLEAU F, 1993, ONCOGENE, V8, P849; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; TRIPATHY D, 1994, HEMATOL ONCOL CLIN N, V8, P29, DOI 10.1016/S0889-8588(18)30186-2; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	49	146	147	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1513	1525		10.1038/sj.onc.1201331	http://dx.doi.org/10.1038/sj.onc.1201331			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380403				2022-12-28	WOS:A1997XX36900002
J	Rutberg, SE; Saez, E; Lo, S; Jang, SI; Markova, N; Spiegelman, BM; Yuspa, SH				Rutberg, SE; Saez, E; Lo, S; Jang, SI; Markova, N; Spiegelman, BM; Yuspa, SH			Opposing activities of c-Fos and Fra-2 on AP-1 regulated transcriptional activity in mouse keratinocytes induced to differentiate by calcium and phorbol esters	ONCOGENE			English	Article						c-Fos; Fra-2; mouse keratinocytes; differentiation; calcium; phorbol ester	PROTEIN-KINASE-C; HUMAN INVOLUCRIN GENE; HUMAN EPIDERMAL-KERATINOCYTES; CROSS-LINKED ENVELOPE; HUMAN KERATIN-1 GENE; SKIN CARCINOGENESIS; PROXIMAL PROMOTER; RETINOIC ACID; CELL-ENVELOPE; EXPRESSION	The major differentiation products of maturing keratinocytes contain AP-I regulatory motifs, and AP-1 DNA binding activity increases in cultured keratinocytes induced to differentiate by calcium. Here, we have analysed AP-I transcriptional activity in mouse keratinocytes treated with calcium and 12-O-tetradecanoyl phorbol-13-acetate (TPA), two agents that induce terminal differentiation of keratinocytes with different phenotypic consequences. Reporter constructs representing multimers of AP-I sequences found in keratinocyte marker genes demonstrated that the calcium-induced AP-I DNA binding activity does not correlate with transcriptional activation. Moreover, expression from active subunits of the profilaggrin and spr 1 promoters increased in calcium-treated keratinocytes when the AP-1 sites were disrupted, indicating that AP-I may negatively regulate certain promoters in these cells. In contrast, AP-1 reporter activity was increased in keratinocytes treated with TPA. This induction was dependent upon the expression of c-Fos since AP-I transcriptional activity was not increased in TPA-treated keratinocytes derived from c-fos null mice. Analysis of AP-1 protein expression in calcium-and TPA-treated keratinocytes demonstrated that only TPA increased the expression of c-Jun, while Jun B and Jun D were induced by both of these agents. c-Fos was expressed only in TPA treated keratinocytes, Fra-2 was expressed only in calcium-treated cells, and Fra-1 was expressed in both. Exogenous expression of Fra-2 repressed AP-1 transcriptional activity in TPA-treated keratinocytes, while c-Fos expression activated the AP-I sequence in calcium-treated keratinocytes. These data indicate that Fra-2 and c-Fos play opposing roles in regulating AP-1 activity in keratinocytes and that multiple inducer-dependent regulatory pathways may exist for the expression of keratinocyte differentiation markers.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; NIAMSD,SKIN BIOL LAB,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AU YPT, 1994, CIRC RES, V75, P15, DOI 10.1161/01.RES.75.1.15; Bernerd Francoise, 1993, Gene Expression, V3, P187; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P1619; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRUDA MC, 1994, ONCOGENE, V9, P2537; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUFF CA, 1993, J BIOL CHEM, V268, P377; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; JETTEN AM, 1989, J INVEST DERMATOL, V93, P108, DOI 10.1111/1523-1747.ep12277374; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARTASOVA T, 1987, NUCLEIC ACIDS RES, V15, P5945, DOI 10.1093/nar/15.15.5945; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LICHTI U, 1988, CANCER RES, V48, P74; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LU B, 1994, J BIOL CHEM, V269, P7443; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PARKINSON EK, 1984, CARCINOGENESIS, V5, P1071, DOI 10.1093/carcin/5.8.1071; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; ReifelMiller AE, 1996, J BIOL CHEM, V271, P21666, DOI 10.1074/jbc.271.35.21666; REZZONICO R, 1995, ONCOGENE, V11, P1069; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROOP DR, 1988, CANCER RES, V48, P3245; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; Rutberg SE, 1996, ONCOGENE, V13, P167; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SONOBE MH, 1995, ONCOGENE, V10, P689; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TOFTGARD R, 1985, CANCER RES, V45, P5845; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WIRTH PJ, 1987, CANCER RES, V47, P2831; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; YUSPA SH, 1982, CANCER RES, V42, P2344; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	64	61	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1337	1346		10.1038/sj.onc.1201293	http://dx.doi.org/10.1038/sj.onc.1201293			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315102				2022-12-28	WOS:A1997XV84500012
J	Qi, XM; He, HL; Zhong, HY; Distelhorst, CW				Qi, XM; He, HL; Zhong, HY; Distelhorst, CW			Baculovirus p35 and Z-VAD-fmk inhibit thapsigargin-induced apoptosis of breast cancer cells	ONCOGENE			English	Article						thapsigargin; apoptosis; Bcl-1; ICE-like protease	ICE FAMILY PROTEASES; ENDOPLASMIC-RETICULUM; CAENORHABDITIS-ELEGANS; LYMPHOMA-CELLS; DEATH; PROTEIN; CALCIUM; EXPRESSION; BCL-2; ACTIVATION	Programmed cell death, or apoptosis, is inhibited by the antiapoptotic oncogene, Bcl-2, and is mediated by a cascade of aspartate-specific cysteine proteases, or caspases, related to interleukin 1-beta converting enzyme, Depending on cell type, apoptosis can be induced by treatment with thapsigargin (TG); a selective inhibitor of the endoplasmic reticulum-associated calcium-ATPase. The role of caspases in mediating TG-induced apoptosis was investigated in the Bcl-2-negative human breast cancer cell line, MDA-MB-468. Apoptosis developed in MDA-MB-468 cells over a period of 24-72 h following treatment with 100 nM TG, and was prevented by Bcl-2 overexpression, TG-induced apoptosis was associated with activation of caspase-3 and was inhibited by stable expression of the baculovirus p35 protein, an inhibitor of caspase activity, Also, TG-induced apoptosis was inhibited by treating cells with Z-VAD-fmk, a cell-permeable fluoromethylketone inhibitor of caspases, These findings indicate that TG-induced apoptosis of MDA-MB-468 breast cancer cells is subject to inhibition by Bcl-2 and is mediated by caspase activity, This model system should be useful for further investigation directed toward understanding the role of calcium in signaling apoptosis, and its relationship to Bcl-2 and the caspase proteolytic cascade.	CASE WESTERN RESERVE UNIV,IRELAND CANC CTR,DEPT MED,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL CANCER INSTITUTE [R21CA066221, T32CA059366] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA59366, R21 CA/AG66221] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG DK, 1994, CANCER RES, V54, P5280; ARMSTRONG DK, 1992, CANCER RES, V52, P3418; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CARTIER JL, 1994, J VIROL, V68, P7728, DOI 10.1128/JVI.68.12.7728-7737.1994; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FURUYA Y, 1994, CANCER RES, V54, P6167; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; HAY BA, 1994, DEVELOPMENT, V120, P2121; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HERSHBERGER PA, 1994, J VIROL, V68, P3467, DOI 10.1128/JVI.68.6.3467-3477.1994; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LI WWF, 1993, J BIOL CHEM, V268, P12003; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; McCloskey DE, 1996, RECENT PROG HORM RES, V51, P493; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Reynolds JE, 1996, J BIOL CHEM, V271, P27739, DOI 10.1074/jbc.271.44.27739; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; Shimizu S, 1996, ONCOGENE, V12, P2251; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V	40	42	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1207	1212		10.1038/sj.onc.1201290	http://dx.doi.org/10.1038/sj.onc.1201290			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294614				2022-12-28	WOS:A1997XU99100010
J	Soder, AI; Going, JJ; Kaye, SB; Keith, WN				Soder, AI; Going, JJ; Kaye, SB; Keith, WN			Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization	ONCOGENE			English	Article						telomerase; in situ hybridization; gene expression; hTR; ribonucleoproteins	CANCER; CELLS	Maintenance of telomere structure by the ribonucleoprotein enzyme telomerase is considered central to the development of most human cancers, However, regulatory mechanisms governing telomerase expression during oncogenesis are largely unknown. We address potential tumour-specific regulation of telomerase RNA gene expression by RNA in situ hybridization to over 300 tumour samples of germ cell and epithelial origin, Twenty-six per cent of non-small cell lung cancers (NSCLC), expressed detectable levels of the telomerase RNA gene (hTR), and interestingly expression was almost confined to squamous carcinomas (41%), being rare in pulmonary adenocarcinomas and large-cell anaplastic carcinomas (P=0.006), Low frequency hTR expression was also associated with adenocarcinoma of the breast (13%), and ovary (17%), In comparison, hTR expression was detected in 43% of cervical cancers with no significant differences in frequency between squamous-cell carcinoma and adenocarcinoma or in transitions between intraepithelial neoplasia and invasive carcinoma, In contrast to the common epithelial cancers, the malignant cells in 73% of testicular germ-cell tumours (seminomas and teratomas), expressed hTR consistent with hTR expression in normal testicular germ cells, Differentiated tissues within ovarian germ cell tumours and in testicular teratomas lacked detectable hTR expression, These studies show that different tumour types have distinct patterns of hTR expression, which has implications for our understanding of mechanisms regulating telomerase activity and for targeting the telomerase RNA component as an anti-cancer therapy.	Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland; Glasgow Royal Infirm, Dept Pathol, Glasgow G4 0SF, Lanark, Scotland	Beatson Institute; University of Glasgow; University of Glasgow	Keith, WN (corresponding author), Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Alexander Stone Bldg,Garscube Estate,Switchback R, Glasgow G61 1BD, Lanark, Scotland.		Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Going, James/0000-0001-9120-919X				BENDA JA, 1994, SEMIN ONCOL, V21, P3; Breslow RA, 1997, J NATL CANCER I, V89, P618, DOI 10.1093/jnci/89.9.618; Burger AM, 1997, BRIT J CANCER, V75, P516, DOI 10.1038/bjc.1997.90; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Holt SE, 1996, MOL CELL BIOL, V16, P2932; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Lundblad V, 1996, CELL, V87, P369, DOI 10.1016/S0092-8674(00)81358-6; Morin GB, 1996, SEMIN CELL DEV BIOL, V7, P5, DOI 10.1006/scdb.1996.0003; Parkinson EK, 1997, EUR J CANCER, V33, P727, DOI 10.1016/S0959-8049(97)00063-4; Raymond E, 1996, CURR OPIN BIOTECH, V7, P583, DOI 10.1016/S0958-1669(96)80068-1; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; Villeponteau B, 1996, SEMIN CELL DEV BIOL, V7, P15, DOI 10.1006/scdb.1996.0004; Wright WE, 1996, DEV GENET, V18, P173; Yashima K, 1997, J CLIN PATHOL, V50, P110, DOI 10.1136/jcp.50.2.110	21	68	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					979	983		10.1038/sj.onc.1201620	http://dx.doi.org/10.1038/sj.onc.1201620			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519871				2022-12-28	WOS:000072335900003
J	Veldhoen, N; Milner, J				Veldhoen, N; Milner, J			Isolation of canine p53 cDNA and detailed characterization of the full length canine p53 protein	ONCOGENE			English	Article						DNA binding; damaged DNA; full length canine p53	TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING; IN-VITRO; MUTATIONS; SEQUENCE; CANCER; OVEREXPRESSION; COMPLEXES; VARIANTS; CLEAVAGE	The p53 tumour suppressor protein plays a central role in the maintenance of genomic integrity. Mutations of the p53 gene are found in a number of canine cancers and many contribute to tumour formation, Here we describe isolation and expression of the complete wild type canine p53 cDNA. The encoded full length canine p53 protein displays strong sequence homology with p53 proteins from other higher vertebrates, Canine p53 protein produced in vitro was shown to recognize and bind to p53-specific DNA targets derived from the p21 and GADD45 promoters and to a consensus p53 binding site, We also show that canine p53 associates with oligonucleotides representing damaged DNA sites and undergoes proteolytic cleavage similar to that described for murine and human p53 proteins. Finally, we show that the canine p53 protein is able to transcriptionally activate a p53-dependent reporter gene in vivo, The results suggest that canine p53 is similar both in structure and function to human p53 and that canine cancer may provide a useful clinical model in the search for effective anti-cancer therapies based on p53.	Univ York, Dept Biol, YCRC P53 Res Grp, York YO1 5DD, N Yorkshire, England	University of York - UK	Veldhoen, N (corresponding author), Univ York, Dept Biol, YCRC P53 Res Grp, York YO1 5DD, N Yorkshire, England.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DEVILEE P, 1994, ANTICANCER RES, V14, P2039; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FREBOURG T, 1992, CANCER RES, V52, P6976; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; Gamblin RM, 1997, AM J VET RES, V58, P857; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALL AR, 1995, ONCOGENE, V10, P561; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HARVEY M, 1993, ONCOGENE, V8, P2457; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; JUVEN T, 1993, ONCOGENE, V8, P341; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAEGEL SA, 1995, CANCER LETT, V92, P181, DOI 10.1016/0304-3835(95)03779-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN J, 1994, COLD SPRING HARB SYM, V59, P215, DOI 10.1101/SQB.1994.059.01.026; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MAYR B, 1994, BRIT VET J, V150, P81, DOI 10.1016/S0007-1935(05)80099-5; Mayr B, 1997, VET RES COMMUN, V21, P369, DOI 10.1023/A:1005820607258; Molinari M, 1996, ONCOGENE, V13, P2077; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sagartz JE, 1996, VET PATHOL, V33, P213, DOI 10.1177/030098589603300211; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Teifke JP, 1996, J COMP PATHOL, V114, P205, DOI 10.1016/S0021-9975(96)80010-7; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; vanLeeuwen IS, 1997, CANCER LETT, V111, P173, DOI 10.1016/S0304-3835(96)04529-6; vanLeeuwen IS, 1996, ANTICANCER RES, V16, P3737; Veldhoen N, 1998, ONCOGENE, V16, P249, DOI 10.1038/sj.onc.1201489; WADA H, 1994, LEUKEMIA, V8, P53; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wolf JC, 1997, VET PATHOL, V34, P394, DOI 10.1177/030098589703400503	40	33	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1077	1084		10.1038/sj.onc.1201863	http://dx.doi.org/10.1038/sj.onc.1201863			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519881				2022-12-28	WOS:000072335900013
J	Lin, JC; Naujokas, M; Zhu, H; Nolet, S; Park, M				Lin, JC; Naujokas, M; Zhu, H; Nolet, S; Park, M			Intron-exon structure of the MET gene and cloning of an alternatively-spliced Met isoform reveals frequent exon-skipping of a single large internal exon	ONCOGENE			English	Article						MET receptor tyrosine kinase; genomic structure; alternative splicing; exon-skipping; hepatocyte growth factor receptor	HEPATOCYTE GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; TYROSINE KINASE RECEPTOR; C-MET; SCATTER FACTOR; PROTOONCOGENE PRODUCT; FACTOR/SCATTER FACTOR; HGF RECEPTOR; EXPRESSION; OVEREXPRESSION	Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional factor that stimulates epithelial cell mitogenesis, motility, invasion, and morphogenesis. Its receptor is encoded by the MET proto-oncogene, a transmembrane receptor tyrosine kinase. Several studies have suggested a role for MET as a dominant oncogene in tumor development and progression. Conversely, MET is located at a region on chromosome 7q31 frequently deleted in carcinomas, suggesting that recessive mutations in MET may exist in certain cancers. To facilitate a search for mutations in MET, we have obtained the intron-exon structure of the human MET gene. We present the genomic structure of the first member of the Met receptor family to be characterized. Interestingly, MET contains a large second exon of 1214 nucleotides. We show that this exon, containing the AUG for the Met receptor, is frequently skipped in normal human tissues and cell lines, and corresponds to a ubiquitously expressed 7 kb Met transcript. This transcript yields no detectable protein product in vivo. Thus, unlike other genes, in which alternative splicing often gives rise to proteins,vith distinct activities, exon-skipping of MET exon 2 is predicted to decrease the abundance of a Met mRNA encoding a functional Met receptor.	McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Biochem, Montreal, PQ, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.							BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORDANO S, 1989, ONCOGENE, V4, P1983; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; JUCKER M, 1994, LEUKEMIA RES, V18, P7, DOI 10.1016/0145-2126(94)90003-5; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE CC, 1995, J BIOL CHEM, V270, P507, DOI 10.1074/jbc.270.2.507; Lin JC, 1996, ONCOGENE, V13, P2001; LIU C, 1992, ONCOGENE, V7, P181; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maniatis T., 1992, MOL CLONING LAB MANU; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MOTOYAMA T, 1979, Acta Medica et Biologica, V27, P49; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PIAO XH, 1994, BLOOD, V83, P476; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RONSIN C, 1993, ONCOGENE, V8, P1195; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Scotlandi K, 1996, AM J PATHOL, V149, P1209; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Sterner DA, 1996, P NATL ACAD SCI USA, V93, P15081, DOI 10.1073/pnas.93.26.15081; TAKAHASHI S, 1995, CANCER RES, V55, P4114; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Yang XM, 1996, DEVELOPMENT, V122, P2163; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yonemura Y, 1996, INT J ONCOL, V8, P555; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	51	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					833	842		10.1038/sj.onc.1201599	http://dx.doi.org/10.1038/sj.onc.1201599			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484774				2022-12-28	WOS:000072053200002
J	Zhuang, SM; Schippert, A; Haugen-Strano, A; Wiseman, RW; Soderkvist, P				Zhuang, SM; Schippert, A; Haugen-Strano, A; Wiseman, RW; Soderkvist, P			Inactivations of p16(INK4a)-alpha, p16(INK4a)-beta and p15(INK4b) genes in 2 ',3 '-dideoxycytidine- and 1,3-butadiene-induced murine lymphomas	ONCOGENE			English	Article						p16(INK4a)-alpha; p16(INK4a)-beta; p15(INK4b); murine lymphomas; 1,3-butadiene; 2 ',3 '-dideoxycytidine	TUMOR-SUPPRESSOR GENE; DEPENDENT KINASE INHIBITORS; ACUTE LYMPHOCYTIC-LEUKEMIA; CELL-CYCLE INHIBITION; METHYL-N-NITROSOUREA; RETINOBLASTOMA-PROTEIN; PANCREATIC-CANCER; THYMIC LYMPHOMAS; CPG ISLAND; MICE	The p16(INK4a) (alpha and beta form) and p15(INK4b) genes were analysed for homozygous deletion, hypermethylation and point mutation in B6C3F1 mouse lymphomas induced by 2',3'-dideoxycytidine or 1,3-butadiene, Although the p16(INK4a)-alpha gene appeared normal in DNA from 2',3'-dideoxycytidine-induced lymphomas, Southern analyses revealed homozygous deletions or rearrangements of the p16(INK4a)-beta and/or p15(INK4b) genes in four of 16 tumours, Surprisingly, two of these lymphomas showed exclusive deletions of the p16(INK4a) EI beta exon, The p15(INK4b) promoter region was hypermethylated in two additional 2',3'-dideoxycytidine-induced lymphomas, In contrast, homozygous deletions spanning the p16(INK4a), and p15(INK4b) loci were observed in only two of 31 1,3-butadiene-induced tumours, Thus, these cyclin dependent kinase inhibitor genes may play a significant role in chemically induced mouse lymphomas and support the contention of tumour suppressor activity for the p19(ARF) protein encoded by the p16(INK4a)-beta gene, Different genetic pathways may be involved in the development of these chemically induced tumours since we have previously shown that mutations in p53 and rns genes are common in 1,3-butadiene- but not 2',3'-dideoxycytidine-induced lymphomas,.	Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, S-58185 Linkoping, Sweden; NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA	Linkoping University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Zhuang, SM (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, S-58185 Linkoping, Sweden.			Zhuang, Shi-Mei/0000-0002-2512-3942				ANGEL JM, 1989, J NATL CANCER I, V81, P1652, DOI 10.1093/jnci/81.21.1652; Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; Batova A, 1997, CANCER RES, V57, P832; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; DIVINE BJ, 1990, ENVIRON HEALTH PERSP, V86, P119, DOI 10.2307/3430943; DRINKWATER NR, 1991, PROG EXP TUMOR RES, V33, P1; Flores JF, 1996, CANCER RES, V56, P5023; Fueyo J, 1996, ONCOGENE, V13, P1615; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARRIS G, 1994, CARCINOGENESIS, V15, P1211, DOI 10.1093/carcin/15.6.1211; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; Herzog CR, 1996, ONCOGENE, V13, P1885; HERZOG CR, 1994, CANCER RES, V54, P4007; Heyman M, 1996, BLOOD, V87, P1657, DOI 10.1182/blood.V87.4.1657.bloodjournal8741657; HIRAMA T, 1995, BLOOD, V86, P841; HOOPER WC, 1991, LEUKEMIA RES, V15, P179, DOI 10.1016/0145-2126(91)90118-D; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; *IARC, 1992, IARC MON EV CARC RIS, V54, P237; ISHIZAKA ST, 1989, CANCER RES, V49, P1214; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Liggett WH, 1996, CANCER RES, V56, P4119; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LOIS AF, 1995, CANCER RES, V55, P4010; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; MAO L, 1995, CANCER RES, V55, P2995; MATANOSKI GM, 1990, ENVIRON HEALTH PERSP, V86, P107, DOI 10.2307/3430942; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MELNICK RL, 1990, CANCER RES, V50, P6592; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NEWCOMB EW, 1988, CANCER RES, V48, P5514; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Rao GN, 1996, CANCER RES, V56, P4666; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; SADO T, 1985, J IMMUNOL, V134, P704; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIEBERT R, 1995, BRIT J HAEMATOL, V91, P350, DOI 10.1111/j.1365-2141.1995.tb05302.x; STARNES MC, 1987, J BIOL CHEM, V262, P988; STONE S, 1995, CANCER RES, V55, P2988; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; YANG R, 1995, CANCER RES, V55, P2503; Zhuang SM, 1996, CANCER RES, V56, P3338; Zhuang SM, 1997, CANCER RES, V57, P2710	52	36	37	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	1998	16	6					803	808		10.1038/sj.onc.1201600	http://dx.doi.org/10.1038/sj.onc.1201600			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488045				2022-12-28	WOS:000071931800013
J	Eng, C; Myers, SM; Kogon, MD; Sanicola, M; Hession, C; Cate, RL; Mulligan, LM				Eng, C; Myers, SM; Kogon, MD; Sanicola, M; Hession, C; Cate, RL; Mulligan, LM			Genomic structure and chromosomal localization of the human GDNFR-alpha gene	ONCOGENE			English	Article						RET; GFR alpha-1; GDNF; Exon-intron; 10q	MICE LACKING GDNF; MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; NEOPLASIA TYPE 2B; RET PROTOONCOGENE; DISEASE PHENOTYPE; POINT MUTATION; MEN 2A; RECEPTOR; FMTC	GDNFR-alpha is a glycosyl-phosphotidylinositol-linked receptor for glial cell line-derived neurotrophic factor (GDNF), GDNF binds to GDNFR-alpha and this complex, in turn, is believed to interact with the RET receptor tyrosine kinase to effect downstream signalling. GDNFR-alpha belongs to a novel gene family without strong homology to known genes. Thus, little information has been available to help predict genomic structure or location of this gene. In this study, the genomic organization of human GDNFR-alpha was delineated through a combination of PAC clone characterization, long distance PCR and sequence analyses. Exon-intron boundaries were defined by comparing the size and sequence of the genomic PCR products to those predicted by the cDNA sequence. The human GDNFR-alpha gene comprises 9 exons. GDNFR-alpha PAC clones were used for FISH analysis to map this gene to 10q26.	Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Richard & Sara Smith Labs, Boston, MA 02115 USA; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Paediat, Kingston, ON K7L 3N6, Canada; Biogen Inc, Dept Mol Biol, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; University of Cambridge; Queens University - Canada; Queens University - Canada; Biogen	Eng, C (corresponding author), Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Richard & Sara Smith Labs, SM822 1 Jimmy Fund Way, Boston, MA 02115 USA.			Eng, Charis/0000-0002-3693-5145				Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BOLINO A, 1995, ONCOGENE, V10, P2415; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Ivanchuk SM, 1996, HUM MOL GENET, V5, P2023, DOI 10.1093/hmg/5.12.2023; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Leong S, 1981, ADV THYROID NEOPLASI, P95; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Moore DD, 1995, GLOB MOB SURV; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0	30	10	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					597	601		10.1038/sj.onc.1201573	http://dx.doi.org/10.1038/sj.onc.1201573			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482105				2022-12-28	WOS:000071816600004
J	Ueffing, M; Lovric, J; Philipp, A; Mischak, H; Kolch, W				Ueffing, M; Lovric, J; Philipp, A; Mischak, H; Kolch, W			Protein kinase C-epsilon associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity	ONCOGENE			English	Article						PKC epsilon; Raf-1 kinase; growth factors; autocrine loops	ACTIVATES RAF-1; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; RAT FIBROBLASTS; TYROSINE KINASE; CELLS; PHOSPHORYLATION; ISOZYMES; OVEREXPRESSION; MECHANISMS	Several observations indicate that the Raf-1 kinase is a downstream effector of protein kinase C-epsilon (PKC epsilon). We recently have shown that Raf-1 is constitutively activated in PKC epsilon transformed Rat6 fibroblasts, and transformation can be reverted by expression of a dominant negative Raf-1, but not a dominant negative Ras mutant (Cacace et al., 1996), Cai et al, (1997) demonstrated that PKC epsilon induced proliferation of NIH3T3 cells is independent of Ras or Src, but depends on Raf-1. These authors further suggested that PKC epsilon activates Raf-1 by direct phosphorylation. Here we have investigated the functional interaction between PKC epsilon and Raf-1, PKCE, but not PKC alpha, was found to bind to the Raf-1 kinase domain, The association appeared to be direct, as it could be reconstituted in vitro with purified proteins, Raf-1 and PKC epsilon could be co-precipitated from Sf-9 insect cells and PKC epsilon transformed NIH313 cells (NIH/epsilon). The association was negatively regulated by ATP in vitro and by TPA treatment in NIH/epsilon cells, but not in Sf-9 insect cells, Raf-1 was constitutively activated in NIH/epsilon cells, How ever, using coexpression experiments in Sf-9 cells and transiently transfected A293 cells we did not obtain any evidence for a direct activation of Raf-1 by PKC epsilon. PKCE did not induce translocation of Raf-1 to the membrane, Furthermore, PKCE did not activate Raf-1 nor enhance the kinase activity of Raf-1 that had been pre-activated by coexpression of Ras or the Lck tyrosine kinase, In contrast, conditioned media from PKC epsilon transformed cells induced a robust activation of Raf-1. This activation could be partially reproduced by recombinant TGF beta, a growth factors secreted by PKC epsilon transformed Rat6 cells. In conclusion, our results suggest that PKC epsilon stimulates Raf-1 indirectly by inducing the production of autocrine growth factors.			Ueffing, M (corresponding author), GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOL BIOL & TUMORGENET,MARCHIONINSTR 25,D-81377 MUNICH,GERMANY.		Mischak, Harald/E-8685-2011; Admin, SBI/HGB-2738-2022; Kolch, Walter/ABF-2102-2021	Kolch, Walter/0000-0001-5777-5016; Lovric, Josip/0000-0002-0338-6581; Mischak, Harald/0000-0003-0323-0306				ARITA Y, 1992, CANCER RES, V52, P4514; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; CACACE AM, 1993, ONCOGENE, V8, P2095; Cacace AM, 1996, ONCOGENE, V13, P2517; CACACE AM, UNPUB; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GOODNIGHT J, 1994, PROTEIN KINASE C DIF, P160; HA KS, 1993, J BIOL CHEM, V268, P10534; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KIESER A, 1994, ONCOGENE, V9, P963; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI PM, 1993, ONCOGENE, V8, P1731; Malarkey K, 1996, CELL SIGNAL, V8, P123, DOI 10.1016/0898-6568(95)02036-5; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MISCHAK H, 1993, J BIOL CHEM, V268, P60090; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Perletti GP, 1996, ONCOGENE, V12, P847; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681	37	70	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2921	2927		10.1038/sj.onc.1201477	http://dx.doi.org/10.1038/sj.onc.1201477			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416835				2022-12-28	WOS:A1997YK37700004
J	Schwartz, D; Almog, N; Peled, A; Goldfinger, N; Rotter, V				Schwartz, D; Almog, N; Peled, A; Goldfinger, N; Rotter, V			Role of wild type p53 in the G(2) phase: regulation of the gamma-irradiation-induced delay and DNA repair	ONCOGENE			English	Article						p53; G(2) checkpoint; DNA damage; micronucleated cells	NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE CHECKPOINTS; SUPPRESSOR PROTEIN P53; C-TERMINAL DOMAIN; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; TUMOR-SUPPRESSOR; FLOW-CYTOMETRY; NUCLEAR ACCUMULATION; INDUCED MICRONUCLEI	Upregulation of the p53 protein was shown to induce cell cycle arrest at the G(1)/S border and in some cases at the G(2)/M border. Furthermore, it was suggested that p53 is associated with the induction of the various DNA repair pathways. Previously, we demonstrated that cells coexpressing endogenous wild type p53 protein, together with dominant negative mutant p53, exhibit deregulation of apoptosis, G(1) arrest and delay in G(2) following gamma-irradiation. In the present study, we investigated the role of p53 protein in the DNA damage response at the G(2) phase. Using p53-null, wild type p53 and mutant p53-producer cell lines, we found that the two C-terminally spliced p53 forms could prevent gamma-irradiation induced mutagenesis prior to mitosis, at the G(2)/M checkpoint. We found that at the G(2) phase, p53 may facilitate repair of DNA breaks giving rise to micronuclei, and regulate the exit from the G(2) checkpoint. At the G(1) phase, only the regularly spliced form of p53 caused growth arrest. In contrast, both the regularly and the alternatively spliced p53 forms directed postmitotic micronucleated cells towards apoptosis. These results provide a functional explanation for the cell cycle-independent expression of p53 in normal cycling cells, as well as in cells where p53 is up-regulated, following DNA damage.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRAIN R, 1994, ONCOGENE, V9, P1775; CHEN IT, 1995, ONCOGENE, V11, P1931; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANOVA M, 1990, LEUKEMIA RES, V14, P417, DOI 10.1016/0145-2126(90)90027-7; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, V1, P261; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAWLEY RS, 1996, GENE DEV, V10, P2382; HEDDLE JA, 1977, MUTAT RES, V44, P63, DOI 10.1016/0027-5107(77)90115-4; HONG JH, 1994, RADIAT RES, V140, P17, DOI 10.2307/3578563; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1995, CANCER RES, V55, P7; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McDonald E, 1996, CANCER RES, V56, P2250; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NUSSE M, 1994, METHOD CELL BIOL, V42, P149; NUSSE M, 1992, INT J RADIAT BIOL, V62, P587, DOI 10.1080/09553009214552511; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PAULES RS, 1995, CANCER RES, V55, P1763; Peled A, 1996, ONCOGENE, V13, P1677; POWELL SN, 1995, CANCER RES, V55, P1643; REMVIKOS Y, 1990, INT J CANCER, V45, P450, DOI 10.1002/ijc.2910450313; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHREIBER GA, 1992, INT J RADIAT BIOL, V62, P695, DOI 10.1080/09553009214552651; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; STEWART N, 1995, ONCOGENE, V10, P109; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UNGER C, 1994, CANCER RES, V54, P3651; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	75	71	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2597	2607		10.1038/sj.onc.1201436	http://dx.doi.org/10.1038/sj.onc.1201436			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399647				2022-12-28	WOS:A1997YG73200009
J	Muller, C; Salles, B				Muller, C; Salles, B			Regulation of DNA-dependent protein kinase activity in leukemic cells	ONCOGENE			English	Article						DNA-PK; Ku autoantigen; CLL lymphocytes	CHRONIC LYMPHOCYTIC-LEUKEMIA; STRAND BREAK REPAIR; V(D)J RECOMBINATION; KU-PROTEIN; BINDING; EXPRESSION; AUTOANTIGEN; RESISTANCE; ANTIBODIES; ENDS	The DNA-dependent protein kinase (DNA-PK) complex is composed of a catalytic (DNA-PKcs), and a regulatory subunit (Ku70/Ku86 heterodimer), The expression and function of DNA-PK subunits was investigated in purified blood lymphocytes obtained from patients with chronic lymphocytic leukemia (CLL) either refractory to chemotherapy or untreated, Variations in DNA-PK activity were found amongst CLL samples by comparison to human cell lines, It was noticeable that the low DNA-PK activity was associated with samples from untreated patients that exhibited a sensitivity phenotype, determined in vitro, to the radiomimetic agent neocarcinostatin by comparison to samples from refractory patients, The regulation in DNA-PK activity was associated with Ku heterodimer expression while DNA-PKcs was unaffected, Moreover, the presence of an altered form of the Ku86 subunit was identified in samples with low DNA-PK activity, These results suggest a regulation process of the DNA-PK activity in fresh human cells.	CNRS,UPR 9062,INST PHARMACOL & BIOL STRUCT,F-31077 TOULOUSE,FRANCE; CHU PURPAN,SERV HEMATOL,F-31300 TOULOUSE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse			salles, bernard/B-8531-2008; MULLER, Catherine/M-2185-2018; MULLER, Catherine/E-2060-2011					ANDERSON CW, 1994, J PROTEIN CHEM, V13, P500; Barret JM, 1996, MOL PHARMACOL, V49, P766; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BRAMSON J, 1995, MUTAT RES-DNA REPAIR, V336, P269, DOI 10.1016/0921-8777(94)00063-C; BRAMSON J, 1995, CANCER LETT, V90, P139, DOI 10.1016/0304-3835(95)03696-T; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; FALZON M, 1993, J BIOL CHEM, V268, P10546; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Han ZY, 1996, J BIOL CHEM, V271, P14098, DOI 10.1074/jbc.271.24.14098; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KIPPS TJ, 1995, CHRONIC LYMPHOCYTIC, P1017; MINORI T, 1986, J BIOL CHEM, V261, P10375; MULLER C, 1994, INT J CANCER, V56, P749, DOI 10.1002/ijc.2910560523; ORFAO A, 1992, LEUKEMIA, V6, P47; PANASCI L, 1988, CANCER RES, V48, P1972; REEVES WH, 1987, J RHEUMATOL, V14, P97; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	25	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2343	2348		10.1038/sj.onc.1201402	http://dx.doi.org/10.1038/sj.onc.1201402			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393878				2022-12-28	WOS:A1997YE15700008
J	Barsky, SH; Sternlicht, MD; Safarians, S; Nguyen, M; Chin, K; Stewart, SD; Hiti, AL; Gray, JW				Barsky, SH; Sternlicht, MD; Safarians, S; Nguyen, M; Chin, K; Stewart, SD; Hiti, AL; Gray, JW			Evidence of a dominant transcriptional pathway which regulates an undifferentiated and complete metastatic phenotype	ONCOGENE			English	Article						somatic cell hybridization; spontaneous metastasis; human-human fusions	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-MALIGNANT-MELANOMA; GROWTH-FACTOR RECEPTOR; SOMATIC-CELL HYBRIDS; HUMAN LUNG-CANCER; DNA METHYLTRANSFERASE; MONOCLONAL-ANTIBODY; EPITHELIAL-CELLS; PROSTATE-CANCER; SOLID TUMORS	The highly metastatic amelanotic C8161 human melanoma line was found to exhibit complete dominance of its undifferentiated and metastatic phenotype in multiple somatic cell hybridization studies designed to bypass the presence of potential tumor suppressor genes. In a three armed approach involving somatic cell fusions of C8161 with recipient lines of greater differentiation, different lineage, and different tumorigenicity status, the metastatic and undifferentiated phenotype of C8161 was promiscuously dominant. In somatic cell hybrids produced between the C8161 and a group of non-metastatic human melanoma lines which exhibited melanocyte differentiation markers including S100, HMB-45, NKI/ C3, and melanin, the fusions were uniformly metastatic and undifferentiated. In somatic cell hybrids of C8161 and MCF-7 the fusions exhibited an estrogen independent and unresponsive, estrogen receptor (ER) negative, and highly metastatic phenotype. In fusions between C8161 and HMS-1, an immortalized 'benign' human myoepithelial line which produced an abundant extracellular matrix (ECM) and high levels of protease and angiogenic inhibitors including maspin, tissue inhibitor of metalloproteinase-1 (TIMP-1), alpha 1-antitrypsin (alpha 1-AT), protease nexin II (PN-II), thrombospondin-l and soluble basic fibroblast growth factor (bFGF) receptors, the hybrids showed complete absence of matrix, absent maspin expression, markedly decreased protease inhibitor and angiogenic inhibitor production, high levels of proteases and angiogenic factors, and a highly metastatic phenotype. In our somatic cell fusions, the human-human hybrids represented true and complete fusions and not hybrid clones selected for by loss of dominant-acting growth suppressor genes. This finding was supported by detailed comparative genomic hybridization (CGH) studies, Q-banding karyotype analysis, and autofusions of representative clones. The purposeful creation of inherently unstable human-murine fusions between C8161 and B16-F1 where loss of putative suppressor loci would be expected, resulted in fusions exhibiting decreased growth and non-metastatic behavior with progressive chromosomal loss. Neither p53, nm23, DNA methyltransferase, activated I as, fibroblast growth factor-4 (FGF-4), or epidermal growth factor receptor (EGFR) mediated the acquisition of the metastatic or undifferentiated phenotype within the C8161-human fusions. These studies are the first studies ever to successfully transfer the complete metastatic phenotype by somatic cell fusion and support the presence of a new high level regulatory pathway(s) involving dominant trans-acting factors which act pleiotropically to regulate an undifferentiated and highly metastatic phenotype.	UNIV CALIF LOS ANGELES,SCH MED,DIV SURG ONCOL,LOS ANGELES,CA 90024; UNIV CALIF SAN FRANCISCO,CTR CANC,CANC GENET PROGRAM,SAN FRANCISCO,CA 94143; CEDARS SINAI MED CTR,LAB CYTOGENET,LOS ANGELES,CA 90211; UNIV SO CALIF,DEPT PATHOL,LOS ANGELES,CA 90033	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; Cedars Sinai Medical Center; University of Southern California	Barsky, SH (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [R01CA040225, R01CA056735] Funding Source: NIH RePORTER; NCI NIH HHS [CA01351, CA40225, CA56735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARSKY SH, 1983, LAB INVEST, V49, P140; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; CHAMBERS AF, 1992, BIOCHEM CELL BIOL, V70, P817, DOI 10.1139/o92-124; CHENG L, 1988, LAB INVEST, V58, P346; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; ERICKSON LA, 1984, ANAL BIOCHEM, V137, P454, DOI 10.1016/0003-2697(84)90113-1; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FUJIWARA T, 1993, CANCER RES, V53, P4129; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GOPALAKRISHNA R, 1988, P NATL ACAD SCI USA, V85, P612, DOI 10.1073/pnas.85.2.612; GOWN AM, 1984, AM J PATHOL, V114, P309; HARRIS H, 1988, CANCER RES, V48, P3302; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HERRON GS, 1986, J BIOL CHEM, V261, P2814; ICHIKAWA T, 1994, CANCER RES, V54, P2299; ITO M, 1994, CANCER LETT, V78, P33, DOI 10.1016/0304-3835(94)90028-0; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; KAIGHN ME, 1990, CANCER RES, V50, P1890; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOCKSHIN A, 1985, CANCER RES, V45, P345; MACDOUGALL JR, 1995, CANCER RES, V55, P4174; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUELLER BM, 1991, CANCER RES, V51, P2193; NEVINS JR, 1987, METHODS ENZYMOLOGY G, P234; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PIPER J, 1995, CYTOMETRY, V19, P10, DOI 10.1002/cyto.990190104; QUINLAN DC, 1992, CANCER RES, V52, P4828; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; RODER JC, 1978, J IMMUNOL, V121, P2509; SIDEBOTTOM E, 1983, BRIT J CANCER, V47, P399, DOI 10.1038/bjc.1983.60; SOMMERS CL, 1990, CANCER RES, V50, P67; SPRUCK CH, 1993, CANCER RES, V53, P1162; STAROSELSKY AH, 1991, CANCER RES, V51, P6292; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Sternlicht MD, 1996, IN VITRO CELL DEV-AN, V32, P550; TAKAHASHI K, 1984, VIRCHOWS ARCH B, V45, P385, DOI 10.1007/BF02889881; TSUCHIDA T, 1987, J NATL CANCER I, V78, P55, DOI 10.1093/jnci/78.1.55; VENNEGOOR C, 1985, INT J CANCER, V35, P287, DOI 10.1002/ijc.2910350302; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WELCH DR, 1994, ONCOGENE, V9, P255; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314	58	16	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2077	2091		10.1038/sj.onc.1201379	http://dx.doi.org/10.1038/sj.onc.1201379			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366525				2022-12-28	WOS:A1997YC28400009
J	Gallo, R; Provenzano, C; Carbone, R; DiFiore, PP; Castellani, L; Falcone, G; Alema, S				Gallo, R; Provenzano, C; Carbone, R; DiFiore, PP; Castellani, L; Falcone, G; Alema, S			Regulation of the tyrosine kinase substrate Eps8 expression by growth factors, v-Src and terminal differentiation	ONCOGENE			English	Article						tyrosine kinase; Eps8; Shc; differentiation; signal transduction	QUAIL MYOTUBES; CONSTITUTIVE PHOSPHORYLATION; HIGH-EFFICIENCY; SHC PROTEINS; TRANSFORMATION; DOMAIN; CELLS; FIBROBLASTS; ONCOGENES; MUSCLE	SH3-containing proteins are involved in signal transduction by a number of growth factor receptors and in the organization of the cytoskeleton. The recently identified Eps8 protein, which contains an SH3 domain, is coupled functionally and physically to the EGFR and is tyrosine phosphorylated by this receptor and other receptors as well,Here, we examined the regulation of eps8 expression in response to mitogenic or differentiative signals, We show that Eps8 is expressed at low levels in resting fibroblasts, but its expression is strongly induced during activation by serum, phorbol esters and the v-src oncogene, Conversely, expression of Eps8, but not of other EGFR substrates such as She or Eps15, is virtually extinguished in non-proliferating, terminally differentiated murine myogenic cells, The putative role of Eps8 protein as a v-Src substrate was analysed in murine fibroblasts and in quail myogenic cells expressing a temperature-sensitive variant of the tyrosine kinase, Tyrosine phosphorylation of Eps8 was detected only at the permissive temperature, A non-myristylated, transformation-defective mutant of v-Src did not phosphorylate Eps8, whereas it phosphorylated She. Together, these findings indicate that Eps8 may be a critical substrate of v-Src, They further establish Eps8 as an example of a signal transducer whose expression senses the balance between growth and differentiation and might, therefore, be involved in the determination of the phenotype.	CNR, IST BIOL CELLULARE, I-00137 ROME, ITALY; EUROPEAN INST ONCOL, I-20141 MILAN, ITALY; UNIV BARI, IST MICROBIOL, I-70124 BARI, ITALY; UNIV ROMA TOR VERGATA, DIPARTIMENTO MED SPERIMENTALE & SCI BIOCHIM, I-00133 ROME, ITALY	Consiglio Nazionale delle Ricerche (CNR); IRCCS European Institute of Oncology (IEO); Universita degli Studi di Bari Aldo Moro; University of Rome Tor Vergata			Falcone, Germana/A-3735-2016; Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Castellani, Loriana/0000-0002-8519-3504; Alema, Stefano/0000-0002-9869-6354; Falcone, Germana/0000-0002-3508-7623	Telethon [800] Funding Source: Medline	Telethon(Fondazione Telethon)		ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CASTAGNINO P, 1995, ONCOGENE, V10, P723; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; Castellani L, 1996, J CELL SCI, V109, P1335; CATLING AD, 1993, ONCOGENE, V8, P1875; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FALCONE G, 1992, ONCOGENE, V7, P1913; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KARLSSON T, 1995, ONCOGENE, V10, P1475; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSICH L, 1984, MOL CELL BIOL, V4, P1420, DOI 10.1128/MCB.4.7.1420; Matoskova B, 1996, ONCOGENE, V12, P2679; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERDERAME MF, 1995, MOL BIOL CELL, V6, P953, DOI 10.1091/mbc.6.8.953; WONG WT, 1994, ONCOGENE, V9, P3057; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7	34	31	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	1997	15	16					1929	1936		10.1038/sj.onc.1201344	http://dx.doi.org/10.1038/sj.onc.1201344			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365239				2022-12-28	WOS:A1997YA87200007
J	Jager, R; Herzer, U; Schenkel, J; Weiher, H				Jager, R; Herzer, U; Schenkel, J; Weiher, H			Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice	ONCOGENE			English	Article						bcl-2; transgenic mice; mammary gland; involution; tumorigenesis	HUMAN BREAST; CHROMOSOMAL BREAKPOINT; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; IN-VIVO; EXPRESSION; PROTEIN; DEATH; GENE; TISSUE	Expression of the apoptosis-inhibitory protein Bcl-2 has frequently been detected in human cancer including mammary carcinoma. The functional significance of its expression has been well established in experimental tumors of the lymphoid system, however, remains to be elucidated for epithelial tumors. In order to assess the role of Bcl-2 in mammary tumorigenesis me have generated WAP-bcl-2 transgenic mice. The strong overexpression of Bcl-2 in lactating mammary glands was preserved during early postlactational involution and apoptosis of alveolar epithelial cells was prevented without influencing the dedifferentiation of the milk-producing epithelium. Although Bcl-2 overexpression was not sufficient to induce spontaneous tumors it, however, led to an accelerated development of MMTVmyc transgene-induced mammary tumors. In the mammary glands of MMTVmyc transgenic mice, a high proportion of apoptotic cells was detected which was significantly reduced in the mammary glands of WAP-bcl-2/MMTVmyc double transgenic mice. Taken together, these results suggest that Bcl-2 contributes to mammary tumorigenesis by inhibiting apoptosis.	FORSCHUNGSZENTRUM KARLSRUHE,GENET INST,D-76021 KARLSRUHE,GERMANY	Helmholtz Association; Karlsruhe Institute of Technology			Jager, Richard/B-9478-2009	Jager, Richard/0000-0002-1623-1917				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ANDRES AC, 1995, INT J CANCER, V63, P288, DOI 10.1002/ijc.2910630224; ANDRES AC, 1991, ONCOGENE, V6, P771; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BCHINI O, 1991, ENDOCRINOLOGY, V128, P539, DOI 10.1210/endo-128-1-539; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; BURDON T, 1991, J BIOL CHEM, V266, P6909; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; HAGUE A, 1994, ONCOGENE, V9, P3367; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; HOGAN B, 1986, MANIPULATING MOUSE E; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; JIANG SX, 1995, J PATHOL, V177, P135, DOI 10.1002/path.1711770206; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LI B, 1996, MOL CARCINOG, V14, P75; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lund LR, 1996, DEVELOPMENT, V122, P181; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pullan S, 1996, J CELL SCI, V109, P631; SANDGREN EP, 1995, CANCER RES, V55, P3915; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRANGE R, 1992, DEVELOPMENT, V115, P49; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WANG TTY, 1995, CANCER RES, V55, P2487; WONG P, 1994, EUR J BIOCHEM, V221, P917, DOI 10.1111/j.1432-1033.1994.tb18807.x; WONG P, 1993, J BIOL CHEM, V268, P5021; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	56	137	140	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1787	1795		10.1038/sj.onc.1201353	http://dx.doi.org/10.1038/sj.onc.1201353			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362445				2022-12-28	WOS:A1997XZ72500005
J	Pells, S; Divjak, M; Romanowski, P; Impey, H; Hawkins, NJ; Clarke, AR; Hooper, ML; Williamson, DJ				Pells, S; Divjak, M; Romanowski, P; Impey, H; Hawkins, NJ; Clarke, AR; Hooper, ML; Williamson, DJ			Developmentally-regulated expression of murine K-ras isoforms	ONCOGENE			English	Article						ras; expression; splicing	STEM-CELL LINE; C-MYC; DIFFERENTIAL EXPRESSION; PROTO-ONCOGENE; N-RAS; MOUSE; GENE; TRANSFORMATION; PROTEINS; MEMBRANE	The products (p21) of the three mammalian H-, N- and K-ras genes play important roles in intracellular signal transduction, linking membrane receptor kinases to the nuclear pathway through raf and mitogen activated protein kinase. They are involved in the regulation of proliferation and differentiation, and activating mutations of these genes are commonly associated with human cancers. Two p21 proteins are encoded by the K-ras gene (p21(K-rasA) and p21(K-rasB)) due to alternative splicing of the fast exon. While the four p21(ras) proteins are highly homologous, their sequences diverge significantly at the C-termini, to which distinct biochemical and perhaps even functional differences may be ascribed. However, H-, N- and K-rasB appear to be ubiquitously expressed, with little evidence of tissue-specific or developmental regulation. In contrast, we now demonstrate that the expression of K-rasA is strikingly different, K-rasA is induced during differentiation of pluripotent embryonal stem cells in vitro. Its expression during early embryogenesis is limited temporally and spatially in a tissue-specific distribution which is largely maintained as an adult. This suggests a distinct biological role for p21(K-rasA).	UNIV EDINBURGH,DEPT PATHOL,CRC LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; ST VINCENTS HOSP,CTR IMMUNOL,DARLINGHURST,NSW 2010,AUSTRALIA; UNIV NEW S WALES,SCH PATHOL,KENSINGTON,NSW 2052,AUSTRALIA	University of Edinburgh; St Vincents Hospital Sydney; University of New South Wales Sydney			Clarke, Alan R/A-6256-2008; Hawkins, Nicholas J/A-8461-2008; clarke, alan r/P-2820-2014	Hawkins, Nicholas J/0000-0002-2204-3189; Clarke, Alan/0000-0002-4281-426X; Pells, Stephen/0000-0001-5866-5759				AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CARBONE A, 1991, ONCOGENE, V6, P731; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; ELLIS RW, 1982, MOL CELL BIOL, V2, P1339, DOI 10.1128/MCB.2.11.1339; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANDYSIDE AH, 1989, ROUX ARCH DEV BIOL, V198, P48, DOI 10.1007/BF00376370; Hogan B. L. M, 1983, CANCER SURV, V2, P115; JACKS T, 1995, COMMUNICATION; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LOCKETT TJ, 1987, EXP CELL RES, V173, P370, DOI 10.1016/0014-4827(87)90277-1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MARTIN GR, 1975, TERATOMAS DIFFERENTI, P169; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1983, TERATOCARCINOMA STEM, P451; MULLER R, 1982, MOL CELL BIOL, V3, P1062; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; PAL SK, 1993, MOL REPROD DEV, V35, P8, DOI 10.1002/mrd.1080350103; SEJERSEN T, 1985, EXP CELL RES, V160, P19, DOI 10.1016/0014-4827(85)90232-0; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YAMAUCHI N, 1994, MOL CELL BIOL, V14, P6655, DOI 10.1128/MCB.14.10.6655; YASWEN P, 1985, MOL CELL BIOL, V5, P780, DOI 10.1128/MCB.5.4.780	39	71	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1781	1786		10.1038/sj.onc.1201354	http://dx.doi.org/10.1038/sj.onc.1201354			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362444				2022-12-28	WOS:A1997XZ72500004
J	Hui, R; Campbell, DH; Lee, CSL; McCaul, K; Horsfall, DJ; Musgrove, EA; Daly, RJ; Seshadri, R; Sutherland, RL				Hui, R; Campbell, DH; Lee, CSL; McCaul, K; Horsfall, DJ; Musgrove, EA; Daly, RJ; Seshadri, R; Sutherland, RL			EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer	ONCOGENE			English	Article						EMS1; 11q13; prognosis; breast cancer	TYROSINE KINASE-ACTIVITY; SQUAMOUS-CELL CARCINOMA; PP60C-SRC PROTEIN-KINASE; CHROMOSOME 11Q13; CYCLIN D1; ONCOGENE AMPLIFICATION; POOR-PROGNOSIS; C-SRC; CLINICAL-SIGNIFICANCE; EXPRESSION	Chromosome 11q13 is amplified in about 13% of primary breast cancers, CCND1, encoding the cell cycle regulatory gene cyclin D1, and EMS1, encoding a filamentous actin binding protein, are favoured candidate onocogenes, whereas INT-2 is an unexpressed gene at this locus. In this study we tested the possibility that different regions of this large amplicon could be independently amplified and subsequently defined the phenotype of EMS1 amplified tumours in a series of 961 primary breast carcinomas. Using DNA slot blots, EMS1 was amplified in 15.2% of samples: 5.4% were coamplified for CCND1; 7.9% coamplified for INT-2 and 6.7% showed EMS1 amplification alone. The degree of amplification of CCND1 and INT-2 was highly correlated (P=0.0001). In contrast, no such relationship existed between EMS1 and CCND1 or INT-2 amplification, demonstrating independent amplification of EMS1 in 44% of amplified tumours. EMS1 amplification (greater than or equal to twofold increase in copy number) was positively correlated with patient age greater than or equal to 50 years (P=0.025), ER positivity (P=0.022), PgR positivity (P = 0.018), and was negatively correlated with HER-2/neu (c-erbB2) amplification (P=0.01). In common with CCND1/INT-2, EMS1 amplification was associated with increased risk of relapse in patients with lymph node-negative disease (P=0.028). In contrast, EMS1 and CCND1/INT-2 amplification appeared to confer different phenotypes in ER positive and negative tumours. A greater than or equal to threefold increase in EMS1 copy number was associated with an apparent increased risk of relapse and death in patients with ER negative tumours, but was without effect in ER positive tumours. In contrast, CCND1/INT-2 amplification had no effect in the patients with ER negative tumours but was associated with early relapse in ER positive patients. Thus EMS1 amplification may identify subgroups of breast cancer patients with increased probability of relapse and death distinct from those identified by CCND1/INT-2 amplification. Further studies are required to more clearly determine the functional consequences of EMS1 overexpression and a biological basis for the relationship between EMS1 amplification and phenotype in breast cancer.	ST VINCENTS HOSP, GARVAN INST MED RES, CANC RES PROGRAM, SYDNEY, NSW 2010, AUSTRALIA; S AUSTRALIAN HLTH COMMISS, EPIDEMIOL UNIT, ADELAIDE CITY CTR, SA 5000, AUSTRALIA; FLINDERS MED CTR, DEPT SURG, BEDFORD PK, SA 5042, AUSTRALIA; FLINDERS MED CTR, DEPT HAEMATOL, BEDFORD PK, SA 5042, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Flinders Medical Centre; Flinders Medical Centre			Sutherland, Robert L/A-8378-2008; McCaul, Kieran A/B-8751-2008; Daly, Roger J/C-8179-2009	Daly, Roger/0000-0002-5739-8027; Campbell, Douglas/0000-0001-9699-1854				ADNANE J, 1989, ONCOGENE, V4, P1389; BERNS EMJJ, 1995, GENE, V159, P11, DOI 10.1016/0378-1119(94)00534-Y; BERNS EMJJ, 1992, EUR J CANCER, V28A, P697, DOI 10.1016/S0959-8049(05)80129-7; BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; BORG A, 1990, CANCER RES, V50, P4332; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; Bringuier PP, 1996, ONCOGENE, V12, P1747; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FANTL V, 1993, CANCER SURV, V18, P77; GAFFEY MJ, 1993, MODERN PATHOL, V6, P654; Hui R, 1996, CLIN CANCER RES, V2, P923; HUI R, 1997, UNPUB; JACOBS C, 1983, CANCER RES, V43, P1696; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MAA MC, 1992, ONCOGENE, V7, P2429; MACHOTKA SV, 1989, CLIN CHIM ACTA, V184, P207, DOI 10.1016/0009-8981(89)90053-3; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Patel AM, 1996, ONCOGENE, V12, P31; PETERS G, 1995, BREAST CANCER RES TR, V33, P125, DOI 10.1007/BF00682720; ROMAIN S, 1994, BRIT J CANCER, V70, P304, DOI 10.1038/bjc.1994.297; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; Seshadri R, 1996, CLIN CANCER RES, V2, P1177; Seshadri R, 1996, INT J CANCER, V69, P135, DOI 10.1002/(SICI)1097-0215(19960422)69:2<135::AID-IJC12>3.0.CO;2-8; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; THEILLET C, 1990, ONCOGENE, V5, P147; TSUDA H, 1989, CANCER RES, V49, P3104; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WILLIAMS ME, 1993, ARCH OTOLARYNGOL, V119, P1238; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221	46	81	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1617	1623		10.1038/sj.onc.1201311	http://dx.doi.org/10.1038/sj.onc.1201311			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380415				2022-12-28	WOS:A1997XX36900014
J	Kimura, Y; Furuhata, T; Shiratsuchi, T; Nishimori, H; Hirata, K; Nakamura, Y; Tokino, T				Kimura, Y; Furuhata, T; Shiratsuchi, T; Nishimori, H; Hirata, K; Nakamura, Y; Tokino, T			GML sensitizes cancer cells to Taxol by induction of apoptosis	ONCOGENE			English	Article						p53; gml; apoptosis; chemosensitivity	ANTICANCER AGENTS; THYMOCYTE APOPTOSIS; OVARIAN-CANCER; P53; CYTOTOXICITY; EXPRESSION; RADIATION; INCREASE; DRUG	Recently we identified a novel gene, gml, whose expression is regulated in a p53-dependent manner and found that gml expression was correlated with the sensitivity of esophageal cancer cells to anticancer drugs. To further investigate the biological mechanism of gml in determining the chemosensitivity of cancer cells to clinically useful agents, we introduced gml cDNA into TE10, an esophageal cancer cell line that lacks endogenous gml expression. In two resulting stable cell lines which expressed gml cDNA in the absence of wild-type p53, cell death occurred within 6 h after treatment with Taxol. TE10 parent cells or TE10 cells transfected with vector alone displayed relative resistance for 36 h. Induction of gml did not by itself affect viability. Morphological analysis confirmed that the increased chemosensitivity to Taxol conferred by gml was due to apoptosis. These data suggest that reduced expression of gml is likely to be associated with poor response rates to chemotherapy, and that an assay for gml expression might serve a clinical purpose as a predictor of chemotherapeutic sensitivity.	SAPPORO MED UNIV,DEPT SURG 1,SAPPORO,HOKKAIDO,JAPAN	Sapporo Medical University	Kimura, Y (corresponding author), UNIV TOKYO,INST MED SCI,MOL MED LAB,4-6-1 SHIROKANEDAI,TOKYO,JAPAN.		Tokino, Takashi/AAI-9887-2021	Kimura, Yasutoshi/0000-0002-7790-9250				CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Delia D, 1996, NAT MED, V2, P724, DOI 10.1038/nm0796-724; DONALDSON KL, 1994, INT J CANCER, V57, P847, DOI 10.1002/ijc.2910570614; Furuhata T, 1996, ONCOGENE, V13, P1965; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREGORY RE, 1993, CLIN PHARMACY, V12, P401; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SIRE EAG, 1995, ANN ONCOL, V6, P589, DOI 10.1093/oxfordjournals.annonc.a059249; SLICHENMYER WJ, 1991, ANTI-CANCER DRUG, V2, P519, DOI 10.1097/00001813-199112000-00002; TISHLER RB, 1995, CANCER RES, V55, P6021; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	18	16	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1369	1374		10.1038/sj.onc.1201255	http://dx.doi.org/10.1038/sj.onc.1201255			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315106				2022-12-28	WOS:A1997XV84500016
J	Su, YA; Lee, MM; Hutter, CM; Meltzer, PS				Su, YA; Lee, MM; Hutter, CM; Meltzer, PS			Characterization of a highly conserved gene (OS4) amplified with CDK4 in human sarcomas	ONCOGENE			English	Article						neoplasm; genetics; chromosome 12q; homogeneously staining region	HUMAN-MALIGNANT GLIOMAS; SOFT-TISSUE SARCOMAS; HUMAN CANCERS; AMPLIFICATION; MDM2; REGION; DNA; SAS; MICRODISSECTION; AMPLICONS	Amplification and overexpression of genes involved in growth control occur frequently in human Here, we report characterization of the fun length OS4 cDNA derived from 12q13-q15 (Su et al., Proc. Natl. Acad. Sci. USA, 91: 9121-9125, 1994), a region frequently amplified in sarcomas and brain tumors. This cDNA consists of 4833 base pairs (bp) encoding an open reading frame (ORF) of 283 amino acids, The ORF predicts a water-soluble acidic (pi 5.50) polypeptide with a molecular weight of 31 759. Database searches revealed highly significant similarity between OS4 and eight proteins predicted from genomic sequences of Caenorhabditis elegans, Schizosaccaharomyces pombe, and Saccharomyces cerevisiae. Thus, OS4 defines a novel evolutionarily conserved gene superfamily. Northern and database analyses revealed OS4 transcripts in numerous human tissues demonstrating its ubiquitous expression. We also observed overexpression of OS4 in three cancer cell lines with amplification of this gene. Furthermore, we detected OS4 amplification in 5/5 primary sarcomas with known amplification of the closely linked marker CDK4. These results demonstrate that the highly conserved OS4 gene is frequently included in the 22q13-q15 amplicon and may contribute to the development of a subset of sarcomas.	NATL HUMAN GENOME RES INST, NIH, CANC GENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; BROWN T, 1993, CURRENT PROTOCOLS MO; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; ELKAHLOUN AG, 1997, IN PRESS GENOMICS; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Gracia E, 1996, HUM MOL GENET, V5, P595, DOI 10.1093/hmg/5.5.595; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; KHATIB ZA, 1993, CANCER RES, V53, P5535; LEACH FS, 1993, CANCER RES, V53, P2231; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RHIM JS, 1975, INT J CANCER, V15, P23, DOI 10.1002/ijc.2910150104; ROBERTS WM, 1989, CANCER RES, V49, P5407; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SMITH SH, 1992, CANCER RES, V52, P3746; Su YA, 1996, MOL CARCINOGEN, V15, P270, DOI 10.1002/(SICI)1098-2744(199604)15:4<270::AID-MC4>3.0.CO;2-K; SU YA, 1994, P NATL ACAD SCI USA, V91, P9121, DOI 10.1073/pnas.91.19.9121	23	38	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1289	1294		10.1038/sj.onc.1201294	http://dx.doi.org/10.1038/sj.onc.1201294			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315096				2022-12-28	WOS:A1997XV84500006
J	Packham, G; Cleveland, JL				Packham, G; Cleveland, JL			Induction of ornithine decarboxylase by IL-3 is mediated by sequential c-Myc-independent and c-Myc-dependent pathways	ONCOGENE			English	Article						c-Myc; ODC; IL-3	CELL-CYCLE ARREST; INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; SIGNALING PATHWAYS; PROTEIN COMPLEX; REPRESSOR SIN3; DNA-BINDING; IN-VIVO; MAX	Enforced c-Myc expression promotes continuous, growth factor-independent, cell cycle progression and activates expression of the ornithine decarboxylase (ODC) gene and its promoter. c-Myc-responsiveness of murine ODC is mediated by two conserved c-Myc:Max E-boxes in ODC intron 1. c-Myc and ODC are both required for cell growth and their expression is sequentially induced in G(0)/G(1) cells stimulated with mitogens, yet their expression is not modulated by the cell cycle in proliferating cells. Here we demonstrate that regulation of ODC and its promoter by Interleukin-3 (IL-3) in murine myeloid cells is mediated in part by c-Myc. c-Myc induced ODC through the same transcription start site as IL-3 and, in asynchronously growing cells, maximal activity of the ODC promoter required the intronic c-Myc binding sites. However, induction of ODC following IL-3 stimulation of quiescent cells is mediated by at least two pathways. The first phase of this response was independent of the intronic c-Myc:Max E-boxes and de novo protein synthesis. Sustained induction of the ODC promoter however required the c-Myc:Max binding sites and protein synthesis. Accumulation of c-Myc following stimulation of quiescent cells with IL-3 correlated with the delayed phase of the response. Consistent with a two pathway model of ODC regulation, inducible overexpression of dominant negative form of c-Myc (In373-Myc), which specifically inhibits the c-Myc-Max network, inhibited the delayed, but not immediate, induction of ODC promoter activity in response to IL-3. Dominant negative c-Myc protein also effectively suppressed induction of the endogenous ODC gene by IL-3. Therefore, c-Myc functions as a direct and required regulator of ODC. These results also suggest a model whereby c-Myc's role in regulating its targets may be to convert a transient, immediate-early, activation event into the persistent induction of gene expression.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; ST MARYS HOSP, SCH MED, IMPERIAL COLL, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, SCH MED, IMPERIAL COLL, DEPT MED MICROBIOL, LONDON W2 1PG, ENGLAND	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA 21765] Funding Source: Medline; NIDDK NIH HHS [DK44158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSEN MS, 1992, J BIOL CHEM, V267, P18866; ARMATI B, 1993, CELL, V72, P233; ARMATI B, 1994, CURR OPIN GENET DEV, V4, P102; ARMATI B, 1992, NATURE, V359, P423; ARMATI B, 1993, EMBO J, V12, P5083; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; BRABANT M, 1988, P NATL ACAD SCI USA, V85, P2200, DOI 10.1073/pnas.85.7.2200; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COLMAN MS, 1996, NUCLEIC ACIDS RES, V21, P5372; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEAN M, 1987, ONCOGENE RES, V1, P279; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HO YS, 1987, NUCLEIC ACIDS RES, V15, P6746, DOI 10.1093/nar/15.16.6746; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATZ A, 1988, J BIOL CHEM, V263, P7604; KATZAV S, 1995, ONCOGENE, V11, P1079; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MANZELLA L, 1994, FEBS LETT, V348, P177, DOI 10.1016/0014-5793(94)00592-3; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MOSHIER JA, 1992, NUCLEIC ACIDS RES, V20, P2581, DOI 10.1093/nar/20.10.2581; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Packham G, 1996, ONCOGENE, V13, P461; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PACKHAM G, 1995, CELL MOL BIOL RES, V40, P699; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6387; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHUETZ JD, 1995, CELL GROWTH DIFFER, V6, P1321; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHOR J, 1995, ONCOGENE, V10, P587; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; TOBIAS KE, 1995, ONCOGENE, V11, P1721; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WATERS CM, 1991, ONCOGENE, V6, P797; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; Wu SJ, 1996, ONCOGENE, V12, P621; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	73	33	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1219	1232		10.1038/sj.onc.1201273	http://dx.doi.org/10.1038/sj.onc.1201273			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294616				2022-12-28	WOS:A1997XU99100012
J	Chauhan, D; Pandey, P; Ogata, A; Teoh, G; Treon, S; Urashima, M; Kharbanda, S; Anderson, KC				Chauhan, D; Pandey, P; Ogata, A; Teoh, G; Treon, S; Urashima, M; Kharbanda, S; Anderson, KC			Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism	ONCOGENE			English	Article						multiple myeloma; irradiation; dexamethasone; apoptosis	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH FACTOR; JUN; DNA; EXPRESSION; PHOSPHORYLATION; INTERLEUKIN-6	The stress-activated protein kinases (SAPKs), also known as c-Jun amino-terminal kinases (JNKs), are activated in response to diverse stimuli including DNA damage, heat shock, interleukin-1, tumor necrosis factor-alpha and Fas, Although all these inducers cause apoptosis, whether SAPK/JNK activation is required for apoptosis is controversial, In this study, we demonstrate that ionizing radiation (IR) and dexamethasone (Dex) induce apoptosis in multiple myeloma (MM) derived cell lines, as well as in patient cells, IR-induced apoptosis is associated with activation of SAPK/JNK and p38 kinase, in contrast to Dex-induced apoptosis, which is not associated with activation of stress kinases, Moreover, Dex-induced apoptosis is associated with a significant decrease in the activities of mitogen activated protein kinase (MAPK) and p70(S6K), whereas IR-treatment does not alter the activity of these kinases. Both IR and Dex induce poly (ADP ribose) polymerase (PARP) cleavage, a signature event of apoptosis. Finally, interleukin-6 (IL-6) inhibits Dex-induced apoptosis, downregulation of MAP and p70(S6K) growth kinases and PARP cleavage; in contrast, IL-6 does not inhibit IR-induced apoptosis, activation of SAPK/JNK, and PARP cleavage, Taken together, our findings suggest that SAPK/JNK activation is not required for apoptosis in MM cells, and that there are at least two distinct apoptotic signaling pathways: (i) SAPK/JNK-associated, which is induced by IR and unaffected by IL-6; and (ii) SAPK/JNK-independent, which is induced by Dex, associated with downregulation of MAPK and p70(S6K) and inhibited by IL-6.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Ogata, Atsushi/0000-0003-3944-3442				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHAUHAN D, 1995, J EXP MED, V182, P1801, DOI 10.1084/jem.182.6.1801; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; DUKE RC, 1992, CURRENT PROTOCOLS IM, V1; FRANK R, 1992, NUCLEIC ACIDS RES, V20, P5243; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P128; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATA H, 1995, BLOOD, V86, P1939, DOI 10.1182/blood.V86.5.1939.bloodjournal8651939; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; LIMOLI CL, 1993, RADIAT RES, V134, P160, DOI 10.2307/3578455; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SHIMA Y, 1995, BLOOD, V85, P757, DOI 10.1182/blood.V85.3.757.bloodjournal853757; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTENDORF JJ, 1995, BLOOD, V85, P3566, DOI 10.1182/blood.V85.12.3566.bloodjournal85123566; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZIA Z, 1995, SCIENCE, V270, P1326	45	148	155	3	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					837	843		10.1038/sj.onc.1201253	http://dx.doi.org/10.1038/sj.onc.1201253			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266970				2022-12-28	WOS:A1997XQ11700010
J	Hipp, ML; Bauer, G				Hipp, ML; Bauer, G			Intercellular induction of apoptosis in transformed cells does not depend on p53	ONCOGENE			English	Article						apoptosis; p53; TGF-beta	WILD-TYPE P53; BETA-INDUCED ELIMINATION; DNA STRAND BREAKS; TUMOR-SUPPRESSOR; TGF-BETA; P53-DEPENDENT APOPTOSIS; INDEPENDENT PATHWAYS; BCL-2 PROTEINS; CYCLE CONTROL; IN-VIVO	Transformed fibroblast from p53 null/null mice were tested for their sensitivity to intercellular induction of apoptosis by TGF-beta-treated nontransformed cells. They were found to be as sensitive as p53-positive transformed cells. Based on morphological criteria, detection of chromatin condensation and DNA strand breaks, death of p53-negative transformed cells was due to apoptosis. p53-negative nontransformed cells were as efficient in the induction of apoptosis in transformed cells as p53-positive nontransformed cells. These data show that intercellular induction of apoptosis in transformed cells does not depend on functional p53. Therefore it may be assumed that mutations of p53 or modulation of its concentration are without relevance for this particular aspect of control of oncogenesis.	UNIV FREIBURG,ABT VIROL,INST MED MIKROBIOL & HYG,D-79104 FREIBURG,GERMANY	University of Freiburg								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BASSLER D, 1997, IN PRESS EXP CELL RE; BAUER G, 1982, J BIOL CHEM, V257, P1405; BAUER G, 1995, INT J ONCOL, V6, P1227; Bauer G, 1996, HISTOL HISTOPATHOL, V11, P237; BECK E, 1997, IN PRESS EXP CELL RE; BRONNER MP, 1995, AM J PATHOL, V146, P20; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Descalzo AM, 1997, INT J ONCOL, V10, P765; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELEIRY WS, 1994, CANCER RES, V54, P1169; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAUKROGER JM, 1993, J GEN VIROL, V74, P2275, DOI 10.1099/0022-1317-74-10-2275; GORCZYCA W, 1993, CANCER RES, V53, P1945; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; GOTZ C, 1995, INT J ONCOL, V6, P1129; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GU ZM, 1994, ONCOGENE, V9, P629; Hackenjos K, 1996, ONCOL REP, V3, P27; HAVRE PA, 1995, CANCER RES, V55, P4420; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JURGENSMEIER JM, 1994, CANCER RES, V54, P393; JURGENSMEIER JM, 1997, IN PRESS INT J CANC; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Langer C, 1996, EXP CELL RES, V222, P117, DOI 10.1006/excr.1996.0015; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Melchinger W, 1996, INT J ONCOL, V9, P927; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Panse J, 1997, CARCINOGENESIS, V18, P259, DOI 10.1093/carcin/18.2.259; PICHT G, 1995, EXP CELL RES, V218, P71, DOI 10.1006/excr.1995.1132; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SCHAEFER D, 1995, INT J CANCER, V60, P520, DOI 10.1002/ijc.2910600416; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WEHRLE I, 1994, INT J ONCOL, V5, P1341; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	60	32	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					791	797		10.1038/sj.onc.1201247	http://dx.doi.org/10.1038/sj.onc.1201247			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266965				2022-12-28	WOS:A1997XQ11700005
J	Tolkacheva, T; Feuer, B; Lorenzi, MV; Saez, R; Chan, AML				Tolkacheva, T; Feuer, B; Lorenzi, MV; Saez, R; Chan, AML			Cooperative transformation of NIH3T3 cells by G alpha 12 and Rac1	ONCOGENE			English	Article						Rac1; RhoA; Cdc42Hs; G alpha 12; oncogene; transformation	ACTIN STRESS FIBERS; GENE-PRODUCT; G-PROTEINS; RAS TRANSFORMATION; ALPHA-SUBUNITS; CDC42 GTPASES; RHO; BINDING; KINASE; FAMILY	The heterotrimeric G-protein, G alpha 12, together with the closely-related G alpha 13, are members of the G12 class of alpha-subunits important in mediating the signaling from seven transmembrane domain-spanning receptors, Recent evidence implicating both G alpha 12 and G alpha 13 in the activation of signaling pathways involving members of the RHO gene family led us to examine the role of Rad, RhoA and Cdc42Hs in the transforming properties of G alpha 12. Asparagine 17 (Asn 17) dominant inhibitory mutants of Rad, and to a lesser extent RhoA, block focus forming ability of the GTPase-deficient mutant of G alpha 12 (G alpha 12 Leu 229) in NIH3T3 cells, In turn, wild-type G alpha 12 cooperates well with Rad Val 12 but not with RhoA Leu 63 mutant in transforming NIH3T3 cells, Interestingly, the morphology of foci induced by G alpha 12 and RhoA mutants are strikingly similar and is distinct from those displayed by Rad Val 12 mutant, The fact that G alpha 12's ability to induce mitogenesis in NIH3T3 cells is not significantly perturbed by C3 ribosyltransferase suggested that RhoA does not play a major role in G alpha 12-induced mitogenic events, Activated mutant of Rad has previously been demonstrated to stimulate the activity of the stress-induced c-Jun IV-terminal kinase/stress-activated protein kinases (JNK/SAPKs), Transient co-transfection of Rad Val 12 mutant with the wild-type G alpha 12 in COS7 cells leads to the further activation of an exogenously expressed hemagglutinin(HA)-tagged JNK. Furthermore, the cooperation between G alpha 12 and Rad in cellular transformation is correlated with their ability to stimulate transcription from c-fos serum response element (SRE).	CUNY MT SINAI SCH MED,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Li WQ, 1996, ONCOGENE, V13, P731; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Zhang YH, 1996, ONCOGENE, V12, P2377	36	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					727	735		10.1038/sj.onc.1201229	http://dx.doi.org/10.1038/sj.onc.1201229			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264413				2022-12-28	WOS:A1997XP68300012
J	Douville, E; Downward, J				Douville, E; Downward, J			EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2	ONCOGENE			English	Article						SOS; Rsk; phosphorylation	NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; TERNARY COMPLEX-FORMATION; SIGNAL-TRANSDUCTION; MAP KINASE; S6 KINASE; IN-VIVO; SUBSTRATE RECOGNITION; DEPENDENT ACTIVATION	SOS, the guanine nucleotide exchange factor for Ras, becomes phosphorylated on serine and threonine residues following stimulation of cells with growth factors. These phosphorylations may play a role in negative feedback of Ras stimulation and have been shown to be mediated in part by the MAP kinases Erk-1 and Erk-2. Here we show that in addition to MAP kinase, a major mitogen activated kinase for SOS is p90 Rsk-2, a downstream target of MAP kinase. p90 Rsk-2 phosphorylates SOS in an in gel assay and also in solution in vitro. The ability of p90 Rsk-2 to phosphorylate SOS increases greatly following EGF treatment of PC12 cells and is blocked by expression of N17 Ras or treatment with the MEK inhibitor PD98059. Phosphopeptide mapping revealed that the sites phosphorylated by p90 Rsk-2 in vitro were also phosphorylated in intact cells in response to EGF treatment. Several major sites of in vivo phosphorylation correlated with p90 Rsk-2 phosphorylation sites rather than MAP kinase sites. It is therefore likely that p90 Rsk-2 plays an important role in the down regulation of the Ras activation pathway through SOS.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				ADCOCK MR, 1993, NATURE, V363, P83; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASU T, 1994, ONCOGENE, V9, P3483; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Byrne JL, 1996, ONCOGENE, V13, P2055; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Cano E, 1996, ONCOGENE, V12, P805; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen RH, 1996, ONCOGENE, V12, P1493; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Holt KH, 1996, MOL CELL BIOL, V16, P577; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; Klarlund JK, 1996, J BIOL CHEM, V271, P16674, DOI 10.1074/jbc.271.28.16674; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; MARTE BM, 1995, ONCOGENE, V10, P167; MARTE BM, 1996, CURR BIOL, V7, P1; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SASTRY L, 1995, ONCOGENE, V11, P1107; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TOSHIHIRO N, 1996, CELL, V86, P465; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	63	128	129	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	1997	15	4					373	383		10.1038/sj.onc.1201214	http://dx.doi.org/10.1038/sj.onc.1201214			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242373				2022-12-28	WOS:A1997XM23800001
J	Coopersmith, CM; Gordon, JI				Coopersmith, CM; Gordon, JI			gamma-ray-induced apoptosis in transgenic mice with proliferative abnormalities in their intestinal epithelium: Re-entry of villus enterocytes into the cell cycle does not affect their radioresistance but enhances the radiosensitivity of the crypt by inducing p53	ONCOGENE			English	Article						radiation; apoptosis; cell cycle; intestinal epithelium; transgenic mice; p53	MOUSE SMALL-INTESTINE; RADIATION-INDUCED APOPTOSIS; BCL-2 HOMOLOG BAK; IN-VIVO; TUMOR-ANTIGEN; T-ANTIGEN; DIFFERENTIATION PROGRAMS; CHROMOSOMAL BREAKPOINT; GASTROINTESTINAL-TRACT; DNA FRAGMENTATION	The radiosensitivity of proliferating crypt epithelial cells makes the gut a major limiting factor in the use of radiotherapy for treatment of abdominal cancers, As post-mitotic epithelial cells migrate from mouse small intestinal crypts to the base of adjacent villi, they rapidly lose their ability to undergo apoptosis in response to ionizing irradiation (IR), To determine whether this radioresistance reflects withdrawal from the cell cycle, we used a lineage-specific promoter to direct expression of wild type Simian virus 40 T antigen (SV40 TAgWt) to villus, but not crypt, enterocytes in FVB/N transgenic mice, SV40 TAgWt induced, pRB-dependent, re-entry into the cell cycle is not associated with the acquisition of IR-stimulated apoptosis 4 h or 24 h after 6 Gy or 12 Gy of gamma-irradiation, Coexpression of SV40 TAgWt and K-ras(Val12) produces dysplasia in cycling villus enterocytes but no shift towards apoptotic responsiveness to IR, These findings suggest that the radioresistance of villus enterocytes is not simply due to their cell cycle arrest and may be a reflection of their microenvironment, Remarkably, reentry of villus enterocytes to the cell cycle increases the radiosensitivity of the crypt epithelium without changing Bcl-2, Bcl-x(L), Bak, or Bar expression, This effect is only manifest after IR and, based upon results obtained with mutant SV40 TAgs, depends upon reaching a critical level of proliferation in villus enterocytes, Like the normal crypt response to IR, the villus-derived enhancement of IR-stimulated crypt apoptosis is associated with an induction of p53 and Raf-l, and is dependent upon p53, Unlike the normal crypt response to IR, the p53 induction involves cells distributed throughout the crypt and the apoptotic response is not confined to the lower half of the crypt, These results indicate that signals initiated by cycling enterocytes can be transmitted to the crypt epithelium to induce p53 and influence their IR-induced apoptosis, Understanding the underlying signaling pathways may provide clues about how to modify a normal crypt's radiosensitivity for therapeutic benefit.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bry L, 1996, P NATL ACAD SCI USA, V93, P1161, DOI 10.1073/pnas.93.3.1161; CALVERT R, 1990, ANAT REC, V227, P199, DOI 10.1002/ar.1092270208; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHEN JD, 1992, ONCOGENE, V7, P1167; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHWALINSKI S, 1988, CELL TISSUE KINET, V21, P317, DOI 10.1111/j.1365-2184.1988.tb00790.x; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COOPERSMITH CM, 1997, IN PRESS J CELL BIOL; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALL PA, 1994, J CELL SCI, V107, P3569; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; Kitada S, 1996, ONCOGENE, V12, P187; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; MCCALLUM DE, IN PRESS ONCOGENE; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MERRITT AJ, 1994, CANCER RES, V54, P614; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POTTEN CS, 1994, INT J RADIAT BIOL, V65, P71, DOI 10.1080/09553009414550101; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Pullan S, 1996, J CELL SCI, V109, P631; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STEPHENS L C, 1989, Cancer Bulletin (Houston), V41, P106; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WANG HG, 1994, ONCOGENE, V9, P2751; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x; WRIGHT NA, 1984, BIOL EPITHELIAL CELL, P843; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhan QM, 1996, ONCOGENE, V13, P2287	66	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					131	141		10.1038/sj.onc.1201176	http://dx.doi.org/10.1038/sj.onc.1201176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244349				2022-12-28	WOS:A1997XK37200002
J	Vincent, F; Nagashima, M; Takenoshita, S; Khan, MA; Gemma, A; Hagiwara, K; Bennett, WP				Vincent, F; Nagashima, M; Takenoshita, S; Khan, MA; Gemma, A; Hagiwara, K; Bennett, WP			Mutation analysis of the transforming growth factor-beta type II receptor in human cell Lines resistant to growth inhibition by transforming growth factor-beta	ONCOGENE			English	Article						single-strand conformation polymorphism analysis; somatic mutation; polymerase chain reaction; genomic DNA; microsatellite instability	TGF-BETA; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CARCINOMA-CELLS; GENE; EXPRESSION; GROWTH-FACTOR-BETA-1; BINDING; COLON; OVEREXPRESSION	The transforming growth factor-beta (TGF-beta) binds the type II TGF-beta growth factor receptor (RII) to inhibit the growth of most epithelial tissues, Most human colon and gastric cancers with microsatellite instability (MI) have frameshift mutations in polynucleotide repeats within the RII coding region; these mutations truncate the receptor protein and disable the serine/threonine kinase to produce TGF-beta resistance, To further investigate the type, frequency and tissue distribution of RII mutations, we selected 24 human cancer cell lines from various tissues which were previously reported to be resistant to the inhibitory effects of TGF-beta, We developed protocols for non-isotopic SSCP analysis of PCR products from genomic DNA samples, and we tested them for microsatellite instability, PCR-SSCP analysis followed by DNA sequencing identified deletion mutations in the exon 3 poly-adenine tract in three colon tumor cell lines: LS174T and SW48 had a single base deletion and LS411 had a two base deletion. Among the 24 previously unreported cell lines, only these three demonstrated microsatellite instability. These and other recent data indicate that RII mutations are essentially confined to colon and gastric cancers with microsatellite instability. The narrow spectrum of tissues containing RII mutations illustrates the complexity of genetic checkpoints in human carcinogenesis.	NCI, HUMAN CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA; IFREMER, F-44311 NANTES 03, FRANCE; GUNMA UNIV, SCH MED, DEPT SURG, MAEBASHI, GUMMA 371, JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ifremer; Gunma University				VINCENT-HUBERT, Francoise/0000-0002-2266-9237				ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; *AM TYP CULT COLL, 1992, AM TYP CULT COLL CAT; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Hagiwara K, 1996, NUCLEIC ACIDS RES, V24, P2460, DOI 10.1093/nar/24.12.2460; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HOWE PH, 1993, J BIOL CHEM, V268, P21448; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; LIN HY, 1994, CELL MOL BIOL, V40, P337; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MYEROFF LL, 1995, CANCER RES, V55, P5545; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REISS M, 1993, CANCER RES, V53, P899; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Schutte M, 1996, CANCER RES, V56, P2527; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takenoshita S, 1996, GENOMICS, V36, P341, DOI 10.1006/geno.1996.0471; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; TAKENOSHITA S, 1997, IN PRESS CARCINOGENE; VINCENT F, BIOCHEM BIOPH RES CO, V223, P561; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAN ZF, 1994, J BIOL CHEM, V269, P13231; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	45	58	59	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					117	122		10.1038/sj.onc.1201166	http://dx.doi.org/10.1038/sj.onc.1201166			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233784				2022-12-28	WOS:A1997XH58600013
J	Bergemann, AD; Zhang, L; Chiang, MK; Brambilla, R; Klein, R; Flanagan, JG				Bergemann, AD; Zhang, L; Chiang, MK; Brambilla, R; Klein, R; Flanagan, JG			Ephrin-B3, a ligand for the receptor EphB3, expressed at the midline of the developing neural tube	ONCOGENE			English	Article						Eph; ephrin; receptor; kinase; development; neural	PROTEIN-TYROSINE KINASE; GROWTH-FACTOR; FLOOR PLATE; KIT-LIGAND; TRANSMEMBRANE LIGANDS; MOLECULAR-CLONING; COMMISSURAL AXONS; MESSENGER-RNAS; NERVOUS-SYSTEM; IN-VITRO	The ephrins are a family of ligands that bind to Eph family receptor tyrosine kinases, and have been implicated in axon guidance and other patterning processes during vertebrate development. We describe here the identification and characterization of murine ephrin-B3. The cDNA encodes a 340 amino acid transmembrane molecule, most closely related to the two other known transmembrane ligands, ephrin-B1 and ephrin-B2. In addition to homology in their extracellular receptor binding domains, these transmembrane ligands share striking homology between their cytoplasmic domains, with 31 of the last 34 amino acids of ephrin-B3 being identical to ephrin-B2, suggesting functional interactions of the cytoplasmic tail. While most Eph family ligands are promiscuous in their interactions with Eph receptors, binding studies with the five receptors known to bind other transmembrane ligands only revealed a high affinity interaction of ephrin-B3 with EphB3, with a dissociation constant of approximately 1 nM. In situ hybridization of mouse embryos showed ephrin-B3 is expressed prominently at the dorsal and ventral midline of the neural tube, particularly in the floor plate, a structure with key functions in patterning the nervous system. The isolation of this ligand may help to elucidate the molecular basis of patterning activities at the neural tube midline.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	Harvard University; Harvard Medical School; European Molecular Biology Laboratory (EMBL)	Flanagan, JG (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.		Klein, Ruediger/C-6147-2008; Flanagan, John/AAM-2995-2020; Brambilla, Riccardo/A-6082-2010	Klein, Ruediger/0000-0002-3109-0163; Brambilla, Riccardo/0000-0003-3569-5706; Bergemann, Andrew/0000-0002-0027-7662	NICHD NIH HHS [HD29417] Funding Source: Medline; NIDDK NIH HHS [DK45580] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD029417, R01HD029417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045580] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brambilla R, 1996, MOL CELL NEUROSCI, V8, P199, DOI 10.1006/mcne.1996.0057; BRAMBILLA R, 1996, MOL CELL NEUROSCI, V6, P487; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CIOSSEK T, 1995, ONCOGENE, V10, P97; CIOSSEK T, 1995, ONCOGENE, V11, P2085; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Donoghue MJ, 1996, MOL CELL NEUROSCI, V8, P185, DOI 10.1006/mcne.1996.0056; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Flanagan JG, 1997, CELL, V90, P403; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLANAGAN JG, IN PRESS ANN REV NEU, V21; FLETCHER FA, 1994, GENOMICS, V24, P127, DOI 10.1006/geno.1994.1589; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GANJU P, 1994, ONCOGENE, V9, P1613; Gao PP, 1996, P NATL ACAD SCI USA, V93, P11161, DOI 10.1073/pnas.93.20.11161; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; Kilpatrick TJ, 1996, MOL CELL NEUROSCI, V7, P62, DOI 10.1006/mcne.1996.0005; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Nicola NA, 1996, GROWTH FACTORS, V13, P141, DOI 10.3109/08977199609034574; NIETO MA, 1992, DEVELOPMENT, V116, P1137; Ohta K, 1996, MECH DEVELOP, V54, P59, DOI 10.1016/0925-4773(95)00461-0; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SAJJADI FG, 1993, ONCOGENE, V8, P1807; Sakano S, 1996, ONCOGENE, V13, P813; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SMITH A, 1997, CURRENT BIOL; SOANS C, 1994, ONCOGENE, V9, P3353; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WU Q, 1995, DEVELOPMENT, V121, P4005; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Zhang JH, 1996, J NEUROSCI, V16, P7182; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	69	62	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	1998	16	4					471	480		10.1038/sj.onc.1201557	http://dx.doi.org/10.1038/sj.onc.1201557			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484836				2022-12-28	WOS:000071739400005
J	Cambier, N; Chopra, R; Strasser, A; Metcalf, D; Elefanty, AG				Cambier, N; Chopra, R; Strasser, A; Metcalf, D; Elefanty, AG			BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner	ONCOGENE			English	Article						BCR-ABL oncogene; apoptosis	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR P53; V-ABL; PHILADELPHIA-CHROMOSOME; PROGENITOR CELLS; CLONAL ANALYSIS; RAS ONCOGENE; BLAST CRISIS; DNA-DAMAGE	The hallmark of chronic myeloid leukemia (CML) is the chimeric tyrosine kinase oncogene bcp - abl. Since expression of bcr - abl mRNA frequently increases with disease progression and a duplication of the Philadelphia chromosome (harbouring the bcr - abl hybrid locus) represents the most frequent karyotypic abnormality in acute phase CML, we hypothesized that the level of BCR - ABL protein may affect the disease phenotype. Therefore, the biological effects of high and low levels of BCR - ABL expression were compared in growth factor-dependent and -independent myeloid and lymphoid cell lines. Our results demonstrated that low levels of BCR - ABL were sufficient to render these cell lines growth factor independent and tumorigenic, but higher levels were mandatory for additional protection against apoptotic stimuli. The provision of growth factor or an activated ras oncogene did not afford the same degree of protection as high levels of BCR - ABL and there were qualitative differences between the survival signals mediated by BCR - ABL and Bcl-2. These results have enabled us to establish a dose-dependent hierarchy of BCR - ABL induced biological effects, thus distinguishing the activation of pathways mediating protection from cytokine withdrawal from those protecting against other apoptotic stimuli.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute	Elefanty, AG (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Parkville, Vic 3050, Australia.		Elefanty, Andrew G/A-6066-2008; Strasser, Andreas/C-7581-2013	Strasser, Andreas/0000-0002-5020-4891; Elefanty, Andrew/0000-0001-6448-8314	NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Albrecht T, 1996, BRIT J HAEMATOL, V95, P501, DOI 10.1046/j.1365-2141.1996.d01-1934.x; AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; ANDREWS DF, 1987, LEUKEMIA, V1, P718; ANTONIOU M, 1993, J CELL BIOL, V123, P1055, DOI 10.1083/jcb.123.5.1055; BAKER DA, 1994, LEUKEMIA, V8, P1970; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BOSWELL HS, 1990, EXP HEMATOL, V18, P452; CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUMENIL D, 1994, EXP HEMATOL, V22, P178; ELEFANTY AG, 1992, BLOOD, V79, P1271; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; GROFFEN J, 1987, CHRONIC MYELOID LEUK, P983; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hariharan I K, 1988, Oncogene Res, V3, P387; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; JACOB MC, 1991, CYTOMETRY, V12, P550, DOI 10.1002/cyto.990120612; KANTARJIAN HM, 1987, AM J MED, V83, P445, DOI 10.1016/0002-9343(87)90754-6; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KEATING A, 1987, CHRONIC MYELOID LEUK, P1021; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1979, INT J CANCER, V24, P616, DOI 10.1002/ijc.2910240515; METCALF D, 1995, LEUKEMIA, V9, P1556; METCALF D, 1977, RECENT RESULTS CANC, V61, P120; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nishii K, 1996, ONCOGENE, V13, P2225; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; SAKAI N, 1994, EXP CELL RES, V215, P131, DOI 10.1006/excr.1994.1324; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368	74	98	101	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					335	348		10.1038/sj.onc.1201490	http://dx.doi.org/10.1038/sj.onc.1201490			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467959				2022-12-28	WOS:000071582100006
J	Steegenga, WT; Riteco, N; Jochemsen, AG; Fallaux, FJ; Bos, JL				Steegenga, WT; Riteco, N; Jochemsen, AG; Fallaux, FJ; Bos, JL			The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells	ONCOGENE			English	Article						p53; adenovirus; E1A; large E1B; E4orf6	HUMAN PAPILLOMAVIRUS TYPE-16; TRANSFORMED-CELLS; EARLY REGION-4; TUMOR-ANTIGEN; E6 ONCOPROTEIN; CELLULAR P53; WILD-TYPE; TRANSCRIPTIONAL REPRESSION; BINDING PROTEIN; EXPRESSION	It has recently been shown that an adenovirus mutant lacking expression of the large E1B protein (Delta E1B) selectively replicates in p53 deficient cells. However, apart from the large E1B protein the adenovirus early region encodes the E1A and E4orf6 proteins which also have been reported to affect p53 expression as well as its functioning. After infection with wild-type adenovirus we observed a dramatic decrease in wild-type p53 expression while no down-regulation of p53 could be detected after infection with the Delta E1B virus. The different effects of the wild-type and Delta E1B adenovirus on p53 expression were not only found in cells expressing wild-type p53 but mere also observed when tumor cells expressing highly stabilized mutant p53 were infected with these two viruses. Infection with different adenovirus mutants indicated the importance of a direct interaction between p53 and the large E1B protein for reduced p53 expression after infection. Moreover, coexpression of the E4orf6 protein was found to be required for this phenomenon, while expression of E1A is dispensable. Tn addition, we provide evidence that p53 is actively degraded in wild-type adenovirus-infected cells but not in Delta E1B-infected cells.	Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands; Leiden Univ, Sylvius Labs, Mol Carcinogenesis Lab, NL-2300 RA Leiden, Netherlands	Utrecht University; Leiden University; Leiden University - Excl LUMC	Steegenga, WT (corresponding author), Univ Utrecht, Physiol Chem Lab, POB 80042, NL-3508 TA Utrecht, Netherlands.							Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRAHAM FL, 1991, GENE TRANSFER EXPRES; GRAND RJA, 1995, VIROLOGY, V210, P323, DOI 10.1006/viro.1995.1349; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grand RJA, 1996, VIROLOGY, V218, P23, DOI 10.1006/viro.1996.0162; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JOCHEMSEN AG, 1987, EMBO J, V6, P3399, DOI 10.1002/j.1460-2075.1987.tb02663.x; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Marcellus RC, 1996, J VIROL, V70, P6207, DOI 10.1128/JVI.70.9.6207-6215.1996; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; STEEGENGA WT, 1995, ONCOGENE, V11, P49; STEEGENGA WT, 1995, VIROLOGY, V212, P543, DOI 10.1006/viro.1995.1512; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; STRATFORDPERRIC.LD, 1991, HUMAN GENE TRANSFER; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VANDENHEUVEL SJL, 1993, J VIROL, V67, P5226, DOI 10.1128/JVI.67.9.5226-5234.1993; VOJTESEK B, 1993, J CELL SCI, V105, P607; WEINBERG DH, 1983, P NATL ACAD SCI-BIOL, V80, P5383, DOI 10.1073/pnas.80.17.5383; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	53	144	150	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					349	357		10.1038/sj.onc.1201540	http://dx.doi.org/10.1038/sj.onc.1201540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467960				2022-12-28	WOS:000071582100007
J	Sun, ZJ; Pan, J; Bubley, G; Balk, SP				Sun, ZJ; Pan, J; Bubley, G; Balk, SP			Frequent abnormalities of TSG101 transcripts in human prostate cancer	ONCOGENE			English	Article						prostate cancer; tumor suppressor; aberrant RNA splicing; TSG101	DEPENDENT PROTEIN-KINASE; FHIT GENE; STATHMIN; CELLS; PHOSPHORYLATION; PHOSPHOPROTEIN; EXPRESSION; 3P14.2	TSG101 has been identified as a candidate tumor suppressor gene and abnormal transcripts have been identified in a substantial fraction of breast cancers, To determine whether TSG101 expression is commonly altered in other tumors, a series of 15 primary and metastatic prostate cancers were analysed by reverse transcriptase-PCR amplification, Abnormal transcripts with extensive deletions in the coding region were found in nine of these tumors, while only the normal transcript was found in control and benign prostatic hypertrophy tissues, More than one abnormal transcript was found in four of these nine cases and distinct abnormal TSG101 transcripts were found in separate biopsies taken from one tumor, Importantly, the normal TSG101 transcript was undetectable in two metastatic prostate cancers, indicating the absence of TSG101 protein, Sequence analysis demonstrated that there were at least sh distinct deletions, with four of these deletions found in more than one tumor sample, The most commonly identified deletion, from bp 153 to 1055, was identical to a deletion reported previously in breast cancer, These results demonstrate that TSG101 transcripts are frequently abnormal in prostate cancer and suggest that loss of TSG101 protein contributes to disease development or progression.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Sun, ZJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA065647, R01CA070297, R29CA070297] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA070297-03, R29 CA070297, R01 CA070297, CA65647, R01 CA070297-12, CA70297] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERETTA L, 1993, J BIOL CHEM, V268, P20076; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; DURAJ J, 1995, LEUKEMIA RES, V19, P457, DOI 10.1016/0145-2126(94)00154-3; EUSTACE W, 1995, FEBS LETT, V364, P309, DOI 10.1016/0014-5793(95)00416-7; GUSSOW D, 1987, J IMMUNOL, V139, P3132; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LEIGHTON IA, 1993, MOL CELL BIOCHEM, V128, P151, DOI 10.1007/BF01076766; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAMURA K, 1995, ELECTROPHORESIS, V16, P1530, DOI 10.1002/elps.11501601253; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8	16	45	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3121	3125		10.1038/sj.onc.1201521	http://dx.doi.org/10.1038/sj.onc.1201521			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444960				2022-12-28	WOS:000070968000012
J	Thien, CBF; Langdon, WY				Thien, CBF; Langdon, WY			Tyrosine kinase activity of the EGF receptor is enhanced by the expression of oncogenic 70Z-Cbl	ONCOGENE			English	Article						growth factor; oncogene; receptor; signal transduction; tyrosine kinase	EPIDERMAL GROWTH-FACTOR; C-CBL PROTOONCOGENE; CELL ANTIGEN RECEPTOR; PC12 CELLS; ADAPTER PROTEINS; SH3 DOMAIN; V-CBL; PHOSPHOTYROSINE PHOSPHATASE; NEURONAL DIFFERENTIATION; PHOSPHORYLATED CBL	The 120kD product of the c-Cbl oncogene is a prominent substrate of protein tyrosine kinases that lacks a known catalytic activity but possesses an array of binding sites for cytoplasmic signalling proteins, An oncogenic form of Cbl was recently identified in the 70Z/3 pre-B cell lymphoma which has a small deletion at the N-terminus of the Ring finger domain. This form of Cbl, termed 70Z-Cbl, exhibits an enhanced level of tyrosine phosphorylation compared with c-Cbl, Here we demonstrate that the expression of 70Z-Cbl induces a tenfold enhancement in the kinase activity of the EGF receptor in serum-starved and EGF-stimulated cells, In serum-starved cells this results in EGF receptor autophosphorylation and the recruitment of Grb2, Shc and Sos1 but does not induce a corresponding increase in MAP kinase activity, Furthermore the expression of 70Z-Cbl greatly enhances EGF-induced tyrosine phosphorylation of the protein tyrosine phosphatase SHP-2, We also show that the Cbl/EGF receptor complex is predominantly associated with CrkII and is distinct to the Grb2/Shc/Sos1 complex that associates with the EGF receptor. These findings therefore demonstrate a biochemical effect of an oncogenic Cbl protein and support predictions from C, elegans that Cbl functions as regulator of receptor tyrosine kinases.	UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT PATHOL,NEDLANDS,WA 6907,AUSTRALIA	University of Western Australia			Thien, Christine/GQP-0424-2022	Thien, Christine/0000-0003-3884-5546				Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASE RD, 1994, J BIOL CHEM, V269, P10467; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20241; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; JONGEWARD GD, 1995, GENETICS, V139, P1553; Khwaja A, 1996, ONCOGENE, V12, P2491; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; Kontani K, 1996, J BIOL CHEM, V271, P1534; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PANCHAMOORTHY G, 1996, J BIOL CHEM, V271, P387; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Sattler M, 1996, ONCOGENE, V12, P839; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SCHAEFER E, 1996, PROMEGA NOTES, V59, P2; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSYGANKOV AY, 1996, J BIOL CHEM, V271; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	64	55	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2909	2919		10.1038/sj.onc.1201468	http://dx.doi.org/10.1038/sj.onc.1201468			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416834				2022-12-28	WOS:A1997YK37700003
J	Matsumoto, K; Asano, T; Endo, T				Matsumoto, K; Asano, T; Endo, T			Novel small GTPase M-Ras participates in reorganization of actin cytoskeleton	ONCOGENE			English	Article						small GTPase; Ras family; Rho family; actin cytoskeleton; microspikes; stress fibers	NUCLEOTIDE EXCHANGE FACTORS; BINDING PROTEIN; SMOOTH-MUSCLE; CDC42 GTPASES; STRESS FIBERS; GENE-PRODUCT; RHO-PROTEIN; CELL-CYCLE; C-MYC; GROWTH	During an attempt to elucidate regulatory mechanisms of skeletal muscle cell differentiation, we cloned cDNAs encoding a novel smalt GTPase from cDNA libraries of the mouse skeletal muscle cell Line C2 and rat brain. It was designated as M-Ras due to the structural similarity to Ras family proteins. M-Ras contained conserved motifs for GDP/GTP-binding and GTPase activities, whereas it varied from the other Ras family proteins at several amino acids within the extended effector domain. From the C-terminal sequence, M-Ras is presumed to be anchored to the cell membrane with a geranylgeranyl group in combination with a polybasic region. Bacterially expressed recombinant M-Ras exerted the GTP-binding and GTPase activities. A mutant M-Ras(G22V) was unable to hydrolyze bound GTP, indicating that it serves as a constitutively active form. Epitope-tagging experiments showed that M-Ras was concentrated on certain plasma membrane-associated structures. Transfection of M-Ras cDNA and microinjection of the M-Ras(G22V) protein into fibroblasts induced formation of the peripheral microspikes. In addition, the actin stress fibers disappeared and instead numerous actin foci were formed in the injected cells. The transfected cells eventually exhibited dendritic appearances,vith microspikes. Consequently, M-Ras is likely to participate in reorganization of the actin cytoskeleton.	CHIBA UNIV,FAC SCI,DEPT BIOL,INAGE KU,CHIBA 263,JAPAN	Chiba University								BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Dutartre H, 1996, J CELL SCI, V109, P367; Endo T, 1996, J BIOL CHEM, V271, P27855, DOI 10.1074/jbc.271.44.27855; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARRELL F, 1992, J LAB CLIN MED, V120, P533; Foster R, 1996, MOL CELL BIOL, V16, P2689; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8988; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HATA Y, 1991, J BIOL CHEM, V266, P6571; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Nei M., 1987, MOL EVOLUTIONARY GEN; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; REY I, 1994, ONCOGENE, V9, P685; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SELF AJ, 1993, ONCOGENE, V8, P655; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANKRANEN HJ, 1994, CARCINOGENESIS, V15, P307, DOI 10.1093/carcin/15.2.307; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WILDEY GM, 1993, BIOCHEM BIOPH RES CO, V194, P552, DOI 10.1006/bbrc.1993.1855; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yaffe D, 1969, Curr Top Dev Biol, V4, P37, DOI 10.1016/S0070-2153(08)60480-9; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	60	76	81	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2409	2417		10.1038/sj.onc.1201416	http://dx.doi.org/10.1038/sj.onc.1201416			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395237				2022-12-28	WOS:A1997YE96300003
J	Takemura, M; Kitagawa, T; Izuta, S; Wasa, J; Takai, A; Akiyama, T; Yoshida, S				Takemura, M; Kitagawa, T; Izuta, S; Wasa, J; Takai, A; Akiyama, T; Yoshida, S			Phosphorylated retinoblastoma protein stimulates DNA polymerase alpha	ONCOGENE			English	Article						Rb protein; DNA polymerase alpha; protein-protein interaction; DNA replication; phosphorylation	HUMAN CYCLIN-E; T-ANTIGEN; TRANSCRIPTION FACTOR; GENE-PRODUCT; SV40 ORIGIN; CALF THYMUS; REPLICATION INVITRO; CELL-CYCLE; RB PROTEIN; IN-VITRO	Human retinoblastoma (Rb) protein, immunopurified from an extract of recombinant baculovirus infected cells, stimulated 10-100-fold the activity of DNA polymerase alpha from calf thymus or human HeLa cells, Purified Rb protein is composed of two electrophoretically distinguishable forms, i.e., partially phosphorylated and under-phosphorylated forms. Dephosphorylation of Rb protein by protein phosphatase 2A largely diminished its stimulatory effect, On the other hand, a hyperphosphorylated Rb protein, obtained from insect cells overexpressing Rb protein, cyclin E and cyclin-dependent kinase 2 simultaneously, stimulated DNA polymerase alpha more strongly than the singly-expressed Rb protein. These results indicate that the phosphorylation is crucial for the stimulation, Rb protein isolated from human Burkitt lymphoma Raji cells also stimulated DNA polymerase alpha. In contrast, Rb protein did not affect eukaryotic DNA primase or Klenow fragment of Escherichia coli DNA polymerase I, By immunoprecipitation using anti-DNA polymerase alpha antibody, Rb protein in nuclear extract of Raji cells was coprecipitated with DNA polymerase alpha, This result indicates that DNA polymerase alpha exists as a complex containing phosphorylated Rb protein in cells. DNA polymerase alpha specifically bound to a purified Rb protein-immobilized Sepharose column. Rb protein also bound to DNA polymerase alpha trapped to anti-DNA polymerase a antibody-Sepharose column, suggesting the direct association of these two proteins, These observations suggest a new function of phosphorylated Rb protein in the regulation of DNA replication.	NAGOYA UNIV,SCH MED,DIS MECHANISM & CONTROL RES INST,CANC CELL BIOL LAB,NAGOYA,AICHI 466,JAPAN; KUMAMOTO UNIV,FAC SCI,DEPT BIOL SCI,KUMAMOTO 860,JAPAN; NAGOYA UNIV,SCH MED,DEPT PHYSIOL,NAGOYA,AICHI 466,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN	Nagoya University; Kumamoto University; Nagoya University; Osaka University								AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; AMIN AA, 1994, J BIOL CHEM, V269, P7735; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURUICHI Y, 1993, BIOSCI BIOTECH BIOCH, V57, P147, DOI 10.1271/bbb.57.147; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1994, COLD SPRING HARB SYM, V59, P97, DOI 10.1101/SQB.1994.059.01.013; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; NAKAMURA H, 1984, EXP CELL RES, V151, P123, DOI 10.1016/0014-4827(84)90362-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; SAVOYSKY E, 1992, BIOCHEM BIOPH RES CO, V187, P697, DOI 10.1016/0006-291X(92)91251-K; SAVOYSKY E, 1993, ONCOGENE, V8, P319; SIMBULAN CMG, 1993, J BIOL CHEM, V268, P93; SIMBULAN CMG, 1994, BIOCHEMISTRY-US, V33, P9007, DOI 10.1021/bi00196a019; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SUZUKI M, 1994, J BIOL CHEM, V269, P10225; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P46, DOI 10.1006/bbrc.1994.1191; TAMAI K, 1988, BIOCHIM BIOPHYS ACTA, V950, P263, DOI 10.1016/0167-4781(88)90122-4; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TUNG HYL, 1984, EUR J BIOCHEM, V138, P635, DOI 10.1111/j.1432-1033.1984.tb07962.x; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; YOKOTA J, 1988, ONCOGENE, V3, P471; YOSHIDA S, 1974, BIOCHIM BIOPHYS ACTA, V353, P463, DOI 10.1016/0005-2787(74)90052-5; YOSHIDA S, 1989, J BIOCHEM-TOKYO, V106, P389, DOI 10.1093/oxfordjournals.jbchem.a122863	50	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2483	2492		10.1038/sj.onc.1201431	http://dx.doi.org/10.1038/sj.onc.1201431			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395244				2022-12-28	WOS:A1997YE96300010
J	Isfort, RJ; Cody, DB; Doersen, CJ; Richards, WG; Yoder, BK; Wilkinson, JE; Kier, LD; Jirtle, RL; Isenberg, JS; Klounig, JE; Woychik, RP				Isfort, RJ; Cody, DB; Doersen, CJ; Richards, WG; Yoder, BK; Wilkinson, JE; Kier, LD; Jirtle, RL; Isenberg, JS; Klounig, JE; Woychik, RP			The tetratricopeptide repeat containing Tg737 gene is a liver neoplasia tumor suppressor gene	ONCOGENE			English	Article						Tg737; tumor suppressor gene; liver neoplasia	POLYCYSTIC KIDNEY-DISEASE; STEM-CELLS; HUMAN HOMOLOG; SNAP HELIX; GROWTH; PROTEIN; DIFFERENTIATION; MUTATION; MOUSE; CARCINOGENESIS	The Tg737 gene was investigated for gross alterations in a series of rodent/human liver tumors and human tumorigenic cell lines. The Tg737 gene was found to be altered in approximately 40% of the rodent chemically-induced liver tumors, 40% of the human liver tumors, and in liver, kidney and pancreatic human tumor cell lines. Ectopic re-expression of the Tg737 gene in a Tg737 deleted mouse liver tumor cell line resulted in suppression of tumorigenic growth, without altering in vitro cell culture growth. Treatment of mice which are either homozygous normal or heterozygous deleted at the Tg737 locus with the carcinogen diethylnitrosamine resulted in an increase in preneoplastic foci formation in the Tg737 heterozygous deleted mice. Ectopic expression of the Tg737 gene results in multinucleated cells, loss of Tg737 gene expression results in the proliferation of liver stem cells (oval cells) without concomitant differentiation, and reexpression of the Tg737 gene reestablished responsiveness to external differentiation factors. We believe this is the first report demonstrating tumor suppression activity for a tetratricopeptide repeat gene family member and provides insights into the function of this family of genes in mammalian cells.	OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; UNIV TENNESSEE,SCH VET MED,KNOXVILLE,TN; MONSANTO AGR CO,ST LOUIS,MO; DUKE UNIV,MED CTR,DURHAM,NC; INDIANA UNIV,SCH MED,DEPT PHARMACOL & TOXICOL,INDIANAPOLIS,IN 46202	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Monsanto; Duke University; Indiana University System; Indiana University-Purdue University Indianapolis	Isfort, RJ (corresponding author), PROCTER & GAMBLE CO,MIAMI VALLEY LABS,POB 398707,CINCINNATI,OH 45247, USA.		Woychik, Richard P/C-8345-2019	Woychik, Richard P/0000-0001-8196-1732				ATERMAN K, 1992, J CANCER RES CLIN, V118, P87, DOI 10.1007/BF01187498; AVNER ED, 1994, LANCET, V344, P833, DOI 10.1016/S0140-6736(94)92820-7; Avner Ellis D., 1994, V5, P63; BIRCHMEIER W, 1994, BIOESSAYS, V16, P305, DOI 10.1002/bies.950160503; BRILL S, 1993, P SOC EXP BIOL MED, V204, P261; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; COLEMAN WB, 1993, AM J PATHOL, V142, P1373; FACTOR VM, 1994, AM J PATHOL, V145, P409; Fausto N, 1990, CURR OPIN CELL BIOL, V2, P1036, DOI 10.1016/0955-0674(90)90153-6; FRANCH HA, 1995, J CELL BIOL, V129, P245, DOI 10.1083/jcb.129.1.245; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HENNINGS H, 1993, P SOC EXP BIOL MED, V202, P1; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; ISFORT R, 1987, ONCOGENE RES, V2, P81; ISFORT RJ, 1994, INT J CANCER, V59, P114, DOI 10.1002/ijc.2910590121; ISFORT RJ, 1995, MOL CARCINOGEN, V14, P170, DOI 10.1002/mc.2940140306; ISFORT RJ, 1997, IN PRESS J CELL SCI; ISFORT RJ, 1997, IN PRESS MOL CARCINO; KUMADA K, 1995, J CELL SCI, V108, P895; LEBOEUF RA, 1986, CARCINOGENESIS, V7, P1431, DOI 10.1093/carcin/7.9.1431; LILLEBERG SL, 1992, PROG CLIN BIOL RES, V376, P203; LILLEBERG SL, 1992, MOL CARCINOGEN, V6, P159, DOI 10.1002/mc.2940060211; MARCEAU N, 1989, IN VITRO CELL DEV B, V25, P336; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; NICKOLOFF BJ, 1988, AM J PATHOL, V132, P543; PUGH TD, 1992, CANCER RES, V52, P280; Richards WG, 1996, AM J PATHOL, V149, P1919; RICHARDS WG, 1997, IN PRESS HEPATOLOGY; RIJKSEN G, 1993, J CELL PHYSIOL, V154, P393, DOI 10.1002/jcp.1041540223; RUBIN H, 1993, DIFFERENTIATION, V53, P123, DOI 10.1111/j.1432-0436.1993.tb00652.x; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHRICK JJ, 1995, HUM MOL GENET, V4, P559, DOI 10.1093/hmg/4.4.559; SELL S, 1993, INT J DEV BIOL, V37, P189; SELL S, 1994, LAB INVEST, V70, P6; SIKORSKI RS, 1993, MOL CELL BIOL, V13, P1212, DOI 10.1128/MCB.13.2.1212; SORIANO P, 1991, CELL, V64, P692; THORGEIRSSON SS, 1993, AM J PATHOL, V142, P1331; WILLIAMS ED, 1992, AM J PATHOL, V141, P773	40	30	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1797	1803		10.1038/sj.onc.1201535	http://dx.doi.org/10.1038/sj.onc.1201535			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362446				2022-12-28	WOS:A1997XZ72500006
J	Sobczak, K; Kozlowski, P; Napierala, M; Czarny, J; Wozniak, M; Kapuscinska, M; Losko, M; Koziczak, M; Jasinska, A; Powierska, J; Braczkowski, R; Breborowicz, J; Godlewski, D; Mackiewicz, A; Krzyzosiak, W				Sobczak, K; Kozlowski, P; Napierala, M; Czarny, J; Wozniak, M; Kapuscinska, M; Losko, M; Koziczak, M; Jasinska, A; Powierska, J; Braczkowski, R; Breborowicz, J; Godlewski, D; Mackiewicz, A; Krzyzosiak, W			Novel BRCA1 mutations and more frequent intron-20 alteration found among 236 women from western Poland	ONCOGENE			English	Article						BRCA1; mutations and variants; SSCP-heteroduplex analysis; Polish women; positive family history	BREAST-CANCER SUSCEPTIBILITY; POLYMERASE CHAIN-REACTION; OVARIAN-CANCER; GERMLINE MUTATIONS; RAPID DETECTION; GENE; FAMILIES; P53; DNA; PCR	Three different novel BRCA1 mutations, five independent cases of the same 12 bp insertion-duplication in intron-20 and two novel rare BRCA1 sequence variants were identified among 122 Polish women with positive, in most cases moderate family history of breast and/or ovarian cancer, 80 controls and 34 unselected breast cancer tissue specimens, All mutations and variants were germline. The 4153 delA frameshift mutation, the Tyr105Cys missense mutation and two cases of the alteration in intron-20 were found in the group of healthy women with positive family history. Two other cases of the intronic insertion mere found in unselected controls. Their carriers had no family history of breast or ovarian cancer but other cancers occurred in their families. The 1782 Trp/STOP nonsense mutation and one case of the insertion in intron-20 were first found in tissue specimens of breast cancer patient and breast/ovarian cancer patient, respectively. Their carriers also had no family history of breast or ovarian cancer. The distribution of the insertion in intron-20 in analysed groups and results of RT-PCR experiments suggest a less prominent role for this variant considered earlier a splicing mutation. This study shows also, that more population-oriented research is needed, involving women with less profound or even no family history of breast and ovarian cancer, to better understand the role and significance of different BRCA1 variants and mutations.	POLISH ACAD SCI,INST BIOORGAN CHEM,CANC GENET LAB,PL-61704 POZNAN,POLAND; WIELKOPOLSKA CANC CTR,CANC EPIDEMIOL & PREVENT UNION,PL-61866 POZNAN,POLAND; SILESIAN UNIV,SCH MED,DEPT INTERNAL MED,BYTOM,POLAND; UNIV SCH MED SCI,CHAIR ONCOL,PL-61878 POZNAN,POLAND; UNIV SCH MED SCI,WIELKOPOLSKA CANC CTR,DEPT CANC IMMUNOL,PL-61866 POZNAN,POLAND	Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; Wielkopolskie Centrum Onkologii; Medical University Silesia; Wielkopolskie Centrum Onkologii			Kozlowski, Piotr/I-1860-2019; Woźniak, Marcin/F-2936-2013; Wozniak, Marcin/B-6319-2018	Kozlowski, Piotr/0000-0003-3770-7715; Woźniak, Marcin/0000-0003-4491-3824; Wozniak, Marcin/0000-0002-3213-229X; Sobczak, Krzysztof/0000-0001-8352-9812; Jasinska, Anna/0000-0002-1897-4570				ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FRIEND S, 1995, NAT GENET, V11, P238, DOI 10.1038/ng1195-238; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; Johannsson O, 1996, AM J HUM GENET, V58, P441; Kozlowski P, 1996, NUCLEIC ACIDS RES, V24, P1177, DOI 10.1093/nar/24.6.1177; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P42; Langston AA, 1996, AM J HUM GENET, V58, P881; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1991, LANCET, V338, P82; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SOBCZAK K, 1995, ACTA BIOCHIM POL, V42, P363; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; THOMPSON WD, 1994, CANCER, V74, P279; Wagner TMU, 1996, LANCET, V347, P1263, DOI 10.1016/S0140-6736(96)90781-3; WOOSTER R, 1995, TRENDS GENET, V11, P3, DOI 10.1016/S0168-9525(00)88974-X; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; ZATONSKI WA, 1993, CANC POLAND	32	22	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1773	1779		10.1038/sj.onc.1201360	http://dx.doi.org/10.1038/sj.onc.1201360			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362443	Bronze			2022-12-28	WOS:A1997XZ72500003
J	Metcalfe, SM; Canman, CE; Milner, J; Morris, RE; Goldman, S; Kastan, MB				Metcalfe, SM; Canman, CE; Milner, J; Morris, RE; Goldman, S; Kastan, MB			Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells	ONCOGENE			English	Article						rapamycin; p53; G1 arrest	ATAXIA-TELANGIECTASIA GENE; P34CDC2 KINASE ACTIVATION; CYCLE CHECKPOINT PATHWAY; P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASE; MESSENGER-RNA; GROWTH ARREST; TARGET	Certain growth regulatory kinases contain domain related to the phospho-inositol 3 (PI-3) kinase catalytic site, These include the ATM gene product, DNA-PKcs, and the target of rapamycin (TOR in yeast: and FRAP in mammalian cells), Rapamycin inhibits growth factor signalling and induces G1 arrest in many cell types, Some growth regulatory PI-3 kinases appear functionally linked to p53 and we have explored potential links between cellular effects induced by rapamycin and p53. In p53 null cells rapamycin inhibited cell cycling but did not induce G1 arrest, In cells which showed selective G1 arrest in response to rapamycin, rapamycin had no effect on basal levels of p53 protein, Similarly p21(WAF1) protein,vas not induced by rapamycin, The kinetics of the cellular p53/p21(WAF1) response to ionising radiation was unaffected by rapamycin; and the ability of growth factor to protect against p53-mediated apoptosis in response to DNA damage was also unaffected by rapamycin. The ATM gene is mutated in the cancer susceptibility syndrome ataxia telangiectasia (AT) but such mutant cells showed a similar sensitivity to rapamycin compared to their normal counterparts, RKO cell lines of common genetic background, but with different levels of functional p53 protein, also responded similarly to rapamycin, Thus, although rapamycin and p53 are each able to induce G1 arrest, they appear to act through independent growth regulatory pathways.	JOHNS HOPKINS UNIV HOSP, CTR ONCOL, BALTIMORE, MD 21287 USA; UNIV YORK, YCRC P53 RES GRP, YORK YO1 5DD, N YORKSHIRE, ENGLAND; STANFORD UNIV, MED CTR,SCH MED,DEPT CARDIOTHORAC SURG, TRANSPLANTAT IMMUNOL LAB, STANFORD, CA 94305 USA	Johns Hopkins University; Johns Hopkins Medicine; University of York - UK; Stanford University	Metcalfe, SM (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT SURG, CAMBRIDGE CB2 2QQ, ENGLAND.			, Christine/0000-0001-8892-7430	NATIONAL CANCER INSTITUTE [R01CA061949, T32CA060441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005777, R37ES005777] Funding Source: NIH RePORTER; NCI NIH HHS [CA61949, T32CA60441] Funding Source: Medline; NIEHS NIH HHS [ES05777] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; BARBER NC, 1996, IN PRESS MOL BIOL CE; Beamish H, 1996, ONCOGENE, V13, P963; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CANMAN CE, 1994, CANCER RES, V54, P5054; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CAO W, 1995, TRANSPLANTATION, V59, P390, DOI 10.1097/00007890-199502150-00014; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; GORCZYCA W, 1993, CANCER RES, V53, P1945; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hollis CM, 1996, BIOCHEM SOC T, V24, pS66, DOI 10.1042/bst024066s; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; METCALFE S, 1991, TRANSPLANTATION, V51, P1318, DOI 10.1097/00007890-199106000-00039; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORICE WG, 1993, J BIOL CHEM, V268, P3734; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PERROTAPPLANAT M, 1995, J CELL SCI, V108, P2037; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHI YF, 1995, CANCER RES, V55, P1982	43	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1635	1642		10.1038/sj.onc.1201341	http://dx.doi.org/10.1038/sj.onc.1201341			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349496				2022-12-28	WOS:A1997XY63100002
J	Mochizuki, T; Kitanaka, C; Noguchi, K; Sugiyama, A; Kagaya, S; Chi, SJ; Asai, A; Kuchino, Y				Mochizuki, T; Kitanaka, C; Noguchi, K; Sugiyama, A; Kagaya, S; Chi, SJ; Asai, A; Kuchino, Y			Pim-1 kinase stimulates c-Myc-mediated death signaling upstream of caspase-3 (CPP32)-like protease activation	ONCOGENE			English	Article						Pim-1; c-Myc; caspase; apoptosis; serine/threonine kinase; transformation	PROGRAMMED CELL-DEATH; BCL-2 HOMOLOG BAK; E-MU-MYC; TRANSGENIC MICE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; INDUCED APOPTOSIS; GLIOMA-CELLS; CYCLE ARREST; GENE-PRODUCT; IN-VIVO	Pim-1 oncoprotein is a serine/threonine kinase that can closely cooperate with c-Myc in lymphomagenesis, as does Bcl-2. Although the molecular mechanism of this cooperative transformation remains unknown, it is speculated that, similar to Bcl-2, Pim-1 contributes to transformation by inhibiting apoptosis. In this study, therefore, we examined the effect of Pim-1 expression on c-Myc-mediated apoptosis of Rat-1 fibroblasts triggered by serum deprivation. Our results showed that, rather than inhibiting apoptosis, Pim-1 expression stimulated c-Myc-mediated apoptosis in Rat-1 fibroblasts. Pim-1 stimulated c-Myc-mediated apoptosis through an enhancement of the c-Myc-mediated activation of caspase-3 (CPP32)-like proteases, since the suppression of this activity by a specific caspase inhibitor abolished the apoptosis stimulation by Pim-1. A kinase-defective Pim-1 mutant failed to stimulate c-Myc-mediated apoptosis, and Pim-1 expression alone in the absence of c-Myc overexpression did not induce apoptosis of serum-deprived Rat-1 cells, indicating that the kinase activity of Pim-1 and the activated c-Myc signaling pathway mere required for apoptosis stimulation by Pim-1. Together, these results suggest that Pim-1 oncoprotein stimulates as a serine/threonine kinase the death signaling elicited by c-Myc at a step upstream of caspase-3-like protease activation in Rat-1 fibroblasts. Our results also suggest that Pim-1 kinase might function cooperatively with c-Myc through the phosphorylation of a factor(s) which regulates the common signaling pathway involved in c-Myc-mediated apoptosis and transformation.	NATL CANC CTR,RES INST,DIV BIOPHYS,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,SCH MED,DEPT NEUROSURG,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; University of Tokyo								Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASAI A, 1994, CELL GROWTH DIFFER, V5, P1153; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CROIX BS, 1996, NAT MED, V2, P1204; CUYPERS HT, 1984, CELL, V37, P141; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOOVER D, 1991, J BIOL CHEM, V266, P14018; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PADMA R, 1991, CANCER RES, V51, P2486; Poluha W, 1996, MOL CELL BIOL, V16, P1335; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WINGETT D, 1992, NUCLEIC ACIDS RES, V20, P3183, DOI 10.1093/nar/20.12.3183; Zornig M, 1996, ONCOGENE, V12, P1789	51	33	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1471	1480		10.1038/sj.onc.1201326	http://dx.doi.org/10.1038/sj.onc.1201326			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333023				2022-12-28	WOS:A1997XW41100011
J	Resnick, RJ; Taylor, SJ; Lin, Q; Shalloway, D				Resnick, RJ; Taylor, SJ; Lin, Q; Shalloway, D			Phosphorylation of the Src substrate Sam68 by Cdc2 during mitosis	ONCOGENE			English	Article						Sam68; mitosis; Cdc2; Src	RNA-BINDING PROTEIN; C-SRC; KINASE; CELLS; GENE; ASSOCIATION; P62; PP60(C-SRC); ACTIVATION; POLYMERASE	Sam68 (Src-associated in mitosis) is an SH3 (Srchomology 3), SH2 (Src-homology 2), and RNA binding protein which associates with and is tyrosine phosphorylated by mild-type and activated forms of c-Src in a mitosis-specific manner. We now show that Sam68 immunoprecipitated from either HeLa S3 or NIH3T3 cells is phosphorylated on threonine residues exclusively during mitosis as well as on serine residues during both interphase and mitosis. Recombinant Sam68, expressed as a glutathione S-transferase (GST) fusion protein, was phosphorylated on threonine and serine residues after incubation with mitotic lysates several-fold more extensively than after incubation with unsynchronized lysates. Cdc2 was identified as the kinase responsible for the mitotic threonine phosphorylation by (1) immunodepletion of the mitotic Sam68 kinase from cell lysates with anti-Cdc2 antibodies, (2) inhibition of Sam68 phosphorylation in vitro and in vivo by the cyclin-dependent kinase inhibitor olomoucine and (3) phosphorylation of Sam68 by purified Cdc2. These data demonstrate that Sam68 is a direct target of Cdc2 and may therefore mediate some of its biological effects during mitosis.	CORNELL UNIV, BIOCHEM MOL & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University					NCI NIH HHS [CA 32317] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032317] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; LEE KS, 1995, MOL CELL BIOL, V15, P7143; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MEIJER L, 1991, EUR J BIOCHEM, V196, P557, DOI 10.1111/j.1432-1033.1991.tb15850.x; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; STOVER DR, 1994, J BIOL CHEM, V269, P26885; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0	41	44	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1247	1253		10.1038/sj.onc.1201289	http://dx.doi.org/10.1038/sj.onc.1201289			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315091				2022-12-28	WOS:A1997XV84500001
J	Martin, M; Vozenin, MC; Gault, N; Crechet, F; Pfarr, CM; Lefaix, JL				Martin, M; Vozenin, MC; Gault, N; Crechet, F; Pfarr, CM; Lefaix, JL			Coactivation of AP-1 activity and TGF-beta 1 gene expression in the stress response of normal skin cells to ionizing radiation	ONCOGENE			English	Article						AP-1; fos; jun; TGF-beta 1; skin; gamma-irradiation	TRANSFORMING GROWTH FACTOR-BETA-1; IMMEDIATE-EARLY GENES; C-FOS; FACTOR-BETA; PIG SKIN; FIBROBLAST GROWTH; MUSCULAR FIBROSIS; BINDING-PROTEINS; GAMMA-RAYS; JUN	Activation of the AP-1 transcription factor and TGF-beta 1 growth factor by ionizing radiation was studied both in vivo in pig skin, and in vitro in human fibroblasts and keratinocytes, Three and 6h after irradiation, the Fos and Jun proteins and their binding activity to an AP-1 consensus sequence were strongly induced by high doses of gamma-rays, c-Fos, c-Jun and JunB proteins were found to be present in gel-shift complexes by probing with specific antibodies, Both keratinocytes and fibroblasts exhibited heightened AP-1 activity following irradiation, As we previously found that TGF-beta 1 is involved in the development of skin lesions induced by radiation, TGF-beta 1 gene expression was also examined, Two and 6h after irradiation, the levels of TGF-beta 1 transcripts were increased in skin, By immunostaining, TGF-beta 1 protein levels were found to be increased in fibroblasts, keratinocytes and endothelial cells, As promoter contains AP-1 binding sites, between AP-1 activity and TGF-beta 1 induction was addressed, The -365 TGF-beta 1 promoter fragment, which contains a high affinity AP-1 site, exhibited increased binding to Jun and Fos proteins following irradiation, These results suggest that stress-inducible TGF-beta 1 expression is mediated by the activation of AP-1 transcription factor.	INST PASTEUR,UNITE VIRUS ONCOGENES,CNRS,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Martin, M (corresponding author), CEA,LAB RADIOBIOL & ETUDE GENOME,DVS,F-91191 GIF SUR YVETTE,FRANCE.		Martin, Michele T/C-5554-2008; Vozenin, Marie-Catherine/AAR-2268-2021; Pfarr, Curt/HHD-1410-2022	Martin, Michele T/0000-0003-0530-6466; Vozenin, Marie-Catherine/0000-0002-2109-8073; Gault, Nathalie/0000-0001-6233-1946				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASIEDU CK, 1994, BBA-GENE STRUCT EXPR, V1219, P55, DOI 10.1016/0167-4781(94)90246-1; BARCELLOSHOFF MH, 1993, CANCER RES, V53, P3880; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; COLLART FR, 1995, RADIAT RES, V142, P18; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; Fan GS, 1996, ONCOGENE, V12, P1909; FINKELSTEIN JN, 1994, INT J RADIAT ONCOL, V28, P621, DOI 10.1016/0360-3016(94)90187-2; GILLARDON F, 1995, NEUROREPORT, V6, P1766, DOI 10.1097/00001756-199509000-00014; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GUBITS RM, 1993, INT J RADIAT ONCOL, V27, P637, DOI 10.1016/0360-3016(93)90390-H; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hsing AY, 1996, CANCER RES, V56, P5146; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P7041; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YJ, 1995, J BIOL CHEM, V270, P28790, DOI 10.1074/jbc.270.48.28790; LEFAIX JL, 1993, BRIT J RADIOL, V66, P537, DOI 10.1259/0007-1285-66-786-537; MARTIN M, 1993, CANCER RES, V53, P3246; MARTIN M, 1993, RADIAT RES, V134, P63, DOI 10.2307/3578502; MARTIN M, 1989, J INVEST DERMATOL, V93, P497, DOI 10.1111/1523-1747.ep12284053; MASSAGUE J, 1990, CELL BIOL, V6, P597; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RANDALL K, 1995, INT J RADIAT BIOL, V68, P301, DOI 10.1080/09553009514551231; RAYNAL S, 1995, INT J ONCOL, V7, P337; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; RUBIN P, 1995, INT J RADIAT ONCOL, V33, P99, DOI 10.1016/0360-3016(95)00095-G; SAHIJDAK WM, 1994, RADIAT RES, V138, pS47, DOI 10.2307/3578760; Saltis J, 1996, MOL CELL ENDOCRINOL, V116, P227, DOI 10.1016/0303-7207(95)03721-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; VOZENIN MC, 1997, IN PRESS CYTOTECHNOL; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WEICHSELBAUM R, 1993, MOL BIOL ONCOLOGISTS, P213; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Welter JF, 1995, ONCOGENE, V11, P2681; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	42	96	101	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					981	989		10.1038/sj.onc.1201433	http://dx.doi.org/10.1038/sj.onc.1201433			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285693				2022-12-28	WOS:A1997XR76700011
J	Oh, JW; Katz, A; Harroch, S; Eisenbach, L; Revel, M; Chebath, J				Oh, JW; Katz, A; Harroch, S; Eisenbach, L; Revel, M; Chebath, J			Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells	ONCOGENE			English	Article						interleukin-6; cancer; melanoma; IRF-1; Waf-1; growth control	ACUTE-PHASE RESPONSE; REGULATORY FACTOR-I; INTERLEUKIN-6 RECEPTOR; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCER; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS; MOLECULAR-CLONING; STAT FAMILY; IFN-BETA	Interleukin-6 (IL-6) inhibits the growth of melanocytes and of early stage melanoma cells, but not that of advanced melanoma cells. The in vitro IL-6 response can be restored in the highly metastatic melamona B16-F10.9 by addition of recombinant soluble IL-6 receptor alpha-chain (sIL-6R). The F10.9 cells then undergo irreversible growth-arrest and show increased adherence with changes from epithelioid to spindleoid morphology. The sIL-6R is required for IL-6 to induce a sustained activation of the various Stat transcription factors which bind to specific IL-6 inducible enhancers. The sIL-6R and IL-6 combination causes an increase in the level of the anti-oncogenic transcription factor IRF-1 protein and DNA-binding, which remain elevated for 24 h. The promoter activity of the anti-oncogenic p21/Waf-1/Cip-1 gene is induced and accumulation of the p21, protein is observed. These results illustrate the potent agonist activity of sIL-6R on molecular pathways which could mediate the growth-arrest and differentiation of the metastatic melanoma cells. Previously observed antimetastatic effects of IL-6 therapy in mice bearing F10.9 tumors may be at least partly due to direct growth inhibition and differentiation elicited by sIL-6R present in biological fluids.	WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science				Chebath, Judith/0000-0002-8151-7428; Eisenbach, Lea R/0000-0002-4816-1968				Akira S, 1995, ANN NY ACAD SCI, V762, P15; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARMSTRONG CA, 1994, J INVEST DERMATOL, V102, P278, DOI 10.1111/1523-1747.ep12371782; CHEN YQ, 1995, CANCER RES, V55, P4536; CHERNAJOVSKY Y, 1984, DNA-J MOLEC CELL BIO, V3, P297, DOI 10.1089/dna.1.1984.3.297; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COFFER P, 1995, ONCOGENE, V10, P985; COLOMBO MP, 1992, MELANOMA RES, V2, P181, DOI 10.1097/00008390-199209000-00006; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FRIELING JTM, 1994, CYTOKINE, V6, P376, DOI 10.1016/1043-4666(94)90061-2; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAILLARD JP, 1993, EUR J IMMUNOL, V23, P820, DOI 10.1002/eji.1830230408; Ganapathi MK, 1996, CELL GROWTH DIFFER, V7, P923; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HALIMI H, 1995, EUR CYTOKINE NETW, V6, P135; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARPER JW, 1993, CELL, V75, P805; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HARROCH S, 1993, J BIOL CHEM, V268, P9092; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; KATZ A, 1993, INT J CANCER, V53, P812, DOI 10.1002/ijc.2910530518; KATZ A, 1993, J IMMUNOTHER, V13, P98, DOI 10.1097/00002371-199302000-00004; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; Mackiewicz A, 1995, ANN NY ACAD SCI, V762, P361; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MACKIEWICZ A, 1995, CYTOKINE, V7, P142, DOI 10.1006/cyto.1995.1019; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NOVICK D, 1991, HYBRIDOMA, V10, P137, DOI 10.1089/hyb.1991.10.137; NOVICK D, 1992, CYTOKINE, V4, P6, DOI 10.1016/1043-4666(92)90029-Q; NOVICK D, 1990, J CHROMATOGR, V510, P331, DOI 10.1016/S0021-9673(01)93767-7; Oh JW, 1996, CYTOKINE, V8, P401, DOI 10.1006/cyto.1996.0055; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PORGADOR A, 1989, J IMMUNOGENET, V16, P291; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Revel M, 1995, ANN NY ACAD SCI, V762, P342; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROSEJOHN S, 1993, J BIOL CHEM, V268, P22084; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SILVANI A, 1995, CANCER RES, V55, P2200; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Su Zao-Zhong, 1995, Molecular and Cellular Differentiation, V3, P225; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	69	27	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					569	577		10.1038/sj.onc.1201213	http://dx.doi.org/10.1038/sj.onc.1201213			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247310				2022-12-28	WOS:A1997XN25500008
J	Prasad, R; Zhadanov, AB; Sedkov, Y; Bullrich, F; Druck, T; Rallapalli, R; Yano, T; Alder, H; Croce, CM; Huebner, K; Mazo, A; Canaani, E				Prasad, R; Zhadanov, AB; Sedkov, Y; Bullrich, F; Druck, T; Rallapalli, R; Yano, T; Alder, H; Croce, CM; Huebner, K; Mazo, A; Canaani, E			Structure and expression pattern of human ALR, a novel gene with strong homology to ALL-1 involved in acute leukemia and to Drosophila trithorax	ONCOGENE			English	Article						ALL-1; leukemia; SET domain; PHD fingers	BITHORAX COMPLEX; DNA-BINDING; SEQUENCE SIMILARITY; BMI-1 PROTOONCOGENE; PROTEIN; POLYCOMB; DOMAINS; ENCODES; FINGER; TRANSLOCATIONS	The ALL-1 gene is involved in human acute leukemia through chromosome translocations or internal rearrangements. ALL-1 is the human homologue of Drosophila trithorax. The latter is a member of the trithorax group (trx-G) genes which together with the Polycomb group (Pc-G) genes act as positive and negative regulators, respectively, to determine the body structure of Drosophila. We have cloned a novel human gene, ALR, which encodes a gigantic 5262 amino acid long protein containing a SET domain, five PHD fingers, potential zinc fingers, and a very long run of glutamines interrupted by hydrophobic residues, mostly leucine. The SET motif, PDH fingers, zinc fingers and two other regions are most similar to domains of ALL-1 and TRX. The first two motifs are also found in other trx-G and Pc-G proteins. The ALR gene was mapped to chromosome band 12q12-13, adjacent to the VDR gene. This region is involved in duplications and translocations associated with cancer. The analysis of ALR expression showed that its similar to 18 kb long mRNA is expressed, like ALL-1, in most adult tissues, including a variety of hematopoietic cells, with the exception of the liver. Whole mount in situ hybridization to early mouse embryos indicates expression in multiple tissues. Based on similarities in structure and expression pattern, ALR is likely to play a similar role to ALL-1 and trx, although its target genes have yet to be identified.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC INST,PHILADELPHIA,PA 19107	Weizmann Institute of Science; Jefferson University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [P01CA050507, R35CA039860] Funding Source: NIH RePORTER; NCI NIH HHS [CA39860, CA50507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; ASHAR HR, 1995, CELL, V82, P57; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BULFONE A, 1993, MECH DEVELOP, V40, P129, DOI 10.1016/0925-4773(93)90071-5; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHIANG A, 1995, DEVELOPMENT, V121, P1681; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Fasman KH, 1996, NUCLEIC ACIDS RES, V24, P57, DOI 10.1093/nar/24.1.57; FEARMAN A, 1993, DEVELOPMENT, V118, P919; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hermesz E, 1996, DEVELOPMENT, V122, P41; Hobert O, 1996, MECH DEVELOP, V55, P171, DOI 10.1016/0925-4773(96)00499-6; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JIANG JX, 1995, GENOMICS, V30, P91, DOI 10.1006/geno.1995.0015; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; Karlin S, 1996, P NATL ACAD SCI USA, V93, P1560, DOI 10.1073/pnas.93.4.1560; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KRAUTER K, 1995, NATURE, V377, P321; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; LONIE A, 1994, DEVELOPMENT, V120, P2629; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MILNER CM, 1993, BIOCHEM J, V290, P811, DOI 10.1042/bj2900811; MITELMAN F, 1994, CATALOG CHROMOSOME A; NOMURA M, 1994, DIFFERENTIATION, V57, P39, DOI 10.1046/j.1432-0436.1994.5710039.x; Oliver G, 1995, DEVELOPMENT, V121, P4045; OLIVER G, 1995, DEVELOPMENT, V121, P693; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; RAIMONDI SC, 1993, BLOOD, V81, P2237; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9337; SCHICHMAN SA, 1995, JAMA-J AM MED ASSOC, V273, P571, DOI 10.1001/jama.273.7.571; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SIDMAN RL, 1959, EXP NEUROL, V1, P322, DOI 10.1016/0014-4886(59)90024-X; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; THOMPSON KA, 1994, BIOCHEM BIOPH RES CO, V198, P1143, DOI 10.1006/bbrc.1994.1162; TILLIB S, 1995, MECH DEVELOP, V53, P113, DOI 10.1016/0925-4773(95)00429-7; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tripoulas N, 1996, GENETICS, V143, P913; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZHANDANOV AB, 1995, DEV DYNAM, V202, P354; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	62	78	82	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					549	560		10.1038/sj.onc.1201211	http://dx.doi.org/10.1038/sj.onc.1201211			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247308				2022-12-28	WOS:A1997XN25500006
J	Lee, SW; Reimer, CL; Oh, P; Campbell, DB; Schnitzer, JE				Lee, SW; Reimer, CL; Oh, P; Campbell, DB; Schnitzer, JE			Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells	ONCOGENE			English	Article						caveolin; breast cancer; cell cycle; growth inhibition; p53	SUPPRESSOR GENES; CAPILLARY-PERMEABILITY; PROTEIN-COMPONENT; EPITHELIAL-CELLS; SEQUENCE; TRANSPORT; IDENTIFICATION; CANDIDATE; PARADIGM; VESICLES	Cancer development is a multistage process that results from the step-wise acquisition of somatic alterations in diverse genes, Recent studies indicate that caveolin-1 expression correlates with the level of oncogenic transformation in NIH3T3 cells, suggesting that caveolin in caveolae mag regulate normal cell proliferation, In order to better understand potential functions of caveolin-1 in cancer development, we have studied expression levels of caveolin-1 in human breast cancer cells, and have found that caveolin expression is significantly reduced in human breast cancer cells compared with their normal mammary epithelial counterparts, When the caveolin cDNA linked to the CMV promoter is transfected into human mammary cancer cells having no detectable endogenous caveolin, overexpression of caveolin-1 resulted in substantial growth inhibition, as seen by the 50% decrease in growth rate and by similar to 15-fold reduction in colony formation in soft agar, In addition, characterization of caveolin-1 expression during cell cycle progression indicates that expression of alpha-caveolin-1 is regulated during cell cycle, Furthermore p53-deficient cells showed a loss in caveolin expression, In summary, the overall expression patterns, its ability to inhibit tumor growth in culture, its regulation during the cell cycle, and the loss of expression in p53-deficient cells all are consistent with an important growth regulating function for caveolin-1 in normal human mammary cells, that needs to be repressed in oncogenic transformation and tumor cell growth.	Harvard Univ, Inst Med, Sch Med, Beth Israel Deaconess Med Ctr,Dept Med, Boston, MA 02115 USA; Harvard Univ, Inst Med, Sch Med, Beth Israel Deaconess Med Ctr,Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Lee, SW (corresponding author), Harvard Univ, Inst Med, Sch Med, Beth Israel Deaconess Med Ctr,Dept Med, Suite 921,77 Ave Louis Pasteur, Boston, MA 02115 USA.				NCI NIH HHS [CA66271] Funding Source: Medline; NHLBI NIH HHS [HL43278] Funding Source: Medline; NIA NIH HHS [AG13314-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066271] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013314] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BISHOP JM, 1995, GENE DEV, V9, P1309, DOI 10.1101/gad.9.11.1309; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EMERMAN JT, 1990, IN VITRO CELL DEV B, V26, P1186; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LEE SW, 1996, NAT MED, V2, P772; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li SW, 1996, J BIOL CHEM, V271, P3863; Liotta L A, 1991, Important Adv Oncol, P85; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Schnitzer JE, 1996, AM J PHYSIOL-HEART C, V270, pH416, DOI 10.1152/ajpheart.1996.270.1.H416; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P124, DOI 10.1016/1050-1738(93)90012-U; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	38	393	405	0	20	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1391	1397		10.1038/sj.onc.1201661	http://dx.doi.org/10.1038/sj.onc.1201661			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525738				2022-12-28	WOS:000072572400003
J	Zamzami, N; Marzo, I; Susin, SA; Brenner, C; Larochette, N; Marchetti, P; Reed, J; Kofler, R; Kroemer, G				Zamzami, N; Marzo, I; Susin, SA; Brenner, C; Larochette, N; Marchetti, P; Reed, J; Kofler, R; Kroemer, G			The thiol crosslinking agent diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition	ONCOGENE			English	Article						cytochrome c; mitochondrial transmembrane potential; permeability transition; programmed cell death	PROGRAMMED CELL-DEATH; POLYCYSTIC KIDNEY; GLUTATHIONE; PORE; OXIDATION; REDUCTION; OXYGEN; PHOSPHORYLATION; INACTIVATION; GENERATION	In several different cell lines, Bcl-2 prevents the induction of apoptosis (DNA fragmentation, PARP cleavage, phosphatidylserine exposure) by the pro-oxidant terbutylhydroperoxide (t-BHP) but has no cytoprotective effect when apoptosis is induced by the thiol crosslinking agent diazenedicarboxylic acid bis 5,N-dimethylamide (diamide), Both t-BHP and diamide cause a disruption of the mitochondrial transmembrane potential Delta Psi(m), that is not inhibited by the broad spectrum caspase inhibitor z-VAD.fmk, although z-VAD.fmk does prevent nuclear DNA fragmentation and poly(ADP-ribose) polymerase cleavage in these models, Bcl-2 stabilizes the Delta Psi(m) of t-BHP-treated cells but has no inhibitory effect on the Delta Psi(m) collapse induced by diamide, As compared to normal controls, isolated mitochondria from Bcl-2 overexpressing cells are relatively resistant to the induction of Delta Psi(m) disruption by t-BHP in vitro, Such Bcl-2 overexpressing mitochondria also fail to release apoptosis-inducing factor (AIF) and cytochrome c from the intermembrane space, whereas control mitochondria not overexpressing Bcl-2 do liberate AIF and cytochrome c in response to t-BHP. In contrast, Bcl-2 does not confer protection against diamide-triggered Delta Psi(m) collapse and the release of AIF and cytochrome c, This indicates that Bcl-2 suppresses the permeability transition (PT) and the associated release of intermembrane proteins induced by t-BHP but not by diamide, To further investigate the mode of action of Bcl-2, semi-purified PT pore complexes were reconstituted in liposomes in a cell-free, organelle-free system, Recombinant Bcl-2 or Bcl-X, proteins augment the resistance of reconstituted PT pore complexes to pore opening induced by t-BHP, In contrast, mutated Bcl-2 proteins which have lost their cytoprotective potential also lose their PT-modulatory capacity, Again, Bcl-2 fails to confer protection against diamide in this experimental system, The reconstituted PT pore complex itself cannot release cytochrome c encapsulated into liposomes, Altogether these data suggest that pro-oxidants, thiol-reactive agents, and Bcl-2 can regulate the PT pore complex in a direct fashion, independently from their effects on cytochrome c, Furthermore, our results suggest a strategy for inducing apoptosis in cells overexpressing apoptosis-inhibitory Bcl-2 analogs.	CNRS, Unite Propre Rech 420, F-94801 Villejuif, France; Burnham Inst, La Jolla, CA 92037 USA; Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria	Centre National de la Recherche Scientifique (CNRS); Sanford Burnham Prebys Medical Discovery Institute; University of Innsbruck	Kroemer, G (corresponding author), CNRS, Unite Propre Rech 420, 19 Rue Guy Moquet, F-94801 Villejuif, France.		brenner, catherine/AAE-8632-2020; Marzo, Isabel/E-6918-2016; Susin, Santos A/Q-6754-2017; LAROCHETTE, Nathanael/R-4298-2017; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	Marzo, Isabel/0000-0002-2315-9079; Susin, Santos A/0000-0002-3366-1628; LAROCHETTE, Nathanael/0000-0002-7936-678X; KROEMER, Guido/0000-0002-9334-4405; MARCHETTI, Philippe/0000-0002-4663-6800				Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; BEAVER JP, 1995, EUR J CELL BIOL, V68, P47; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; DROGE W, 1994, FASEB J, V8, P1131; Ellerby HM, 1997, J NEUROSCI, V17, P6165; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREEN DR, 1994, IMMUNOL REV, V142, P321, DOI 10.1111/j.1600-065X.1994.tb00895.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KAMADA S, 1995, CANCER RES, V55, P354; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Kinnally KW, 1996, J BIOENERG BIOMEMBR, V28, P115, DOI 10.1007/BF02110641; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer Guido, 1997, P1111; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Macho A, 1997, J IMMUNOL, V158, P4612; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARZO I, 1998, IN PRESS J EXP MED; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; REED DJ, 1995, BBA-MOL BASIS DIS, V1271, P43, DOI 10.1016/0925-4439(95)00008-R; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SATO N, 1995, J IMMUNOL, V154, P3194; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YING XM, 1994, NATURE, V369, P321; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	59	149	170	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1055	1063		10.1038/sj.onc.1201864	http://dx.doi.org/10.1038/sj.onc.1201864			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519879				2022-12-28	WOS:000072335900011
J	Welsh, M; Zhou, SY; Frantz, JD; Trub, T; Reedquist, KA; Karlsson, T; Miyazaki, M; Cantley, LC; Band, H; Shoelson, SE				Welsh, M; Zhou, SY; Frantz, JD; Trub, T; Reedquist, KA; Karlsson, T; Miyazaki, M; Cantley, LC; Band, H; Shoelson, SE			Stimulation through the T cell receptor leads to interactions between SHB and several signaling proteins	ONCOGENE			English	Article						Shb; Jurkat T cells; T cell receptor; p36/38; SH2 domain; PTB domain	ANTIGEN RECEPTOR; TYROSINE KINASE; ZETA-CHAIN; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASE C-GAMMA-1; ADAPTER PROTEIN; ACTIVATION; DOMAIN; PHOSPHOTYROSINE; ASSOCIATION	Shb is a recently described Src homology 2 (SH2) domain-containing adaptor protein. Here we show that Shb is expressed in lymphoid tissues, and is recruited into signaling complexes upon activation of Jurkat T cells. Grb2 binds proline-rich motifs in Shb via its SH3 domains, As a result, a number of proteins detected in anti-Shb and anti-Grb2 immunoprecipitates are shared, including phosphoproteins of 22, 36/38, 55/57 and 70 kDa. Shb-association with p22, which represents the T cell receptor associated zeta chain, occurs through the Shb SH2 domain. The central region of Shb binds p36/38. Since this interaction was inhibited by phosphotyrosine, this region of Shb is likely to contain a non-SH2 PTB (phosphotyrosine binding) domain. The Shb PTB domain tvas found to preferentially bind the sequence Asp-Asp-X-pTyr when incubated with a phosphopeptide library, A peptide corresponding to a phosphorylation site in 34 kDa Lnk inhibited association between Shb and p36/38. Overexpression of Shb in Jurkat cells led to increased basal phosphorylation of Shb-associated p36/38 and p70 proteins, Inactivation of the Shb SH2 domain by an R522K mutation resulted in a reduced stimulation of tyrosine phosphorylation of several proteins in response to CD3 crosslinking when expressed in Jurkat cells. Together, our results show three distinct domains of Shb all participate in the formulation of multimeric signaling complexes in activated T cells. These results indicate that the Shb protein functions in T cell receptor signaling.	Uppsala Univ, Dept Med Cell Biol, Uppsala, Sweden; Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Rheumatol & Immunol, Lymphocyte Biol Sect, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Div Signal Transduct, Boston, MA USA	Uppsala University; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Welsh, M (corresponding author), Biomedicum, Dept Med Cell Biol, Box 571, S-75123 Uppsala, Sweden.		Welsh, Michael/AAF-8564-2020; Miyazaki, Masaya/F-8520-2012; Cantley, Lewis C/D-1800-2014	Welsh, Michael/0000-0002-5467-9755; Miyazaki, Masaya/0000-0003-4031-7224; Cantley, Lewis C/0000-0002-1298-7653	NIAMS NIH HHS [AR36308] Funding Source: Medline; NIDDK NIH HHS [DK36836, DK45943] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK045943] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUDAY L, 1994, J BIOL CHEM, V269, P9019; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; KARLSSON T, 1995, ONCOGENE, V10, P1475; Karlsson T, 1996, ONCOGENE, V13, P955; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; THOMPSON PA, 1992, ONCOGENE, V7, P719; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; TRUB T, 1995, J BIOL CHEM, V270, P18205; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WELSH M, 1994, ONCOGENE, V9, P19; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407	28	50	55	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					891	901		10.1038/sj.onc.1201607	http://dx.doi.org/10.1038/sj.onc.1201607			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484780				2022-12-28	WOS:000072053200008
J	Kwon, TK; Nordin, AA				Kwon, TK; Nordin, AA			Identification of cdk2 binding sites on the p27(Kip1) cyclin-dependent kinase inhibitor	ONCOGENE			English	Article						cell cycle; cdk inhibitors; p27(Kip1); cdk2; cyclin E; point mutations	CELL-CYCLE; POTENTIAL MEDIATOR; TUMOR SUPPRESSION; ARREST; P21; ACCUMULATION; INDUCTION; CLONING; PCNA; BETA	A cdk2 binding domain on p27(Kip1) located within the sequence of amino acids 53-85 was further characterized by generating a series of point mutations within amino acid residues 62-75. Two regions, FDF (residues 62-64) and GXY (residues 72 and 74), were identified within the beta hairpin region of p27(Kip1)., Mutations within these regions essentially completely inhibited the binding to in vitro translated cdk2 and cdk2/cyclin E complexes formed in vitro or in vivo., The p27(Kip1) GST-fusion protein of the point mutation that replaces phenylalanine at residue 64 to alanine (F64A) showed approximately twofold less inhibition of cdk2 kinase activity. The cellular response to the introduction of the F64A mutant form of p27(Kip1) was compared to that of p27(Kip1) wild type by transfecting HeLa cells with constructs of full length sense and antisense coding sequences, Overexpression of the F64A mutant form of p27(Kip1) bound significantly lower levels of cdk2 as compared to wild type and did not effect the cdk2 related kinase activity of the transfected HeLa cells. Overexpression of wild type p27(Kip1) resulted in a reduction of the level of cdk2 kinase activity and effectively suppressed the growth of the transfected HeLa cells.	NIA, Gerontol Res Ctr, Immunol Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Nordin, AA (corresponding author), NIA, Gerontol Res Ctr, Immunol Lab, NIH, 4940 Eastern Ave,Box 21, Baltimore, MD 21224 USA.							Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chesnut JD, 1996, J IMMUNOL METHODS, V193, P17, DOI 10.1016/0022-1759(96)00032-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fotedar R, 1996, ONCOGENE, V12, P2155; FRANCOISE G, 1995, ONCOGENE, V10, P2281; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kwon TK, 1996, CELL GROWTH DIFFER, V7, P1305; Kwon TK, 1996, BIOCHEM BIOPH RES CO, V220, P703, DOI 10.1006/bbrc.1996.0468; Lin JY, 1996, MOL CELL BIOL, V16, P1786; MICHIELI P, 1994, CANCER RES, V54, P3391; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHUHEI M, 1995, GENE DEV, V9, P650; Steffan NH, 1989, GENE, V77, P51; TOSHIYASU H, 1995, BLOOD, V86, P841; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	34	11	13	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					755	762		10.1038/sj.onc.1201586	http://dx.doi.org/10.1038/sj.onc.1201586			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488039				2022-12-28	WOS:000071931800007
J	Gandrillon, O; Samarut, J				Gandrillon, O; Samarut, J			Role of the different RAR isoforms in controlling the erythrocytic differentiation sequence. Interference with the v-erbA and p135(gap-myb-ets) nuclear oncogenes	ONCOGENE			English	Article						nuclear hormone receptors; erythroleukemia; viral transformation	RETINOIC ACID RECEPTORS; AVIAN ERYTHROBLASTOSIS VIRUS; ETS FUSION ONCOPROTEIN; LEUKEMIA-VIRUS; TRANSCRIPTIONAL ACTIVATION; PROGENITOR CELLS; THYROID-HORMONE; MYELOID CELLS; TARGET-CELLS; SELF-RENEWAL	Little is known as to how the nuclear oncogenes v-erbA and p135(gag-myb-ets) do transform cells. The elucidation of their molecular mechanisms of action requires the identification of relevant target genes. We analysed the possibility for the RAR beta gene to represent such a target gene. We first show that the RAR beta gene induction is a specific and direct process, requiring the continous presence of retinoids and under the control of the RAR alpha isoform exclusively. We then show that the expression of either the v-erbA or the p135(gag-myb-ets) oncogene is not sufficient to block the RAR beta gene induction. We confirmed the loss of RARE gene response in certain cell lines but we discarded the possibility that this lass might represent a necessary step for cell lines immortalization. We further show that the RAR alpha isoform activation is necessary and sufficient to induce the growth inhibition and the differentiation stimulation characteristic for the commitment-inducing ability of retinoids in chicken erythrocytic progenitor cells. We therefore propose a model showing that RAR alpha but not RAR beta is the key mediator for commitment to differentiation and that it should control two different set of genes whose expression is differentially affected by the v-erbA and the p135(gag-myb-ets) oncogenes.	Ecole Normale Super Lyon, Dept Biol Mol & Cellulaire, F-69364 Lyon 7, France	Ecole Normale Superieure de Lyon (ENS de LYON)	Gandrillon, O (corresponding author), Ecole Normale Super Lyon, Dept Biol Mol & Cellulaire, 46 Allee Italie, F-69364 Lyon 7, France.		Samarut, Jacques/AAD-2587-2019					ALMOUSTAFA AE, 1994, CELL GROWTH DIFFER, V5, P863; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; Botling J, 1996, CELL GROWTH DIFFER, V7, P1239; CassarMalek I, 1997, ONCOGENE, V14, P1099, DOI 10.1038/sj.onc.1200928; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1995, INT J ONCOL, V6, P215; Geisen C, 1997, CANCER RES, V57, P1460; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HERMANN T, 1993, ONCOGENE, V8, P55; Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610; Jing YK, 1996, FASEB J, V10, P1064, DOI 10.1096/fasebj.10.9.8801168; KRAUT N, 1995, ONCOGENE, V10, P1027; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; Mills KJ, 1996, CELL GROWTH DIFFER, V7, P327; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PAIN B, 1990, New Biologist, V2, P284; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Rascle A, 1996, MOL CELL BIOL, V16, P6338; REICHERT U, 1993, MOL BIOL THERAPEUTIC, V5, P117; Rogers MB, 1996, CELL GROWTH DIFFER, V7, P115; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Rusten LS, 1996, BLOOD, V87, P1728; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARIF M, 1992, ONCOGENE, V7, P953; SPANJAARD RA, 1995, J BIOL CHEM, V270, P17429, DOI 10.1074/jbc.270.29.17429; WOODS C, 1995, ENDOCRINOLOGY, V136, P85, DOI 10.1210/en.136.1.85; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	51	13	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	1998	16	5					563	574		10.1038/sj.onc.1201550	http://dx.doi.org/10.1038/sj.onc.1201550			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482102				2022-12-28	WOS:000071816600001
J	Cayrol, C; Knibiehler, M; Ducommun, B				Cayrol, C; Knibiehler, M; Ducommun, B			p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells	ONCOGENE			English	Article						cell cycle; cyclin-dependent kinase; growth arrest; p21(CIP1/WAF1); PCNA	DEPENDENT-KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; C-TERMINAL REGION; NUCLEAR ANTIGEN; DNA-REPLICATION; TUMOR SUPPRESSION; P21(WAF1/CIP1); PROTEIN; EXPRESSION; P21(CIP1)	A unique feature of p21 that distinguishes it from the other cyclin-dependent kinase (CDK) inhibitors is its ability to associate with the proliferating cell nuclear antigen (PCNA), an auxiliary factor for DNA polymerases delta and epsilon. While it is now well established that inhibition of cyclin/CDK complexes by p21 can result in G1 cell cycle arrest, the consequences of p21/PCNA interaction on cell cycle progression have not yet been determined. Here, we show, using a tetracycline-regulated system, that expression of wild-type p21 in p53-deficient DLD1 human colon cancer cells inhibits DNA synthesis and causes G1 and G2 cell cycle arrest. Similar effects are observed in cells expressing p21(CDK-) mutant impaired in the interaction with CDKs, but not in cells expressing p21(PCNA-), a mutant deficient for the interaction with PCNA. Analysis of cells treated with a p21-derived PCNA-binding peptide provides additional evidence that the growth inhibitory effects of p21 and p21(CDK-) result from their ability to bind to PCNA. Our results suggest that p21 might inhibit cell cycle progression by two independent mechanisms, inhibition of cyclin/CDK complexes, and inhibition of PCNA function resulting in both G1 and G2 arrest.	Univ Toulouse 3, CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.		CAYROL, Corinne/C-2106-2011; DUCOMMUN, Bernard/B-3208-2008	CAYROL, Corinne/0000-0002-7813-4397; DUCOMMUN, Bernard/0000-0002-7126-8368				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBOULE N, 1995, INT J CANCER, V63, P611, DOI 10.1002/ijc.2910630502; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CHEN YQ, 1995, CANCER RES, V55, P4536; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar R, 1996, ONCOGENE, V12, P2155; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOUBIN F, 1995, ONCOGENE, V10, P2281; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JUNG JM, 1995, ONCOGENE, V11, P2021; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Knibiehler M, 1996, FEBS LETT, V391, P66, DOI 10.1016/0014-5793(96)00702-8; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Savio M, 1996, ONCOGENE, V13, P1591; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Tournier S, 1996, MOL BIOL CELL, V7, P651, DOI 10.1091/mbc.7.4.651; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZAKUT R, 1995, ONCOGENE, V11, P393	49	309	316	3	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					311	320		10.1038/sj.onc.1201543	http://dx.doi.org/10.1038/sj.onc.1201543			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467956	Bronze			2022-12-28	WOS:000071582100003
J	Alblas, J; Slager-Davidov, R; Steenbergh, PH; Sussenbach, JS; van der Burg, B				Alblas, J; Slager-Davidov, R; Steenbergh, PH; Sussenbach, JS; van der Burg, B			The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells	ONCOGENE			English	Article						Erk; Jun kinase; AP1; MCF7; phorbol ester; cell cycle	ACTIVATED PROTEIN-KINASES; ESTROGEN-RECEPTOR ACTIVITY; C-JUN; GROWTH-FACTOR; GENE-EXPRESSION; REGULATORY ELEMENTS; CARCINOMA-CELLS; FOS PROTEINS; DIFFERENTIATION; PROLIFERATION	In MCF7 breast cancer cells, mitogen-activated protein (MAP) kinase (i.e. Erk-1/2) is activated by the mitogen insulin, but also by the growth inhibiting agent TPA, though with very different kinetics, Insulin induces a relatively transient activation of Erk2 ( < 15 min), whereas TPA is able to induce a prolonged activation of Erk2 ( > 6 h), Expression of immediate-early genes of the c-fos and c-jun families, whose transcription and activation are regulated by MAP kinases, is differentially induced by insulin and TPA, Whereas insulin stimulates prolonged induction of c-jun, but not of junB mRNA, resulting in c-jun expression during the entire G(1) period, the growth inhibitor TPA induces junB much longer than c-jun. Inhibition of the Erk2 pathway by PD98059, specific for the upstream MAP kinase kinase (MEK1), abolishes TPA-stimulated junB but not insulin-induced c-jun, In agreement with this, insulin readily stimulates Jun kinase (JNK), whereas TPA does not, Furthermore, insulin-induced pRB hyperphosphorylation at the G(1)-S transition and S-phase entry is insensitive to MAP kinase inhibition by PD98059, On the other hand, PD98059 reverts the inhibitory effect of TPA on cell cycle entry as web as on pRB hyperphosphorylation, indicating that Erk effecters function as inhibitors of proliferation in MCF7 cells.	Univ Utrecht, Physiol Chem Lab, Stratenum, NL-3584 CG Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Alblas, J (corresponding author), Univ Utrecht Hosp, Dept Pulm Dis, Room G03550,POB 85500, NL-3508 GA Utrecht, Netherlands.			Alblas, Jacqueline/0000-0002-2996-9697				ABE M, 1986, J CELL PHYSIOL, V126, P126, DOI 10.1002/jcp.1041260117; ALKHALAF M, 1992, MOL ENDOCRINOL, V6, P1625, DOI 10.1210/me.6.10.1625; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; CARTER R, 1991, ONCOGENE, V6, P229; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DEGROOT RP, 1991, CELL GROWTH DIFFER, V2, P631; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HASHIMOTO M, 1993, ENDOCRINOLOGY, V133, P1934, DOI 10.1210/en.133.5.1934; HERBER B, 1994, ONCOGENE, V9, P1295; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1994, CELL GROWTH DIFFER, V5, P259; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUKAS J, 1994, ONCOGENE, V9, P707; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAYO MW, 1994, ONCOGENE, V9, P1999; MELAMED D, 1993, CELL GROWTH DIFFER, V4, P689; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NISHINA Y, 1993, EXP CELL RES, V208, P492, DOI 10.1006/excr.1993.1271; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; REDNER RL, 1992, ONCOGENE, V7, P43; RUPPRECHT HD, 1993, AM J PHY SL, V265, P351; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHLINGENSIEPEN KH, 1993, DEV GENET, V14, P305, DOI 10.1002/dvg.1020140408; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; VALETTE A, 1987, CANCER RES, V47, P1615; VANDERBURG B, 1990, CANCER RES, V50, P7770; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; VANDERBURG B, 1990, MOL ENDOCRINOL, V4, P1720, DOI 10.1210/mend-4-11-1720; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VANZOELEN EJJ, 1993, GROWTH FACTORS PRACT, P13; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030	63	73	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					131	139		10.1038/sj.onc.1201485	http://dx.doi.org/10.1038/sj.onc.1201485			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467952				2022-12-28	WOS:000071236800016
J	Caricasole, AAD; van Schaik, RHN; Zeinstra, LM; Wierikx, CDJ; van Gurp, RJHLM; van den Pol, M; Looijenga, LHJ; Oosterhuis, JW; Pera, MF; Ward, A; de Bruijn, D; Kramer, P; de Jong, FH; van den Eijnden-van Raaij, AJM				Caricasole, AAD; van Schaik, RHN; Zeinstra, LM; Wierikx, CDJ; van Gurp, RJHLM; van den Pol, M; Looijenga, LHJ; Oosterhuis, JW; Pera, MF; Ward, A; de Bruijn, D; Kramer, P; de Jong, FH; van den Eijnden-van Raaij, AJM			Human growth-differentiation factor 3 (hGDF3): developmental regulation in human teratocarcinoma cell lines and expression in primary testicular germ cell tumours	ONCOGENE			English	Article						teratocarcinoma; germ cell tumour; TGF beta; embryonal carcinoma	EMBRYONAL CARCINOMA-CELLS; BETA SUPERFAMILY; ADULT TESTIS; ACTIVIN-A; TUMORS; RECEPTORS; MEMBERS	We describe the cloning and initial characterization of a novel cDNA from human embryonal carcinoma CEC) cells, This cDNA, which we named human growth differentiation factor 3 (hGDF3), encodes the homologue of mouse GDF3, a TGF beta superfamily member belonging to the Growth/Differentiation Factors. We have analysed the expression of hGDF3 in human embryonal carcinoma cell lines and in primary testicular germ cell tumours of adolescents and adults (TGCTs), Expression of hGDF3 in human EC cell lines is stem cell-specific, is down-regulated upon RA-mediated differentiation and is increased upon culture of the cells in the presence of activin A, In TGCTs, hGDF3 expression is low in seminomas, while expression in non-seminomas is readily detectable and appears to be associated with the EC and yolk sac components in the tumours, We have also mapped the hGDF3 locus to the short arm of human chromosome 12, a region consistently overrepresented in human testicular germ cell rumours, Thus, hGDF3 represents an embryonal carcinoma stem cell-associated marker both in vitro and in vivo.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Erasmus Univ, Dept Endocrinol & Reprod, NL-3000 DR Rotterdam, Netherlands; Acad Hosp Rotterdam, Dr Daniel Den Hoed Canc Ctr, Expt Pathooncol Lab, NL-3075 EA Rotterdam, Netherlands; Monash Univ, Med Ctr, Inst Reprod & Dev, Clayton, Vic 3168, Australia; Univ Bath, Sch Biol & Biochem, Bath BA2 7AY, Avon, England; Dept Human Genet, NL-6500 HB Nijmegen, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Monash University; University of Bath	Caricasole, AAD (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		PERA, MARTIN/A-9812-2012; De Jong, Frank H/A-9876-2011; de Bruijn, D.R.H./L-4233-2015; van Schaik, Ron H.N./G-6816-2013; Looijenga, Leendert/B-8145-2019	PERA, MARTIN/0000-0001-6239-0428; De Jong, Frank H/0000-0003-3578-1065; Looijenga, Leendert/0000-0002-8146-1911; Ward, Andrew/0000-0001-8311-5695				ANDREWS P, 1987, TERATOCARCINOMAS EMB; ANDREWS PW, 1994, LAB INVEST, V71, P243; BAARENDS WM, 1995, ENDOCRINOLOGY, V136, P5614, DOI 10.1210/en.136.12.5614; CARICASOLE A, 1993, NUCLEIC ACIDS RES, V21, P1873, DOI 10.1093/nar/21.8.1873; DAMJANOV I, 1993, LAB INVEST, V68, P220; DEJONG B, 1990, CANCER GENET CYTOGEN, V48, P143, DOI 10.1016/0165-4608(90)90115-Q; DEJONG FH, 1993, BIOCHEM BIOPH RES CO, V192, P1334, DOI 10.1006/bbrc.1993.1562; DEJONG FH, 1994, FRONTIERS ENDOCRINOL, V3; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; JONES CM, 1992, MOL ENDOCRINOL, V6, P1961, DOI 10.1210/me.6.11.1961; KEITZ ATV, 1994, UROLOGY, V5, P28; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; Mosselman S, 1996, P NATL ACAD SCI USA, V93, P2884, DOI 10.1073/pnas.93.7.2884; MUMMERY CL, 1990, CELL DIFFER DEV, V30, P195, DOI 10.1016/0922-3371(90)90139-N; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; PERA MF, 1988, DIFFERENTIATION, V39, P139, DOI 10.1111/j.1432-0436.1988.tb00089.x; PERA MF, 1987, INT J CANCER, V40, P334, DOI 10.1002/ijc.2910400309; Sambrook J., 2002, MOL CLONING LAB MANU; SHIOZAKI M, 1992, P NATL ACAD SCI USA, V89, P1553, DOI 10.1073/pnas.89.5.1553; SINKE RJ, 1992, GENOMICS, V12, P206, DOI 10.1016/0888-7543(92)90367-2; VANDENEIJNDENVANRAAIJ AJM, 1991, MECH DEVELOP, V33, P157, DOI 10.1016/0925-4773(91)90082-H; VANSCHAIK RHN, 1997, IN PRESS BR J CANC; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; ZHANG J, 1989, HUM GENET, V83, P359, DOI 10.1007/BF00291381	26	51	80	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					95	103		10.1038/sj.onc.1201515	http://dx.doi.org/10.1038/sj.onc.1201515			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467948				2022-12-28	WOS:000071236800012
J	Viglietto, G; Romano, A; Manzo, G; Chiappetta, G; Paoletti, I; Califano, D; Galati, MG; Mauriello, V; Bruni, P; Lago, CT; Fusco, A; Persico, VG				Viglietto, G; Romano, A; Manzo, G; Chiappetta, G; Paoletti, I; Califano, D; Galati, MG; Mauriello, V; Bruni, P; Lago, CT; Fusco, A; Persico, VG			Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization	ONCOGENE			English	Article						PlGF; VEGF; TSH; thyroid goiter; hypervascularization	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TYROSINE KINASE; PLACENTA; CELLS; EXPRESSION; HEPARIN; IDENTIFICATION; THYROTROPIN; STIMULATION	Placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) represent two closely related angiogenic growth factors active as homodimers or heterodimers. Since goiters of the thyroid gland are extremely hypervascular, we investigated the expression of PlGF, VEGF and their receptors, Flt-1 and Flk-1/KDR, in a small panel of human goiters from patients with Graves's disease, in an animal model of thyroid goitrogenesis and in in vitro cultured thyroid cells. Here we report that the mRNA expression of PlGF, VEGF and their receptors is markedly enhanced in biopsies of goiters resected from Graves's patients. in vivo studies demonstrated that in the thyroid gland of thiouracil-fed rats, increased mRNA and protein expression of PlGF, VEGF, Flt-1 and Flk-1/KDR occurred subsequent to the rise in the serum thyroid stimulating hormone (TSH) levels and in parallel with thyroid capillary proliferation. In vitro studies confirmed the existence of such TSH-dependent paracrine communication between thyroid epithelial cells and endothelium since the conditioned medium collected from TSH-stimulated thyrocytes acquired mitogenic activity for human umbilical vein endothelial (HUVE) cells, Altogether, these data suggest that PlGF and VEGF, released by thyrocytes in response to the chronic activation of the TSH receptor pathway, may act through a paracrine mechanism on thyroid endothelium.	CNR, INT INST GENET & BIOPHYS, I-80125 NAPLES, ITALY; IST NAZL TUMORI FONDAZ SENATORE PASCALE, I-80131 NAPLES, ITALY; UNIV REGGIO CALABRIA, FAC MED & CHIRURG CATANZARO, DIPARTIMENTO MED SPERIMENTALE & CLIN, CALABRIA, ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Universita Mediterranea di Reggio Calabria			Viglietto, Giuseppe/AAC-2852-2019; Califano, Daniela/Y-6313-2018	Viglietto, Giuseppe/0000-0003-2327-7515; Califano, Daniela/0000-0001-6945-3209; Fusco, Alfredo/0000-0003-3332-5197				BRANDT R, 1994, J BIOL CHEM, V269, P17320; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DiPalma T, 1996, MAMM GENOME, V7, P6, DOI 10.1007/s003359900003; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GOODMAN AL, 1987, ENDOCRINOLOGY, V121, P2131, DOI 10.1210/endo-121-6-2131; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; ROGNONI JB, 1984, ACTA ENDOCRINOL-COP, V105, P40, DOI 10.1530/acta.0.1050040; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO K, 1995, J CLIN INVEST, V96, P1295, DOI 10.1172/JCI118164; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SMEDS S, 1983, LAB INVEST, V48, P285; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TERMAN BI, 1991, ONCOGENE, V6, P1677; VANSANDE J, 1975, ENDOCRINOLOGY, V96, P781, DOI 10.1210/endo-96-3-781; Viglietto G, 1996, ONCOGENE, V13, P577; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WILSON JD, 1989, THYROID TXB ENDOCRIN; WOLLMAN SH, 1978, ENDOCRINOLOGY, V103, P2306, DOI 10.1210/endo-103-6-2306; WYNFORDTHOMAS D, 1982, J ENDOCRINOL, V94, P131, DOI 10.1677/joe.0.0940131; YUN K, 1986, J ENDOCRINOL, V111, P397, DOI 10.1677/joe.0.1110397; Ziche M, 1997, LAB INVEST, V76, P517	33	90	93	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	1997	15	22					2687	2698		10.1038/sj.onc.1201456	http://dx.doi.org/10.1038/sj.onc.1201456			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400995				2022-12-28	WOS:A1997YH46800006
J	Kovar, H; Jug, G; Aryee, DNT; Zoubek, A; Ambros, P; Gruber, B; Windhager, R; Gadner, H				Kovar, H; Jug, G; Aryee, DNT; Zoubek, A; Ambros, P; Gruber, B; Windhager, R; Gadner, H			Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors	ONCOGENE			English	Article						Ewing tumors; p16; Rb; cyclin D; prognosis	KINASE-4 INHIBITOR GENE; P53 MUTATIONS; HOMOZYGOUS DELETIONS; CHIMERIC TRANSCRIPTS; CDK4 AMPLIFICATION; SOMATIC MUTATIONS; P16/MTS1 GENE; ABSENCE; CANCER; EXPRESSION	The pRB cell cycle regulatory cascade is frequently perturbed in neoplasia by overexpression of a component of the pRB-phosphorylating cyclin D1/CDK4 complex or by inactivation of pRB or the CDK4 inhibitors p16 and p15, We investigated the status and expression of p16, p15, CCND1, CDK4 and RE genes in the Ewing family of tumors, P16 loss was observed in 8 of 27 tumors (30%) and in 12 of 23 (52%) tumor cell lines from unrelated patients, There were no discrepancies in the p16 status between primary tumors and the corresponding cell lines and between cell Lines established from consecutive tumor samples, p15 was codeleted in most cases but p15 mRNA was absent also in cell lines retaining the gene, In addition, posttranscriptional p16 inactivation was observed in two cases, Although no evidence for CDK4 or CCND1 amplification was obtained, expression of these genes varied considerably in the cell lines in a case specific manner, In wild-type p16 cell lines, pRB expression was lost in one case, Our data indicate that, despite the absence of cytogenetically detectable 9p21 chromosomal aberrations, p16 deletions constitute the most frequent secondary molecular aberration in Ewing tumors so far, These results are discussed in the context of the stage of disease and the clinical outcome of the patients, The potential prognostic impact of these findings remains to be further evaluated.	UNIV VIENNA, DEPT ORTHOPED, A-1090 VIENNA, AUSTRIA	University of Vienna	Kovar, H (corresponding author), ST ANNA CHILDRENS HOSP, CHILDRENS CANC RES INST, KINDERSPITALGASSE 6, A-1090 VIENNA, AUSTRIA.		Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Windhager, Reinhard/0000-0002-6321-1804; Kovar, Heinrich/0000-0001-6873-9109				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; BARTKOVA J, 1995, CANCER RES, V55, P949; BELTINGER CP, 1995, CANCER RES, V55, P2053; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHEN TC, 1995, J PATHOL, V176, P243, DOI 10.1002/path.1711760306; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DURO D, 1995, ONCOGENE, V11, P21; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HE J, 1994, CANCER RES, V54, P5804; Hengstschlager M, 1996, DNA CELL BIOL, V15, P41, DOI 10.1089/dna.1996.15.41; HIRAMA T, 1995, BLOOD, V86, P841; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hui AM, 1996, HEPATOLOGY, V24, P575, DOI 10.1002/hep.510240319; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHATIB ZA, 1993, CANCER RES, V53, P5535; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; MALKIN D, 1994, CANCER RES, V54, P2077; MAO L, 1995, CANCER RES, V55, P2995; MORI T, 1994, CANCER RES, V54, P3396; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; PETER M, 1997, IN PRESS ONCOGENE; RAFFEL C, 1993, NEUROSURGERY, V33, P301, DOI 10.1227/00006123-199308000-00018; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHULZE A, 1994, ONCOGENE, V9, P3475; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, CANCER RES, V55, P2988; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VOGAN K, 1993, CANCER RES, V53, P5269; WADA M, 1993, BLOOD, V82, P3163; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	41	107	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2225	2232		10.1038/sj.onc.1201397	http://dx.doi.org/10.1038/sj.onc.1201397			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393981				2022-12-28	WOS:A1997YD01900011
J	Rousseau, S; Houle, F; Landry, J; Huot, J				Rousseau, S; Houle, F; Landry, J; Huot, J			p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells	ONCOGENE			English	Article						VEGF; p38 MAP kinase; cell migration	HEAT-SHOCK PROTEIN; GTP-BINDING PROTEIN; SIGNAL-TRANSDUCTION; TYROSINE KINASE; INFLAMMATORY CYTOKINES; SMOOTH-MUSCLE; STRESS FIBERS; FACTOR VEGF; PHOSPHORYLATION; MITOGEN	Vascular endothelial growth factor (VEGF) is a potent chemotactic agent for endothelial cells. Yet the signalling pathways that modulate the motogenic effects of VEGF in vascular endothelial cells are still ill defined. In the present study, we found in primary cultures of human umbilical vein endothelial cells (HUVEC) that VEGF increased cell migration and induced a marked reorganization of the microfilament network that was characterized by the formation of stress fibers and the recruitment of vinculin to focal adhesions, VEGF also stimulated the mitogen activated protein (MAP) kinases ERK (extracellular signal-regulated kinase) and p38 (stress activated protein kinase-2), but not SAPK1/JNK (stress activated protein kinase-1/c-Jun NH2-terminal kinase). Activation of p38 resulted in activation of MAP kinase activated protein kinase-2/3 and phosphorylation of the F-actin polymerization modulator, heat shock protein 27 (HSP27). Inhibiting the VEGF-induced activation of ERK with PD098059 did mot influence actin organization or cell migration but totally inhibited the VEGF-induced incorporation of thymidine into DNA. Inhibition of p38 activity by the specific inhibitor SB203580 led to an inhibition of HSP27 phosphorylation, actin reorganization and cell migration. The results indicate that the p38 pathway conveys the VEGF signal to microfilaments inducing rearrangements of the actin cytoskeleton that regulate cell migration. By modulating cell migration, p38 may thus be an important regulator of angiogenesis.	UNIV LAVAL,CTR RECH CANCEROL,HOTEL DIEU,QUEBEC CITY,PQ G1R 2J6,CANADA	Laval University			Rousseau, Simon/A-1800-2009	Rousseau, Simon/0000-0002-8773-575X				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ENOMOTO T, 1994, BIOCHEM BIOPH RES CO, V202, P1716, DOI 10.1006/bbrc.1994.2133; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Guay J, 1997, J CELL SCI, V110, P357; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1996, CANCER RES, V56, P273; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Hyder SM, 1996, CANCER RES, V56, P3954; JONGSTRABILEN J, 1992, J CELL BIOL, V118, P1443, DOI 10.1083/jcb.118.6.1443; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; KUZUYA M, 1994, EXP CELL RES, V215, P310, DOI 10.1006/excr.1994.1347; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEVESQUE L, 1995, BRIT J PHARMACOL, V116, P1673, DOI 10.1111/j.1476-5381.1995.tb16390.x; MADRI JA, 1988, ENDOTHELIAL CELL BIO, P167; MARCEAU F, 1992, INT J IMMUNOPHARMACO, V14, P525, DOI 10.1016/0192-0561(92)90113-Y; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORIOKA K, 1987, BIOCHEM BIOPH RES CO, V145, P969, DOI 10.1016/0006-291X(87)91060-6; OBERG C, 1994, GROWTH FACTORS, V10, P115, DOI 10.3109/08977199409010985; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SEETHARAM L, 1995, ONCOGENE, V10, P135; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; TAKAISHI K, 1994, ONCOGENE, V9, P273; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	55	696	709	0	39	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2169	2177		10.1038/sj.onc.1201380	http://dx.doi.org/10.1038/sj.onc.1201380			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393975				2022-12-28	WOS:A1997YD01900005
J	Floettmann, JE; Rowe, M				Floettmann, JE; Rowe, M			Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappa B activation	ONCOGENE			English	Article						EBV; LMP1; NF-KB; TNF-receptor; TRAF; signaling	CELL-DEATH; TRANSFORMING PROTEIN; LYMPHOCYTE-TRANSFORMATION; MONOCLONAL-ANTIBODIES; TRANSIENT EXPRESSION; CYTOPLASMIC DOMAIN; SEQUENCE VARIATION; NUCLEAR PROTEIN-2; TNF RECEPTOR; PHENOTYPE	The Epstein-Barr virus Latent Membrane Protein-1 (LMP1) has structural features and functions consistent with it being a constitutively active cell surface receptor. The known association of LMP1 with members of the TRAF family of proteins suggests that LMP1 transduces signals similarly to the Tumour Necrosis Factor Receptor (TNFR) family of cell surface receptors that signal by forming dimers or trimers in response to binding of extracellular ligands. However, interactions between LMP1 and the TRAFs have so far only been described for the C-terminal activation region 1 (CTAR1) of LMP1 and no direct interactions of the TRAFs with the second NF-kappa B activation domain (CTAR2) have been reported. We have now mapped the NF-kappa B activation domain of CTAR2 to a highly conserved stretch of 6 amino acids at the far C-terminus (codons 379 to 384 in B95.8 LMP1). In addition, we constructed chimeric receptor molecules which contain the ligand-binding extracellular domain and the transmembrane domain of rat CD2 fused to the C-terminus of LMP1 encoding the CTAR1 and/or the CTAR2 domain. Interestingly, the function of a chimera encoding CTAR2 alone, as well as the function of a chimera encoding both CTAR1 and CTAR2 was found to be inducible upon antibody-mediated crosslinking. These inducible chimeric proteins also allowed us to demonstrate that LMP1 mediated NF-kappa B activation is an immediate event following activation of LMP1.	UNIV WALES COLL MED,DEPT MED,CARDIFF CF4 4XX,S GLAM,WALES	Cardiff University			Rowe, Martin/B-2880-2009	Rowe, Martin/0000-0003-4139-7326				Ansieau S, 1996, P NATL ACAD SCI USA, V93, P14053, DOI 10.1073/pnas.93.24.14053; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CLARK SJ, 1988, J EXP MED, V167, P1861, DOI 10.1084/jem.167.6.1861; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; Devergne O, 1996, MOL CELL BIOL, V16, P7098; ELIOPOULOS A, 1997, IN PRESS ONCOGENE, V14; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUEN DS, 1995, ONCOGENE, V10, P549; JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1996, FIELDS VIROLOGY, V2, P2343; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; MILLER WE, 1994, J GEN VIROL, V75, P2729, DOI 10.1099/0022-1317-75-10-2729; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Palefsky JM, 1996, J INFECT DIS, V173, P710, DOI 10.1093/infdis/173.3.710; PENG M, 1992, ONCOGENE, V7, P1775; PILON M, 1991, J IMMUNOL, V146, P1047; RICKINSON A, 1996, FIELDS VIROLOGY, V2, P2397; ROBERTSON ES, 1995, EBV REPORT, V2, P73; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wang S, 1996, CANCER RES, V56, P4610; YOUNG DC, 1993, ANAL BIOCHEM, V215, P24, DOI 10.1006/abio.1993.1549	46	106	108	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1851	1858		10.1038/sj.onc.1201359	http://dx.doi.org/10.1038/sj.onc.1201359			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362452				2022-12-28	WOS:A1997XZ72500012
J	Bounacer, A; Wicker, R; Caillou, B; Cailleux, AF; Sarasin, A; Schlumberger, M; Suarez, HG				Bounacer, A; Wicker, R; Caillou, B; Cailleux, AF; Sarasin, A; Schlumberger, M; Suarez, HG			High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation	ONCOGENE			English	Article						radiation-associated tumors; ret protooncogene; activating rearrangements; RET/PTC oncogene	CHERNOBYL NUCLEAR ACCIDENT; TYROSINE KINASE; PAPILLARY CARCINOMAS; MOLECULAR CHARACTERIZATION; PROTOONCOGENE ACTIVATION; TRANSFORMING GENE; RET/PTC ONCOGENE; MUTATIONS; CANCER; RAS	A high frequency (about 60%) of ret rearrangements in papillary thyroid carcinomas of children exposed to radioactive fallout in Belarus the Chernobyl after accident, has been reported by three recent studies (Fugazzola et al., 1995; Ito et al., 1994; Klugbauer et al., 1995). These studies suggested that the radiation exposure may be a direct inducer of activating rearrangements in the vet gene. In order to confirm the postulated link between irradiation and the role of the ret protooncogene in thyroid tumorigenesis, we analysed for the presence of ret activating rearrangements using RT-PCR, XL-PCR, Southern blot and direct sequencing techniques, 39 human thyroid tumors (19 papillary carcinomas and 20 follicular adenomas), from patients who had received external radiation for benign or malignant conditions. As controls, eve studied 39 'spontaneous' tumors (20 papillary carcinomas and 19 follicular adenomas). Our data concerning the radiation-associated tumors, showed that: (1) the overall frequency of ret rearrangements was 84% in papillary carcinomas (16/19) and 45% (9/20) in follicular adenomas; (2) in contrast with the results obtained in the Chernobyl tumors, the most frequently observed chimeric gene was RET/PTC1 instead of the RET/PTC3 and (3) all the tumors were negative for RET/PTC2. In the 'spontaneous' tumors, only the papillary carcinomas presented a I et rearrangement (15%:3/20): 1 RET/PTC1, 1 RET/ PTC3 and 1 uncharacterized. In conclusion, our results confirm the crucial role played by the ret proto-oncogene activating rearrangements in the development of radiation-associated thyroid tumors appearing after therapeutic or accidental ionizing irradiation, and show, for the first time, the presence of RET/PTC genes in follicular adenomas appeared after external irradiation.	INST RECH SCI CANC, GENET MOL LAB, UPR 42, CNRS IFC 1, F-94801 VILLEJUIF, FRANCE; INST GUSTAVE ROUSSY, F-94805 VILLEJUIF, FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; CHALLETON C, 1995, ONCOGENE, V11, P601; CONARD RA, 1970, J AMER MED ASSOC, V214, P316, DOI 10.1001/jama.214.2.316; Delvincourt C, 1996, CLIN BIOCHEM, V29, P267, DOI 10.1016/0009-9120(96)00006-9; Diallo I, 1996, RADIOTHER ONCOL, V38, P269, DOI 10.1016/0167-8140(96)01713-6; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DUFFY BJ, 1950, J CLIN ENDOCRINOL, V10, P1296, DOI 10.1210/jcem-10-10-1296; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; Fogelfeld L, 1996, J CLIN ENDOCR METAB, V81, P3039, DOI 10.1210/jc.81.8.3039; FRAKER DL, 1995, SURG CLIN N AM, V75, P365, DOI 10.1016/S0039-6109(16)46627-2; Fugazzola L, 1996, ONCOGENE, V13, P1093; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P259; JACKSON DP, 1989, LANCET, V1, P1391; JHIANG SM, 1992, ONCOGENE, V7, P1331; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; LEMOINE NR, 1988, CANCER RES, V48, P4459; MICHELIN S, 1993, ONCOGENE, V8, P1983; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Nikiforov YE, 1996, ONCOGENE, V13, P687; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; SANGER F, 1977, P NATL ACAD SCI USA, V82, P488; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1994, ONCOGENE, V9, P509; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHORE RE, 1993, AM J EPIDEMIOL, V137, P1068, DOI 10.1093/oxfordjournals.aje.a116610; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; SHORE RE, 1985, J NATL CANCER I, V74, P1177; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; STARY A, 1992, NUCLEIC ACIDS RES, V20, P4269, DOI 10.1093/nar/20.16.4269; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1990, ONCOGENE, V5, P565; Sugg SL, 1996, J CLIN ENDOCR METAB, V81, P3360, DOI 10.1210/jc.81.9.3360; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; WOOD JW, 1969, AM J EPIDEMIOL, V89, P4, DOI 10.1093/oxfordjournals.aje.a120914; WRIGHT PA, 1991, ONCOGENE, V6, P471; WYNFORDTHOMAS D, 1993, CRIT REV ONCOGENESIS, V4, P1; ZOU MJ, 1994, CANCER, V73, P176, DOI 10.1002/1097-0142(19940101)73:1<176::AID-CNCR2820730130>3.0.CO;2-T	56	239	252	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1263	1273		10.1038/sj.onc.1200206	http://dx.doi.org/10.1038/sj.onc.1200206			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315093				2022-12-28	WOS:A1997XV84500003
J	Golubovskaya, VM; Presnell, SC; Hooth, MJ; Smith, GJ; Kaufmann, WK				Golubovskaya, VM; Presnell, SC; Hooth, MJ; Smith, GJ; Kaufmann, WK			Expression of telomerase in normal and malignant rat hepatic epithelia	ONCOGENE			English	Article						telomerase; rat liver; hepatocyte; stem cell; hepatocarcinogenesis	STEM-LIKE CELLS; IMMORTAL CELLS; RNA COMPONENT; CANCER; LIVER; TISSUES; HEPATOCARCINOGENESIS; DIFFERENTIATION; PROLIFERATION; PROGRESSION	Telomerase is a ribonucleoprotein that synthesizes telomeric DNA repeats onto the ends of chromosomes. More than 85% of human cancers express telomerase activity and a large proportion of human hepatocellular carcinomas are positive, To study the role of telomerase expression in rat hepatocarcinogenesis, telomerase activity was assayed in various rat tissues and in two types of liver epithelial cells: hepatocytes and hepatic epithelial stem-like cells. In the present study, we demonstrate that telomerase activity in rats is tissue-specific and stable with animal aging. Liver and testis were found to be telomerase positive, spleen had low or no activity, and kidney was negative, Telomerase activity did not change significantly in 18 month-old rats compared to 2 month-old rats, but was moderately (twofold) increased during liver regeneration induced by a 2/3's partial hepatectomy. Telomerase activity was detected in isolated rat hepatocytes and low passage hepatic epithelial stem-like cells (WB-F344). Telomerase activity displayed significant variations in a propagable clone of WB-F344 cells. At low passage levels after establishment in vitro (passages 4-9) non-tumorigenic WB-F344 cells expressed telomerase activity. During further in vitro passaging these cells lost expression of telomerase. Expression of telomerase in the tumor-derived lines of WB-F344 cells but not in the selectively cycled, parental lineages of these cells suggests that there may be a role for telomerase in hepatocarcinogenesis.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL & LAB MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM TOXICOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA 59486, CA 59495, CA 64340] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064340, R01CA059486] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACCHETTI S, 1995, INT J ONCOL, V7, P423; BIESSMANN H, 1992, ADV GENET, V30, P185, DOI 10.1016/S0065-2660(08)60321-1; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CAYAMA E, 1978, NATURE, V275, P60, DOI 10.1038/275060a0; CHADENEAU C, 1995, ONCOGENE, V11, P893; CHIAO C, 1995, AM J PATHOL, V146, P1248; COLEMAN WB, 1993, AM J PATHOL, V142, P1373; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gilley D, 1996, MOL CELL BIOL, V16, P66; Greaves M, 1996, TRENDS GENET, V12, P127, DOI 10.1016/0168-9525(96)30016-4; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GRISHAM JW, 1993, P SOC EXP BIOL MED, V204, P270; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HEALY KC, 1995, ONCOL RES, V7, P121; HUFF J, 1991, ENVIRON HEALTH PERSP, V93, P247, DOI 10.2307/3431195; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KAUFMANN WK, 1981, CANCER RES, V41, P4653; KAUFMANN WK, 1986, CARCINOGENESIS, V7, P669, DOI 10.1093/carcin/7.4.669; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; Kyo S, 1997, CANCER RES, V57, P610; LEE LW, 1989, AM J PATHOL, V135, P63; LEVIS RW, 1993, CELL, V75, P1083, DOI 10.1016/0092-8674(93)90318-K; MAKAROV VL, 1993, CELL, V73, P775, DOI 10.1016/0092-8674(93)90256-P; McClintock B, 1941, GENETICS, V26, P234; OLOVNIKOV A M, 1971, Doklady Biochemistry, V201, P394; PROWSE K, 1995, P NATL ACAD SCI USA, V201, P4818; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Strahl C, 1996, MOL CELL BIOL, V16, P53; TAHARA H, 1995, CANCER RES, V55, P2734; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; Yoshimi N, 1996, MOL CARCINOGEN, V16, P1, DOI 10.1002/(SICI)1098-2744(199605)16:1<1::AID-MC1>3.0.CO;2-N; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZHANG Y, 1995, LIVER REGENERATION C, P179	45	19	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1233	1240		10.1038/sj.onc.1201278	http://dx.doi.org/10.1038/sj.onc.1201278			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294617				2022-12-28	WOS:A1997XU99100013
J	MacGrogan, D; Pegram, M; Slamon, D; Bookstein, R				MacGrogan, D; Pegram, M; Slamon, D; Bookstein, R			Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas	ONCOGENE			English	Article						tumor suppressor gene; DPC4; mutation; prostate cancer; colorectal cancer	COMPARATIVE GENOMIC HYBRIDIZATION; GROWTH-FACTOR-BETA; ALLELIC IMBALANCE; CANCER; GENE; DCC; LOCI; P53	Allelic deletions of chromosome 18q are reported to be common in prostate and colorectal cancers, suggesting that one or more tumor suppressor genes on 18q are involved in the genesis of these neoplasms, The DPC4 gene, a recently identified candidate tumor suppressor in 18q21, was examined for evidence of inactivation in prostatic carcinomas, and results compared to those of a parallel analysis of colorectal carcinomas, for which DPC4 mutation has been reported in similar to 10% of cases, In this study, only three (10%) of 29 informative primary prostate cancers showed allelic loss of chromosome 18q21 markers, and no point mutations or deletions of DPC4 were detected in the complete set of 45 primary or metastatic cases, In contrast, five (56%) of nine primary colorectal tumors displayed allelic loss of 18q markers and in one of these a somatically acquired G-->T missense mutation was found in exon 1. Of twelve colorectal tumor cell lines, one showed a G-->C missense mutation in exon 8 and two had partial homozygous deletions that would likely abrogate gene function, These data suggest that DPC4 is rarely if ever mutated during prostatic oncogenesis, whereas inactivation of this gene may contribute to the genesis of a subset of colorectal carcinomas.	CANJI INC,DEPT BIOL MOL,SAN DIEGO,CA 92121; UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			MacGrogan, Donal/AAR-7392-2021; MacGrogan, Donal/E-8604-2016	MacGrogan, Donal/0000-0003-2808-8422; MacGrogan, Donal/0000-0003-2808-8422	NCI NIH HHS [1R01 CA 60358, 1K12 CA01714] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001714, R01CA060358] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; Cher ML, 1996, CANCER RES, V56, P3091; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Cunningham JM, 1996, CANCER RES, V56, P4475; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GAO X, 1993, CANCER RES, V53, P2723; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; JOOS S, 1995, GENE CHROMOSOME CANC, V14, P267, DOI 10.1002/gcc.2870140405; Kim SK, 1996, CANCER RES, V56, P2519; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nagatake M, 1996, CANCER RES, V56, P2718; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Sambrook J., 2002, MOL CLONING LAB MANU; Schutte M, 1996, CANCER RES, V56, P2527; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; VISAKORPI T, 1995, CANCER RES, V55, P342; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WILDING G, 1989, MOL CELL ENDOCRINOL, V62, P79, DOI 10.1016/0303-7207(89)90115-9; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	30	114	121	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1111	1114		10.1038/sj.onc.1201232	http://dx.doi.org/10.1038/sj.onc.1201232			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285566				2022-12-28	WOS:A1997XT16100013
J	Nathan, CA; Carter, P; Liu, L; Li, BD; Abreo, F; Tudor, A; Zimmer, SG; DeBenedetti, A				Nathan, CA; Carter, P; Liu, L; Li, BD; Abreo, F; Tudor, A; Zimmer, SG; DeBenedetti, A			Elevated expression of eIT4E and FGF-2 isoforms during vascularization of breast carcinomas	ONCOGENE			English	Article						eIF4E oncogene; FGF-2 isoforms; tumor vascularization; translation initiation; breast cancer progression; immunohistology	FIBROBLAST GROWTH-FACTOR; RAT EMBRYO FIBROBLASTS; MESSENGER-RNA; INITIATION FACTOR-4E; TRANSLATION; CELLS; TRANSFORMATION; AMPLIFICATION; CANCER	The translation initiation factor eIF4E is a novel protooncogene found over expressed in most breast carcinomas (Kerekatte et al., 1995), but the pathology where this elevation is initially manifested and its possible role in cancer progression are unknown, We report that eIF4E is markedly increased in vascularized malignant ductules of invasive carcinomas, whereas necrotic and avascular ductal carcinomas lit situ display significantly lower levels, eIF4E facilitates the synthesis of FGF-2, a powerful tumor angiogenic factor, Conversely, reducing eIF4E with antisense RNA in MDA-435 cells suppresses their tumorigenic and angiogenic properties, consistent with loss of FGF-2 synthesis, These findings suggest a causal role for eIF4E in tumor vascularization.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM, SHREVEPORT, LA 71105 USA; LOUISIANA STATE UNIV, MED CTR, DEPT OTOLARYNGOL, SHREVEPORT, LA USA; LOUISIANA STATE UNIV, MED CTR, DEPT SURG, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, MED CTR, DEPT PATHOL, SHREVEPORT, LA 71130 USA; UNIV KENTUCKY, MED CTR, LUCILLE P MARKEY CANC CTR, LEXINGTON, KY 40536 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Kentucky				de benedetti, arrigo/0000-0002-4198-8647	NCI NIH HHS [CA69148-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; ASCHER NL, 1979, TRANSPLANTATION, V27, P254, DOI 10.1097/00007890-197904000-00010; CHAMPEME MH, 1994, MODERN PATHOL, V7, P900; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; EDGINGTON TS, 1995, FASEB J, V9, P841, DOI 10.1096/fasebj.9.10.7615153; FOLKMAN J, 1986, CANCER RES, V46, P467; FRYKBERG ER, 1994, WORLD J SURG, V18, P45, DOI 10.1007/BF00348191; GABRA N, 1994, BIOCHEM BIOPH RES CO, V205, P1423, DOI 10.1006/bbrc.1994.2824; GRAFF JR, 1995, INT J CANCER, V60, P255; HALABAN R, 1988, ONCOGENE RES, V3, P177; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARLOW E, 1988, ANTIBODIES LABORATOR, P403; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; LI BDL, 1997, IN PRESS CANCER; LIPPMAN M, 1996, 19 ANN SAN ANT BREAS, V41, P191; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; MORRISON RS, 1990, CANCER RES, V50, P2524; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Souttou B, 1996, INT J CANCER, V68, P675, DOI 10.1002/(SICI)1097-0215(19961127)68:5<675::AID-IJC19>3.0.CO;2-0; SU ZZ, 1993, ONCOGENE, V8, P1211; TAKEI Y, 1993, J CLIN BIOCHEM NUTR, V15, P57; THEILLET C, 1989, ONCOGENE, V4, P915; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VISSCHER DW, 1995, MODERN PATHOL, V8, P665; WELLSTEIN A, 1991, MOL F ONCOLOGY, P403; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5	38	111	114	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1087	1094		10.1038/sj.onc.1201272	http://dx.doi.org/10.1038/sj.onc.1201272			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285563				2022-12-28	WOS:A1997XT16100010
J	Baldassarre, G; Romano, A; Armenante, F; Rambaldi, M; Paoletti, I; Sandomenico, C; Pepe, S; Staibano, S; Salvatore, G; DeRosa, G; Persico, MG; Viglietto, G				Baldassarre, G; Romano, A; Armenante, F; Rambaldi, M; Paoletti, I; Sandomenico, C; Pepe, S; Staibano, S; Salvatore, G; DeRosa, G; Persico, MG; Viglietto, G			Expression of teratocarcinoma-derived growth factor-1 (TDGF-1) in testis germ cell tumors and its effects on growth and differentiation of embryonal carcinoma cell line NTERA2/D1	ONCOGENE			English	Article						TDGF-1; teratocarcinoma; seminoma; cell differentiation	HEXAMETHYLENE BISACETAMIDE HMBA; FACTOR-RELATED PROTEIN; RETINOIC ACID; FACTOR-ALPHA; COLORECTAL TUMORS; TGF-ALPHA; CANCER; CRIPTO; GENE; AMPHIREGULIN	The teratocarcinoma-derived growth factor-1 (TDGF-1) gene codes for a 188-aminoacid glycoprotein that shares structural homology with the epidermal growth factor (EGF) family of growth factors, TDGF-1 is highly expressed in the undifferentiated embryonal carcinoma stem cell line NTERA2 clone D1 (NT2/D1) and its expression is downregulated in response to differentiating agents such as retinoic acid (RA) and hexamethylen-bisacetamide (HMBA), To assess the role of TDGF-1 in the onset and/or progression of human germ cell tumors, we analysed TDGF-1 expression by Northern blot and immunostaining in a panel of 59 human germ cell tumors of different histological origins, We show that TDGF-1 expression is markedly elevated in a subset of human testicular germ cell tumors as compared to normal testes, TDGF-1 overexpression occurs in about 100% of tumors with non-seminomatous phenotype, such as embryonal carcinomas and malignant undifferentiated teratocarcinomas, To address the questions of how TDGF-1 (previously called CRIPTO) may affect the growth and/or the differentiation of embryonal carcinoma cells, we have characterized the effects of exogenous recombinant TDGF-1 protein on the proliferation rate and differentiation potential of NT2/D1, Exogenous TDGF-1 protein stimulated DNA synthesis and cell proliferation in both undifferentiated and differentiated NT2/D1 cells, However, TDGF-1 protein treatment was unable to block differentiation induced by both RA and HMBA, These results suggest that TDGF-1 growth factor may represent an autocrine growth factor that may be involved in the process of development of testicular neoplasms.	CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; FDN SENATORE PASCALE,IST NAZL TUMORI NAPOLI,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO ENDOCRINOL & ONCOL SPERIMENTALE & CL,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,IST PATOL,I-80131 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); IRCCS Fondazione Pascale; University of Naples Federico II; University of Naples Federico II			Viglietto, Giuseppe/AAC-2852-2019; Baldassarre, Gustavo/K-1350-2016	Viglietto, Giuseppe/0000-0003-2327-7515; Baldassarre, Gustavo/0000-0002-9750-8825; DE ROSA, Gaetano/0000-0002-3635-5853; Sandomenico, Claudia/0000-0003-3709-0807				ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Baldassarre G, 1996, INT J CANCER, V66, P538, DOI 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3; BASELGA J, 1993, ONCOGENE, V8, P3257; BOS JL, 1989, CANCER RES, V49, P4682; BRANDT R, 1994, J BIOL CHEM, V269, P17320; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DMITROVSKY E, 1990, ONCOGENE, V5, P534; DONO R, 1993, DEVELOPMENT, V118, P1157; KURIE JM, 1993, DIFFERENTIATION, V54, P115; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MURTY VVV, 1994, ONCOGENE, V9, P3228; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; SAEKI T, 1992, CANCER RES, V52, P3467; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALOMON DS, 1995, CURRENT OPINION ENDO, V2, P500; Sambrook J., 2002, MOL CLONING LAB MANU; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPORN MB, 1992, ANN INTERN MED, V117, P408, DOI 10.7326/0003-4819-117-5-408; TIENARI J, 1995, DIFFERENTIATION, V59, P193, DOI 10.1046/j.1432-0436.1995.5930193.x; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; ULBRIGHT TM, 1994, DIAGNOSTIC SURG PATH, V46, P1885	38	54	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					927	936		10.1038/sj.onc.1201260	http://dx.doi.org/10.1038/sj.onc.1201260			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285688				2022-12-28	WOS:A1997XR76700006
J	Kawada, M; Yamagoe, S; Murakami, Y; Suzuki, K; Mizuno, S; Uehara, Y				Kawada, M; Yamagoe, S; Murakami, Y; Suzuki, K; Mizuno, S; Uehara, Y			Induction of p27(Kip1) degradation and anchorage independence by Ras through the MAP kinase signaling pathway	ONCOGENE			English	Article						ras; anchorage independence; cell cycle; p27(Kip1)	CELL-CYCLE ARREST; PROTEIN-KINASE; G1 PHASE; POTENTIAL MEDIATOR; TRANSFORMED-CELLS; CDK6 INHIBITOR; GROWTH; PROGRESSION; ACTIVATION; LINKS	While most untransformed cells require substrate attachment for growth (anchorage dependence), the oncogenic transformed cells lack this requirement (anchorage independence) and are often tumorigenic. However, the mechanism of loss of anchorage dependence is not fully understood. When rat normal fibroblasts were cultured in suspension without substrate attachment, the cell cycle arrested in G1 phase and the cyclin-dependent kinase inhibitor p27(Kip1) protein and its mRNA accumulated. Conditional expression of oncogenic Ras induced the G1-S transition of the cell cycle and significantly shortened the half-life of p27(Kip1) protein without altering its mRNA level. Inhibition of the activation of mitogen-activated protein (MAP) kinase by cyclic AMP-elevating agents and a MEK inhibitor prevented the oncogenic Ras-induced degradation of p27(KiP1). These results suggest that the loss of substrate attachment induces the cell cycle arrest through the upregulation of p27(Kip1) mRNA, but the oncogenic Ras confers anchorage independence by accelerating p27(Kip1) degradation through the activation of the MAP kinase signaling pathway. Furthermore, we have found that p27(Kip1) is phosphorylated by MAP kinase in vitro and the phosphorylated p27(Kip1) cannot bind to and inhibit cdk2.	NATL INST HLTH,DEPT BIOACT MOL,SHINJUKU KU,TOKYO 162,JAPAN					Kawada, Manabu/0000-0001-9348-4240				BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FUKAZAWA H, 1995, ANAL BIOCHEM, V228, P83, DOI 10.1006/abio.1995.1318; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kang JS, 1996, MOL CELL BIOL, V16, P3370; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LOVEC H, 1994, ONCOGENE, V9, P323; Luo Y, 1996, MOL CELL BIOL, V16, P6744; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maki CG, 1996, CANCER RES, V56, P2649; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Nakajima T, 1996, J BIOL CHEM, V271, P24842, DOI 10.1074/jbc.271.40.24842; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SOUTHGATE J, 1995, BRIT J CANCER, V72, P1214, DOI 10.1038/bjc.1995.488; Spirin KS, 1996, CANCER RES, V56, P2400; Takeuchi S, 1996, CANCER RES, V56, P738; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Winston JT, 1996, ONCOGENE, V12, P127; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	56	180	184	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					629	637		10.1038/sj.onc.1201228	http://dx.doi.org/10.1038/sj.onc.1201228			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264403				2022-12-28	WOS:A1997XP68300002
J	Collins, LR; Ricketts, WA; Olefsky, JM; Brown, JH				Collins, LR; Ricketts, WA; Olefsky, JM; Brown, JH			The G(12) coupled thrombin receptor stimulates mitogenesis through the Shc SH2 domain	ONCOGENE			English	Article						G alpha(12); Shc; AP-1; thrombin	INDUCE NEOPLASTIC TRANSFORMATION; NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL GROWTH-FACTOR; TYROSINE-KINASE; SIGNAL TRANSDUCTION; ASTROCYTOMA-CELLS; ADAPTER PROTEIN; RAS; ACTIVATION; PATHWAY	Our previous studies in 1321N1 astrocytoma cells demonstrate that thrombin stimulates Ras-dependent mitogenesis through the pertussis toxin insensitive G protein G(12). While the direct effecters of G(12) are unknown, G alpha(12) can transform fibroblasts, utilize Ras and Rac dependent signaling pathways and stimulate GTP loading of Ras. Here we have examined the role of the Shc adaptor protein in mitogenic signaling by the thrombin receptor in 1321N1 cells. As has been reported in other systems, thrombin stimulation results in tyrosine phosphorylation of Shc in 1321N1 cells. We also show that transient expression of G alpha(12) results in tyrosine phosphorylation of Shc, thereby identifying Shc as the most proximal G(12) effector to date. In addition, we demonstrate by microinjection that thrombin stimulated mitogenesis requires Shc and occurs specifically through the Shc SH2 domain. Expression of the SH2 domain of Shc also inhibits G alpha(12) mediated induction of an AP-1 dependent reporter gene demonstrating that G(12) utilizes Shc to propagate downstream signals. Our data indicate that Shc is essential for stimulation of Ras dependent mitogenesis and gene expression by the G(12) coupled thrombin receptor.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NIDDK NIH HHS [DK33651] Funding Source: Medline; NIGMS NIH HHS [F31 GM17277, GM36927] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927, R56GM036927, F31GM017277] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASU T, 1994, ONCOGENE, V9, P3483; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	33	28	30	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					595	600		10.1038/sj.onc.1201220	http://dx.doi.org/10.1038/sj.onc.1201220			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247313				2022-12-28	WOS:A1997XN25500011
J	Nathan, CAO; Liu, L; Li, BD; Abreo, FW; Nandy, I; DeBenedetti, A				Nathan, CAO; Liu, L; Li, BD; Abreo, FW; Nandy, I; DeBenedetti, A			Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer	ONCOGENE			English	Article						eIF4E; carcinomas; head and neck; surgical margins	SQUAMOUS-CELL CARCINOMA; EXPRESSION; OVEREXPRESSION; TRANSFORMATION; PROTOONCOGENE	Head and neck squamous cell cancers (HNSCC) have a high local recurrence rate due to incomplete tumor resection. The use of molecular markers to establish surgical margins may decrease local recurrence. Surgical margins are determined by histopathologic analysis on frozen sections, We postulate that genetic and molecular changes precede gross histologic alterations. Tumor markers may improve the reliability of pathology examination, but those evaluated to date lack the sensitivity needed for routine clinical use. Western blot analysis showed elevated eIF4E in all 26 HNSCC in contrast to its low expression in benign lesions. Surgical margins were analysed for eIF4E in 23 patients. Twelve patients showed elevated eIF4E in histologically negative margins. Cancer has recurred in 5 of the 12 patients as opposed to none of the 11 patients with eIF4E negative margins (P = 0.02, Log rank test). This is the first report of eIF4E in HNSCC, as a sensitive and specific marker for HNSCC, with potential for defining clear resection margins. The correlation between elevated levels of eIF4E at the margins and recurrence highlights its ability to detect malignant cells prior to clear-cut alterations in morphology, The accuracy and simplicity of these assays underscore the usefulness of eIF4E in managing HNSCC.	VAMC, SHREVEPORT, LA USA; LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOL BIOL, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, MED CTR, DEPT SURG, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, MED CTR, DEPT PATHOL, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, MED CTR, DEPT BIOMETRY & ACAD COMP, SHREVEPORT, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Nathan, CAO (corresponding author), LOUISIANA STATE UNIV, MED CTR, DEPT OTOLARYNGOL HEAD & NECK SURG, SHREVEPORT, LA 71130 USA.			de benedetti, arrigo/0000-0002-4198-8647	NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER; NCI NIH HHS [CA69148-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; BECHHARDT RN, 1995, ARCH OTOLARYNGOL, V121, P1265; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; DAVIDSON TM, 1981, OTOLARYNG HEAD NECK, V89, P244, DOI 10.1177/019459988108900219; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; FIELD JK, 1989, ONCOGENE, V4, P1463; Folkman J, 1976, Int Rev Exp Pathol, V16, P207; GANDOUREDWARDS RF, 1993, HEAD NECK-J SCI SPEC, V15, P373, DOI 10.1002/hed.2880150502; GILBERT H, 1974, J SURG ONCOL, V6, P357, DOI 10.1002/jso.2930060502; HARLOW E, 1988, ANTIBODIES LABORATOR, P403; JESSE RH, 1976, AM J SURG, V132, P435, DOI 10.1016/0002-9610(76)90314-7; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KIARIS H, 1995, BRIT J CANCER, V72, P123, DOI 10.1038/bjc.1995.287; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LOOSER KG, 1978, HEAD NECK SURG, V1, P107, DOI 10.1002/hed.2890010203; MAESTRO R, 1992, ONCOGENE, V7, P1159; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rousseau D, 1996, ONCOGENE, V13, P2415; SHANTZ LM, 1994, CANCER RES, V54, P2313; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3	23	157	167	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	1997	15	5					579	584		10.1038/sj.onc.1201216	http://dx.doi.org/10.1038/sj.onc.1201216			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247311				2022-12-28	WOS:A1997XN25500009
J	Pacini, F; Vivaldi, A; Santoro, M; Fedele, M; Fusco, A; Romei, C; Basolo, F; Pinchera, A				Pacini, F; Vivaldi, A; Santoro, M; Fedele, M; Fusco, A; Romei, C; Basolo, F; Pinchera, A			Simian virus 40-like DNA sequences in human papillary thyroid carcinomas	ONCOGENE			English	Article						SV40; thyroid cancer; autoimmune thyroiditis; oncogene	LARGE T-ANTIGEN; TRANSGENIC MICE; CHOROID-PLEXUS; RET ONCOGENE; CANCER; TUMORS; CELLS; EXPRESSION; RADIATION; EXPOSURE	Sequences of the SV40 virus, a virus of Asian macaques, have been found in human tumors, such as pleural mesotheliomas, ependimomas and choroid plexus tumors, Transgenic mice carrying the SV40 large T gene under the transcriptional control of the thyroglobulin gene promoter, develop thyroid dedifferentiation and follicular thyroid cell proliferation, leading to thyroid hyperplasia and adenocarcinomas. On these bases we investigated the presence of SV40 DNA sequences in 69 samples of papillary thyroid carcinomas (PTC) and in other thyroid and non-thyroid carcinomas, as well as in benign thyroid diseases. By Southern blot and PCR amplification followed by sequence analysis, we found the presence of SV40-related sequences integrated in the tumoral DNA of three cases of PTC. At least the 203 bp fragment of the aminoterminus of large T antigen, the 294 bp fragment of the VP1 gene and the 483 bp entire regulatory region were present in the tumoral DNA of these patients. SV40 sequences were not found in tissues other than PTC. Our results demonstrate that, in addition to previous findings in mesotheliomas and brain tumors, SV40 is somehow linked to papillary thyroid carcinoma. Although our data do not demonstrate a causative role in the development of PTC, this possibility must be considered and requires further studies.	Univ Pisa, Ist Endocrinol Metodol Clin & Med Lavoro, I-56124 Pisa, Italy; Univ Pisa, Ist Anat Patol, I-56124 Pisa, Italy; Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Ist Nazl Tumori, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Pisa; University of Pisa; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria	Pacini, F (corresponding author), Univ Pisa, Ist Endocrinol Metodol Clin & Med Lavoro, Via Paradisa 2, I-56124 Pisa, Italy.		Basolo, Fulvio/AAC-2727-2019; Fedele, Monica/C-1417-2015	Basolo, Fulvio/0000-0003-1657-5020; Fedele, Monica/0000-0002-9171-1312; Fusco, Alfredo/0000-0003-3332-5197				ARTHUR RR, 1989, PROG MED VIROL, V36, P42; BALKANY C, 1995, THYROID, V5, P47, DOI 10.1089/thy.1995.5.47; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Bond JA, 1996, INT J CANCER, V67, P563, DOI 10.1002/(SICI)1097-0215(19960807)67:4<563::AID-IJC16>3.0.CO;2-8; CARBONE M, 1994, ONCOGENE, V9, P1781; CIAMPOLILLO A, 1989, LANCET, V1, P1096; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; DAS BC, 1992, J MED VIROL, V36, P239, DOI 10.1002/jmv.1890360402; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; GALANTI MR, 1995, INT J CANCER, V61, P615, DOI 10.1002/ijc.2910610506; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1995, ONCOGENE, V10, P1789; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; Martini F, 1996, CANCER RES, V56, P4820; MELNICK JL, 1962, P SOC EXP BIOL MED, V109, P965, DOI 10.3181/00379727-109-27392; MILLER RW, 1995, ENVIRON HEALTH PERSP, V103, P41, DOI 10.2307/3432343; MORRIS JA, 1961, P SOC EXP BIOL MED, V108, P56, DOI 10.3181/00379727-108-26843; Pettersson B, 1996, INT J CANCER, V65, P13, DOI 10.1002/(SICI)1097-0215(19960103)65:1&lt;13::AID-IJC3&gt;3.0.CO;2-4; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1994, ONCOGENE, V9, P509; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; TAKAHASHI MH, 1995, BRIT J CANCER, V72, P813, DOI 10.1038/bjc.1995.418; WILLIAMS ED, 1979, CLIN ENDOCRINOL META, V8, P193, DOI 10.1016/S0300-595X(79)80017-1; WILLIAMS ED, 1995, J ENDOCRINOL INVEST, V18, P144, DOI 10.1007/BF03349725	31	48	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	1998	16	5					665	669		10.1038/sj.onc.1201552	http://dx.doi.org/10.1038/sj.onc.1201552			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482113				2022-12-28	WOS:000071816600012
J	Alric, S; Froeschle, A; Piquemal, D; Carnac, G; Bonnieu, A				Alric, S; Froeschle, A; Piquemal, D; Carnac, G; Bonnieu, A			Functional specificity of the two retinoic acid receptor RAR and RXR families in myogenesis	ONCOGENE			English	Article						myogenesis; retinoic acid; RAR; RXR; dominant negative; MyoD	INDUCED GRANULOCYTIC DIFFERENTIATION; EMBRYONAL CARCINOMA-CELLS; NUCLEAR HORMONE RECEPTORS; X-RECEPTOR; MUTANT MICE; SIGNALING PATHWAYS; RESPONSE ELEMENT; THYROID-HORMONE; GENE-REGULATION; MUSCLE-CELLS	In C2 myoblasts, retinoic acid (RA) is an efficient inducer of both growth arrest and differentiation. These RA effects are mediated through at least two classes of retinoic acid receptors (RARs and RXRs), which belong to the nuclear receptor superfamily. To determine the role played by each RAR or RXR family in this model system, we have analysed the effects of RA in C2 myoblasts expressing a dominant negative RAR (dnRAR) or a dominant negative RXR (dnRXR), The stable expression of dnRAR or dnRXR in C2 cells delays the RA-induced growth arrest and differentiation, an effect which is more pronounced in C2-dnRXR myoblasts, Furthermore, the RA-inducible expression of MyoD gene is lost in C2-dnRXR but not in C2-dnRAR cells, indicating that each family of retinoid receptors RAR and RXR may regulate distinct subsets of RA-responsive genes. Finally, using C2 cell lines with different retinoid responsiveness, we provided evidence for a link between the RXR and MyoD families in the process of myogenic differentiation, These results illustrate a critical role for RA-receptors in RA-control of C2 myogenesis and provide tools for studying the function of RA and its receptors during vertebrate development.	INRA, Lab Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France; Univ Montpellier 2, INSERM, U431, F-34095 Montpellier, France; CNRS, CRBM, Cell Biol Unit, F-34033 Montpellier, France	INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Bonnieu, A (corresponding author), INRA, Lab Differenciat Cellulaire & Croissance, Pl Viala, F-34060 Montpellier 1, France.		Bonnieu, Anne/ABA-7182-2020; Carnac, Gilles/N-6744-2018	Piquemal, David/0000-0002-5870-4276; Carnac, Gilles/0000-0002-3518-8774				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; CARNAC G, 1993, ENDOCRINOLOGY, V133, P2171, DOI 10.1210/en.133.5.2171; CARNAC G, 1993, ONCOGENE, V8, P3103; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN YP, 1991, ROUX ARCH DEV BIOL, V200, P162, DOI 10.1007/BF00190236; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10056, DOI 10.1073/pnas.89.21.10056; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DE LUCA LM, 1991, FASEB J, V5, P2924; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; DOWNES M, 1994, ENDOCRINOLOGY, V134, P2658, DOI 10.1210/en.134.6.2658; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Froeschle A, 1996, ONCOGENE, V12, P411; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Gudas Lorraine J., 1994, P443; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hofmann Clementine, 1994, P387; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kastner P, 1997, DEVELOPMENT, V124, P313; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KONIECZNY SF, 1989, ONCOGENE, V4, P473; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; KRUYT FAE, 1992, DIFFERENTIATION, V49, P27, DOI 10.1111/j.1432-0436.1992.tb00766.x; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOHNES D, 1995, J STEROID BIOCHEM, V53, P475, DOI 10.1016/0960-0760(95)00094-G; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MONTARRAS D, 1991, NEW BIOL, V3, P592; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NILSEN DA, 1983, P NATL ACAD SCI USA, V80, P5198; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; Sucov HM, 1995, DEVELOPMENT, V121, P3997; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WAGNER M, 1992, DEVELOPMENT, V116, P55; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	82	22	22	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					273	282		10.1038/sj.onc.1201484	http://dx.doi.org/10.1038/sj.onc.1201484			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464546				2022-12-28	WOS:000071427100015
J	Blackshear, PE; Goldsworthy, SM; Foley, JF; McAllister, KA; Bennett, LM; Collins, NK; Bunch, DO; Brown, P; Wiseman, RW; Davis, BJ				Blackshear, PE; Goldsworthy, SM; Foley, JF; McAllister, KA; Bennett, LM; Collins, NK; Bunch, DO; Brown, P; Wiseman, RW; Davis, BJ			Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice.	ONCOGENE			English	Article						Brca1; Brca2; mitosis; meiosis	BREAST-CANCER; SPERMATOGENIC CELLS; EPITHELIAL-CELLS; MESSENGER-RNA; GENE; DIFFERENTIATION; SUSCEPTIBILITY; TISSUES	The mouse homologues of the breast cancer susceptibility genes, Brca1 and Brca2, are expressed in a cell cycle-dependent fashion in vitro and appear to be regulated by similar or overlapping pathways, Therefore, we compared the non isotopic in situ hybridization expression patterns of Brca1 and Brca2 mRNA in vivo in mitotic and meiotic cells during mouse embryogenesis, mammary gland development, and in adult tissues including testes, ovaries, and hormonally altered ovaries, Brca1 and Brca2 are expressed concordantly in proliferating cells of embryos, and the mammary gland undergoing morphogenesis and in most adult tissues, The expression pattern of Brca1 and Brca2 correlates with the localization of proliferating cell nuclear antigen, an indicator of proliferative activity, In the ovary, Brca1 and Brca2 exhibited a comparable hormone-independent pattern of expression in oocytes, granulosa cells and thecal cells of developing follicles, In the testes, Brca1 and Brca2 were expressed in mitotic spermatogonia and early meiotic prophase spermatocytes, Northern analyses of prepubertal mouse testes revealed that the time course of Brca2 expression was delayed in spermatogonia relative to Brca1. Thus, while Brca1 and Brca2 share concordant cell-specific patterns of expression in most proliferating tissues, these observations suggest that they may have distinct roles during meiosis.	NIEHS, Res Triangle Pk, NC 27709 USA; Pathol Associates Int, Durham, NC 27713 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Blackshear, PE (corresponding author), NIEHS, POB 12233, Res Triangle Pk, NC 27709 USA.			Bunch, Donna/0000-0002-3638-0522; Foley, Julie/0000-0001-9726-2821				BELIVE AR, 1977, J CELL BIOL, V74, P68; CLEVELAND DW, 1990, CELL, V60, P701, DOI 10.1016/0092-8674(90)90083-Q; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; DANIEL CWA, 1987, POSTNATAL DEV RODENT; FOLEY J, 1993, ENVIRON HEALTH PERSP, V101, P199, DOI 10.2307/3431868; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; KURIYAMA R, 1992, BIOESSAYS, V14, P81, DOI 10.1002/bies.950140203; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; McAllister KA, 1997, CANCER RES, V57, P3121; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OBRIEN DA, 1989, ENDOCRINOLOGY, V125, P2973, DOI 10.1210/endo-125-6-2973; Phillips KW, 1997, LAB INVEST, V76, P419; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Smith H S, 1991, Basic Life Sci, V57, P329; Stratton MR, 1996, HUM MOL GENET, V5, P1515, DOI 10.1093/hmg/5.Supplement_1.1515; Vaughn JP, 1996, CANCER RES, V56, P4590; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WELCH JE, 1995, DEV GENET, V16, P179, DOI 10.1002/dvg.1020160210; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Zabludoff SD, 1996, ONCOGENE, V13, P649	30	79	80	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					61	68		10.1038/sj.onc.1201506	http://dx.doi.org/10.1038/sj.onc.1201506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467943				2022-12-28	WOS:000071236800007
J	Mao, WG; Irby, R; Coppola, D; Fu, L; Wloch, M; Turner, J; Yu, H; Garcia, R; Jove, R; Yeatman, TJ				Mao, WG; Irby, R; Coppola, D; Fu, L; Wloch, M; Turner, J; Yu, H; Garcia, R; Jove, R; Yeatman, TJ			Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential	ONCOGENE			English	Article						EGFR; Src; colon cancer	EPIDERMAL-GROWTH-FACTOR; HUMAN COLORECTAL CARCINOMAS; HUMAN BREAST-CANCER; NUDE-MICE; PP60C-SRC ACTIVITY; IN-VIVO; FAMILY KINASES; TRANSFORMATION; LINES; EXPRESSION	Recent data suggest that signal transduction may have a critical role in the development and regulation of the metastatic phenotype. Here, we investigated the role of c-Src activation in the process of human colon cancer metastasis to the Liver, Our data, derived from two different sets of human colon cancer cell line metastatic variants, suggest that not only do highly-metastatic cells display constitutively elevated c-Src protein kinase activity when compared to poorly metastatic cells, but also that receptor tyrosine kinases participate in the ligand-activation of c-Src above basal levels. Specifically, the epidermal growth factor receptor (EGFR), p185HER2/Neu and the hepatocyte growth factor receptor (c-Met) appear to be Linked to the process because they preferentially activate c-Src in highly-metastatic cells, EGFR was found to associate with c-Src in colon cancer cells and specific inhibitors of the EGFR resulted in a reduction of c-Src activity to basal levels. In addition, c-Src transfectants displayed partially-activated EGFRs, suggesting a feedback role for c-Src in the regulation of the EGFR. p185HER2/Neu was also identified in immunocomplexes of c-Src following Ligand activation of the EGFR, but only in highly-metastatic cells, Collectively, these observations suggest a paradigm whereby c-Src interacts with multiple cell-surface growth factors in a catalytic fashion for the development of tumor cells with metastatic potential.	Univ S Florida, H Lee Moffitt Canc Ctr, Dept Surg, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Yeatman, TJ (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Dept Surg, Tampa, FL 33612 USA.			YU, Hua/0000-0003-0931-1000				ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHAKRABARTY S, 1995, CLIN EXP METASTAS, V13, P191, DOI 10.1007/BF00132207; COFFEY RJ, 1987, CANCER RES, V47, P4590; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; GARCIA R, 1991, ONCOGENE, V6, P1983; GREENBERG AH, 1989, INVAS METAST, V9, P360; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; JESSUP JM, 1989, CANCER RES, V49, P6906; JESSUP JM, 1988, CANCER RES, V48, P1689; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mahvi DM, 1996, HUM GENE THER, V7, P1535, DOI 10.1089/hum.1996.7.13-1535; Mayer K, 1996, ANTICANCER RES, V16, P1733; MORIKAWA K, 1988, CANCER RES, V48, P1943; MORIKAWA K, 1988, CANCER RES, V48, P6863; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PENA SV, 1995, GASTROENTEROLOGY, V108, P117, DOI 10.1016/0016-5085(95)90015-2; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RADINSKY R, 1993, CANCER METAST REV, V12, P345, DOI 10.1007/BF00665962; Rewcastle GW, 1996, J MED CHEM, V39, P1823, DOI 10.1021/jm9508651; Shah V, 1994, In Vivo, V8, P321; TALAMONTI MA, 1991, J CLIN INVEST, V91, P53; TATSUKA PM, 1996, MOL CARCINOG, V15, P300; TERMUHLEN PM, 1993, J SURG RES, V54, P54; WANG P, 1991, BRIT J CANCER, V64, P531, DOI 10.1038/bjc.1991.344; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WEERNINK PAO, 1994, FEBS LETT, V352, P296, DOI 10.1016/0014-5793(94)00977-5; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WITTY JP, 1994, CANCER RES, V54, P4805; YEATMAN TJ, 1993, SEMIN SURG ONCOL, V9, P256; Yeatman TJ, 1996, CLIN EXP METASTAS, V14, P246; ZIRVI KA, 1993, CANCER LETT, V72, P39, DOI 10.1016/0304-3835(93)90008-W	53	171	184	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3083	3090		10.1038/sj.onc.1201496	http://dx.doi.org/10.1038/sj.onc.1201496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444956				2022-12-28	WOS:000070968000008
J	Haas, K; Johannes, C; Geisen, C; Schmidt, T; Karsunky, H; BlassKampmann, S; Obe, G; Moroy, T				Haas, K; Johannes, C; Geisen, C; Schmidt, T; Karsunky, H; BlassKampmann, S; Obe, G; Moroy, T			Malignant transformation by cyclin E and Ha-Ras correlates with lower sensitivity towards induction of cell death but requires functional Myc and CDK4	ONCOGENE			English	Article						cyclin E; malignant transformation; Myc; CDK inhibitors; polyploidy	RETINOBLASTOMA-PROTEIN; COLORECTAL CARCINOMAS; PHASE-TRANSITION; KINASE-ACTIVITY; BREAST-CANCER; E GENE; C-MYC; D1; FIBROBLASTS; INHIBITION	We demonstrate in this paper that the G1 phase specific cell cycle regulator cyclin E is able to provoke focus formation when cotransfected with activated Ha-ras into primary rat embryo fibroblasts (REFs). Cyclin E/Ha-ras transformed cells are highly tumorigenic in synergeneic rats, are able to form colonies in soft agar and show protection towards apoptosis upon serum starvation or DNA damage compared to cells transformed by the combination of Myc, cyclin D1 or SV40 large T-antigen and Ha-ras. Lines that were established after cyclin El Ha-ras or cyclin D1/Ha-ras transformation contain a large percentage of polyploid cells, This was not observed in cells transformed with other oncoproteins and Ha-ras pointing to an involvement of D-and E type cyclins in genomic instability. The cyclin dependent kinase inhibitors p21 and p27 but also p16 completely abrogate focus formation by cyclin E and Ha-ras suggesting that the oncogenic activity of cyclin E still requires functional G1 specific cyclin/CDK complexes. Moreover, inhibition of Myc function also blocks the oncogenic activity of cyclin E indicating a requirement of Myc for cyclin E function, The findings presented here demonstrate that cyclin E can act as an oncoprotein with a potential involvement in genomic instability and the prevention of cell death, Our data also present more evidence for a strict functional interdependency between G1 cyclin/CDK complexes and c-Myc.	UNIV ESSEN GESAMTHSCH KLINIKUM,IFZ,INST ZELLBIOL TUMORFORSCH,D-45172 ESSEN,GERMANY; UNIV ESSEN GESAMTHSCH,GENET ABT,D-45172 ESSEN,GERMANY	University of Duisburg Essen; University of Duisburg Essen			Moroy, Tarik/D-9923-2011					Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Botz J, 1996, MOL CELL BIOL, V16, P3401; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Datta NS, 1996, MOL BIOL CELL, V7, P209, DOI 10.1091/mbc.7.2.209; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Draetta G.F., 1997, CURR BIOL, V7, P50; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Geng Y, 1996, ONCOGENE, V12, P1173; GONG JP, 1994, CANCER RES, V54, P4285; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HALL M, 1995, ONCOGENE, V11, P1581; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HU J, 1992, MOL CELL BIOL, V12, P971; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P940; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEACH FS, 1993, CANCER RES, V53, P1986; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mumberg D, 1996, ONCOGENE, V13, P2493; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SoferLevi Y, 1996, ONCOGENE, V13, P2431; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; Zhang Y, 1996, J BIOL CHEM, V271, P4266	54	47	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2615	2623		10.1038/sj.onc.1201434	http://dx.doi.org/10.1038/sj.onc.1201434			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399649				2022-12-28	WOS:A1997YG73200011
J	Milner, AE; Grand, RJA; Vaughan, ATM; Armitage, RJ; Gregory, CD				Milner, AE; Grand, RJA; Vaughan, ATM; Armitage, RJ; Gregory, CD			Differential effects of BCL-2 on survival and proliferation of human B-lymphoma cells following gamma-irradiation	ONCOGENE			English	Article						apoptosis; CD40; cell cycle; Burkitt lymphoma; gamma-irradiation; Bcl-2	RADIATION-INDUCED APOPTOSIS; BONE-MARROW CELLS; WILD-TYPE P53; CYCLE PROGRESSION; GENE-EXPRESSION; DNA-DAMAGE; DEATH; GROWTH; LINES; PROTECTS	Bcl-2 can inhibit apoptosis induced by a variety of stimuli, including radiation and its presence in tumour cells would be expected to indicate poor prognosis. Bcl-2-expressing tumours, however, are often low-grade and highly responsive to therapy. To investigate this apparent paradox, we analysed in vitro the responses of Burkitt lymphoma (BL) cells to gamma-irradiation in the presence and absence of Bcl-2. High-level expression of Bcl-2 was shown to promote BL cell survival following irradiation. However, a significant proportion of Bcl-2-rescued cells subsequently underwent apoptosis after an extended period in culture. In addition, in different BL lines, Bcl-2 was found either to promote or to inhibit long-term proliferative activity following gamma-irradiation. This differential regulation of proliferation correlated both with differential effects of Bcl-2 on the cell cycle and with differences in p53 status. Thus, by one week after irradiation, BL cells expressing only wild-type p53 (wt/wt) had arrested in G1, whereas those with a mutant allele (wt/mu) were arrested in all phases of the cell cycle. The proportion of Bcl-2-rescued cells subsequently underwent apoptosis was reduced Ligation of CD40 at the time of irradiation in wt/wt BL cells, but not in wt/mu cells, CD40-ligation reduced both G1-arrest and apoptosis in parallel. These results indicate that, whilst Bcl-2 can delay apoptosis in BL cells following gamma-irradiation, the protein can also cause growth-arrest and thereby promote apoptosis, Long-term survival following Bcl-2-mediated rescue of gamma-irradiated cells may depend on p53 status and require additional death-repressing or growth-promoting signals.	UNIV BIRMINGHAM,SCH MED,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; LOYOLA UNIV,CARDINAL BERNADINE CANC CTR,CHICAGO,IL 60611	University of Birmingham; University of Birmingham; Loyola University Chicago			Gregory, Chris/C-6927-2019	Gregory, Chris/0000-0002-7553-0132	NATIONAL CANCER INSTITUTE [R01CA055840, R55CA055840] Funding Source: NIH RePORTER; NCI NIH HHS [CA55840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BRACEY TS, 1995, ONCOGENE, V10, P2391; CAMPOS L, 1993, BLOOD, V81, P3091; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Gilbert MS, 1996, CELL DEATH DIFFER, V3, P215; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Herod JJO, 1996, CANCER RES, V56, P2178; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; ISHIDA T, 1995, J IMMUNOL, V155, P5527; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KRUMAN II, 1991, J CELL PHYSIOL, V148, P267, DOI 10.1002/jcp.1041480212; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; LEPELLEY P, 1995, LEUKEMIA, V9, P726; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Lock RB, 1996, CANCER RES, V56, P4006; MARVEL J, 1994, ONCOGENE, V9, P1117; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MILNER AE, 1993, ONCOGENE, V8, P3385; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OCONNOR PM, 1993, CANCER RES, V53, P4776; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PEZZELLA F, 1992, BRIT J CANCER, V65, P87, DOI 10.1038/bjc.1992.16; PIETENPOL JA, 1994, CANCER RES, V54, P3714; PIRIS MA, 1994, BRIT J CANCER, V69, P337, DOI 10.1038/bjc.1994.61; RADFORD IR, 1994, INT J RADIAT BIOL, V66, P557, DOI 10.1080/09553009414551621; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Sangfelt O, 1996, INT J CANCER, V67, P106, DOI 10.1002/(SICI)1097-0215(19960703)67:1<106::AID-IJC18>3.0.CO;2-C; SEKI H, 1995, CELL IMMUNOL, V163, P30, DOI 10.1006/cimm.1995.1095; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Silvestrini R, 1996, J CLIN ONCOL, V14, P1604, DOI 10.1200/JCO.1996.14.5.1604; Soldatenkov VA, 1996, INT J ONCOL, V9, P547; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; Tjalma W, 1997, J CLIN PATHOL, V50, P33, DOI 10.1136/jcp.50.1.33; Walker A, 1997, CANCER RES, V57, P1939; Wang H, 1996, ONCOGENE, V13, P373; Wilson WH, 1997, BLOOD, V89, P601, DOI 10.1182/blood.V89.2.601; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	46	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1815	1822		10.1038/sj.onc.1201355	http://dx.doi.org/10.1038/sj.onc.1201355			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362448				2022-12-28	WOS:A1997XZ72500008
J	Mundt, M; Hupp, T; Fritsche, M; Merkle, C; Hansen, S; Lane, D; Groner, B				Mundt, M; Hupp, T; Fritsche, M; Merkle, C; Hansen, S; Lane, D; Groner, B			Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential	ONCOGENE			English	Article						p53 phosphorylation; allosteric activation; in vitro transcription; specific DNA binding; latent and activated p53	DNA-BINDING FUNCTION; TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; CASEIN KINASE-II; CELL-CYCLE; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION; PROMOTER; DOMAIN	The tumor suppressor protein p53 is a transcription factor frequently inactivated in human cancers. We have studied the DNA binding potential and the transcriptional activity of p53 variants and p53 protein complexes in in vitro transcription assays, p53 specific transcription was measured via introduction of radioactive UTP into G-free cassette transcripts regulated by promoter sequences containing p53 response elements. Latent and activated p53 fractions were prepared from insect cells infected with p53 encoding baculoviruses by chromatography on heparin columns, p53 fractions distinguishable by their specifc DNA binding activities and their recognition by monoclonal antibody PAb421 were obtained. Specific DNA binding and binding to PAb421 are mutually exclusive. The C-terminus of p53 can be phosphorylated by casein kinase II, protein kinase C and cyclin dependent kinases. The antibody PAb421 binds within the PKC phosphorylation site of p53 and is able to activate DNA binding of latent p53 in vitro. Activation of p53 by PAb421 also results in enhanced transactivation in vitro. Dephosphorylation of latent p53 with phosphatase 2A does not change these properties. This suggests that a conformational change in the carboxyl terminal domain of p53 controls the transactivation potential of p53.	INST EXPT CANC RES, TUMOR BIOL CTR, D-79106 FREIBURG, GERMANY; UNIV DUNDEE, DEPT PATHOL, NINEWELLS HOSP & MED SCH, DUNDEE DD1 4HN, SCOTLAND; UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND	University of Dundee; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ABARZUA P, 1995, CANCER RES, V55, P3490; ADDISON C, 1990, ONCOGENE, V5, P423; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUCHS B, 1995, ONCOGENE, V10, P789; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUDAS JM, 1994, CELL GROWTH DIFFER, V5, P295; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEINHITPASS L, 1991, NUCLEIC ACIDS RES, V19, P1227, DOI 10.1093/nar/19.6.1227; KUGLER W, 1990, NUCLEIC ACIDS RES, V18, P6943, DOI 10.1093/nar/18.23.6943; LANE DP, 1995, PHILOS T ROY SOC B, V347, P83, DOI 10.1098/rstb.1995.0013; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MILNER J, 1990, ONCOGENE, V5, P1683; MOLINARI M, 1995, ONCOGENE, V10, P1849; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PRICE BD, 1993, ONCOGENE, V8, P3055; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0	43	47	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	1997	15	2					237	244		10.1038/sj.onc.1201174	http://dx.doi.org/10.1038/sj.onc.1201174			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244359				2022-12-28	WOS:A1997XK37200012
J	Watson, MA; Darrow, C; Zimonjic, DB; Popescu, NC; Fleming, TP				Watson, MA; Darrow, C; Zimonjic, DB; Popescu, NC; Fleming, TP			Structure and transcriptional regulation of the human mammaglobin gene, a breast cancer associated member of the uteroglobin gene family localized to chromosome 11q13	ONCOGENE			English	Article						mammaglobin; breast cancer; genomic organization; promoter	STEROID-BINDING-PROTEIN; TRANSGENIC MICE; SECRETORY PROTEIN; DNA-SEQUENCE; C-3 GENES; PROMOTER; CELLS; PROSTATE; ANTIGEN; MAP	The mammaglobin gene encodes a novel secreted protein whose corresponding mRNA is frequently up-regulated in human breast cancer, In non-malignant tissues, expression is also strictly limited to the mammary epithelium. To better understand the mechanisms controlling these patterns of expression, we have isolated the human mammaglobin gene and performed an initial assessment of its promoter activity, Mammaglobin gene architecture is very similar to that of a family of related genes that includes uteroglobin and rat prostatein subunits C1, C2, and C3. However, the mammaglobin gene itself is not well conserved phylogenetically. The human mammaglobin gene is localized by fluorescent in situ hybridization to chromosome 11 band q13, a genomic region frequently amplified in breast neoplasia, The sequence of proximal 1 kb of mammaglobin promoter contains several potential transcriptional control elements and directs high-level expression of a transfected reporter construct in human breast tumor cell lines, However, comparable levels of reporter gene expression are also seen in non-mammary human cell lines, These data suggest that, unlike related gene family members, the striking breast-specific expression and tumor-associated overexpression of mammaglobin is mediated by complex transcriptional control at more distal sequence elements,.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA; NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Watson, MA (corresponding author), Washington Univ, Sch Med, Dept Pathol, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.		Zimonjic, Drazen/AAX-7513-2020					ALLISON J, 1989, MOL CELL BIOL, V9, P2254, DOI 10.1128/MCB.9.5.2254; Britten RJ, 1996, P NATL ACAD SCI USA, V93, P9374, DOI 10.1073/pnas.93.18.9374; CELIS L, 1993, MOL CELL ENDOCRINOL, V94, P165, DOI 10.1016/0303-7207(93)90165-G; Chen JH, 1996, ONCOGENE, V13, P1667; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; FANTL V, 1993, CANCER SURV, V18, P77; GILLETT C, 1994, CANCER RES, V54, P1812; Greenberg N M, 1992, Cancer Treat Res, V61, P379; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HURST HC, 1983, EMBO J, V2, P769, DOI 10.1002/j.1460-2075.1983.tb01498.x; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; LEA OA, 1979, J BIOL CHEM, V254, P6196; LEE CS, 1992, J BIOL CHEM, V267, P5797; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; McKnight R A, 1992, Cancer Treat Res, V61, P399; MIELE L, 1987, ENDOCR REV, V8, P474, DOI 10.1210/edrv-8-4-474; MIELE L, 1994, J ENDOCRINOL INVEST, V17, P679, DOI 10.1007/BF03349687; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; PARKER M, 1982, NATURE, V298, P92, DOI 10.1038/298092a0; PARKER MG, 1983, J BIOL CHEM, V258, P12; Ray MK, 1996, MOL CELL BIOL, V16, P2056; SANDMOLLER A, 1994, ONCOGENE, V9, P2805; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; THOREY IS, 1993, MOL CELL BIOL, V13, P6742, DOI 10.1128/MCB.13.11.6742; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATSON MA, 1994, CANCER RES, V54, P4598; Watson MA, 1996, CANCER RES, V56, P860; ZHUANG Z, 1995, CANCER RES, V55, P4676; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V80, P100, DOI 10.1016/0165-4608(94)00161-4	32	82	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					817	824		10.1038/sj.onc.1201597	http://dx.doi.org/10.1038/sj.onc.1201597			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488047				2022-12-28	WOS:000071931800015
J	Girard, L; Jolicoeur, P				Girard, L; Jolicoeur, P			A full-length Notch1 allele is dispensable for transformation associated with a provirally activated truncated Notch1 allele in Moloney MuLV-infected MMTVD/myc transgenic mice	ONCOGENE			English	Article						Notch1; transgenic mice; targeted mutagenesis; retrovirus; MuLV	DROSOPHILA NOTCH; INSERTIONAL MUTAGENESIS; HUMAN HOMOLOG; C-ELEGANS; GENE; RECEPTOR; MYOGENESIS; NEOPLASMS; LIN-12; DOMAIN	The Notch1 gene was previously found to be targetted by provirus insertion in a high proportion of T-cell lymphomas arising in Moloney MuLV-inoculated MMTVD/myc transgenic mice, Proviral activation of Notch1 was associated with overexpression of truncated Notch1, deleted of the sequences coding for the extracellular domain, The high levels of truncated Notch1 RNA and proteins in these tumors are thought to be involved in the oncogenic transformation, However, in addition to these truncated RNA and proteins, high level expression of full-length Notch1 RNA and proteins was also observed in several tumors, suggesting that they could also contribute to the transformation process, To test this hypothesis, me used a genetic approach and studied MMTVD/myc transgenic mice in which one of the Notch1 alleles was mutated by targeted mutagenesis (Notch(+/-) mice). Heterozygote (Notch1(+/-)) and wild-type (Notch1(+/+)) transgenic mice were inoculated with Moloney MuLV and the frequency of Notch1 rearrangements was compared between both groups. Notch1 was rearranged at similar frequencies in both groups, indicating that the full-length Notch1 allele is dispensable in tumors harboring an activated Notch1 allele.	Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3J 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Mol Biol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.							ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Christensen S, 1996, DEVELOPMENT, V122, P1373; CONLON RA, 1995, DEVELOPMENT, V121, P1533; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; HANNA Z, 1993, ONCOGENE, V8, P1661; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KENYON C, 1995, CELL, V82, P171, DOI 10.1016/0092-8674(95)90302-X; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; NYE JS, 1994, DEVELOPMENT, V120, P2421; PAQUETTE Y, 1992, MOL CELL BIOL, V12, P3522, DOI 10.1128/MCB.12.8.3522; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8	24	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	1998	16	4					517	522		10.1038/sj.onc.1201562	http://dx.doi.org/10.1038/sj.onc.1201562			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484841	Green Submitted			2022-12-28	WOS:000071739400010
J	Gaozza, E; Baker, SJ; Vora, RK; Reddy, EP				Gaozza, E; Baker, SJ; Vora, RK; Reddy, EP			AATYK: A novel tyrosine kinase induced during growth arrest and apoptosis of myeloid cells	ONCOGENE			English	Article						AATYK; apoptosis; differentiation; SH3 binding motifs; tyrosine kinase; myeloid cells	GRANULOCYTIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; HEMATOPOIETIC-CELLS; CONSERVED FEATURES; SIGNALING PROTEINS; LINE; EXPRESSION; DEATH; GENE; INTERLEUKIN-3	Apoptosis, or programmed cell death, is a process where developmental or environmental stimuli activate a genetic program to implement a series of events that culminate in cell death, To study the nature of genes that are induced during the apoptotic death of myeloid precursor cells. we utilized the 32Dc13 cell line, which is derived from normal mouse bone marrow, is non-tumorigenic and diploid, These cells are strictly dependent on IL-3 for growth and apoptose when deprived of IL-3, However, when these cells are transferred to medium containing G-CSF, the cell number increases 3-5-fold and after 12 days the entire population is differentiated into granulocytes followed by apoptotic death, In our search for genes that are induced during apoptosis and/or terminal differentiation of 32Dc13 cells, we identified a novel gene termed AATYK (Apoptosis Associated Tyrosine Kinase), whose expression is dramatically upregulated during IL-3 deprivation as well as G-CSF-induced terminal differentiation. In this report, we describe the sequence of the cDNA clone, derived from the mRNA transcript of this gene, These studies show that this gene encodes a protein with a tyrosine kinase domain at the N-terminal end and a proline-rich domain at the C-terminal end, We also report that the expression of this gene is blocked in v-abl or bcr-abl transformed myeloid cells which are unable to apoptose when grown in the absence of IL-3, However, AATYK expression is induced in 32D cells transformed by the v-abl gene when these cells are incubated in the presence of DMSO, which induces growth arrest and apoptotic death of the cells, On the other hand, DMSO fails to induce apoptosis or AATYK expression in 32D cells transformed by the bcr-abl oncogene, suggesting that AATYK expression may be a necessary pre-requisite for the induction of growth arrest and/or apoptosis of myeloid precursor cells.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA068239] Funding Source: NIH RePORTER; NCI NIH HHS [CA68239] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COTTER TG, 1994, IMMUNOL REV, V142, P93, DOI 10.1111/j.1600-065X.1994.tb00884.x; GORDON N, 1995, BRAIN DEV-JPN, V17, P73, DOI 10.1016/0387-7604(94)00109-B; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HOFFMAN B, 1994, ONCOGENE, V9, P1807; Ishino M, 1995, ONCOGENE, V11, P2331; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KREIDER BL, 1990, MOL CELL BIOL, V131, P227; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Lung CC, 1996, TRENDS GENET, V12, P389, DOI 10.1016/S0168-9525(96)90093-1; METTUS RV, 1994, ONCOGENE, V9, P3077; Narayanan V, 1997, PEDIATR NEUROL, V16, P9, DOI 10.1016/S0887-8994(96)00257-3; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OGAWA M, 1993, BLOOD, V81, P2844; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; RANE SG, 1994, ONCOGENE, V9, P2415; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; ROVERA G, 1989, ANN NY ACAD SCI, V567, P154, DOI 10.1111/j.1749-6632.1989.tb16467.x; ROVERA G, 1987, ONCOGENE, V1, P29; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Sieff C A, 1994, Curr Opin Hematol, V1, P310; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; VALTIERI M, 1987, J IMMUNOL, V138, P3829; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; Yuan JY, 1996, J CELL BIOCHEM, V60, P4, DOI 10.1002/(SICI)1097-4644(19960101)60:1<4::AID-JCB2>3.0.CO;2-1; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368	41	61	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3127	3135		10.1038/sj.onc.1201575	http://dx.doi.org/10.1038/sj.onc.1201575			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444961				2022-12-28	WOS:000070968000013
J	Chen, Q; Turner, J; Watson, AJM; Dive, C				Chen, Q; Turner, J; Watson, AJM; Dive, C			v-Abl protein tyrosine kinase (PTK) mediated suppression of apoptosis is associated with the up-regulation of Bcl-X-L	ONCOGENE			English	Article						apoptosis; v-Abl tyrosine kinase; Bcl-X-L survival signals	PROGRAMMED CELL-DEATH; HEMATOPOIETIC-CELLS; ACTIVATION; INTERLEUKIN-3; GROWTH; GENE; SURVIVAL; LINE; BAX; PHOSPHORYLATION	We demonstrated previously that the activation of v-Abl protein tyrosine kinase (PTK) in IC.DP murine pre-mast cells resulted in suppression of apoptosis after withdrawal of interleukin 3 (IL-3), that protein kinase C (PKC) translocated to the nucleus 6 h after v-Abl PTK activation and that inhibition of PKC restored apoptosis after IL-3 deprivation in the presence of v-Abl PTK activity. Here we demonstrate that v-Abl PTK activation is followed by an approximately twofold increase in mRNA level of Bcl-X-L by 6 h and a corresponding increase in Bcl-X-L protein level by 24 h. Bcl-x(L) RNA and protein decreased in IL-3 deprived cells in the absence of v-Abl PTK activity. Exposure of cells with v-Abl PTK active to the PKC inhbitor calphostin C (125 ng/ml) prevented the increase in Bcl-x(L) protein and resulted in apoptosis. No changes in Bax or Bcl-2 protein level were noted after IL-3 withdrawal and/or activation of v-Abl PTK. Bak was barely detectable and Bad protein level decreased in cells undergoing apoptosis. The data suggest that suppression of apoptosis by v-Abl PTK in the absence of IL-3 is associated with PKC signalling and the upregulation of Bcl-x(L) in IC.DP cells.	UNIV MANCHESTER, SCH BIOL SCI, MOL PHARMACOL GRP, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV MANCHESTER, DEPT MED, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester; University of Manchester				Dive, Caroline/0000-0002-1726-8850				BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHAPMAN RS, 1994, CANCER RES, V54, P5131; CHAPMAN RS, 1995, MOL PHARMACOL, V48, P334; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen Q, 1997, J CELL SCI, V110, P379; CHUNG SW, 1995, ONCOGENE, V10, P1261; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Dive C, 1992, Semin Cancer Biol, V3, P417; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; EVANS CA, 1995, J CELL SCI, V108, P2591; EVANS CA, 1993, CANCER RES, V53, P1735; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Guan RJ, 1996, ONCOGENE, V12, P2605; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; KORSMEYER SJ, 1992, BLOOD, V80, P879; Maniatis T, 1989, MOL CLONING; MAY WS, 1994, J BIOL CHEM, V269, P26865; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shuai K, 1996, ONCOGENE, V13, P247; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	43	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2249	2254		10.1038/sj.onc.1201371	http://dx.doi.org/10.1038/sj.onc.1201371			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393984				2022-12-28	WOS:A1997YD01900014
J	Gulliford, TJ; Huang, GC; Ouyang, XM; Epstein, RJ				Gulliford, TJ; Huang, GC; Ouyang, XM; Epstein, RJ			Reduced ability of transforming growth factor-alpha to induce EGF receptor heterodimerization and downregulation suggests a mechanism of oncogenic synergy with ErbB2	ONCOGENE			English	Article						ErbB2; transforming growth factor-alpha; EGF; oligomerization; downregulation	AUTOPHOSPHORYLATION SITES; BIOLOGICAL-ACTIVITIES; KINASE-ACTIVITY; A431 CELLS; NEU; ACTIVATION; EXPRESSION; C-ERBB-2; IDENTIFICATION; ANTIBODIES	The epidermal growth factor receptor (EGFR) is activated by a variety of ligands including EGF and transforming growth factor-alpha (TGF alpha), whereas no ligand for the homologous ErbB2 oncoprotein has yet been identified. Here we use both an ErbB2 phosphoantibody (aPY(1222)) and an activation-specific EGFR antibody to show that low concentrations of EGF induce more efficient tyrosine phosphorylation of ErbB2 in A431 cells than does equimolar TGF alpha, while EGFR is more potently activated by TGF alpha. Co-precipitation studies confirm that heterodimerization of activated EGFR and transphosphorylated ErbB2 is readily induced by EGF but not TGF alpha. ECFR downregulation is also more efficiently induced by EGF, suggesting that ligand-dependent modification of ErbB2 may be required to terminate EGFR signalling in cells expressing both receptor types. These findings indicate that EGF and TGF alpha differ in their abilities to induce tyrosine phosphorylation and heterodimerization of ErbB2, and raise the possibility that ErbB2 exerts its oncogenic effect in part by impairing TGF alpha-dependent EGFR downregulation.	UNIV LONDON IMPERIAL COLL SCI & TECHNOL, SCH MED, DIV MED, LONDON W6 8RF, ENGLAND; CHARING CROSS HOSP, CANC RES CAMPAIGN LABS, LONDON W6 8RF, ENGLAND	Imperial College London; Imperial College London					PHS HHS [R0169513] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; EPSTEIN RJ, 1995, ONCOGENE, V11, P315; GABELMAN BM, 1992, EXP CELL RES, V201, P113, DOI 10.1016/0014-4827(92)90354-B; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; GAN BS, 1987, J PHARMACOL EXP THER, V242, P331; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LEE DC, 1995, PHARMACOL REV, V47, P51; Mellon JK, 1996, BRIT J CANCER, V73, P654, DOI 10.1038/bjc.1996.114; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; Ouyang XM, 1996, J BIOL CHEM, V271, P21786, DOI 10.1074/jbc.271.36.21786; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STROMBERG K, 1992, CANCER RES, V52, P341; Taylor ICA, 1995, ONCOGENE, V11, P2619; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594; XIE YM, 1995, ONCOGENE, V10, P2409; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	34	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2219	2223		10.1038/sj.onc.1201595	http://dx.doi.org/10.1038/sj.onc.1201595			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393980				2022-12-28	WOS:A1997YD01900010
J	Baskaran, K; Erfurth, F; Taborn, G; Copeland, NG; Gilbert, DJ; Jenkins, NA; Iannaccone, PM; Domer, PH				Baskaran, K; Erfurth, F; Taborn, G; Copeland, NG; Gilbert, DJ; Jenkins, NA; Iannaccone, PM; Domer, PH			Cloning and developmental expression of the murine homolog of the acute leukemia proto-oncogene AF4	ONCOGENE			English	Article						AF4; MLL; acute leukemia; transcription factor	BONE MORPHOGENETIC PROTEIN-4; DIFFERENTIAL EXPRESSION; PROMYELOCYTIC LEUKEMIA; DROSOPHILA-TRITHORAX; TRANSCRIPTION FACTOR; BINDING DOMAINS; GENE-EXPRESSION; MICE LACKING; DNA-BINDING; ALL-1 GENE	AF4 is the 4q21 gene involved in the acute lymphoblastic leukemia associated t(4;11)(q21;q23) where it forms a fusion gene with MLL, In order to gain insight into AF4's role in leukemogenesis we have studied its functional domains and expression pattern during murine development, We have cloned the murine homolog, Af4. We have demonstrated that 5' half of Af4 encodes a region with transcriptional transactivation activity which is disrupted by the t(4;11) in human leukemias, We have also localized the murine AF4 protein to the nucleus supporting a role for AF4 in transcription, The developmental expression pattern of Af4 was determined in situ hybridization and suggests Af4 plays an important role in the development of the hematopoietic, cardiovascular, skeletal and central nervous systems, A repeating pattern of Af4 expression in development is downregulation with differentiation of a tissue, Among the cell types where this pattern of down-regulation is noted are B-lymphocytes. These findings raise the possibility that the disruption of normal AF4 function by the translocation may contribute to leukemogenesis.	UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHILDRENS MEM INST EDUC & RES,CHICAGO,IL 60614; FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702	University of Chicago; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [R29 CA 65911-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA065911] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Chakrabarti L, 1996, HUM MOL GENET, V5, P275, DOI 10.1093/hmg/5.2.275; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN CS, 1993, BLOOD, V82, P1080; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; COLLINS SJ, 1987, BLOOD, V70, P1233; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Fidanza V, 1996, CANCER RES, V56, P1179; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Green EL, 1981, GENETICS PROBABILITY, P77; GRIOGORIADIS AE, 1995, TRENDS GENET, V11, P436; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; HAUANG S, 1992, NATURE, V360, P745; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; KAPPIANPUR AR, 1994, BLOOD, V83, P1200; KEHRL JH, 1995, STEM CELLS, V13, P223, DOI 10.1002/stem.5530130304; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; MITELMAN F, 1992, GENE CHROMOSOME CANC, V5, P57, DOI 10.1002/gcc.2870050109; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OKUDA T, 1996, CELL, V78, P45; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; PUI CH, 1991, BLOOD, V77, P440; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1993, DEVELOPMENT, V118, P47; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sitzmann J, 1995, ONCOGENE, V11, P2273; SPENCE RP, 1988, CANCER RES, V48, P324; STEA B, 1988, INT J RADIAT ONCOL, V15, P1233, DOI 10.1016/0360-3016(88)90209-X; Theiler K, 1989, HOUSE MOUSE ATLAS EM, P78; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; YOUNG PE, 1995, BLOOD, V85, P96, DOI 10.1182/blood.V85.1.96.bloodjournal85196; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735; ZION L, 1995, BLOOD, V86, P2876	57	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1967	1978		10.1038/sj.onc.1201365	http://dx.doi.org/10.1038/sj.onc.1201365			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365243				2022-12-28	WOS:A1997YA87200011
J	Kagawa, S; Fujiwara, T; Hizuta, A; Yasuda, T; Zhang, WW; Roth, JA; Tanaka, N				Kagawa, S; Fujiwara, T; Hizuta, A; Yasuda, T; Zhang, WW; Roth, JA; Tanaka, N			p53 expression overcomes p21(WAF1/CIP1)-mediated G(1) arrest and induces apoptosis in human cancer cells	ONCOGENE			English	Article						p53; p21(WAF1/CIP1); apoptosis; G(1) arrest; adenoviral vector	WILD-TYPE P53; ADENOVIRUS-MEDIATED TRANSFER; CYCLIN-DEPENDENT KINASES; LUNG-CANCER; IN-VIVO; TUMOR SUPPRESSION; GENE-TRANSFER; P21; INHIBITOR; GROWTH	The p21(WAF1/CIP1) gene, which encodes a cyclin-dependent kinase inhibitor, may be critical for tumor suppressor gene p53-induced cell cycle arrest The p53 gene is known to regulate G(1) checkpoint, which can either induce G(1) arrest or initiate apoptosis, To directly examine the role of p21(WAF1/CIP1) in the control of p53 function, we have introduced human p21(WAF1/CIP1) gene into a p53-deficient human non-small cell lung cancer cell line H1299 using a p21(WAF1/CIP1)-expressing adenoviral vector (AdCMVp21). Infection with AdCMVp21 resulted in high levels of p21(WAF1/CIP1) expression and significantly suppressed the growth of H1299 cells through the G, arrest of the cell cycle, In contrast, transient expression of the wild-type p53 gene by a recombinant adenoviral vector (AdCMVp53) in H1299 cells induced apoptotic cell death and resulted in a rapid loss of cell viability, We then examined the effects of combined infection with AdCMVp21 and AdCMVp53 on H1299 cells to explore the dominant function of these molecules, Interestingly, introduction of exogenous p53 overcame p21(WAF1/CIP1)-mediated cell cycle arrest at G(1) and induced apoptosis, although viral-transduced p21(WAF1/CIP1) expression level was unaffected, These observations suggest that p53 expression converts a p21(WAF1/CIP1)-mediated growth arrest into apoptosis, The result was repeated with two additional human colon adenocarcinoma cell lines with the different p53 status, mutant p53-expressing DLD-1 and wild-type p53-expressing LoVo, suggesting that this phemonenon is a general event among human cancer cells, Thus, p53-mediated apoptotic pathway is dominant over the growth arrest pathway, indicating that p53 may be an essential upstream mediator of p21(WAF1/CIP1) in the regulation of a cell process leading either to growth arrest or to apoptotic suicide.	OKAYAMA UNIV,SCH MED,DEPT SURG 1,OKAYAMA 700,JAPAN; OKAYAMA UNIV,SCH MED,DEPT CELL CHEM,OKAYAMA 700,JAPAN; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT THORAC & CARDIOVASC SURG,HOUSTON,TX 77030	Okayama University; Okayama University; University of Texas System; UTMD Anderson Cancer Center			Kagawa, Shunsuke/B-2189-2011	Kagawa, Shunsuke/0000-0002-3610-8211				CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN YQ, 1995, CANCER RES, V55, P4536; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUJIWARA T, 1993, CANCER RES, V53, P4129; FUJIWARA T, 1994, CANCER RES, V54, P2287; GomezManzano C, 1996, CANCER RES, V56, P694; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG WW, 1994, CANCER GENE THER, V1, P5	23	81	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1903	1909		10.1038/sj.onc.1201362	http://dx.doi.org/10.1038/sj.onc.1201362			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365236				2022-12-28	WOS:A1997YA87200004
J	Yamaguchi, R; Mazaki, Y; Hirota, K; Hashimoto, S; Sabe, H				Yamaguchi, R; Mazaki, Y; Hirota, K; Hashimoto, S; Sabe, H			Mitosis specific serine phosphorylation and downregulation of one of the focal adhesion protein, paxillin	ONCOGENE			English	Article						focal adhesion proteins; mitosis; paxillin; phosphorylation; protein-degradation	I-KAPPA-B; UBIQUITIN-PROTEASOME PATHWAY; TUMOR-NECROSIS-FACTOR; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; CELL-ADHESION; BINDING-SITE; C-SRC	Mitotic cells typically lack well-formed focal adhesions, As an approach to explore the dynamic process regulating the focal adhesion assembly, we examined states of focal adhesion proteins during mitosis of the cell cycle. We found that the amount of paxillin was significantly reduced during mitosis of the cell cycle, whereas other focal adhesion proteins including talin, vinculin and Focal Adhesion Kinase did not. Proteolytic degradation appeared to be involved in the mitotic reduction, but transcriptional and/or translational controls of the mRNA were not essential for this downregulation. Moreover, concurrent with the decreased protein level, phosphorylation status of paxillin altered during mitosis; mitotic paxillin was phosphorylated primarily on serine and dephosphorylated on tyrosine while interphase one was phosphorylated both on serine and tyrosine. We found that mitotic phosphorylation created an electrophoretically slow-migrating population of paxillin which was barely detected in interphase cells. This mitotic specific modification occurred with both alpha and beta isoforms of paxillin. We also examined the fate of paxillin protein by changing its protein amount. We found that majority of paxillin overexpressed was subjected to the specific modification but not to the downregulation in the mitotic arrested cells. On the other hand, paxillin exogenously expressed at a moderate level was subjected to both the mitotic modification and downregulation. Collectively, we concluded that paxillin's specific serine phosphorylation together with the proteolytic downregulation of a limited fraction of paxillin is taken place during the mitosis of the cell cycle.	JAPAN SCI & TECHNOL CORP, PRECURSORY RES EMBRYON SCI & TECHNOL, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, INST VIRUS RES, KYOTO 606, JAPAN	Japan Science & Technology Agency (JST); Kyoto University			Sabe, Hisataka/A-4066-2012; Sabe, Hisataka/GPF-4385-2022; Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827; Yamaguchi, Ryuji/0000-0002-1706-7063; Mazaki, Yuichi/0000-0003-4192-0834				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Moir RD, 1995, INT REV CYTOL, V162B, P141; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PFALLER R, 1995, J BIOL CHEM, V270, P19066, DOI 10.1074/jbc.270.32.19066; POMIES P, 1992, BIOCHEM BIOPH RES CO, V189, P1429, DOI 10.1016/0006-291X(92)90234-C; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sambrooke J., 1989, MOL CLONING LAB MANU; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tanaka T, 1996, FEBS LETT, V399, P53, DOI 10.1016/S0014-5793(96)01280-X; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOOD CK, 1994, J CELL SCI, V107, P709; YAMAGUCHI R, 1994, FEBS LETT, V356, P114, DOI 10.1016/0014-5793(94)01246-6	43	48	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	1997	15	15					1753	1761		10.1038/sj.onc.1201345	http://dx.doi.org/10.1038/sj.onc.1201345			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362441				2022-12-28	WOS:A1997XZ72500001
J	Masutani, H; MagnaghiJaulin, L; Ali, SAS; Groisman, R; Robin, P; HarelBellan, A				Masutani, H; MagnaghiJaulin, L; Ali, SAS; Groisman, R; Robin, P; HarelBellan, A			Activation of the c-fos SRE through SAP-1a	ONCOGENE			English	Article						c-fos; SAP-1; serum response element (SRE); serum response factor (SRF); ternary complex factor (TCF)	SERUM RESPONSE FACTOR; FACTOR-DEPENDENT TRANSCRIPTION; DNA-BINDING SPECIFICITIES; TERNARY COMPLEX-FORMATION; FACTORS ELK-1; MAP KINASE; PROTEIN ELK-1; FACTOR P62TCF; GROWTH-FACTOR; ETS FAMILY	TCFs, which are members of the Ets family of transcription factors, are recruited to the Serum Response Element (SRE) in the c-fos promoter by SRF. These Ets proteins, which are substrates for the MAP kinases, are direct targets of the Ras/MAP kinase signal transduction pathway, In this paper, we demonstrate that one of the TCFs, SAP-la, displays a significant level of autonomous binding to the SRE Ets box, in contrast to previous observations, deletion of the SRF binding domain did not modulate the autonomous binding of SAP-la. Also, the autonomous binding was not modulated by the phosphorylation of SAP-la by MAP kinases, The autonomous binding was also detected in live cells: transfected SAP-la was able to restore the response of a CArG-less SRE in PC12 cells. The response occurred in the absence of SRF recruitment since a mutant of SAP-la in which the B-box, a domain required for interaction with SRF, had been deleted was still able to transactivate the CArG-less SRE. The transactivation was repressed by a Ras transdominant negative mutant, indicating the involvement of the Ras/MAP kinase pathway. Taken together, these data demonstrate that SAP-la is capable of binding to the c-fos SRE in the absence of SRF.	INST GUSTAVE ROUSSY,LAB BIOL TUMEURS HUMAINES,CNRS,URA 1156,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Harel-Bellan, Annick/M-9795-2015; Masutani, Hiroshi/B-5114-2014	Groisman, Sonia/0000-0003-1153-3841; Harel-Bellan, Annick/0000-0002-2339-153X; Groisman, Regina/0000-0003-3990-7622; Masutani, Hiroshi/0000-0001-7633-2827				BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gille H, 1996, MOL CELL BIOL, V16, P1094; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TROUCHE D, 1991, BLOOD, V77, P55; TROUCHE D, 1993, BIOCHEM BIOPH RES CO, V196, P611, DOI 10.1006/bbrc.1993.2293; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	34	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1661	1669		10.1038/sj.onc.1201328	http://dx.doi.org/10.1038/sj.onc.1201328			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349499				2022-12-28	WOS:A1997XY63100005
J	Rao, L; Modha, D; White, E				Rao, L; Modha, D; White, E			The E1B 19K protein associates with lamins in vivo and its proper localization is required for inhibition of apoptosis	ONCOGENE			English	Article						apoptosis; adenovirus E1B 19K; lamins	ADENOVIRUS TUMOR-ANTIGEN; PROGRAMMED CELL-DEATH; FATTY-ACID ACYLATION; BCL-2 HOMOLOG BAK; 19-KILODALTON PROTEIN; INTERMEDIATE FILAMENTS; TRANSFORMED-CELLS; NUCLEAR LAMINA; MEMBRANE; DNA	Expression of the E1B 19K protein is required to inhibit apoptosis induced by E1A during adenovirus infection and transformation. E1B 19K is homologous to Bcl-2 in function and the two proteins also share limited amino acid sequence homology. Consequently, the E1B 19K and Bcl-2 proteins bind to and inhibit the cellular death-inducing proteins Bax, Bak and Nbk/Bik. Both E1B 19K and Bcl-2 localize to membranes of the nucleus and the endoplasmic reticulum. In addition to membrane association, and unlike Bcl-2, the E1B 19K protein is found associated with intermediate filament proteins in the cytoplasm and the nuclear lamina and copurifies with the lamins both during infection and transformation. While a membrane targeting domain at the C-terminus of Bcl-2 ensures its proper localization, the mechanism by which the E1B 19K protein localizes is unknown. Not surprisingly, lamin A fragments were cloned from a yeast two-hybrid screen for E1B 19K-interacting proteins. The interaction was demonstrated in yeast and mammalian cells in vivo and in vitro and was unique and specific to E1B 19K, with no interaction evident between Bcl-2 and lamin A. Mutants of lamin A/C which localized inappropriately in the cytoplasm or nucleus but retained E1B 19K binding, interfered with the nuclear envelope and cytoplasmic membrane targeting of the E1B 19K protein. Improper localization impaired the ability of the E1B 19K protein to inhibit apoptosis. Thus, proper localization of the E1B 19K protein is required for its function and the interaction of the E1B 19K protein with lamin A/C may represent a means for nuclear envelope localization.	CANC INST NEW JERSEY, CTR ADV BIOTECHNOL & MED, PISCATAWAY, NJ 08854 USA; CANC INST NEW JERSEY, DEPT MOL BIOL & BIOCHEM, PISCATAWAY, NJ 08854 USA; RUTGERS STATE UNIV, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick			White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA53370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053370, R01CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GRAND RJA, 1985, FEBS LETT, V181, P229, DOI 10.1016/0014-5793(85)80265-9; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MCGLADE CJ, 1987, J VIROL, V61, P3227, DOI 10.1128/JVI.61.10.3227-3234.1987; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; NIGG EA, 1993, CELL BIOL, V3, P245; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PERSSON H, 1982, J VIROL, V42, P905, DOI 10.1128/JVI.42.3.905-917.1982; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHLESINGER MJ, 1983, METHOD ENZYMOL, V96, P795; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TARODI B, 1993, INT J ONCOL, V3, P467; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WHITE E, 1994, SEMIN VIROL, V5, P341, DOI 10.1006/smvy.1994.1038; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZHANG S, 1992, J VIROL, V66, P2302, DOI 10.1128/JVI.66.4.2302-2309.1992	56	57	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1587	1597		10.1038/sj.onc.1201323	http://dx.doi.org/10.1038/sj.onc.1201323			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380411				2022-12-28	WOS:A1997XX36900010
J	Bosch, E; Cherwinski, H; Peterson, D; McMahon, M				Bosch, E; Cherwinski, H; Peterson, D; McMahon, M			Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1	ONCOGENE			English	Article						A-Raf; B-Raf; c-Raf-1; protein-serine/threonine kinases; oncogenes; transformation	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; NIH 3T3 CELLS; GROWTH-FACTOR; MAP KINASE; B-RAF; IN-VITRO; 14-3-3 PROTEIN; C-RAF; PHOSPHORYLATION	The catalytic domains of the Raf family of protein kinases (Delta Raf) differ in their ability to activate MEK in vitro and in vivo and in their ability to oncogenically transform mammalian cells, The kinase domain of B-Raf is more active than the equivalent portion of Raf-1 which in turn is more active than A-Raf, In Raf-1 the phosphorylation or mutation to aspartic acid of two key tyrosine residues upstream of the ATP binding site has been demonstrated to significantly potentiate catalytic activity. In A-Raf the analogous amino acids are also tyrosine whereas in B-Raf they are aspartic acid. To determine if these differences in amino acid sequence influence the relative catalytic activity of the Raf kinase domains we constructed forms of Delta A-Raf, Delta B-Raf and Delta Raf-1 that encode either aspartic acid [DD], phenylalanine [FF] or tyrosine [YY] at these positions, These proteins were expressed both in mammalian cells as fusions with the hormone binding domain of the estrogen receptor and as epitope-tagged proteins in Sf9 insect cells to test their oncogenic and catalytic potentials. When expressed in Rat1 or 3T3 cells in the presence of hormone all of the Delta Raf-1:ER and Delta A-Raf:ER proteins were transforming with the exception of the [FF] form of Delta A-Raf. In general the [DD] forms of the Delta Raf-1:ER and Delta A-Raf:ER proteins were the most potently oncogenic which correlated with their ability to elicit activation of the MAP kinase pathway, Consistent with the transformation data, the catalytic activity of the [DD] forms of Delta A-Raf:ER and Delta Raf-1:ER was about ten times greater than the cognate [FF] and [YY] forms of the proteins, By contrast all of the Delta B-Raf:ER proteins were highly transforming and Delta B-Raf catalytic activity was largely unaffected by mutation of the aforementioned aspartic acids to either tyrosine or phenylalanine. Similar results were obtained with epitope-tagged forms of Delta A-Raf, Delta B-Raf and Delta Raf-1 expressed in Sf9 cells, These data provide support for the model that key tyrosine residues in the protein kinase domains of A-Raf and Raf-1 are important in the regulation of catalytic activity. In addition they demonstrate that the higher intrinsic activity of B-Raf cannot be explained simply by the presence of aspartic acids at the analogous positions.	DNAX RES INST MOL & CELLULAR BIOL INC, DEPT CELL SIGNALING, PALO ALTO, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			McMahon, Martin/L-3303-2013	McMahon, Martin/0000-0003-2812-1042				AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; ASHWORTH A, 1992, ONCOGENE, V7, P2555; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MCCARTHY SA, 1992, J BIOL CHEM, V267, P21617; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Papin C, 1996, ONCOGENE, V12, P2213; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; RAPP UR, 1991, ONCOGENE, V6, P495; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SOZERI O, 1992, ONCOGENE, V7, P2259; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	68	72	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1021	1033		10.1038/sj.onc.1201270	http://dx.doi.org/10.1038/sj.onc.1201270			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285556				2022-12-28	WOS:A1997XT16100003
J	Serebriiskii, I; Estojak, J; Sonoda, G; Testa, JR; Golemis, EA				Serebriiskii, I; Estojak, J; Sonoda, G; Testa, JR; Golemis, EA			Association of Krev-1/rapla with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22	ONCOGENE			English	Article						Krit1; Krev-1/Rapla; 7q21-22; ankyrin repeat; interaction	BUD-SITE-SELECTION; GTP-BINDING PROTEINS; RAS-RELATED GENE; SACCHAROMYCES-CEREVISIAE; CHILDHOOD MONOSOMY-7; SUPPRESSOR ACTIVITY; ACTIVATING PROTEIN; HUMAN-NEUTROPHILS; TUMOR-SUPPRESSOR; SIGNAL PATHWAY	Krev-1/rap1A is an evolutionarily conserved Ras-family GTPase whose cellular function remains unclear, hut which has been proposed to function as a tumor suppressor gene, and may act as a Ras antagonist, To elucidate Krev-1 activity, we have used LexA-Krev-1 in a two-hybrid screen of a HeLa cell cDNA library, Of the two cDNA classes isolated, one contained a single isolate encoding the known Krev-1 interactor Raf, while the second contained multiple isolates coding for a previously undescribed protein which we have designated Krit1 (for Krev Interaction Trapped 1), The full length Krit1 cDNA encodes a protein of 529 amino acids, with an amino-terminal ankyrin repeat domain and a novel carboxy-terminal domain required for association with Krit1, Krit1 interacted strongly with Krev-1 but only weakly with Ras, suggesting it might specifically regulate Krev-1 activities, Krit1 mRNA and protein are expressed endogenously at low levels, with tissue specific variation, Intriguingly, the Krit cDNA has been mapped by FISH to chromosome 7q21-22, a region known to be frequently deleted or amplified in multiple forms of cancer.	FOX CHASE CANC CTR,DIV BASIC SCI,PHILADELPHIA,PA 19111; FOX CHASE CANC CTR,DIV MED SCI,PHILADELPHIA,PA 19111	Fox Chase Cancer Center; Fox Chase Cancer Center				Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [R29CA063366, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927, R29 CA63366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BELL DW, 1995, CYTOGENET CELL GENET, V70, P263, DOI 10.1159/000134048; BENDER A, 1993, P NATL ACAD SCI USA, V90, P9926, DOI 10.1073/pnas.90.21.9926; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOKOCH GM, 1994, CURR OPIN IMMUNOL, V6, P98, DOI 10.1016/0952-7915(94)90040-X; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; *CONS I GEN RES, 1995, NATURE, V377, P3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JELINEK MA, 1992, ONCOGENE, V7, P1687; KERE J, 1987, BLOOD, V70, P1349; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Law SF, 1996, MOL CELL BIOL, V16, P3327; LUNAFINEMAN S, 1995, BLOOD, V85, P1985, DOI 10.1182/blood.V85.8.1985.bloodjournal8581985; MALY FE, 1994, J BIOL CHEM, V269, P18743; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Moult J, 1996, CURR OPIN BIOTECH, V7, P422, DOI 10.1016/S0958-1669(96)80118-2; NASSAR N, 1995, NATURE, V375, P554; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PEDERSENBJERGAARD J, 1982, BLOOD, V60, P172; PIZON V, 1988, ONCOGENE, V3, P201; PIZON V, 1994, J CELL SCI, V107, P1661; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; QUINN MT, 1992, BLOOD, V79, P1563; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; SAKODA T, 1992, ONCOGENE, V7, P1705; SARGENT MS, 1994, CANCER GENET CYTOGEN, V77, P65, DOI 10.1016/0165-4608(94)90151-1; SATO KY, 1994, CANCER RES, V54, P552; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WEISS K, 1987, LEUKEMIA, V1, P97; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WOJTASZEK PA, 1993, ONCOGENE, V8, P755; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YAMADA T, 1990, GENE CHROMOSOME CANC, V2, P88, DOI 10.1002/gcc.2870020203; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; [No title captured]	62	168	175	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1043	1049		10.1038/sj.onc.1201268	http://dx.doi.org/10.1038/sj.onc.1201268			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285558				2022-12-28	WOS:A1997XT16100005
J	Candau, R; Scolnick, DM; Darpino, P; Ying, CY; Halazonetis, TD; Berger, SL				Candau, R; Scolnick, DM; Darpino, P; Ying, CY; Halazonetis, TD; Berger, SL			Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity	ONCOGENE			English	Article						adaptor; genetics; mdm-2; p53; transcription	WILD-TYPE P53; TATA-BINDING PROTEIN; PUTATIVE TRANSCRIPTIONAL ADAPTER; TUMOR-SUPPRESSOR GENE; DNA-BINDING; OLIGOMERIZATION DOMAIN; TETRAMERIZATION DOMAIN; REPRESSION FUNCTIONS; BASAL TRANSCRIPTION; OVERLAPPING DOMAINS	The ability of p53 to function as a tumor suppressor is linked to its function as a transcriptional activator, since p53 mutants that do not transactivate are unable to suppress tumor cell growth, Previous studies identified an activation domain in the amino terminal 40 residues of the protein, a region that binds to several general transcription factors and to some oncogene products, For example, mdm-2, a cellular oncoprotein, binds to this region and represses p53 transactivation, Here we describe a new activation domain within the amino terminus of p53 that maps between amino acids 40-83, and whose residues trp-53 and phe-54 are critical for function both in yeast and in mammalian cells, In vivo studies in yeast show that the new activation subdomain, unlike the previously described, is mdm-2 independent, Both p53 activation subdomains (1-40 and 40-83) require the yeast adaptor complex ADA2/ADA3/GCN5 for transcriptional activation, Moreover, since activation by p53 requires GCN5's enzymatic histone acetyltransferase domain, p53 may regulate gene expression by influencing chromatin modification.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute			Halazonetis, Thanos/D-7923-2011	Berger, Shelley/0000-0001-5398-4400				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BLAIR WS, 1994, J VIROL, V68, P3803, DOI 10.1128/JVI.68.6.3803-3808.1994; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1996, MOL CELL BIOL, V16, P593; CANDAU R, IN PRESS EMBO J; CANDAU R, 1996, J BIOL CHEM, V271, P527; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GILL G, 1988, NATURE, V334, P4721; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEONARDO AD, 1994, GENE DEV, V8, P2540; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIENHARDSCHMITZ M, 1994, J BIOL CHEM, V41, P25613; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOIDL P, 1994, CHROMOSOMA, V103, P441; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OHASHI Y, 1994, MOL CELL BIOL, V14, P2731, DOI 10.1128/MCB.14.4.2731; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROSE MD, 1988, METHODS YEAST GENETI; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1996, CANCER RES, V56, P158; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WU L, 1996, NATURE GENTE, V14, P429; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	91	121	125	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					807	816		10.1038/sj.onc.1201244	http://dx.doi.org/10.1038/sj.onc.1201244			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266967				2022-12-28	WOS:A1997XQ11700007
J	Ruchaud, S; Seite, P; Foulkes, NS; SassoneCorsi, P; Lanotte, M				Ruchaud, S; Seite, P; Foulkes, NS; SassoneCorsi, P; Lanotte, M			The transcriptional repressor ICER and cAMP-induced programmed cell death	ONCOGENE			English	Article						apoptosis; leukaemia; cAMP-signalling; transcription factors; CREM; ICER	LONG-TERM DESENSITIZATION; DNA FRAGMENTATION; RETINOIC ACID; CREM GENE; RESPONSIVE-ELEMENT; CYCLIC-NUCLEOTIDES; CHOLERA-TOXIN; KINASE-I; APOPTOSIS; EXPRESSION	The cAMP pathway plays a central role in the response to hormonal signals for cell proliferation, differentiation and apoptosis, In IPC-81 leukaemia cells, activation of the cAMP pathway by prostaglandin E1 treatment, or other cAMP-elevating agents, induces apoptosis within 4-6 h. Inhibition of mRNA or protein synthesis during the first 2h of cAMP induction protects cells from apoptosis, suggesting a requirement for early gene expression. cAMP-dependent protein kinase phosphorylates a class of nuclear factors and thereby regulates the transcription of a specific set of genes. Here we show that CREM (cAMP Responsive Element Modulator) expression is induced rapidly upon prostaglandin E1 treatment of IPC-81 cells. The induced transcripts correspond to the early product ICER (Inducible cAMP Early Repressor), ICER expression remains elevated until the burst of cell death, Protein synthesis inhibitors which prevent cAMP-induced apoptosis also block de novo ICER synthesis, Transfected IPC-81 cell lines, constitutively expressing high level of ICER are resistant to cAMP-induced cell death, In these transfected cells, cAMP fails to upregulate the ICER transcripts demonstrating that ICER exerts strongly its repressor function on CRE-containing genes. That an early expression of ICER blocks apoptosis, suggests that gene repression by endogenous ICER in IPC-81 is unsufficient or occurs too late to protect cells against death. ICER transfected cells rescued from cAMP-induced apoptosis are growth arrested, It shows for the first time that CREM activation directly participates to the decision of the cell to die. ICER, by sequentially repressing distinct sets of CRE-containing genes could modulate cell fate.	HOP ST LOUIS,CTR G HAYEM,INSERM U301,F-75010 PARIS,FRANCE; INST GENET BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)			Ruchaud, Sandrine/AAJ-2179-2021; Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891; Seite, Paule/0000-0002-7809-7610				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRAUMANN TJ, 1995, J CHROMATOGR, V350, P105; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DOWD DR, 1992, MOL CELL BIOL, V12, P3600, DOI 10.1128/MCB.12.8.3600; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; DUPREZ E, 1993, J BIOL CHEM, V268, P8332; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRIEDMAN DL, 1976, PHYSIOL REV, V56, P652, DOI 10.1152/physrev.1976.56.4.652; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Green DR, 1996, CELL DEATH DIFFER, V3, P339; GROUL DJ, 1993, MOL ENDOCRINOL, V7, P104; HAWLEY RG, 1994, GENE THER, V1, P136; HAYARI Y, 1985, EUR J IMMUNOL, V15, P43, DOI 10.1002/eji.1830150109; HITTELMAN KJ, 1973, PROSTAGLANDINS, P151; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOMNA V, 1978, BIOCHEM BIOPH RES CO, V82, P1246; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; HOUGE G, 1993, FEBS LETT, V315, P16, DOI 10.1016/0014-5793(93)81123-H; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KIZAKI H, 1989, J IMMUNOL, V143, P1790; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LANOTTE M, 1986, LEUKEMIA RES, V10, P1319, DOI 10.1016/0145-2126(86)90340-1; LANOTTE M, 1986, EXP HEMATOL, V14, P724; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McConkey D J, 1992, Semin Immunol, V4, P371; MCCONKEY DJ, 1993, FASEB J, V7, P580, DOI 10.1096/fasebj.7.6.8386120; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORI K, 1989, BIOCHEM BIOPH RES CO, V162, P1535, DOI 10.1016/0006-291X(89)90849-8; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OLSSON IL, 1982, CANCER RES, V42, P3922; POTTEN CS, 1988, CELL, V53, P676; PRATT RM, 1975, P NATL ACAD SCI USA, V72, P874, DOI 10.1073/pnas.72.3.874; ROSSI GB, 1980, BLOOD, V56, P74; Rowan S, 1997, LEUKEMIA, V11, P457, DOI 10.1038/sj.leu.2400626; Ruchaud S., 1995, Cellular Pharmacology, V2, P127; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; SONNENBURG WK, 1988, J BIOL CHEM, V263, P6155; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUSUKI K, 1990, BIOCHEM BIOPH RES CO, V171, P827; TAETLE R, 1980, CANCER RES, V40, P1223; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TORTORA G, 1988, BLOOD, V71, P230; VINTERMYR OK, 1993, EXP CELL RES, V206, P157, DOI 10.1006/excr.1993.1132; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1987, GENE, V53, P121, DOI 10.1016/0378-1119(87)90099-0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40	70	38	39	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					827	836		10.1038/sj.onc.1201248	http://dx.doi.org/10.1038/sj.onc.1201248			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266969				2022-12-28	WOS:A1997XQ11700009
J	Petti, LM; Irusta, PM; DiMaio, D				Petti, LM; Irusta, PM; DiMaio, D			Oncogenic activation of the PDGF beta receptor by the transmembrane domain of p185(neu)	ONCOGENE			English	Article						growth factor receptor; cell transformation; tyrosine phosphorylation	GROWTH-FACTOR RECEPTOR; PAPILLOMAVIRUS-E5 TRANSFORMING PROTEIN; CHRONIC MYELOMONOCYTIC LEUKEMIA; TYROSINE KINASE-ACTIVITY; SIMIAN SARCOMA-VIRUS; SIGNAL-TRANSDUCTION; TUMORIGENIC TRANSFORMATION; INSULIN-RECEPTOR; POINT MUTATION; E5 PROTEIN	We replaced the transmembrane domain of the wild type murine PDGF beta receptor with that of p185(neu*), the oncogenic form of p185(neu), thereby generating a constitutively activated chimeric receptor PR/neu*. Unlike the wild type PDGF beta receptor or a Chimeric receptor containing the transmembrane domain of wild type p185(neu) (PR/neu), PR/neu* induced morphologic transformation, focus formation, and tumorigenicity in mouse C127 fibroblasts. Expression of PR/neu* in mouse Ba/F3 hematopoietic cells, which normally depend on IL-3 for survival and sustained proliferation, induced proliferation in the absence of IL-3. The PR/neu chimera conferred limited IL-3-independent growth of Ba/F3 cells. Only PR/neu* and not PR/neu displayed significantly increased levels of phosphotyrosine compared to the wild type PDGF receptor in C127 and Ba/F3 cells. In addition, PR/neu* immune complexes displayed increased levels of kinase activity in vitro compared to immune complexes of the wild type receptor. Furthermore, novel tyrosine phosphorylated proteins of approximately 60 kDa appeared to specifically complex with PR/neu*, suggesting that PR/neu* may activate distinct signaling pathways. We speculate that the p185(neu*) transmembrane domain in the context of the PDGF beta receptor facilitates receptor homodimerization, thereby inducing tyrosine autophosphorylation followed by association with important signaling substrates and transforming activity. Thus, PR/neu* should be a useful reagent for further characterizing activation and signaling mechanisms of the PDGF beta receptor.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	Yale University	Petti, LM (corresponding author), Albany Med Coll, Dept Microbiol Immunol & Mol Genet, A-68,47 New Scotland Ave, Albany, NY 12208 USA.				NATIONAL CANCER INSTITUTE [R37CA037157, P01CA016038, R01CA037157] Funding Source: NIH RePORTER; NCI NIH HHS [CA16038, CA37157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1992, J BIOL CHEM, V267, P20489; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; ESCOBEDO JA, MOL CELL BIOL, V10, P3858; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; LEE AW, 1992, J BIOL CHEM, V267, P16472; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; LEPTAK C, 1991, J VIROL, V66, P1833; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; RIESE DJ, 1995, ONCOGENE, V10, P1431; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; YAMADA K, 1992, J BIOL CHEM, V267, P12452; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	43	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					843	851		10.1038/sj.onc.1201590	http://dx.doi.org/10.1038/sj.onc.1201590			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484775				2022-12-28	WOS:000072053200003
J	Rousset, R; Fabre, S; Desbois, C; Bantignies, F; Jalinot, P				Rousset, R; Fabre, S; Desbois, C; Bantignies, F; Jalinot, P			The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins	ONCOGENE			English	Article						HTLV-1; Tax; PDZY; two-hybrid	VIRUS TYPE-I; COMPLETE NUCLEOTIDE-SEQUENCE; NMDA RECEPTOR SUBUNITS; NF-KAPPA-B; LEUKEMIA-VIRUS; TRANSGENIC MICE; TRANSCRIPTION FACTORS; TRANSACTIVATOR TAX; GUANYLATE KINASES; GENE	Infection by HTLV-1 has been correlated with the appearance of various proliferative or degenerative diseases. Some of these disorders have been observed in transgenic mice expressing the Tax protein, which is known to transactivate various viral and cellular promoters through interactions with several transcription factors. In this study we show that the C-terminus of this viral oncoprotein represents a motif permitting binding of Tax to the PDZ domains of several cellular proteins. A two-hybrid screen with Tax as bait indeed yielded complementary DNAs coding for six proteins including PDZ domains. Two of them correspond to truncated forms of the PSD-95 and beta 1-syntrophin proteins, another clone codes for a protein homologous to the product of the C. elegans gene lin-7. The other three clones code for new human members of the PDZ family of cellular proteins. The interaction of Tax with the products of these clones was confirmed by immunoprecipitation assays in mammalian cells, and analysis of various mutants of Tax established the importance of the C-terminal amino acids for several of these interactions. These data suggest that Tax could perturb the normal function of targeted cellular proteins by strongly interacting with their PDZ domains.	Ecole Normale Super Lyon, Lab Biol Mol & Cellulaire, CNRS, UMR 49, F-69364 Lyon 07, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Jalinot, P (corresponding author), Ecole Normale Super Lyon, Lab Biol Mol & Cellulaire, CNRS, UMR 49, 46 Allee Italie, F-69364 Lyon 07, France.		Fabre, Stéphane/ABC-1483-2020; Morris, Christelle/M-8168-2014; Rousset, Raphael/E-5908-2017; FABRE, Stéphane/AAQ-8400-2020	Morris, Christelle/0000-0003-1575-4609; Rousset, Raphael/0000-0002-4999-403X; FABRE, Stéphane/0000-0001-7350-9500				AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CRENON I, 1993, ONCOGENE, V8, P867; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; GESSAIN A, 1993, J VIROL, V67, P1015, DOI 10.1128/JVI.67.2.1015-1023.1993; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LAURANCE ME, 1997, J BIOL CHEM, V272, P24646; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MALIK KTA, 1988, J GEN VIROL, V69, P1695, DOI 10.1099/0022-1317-69-7-1695; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Miller J.H., 1972, EXPT MOL GENETICS; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1989, AM J PATHOL, V135, P1025; Niethammer M, 1996, J NEUROSCI, V16, P2157; Ozden S, 1996, J ACQ IMMUN DEF SYND, V13, pS154, DOI 10.1097/00042560-199600001-00024; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; PFEFFER U, 1995, BIOTECHNIQUES, V18, P204; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN S M, 1989, New Biologist, V1, P275; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TSUJIMOTO A, 1988, MOL BIOL MED, V5, P29; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 1996, J ACQ IMMUN DEF SYND, V13, pS63, DOI 10.1097/00042560-199600001-00012	63	162	175	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					643	654		10.1038/sj.onc.1201567	http://dx.doi.org/10.1038/sj.onc.1201567			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482110				2022-12-28	WOS:000071816600009
J	Meiners, S; Brinkmann, V; Naundorf, H; Birchmeier, W				Meiners, S; Brinkmann, V; Naundorf, H; Birchmeier, W			Role of morphogenetic factors in metastasis of mammary carcinoma cells	ONCOGENE			English	Review						HGF; neuregulin; E-cadherin; metastasis; morphogenesis; epithelial-mesenchymal transition	HEPATOCYTE GROWTH-FACTOR; E-CADHERIN EXPRESSION; C-MET RECEPTOR; HUMAN PANCREATIC-CANCER; HUMAN BREAST-CANCER; SCATTER FACTOR; BETA-CATENIN; EPITHELIAL-CELLS; TYROSINE KINASE; TUMOR PROGRESSION	We have analysed the role of the morphogenetic factors hepatocyte growth factor/scatter factor (HGF), neuregulin and E-cadherin in the process of metastasis and morphogenesis of mammary carcinoma cells. The cDNAs for HGF, neuregulin and E-cadherin were stably expressed in anaplastic human MDA MB 435 carcinoma cells. The altered cells were then injected into the mammary fat pads of nude mice, where they form tumors which can spontaneously metastasize to the lungs. We found that expression of HGF or neuregulin promoted metastasis whereas expression of the cell adhesion molecule E-cadherin was inhibitory. Moreover, expression of E-cadherin reconstituted the ability of the cells to form morphogenetic structures in matrigel cultures in response to HGF. These data demonstrate that HGF and neuregulin, which control branching or lobulo-alveolar morphogenesis of normal breast epithelium, do have metastasis-promoting effects on breast carcinoma cells. Moreover, our results suggest that the differential activities of the two factors can be explained by the degree of epithelial differentiation: induction of morphogenesis requires an intact epithelial adhesion and differentiation system, whereas induction of metastasis is observed when the cells have lost their epithelial characteristics.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Birchmeier, W (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.		Brinkmann, Volker/A-6015-2009					ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Boyer B, 1996, CURR TOP MICROBIOL, V213, P179; BRINGUIER PP, 1993, CANCER RES, V53, P3241; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165; DIRENZO MF, 1995, CANCER RES, V55, P1129; DORUDI S, 1993, AM J PATHOL, V142, P981; EBERT M, 1994, CANCER RES, V54, P5775; FERRACINI R, 1995, ONCOGENE, V10, P739; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GAMALLO C, 1993, AM J PATHOL, V142, P987; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Gunthert U, 1996, CURR TOP MICROBIOL, V213, P271; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Jeffers M, 1996, ONCOGENE, V13, P853; JOSEPH A, 1995, J NATL CANCER I, V87, P372, DOI 10.1093/jnci/87.5.372; KANDA H, 1993, ONCOGENE, V8, P3047; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Krane IM, 1996, ONCOGENE, V12, P1781; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LEONE A, 1993, ONCOGENE, V8, P2325; LIOTTA LA, 1988, CANCER SURV, V7, P631; MAYER B, 1993, CANCER RES, V53, P1690; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOLL R, 1993, AM J PATHOL, V143, P1731; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAIDU YM, 1994, P NATL ACAD SCI USA, V91, P5281, DOI 10.1073/pnas.91.12.5281; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; NIEMANN C, 1997, UNPUB J CELL BIOL; OTTO T, 1994, CANCER RES, V54, P3120; OYAMA T, 1994, CANCER RES, V54, P6282; PARK JB, 1989, CANCER RES, V49, P6605; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Powell WC, 1996, CURR TOP MICROBIOL, V213, P1; PRESS MF, 1994, CANCER RES, V54, P5675; PRICE JE, 1990, CANCER RES, V50, P717; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; REICHMANN E, 1994, SEMIN CANCER BIOL, V5, P157; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; Silletti S, 1996, CURR TOP MICROBIOL, V213, P137; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO JV, 1995, J CELL SCI, V108, P413; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; UMBAS R, 1994, CANCER RES, V54, P3929; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zschiesche W, 1997, ANTICANCER RES, V17, P561	105	97	106	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	1998	16	1					9	20		10.1038/sj.onc.1201486	http://dx.doi.org/10.1038/sj.onc.1201486			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467938				2022-12-28	WOS:000071236800002
J	Olson, MF; Sterpetti, P; Nagata, K; Toksoz, D; Hall, A				Olson, MF; Sterpetti, P; Nagata, K; Toksoz, D; Hall, A			Distinct roles for DH and PH domains in the Lbc oncogene	ONCOGENE			English	Article						oncogene; Rho; Dbl; Pleckstrin-homology; exchange factor; actin	PLECKSTRIN HOMOLOGY DOMAIN; NUCLEOTIDE EXCHANGE FACTORS; STRUCTURAL SIMILARITIES; G(BETA-GAMMA) SUBUNITS; EXPRESSION CLONING; PLASMA-MEMBRANE; PROTEIN-RHO; DBL FAMILY; BINDING; TRANSDUCTION	Members of the Dbl-homology (DH) family of proteins promote guanine nucleotide exchange on Rho GTPases, Lbc, which specifically acts on Rho but not Rac or Cdc42, was isolated as a transforming oncogene and is composed of a DH and a Pleckstrin-homology (PH) domain, We show here that the Lbc DH domain alone is capable of stimulating new DNA synthesis in quiescent fibroblasts and Rho-dependent actin stress fiber assembly. However, the PH domain is required for subcellular localization of Lbc along actin stress fibers and for efficient transformation of NIH3T3 cells, The results show that, in contrast to other Dbl-homology proteins, the PH domain of Lbc is dispensable for activation of Rho in vivo, The PH domain-dependent subcellular localization of Lbc may, however, be important for growth factor activation of endogenous Lbc and for oncogenic transformation.	UCL, CRC, SIGNAL TRANSDUCT & ONCOGENE GRP, LONDON WC1E 6BT, ENGLAND; UCL, MRC, MOL CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND; UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA	University of London; University College London; University of London; University College London; University of London; University College London; Tufts University			Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507; 				Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Sambrook J., 2002, MOL CLONING LAB MANU; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOKSOZ D, 1994, ONCOGENE, V9, P621; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Wang DS, 1996, BIOCHEM BIOPH RES CO, V225, P420, DOI 10.1006/bbrc.1996.1189; WANG YL, 1987, J CELL BIOL, V105, P2811, DOI 10.1083/jcb.105.6.2811; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; YAMAMOTO M, 1993, J BIOL CHEM, V268, P21509; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	30	58	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2827	2831		10.1038/sj.onc.1201594	http://dx.doi.org/10.1038/sj.onc.1201594			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419973				2022-12-28	WOS:A1997YJ80300008
J	Kovalchuk, AL; Muller, JR; Janz, S				Kovalchuk, AL; Muller, JR; Janz, S			Deletional remodeling of c-myc-deregulating chromosomal translocations	ONCOGENE			English	Article						BALB/c plasmacytomas; chromosomal translocation; deregulation of c-myc; isotype switching	IMMUNOGLOBULIN HEAVY-CHAIN; CLASS SWITCH RECOMBINATION; MURINE PLASMACYTOMA; ABERRANT REARRANGEMENT; ENHANCER ELEMENT; IGH 3'-ENHANCER; B-CELLS; REGION; LOCUS; GENE	Evidence is presented for the existence of a novel remodeling-by-deletion mechanism that alters the fine structure of c-myc-deregulating chromosomal translocations in t(12;15)-positive BALB/c plasmacytomas. DNA sequence analysis of the t(12;15) in five primary tumors revealed the co-existence of precursor cells harboring genetic recombinations between the immunoglobulin heavy-chain mu locus (Igh mu) and c-myc with clonally related progenitors containing rearrangements between the immunoglobulin heavy-chain alpha locus (Igh alpha) and c-myc. Clonal relatedness was based upon unique junction fragments between the snitch region of Igh mu and c-myc. S mu/c-myc junctions are thus useful clonotypic markers for monitoring the conversion of Igh mu/c-myc-positive tumor precursor clones into Igh alpha/c-myc-positive plasmacytomas. Aberrant isotype switch recombination appears to be the most likely mechanism effecting this conversion event (other possibilities are discussed) which may help to explain the preferred usage of the Igh alpha locus in recombinations with c-myc in t(12;15)-positive plasma cell tumors in BALB/c mice.	NCI,GENET LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Kovalchuk, Alexander/0000-0003-2761-0442				Akasaka T, 1996, BLOOD, V88, P985; Arulampalam V, 1995, MOL IMMUNOL, V32, P1369, DOI 10.1016/0161-5890(95)00102-6; BARD JA, 1995, J IMMUNOL, V154, P201; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROSSEN PE, 1993, GENE CHROMOSOME CANC, V8, P60, DOI 10.1002/gcc.2870080110; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DUNNICK W, 1989, MOL CELL BIOL, V9, P1850, DOI 10.1128/MCB.9.5.1850; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; ELENICH LA, 1991, NUCLEIC ACIDS RES, V19, P396; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GREENBERG R, 1982, NUCLEIC ACIDS RES, V10, P7751, DOI 10.1093/nar/10.23.7751; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; JANZ S, 1993, P NATL ACAD SCI USA, V90, P7361, DOI 10.1073/pnas.90.15.7361; KOTTMANN AH, 1994, EUR J IMMUNOL, V24, P817, DOI 10.1002/eji.1830240407; Kovalchuk AL, 1996, IMMUNOGENETICS, V44, P151, DOI 10.1007/s002510050104; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; MATTHIAS P, 1993, MOL CELL BIOL, V13, P1547, DOI 10.1128/MCB.13.3.1547; Mautner J, 1996, ONCOGENE, V12, P1299; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; Michaelson JS, 1996, J IMMUNOL, V156, P2828; MICHAELSON JS, 1995, NUCLEIC ACIDS RES, V23, P975, DOI 10.1093/nar/23.6.975; MORSE HC, 1976, J IMMUNOL, V117, P541; Muller JR, 1997, BLOOD, V89, P291, DOI 10.1182/blood.V89.1.291.291_291_296; MULLER JR, 1995, CANCER RES, V55, P5012; MULLER JR, 1994, P NATL ACAD SCI USA, V91, P12066, DOI 10.1073/pnas.91.25.12066; OHNO S, 1989, ONCOGENE, V4, P1513; OHNO S, 1991, INT J CANCER, V49, P102, DOI 10.1002/ijc.2910490119; PEAR WS, 1988, ONCOGENE, V2, P499; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; POTTER M, 1983, J NATL CANCER I, V71, P391; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; POTTER M, 1994, CANCER RES, V54, P969; RADBRUCH A, 1986, IMMUNOL REV, V89, P69, DOI 10.1111/j.1600-065X.1986.tb01473.x; SIGURDARDOTTIR D, 1995, J IMMUNOL, V154, P2217; Singh M, 1996, P NATL ACAD SCI USA, V93, P4392, DOI 10.1073/pnas.93.9.4392; VANNESS BG, 1983, NATURE, V301, P425, DOI 10.1038/301425a0; WIENER F, 1984, J EXP MED, V159, P276, DOI 10.1084/jem.159.1.276; WINTER E, 1987, EMBO J, V6, P1663, DOI 10.1002/j.1460-2075.1987.tb02415.x; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; ZELENETZ AD, 1993, GENE CHROMOSOME CANC, V6, P140, DOI 10.1002/gcc.2870060303	44	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2369	2377		10.1038/sj.onc.1201409	http://dx.doi.org/10.1038/sj.onc.1201409			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393881				2022-12-28	WOS:A1997YE15700011
J	Roy, WJ; Watson, RH; Hitchcock, A; Campbell, IG				Roy, WJ; Watson, RH; Hitchcock, A; Campbell, IG			Frequent loss of heterozygosity on chromosomes 7 and 9 in benign epithelial ovarian tumours	ONCOGENE			English	Article						benign; chromosome 6, 7, 9, 11 and 17; loss of heterozygosity; ovarian tumours; tumour suppressor genes, PCR, microsatellite	LOW-GRADE; CARCINOMA; MUTATION; TUMORS; P53; OVEREXPRESSION; REGION; CDKN2; GENE; RARE	It is presently unclear if ovarian cancers arise through malignant transformation of pre-existing benign tumours, The apparent rarity of loss of heterozygosity (LOH) reported for benign tumours has led to speculation that they lack malignant potential and represent a biological entity distinct from ovarian carcinoma, We reasoned that the absence of detectable LOH may be due to the masking of such losses by contamination with normal tissue present in excess in the majority of benign tumour biopsies, Therefore we utilized a microdissection technique to examine for LOH using 14 microsatellite markers on chromosome arms 6q, 7p, 7q, 9p, 11q and 17p in 31 solitary benign epithelial ovarian tumours, LOH was detected on all chromosome arms with the most frequent LOH occurring on 7p (27%) and 9p (26%), In addition, a point mutation in codon 157 of TP53 was detected in one tumour which is the first report of a TP53 mutation in a solitary benign ovarian tumour, In total 48% of tumours harboured genetic alterations which supports the idea that all benign ovarian tumours may carry a genetic predisposition to malignancy and are therefore not inherently different from their malignant counterparts.	UNIV SOUTHAMPTON,PRINCESS ANNE HOSP,SOUTHAMPTON SO16 5YA,HANTS,ENGLAND	University of Southampton			campbell, Ian G/F-6006-2011	Campbell, Ian/0000-0002-7773-4155				BERCHUCK A, 1994, GYNECOL ONCOL, V52, P232, DOI 10.1006/gyno.1994.1037; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CAMPBELL IG, 1995, INT J CANCER, V63, P222, DOI 10.1002/ijc.2910630213; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; DODSON MK, 1993, CANCER RES, V53, P4456; ENGLEFIELD P, 1994, BRIT J CANCER, V70, P905, DOI 10.1038/bjc.1994.418; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULKES WD, 1995, BRIT J CANCER, V72, P883, DOI 10.1038/bjc.1995.428; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; Gabra H, 1996, CANCER RES, V56, P950; Kerr J, 1996, ONCOGENE, V13, P1815; KIM JW, 1995, GYNECOL ONCOL, V57, P199, DOI 10.1006/gyno.1995.1125; MILNER BJ, 1993, CANCER RES, V53, P2128; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; PULS LE, 1992, GYNECOL ONCOL, V47, P53, DOI 10.1016/0090-8258(92)90075-T; Salazar H, 1996, JNCI-J NATL CANCER I, V88, P1810, DOI 10.1093/jnci/88.24.1810; SCHULTZ DC, 1995, CANCER RES, V55, P2150; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146; ZHENG JP, 1993, CANCER RES, V53, P4138	21	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2031	2035		10.1038/sj.onc.1201372	http://dx.doi.org/10.1038/sj.onc.1201372			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366520				2022-12-28	WOS:A1997YC28400004
J	Li, M; Pullano, R; Yang, HL; Lee, HK; Miyamoto, NG; Filmus, J; Buick, RN				Li, M; Pullano, R; Yang, HL; Lee, HK; Miyamoto, NG; Filmus, J; Buick, RN			Transcriptional regulation of OCI-5/glypican 3: Elongation control of confluence-dependent induction	ONCOGENE			English	Article						proteoglycan; SGBS; intestine; promoter; elongation; confluence	HEPARAN-SULFATE PROTEOGLYCAN; RNA-POLYMERASE-II; GOLABI-BEHMEL SYNDROME; INCREASING CELL-DENSITY; PROTEIN-KINASE-C; Z-DNA; NERVOUS-SYSTEM; GENOMIC ORGANIZATION; OVERGROWTH SYNDROME; ENHANCER ELEMENTS	OCI-5/Glypican 3, a member of the glypican family of proteoglycans, is the defective gene in the Simpson-Golabi-Behmel overgrowth syndrome. OCI-5 expression is developmentally regulated in the intestinal epithelium, and the mechanism of its regulation was studied in the rat intestinal epithelial cell line IEC-18. A large induction of OCI-5 transcript and protein was observed at high cell density, Among other glypican family members, kappa-glypican also exhibited a confluence-dependent induction in select cell types. Nuclear run-on analysis indicated that cell-density regulation of OCI-5 occurs at the level of transcription, The rat and mouse OCI-5 promoters were cloned and found to be highly conserved, located within CpG islands and contain regions of alternating purine and pyrimidine residues, No TATA-box or recognizable INR element was observed, Consensus binding sites for AP-2, SP-1, zeste and NF-1/CTF are conserved across human, mouse and rat promoters, 5' deletion mapping of the rat promoter identified regions which enhance and repress promoter activity, with no apparent confluence-dependence or tissue-specificity. Nuclear run-on analysis probing different regions of the gene suggests that elongation control plays a role in the induction of OCI-5 by confluence.	UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DIV CANC RES,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; BERLEX BIOSCI,DEPT IMMUNOL,RICHMOND,CA 94804	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Li, M (corresponding author), UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,610 UNIV AVE,TORONTO,ON M5G 2M9,CANADA.		Li, Madeline/Q-8300-2017	Li, Madeline/0000-0002-3977-7437				Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BANERJEE R, 1986, P NATL ACAD SCI USA, V83, P4988, DOI 10.1073/pnas.83.14.4988; BENGAL E, 1991, J VIROL, V65, P4910, DOI 10.1128/JVI.65.9.4910-4918.1991; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BIRD AP, 1989, NUCLEIC ACIDS RES, V17, P9485, DOI 10.1093/nar/17.22.9485; BLAT C, 1994, EXP CELL RES, V215, P114, DOI 10.1006/excr.1994.1322; BOST LM, 1993, GROWTH FACTORS, V9, P195, DOI 10.3109/08977199309010832; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; ELLIOTT EM, 1985, CAN J BIOCHEM CELL B, V63, P511, DOI 10.1139/o85-070; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUNG WP, 1987, J BIOL CHEM, V262, P9298; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOLABI M, 1984, AM J MED GENET, V17, P345, DOI 10.1002/ajmg.1320170128; HAMBURGER AW, 1991, PATHOBIOLOGY, V59, P329, DOI 10.1159/000163672; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HU YL, 1993, J BIOL CHEM, V268, P27214; HU ZB, 1995, LEUKEMIA, V9, P789; HUGHESBENZIE RM, 1992, AM J MED GENET, V43, P428, DOI 10.1002/ajmg.1320430165; HughesBenzie RM, 1996, AM J MED GENET, V66, P227, DOI 10.1002/(SICI)1096-8628(19961211)66:2<227::AID-AJMG20>3.0.CO;2-U; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGBER DE, 1993, CELL, V75, P1249, DOI 10.1016/0092-8674(93)90612-T; INGBER DE, 1994, INT REV CYTOL, V150, P173; Iwasaki T, 1996, J BIOL CHEM, V271, P22183, DOI 10.1074/jbc.271.36.22183; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAMINE J, 1993, J VIROL, V67, P6828, DOI 10.1128/JVI.67.11.6828-6834.1993; KITAOKA T, 1993, CURR EYE RES, V12, P993, DOI 10.3109/02713689309029225; KRAJEWSKI WA, 1995, FEBS LETT, V358, P13, DOI 10.1016/0014-5793(94)01377-D; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KUMATORI A, 1991, BIOCHEM BIOPH RES CO, V178, P480, DOI 10.1016/0006-291X(91)90132-Q; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LI M, 1997, IN PRESS EXP CELL RE; Lindsay S, 1997, J MED GENET, V34, P480, DOI 10.1136/jmg.34.6.480; LITWACK ED, 1994, J NEUROSCI, V14, P3713; LORIES V, 1992, J BIOL CHEM, V267, P1116; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NAKATO H, 1995, DEVELOPMENT, V121, P3687; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; Oesterreich S, 1996, BIOCHEM BIOPH RES CO, V222, P155, DOI 10.1006/bbrc.1996.0714; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PEREZCASTRO AV, 1995, GENOMICS, V30, P157, DOI 10.1006/geno.1995.9890; Perkinson RA, 1996, J CELL BIOCHEM, V63, P74; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; RAJAGOPALAN M, 1990, J BIOL CHEM, V265, P17294; RAJCHEL A, 1988, NUCLEIC ACIDS RES, V16, P2347, DOI 10.1093/nar/16.5.2347; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SATO T, 1995, J BIOL CHEM, V270, P10314, DOI 10.1074/jbc.270.17.10314; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; TERESPOLSKY D, 1995, AM J MED GENET, V59, P329, DOI 10.1002/ajmg.1320590310; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; Veugelers M, 1997, GENOMICS, V40, P24, DOI 10.1006/geno.1996.4518; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WICE BM, 1995, J BIOL CHEM, V270, P21907, DOI 10.1074/jbc.270.37.21907; Wolfl S, 1996, P NATL ACAD SCI USA, V93, P3664, DOI 10.1073/pnas.93.8.3664; YU M, 1995, ARCH BIOCHEM BIOPHYS, V316, P407, DOI 10.1006/abbi.1995.1054	67	11	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1535	1544		10.1038/sj.onc.1201325	http://dx.doi.org/10.1038/sj.onc.1201325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380405				2022-12-28	WOS:A1997XX36900004
J	ChotteauLelievre, A; Desbiens, X; Pelczar, H; Defossez, PA; deLaunoit, Y				ChotteauLelievre, A; Desbiens, X; Pelczar, H; Defossez, PA; deLaunoit, Y			Differential expression patterns of the PEA3 group transcription factors through murine embryonic development	ONCOGENE			English	Article						murine embryogenesis; ets genes; PEA3 group; transcription factor	ETS GENE FAMILY; DNA-BINDING DOMAIN; CHICK-EMBRYO; CHROMOSOMAL TRANSLOCATION; MOLECULAR-CLONING; ONCOGENE FAMILY; MESSENGER-RNAS; V-MYB; CELLS; LEUKEMIA	ERM, ER81 and PEA3 are three highly related transcription factors belonging to the ETS family. Together they form the PEA3 group within this family. Little data is yet available regarding the roles of these three genes during embryonic development. A prerequisite to investigations in this field is to obtain an accurate spatio-temporal expression map for the erm, er81 and pea3 genes. To this end, we have used in situ hybridization to compare their expression patterns during critical stages of murine embryogenesis. We report that all three genes are expressed in numerous developing organs coming from different embryonic tissues. The three genes appeared co-expressed in different organs but presented specific sites of expression, so that the resultant expression pattern could in fact reveal several distinct functions depending upon isolated and/or various combinations of the PEA3 member expression. These results suggest that erm, er81 and pea3 genes are differentially regulated, probably to serve important functions as cell proliferation control, tissue interaction mediator or cell differentiation, all over successive steps of the mouse organogenesis.	INST BIOL LILLE,UMR 319 CNRS,INST PASTEUR,F-59021 LILLE,FRANCE; USTL,CTR BIOL CELLULAIRE,UNITE DYNAM CELLULES EMBRYONNAIRES & CANCEREUSES,VILLENEUVE DASCQ,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille				Defossez, Pierre-Antoine/0000-0002-6463-9263				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Buttice G, 1996, ONCOGENE, V13, P2297; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DelannoyCourdent A, 1996, INT J DEV BIOL, V40, P1097; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; FAFEUR V, 1997, IN PRESS CELL GROWTH; Ganan Y, 1996, DEVELOPMENT, V122, P2349; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GREVIN D, 1993, INT J DEV BIOL, V37, P519; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Janknecht R, 1996, ONCOGENE, V13, P1745; JANKNECHT R, 1996, MOL CELL BIOL, V16, P1551; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Laget MP, 1996, ONCOGENE, V12, P1325; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; QUEVA C, 1993, ONCOGENE, V8, P2511; QUEVA C, 1992, DEVELOPMENT, V114, P125; ROMANOSPICA V, 1994, INT J ONCOL, V4, P521; SATO H, 1993, ONCOGENE, V8, P395; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Shindoh M, 1996, AM J PATHOL, V148, P693; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; VANBENBUNDER B, 1989, DEVELOPMENT, V109, P265; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	63	126	130	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					937	952		10.1038/sj.onc.1201261	http://dx.doi.org/10.1038/sj.onc.1201261			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285689				2022-12-28	WOS:A1997XR76700007
J	Gabrielli, BG; Clark, JM; McCormack, AK; Ellem, KAO				Gabrielli, BG; Clark, JM; McCormack, AK; Ellem, KAO			Ultraviolet light-induced G2 phase cell cycle checkpoint blocks cdc25-dependent progression into mitosis	ONCOGENE			English	Article						cdc25; cell cycle checkpoint; UV	MATURATION-PROMOTING FACTOR; CDK2 PROTEIN-KINASE; IONIZING-RADIATION; HUMAN FIBROBLASTS; HELA-CELLS; DEPENDENT KINASES; NITROGEN-MUSTARD; DNA-REPLICATION; B IRRADIATION; G1 ARREST	In response to low doses of ultraviolet (U.V.) radiation, cells undergo a G2 delay. In this study we have shown that the G2 delay results in the accumulation of inactive forms of cyclin B1/cdc2 and both the G2 and mitotic complexes of cyclin A/cdk. This appears to be through a block in the cdc25-dependent activation of these complexes. The expression and localisation of cyclin A and cyclin B1/cdk complexes are similar in U.V.-induced G2 delay and normal early G2 phase cells, Cdc25B and cdc25C also accumulate to normal G2 levels in U.V. irradiated cells, but the mitotic phosphorylation associated with increased activity of both cdc25B and cdc25C is absent. The cdc25B accumulates in the nucleus of U.V. irradiated cells and in normal G2 phase cells. Thus the block in cyclin B/cdc2 activation is in part due to the physical separation of cyclin B/cdc2, localised in the cytoplasm, from the cdc25B and cdc25C phosphatases localised in the nucleus, The data positions the U.V.-induced G2 checkpoint at either the S/G2 transition or early G2 phase, prior to the activation of cyclin A/cdk2.			Gabrielli, BG (corresponding author), ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,JOINT ONCOL PROGRAM,QUEENSLAND CANC FUND RES LAB,HERSTON,QLD 4029,AUSTRALIA.		Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BAILLY E, 1992, J CELL SCI, V101, P529; BARKER D, 1995, CANCER RES, V55, P4041; Barth H, 1996, CANCER RES, V56, P2268; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GABRIELLI B, 1994, ADV PROT PHOSPHATASE, V8, P209; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kovelman R, 1996, MOL CELL BIOL, V16, P86; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; NAGATA A, 1991, NEW BIOL, V3, P959; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; Petrocelli T, 1996, ONCOGENE, V12, P1387; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG XQ, 1994, EXP CELL RES, V212, P176, DOI 10.1006/excr.1994.1133; Wang XQ, 1996, CANCER RES, V56, P2510	49	56	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					749	758		10.1038/sj.onc.1201254	http://dx.doi.org/10.1038/sj.onc.1201254			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266961				2022-12-28	WOS:A1997XQ11700001
J	Lores, P; Morin, L; Luna, R; Gacon, G				Lores, P; Morin, L; Luna, R; Gacon, G			Enhanced apoptosis in the thymus of transgenic mice expressing constitutively activated forms of human Rac2GTPase	ONCOGENE			English	Article						Rac2GTPase; thymocyte; apoptosis; transgenic mice	GTP-BINDING-PROTEIN; THYMOCYTE DEVELOPMENT; HEMATOPOIETIC-CELLS; NADPH OXIDASE; LYMPHOCYTES; IDENTIFICATION; RAC	Rac proteins constitute a subgroup of the Rho family of small GTPases and include Rac1, which is expressed ubiquitously, and Rac2, a highly homologous protein only expressed in myelo-monocytic and lymphoid cell lineages. In fibroblasts, Rad plays a crucial role in control of actin cytoskeleton organisation, cell growth and Ras-induced transformation. In phagocyte, Rac1 and Rac2 regulate a specific enzymatic complex, NADPH oxidase. These multiple functions have been ascribed to Rac proteins only on the basis of cell culture and in vitro biochemical studies. To examine the role of Rac2 in vivo in a T cell lineage, we have expressed either wild-type or constitutively-activated forms of human Rac2 (Rac2V12 and Rac2L61) in transgenic mice under control of the thymus specific lck proximal promoter. We report here a striking atrophy of the thymus in mice expressing even low levels of either of the activated mutants of Rac2, while expression of Rac2wt has no effect. This phenotype is correlated with a marked decrease in the number of double positive (CD4 + CD8 +) and single positive (CD4 + CD8 - and CD8 + CD4 -) thymocytes, Cellular and molecular analyses demonstrate that this defect is due to an increase in apoptosis among thymocytes. As Rac2 is normally expressed in thymocytes and activated T cells, me propose that Rac2 dependent pathways could play an important role in control of growth and death of T cells.	INST COCHIN GENET MOL,INSERM,U257,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			LUNA, ROSA/F-3974-2016	LUNA, ROSA/0000-0002-6131-6610; Lores, Patrick/0000-0002-3191-9488				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHETTY M, 1995, BIOCHEM J, V306, P141, DOI 10.1042/bj3060141; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOBAYASHI S, 1995, J BIOCHEM, V117, P758, DOI 10.1093/oxfordjournals.jbchem.a124773; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Osborne BA, 1996, CURR OPIN IMMUNOL, V8, P245, DOI 10.1016/S0952-7915(96)80063-X; QUI RG, 1995, NATURE, V374, P457; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SHIRSAT NV, 1990, ONCOGENE, V5, P769; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	27	60	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					601	605		10.1038/sj.onc.1201378	http://dx.doi.org/10.1038/sj.onc.1201378			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247314				2022-12-28	WOS:A1997XN25500012
J	Martinelli, R; Blandino, G; Scardigli, R; Crescenzi, M; Lombardi, D; Sacchi, A; Soddu, S				Martinelli, R; Blandino, G; Scardigli, R; Crescenzi, M; Lombardi, D; Sacchi, A; Soddu, S			Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells	ONCOGENE			English	Article						differentiation; tumor suppression; cellular environment	GRANULOCYTIC DIFFERENTIATION; LINE; PROLIFERATION; APOPTOSIS; GROWTH; MACROPHAGE; RECEPTOR; BLOCKS	Expression of exogenous wt-p53 in different tumor cell lines can induce growth arrest, apoptosis, or differentiation. Several experimental works have highlighted the relevance of cellular context in the determination of p53-mediated final outcomes. We recently observed that these diverse wt-p53 effects can also be induced by overexpressing wt-p53 in a single cell type-the 32D myeloid progenitors-transformed with different activated oncogenes. Here we show that 32D cells transformed with two different oncogenes, v-src or c-fms [S301,F969], both belonging to the CSF-1 transduction pathway, respond to exogenous wt-p53 expression with the same final outcome-monocytic differentiation. This result is particularly significant since 32D cells do not spontaneously express the CSF-1 receptor, whereas they undergo granulocytic differentiation upon G-CSF stimulation. These data strongly support the idea that wt-p53 suppressing effects result from interactions between p53 activity and the signaling pathways activated in different transformed cells.	CRS,REGINA ELENA CANC INST,MOL ONCOGENESIS LAB,I-00158 ROME,ITALY; UNIV AQUILA,DEPT EXPT MED,I-67100 LAQUILA,ITALY	University of L'Aquila			Blandino, Giovanni/B-1137-2013; Soddu, Silvia/ABH-6774-2020; Soddu, Silvia/K-2467-2018; Crescenzi, Marco/J-3603-2018	Blandino, Giovanni/0000-0002-6970-2241; Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; Crescenzi, Marco/0000-0003-0156-1494; Scardigli, Raffaella/0000-0003-1369-0496				ANDERSON SM, 1990, ONCOGENE, V5, P317; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BLANDINO G, 1995, ONCOGENE, V10, P731; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBERGER JS, 1983, FED PROC, V42, P2762; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HUME DA, 1983, J EXP MED, V158, P1522, DOI 10.1084/jem.158.5.1522; KRUGER A, 1991, ONCOGENE, V6, P245; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; MAVILIO F, 1989, ONCOGENE, V4, P301; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; ROVERA G, 1987, ONCOGENE, V1, P29; Soddu S, 1996, MOL CELL BIOL, V16, P487; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; VALTIERI M, 1987, J IMMUNOL, V138, P3829	24	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					607	611		10.1038/sj.onc.1201218	http://dx.doi.org/10.1038/sj.onc.1201218			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247315				2022-12-28	WOS:A1997XN25500013
J	Freyaldenhoven, BS; Freyaldenhoven, MP; Iacovoni, JS; Vogt, PK				Freyaldenhoven, BS; Freyaldenhoven, MP; Iacovoni, JS; Vogt, PK			Avian winged helix proteins CWH-1, CWH-2 and CWH-3 repress transcription from Qin binding sites	ONCOGENE			English	Article						winged helix domain; transcriptional repression; DNA binding; repression domain	GENE FORK-HEAD; TUMOR ALVEOLAR RHABDOMYOSARCOMA; FAMILY; MEMBER; ONCOGENE; PAX3; RECOGNITION; BELONGS; FUSION	The chicken winged helix proteins, CWH-1, CWH-2 and CWH-3, were isolated and identified by homology cloning using the winged helix sequence of the retroviral oncogene qin as a probe. The CWH proteins act as growth stimulators in chicken embryo fibroblasts and in this activity resemble the Qin protein. Qin is a transcriptional regulator that functions as a repressor, and its oncogenic potential is correlated with the ability to repress transcription. In this communication we show that CWH proteins are localized in the cell nucleus, recognize the Qin DNA binding site and also function as transcriptional repressors. The repression activity of CWH-3 was mapped to the region of amino acids 211 to 311, a domain that is homologous to the major repression domain of Qin.	SCRIPPS RES INST, DIV ONCOVIROL, BCC239, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA	Scripps Research Institute			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BOEGE KA, 1995, GENE CHROMOSOME CANC, V12, P186; Chang HW, 1996, ONCOGENE, V13, P441; CHANG HW, 1995, P NATL ACAD SCI USA, V92, P447, DOI 10.1073/pnas.92.2.447; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1994, LIVER GENE TRANSCRIP, P183; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; FEDERSPIEL MJ, 1994, VIROLOGY, V203, P211, DOI 10.1006/viro.1994.1478; Freyaldenhoven BS, 1997, CANCER RES, V57, P123; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LI J, 1995, CANCER RES, V55, P5540; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; MADDEN SL, 1993, ONCOGENE, V8, P1713; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO DN, 1993, CANCER RES, V53, P5108; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7	29	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					483	488		10.1038/sj.onc.1201189	http://dx.doi.org/10.1038/sj.onc.1201189			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242385				2022-12-28	WOS:A1997XM23800013
J	Mattia, E; Chichiarelli, S; Hickish, T; Gaeta, A; Mancini, C; Cunningham, D; vanRenswoude, J				Mattia, E; Chichiarelli, S; Hickish, T; Gaeta, A; Mancini, C; Cunningham, D; vanRenswoude, J			Inhibition of in vitro proliferation of Epstein Barr Virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1	ONCOGENE			English	Article						EBV; LMP1 expression; antisense oligodeoxynucleotides	HODGKINS-DISEASE; GENE-EXPRESSION; DIFFERENTIATION; TRANSFORMATION		UNIV ROMA LA SAPIENZA,FAC MED & SURG,DEPT EXPT MED & PATHOL,ROME,ITALY; ROYAL MARSDEN HOSP,LYMPHOMA UNIT,SUTTON,SURREY,ENGLAND	Sapienza University Rome; Royal Marsden NHS Foundation Trust	Mattia, E (corresponding author), UNIV ROMA LA SAPIENZA,FAC MED & SURG,INST MICROBIOL,ROME,ITALY.		Chichiarelli, Silvia/F-1226-2011	Hickish, Tamas/0000-0001-6770-7279; Cunningham, David/0000-0001-5158-1069; Chichiarelli, Silvia/0000-0002-5682-0353				BROCKSMITH D, 1991, J PATHOL, V165, P11, DOI 10.1002/path.1711650104; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; CHEUNG RK, 1993, INT IMMUNOL, V5, P707, DOI 10.1093/intimm/5.7.707; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERBST H, 1990, AM J PATHOL, V137, P13; HERBST H, 1992, BLOOD, V80, P484; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; JOSKE DJL, 1992, BLOOD, V80, P2610; KHAN G, 1993, CANCER-AM CANCER SOC, V71, P3124, DOI 10.1002/1097-0142(19930515)71:10<3124::AID-CNCR2820711038>3.0.CO;2-J; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MILLER G, 1990, VIROLOGY, P1921; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; ROTH G, 1994, BLOOD, V84, P582, DOI 10.1182/blood.V84.2.582.bloodjournal842582; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B	23	12	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					489	493		10.1038/sj.onc.1201183	http://dx.doi.org/10.1038/sj.onc.1201183			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242386	Bronze			2022-12-28	WOS:A1997XM23800014
J	Amundadottir, LT; Leder, P				Amundadottir, LT; Leder, P			Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes	ONCOGENE			English	Article						signal transduction; mammary; transformation; oncogenes	EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE-C; HUMAN-BREAST-CANCER; GAP-ASSOCIATED PROTEINS; V-HA-RAS; TRANSGENIC MICE; TYROSINE KINASE; MAP KINASE; TGF-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE	We have assessed five signal transduction pathways to determine the role each might play in the malignant transformation of mammary epithelium initiated by neu, heregulin/NDF, TGF alpha, v-Ha-ras and c-myc in transgenic mice. The study involves a molecular and pharmacologic assessment of Erk/MAP kinase, Jnk/SAP kinase, PI 3-kinase, protein kinase C, and the Src-related kinases Lck and Fyn., Our results indicate that oncogenes capable of transforming mammary gland epithelium activate and require specific signal transduction pathways, For example, mammary tumors initiated by neu, v-Ha-ras as and c-myc have high levels of active Erk/MAP kinase and their anchorage independent growth is strongly inhibited by PD098059, an inhibitor of Mek/ MAP kinase kinase, By contrast, Erk/MAP I;kinase activity is weak in tumors initiated by TI;TFG alpha and heregulin/NDF and the corresponding cell lines are not growth inhibited by PD098059, Similarly, PI 3-kinase is strongly activated in neu, TGF alpha;! and heregulin/NDF initiated tumor cell lines, but not in c-myc or v-Ha-rns initiated tumor cell lines, The anchorage independent growth of all these tumor cell lines are, however, inhibited by the specific PI 3-kinase inhibitor LY294001. Further illustrating this oncogene-based specificity, PP1, a specific inhibitor of the Src-like kinases, Lck and Fyn, blocks anchorage-independent cell growth only in the TGF alpha;cl initiated mammary tumor cell line, Taken together with additional observations, we conclude that certain oncogenes reliably require the recruitment/activation of specific signal transduction pathways, Such specific relationships between the initiating oncogene and a required pathway may reflect a direct activating effect or the parallel activation of a pathway that is a necessary oncogenic collaborator for transformation in the mammary gland, The work points to a molecular basis for targeting therapy when an initiating oncogene can be implicated; for example, because of amplification, increased expression, genetic alteration, or heritable characteristics.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Amundadottir, LT (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.		Amundadottir, Laufey T/L-7656-2016	Amundadottir, Laufey T/0000-0003-1859-8971				AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; Amundadottir LT, 1996, ONCOGENE, V13, P757; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DANKORT AL, 1997, MOL CELL BIOL, V17, P5410; DAVIDSON NE, 1996, MAMMARY TUMOR CELL C, P91; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dolnikov A, 1996, ONCOGENE, V12, P1189; Dubik D, 1996, Cancer Treat Res, V83, P171; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HENNIPMAN A, 1989, CANCER RES, V49, P516; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang CS, 1996, MOL CELL BIOL, V16, P6427; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; JACOBS C, 1983, CANCER RES, V43, P1696; JANES PW, 1994, ONCOGENE, V9, P3601; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Krane IM, 1996, ONCOGENE, V12, P1781; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTE BM, 1995, ONCOGENE, V10, P167; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORRISON BW, 1994, ONCOGENE, V9, P3417; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARK S, 1992, J BIOL CHEM, V267, P17194; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SOLTOFF SP, 1992, COLD SPRING HARB SYM, V57, P75, DOI 10.1101/SQB.1992.057.01.010; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WYSS R, 1987, ANTICANCER RES, V7, P721	69	123	131	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					737	746		10.1038/sj.onc.1201829	http://dx.doi.org/10.1038/sj.onc.1201829			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488037	Bronze			2022-12-28	WOS:000071931800005
J	Zhang, Y; Fujita, N; Oh-hara, T; Morinaga, Y; Nakagawa, T; Yamada, M; Tsuruo, T				Zhang, Y; Fujita, N; Oh-hara, T; Morinaga, Y; Nakagawa, T; Yamada, M; Tsuruo, T			Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis	ONCOGENE			English	Article						endothelial cells; interleukin-11; bone metastasis; bone resorption	OSTEOCLAST DEVELOPMENT; MOLECULAR-CLONING; BREAST-CANCER; HEMATOPOIETIC CYTOKINE; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; MARROW CULTURES; IN-VITRO; RESORPTION; RECEPTOR	The interactions of the cells in the bone microenvironment play important roles in bone remodeling, Osteoblasts are involved in the bone remodeling through the production of soluble factors that regulate proliferation and differentiation of osteoclasts and through cell-cell interactions. Histological studies have suggested that endothelial cells are also associated with some osteolytic bone diseases, However, it is still unclear how endothelial cells contribute to bone resorption, We established bone-derived endothelial cells (BDECs) to study their roles in bone remodeling, The established BDECs promoted bone resorption in a murine neonatal calvaria organ culture system by secreting a soluble bone resorption-inducing factor(s) when stimulated by several inflammatory cytokines. This bone resorption-inducing factor was identified as interleukin-ll (IL-11). IL-11 is known to enhance bone resorption by promoting osteoclastogenesis and by suppressing the activity of osteoblasts, The production of IL-11 in BDECs was also promoted by conditioned medium of human melanoma A375M cells, Because A375M cells formed osteolytic bone metastasis in vivo, BDECs might be involved in pathological osteolysis by producing IL-11, These results suggest that endothelial cells in bone play important roles in the promotion of bone resorption by secreting IL-11 in physiological and pathological conditions.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 170, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.		Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				ALAM ASMT, 1992, ENDOCRINOLOGY, V130, P3617, DOI 10.1210/en.130.6.3617; Bellido T, 1996, J CLIN INVEST, V97, P431, DOI 10.1172/JCI118432; Burki F, 1987, Prog Clin Biol Res, V243A, P569; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CHEREL M, 1995, BLOOD, V86, P2534; COLLINOSDOBY P, 1994, J CELL BIOCHEM, V55, P304, DOI 10.1002/jcb.240550306; DICKSON GR, 1990, BONE, V11, P205, DOI 10.1016/8756-3282(90)90215-K; DICKSON GR, 1987, HISTOCHEMISTRY, V87, P569, DOI 10.1007/BF00492472; ELIAS JA, 1995, ENDOCRINOLOGY, V136, P489, DOI 10.1210/en.136.2.489; FORMIGLI L, 1995, J CELL PHYSIOL, V162, P199, DOI 10.1002/jcp.1041620206; FUJITA N, 1993, CANCER RES, V53, P5022; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GUENTHER HL, 1986, ENDOCRINOLOGY, V119, P193, DOI 10.1210/endo-119-1-193; HENDRIX MJC, 1990, CANCER RES, V50, P4121; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HUGHES FJ, 1993, CALCIFIED TISSUE INT, V53, P362, DOI 10.1007/BF01351844; JAFFE H, ARCH SURG, V20, P355; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Lee SH, 1996, ONCOGENE, V13, P2131; MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756-3282(95)00180-L; MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312; MATSUDA T, 1988, EUR J IMMUNOL, V18, P951, DOI 10.1002/eji.1830180618; Morinaga Y, 1997, INT J CANCER, V71, P422, DOI 10.1002/(SICI)1097-0215(19970502)71:3<422::AID-IJC20>3.0.CO;2-G; Morris JC, 1996, EXP HEMATOL, V24, P1369; Noguchi K, 1996, ONCOGENE, V13, P39; OHISHI K, 1995, CLIN EXP METASTAS, V13, P287, DOI 10.1007/BF00133484; OHNUKI Y, 1980, CANCER RES, V40, P524; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PERKEL VS, 1990, CANCER RES, V50, P6902; Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581; ROODMAN GD, 1993, CALCIFIED TISSUE INT, V53, pS94, DOI 10.1007/BF01673412; SABATINI M, 1988, P NATL ACAD SCI USA, V85, P5235, DOI 10.1073/pnas.85.14.5235; SASAKI A, 1995, CANCER RES, V55, P3551; SOSKOLNE WA, 1979, CELL TISSUE RES, V203, P487; SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756-3282(95)00185-G; SUEN Y, 1994, BLOOD, V84, P4125, DOI 10.1182/blood.V84.12.4125.bloodjournal84124125; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; TASHJIAN AH, 1985, P NATL ACAD SCI USA, V82, P4535, DOI 10.1073/pnas.82.13.4535; TATSUTA T, 1992, J BIOL CHEM, V267, P20383; TRUETA J, 1963, J BONE JOINT SURG BR, V45, P402, DOI 10.1302/0301-620X.45B2.402; VILLANUEVA JE, 1990, J BONE MINER RES, V5, P733; WILKINS BS, 1995, J PATHOL, V177, P295, DOI 10.1002/path.1711770312; Yamada M, 1997, CANCER CHEMOTH PHARM, V40, P31, DOI 10.1007/s002800050621; YANG L, 1994, J BIOL CHEM, V269, P32732; YIN TG, 1993, J IMMUNOL, V151, P2555; YONEDA T, 1994, BREAST CANCER RES TR, V32, P73, DOI 10.1007/BF00666208; ZAIDI M, 1993, BONE, V14, P97, DOI 10.1016/8756-3282(93)90234-2	50	47	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					693	703		10.1038/sj.onc.1201581	http://dx.doi.org/10.1038/sj.onc.1201581			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488033				2022-12-28	WOS:000071931800001
J	Paciucci, R; Tora, M; Diaz, VM; Real, FX				Paciucci, R; Tora, M; Diaz, VM; Real, FX			The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro	ONCOGENE			English	Article						tissue-type plasminogen activator; urokinase-type plasminogen activator; urokinase receptor; annexin II; invasion; pancreas cancer	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; ENDOTHELIAL-CELL RECEPTOR; UROKINASE-RECEPTOR; ANNEXIN-II; EXTRACELLULAR-MATRIX; GENE-TRANSCRIPTION; CARCINOMA-CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; COLON ADENOCARCINOMAS	Plasminogen activators (PAs) play an important role in tumor cell invasion, We have analysed the expression of tissue-type PA (t-PA), urokinase-type PA (u-PA), and their respective receptors, annexin II and u-PAR, in normal and neoplastic cultures of pancreatic cells, as well as in pancreatic tissues, and have examined their role in tumor invasiveness in vitro. Using Northern blotting, Western blotting, and ELISA, t-PA is detected in cultured pancreas cancer cells displaying a well differentiated phenotype but it is undetectable in less differentiated cells and in normal pancreatic cultures, In contrast, u-PA transcripts, protein, and enzymatic activity are detected both in cancer cells and in normal cultures, Higher levels of u-PAR and annexin II are present in cancer cells than in normal cultures and, in SK-PC-1 cells, both receptors are localized in the basolateral membrane, In vitro invasion assays indicate that both t-PA and u-PA contribute to the invasiveness of SK-PC-1 cells through reconstituted extracellular matrix, To determine the relevance of these studies to pancreas cancer, immunohistochemical assays have been used to examine the expression of t-PA, u-PA, and their receptors in normal and neoplastic tissues, t-PA is absent from normal pancreas and from tumor associated pancreatitis, whereas it is detected in the majority of pancreas cancer tissues (16/17), Annexin II is also overexpressed in some tumors (5/13), u-PAR is overexpressed in most tumor samples examined (14/15), while u-PA is weakly detected in a low number of cases (3/14); both u-PAR and u-PA are overexpressed in areas of tumor associated pancreatitis, Indirect evidences indicate that K-ras and p53 mutated proteins can regulate the expression of PAs, In pancreatic cancer we have found an association between codon 12 K-ras mutations and t-PA expression (P=0.04). These results support the contention that, in the exocrine pancreas, activation of t-PA is more specifically associated to neoplastic transformation and to the invasive phenotype, whereas the induction of u-PA/u-PAR system might be more relevant to inflammatory or non-neoplastic events.	Inst Municipal Invest Med, Unit Biol Cellular & Mol, E-08003 Barcelona, Spain		Paciucci, R (corresponding author), Inst Municipal Invest Med, Unit Biol Cellular & Mol, E-08003 Barcelona, Spain.		Arribas, Francisco X Real/H-5275-2015; Díaz, Víctor Manuel/F-5013-2016; Paciucci, Rosanna/AGP-3844-2022	Arribas, Francisco X Real/0000-0001-9501-498X; Díaz, Víctor Manuel/0000-0001-8561-7576; Paciucci, Rosanna/0000-0001-5651-5933				AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BERROZPE G, 1994, INT J CANCER, V58, P185, DOI 10.1002/ijc.2910580207; Blasi Francesco, 1996, Seminars in Thrombosis and Hemostasis, V22, P513, DOI 10.1055/s-2007-999053; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CALDAS C, 1994, CANCER RES, V54, P3568; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARRATO C, 1994, GASTROENTEROLOGY, V107, P160, DOI 10.1016/0016-5085(94)90073-6; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Davis RG, 1995, J IMMUNOL METHODS, V188, P91, DOI 10.1016/0022-1759(95)00207-3; DEVRIES TJ, 1994, AM J PATHOL, V144, P70; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIESS H, 1996, PANCREATIC CANC MOL, P51; GRESS TM, 1995, INT J CANCER, V62, P407, DOI 10.1002/ijc.2910620409; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOORENS A, 1993, AM J PATHOL, V143, P685; HSU DW, 1995, AM J PATHOL, V147, P114; JANKUN J, 1991, CANCER RES, V51, P1221; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KALTHOFF H, 1993, ONCOGENE, V8, P289; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; LIMONGI P, 1995, FEBS LETT, V369, P207, DOI 10.1016/0014-5793(95)00742-R; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; LUND LR, 1991, EMBO J, V10, P3399, DOI 10.1002/j.1460-2075.1991.tb04904.x; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Malats N, 1997, INT J CANCER, V70, P661, DOI 10.1002/(SICI)1097-0215(19970317)70:6<661::AID-IJC6>3.0.CO;2-T; MARS WM, 1993, AM J PATHOL, V143, P949; MEDCALF RL, 1991, MOL ENDOCRINOL, V5, P1773, DOI 10.1210/mend-5-12-1773; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOSER TL, 1994, INT J CANCER, V56, P552, DOI 10.1002/ijc.2910560415; Moss SE, 1997, TRENDS CELL BIOL, V7, P87, DOI 10.1016/S0962-8924(96)10049-0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Nielsen BS, 1996, LAB INVEST, V74, P168; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Paciucci R, 1996, FEBS LETT, V385, P72, DOI 10.1016/0014-5793(96)00352-3; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; PARKKINEN J, 1991, J BIOL CHEM, V266, P16730; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PITTMAN RN, 1995, J NEUROCHEM, V64, P566; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; PYKE C, 1995, CANCER RES, V55, P4132; PYKE C, 1991, AM J PATHOL, V138, P1059; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STURZEBECHER J, 1988, FIBRINOLYSIS, V2, P49; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VERSPAGET HW, 1995, EUR J CANCER, V31A, P1105, DOI 10.1016/0959-8049(95)00170-N; Vila Maya R., 1994, Zentralblatt fuer Pathologie, V140, P225; VILA MR, 1994, LAB INVEST, V71, P423; VILA MR, 1995, LAB INVEST, V72, P395; VILA MR, 1995, LAB INVEST, V73, P409; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; WANG Y, 1994, FEBS LETT, V353, P138, DOI 10.1016/0014-5793(94)01032-3; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILSON EL, 1983, BLOOD, V61, P568; WILSON EL, 1987, J EXP MED, V165, P1609, DOI 10.1084/jem.165.6.1609	78	64	65	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					625	633		10.1038/sj.onc.1201564	http://dx.doi.org/10.1038/sj.onc.1201564			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482108				2022-12-28	WOS:000071816600007
J	Albertoni, M; Daub, DM; Arden, KC; Viars, CS; Powell, C; Van Meir, EG				Albertoni, M; Daub, DM; Arden, KC; Viars, CS; Powell, C; Van Meir, EG			Genetic instability leads to loss of both p53 alleles in a human glioblastoma	ONCOGENE			English	Article						glioma; brain tumour; PCR diagnosis; p53	WILD-TYPE P53; CELL-CYCLE; HUMAN CANCERS; EXPRESSION; AMPLIFICATION; LINES; DNA; CHECKPOINT; CYTOMETRY; MUTATIONS	Little is known about the relationship between genetic recombination mechanisms and loss of tumour suppressor genes in solid tumours. Here, we demonstrate deletion and truncation of both p53 alleles in a primary human glioblastoma and a derived cell line as the combined result of a t(17;20) reciprocal translocation and a 1.1 Mbp genomic deletion on chromosome 17p, starting in intron 4 of the p53 gene and ending at the telomeric CA-repeat marker D17S960. These results (i) suggest that genetic instability can lead to loss of tumour suppressor function in solid cancers, (ii) provide mapping of one such recombination event at the nucleotide level, and (iii) establish the orientation of the p53 gene on chromosome 17 as: centromere 5'-3'-telomere.	CHU Vaudois BH19 109, Dept Neurosurg, Lab Tumour Biol & Genet, CH-1011 Lausanne, Switzerland; Ludwig Inst Canc Res, San Diego, CA 92093 USA; LabCorp, Mol Biol & Pathol, Res Triangle Pk, NC 27709 USA	Ludwig Institute for Cancer Research	Van Meir, EG (corresponding author), CHU Vaudois BH19 109, Dept Neurosurg, Lab Tumour Biol & Genet, CH-1011 Lausanne, Switzerland.			Van Meir, Erwin G./0000-0003-2444-7707				BERMINGHAM JR, 1995, GENOMICS, V29, P70, DOI 10.1006/geno.1995.1216; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Di Leonardo A, 1997, CANCER RES, V57, P1013; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; LUZI P, 1994, CYTOMETRY, V18, P79, DOI 10.1002/cyto.990180205; MAKOSWALES M, 1995, NAT MED, V1, P570; Marchevsky A, 1996, CYTOMETRY, V26, P101; MCPHERSON MJ, 1991, PCR PRACTICAL APPROA, P137; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEYN MS, 1994, INT J RADIAT BIOL, V66, P141; MILLER CW, 1990, CANCER RES, V50, P7950; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PELTOMAKI P, 1993, CANCER RES, V53, P5853; POGRIBNY IP, 1995, CANCER RES, V55, P1894; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; STUDER A, 1985, ACTA NEUROPATHOL, V66, P208, DOI 10.1007/BF00688585; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VAN MEIR EG, 1994, CANCER RES, V54, P649; VANMEYEL DJ, 1994, JNCI-J NATL CANCER I, V86, P1011, DOI 10.1093/jnci/86.13.1011; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	33	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					321	326		10.1038/sj.onc.1201544	http://dx.doi.org/10.1038/sj.onc.1201544			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467957				2022-12-28	WOS:000071582100004
J	Darby, TG; Meissner, J; Ruhlmann, A; Mueller, WH; Scheibe, RJ				Darby, TG; Meissner, J; Ruhlmann, A; Mueller, WH; Scheibe, RJ			Functional interference between retinoic acid or steroid hormone receptors and the oncoprotein Fli-1	ONCOGENE			English	Article						cross-talk; Fli-1; hormone nuclear receptors; repression; erythroleukemia	HUMAN GLUCOCORTICOID RECEPTOR; PROVIRAL INTEGRATION SITE; ONCOGENE FAMILY MEMBER; MURINE LEUKEMIA-VIRUS; ETS GENE FAMILY; A-I GENE; THYROID-HORMONE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; CELL-DIFFERENTIATION	The Fli-1 protein is a member of the ets proto-oncogene family, whose overexpression is a consequence of Friend murine leukemia virus (F-MuLV) integration in Friend erythroleukemic cells. We present evidence that Fli-1 and the retinoic acid receptor (RAR alpha) can reciprocally repress one another's transcriptional activation. Overexpression of Fli-1 inhibits the retinoic acid-induced activation of genes carrying a functional retinoic acid response element (RARE), Conversely, RAR alpha is able to repress Fli-1-mediated transcriptional activation. Transfection analysis of RAR alpha and Fli-1 mutants in cultured cells demonstrate that the DNA binding domain of RAR alpha and the N-terminal region of Fli-1 are required for repression, Gel retardation analysis demonstrates that RAR alpha cannot bind to the Fli-1 binding site in the E74 promoter and the expression of Fli-1 does not affect RAR alpha binding to DIVA, Furthermore, the data suggest an indirect interaction between Fli-1 and RAR alpha mediated by a 'bridging' factor(s) present in nuclear extracts from RM10 erythroleukemia cells, Fli-1 also interferes with the action of receptors for thyroid or glucocorticoid hormone in several hematopoietic cell lines, The RA-induced differentiation and decrease of cell proliferation was blocked in myeloblastic leukemia HL-60 cells overexpressing the N-terminal region of Fli-1 at physiological concentrations of RA. These data suggest that accumulation of Fli-1 can oppose the transcriptional activity of hormone receptors in hematopoietic cells.	Hannover Med Sch, Zentrum Biochem, Dept Clin Chem, D-30623 Hannover, Germany; Hannover Med Sch, Zentrum Biochem, Inst Physiol, D-30623 Hannover, Germany; Max Delbruck Zentrum, Berlin, Germany; Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany	Hannover Medical School; Hannover Medical School; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Hannover Medical School	Scheibe, RJ (corresponding author), Hannover Med Sch, Zentrum Biochem, Dept Clin Chem, D-30623 Hannover, Germany.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Blomhoff R., 1994, VITAMIN A HLTH DIS; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CELADA A, 1992, J IMMUNOL, V148, P1102; CHAMBON P, 1991, FAMILY RETINOIC ACID; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; Chesnut JD, 1996, J IMMUNOL METHODS, V193, P17, DOI 10.1016/0022-1759(96)00032-4; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1991, RETINOIC ACID RECEPT; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GLASS CK, 1991, REGULATION GNEE TRAN; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HROMAS R, 1993, BLOOD, V82, P2998; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; Kastner P, 1994, ROLE NUCL RETINOIC A; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LESSNICK SL, 1995, ONCOGENE, V10, P423; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1994, RETINOID RECEPTORS R; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PFAHL M, 1991, MOL MECH RETINOIC AC; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1990, ONCOGENE, V5, P1761; SHYAM E, 1990, CANCER RES, V50, P5013; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SPORN MB, 1994, RETINOIDS; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	88	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3067	3082		10.1038/sj.onc.1201503	http://dx.doi.org/10.1038/sj.onc.1201503			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444955				2022-12-28	WOS:000070968000007
J	Curtis, DJ; Robb, L; Strasser, A; Begley, CG				Curtis, DJ; Robb, L; Strasser, A; Begley, CG			The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice	ONCOGENE			English	Article						scl; tal-1; p53; ras; lymphomagenesis	ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEIN; PEDIATRIC-ONCOLOGY-GROUP; SCL GENE-PRODUCT; WILD-TYPE P53; CELL LEUKEMIA; ERYTHROID-DIFFERENTIATION; THYMOCYTE DEVELOPMENT; POINT MUTATIONS; TAL1	Abnormal expression of SCL (TAL-1/TCL5) occurs in the majority of paediatric cases of acute T-cell lymphoblastic leukemia (T-ALL), Unexpectedly however, transgenic mice carrying scl coupled to the human T-cell specific CD2 enhancer (CD2-scl) did not spontaneously develop T-cell lymphomas despite high levels of scl expression in their thymocytes, Analogous to other transgenic models of lymphomagenesis, it is likely that additional genetic abnormalities are required to cooperate with scl to trigger lymphomagenesis, Two possible candidates are the p53 and N-ras genes which are mutated in some cases of T-ALL, particularly in relapsed disease, Therefore, we examined lymphomagenesis in the progeny of CD2-scl mice crossed with N-ras transgenic mice or p53 deficient, Surprisingly, the frequency of lymphomas in the p53 nullizygous or N-ras transgenic mice was not enhanced by expression of the scl transgene, In fact, expression of scl in both genetic backgrounds paradoxically reduced the frequency of thymic lymphomas and, at least in the p53 nullizygous mice, shifted the pattern of organ involvement to the peripheral lymphoid organs, In contrast, CD2-scl transgene expression accelerated lymphomagenesis in p53 heterozygous mice, These data suggest that the collaborative effects of scl with N-ras or p53 vary according to the developmental stage of the T-cell.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC, AUSTRALIA; ROYAL MELBOURNE HOSP, COOPERAT RES CTR CELLULAR GROWTH FACTORS, MELBOURNE, VIC, AUSTRALIA; ROYAL MELBOURNE HOSP, ROTARY BONE MARROW RES LAB, MELBOURNE, VIC, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Royal Melbourne Hospital			Strasser, Andreas/C-7581-2013; Curtis, David/H-4996-2014	Strasser, Andreas/0000-0002-5020-4891; Curtis, David/0000-0001-9497-0996	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1992, CANCER SURV, V15, P119; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BORN W, 1988, J IMMUNOL, V140, P3228; BOS JL, 1989, CANCER RES, V49, P4682; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; Condorelli GL, 1996, CANCER RES, V56, P5113; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DICCIANNI MB, 1994, BLOOD, V84, P3105; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELWOOD NJ, 1993, ONCOGENE, V8, P3093; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; LANIER LL, 1986, J IMMUNOL, V137, P2501; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; LUBBERT M, 1990, BLOOD, V75, P1163; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PURDIE CA, 1994, ONCOGENE, V9, P603; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROBB L, 1995, ONCOGENE, V10, P205; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADA M, 1993, BLOOD, V82, P3163; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	45	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	1997	15	24					2975	2983		10.1038/sj.onc.1201467	http://dx.doi.org/10.1038/sj.onc.1201467			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416841				2022-12-28	WOS:A1997YK37700010
J	Beham, A; Marin, MC; Fernandez, A; Herrmann, J; Brisbay, S; Tari, AM; LopezBerestein, G; Lozano, G; Sarkiss, M; McDonnell, TJ				Beham, A; Marin, MC; Fernandez, A; Herrmann, J; Brisbay, S; Tari, AM; LopezBerestein, G; Lozano, G; Sarkiss, M; McDonnell, TJ			Bcl-2 inhibits p53 nuclear import following DNA damage	ONCOGENE			English	Article						apoptosis; bcl-2; nuclear import; p53; prostate cancer	PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; P53-DEPENDENT APOPTOSIS; P53-MEDIATED APOPTOSIS; CARCINOMA-CELLS; LYMPHOID-CELLS; CYCLE ARREST; G(1) ARREST; IN-VIVO; PROTEIN	Bcl-2 is an integral membrane oncoprotein that localizes to membranes of the mitochondria, endoplasmic reticulum, and nuclear envelope, Bcl-2 is a member of a family of cell death regulators and functions to inhibit apoptosis, Using confocal microscopy and immunoblotting we show that the ability of bcl-2 to suppress cell death following genotoxic damage can be a consequence of inhibiting nuclear import of induced wild-type p53 protein, Our data suggests that the ability of bcl-2 to modulate trafficking events is not cell type specific, These data support a 'gatekeeper' mechanism for cell death suppression by bcl-2.	UNIV TEXAS,MD ANDERSON CANCER CTR,DIV MOL PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT IMMUNOBIOL & DRUG CARRIERS,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Marin, Maria C/G-1040-2010; Sarkiss, Mona/AAX-1346-2020; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X	NCI NIH HHS [CA09255] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; CAELLES C, 1994, NATURE, V370, P174; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DEJONG D, 1994, CANCER RES, V54, P256; ELKIND NB, 1995, ONCOGENE, V11, P841; FRITSCHE M, 1993, ONCOGENE, V8, P307; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jordan J, 1997, J NEUROSCI, V17, P1397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAM D, 1994, P NATL ACAD SCI USA, V9, P6569; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARIN MC, 1994, ONCOGENE, V9, P3107; Marin MC, 1996, ONCOGENE, V12, P2259; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; McDonnell TJ, 1997, J UROLOGY, V157, P569, DOI 10.1016/S0022-5347(01)65204-2; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAGASAWA H, 1995, CANCER RES, V55, P1842; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; TU SM, 1995, CANCER LETT, V93, P147, DOI 10.1016/0304-3835(95)03795-X; Wang YS, 1996, ONCOGENE, V12, P2731; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YonishRouach E, 1996, EXPERIENTIA, V52, P1001, DOI 10.1007/BF01920109; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	43	80	83	1	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2767	2772		10.1038/sj.onc.1201464	http://dx.doi.org/10.1038/sj.onc.1201464			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419967				2022-12-28	WOS:A1997YJ80300002
J	deMora, JF; Uren, A; Heidaran, M; Santos, E				deMora, JF; Uren, A; Heidaran, M; Santos, E			Biological activity of p27(kip1) and its amino- and carboxy-terminal domains in G2/M transition of Xenopus oocytes	ONCOGENE			English	Article						p27(kip1); Xenopus oocytes; cell cycle; cdc2 kinase; MPF; GVBD	DEPENDENT-KINASE INHIBITOR; P34CDC2 PROTEIN-KINASE; FIBROBLAST CELL-CYCLE; PHOSPHORYLATION SITES; TYROSINE PHOSPHATASE; ACTIVATING KINASE; CDK6 INHIBITOR; CDC2; P27; CLONING	p27(kip1) is a general inhibitor of Cdks that preferentially accumulates and functions during G1 phase, before the restriction point of the mammalian cell cycle. We observed that injection of purified p27(kip1) into Xenopus oocytes potently inhibits the G2/M transition and activation/dephosphorylation of the maturation promoting factor (MPF, p34(cdc2)/cyclin B complex) kinase associated with germinal vesicle breakdown (GVBD) induced by progesterone or insulin. Addition of exogenous p27(kip1) in vitro to lysates of hormonally matured oocytes blocked the enzymatic activity of the activated MPF kinase present in those extracts. Interestingly, the isolated amino-terminal region of p27(kip1) (p27N), encompassing only the Cdk binding site, exhibited a similar inhibitory behavior in vitro and a weaker inhibitory effect in vivo than the complete p27(kip1) protein. Surprisingly, the remaining carboxy-terminal region of p27(kip1) (p27C) actually induced GVBD when injected alone into the oocytes, and also accelerated the kinetics of insulin-or progesterone-induced GVBD. Consistent with the in vivo observations, p27C formed a complex with, and activated, the MPF kinase in lysates of immature oocytes, although this activation was blocked by simultaneous addition of p27N or complete p27(kip1). Active MPF was able to phosphorylate p27C only in the absence of p27N or whole p27(kip1), suggesting that the inhibitory activity associated with the amino terminus is dominant over the activation produced by p27C. These results demonstrate the functional interaction of p27(kip1) with cyclin B/p34(cdc2) complexes during G2/M progression in oocytes, and suggest that the amino and carboxy terminal portions of this protein may play opposite regulatory roles, reminiscent of the corresponding N- and C-terminal portions of p21(waf). We speculate that accumulation of a truncated, C-terminal p27 fragment may play a physiological regulatory role in progression through G2 and later stages of the cell cycle.			deMora, JF (corresponding author), NCI, MOL & CELLULAR BIOL LAB, DBS, BETHESDA, MD 20892 USA.		de Mora, Jaime Font/H-6304-2015; de Mora, Jaime Font/AAK-7591-2021	de Mora, Jaime Font/0000-0002-6816-2095; de Mora, Jaime Font/0000-0002-6816-2095				APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GRIGORESCU F, 1994, HORM RES, V42, P5; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee TH, 1996, P NATL ACAD SCI USA, V93, P352, DOI 10.1073/pnas.93.1.352; LOUNDGREN K, 1991, CELL, V64, P1111; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MALLER JL, 1994, SEMIN DEV BIOL, V5, P138; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PALEMBELLA VJ, 1994, CELL, V78, P773; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang QM, 1996, CANCER RES, V56, P264	55	16	17	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2541	2551		10.1038/sj.onc.1201420	http://dx.doi.org/10.1038/sj.onc.1201420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399642				2022-12-28	WOS:A1997YG73200004
J	Gottgens, B; McLaughlin, F; Bockamp, EO; Fordham, JL; Begley, CG; Kosmopoulos, K; Elefanty, AG; Green, AR				Gottgens, B; McLaughlin, F; Bockamp, EO; Fordham, JL; Begley, CG; Kosmopoulos, K; Elefanty, AG; Green, AR			Transcription of the SCL gene in erythroid and CD34 positive primitive myeloid cells is controlled by a complex network of lineage-restricted chromatin-dependent and chromatin-independent regulatory elements	ONCOGENE			English	Article						SCL/TAL-1; transcription; regulation; chromatin; enhancer; silencer	LOCUS-CONTROL REGION; LOOP-HELIX PROTEIN; BETA-GLOBIN GENE; FACTOR GATA-1; HEMATOPOIETIC LINEAGES; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; TAL-1 GENE; DIFFERENTIATION; EXPRESSION	The SCL gene (also known as TAL-1) encodes a basic helix-loop-helix transcription factor that is essential for the development of all haematopoietic lineages, and ectopic expression of which results in T cell leukaemia, SCL is expressed in normal pluripotent haematopoietic stem cells and its expression is maintained during differentiation along erythroid, mast and megakaryocytic lineages, but is extinguished following commitment to other cell types, The mechanisms responsible for this pattern of expression are poorly understood, but are likely to illuminate the molecular basis for stem cell development and lineage commitment. We have identified multiple lineage-restricted DNase I hypersensitive sites in a 45 kb region spanning the murine SCL locus, Committed erythroid cells and CD34 positive primitive myeloid cells exhibited both shared and unique DNase I hypersensitive sites whereas none were found in T cells, The function of each hypersensitive site was studied using both transient and stable reporter assays in erythroid, primitive myeloid and T cells, Multiple positive and negative regulatory elements were characterised and found to display lineage-specificity, promoter-specificity and/or chromatin-dependence. These results represent the first description of key components of a complex network of regulatory elements controlling SCL expression during haematopoiesis.	UNIV CAMBRIDGE, CTR MRC, DEPT HAEMATOL, CAMBRIDGE CB2 2QH, ENGLAND; WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA	University of Cambridge; Walter & Eliza Hall Institute			Elefanty, Andrew G/A-6066-2008	Gottgens, Berthold/0000-0001-6302-5705; Green, Anthony/0000-0002-9795-0218; Bockamp, Ernesto/0000-0002-6181-1734; Elefanty, Andrew/0000-0001-6448-8314	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BENZ EJ, 1980, P NATL ACAD SCI-BIOL, V77, P3509, DOI 10.1073/pnas.77.6.3509; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; Bockamp EO, 1997, J BIOL CHEM, V272, P8781, DOI 10.1074/jbc.272.13.8781; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BONIFER C, 1994, NUCLEIC ACIDS RES, V22, P4202, DOI 10.1093/nar/22.20.4202; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CROSS MA, 1994, ONCOGENE, V9, P3013; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; ERNST P, 1995, IMMUNITY, V2, P311, DOI 10.1016/1074-7613(95)90139-6; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GOLDFARB AN, 1992, BLOOD, V58, P537; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HWANG LY, 1993, ONCOGENE, V8, P3043; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; LEROYVIARD K, 1994, BLOOD, V84, P3819, DOI 10.1182/blood.V84.11.3819.bloodjournal84113819; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MAY G, 1995, EMBO J, V14, P564, DOI 10.1002/j.1460-2075.1995.tb07032.x; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MOUTHON MA, 1993, BLOOD, V81, P647; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P187; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZEHETNER G, 1994, NATURE, V367, P489, DOI 10.1038/367489a0; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	79	53	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	1997	15	20					2419	2428		10.1038/sj.onc.1201426	http://dx.doi.org/10.1038/sj.onc.1201426			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395238				2022-12-28	WOS:A1997YE96300004
J	Fukasawa, K; Wiener, F; VandeWoude, GF; Mai, SB				Fukasawa, K; Wiener, F; VandeWoude, GF; Mai, SB			Genomic instability and apoptosis are frequent in p53 deficient young mice	ONCOGENE			English	Article						p53; genomic instability; gene amplification; centrosome; Myc; apoptosis	CELL-CYCLE CONTROL; WILD-TYPE P53; DIHYDROFOLATE-REDUCTASE GENE; C-MYC; CANCER-CELLS; AMPLIFICATION; OVEREXPRESSION; CHECKPOINT; ONCOGENES; MOUSE	The loss of p53 tumor suppressor functions results in genetic instability, characteristically associated with changes in chromosome ploidy and gene amplification. In vivo, we find that cells from various organs of 4 to 6-week old p53-nullizygous (p53 (-/-)) mice display aneuploidy and frequent gene amplification as well as evidence for apoptosis. Regardless of tissue types, many p53 (-/-) cells contain multiple centrosomes and abnormally formed mitotic spindles. Thus, chromosome vivo may be associated with abnormal Moreover, we observed a significant increase in the number of cells overexpressing c-Myc in p53 (-/-) mice. Consistent with previous studies showing that c-Myc overexpression is associated with gene amplification in vitro, many of the p53 (-/-) cells exhibited, in the same cell, c-Myc overexpression and amplified c-myc, dihydrofolate reductase (DHFR), and carbamoyl-phosphate synthetase-aspartate transcarbamoyl-dihydroorotase (CAD) genes. Furthermore, apoptosis was frequently observed in cells isolated from p53 (-/-) mice. The apoptotic cells contained abnormally amplified centrosomes, displayed aneuploidy, high levels of c-Myc expression, as web as gene amplification. These results indicate that a high number of aberrant cells is eliminated by p53-independent pathways in vivo.	MANITOBA CANC TREATMENT & RES FDN, MANITOBA INST CELL BIOL, WINNIPEG, MB R3E 0V9, CANADA; UNIV MANITOBA, DEPT PHYSIOL, WINNIPEG, MB R3E 0V9, CANADA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; UNIV CINCINNATI, COLL MED, DEPT CELL BIOL NEUROBIOL & ANAT, CINCINNATI, OH USA; KAROLINSKA INST, CTR MICROBIOL & TUMOR BIOL, S-17177 STOCKHOLM, SWEDEN	University of Manitoba; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University System of Ohio; University of Cincinnati; Karolinska Institutet			Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201				ALITALO K, 1985, TRENDS BIOCHEM SCI, V10, P194, DOI 10.1016/0968-0004(85)90190-2; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; BISHOP JM, 1995, GENE DEV, V9, P1309, DOI 10.1101/gad.9.11.1309; BLYTH K, 1995, ONCOGENE, V10, P1717; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENIS N, 1991, ONCOGENE, V6, P1453; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEO S, 1994, ONCOGENE, V9, P955; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hessel H, 1996, HISTOCHEM CELL BIOL, V106, P481, DOI 10.1007/BF02473310; HSU B, 1995, ONCOGENE, V11, P175; HUANG AP, 1994, ONCOGENE, V9, P491; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; KARN J, 1989, ONCOGENE, V4, P773; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KUSCHAK TI, 1997, UNPUB; LI X, 1995, CYTOMETRY, V20, P172, DOI 10.1002/cyto.990200210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAI S, 1995, GENOME, V38, P780, DOI 10.1139/g95-099; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; Mai S, 1996, ONCOGENE, V12, P277; MAI S, 1997, UNPUB; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; OTTO E, 1989, J BIOL CHEM, V264, P3390; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PIENTA KJ, 1989, CANCER RES, V49, P2525; RAGIMOV N, 1993, ONCOGENE, V8, P1183; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STARK G, 1993, ADV CANCER RES, V48, P87; STEWART N, 1995, ONCOGENE, V10, P109; TEMIN HM, 1988, CANCER RES, V48, P1697; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WAHL GM, 1989, CANCER RES, V49, P1333; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	49	133	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1295	1302		10.1038/sj.onc.1201482	http://dx.doi.org/10.1038/sj.onc.1201482			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315097				2022-12-28	WOS:A1997XV84500007
J	Sakamuro, D; Sabbatini, P; White, E; Prendergast, GC				Sakamuro, D; Sabbatini, P; White, E; Prendergast, GC			The polyproline region of p53 is required to activate apoptosis but not growth arrest	ONCOGENE			English	Article						p53; apoptosis; transformation; cell cycle	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; NUCLEAR TYROSINE KINASE; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; E1A-INDUCED APOPTOSIS; EMBRYO FIBROBLASTS	p53 is a pivotal regulator of apoptosis but its mechanism of action is obscure. We report that the polyproline (PP) region located between p53's transactivation and DNA binding domains is necessary to induce apoptosis but not cell growth arrest. The PP region was dispensable for DNA binding, inhibition of SAOS-2 tumor cell growth, suppression of E1A+RAS cell transformation, and cell cycle inhibition. A temperature-sensitive dominant inhibitory p53 mutant lacking PP (p53ts Delta PP) retained its ability to cooperate with adenovirus E1A in transformation of primary BRK cells. However, while activation of wt p53 induced apoptosis in E1A+p53ts-transformed cells, activation of p53 Delta PP induced cell cycle arrest but not apoptosis in E1A+p53ts Delta PP-transformed cells. Similarly, PP deletion abolished apoptosis in LoVo colon carcinoma cells, which are killed by wt p53 overexpression. Transactivation was largely unaffected by PP deletion, Significantly, BAX induction was intact, indicating that additional events are required for p53 to induce apoptosis. As a recently described site for familial mutation in at least one breast cancer family, the PP region represents a domain that may be altered in human tumors. We concluded that p53's ability to induce apoptosis is dispensable for inhibiting cell growth and transformation and that the PP region plays a crucial role in apoptotic signaling.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,DEPT MOL BIOL & BIOCHEM,PISCATAWAY,NJ 08854; CANC INST NEW JERSEY,PISCATAWAY,NJ 08854	The Wistar Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey			White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA60088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CRAVEN RJ, 1995, CANCER RES, V55, P3969; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GOGA A, 1995, ONCOGENE, V11, P791; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hansen R, 1995, ONCOGENE, V11, P2535; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HULBOY DL, 1994, CELL GROWTH DIFFER, V5, P1023; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1995, ONCOGENE, V11, P2311; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STEWART N, 1995, ONCOGENE, V10, P109; Sun XF, 1996, ONCOGENE, V13, P407; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197	74	246	253	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					887	898		10.1038/sj.onc.1201263	http://dx.doi.org/10.1038/sj.onc.1201263			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285684				2022-12-28	WOS:A1997XR76700002
J	Xie, KP; Wang, YF; Huang, SY; Xu, L; Bielenberg, D; Salas, T; McConkey, DJ; Jiang, WD; Fidler, IJ				Xie, KP; Wang, YF; Huang, SY; Xu, L; Bielenberg, D; Salas, T; McConkey, DJ; Jiang, WD; Fidler, IJ			Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2	ONCOGENE			English	Article						metastasis; nitric oxide; Bcl-2; apoptosis	VASCULAR ENDOTHELIAL-CELLS; L-ARGININE; CANCER METASTASIS; HUMAN PLATELETS; B-LYMPHOCYTES; TUMOR-CELLS; DEATH; MACROPHAGES; INDUCTION; PATHWAY	Recent studies have shown that the treatment of nonmetastatic K-1735 murine melanoma cells with cytokines induces the production of nitric oxide (NO) and hence cell death, The purpose of this study was to determine the mechanism of this cytokine-induced NO-mediated apoptosis. Incubation of nonmetastatic K-1735 cells with interleukin-1 alpha (IL-1 alpha) and interferon-gamma (IFN-gamma) induced high NO production, Bcl-2 downregulation, and apoptotic cell death, In contrast, incubation of metastatic K-1735 cells with IL-1 alpha. and IFN-gamma did not induce significant production of NO, downregulation of Bcl-2, or cell death. The exposure to exogenous NO derived from the NO donors, sodium nitroprusside (SNP), or GEA5024 produced a dose-dependent apoptotic cell death in both the metastatic and nonmetastatic K-1735 cells, which was associated with downregulation of Bcl-2 at the mRNA level and, to a lesser extent, at the protein level, Nonmetastatic and metastatic K-1735 cells transfected with the Bcl-2 gene were more resistant to apoptosis mediated by both endogenous and exogenous NO, Subsequent to intravenous injection, the tumor cells transfected with the Bcl-2 gene had an increased survival rate in the lungs of nude mice and produced a higher number of experimental lung metastases, These data suggest that NO-induced apoptosis in K-1735 melanoma cells is associated with downregulation of Bcl-2.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Xu, Lei/GRR-9174-2022		NCI NIH HHS [CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUKERMAN SL, 1986, JNCI-J NATL CANCER I, V77, P915; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BERGELSON S, 1994, CANCER RES, V54, P36; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Brune B, 1995, TOXICOL LETT, V82-3, P233, DOI 10.1016/0378-4274(95)03481-1; CHUN SY, 1995, ENDOCRINOLOGY, V136, P2121; CORRALIZA IM, 1993, BIOCHEM BIOPH RES CO, V196, P342, DOI 10.1006/bbrc.1993.2254; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DING AH, 1988, J IMMUNOL, V141, P2407; DONG ZY, 1994, CANCER RES, V54, P789; ELMORE L, 1996, P AACR ANN M, V37, pA119; FANG W, 1995, J IMMUNOL, V155, P66; FIDLER IJ, 1985, CANCER RES, V45, P4714; FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; FIDLER IJ, 1986, CANCER RES, V46, P5167; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Geng YJ, 1996, CANCER RES, V56, P866; GLAVES D, 1986, INVAS METAST, V6, P101; HANNA N, 1980, J NATL CANCER I, V65, P801, DOI 10.1093/jnci/65.4.801; Herberman R B, 1989, Prog Clin Biol Res, V288, P161; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; Hockenbery D M, 1992, Semin Immunol, V4, P413; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFMANN M, 1991, CANCER RES, V51, P5292; Huang SY, 1996, ONCOGENE, V13, P2339; IGNARRO LJ, 1990, P NATL ACAD SCI USA, V87, P5193; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEWISMOLOCK Y, 1994, AM J RESP CELL MOL, V10, P133, DOI 10.1165/ajrcmb.10.2.8110468; LI L, 1991, CANCER RES, V51, P245; LI LM, 1991, CANCER RES, V51, P2531; LIN JK, 1992, CANCER RES, V52, P385; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MartinSanz P, 1996, HEPATOLOGY, V23, P1200; McConkey DJ, 1996, J IMMUNOL, V156, P2624; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PRICE JE, 1986, CANCER RES, V46, P5172; Radinsky R, 1991, Semin Cancer Biol, V2, P169; RADINSKY R, 1994, ONCOGENE, V9, P1977; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; RADOMSKI MW, 1990, BRIT J PHARMACOL, V101, P325, DOI 10.1111/j.1476-5381.1990.tb12709.x; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Sato H., 1976, FUNDAMENTAL ASPECTS, V11, P311; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SUGIMOTO Y, 1987, CANCER RES, V47, P4396; TALMADGE JE, 1982, SCIENCE, V217, P361, DOI 10.1126/science.6953592; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSURUO T, 1986, CLIN EXP METASTAS, V7, P25; WEISS L, 1986, Cancer Reviews, V3, P1; WEISS L, 1986, J THEOR BIOL, V121, P307, DOI 10.1016/S0022-5193(86)80110-2; WHITWORTH PW, 1990, CANCER METAST REV, V8, P319, DOI 10.1007/BF00052607; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WILTROUT RH, 1979, CANCER RES, V39, P4034; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Xie KP, 1997, J NATL CANCER I, V89, P421, DOI 10.1093/jnci/89.6.421; XIE KP, 1995, CANCER RES, V55, P3123; Xie KP, 1996, J LEUKOCYTE BIOL, V59, P797, DOI 10.1002/jlb.59.6.797; XIE KP, 1993, INT J ONCOL, V3, P1043; Xie KP, 1996, CANCER IMMUNOL IMMUN, V43, P109, DOI 10.1007/s002620050310; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	70	77	82	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					771	779		10.1038/sj.onc.1201239	http://dx.doi.org/10.1038/sj.onc.1201239			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266963				2022-12-28	WOS:A1997XQ11700003
J	Kissil, JL; Feinstein, E; Cohen, O; Jones, PA; Tsai, YC; Knowles, MA; Eydmann, ME; Kimchi, A				Kissil, JL; Feinstein, E; Cohen, O; Jones, PA; Tsai, YC; Knowles, MA; Eydmann, ME; Kimchi, A			DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene	ONCOGENE			English	Article						serine/threonine kinase; death gene; tumor suppressor; methylation; 5'-azadeoxycytidine	HUMAN BLADDER-CANCER; DNA-METHYLATION; DEATH; APOPTOSIS; MEDIATOR; LEUKEMIA; BCL-2; P16	DAP-kinase is a novel calmodulin dependent serine/threonine kinase that carries ankyrin repeats and the death domain. It was recently isolated, by a functional selection approach of gene cloning, as a positive mediator of programmed cell death. In this study the expression of DAP-kinase was examined in the cell lines derived from various human neoplasms, DAP-kinase mRNA and protein expression were below the limit of detection in eight out of ten neoplastic derived B-cell lines. In six out of 14 examined bladder carcinoma, in three out of five renal cell carcinoma, and in four out of ten tested breast carcinoma cell lines, the DAP-kinase protein levels were below detection limits or lower than 1% compared to the positive cell lines. Interestingly, DAP-kinase expression could be restored in some of the negative bladder carcinoma and B-cell lines by treatment of cells with 5'-azadeoxycytidine that causes DNA demethylation. The high frequency of loss of DAP-kinase expression in human tumor cell lines, and the occasional involvement of methylation in this process raise the possibility that this novel mediator of cell death may function as a tumor suppressor gene.	WEIZMANN INST SCI, DEPT MOL GENET, IL-76100 REHOVOT, ISRAEL; UNIV SO CALIF, KENNETH NORRIS JR COMPREHENS CANC CTR, LOS ANGELES, CA 90033 USA; MARIE CURIE RES INST, MOL GENET LAB, OXTED RH8 0TL, SURREY, ENGLAND	Weizmann Institute of Science; University of Southern California				Knowles, Margaret/0000-0002-9363-8657	NCI NIH HHS [CA49758] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN A, 1991, BLOOD, V78, P94; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, LANCET, V342, P1184, DOI 10.1016/0140-6736(93)92169-T; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAKAI T, 1991, AM J HUM GENET, V48, P880; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; SKOLNICK MH, 1994, EUR J CANCER, V30A, P1991, DOI 10.1016/0959-8049(94)00392-I; TSAI YC, 1990, CANCER RES, V50, P44; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; TULCHINSKY E, 1995, BBA-GENE STRUCT EXPR, V1261, P243, DOI 10.1016/0167-4781(95)00013-7; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569	30	178	195	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	1997	15	4					403	407		10.1038/sj.onc.1201172	http://dx.doi.org/10.1038/sj.onc.1201172			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242376				2022-12-28	WOS:A1997XM23800004
J	Pasini, A; Geneste, O; Legrand, P; Schlumberger, M; Rossel, M; Fournier, L; Rudkin, BB; Schuffenecker, I; Lenoir, GM; Billaud, M				Pasini, A; Geneste, O; Legrand, P; Schlumberger, M; Rossel, M; Fournier, L; Rudkin, BB; Schuffenecker, I; Lenoir, GM; Billaud, M			Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain	ONCOGENE			English	Article						MEN2; MTC; RET proto-oncogene; tyrosine kinase	MEDULLARY-THYROID CARCINOMA; MEN 2A; CRYSTAL-STRUCTURE; CELL-LINE; PROTOONCOGENE; RECEPTOR; ISOFORMS; FAMILIES; DISEASE; GENE	Multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC) are two dominantly inherited disorders caused by germline mutations of the RET proto-oncogene. The RET gene codes for a receptor tyrosine kinase. The majority of MEN2A and FMTC mutations are clustered in the extra-cellular cysteine-rich domain and result in constitutive activation of the tyrosine kinase through the formation of disulfide-bonded RET homodimers. Recently, two novel paint mutations have been identified in the germline of five distinct FMTC families. Both mutations occur catalytic domain of the RET kinase and lead to the substitution of either glutamic acid 768 or valine 804 by an aspartic acid and a leucine respectively, We have introduced each FMTC mutation in two RET isoforms: RET51 the long isoform (1114 aa) and RET9 the short isoform (1072 aa) which differ in the C-terminal region of the protein. The RET51 isoform carrying either E768D or V804L mutation was autophosphorylated, displayed a transforming activity upon expression in Rat1 fibroblasts and induced neuronal differentiation of PC12 cells. However, the transforming capacity of these RET51-FMTC mutants was found to be severalfold less potent compared to the same isoform carrying either the MEN2A mutation (C634R) or the MEN2B mutation (M918T). In contrast, RET9 containing mutations E768D or V804L was not autophosphorylated, exhibited a poor oncogenic potential in fibroblasts and did not promote neuritic outgrowth upon expression in PC12 cells. Overall, these findings demonstrate that mutations E768D and V804L are gain-of-function mutations that confer to the long RET isoform the capacity to exert a biological effect, although these mutations are more weakly activating than the MEN2A and MEN2B mutations. These results may provide a biochemical basis as to why the phenotypic consequences of these mutations are restricted to thyroid C-cells.	UNIV LYON 1,GENET LAB,CNRS,UMR 5641,F-69372 LYON 08,FRANCE; INST BIOL STRUCT JEAN PIERRE EBEL,CEA,CNRS,CRISTALLOG & CRISTALLOGENESE PROT LAB,F-38027 GRENOBLE 1,FRANCE; INST GUSTAVE ROUSSY,NUCL MED SERV,F-94805 VILLEJUIF,FRANCE; UNIV UTAH,ECCLES INST HUMAN GENET 5440,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,CNRS,UMR 49,F-69364 LYON,FRANCE; HOP EDOUARD HERRIOT,GENET LAB,LYON 03,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); CHU Lyon			Billaud, Marc N/M-6954-2013; LEGRAND, Pierre/G-7709-2011	LEGRAND, Pierre/0000-0003-2431-2255; Rossel, Mireille/0000-0003-2275-0817; RUDKIN, Brian B./0000-0003-3700-1982				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOLINO A, 1995, ONCOGENE, V10, P2415; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Borrello MG, 1995, ONCOGENE, V11, P2419; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; ENG C, 1994, HUM MOL GENET, V3, P234; Fink M, 1996, INT J CANCER, V69, P312, DOI 10.1002/(SICI)1097-0215(19960822)69:4<312::AID-IJC13>3.0.CO;2-7; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Iwashita T, 1996, ONCOGENE, V12, P481; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LORENZO MJ, 1995, ONCOGENE, V10, P1377; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MULLIGAN LM, 1995, J CLIN ENDOCR METAB, V80, P1989, DOI 10.1210/jc.80.7.1989; MYERS SM, 1995, ONCOGENE, V11, P2039; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ROSSEL M, 1995, HUM GENET, V95, P403; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	48	82	82	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					393	402		10.1038/sj.onc.1201199	http://dx.doi.org/10.1038/sj.onc.1201199			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242375				2022-12-28	WOS:A1997XM23800003
J	Worpenberg, S; Burk, O; Klempnauer, KH				Worpenberg, S; Burk, O; Klempnauer, KH			The chicken adenosine receptor 2B gene is regulated by v-myb	ONCOGENE			English	Article						v-myb; oncogene; target gene; differential display; A2b adenosine receptor	C-MYB; CELL-LINES; MIM-1 GENE; MYELOMONOCYTIC CELLS; DIFFERENTIAL DISPLAY; DIFFERENT MECHANISMS; TRANS-ACTIVATION; NF-M; EXPRESSION; ONCOGENE	The retroviral oncogene v-myb is a mutated and truncated version of the c-myb proto-oncogene and encodes a transcription factor (v-Myb) that specifically transforms myelomonocytic cells. v-Myb is thought to transform myelomonocytic cells by affecting the expression of specific target genes, most of which as yet remain unknown. To identify novel v-Myb regulated genes we have employed 'differential display', using a myelomonocytic chicken cell line that expresses a conditional version of v-Myb. Here me describe the identification of the gene encoding the A2b adenosine receptor, a member of the seven transmembrane receptor superfamily, as a v-Myb target gene. Our results provide the first evidence that v-Myb directly regulates a gene encoding a membrane receptor and establish a link between Myb function and adenosine receptor signaling.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY; UNIV FREIBURG,KINDERKLIN,D-79106 FREIBURG,GERMANY	Max Planck Society; University of Freiburg								AKIYAMA Y, 1974, BIKEN J, V17, P105; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUMA MG, 1994, J IMMUNOL, V153, P4159; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CHEN LC, 1983, MOL CELL BIOL, V3, P1077, DOI 10.1128/MCB.3.6.1077; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DESBIENS X, 1991, DEVELOPMENT, V111, P699; EPPELL BA, 1989, J IMMUNOL, V143, P4141; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRISHAM MB, 1989, AM J PHYSIOL, V257, pH1334, DOI 10.1152/ajpheart.1989.257.5.H1334; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JURGENSEN CH, 1990, J IMMUNOL, V144, P653; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LEONARD MW, 1993, DEVELOPMENT, V119, P519; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MARQUARDT DL, 1984, J IMMUNOL, V133, P932; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; Mink S, 1996, MOL CELL BIOL, V16, P1316; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PARMELY MJ, 1993, J IMMUNOL, V151, P389; PLAZA S, 1995, ONCOGENE, V10, P329; QUEVA C, 1992, DEVELOPMENT, V114, P125; SALMON JE, 1993, J IMMUNOL, V151, P2775; Sitzmann J, 1995, ONCOGENE, V11, P2273; STERNECK E, 1992, J BIOL CHEM, V267, P6451; STILES GL, 1992, J BIOL CHEM, V267, P6451; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRUEB B, 1988, NUCLEIC ACIDS RES, V16, P4723, DOI 10.1093/nar/16.10.4723; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	48	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					213	221		10.1038/sj.onc.1201179	http://dx.doi.org/10.1038/sj.onc.1201179			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244356				2022-12-28	WOS:A1997XK37200009
J	Ivanchuk, SM; Myers, SM; Mulligan, LM				Ivanchuk, SM; Myers, SM; Mulligan, LM			Expression of RET 3 ' splicing variants during human kidney development	ONCOGENE			English	Article						kidney; RET; alternative splicing	MICE LACKING GDNF; TYROSINE KINASE; C-RET; HIRSCHSPRUNG DISEASE; RENAL AGENESIS; CELL-LINE; PROTOONCOGENE; RECEPTOR; DEFECTS; ISOFORMS	The mature mammalian kidney arises through a series of reciprocal inductive interactions between two different cell groups, the ureteric bud epithelium and the metanephric mesenchyme, The RET receptor tyrosine kinase is required for induction and development of the metanephric kidney. Differential splicing at the 3' end of RET results in transcripts encoding three isoforms that differ with respect to their C-terminal 9 (RET9), 51 (RET51) or 43 (RET43) amino acids, In vitro assays have identified differences in the abilities of the RET9 and RET51 isoforms to induce differentiation suggesting functional differences between these proteins. We examined the relative expression levels of the three RET 3' splicing variants in developing human kidney using semi-quantitative RT-PCR. We observed consistent expression of the RET9 and RET43 variants in kidney samples spanning 7.5 through 24 weeks gestation, At early gestational ages (7.5-8.5 weeks), RET51 expression was very low (+/-5%) compared to RET9; however, a rapid seven fold increase in expression was detected by 9 weeks. Our data suggest that RET51 may contribute to differentiation-related events occurring after 8.5 weeks gestation rather than to induction of the human kidney.	Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Paediat, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Mulligan, LM (corresponding author), Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada.							Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Chakravarti A, 1996, HUM MOL GENET, V5, P303; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durbec PL, 1996, DEVELOPMENT, V122, P349; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; Ivanchuk SM, 1997, ONCOGENE, V14, P1811, DOI 10.1038/sj.onc.1201016; KWOK JBJ, 1993, ONCOGENE, V8, P2575; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LORENZO MJ, 1995, ONCOGENE, V10, P1377; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Moore, 1982, DEV HUMAN; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MORRISON C, 1994, BBA-GENE STRUCT EXPR, V1219, P493, DOI 10.1016/0167-4781(94)90076-0; MYERS SM, 1995, ONCOGENE, V11, P2039; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Potter EL, 1972, NORMAL ABNORMAL DEV; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1990, ONCOGENE, V5, P1595; Saxen L., 1987, Developmental and Cell Biology Series, V19, P1; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249	34	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					991	996		10.1038/sj.onc.1201622	http://dx.doi.org/10.1038/sj.onc.1201622			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519873				2022-12-28	WOS:000072335900005
J	Yuille, MAR; Coignet, LJA; Abraham, SM; Yaqub, F; Luo, L; Matutes, E; Brito-Babapulle, V; Vorechovsky, I; Dyer, MJS; Catovsky, D				Yuille, MAR; Coignet, LJA; Abraham, SM; Yaqub, F; Luo, L; Matutes, E; Brito-Babapulle, V; Vorechovsky, I; Dyer, MJS; Catovsky, D			ATM is usually rearranged in T-cell prolymphocytic leukaemia	ONCOGENE			English	Article						T-prolymphocytic leukaemia; ATM; tumour suppressor; fluorescent in situ hybridization; single-strand conformation polymorphism; mutations	ATAXIA-TELANGIECTASIA GENE; LEUKEMIA; CANCER; HYBRIDIZATION; RECOMBINATION; MUTATIONS; DELETION; LYMPHOMA; REGION; LOCUS	T-prolymphocytic leukaemia (T-PLL) is a rare, sporadic leukaemia similar to a mature T-cell leukaemia seen in some patients with Ataxia Telangiectasia (A-T), a recessive multisystem disorder caused by mutations of the ATM gene at chromosome 11q23., ATM sequence mutations have been reported in 46% of T-PLL cases, but some cases also have karyotypic abnormalities at 11q, including 11q23., This led us to investigate the structure of the A TM locus in a panel of eight cases, two of which had 11q23 abnormalities, As expected, nucleotide changes were detected in some samples, Two remission samples were wild type, To test for structural lesions, DNA fibres were hybridized with a contig of four labelled cosmids spanning the A TM locus, In all samples there were structural lesions and in four samples both alleles were affected, This provides strong evidence for our suggestion that ATM acts as a tumour suppressor during T-PLL tumorigenesis. Some additional role for ATM during T-PLL tumorigenesis is possible since nucleotide changes were present in addition to structural lesions disrupting both alleles. The mechanism of inactivation appeared to be unusual because multiple structural Lesions on one allele were often observed,.	Royal Marsden Hosp, NHS Trust, Inst Canc Res, Acad Dept Haematol & Cytogenet, London SW3, England; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Karolinska Institutet	Yuille, MAR (corresponding author), Royal Marsden Hosp, NHS Trust, Inst Canc Res, Acad Dept Haematol & Cytogenet, London SW3, England.		Dyer, Martin/F-2691-2014	Dyer, Martin/0000-0002-5033-2236				Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; BAENS M, 1995, GENOMICS, V29, P44, DOI 10.1006/geno.1995.1213; BARTLETT RJ, 1989, LANCET, V1, P496; Bebb G, 1997, LANCET, V349, P1784, DOI 10.1016/S0140-6736(05)61687-X; BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; Coignet LJA, 1996, BLOOD, V87, P1512, DOI 10.1182/blood.V87.4.1512.bloodjournal8741512; DYER MJS, 1993, BLOOD, V82, P865, DOI 10.1182/blood.V82.3.865.bloodjournal823865; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Ginaldi L, 1996, BRIT J HAEMATOL, V93, P921, DOI 10.1046/j.1365-2141.1996.d01-1720.x; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; LAING NG, 1992, AM J MED GENET, V42, P688, DOI 10.1002/ajmg.1320420512; LIPKOWITZ S, 1990, J EXP MED, V172, P409, DOI 10.1084/jem.172.2.409; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; Pawson R, 1997, J CLIN ONCOL, V15, P2667, DOI 10.1200/JCO.1997.15.7.2667; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SEITE P, 1993, ONCOGENE, V8, P3073; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Vorechovsky I, 1996, CANCER RES, V56, P4130; Vorechovsky I, 1996, EUR J HUM GENET, V4, P352; Vorechovsky I, 1996, CANCER RES, V56, P2726; Yuille M. A. R., 1996, Blood, V88, p477A	27	69	70	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					789	796		10.1038/sj.onc.1201603	http://dx.doi.org/10.1038/sj.onc.1201603			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488043				2022-12-28	WOS:000071931800011
J	Nozaki, C; Asai, N; Murakami, H; Iwashita, T; Iwata, Y; Horibe, K; Klein, RD; Rosenthal, A; Takahashi, M				Nozaki, C; Asai, N; Murakami, H; Iwashita, T; Iwata, Y; Horibe, K; Klein, RD; Rosenthal, A; Takahashi, M			Calcium-dependent ret activation by GDNF and neurturin	ONCOGENE			English	Article						Ret; GDNF; neurturin; Ca2+ ion; neuroblastoma	MICE LACKING GDNF; NEUROBLASTOMA CELL-LINES; TYROSINE KINASE; PROTOONCOGENE PRODUCTS; TRANSMITTER SECRETION; HIRSCHSPRUNGS-DISEASE; DOPAMINERGIC-NEURONS; SEQUENCE SIMILARITY; NEUROTROPHIC FACTOR; MOTOR-NEURONS	Glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN) define a new family of neurotrophic factors that play crucial roles in survival and differentiation of various neurons. Recent studies demonstrated that GDNF and NTN use a multicomponent receptor system in which glycosyl-phosphatidylinositol (GPI)-linked cell surface proteins and Ret receptor tyrosine kinase function as the ligand-binding and signalling components, respectively. In the present study, we investigated the role of Ca2+ ions for biochemical and biological activities of Ret because Ret has a unique structure of the extracellular domain with the cadherin-like motif. The results demonstrated that Ca2+ ions might be required for the complex formation of Ret and GDNF or NTN that induces Ret oligomerization and autophosphorylation. Full morphological differentiation of neuroblastoma cells by these neurotrophic factors was also Ca2+-dependent. These findings thus suggested that, in addition to GPI-linked cell surface proteins, Ca2+ ions are components of the signal transducing complex formed by Ret and GDNF protein family.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 466, Japan; Nagoya Univ, Sch Med, Dept Pediat, Showa Ku, Nagoya, Aichi 466, Japan; Genentech Inc, Dept Neurosci, San Francisco, CA 94080 USA	Nagoya University; Nagoya University; Roche Holding; Genentech	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 466, Japan.		Takahashi, Masahide/AAN-4770-2020; ASAI, Naoya/I-7377-2014; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Chakravarti A, 1996, HUM MOL GENET, V5, P303; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Ghosh A, 1996, CURR BIOL, V6, P130, DOI 10.1016/S0960-9822(02)00442-6; IKEDA I, 1990, ONCOGENE, V5, P1291; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Iwashita T, 1996, HUM MOL GENET, V5, P1577, DOI 10.1093/hmg/5.10.1577; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; KUMA K, 1993, MOL BIOL EVOL, V10, P539; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MORIMOTO T, 1995, NEURON, V15, P689, DOI 10.1016/0896-6273(95)90156-6; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1995, CRIT REV ONCOGENESIS, V6, P35, DOI 10.1615/CritRevOncog.v6.i1.30; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0	44	55	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					293	299		10.1038/sj.onc.1201548	http://dx.doi.org/10.1038/sj.onc.1201548			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467954				2022-12-28	WOS:000071582100001
J	Craig, C; Kim, M; Ohri, E; Wersto, R; Katayose, D; Li, ZW; Choi, YH; Mudahar, B; Srivastava, S; Seth, P; Cowan, K				Craig, C; Kim, M; Ohri, E; Wersto, R; Katayose, D; Li, ZW; Choi, YH; Mudahar, B; Srivastava, S; Seth, P; Cowan, K			Effects of adenovirus-mediated p16(INK4A) expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells	ONCOGENE			English	Article						adenovirus; gene therapy; breast cancer; p16; cyclin dependent kinase inhibitors	DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR GENE; CDK INHIBITORS; POTENTIAL MEDIATOR; GROWTH SUPPRESSION; PRODUCT PRB; PROTEIN; P21; PHOSPHORYLATION	We constructed an adenoviral vector containing human p16 cDNA in order to evaluate the cytotoxic effects of exogenous p16 expression on cancer cell proliferation and to explore the potential use of p16 in cancer gene therapy, Following infection of human breast (MCF-7, MDA-MB-231, and BT549), osteosarcoma (U-2 OS and Saos-2), cervical (C33a), and lung cancer (H358) cell lines with the recombinant adenovirus Adp16, high levels of p16 expression were observed in all cell lines. Cancer cell lines which were mutant or null for p16 but wild-type for the retinoblastoma gene product (pRb) (MCF-7, MDA-MB-231, BT549 and U-2 OS) were 7-22-fold more sensitive to the cytotoxic effects of Adp16 than to a control virus, In contrast, cancer cell lines which were wild-type for p16 but mutant or null for pRb (Saos-2, C33a and H358) were <threefold more sensitive to Adp16 when compared to a control virus, Analysis of 5-bromodeoxyuridine incorporation into DNA following infection with Adp16 showed a loss of S phase in those cell lines which were null or mutant for p16 but expressed a functional pRb. This cell cycle arrest was associated with binding of the p16 protein to cyclin-dependent kinase 4 and dephosphorylation of pRb. In contrast, human cancer cell lines expressing a wild-type p16 and a mutant pRb or no pRb showed no substantial loss of S phase following Adp16 infection. Based on these studies, we conclude that p16-mediated cytotoxicity is tightly associated with the presence of functional pRb in human cancer cells, and that tumor cells which are mutant or null for p16 are candidates for Adp16 mediated cancer gene therapy.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathol Branch, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Surg Branch, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA	Seth, P (corresponding author), NCI, Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.							AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; ARAP W, 1995, CANCER RES, V55, P1351; BARTEK J, 1992, ONCOGENE, V7, P101; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Costello JF, 1996, CANCER RES, V56, P2405; CRAIG C, 1997, ONCOGENE, V11, P110; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fueyo J, 1996, ONCOGENE, V12, P103; Geradts J, 1996, AM J PATHOL, V149, P15; GINSBERG HS, 1988, VIROLOGY, P147; GOTTESMAN MM, 1994, J NATL CANCER I, V86, P1277, DOI 10.1093/jnci/86.17.1277; GRAHAM FL, 1991, GENE TRANSFER EXPRES, P109, DOI DOI 10.1385/0-89603-178-0:109; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HERMAN JG, 1995, P AM ASSOC CANC RES, V36, P20; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIN XM, 1995, CANCER RES, V55, P3250; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; Katayose D, 1995, CLIN CANCER RES, V1, P889; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI Y, 1994, ONCOGENE, V9, P2261; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, ONCOGENE, V9, P2159; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SCHUTTE B, 1987, CYTOMETRY, V8, P372, DOI 10.1002/cyto.990080405; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Seth P, 1996, CANCER RES, V56, P1346; SETH P, 1986, VIRUS ATTACHMENT ENT, P191; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	58	112	121	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					265	272		10.1038/sj.onc.1201493	http://dx.doi.org/10.1038/sj.onc.1201493			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464545				2022-12-28	WOS:000071427100014
J	Kim, SK; Su, LK; Oh, Y; Kemp, BL; Hong, WK; Mao, L				Kim, SK; Su, LK; Oh, Y; Kemp, BL; Hong, WK; Mao, L			Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines	ONCOGENE			English	Article						SCLC; PTEN/MMAC1; PTH2; chromosome 9; tumor suppressor	HOMOZYGOUS DELETION; CARCINOMA; MUTATIONS; RB; PROTEIN; CDKN2	Loss of heterozygosity (LOH) at chromosome 10q23-q25 is frequent in small cell lung cancer (SCLC), indicating the presence of putative tumor suppressor genes, PTEN/MMAC1, a newly cloned candidate tumor suppressor gene at 10q23, was mutated in multiple human cancers, We investigated whether mutations of PTEN/MMAC1 play an important role in SCLC tumorigenesis, We examined 16 SCLC cell lines for PTEN/MMAC1 mRNA expression by reverse-transcriptase polymerase chain reaction (RT-PCR) and potential mutations by sequencing analysis of the PTEN/MMAC1 coding region, No mutation was observed in PTEN/MMAC1 cDNAs in 15 cell lines expressing PTEN/MMAC1, One SCLC cell line, DMS79, did not have detectable PTEN/MMAC1 expression, Importantly, we identified a novel homologue of PTEN/MMAC1, termed PTH2, localized to chromosome 9p21-q13 and containing only ten amino acid substitutions compared with the PTEN/MMAC1 coding region, However, because the putative initiation codon for PTEN/MMAC1 gene was changed to arginine in PTH2, the translational initiation site of PTH2 is very likely to differ from that of the PTEN/MMAC1, PTH2 was expressed in two normal lung tissues and two normal colon tissues, but in only four of 16 SCLC cell lines, A missense mutation in PTH2 was identified in a SCLC cell line that did not express PTEN/MMAC1 mRNA, Our data suggest that inactivation of PTEN/MMAC1 is a rare event in SCLC tumorigenesis, However, the PTEN/MMAC1 homologue PTH2 may play a role in SCLC tumorigenesis.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mao, L (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NATIONAL CANCER INSTITUTE [P50CA070907, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA 70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; FEARON ER, 1990, CELL, V61, P757; HOSOE S, 1994, CANCER RES, V54, P1787; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; Kim SK, 1997, CANCER RES, V57, P400; Kim SK, 1996, CANCER RES, V56, P2519; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P2322; MERLO A, 1994, CANCER RES, V54, P640; MILLER CW, 1992, CANCER RES, V52, P1695; MORI N, 1990, ONCOGENE, V5, P1713; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ohta M, 1996, INT J CANCER, V65, P762, DOI 10.1002/(SICI)1097-0215(19960315)65:6<762::AID-IJC9>3.0.CO;2-X; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; RIED T, 1994, CANCER RES, V54, P1801; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Wiest JS, 1997, CANCER RES, V57, P1; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	26	54	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					89	93		10.1038/sj.onc.1201512	http://dx.doi.org/10.1038/sj.onc.1201512			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467947	Bronze			2022-12-28	WOS:000071236800011
J	Mor, O; Read, M; Fried, M				Mor, O; Read, M; Fried, M			p53 in polyoma virus transformed REF52 cells	ONCOGENE			English	Article						p53; polyoma virus; cell cycle; DNA damage; p21; MDM2	WILD-TYPE P53; P53-DEPENDENT G(1) ARREST; DNA-DAMAGE RESPONSE; GROWTH ARREST; HUMAN FIBROBLASTS; T-ANTIGEN; PROTEIN; EXPRESSION; ONCOGENES; IDENTIFICATION	While cellular transformation by small DNA tumour viruses usually involves targeting the product of the p53 tumour suppressor gene by a virally encoded protein, none of the three polyoma virus (Py) specified T antigens have been observed to interact with p53, We show that primary mouse embryo fibroblasts and REF52 cells, which resemble primary cells in requiring co-operating oncogenes for transformation, cannot be transformed by the Py oncogene, middle T-antigen (PyMT), alone, These cells can be transformed by the complete Py early region, which encodes the Py large, middle and small T-antigens, We find that PyMT can transform rodent cells lacking a functional p53 protein (p53 null mouse embryo fibroblasts and DN-REF52 cells which contain a dominant negative p53), In Py transformed REF52 cells (Py-REF52) there is no significant accumulation of p53 protein, as opposed to SV40 transformed REF52 cells (SV-REF52) in which the amount of steady state p53 protein is elevated, However accumulation of p53 is observed following exposure of Py-REF52 cells to u.v. Treatment of Py-REF52 cells with X-rays results in a rapid increase in the levels of the p53-induced proteins p21/WAF1 and MDM2. In untransformed REF52 cells, S-irradiation causes p53 activation, which results in induction of both G1/S and G2/M blocks, In SV-REF52 and DN-REF52 cells, p53 abrogation results in the absence of both the G1/S and G2/M blocks, Only the absence of a G1/S block is observed in Py-REF52 cells exposed to S-irradiation, Together these results indicate that in contrast to most other DNA tumour viruses, Py does not appear to interefere with the DNA damage induced transactivation activities of the p53 protein but absence of a functional p53 protein can mediate transformation by the PyMT oncogene in the absence of other co-operating oncogenes, Possible modes of transformation by Py are discussed.	Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, London WC2A 3PX, England	Cancer Research UK	Fried, M (corresponding author), Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, POB 123, London WC2A 3PX, England.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CUZIN F, 1984, BIOCHIM BIOPHYS ACTA, V781, P193, DOI 10.1016/0167-4781(84)90084-8; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dilworth S M, 1990, Semin Cancer Biol, V1, P407; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORD M, 1985, P NATL ACAD SCI USA, V82, P3370, DOI 10.1073/pnas.82.10.3370; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maniatis T., 1982, MOL CLONING; MICHIELI P, 1994, CANCER RES, V54, P3691; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLSON DC, 1993, ONCOGENE, V8, P2353; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; STEWART N, 1995, ONCOGENE, V10, P109; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	42	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3113	3119		10.1038/sj.onc.1201549	http://dx.doi.org/10.1038/sj.onc.1201549			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444959				2022-12-28	WOS:000070968000011
J	Wang, XT; Gorospe, M; Huang, Y; Holbrook, NJ				Wang, XT; Gorospe, M; Huang, Y; Holbrook, NJ			p27(Kip1) overexpression causes apoptotic death of mammalian cells	ONCOGENE			English	Article						apoptosis; cdk inhibitor; cell growth; Bcl-2	DEPENDENT KINASE INHIBITOR; ANTICANCER AGENTS; CARCINOMA CELLS; CDK INHIBITORS; MICE LACKING; CYCLE ARREST; G(1) ARREST; GROWTH; P21; DIFFERENTIATION	p27(Kip1), a member of the Cip/Kip family of cyclin-dependent kinase (cdk) inhibitors, has been Implicated in mediating G1 arrest in response to a variety of growth inhibitory signals, Its importance in regulating cell growth is emphasized by the fact that mice lacking p27(Kip1) are abnormally large and display hyperplasia of multiple tissues, However, these mice retain the ability to undergo G1 arrest in response to growth inhibitory signals, suggesting that p27(Kip1) may serve other functions important for controlling tissue growth, In the present study, we utilized an adenoviral vector-based expression system to examine the consequences of p27(Kip1) overexpression in the human carcinoma cell lines A549, HeLa and RKO, in human melanoma SK-MEL-110 cells, in human lung fibroblasts IMR90 and in the rat fibroblast line Rat1, We demonstrate that overexpression of p27(Kip1) leads to apoptotic cell death in all cell types, and further show that ectopic expression of Bcl-2 can protect HeLa cells from apoptosis mediated by p27(Kip1) overexpression, To our knowledge, this is the first study demonstrating that p27(Kip1) can induce apoptosis, Our findings provide new insight into the possible functions of this growth regulatory protein, and support the potential utility of gene therapeutic approaches aimed at elevating p27(Kip1) expression for treatment of human cancers.	NIA,GENE EXPRESS & AGING SECT,BIOL CHEM LAB,NIH,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu XP, 1996, ONCOGENE, V12, P1397; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052	31	193	212	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2991	2997		10.1038/sj.onc.1201450	http://dx.doi.org/10.1038/sj.onc.1201450			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416843				2022-12-28	WOS:A1997YK37700012
J	Ji, C; Marnett, LJ; Pietenpol, JA				Ji, C; Marnett, LJ; Pietenpol, JA			Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated p53 and p21 protein levels	ONCOGENE			English	Article						p53; p21; cell cycle synchronization; mimosine; aphidicolin	P53-INDEPENDENT PATHWAY; HUMAN FIBROBLASTS; GROWTH ARREST; DNA-SYNTHESIS; DIFFERENTIATION; MIMOSINE; CHECKPOINTS; SUPPRESSION; IRRADIATION; INHIBITION	Mimosine (MIM) and aphidicolin (APH) are two agents frequently used in tissue culture-based experiments to achieve cell synchronization at late G1 and S phases. Following MIM or APH treatment of human cancer cell lines, a reversible growth arrest in late G1 and S phases of the cell cycle was correlated with moderate increases in p53 and p21 protein levels. Both p53-dependent and -independent increases in p21 were observed following treatment with either agent. However, a striking increase in p21 protein levels and a continuous elevation in both p53 and p21 protein levels were observed over 48 h after cells re-entered the cell cycle following the chemically-induced synchronization. In addition, the increase in p21 protein levels typically seen following treatment of cells with DNA damaging agents, was enhanced when cells were treated with genotoxic agents following MIM or APH synchronization. These findings suggest that caution should be exercised when interpreting results from experiments using cell synchronization agents, in particular, studies designed to investigate p53- and p21-regulatory pathways.	VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,DEPT CHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,VANDERBILT CANC CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University				Li, Tao/0000-0003-3831-901X	NCI NIH HHS [CA68485, CA47479, CA68450] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479, P30CA068485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; CHUAN J, 1997, P AM ASSOC CANC RES, V38, P1324; DAI YM, 1994, VIROLOGY, V205, P210, DOI 10.1006/viro.1994.1636; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1995, ENV HLTH PERSPECT, V5, P55; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STEWART N, 1995, ONCOGENE, V10, P109; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; ZHANG W, 1995, CANCER RES, V55, P668	27	32	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2749	2753		10.1038/sj.onc.1201441	http://dx.doi.org/10.1038/sj.onc.1201441			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9401002				2022-12-28	WOS:A1997YH46800013
J	Kwon, HJ; Yoshida, M; Nagaoka, R; Obinata, T; Beppu, T; Horinouchi, S				Kwon, HJ; Yoshida, M; Nagaoka, R; Obinata, T; Beppu, T; Horinouchi, S			Suppression of morphological transformation by radicicol is accompanied by enhanced gelsolin expression	ONCOGENE			English	Article						radicicol; transformation; oncogene; actin stress fiber; gelsolin	TYROSINE KINASE INHIBITORS; RAT-KIDNEY CELLS; TRICHOSTATIN-A; CARCINOMA-CELLS; NIH3T3 CELLS; HISTONE DEACETYLASE; ACTIN EXPRESSION; FLAT REVERTANTS; PROTEIN; FIBROBLASTS	Radicicol, an inhibitor of Src-family protein-tyrosine kinases, causes morphological reversion of v-src-and v-Ha-ras-transformed fibroblasts and arrest of the cell cycle at both the G1 and the G2 phases, Radicicol was found to inhibit the growth of several other oncogene-transformed cell lines and human carcinoma cell lines and to revert their cell morphology to be flat, In the radicicol-treated flat cells, actin stress fiber bundles were reorganized, Since this effect of radicicol on these cell lines was inhibited by cycloheximide, de novo protein synthesis is required for the morphological reversion, Screening of cellular proteins enhanced in response to radicicol by two-dimensional gel electrophoresis suggested that the amount of gelsolin, an actin regulatory. protein, was distinctly increased upon radicicol treatment, Western blot and Northern blot analyses showed that radicicol enhanced transcription of the gelsolin gene in human carcinoma cell lines, as a result of,which the amount of gelsolin was increased several folds, Injection with an anti-gelsolin antibody into cells and successive treatment with radicicol resulted in approximately 80% reduction of the number of flat cells with stress fibers in comparison with controls treated with an irrelevant antibody, These results show that elevated expression of gelsolin is suppression of transformation actin stress fibers in human carcinoma cells by radicicol.	UNIV TOKYO,GRAD SCH AGR & LIFE SCI,DEPT BIOTECHNOL,BUNKYO KU,TOKYO 113,JAPAN; CHIBA UNIV,FAC SCI,DEPT BIOL,CHIBA 263,JAPAN	University of Tokyo; Chiba University			Yoshida, Minoru/C-8049-2014; 권, 호정/AAS-3642-2021	Yoshida, Minoru/0000-0002-4376-5674; 				Arora PD, 1996, J BIOL CHEM, V271, P20516, DOI 10.1074/jbc.271.34.20516; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BANNO Y, 1992, J BIOL CHEM, V267, P6488; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DELCASTILLO AR, 1992, THROMB HAEMOSTASIS, V67, P248; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; FUJITA H, 1995, EUR J BIOCHEM, V229, P615, DOI 10.1111/j.1432-1033.1995.tb20505.x; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HALL MD, 1988, EXP CELL RES, V179, P115, DOI 10.1016/0014-4827(88)90353-9; HIGGINS PJ, 1991, BIOCHEM J, V279, P883, DOI 10.1042/bj2790883; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWON HJ, 1995, J BIOCHEM-TOKYO, V118, P221, DOI 10.1093/oxfordjournals.jbchem.a124882; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MORIYA S, 1994, INT J ONCOL, V5, P1347; MULLAUER L, 1990, BIOCHEM BIOPH RES CO, V171, P852, DOI 10.1016/0006-291X(90)91224-G; MULLAUER L, 1993, ONCOGENE, V8, P2531; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PATTON WF, 1990, BIOTECHNIQUES, V8, P518; PORTER RM, 1993, J PATHOL, V170, P435, DOI 10.1002/path.1711700406; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sonoda H, 1996, ONCOGENE, V13, P143; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; SUGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P379, DOI 10.1016/S0006-291X(05)80156-1; SUGITA K, 1992, CANCER RES, V52, P168; TANAKA M, 1995, CANCER RES, V55, P3228; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VANDEKERCKHOVE J, 1990, J CELL BIOL, V111, P95, DOI 10.1083/jcb.111.1.95; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; ZHAO JF, 1995, ONCOGENE, V11, P161	43	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2625	2631		10.1038/sj.onc.1201443	http://dx.doi.org/10.1038/sj.onc.1201443			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399650				2022-12-28	WOS:A1997YG73200012
J	Muller, D; Bouchard, C; Rudolph, B; Steiner, P; Stuckmann, I; Saffrich, R; Ansorge, W; Huttner, W; Eilers, M				Muller, D; Bouchard, C; Rudolph, B; Steiner, P; Stuckmann, I; Saffrich, R; Ansorge, W; Huttner, W; Eilers, M			Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes	ONCOGENE			English	Article						Myc; p27; cyclin E; cdk2	UBIQUITIN-PROTEASOME PATHWAY; C-MYC; DEPENDENT KINASES; CELL-CYCLE; TRANSCRIPTIONAL REPRESSOR; ACTIVATES TRANSCRIPTION; IN-VIVO; MAX; GENE; PROTEINS	Activation of Myc triggers a rapid induction of cyclin El cdk2 kinase activity and degradation of p27. Overt degradation of p27 is preceded by a specific dissociation of p27 from cyclin E/cdk2, but not from cyclin D/cdk4 complexes. We now show that cyclin E/cdk2 phosphorylates p27 at a carboxy-terminal threonine residue (T187) in vitro; mutation of this residue to valine stabilises cyclin E/cdk2 complexes. This reaction is not significantly inhibited by high concentrations of p27, suggesting that cdk2 bound to p27 is catalytically active. In vivo, p27 bound to cyclins E and A, but not to D-type cyclins is phosphorylated. Myc-induced release of p27 from cdk2 requires cdk2 kinase activity and is delayed in a T187V mutant of p27. After induction of MSc, p27 phosphorylated at threonine 187 transiently accumulates in a non cdk2 bound form. Our data suggest a mechanism in which p27 is released from cyclin E/cdk2 upon phosphorylation; in Myc-transformed cells, release is efficient as phosphorylated p27 is transiently bound in a non-cdk2 containing complex and subsequently degraded.	ZENTRUM MOL BIOL, D-69120 HEIDELBERG, GERMANY; UNIV HEIDELBERG, DEPT NEUROBIOL, D-69120 HEIDELBERG, GERMANY; EUROPEAN MOL BIOL LAB, BIOCHEM INSTRUMENTAT PROGRAMME, D-69117 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL)			Ansorge, Wilhelm/AAN-8780-2020	Eilers, Martin/0000-0002-0376-6533; Saffrich, Rainer/0000-0002-0547-4550				ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; An SK, 1996, FEBS LETT, V386, P115, DOI 10.1016/0014-5793(96)00427-9; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BERNS K, 1997, IN PRESS ONCOGENE; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Celis JE, 1995, ELECTROPHORESIS, V16, P2177, DOI 10.1002/elps.11501601355; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAAS K, 1997, IN PRESS ONCOGENE; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEREIRA MEF, 1994, J NEUROCHEM, V63, P1578; PEREZROGER I, 1997, IN PRESS ONCOGENE; PEUKERT K, 1997, IN PRESS EMBO J; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PUSCH O, 1997, IN PRESS ONCOGENE; Rao G, 1996, ONCOGENE, V12, P1165; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wilmut I., 1990, TRENDS BIOTECHNOLOGY; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	64	146	149	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	1997	15	21					2561	2576		10.1038/sj.onc.1201440	http://dx.doi.org/10.1038/sj.onc.1201440			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399644				2022-12-28	WOS:A1997YG73200006
J	Widmann, C; Johnson, NL; Gardner, AM; Smith, RJ; Johnson, GL				Widmann, C; Johnson, NL; Gardner, AM; Smith, RJ; Johnson, GL			Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1	ONCOGENE			English	Article						MEK kinase 1; apoptosis; UVC; cisplatin	PROTEIN-KINASE; C-JUN; BINDING PROTEINS; TYROSINE KINASE; CERAMIDE; PATHWAY; GROWTH; ERK; MYC	MEK kinases (MEKKs) are serine-threonine kinases that regulate sequential protein phosphorylation pathways involving mitogen-activated protein kinases (MAPKs), including members of the Jun kinase (JNK) family. MEKK1 is a 196 kDa protein that when cleaved by caspase-3-like proteases generates an active COOH-terminal kinase domain. Expression of the MEKK1 kinase domain is sufficient to induce apoptosis. Mutation of MEKK1 to prevent its proteolytic cleavage protects cells from MEKK1-mediated cell death even though the JNK pathway is still activated, indicating that JNK activation is not sufficient to induce cell death. The inducible acute expression at modest levels of the activated MEKK1 kinase domain can be used to potentiate the apoptotic response to low dose ultraviolet irradiation and cisplatin. Similarly, in L929 fibrosarcoma cells inducible acute expression of the kinase domain of MEKK1 markedly increased the cell death response to tumor necrosis factor alpha(TNF alpha). The findings demonstrate that acute expression of an active farm of MEKK1 can potentiate the cell death response to external stress stimuli. Manipulation of MEKK1 proteolysis and its regulation of signal pathways involved in apoptosis has significant potential for anticancer therapies when used in combination with therapeutic agents at doses that alone have little or modest effects on cell viability.	NATL JEWISH CTR IMMUNOL & RESP MED,PROGRAM MOL SIGNAL TRANSDUCT,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363; Gardner, Anne/0000-0001-7095-772X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871, R01DK048845] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58157] Funding Source: Medline; NIDDK NIH HHS [DK 37871, DK 48845] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CHU G, 1994, J BIOL CHEM, V269, P787; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANGER GR, 1997, IN PRESS EMBO J; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FESHEL K, 1991, AM J PATHOL, V139, P251; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; HEIBI M, 1993, GENE DEV, V7, P2135; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; JNO P, 1997, MOL CELL BIOL, V17, P24; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KRYPRIANOU N, 1991, J NATL CANCER I, V83, P346; KRYRIAKIS JM, 1994, NATURE, V369, P156; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LASSIGNALJOHNSO.N, 1996, J BIOL CHEM, V271, P3229; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; ROITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WYLLIE AH, 1987, BRIT J CANCER, V56, P151; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	32	62	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2439	2447		10.1038/sj.onc.1201421	http://dx.doi.org/10.1038/sj.onc.1201421			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395240				2022-12-28	WOS:A1997YE96300006
J	Qing, J; Maher, VM; Tran, H; Argraves, WS; Dunstan, RW; McCormick, JJ				Qing, J; Maher, VM; Tran, H; Argraves, WS; Dunstan, RW; McCormick, JJ			Suppression of anchorage-independent growth and matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines	ONCOGENE			English	Article						differential mRNA display; fibulin-1D; anchorage-independent growth; tumorigenicity; matrigel invasion	LAMININ-BINDING INTEGRIN; EXTRACELLULAR-MATRIX; MALIGNANT TRANSFORMATION; DIFFERENTIAL DISPLAY; MESSENGER-RNA; HUMAN-FIBROBLASTS; PROTEIN; FIBRONECTIN; ONCOGENE; GENE	Using differential display, we identified an mRNA that is markedly down-regulated in cell line 6A/SB1, derived from a fibrosarcoma formed in an athymic mouse following injection of carcinogen-transformed MSU-1.1 cells, The nontumorigenic parental cell strain, MSU-1.1, expresses high levels of this mRNA, Sequencing of the corresponding cDNA fragment revealed that it corresponded to an expressed sequence tag, which ultimately led to its identification as the fibulin-1D gene, Fibulin-1 is a cysteine-rich, calcium-binding extracellular matrix and plasma protein, which has four isoforms, A-D, derived from alternative splicing, Northern and Western blotting analysis of 16 cell lines established from tumors formed in athymic mice by MSU-1.1-derived cell strains independently transformed in culture showed that 44% exhibited low level or lack of expression of fibulin-1D mRNA and protein, In a similar analysis of 15 malignant cell lines derived from patients, 80% showed low level or no expression, To study the role of fibulin-1D in transformation, we transfected 6A/SB1 cells and a human fibrosarcoma-derived cell line (SHAC) with a fibulin-1D cDNA expression construct, Transfectants displaying high levels of fibulin-1D were isolated and characterized, Elevated expression of fibulin-1D led to reduced ability to form colonies in soft agar and reduced invasive potential as tested in a matrigel in vitro invasion assay, Furthermore, expression of fibulin-1D resulted in a markedly extended latency in tumor formation in athymic mice, These results indicate that low expression of fibulin-1D plays a role in tumor formation and invasion.	MICHIGAN STATE UNIV,DEPT BIOCHEM,CARCINOGENESIS LAB,E LANSING,MI 48824; MICHIGAN STATE UNIV,CTR CANC,DEPT MICROBIOL,E LANSING,MI 48824; MED UNIV S CAROLINA,DEPT CELL BIOL & ANAT,CHARLESTON,SC 29425; MICHIGAN STATE UNIV,DEPT PATHOL,E LANSING,MI 48824	Michigan State University; Michigan State University; Medical University of South Carolina; Michigan State University					NCI NIH HHS [CA60907] Funding Source: Medline; NIA NIH HHS [AG11026] Funding Source: Medline; NIGMS NIH HHS [GM42912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011026] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akamatsu H, 1996, CANCER RES, V56, P4541; ALBINI A, 1987, CANCER RES, V47, P3239; ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ARGRAVES WS, 1991, IN VIVO, V5, P489; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BROWN JC, 1994, J CELL SCI, V107, P329; CALLARD D, 1994, BIOTECHNIQUES, V16, P1096; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; Clinton GM, 1996, P NATL ACAD SCI USA, V93, P316, DOI 10.1073/pnas.93.1.316; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEE SH, 1993, J BIOL CHEM, V268, P14972; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mok SC, 1996, ONCOGENE, V12, P1895; MORGAN TL, 1991, EXP CELL RES, V197, P125, DOI 10.1016/0014-4827(91)90489-H; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; Sasaki T, 1996, EUR J BIOCHEM, V240, P427, DOI 10.1111/j.1432-1033.1996.0427h.x; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; STEEL DM, 1989, J CELL SCI, V93, P515; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; VONDERMARK H, 1991, J BIOL CHEM, V266, P23595; WEINBERG RA, 1989, CANCER RES, V49, P3713; WILSON DM, 1990, CANCER RES, V50, P5587; YANG DJ, 1992, P NATL ACAD SCI USA, V89, P2237, DOI 10.1073/pnas.89.6.2237; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404	43	82	83	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2159	2168		10.1038/sj.onc.1201385	http://dx.doi.org/10.1038/sj.onc.1201385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393974				2022-12-28	WOS:A1997YD01900004
J	Welch, H; Maridonneau-Parini I				Welch, H; Maridonneau-Parini I			Lyn and Fgr are activated in distinct membrane fractions of human granulocytic cells	ONCOGENE			English	Article						Fgr; Lyn; Src; Hck; neutrophil; NB4 cells	PROTEIN-TYROSINE KINASE; ADHERENT HUMAN NEUTROPHILS; FC-GAMMA-RII; FUNCTIONAL ASSOCIATION; PLASMA-MEMBRANE; SRC; FAMILY; P58(C-FGR); RECEPTOR; HCK	We have previously shown that the src-family protein-tyrosine kinase Hck is localized on the azurophil granules of human granulocytes, translocates towards the phagosomes during phagocytosis of opsonized zymosan and is activated during this process. Hck is also activated upon cell stimulation with the calcium ionophore A23187, but not with PMA or the chemotactic peptide fMLP. Here, we investigated whether the src-family kinases Lyn and Fgr are activated under the same conditions. Upon stimulation of human neutrophils or retinoic acid-differentiated NB4 cells with fMLP, only Lyn is activated. Cell stimulation with opsonized zymosan or A23187 leads to simultaneous activation of Lyn and Fgr. In cell fractionation experiments with differentiated NB4 cells, kinases show a similar the subcellular localization: Both co-fractionate quantitatively with plasma-membrane marker in two fractions that sediment at 11000g and 200000g. Lyn is selectively activated in the 200 000 g fraction, whereas Fgr is activated in the 11 000 g fraction and distinct sets of tyrosine phosphorylated proteins are found in these fractions. The results suggest that these kinases exert their functional roles in distinct cellular compartments in human granulocytic cells.	CNRS, INST PHARMACOL & BIOL STRUCT,UPR 9062, F-31077 TOULOUSE, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			Maridonneau-Parini, Isabelle/F-1985-2011	Welch, Heidi/0000-0001-7865-7000; Maridonneau-Parini, Isabelle/0000-0003-0189-0976				BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; ERICKSON HP, 1993, J CELL BIOL, V120, P1079, DOI 10.1083/jcb.120.5.1079; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; Hardie G, 1995, PROTEIN KINASE FACTS, V2; Katagiri K, 1996, J BIOL CHEM, V271, P11557, DOI 10.1074/jbc.271.19.11557; KHANNAGUPTA A, 1994, BLOOD, V84, P294; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KRYPTA RM, 1988, EMBO J, V7, P3837; LANOTTE M, 1991, BLOOD, V77, P1080; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MOHN H, 1995, BIOCHEM J, V309, P657; MORIO T, 1994, EUR J IMMUNOL, V24, P651, DOI 10.1002/eji.1830240325; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TESTA U, 1994, CANCER RES, V54, P4508; VARMUS HE, 1994, BLOOD, V83, P5; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Welch H, 1997, J BIOL CHEM, V272, P102; Welch Heidi, 1996, Methods (Orlando), V9, P607, DOI 10.1006/meth.1996.0067; YAN SR, 1995, J LEUKOCYTE BIOL, V58, P595, DOI 10.1002/jlb.58.5.595; Yan SR, 1995, J INFLAMM, V45, P297; Yan SR, 1996, J BIOL CHEM, V271, P23464, DOI 10.1074/jbc.271.38.23464; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553	33	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	1997	15	17					2021	2029		10.1038/sj.onc.1201356	http://dx.doi.org/10.1038/sj.onc.1201356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366519				2022-12-28	WOS:A1997YC28400003
J	Suhasini, M; Reddy, CD; Reddy, EP; DiDonato, JA; Pilz, RB				Suhasini, M; Reddy, CD; Reddy, EP; DiDonato, JA; Pilz, RB			cAMP-induced NF-kappa B (p50/relB) binding to a c-myb intronic enhancer correlates with c-myb up-regulation and inhibition of erythroleukemia cell differentiation	ONCOGENE			English	Article						c-myb; NF-kappa B; cAMP; erythroid differentiation; murine erythroleukemia cells	DEPENDENT PROTEIN-KINASE; INDUCED ERYTHROID-DIFFERENTIATION; JUN FAMILY MEMBERS; GENE-EXPRESSION; DOWN-REGULATION; TRANSCRIPTION FACTORS; MESSENGER-RNA; B/REL FAMILY; ACTIVATION; LINE	During hexamethylene bisactamide (HMBA)-induced differentiation of murine erythroleukemia (MEL) cells erythroid genes are transcriptionally activated while c-myb and several other nuclear proto-oncogenes are down-regulated. Differentiation is inhibited by cAMP analogues and the adenyl cyclase-stimulating agent forskolin. We found that these drugs prevented the late down-regulation of c-myb which is known to be critical for MEL cell differentiation. Since the increase in c-myb mRNA levels was due to increased mRNA transcription, we examined the transcription factors NF-kappa B and AP-1 which have been implicated in the regulation of c-myb expression. Binding of MEL cell nuclear proteins to a NF-kappa B recognition sequence in c-myb intron 1 was strongly induced by 8-Br-cAMP or forskolin; induction was delayed and correlated with the up-regulation of c-myb. The cAMP-induced NF-kappa B complex contained p50 and RelB; in co-transfection assays, p50 and RelB transactivated a reporter construct containing the c-myb intronic NF-kappa B site upstream of a minimal promoter. 8-Br-cAMP and forskolin also increased the DNA binding activity of AP-1 complexes containing JunB, JunD and c-Fos in MEL cells Which could cooperate with NF-kappa B. We conclude that inhibition of MEL cell differentiation by pharmacological doses of cAMP can be explained by the up-regulation of c-myb which is mediated, at least in part, by NF-kappa B p50/RelB heterodimers.	UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92093; UNIV CALIF SAN DIEGO,CTR CANC,SAN DIEGO,CA 92093; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,SAN DIEGO,CA 92093; TEMPLE UNIV,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Hazen, Stanley L/ABD-5845-2021; Reddy, E. Premkumar/F-6233-2011					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BEEBE SJ, 1986, ENZYMES, V17, P43; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COPPOLA JA, 1989, MOL CELL BIOL, V9, P1714, DOI 10.1128/MCB.9.4.1714; DANISH R, 1992, ONCOGENE, V7, P901; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; ELDRIDGE MG, 1992, BIOTECHNIQUES, V12, P848; FRANCASTEL C, 1994, ONCOGENE, V9, P1957; FRASER PJ, 1987, GENE DEV, V1, P855, DOI 10.1101/gad.1.8.855; GARINGO AD, 1995, J BIOL CHEM, V270, P9169, DOI 10.1074/jbc.270.16.9169; GERONDAKIS S, 1993, CELL GROWTH DIFFER, V4, P617; GHERSA P, 1994, GENE, V151, P331, DOI 10.1016/0378-1119(94)90681-5; GRUMONT RJ, 1994, P NATL ACAD SCI USA, V91, P4367, DOI 10.1073/pnas.91.10.4367; Gudi T, 1996, J BIOL CHEM, V271, P4597; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI CCH, 1994, J BIOL CHEM, V269, P30089; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MELLONI E, 1990, P NATL ACAD SCI USA, V87, P4417, DOI 10.1073/pnas.87.12.4417; MELLONI E, 1989, J BIOL CHEM, V264, P18414; Melotti P, 1996, BLOOD, V87, P2221, DOI 10.1182/blood.V87.6.2221.bloodjournal8762221; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOUDRY R, 1990, EXP CELL RES, V191, P278, DOI 10.1016/0014-4827(90)90015-3; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; Olashaw NE, 1996, J BIOL CHEM, V271, P30307; PILZ RB, 1993, J BIOL CHEM, V268, P20252; PILZ RB, 1992, J BIOL CHEM, V267, P16161; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PROCHOWNIK EV, 1990, BLOOD, V76, P1830; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIFKIND RA, 1987, BLOOD CELLS, V13, P277; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; ROSSON D, 1995, MOL CELL BIOL, V15, P772; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; SERKKOLA E, 1993, FEBS LETT, V334, P327, DOI 10.1016/0014-5793(93)80704-X; SHERMAN ML, 1988, J CELL PHYSIOL, V134, P429, DOI 10.1002/jcp.1041340314; SHERMAN ML, 1986, BIOCHEM BIOPH RES CO, V134, P845, DOI 10.1016/S0006-291X(86)80497-1; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOLOMON WB, 1993, J BIOL CHEM, V268, P5089; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; YAMASAKI H, 1977, P NATL ACAD SCI USA, V74, P3451, DOI 10.1073/pnas.74.8.3451; ZONG H, 1997, CELL, V89, P413	67	36	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1859	1870		10.1038/sj.onc.1201530	http://dx.doi.org/10.1038/sj.onc.1201530			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362453				2022-12-28	WOS:A1997XZ72500013
J	Zhou, XP; Hoang, JM; Cottu, P; Thomas, G; Hamelin, R				Zhou, XP; Hoang, JM; Cottu, P; Thomas, G; Hamelin, R			Allelic profiles of mononucleotide repeat microsatellites in control individuals and in colorectal tumors with and without replication errors	ONCOGENE			English	Article						colon cancer; replication error; microsatellites; mononucleotide repeats	II RECEPTOR GENE; INSTABILITY; CANCER; MUTATIONS; SEQUENCES; COLON; CELLS	We have recently shown that analysis of BAT-26, was sufficient to establish the Replication Error status of colorectal tumors and cell lines without the need for matching normal DNA, BAT-26, a poly(A) tract in the 5th intron of the hMSH2 gene, does not present significant size variation either between the allleles of one individual or between alleles of different individuals, In colorectal tumors without defects in the replication error system (RER- phenotype), BAT-26 is also quasi-monomorphic, On the contrary, in RER+ colorectal tumors, BAT-26 shows unstable shortened alleles, In order to see whether this behaviour was specific for BAT-26, or was a more general phenomenon for mononucleotide repeat microsatellites, we analysed eight other mononucleotide repeats, In control individuals (72 samples) and in RER- colorectal tumors and cell lines (55 samples), these microsatellites were polymorphic, dimorphic, quasi-monomorphic or monomorphic, indicating that the quasi-monomorphic nature of BAT-26 was not a general rule, All of them showed a tendency to be shorter in RER+ colorectal tumors and cell lines (19 samples), but only quasi-monomorphic and monomorphic mononucleotide repeats could be used to determine the RER status of tumors without matching normal DNA, although with a lower efficiency than BAT-26 due to either a smaller range of shortening in RER+ tumors or to a larger number of false negative cases.	INST CURIE,INSERM,U434,F-75005 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Cottu, Paul/ABC-8595-2020					AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; CHEN JS, 1995, CANCER RES, V55, P174; Cottu PH, 1996, ONCOGENE, V13, P2727; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KOLODNER RD, 1995, CANCER RES, V55, P242; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LEFRANCOIS D, 1989, INT J CANCER, V44, P871, DOI 10.1002/ijc.2910440521; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; MALHOSYAN S, 1996, NATURE, V382, P499; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; PELTOMAKI P, 1993, CANCER RES, V53, P5853; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122	20	116	130	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1713	1718		10.1038/sj.onc.1201337	http://dx.doi.org/10.1038/sj.onc.1201337			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349505				2022-12-28	WOS:A1997XY63100011
J	Agarwal, ML; Agarwal, A; Taylor, WR; Wang, ZQ; Wagner, EF; Stark, GR				Agarwal, ML; Agarwal, A; Taylor, WR; Wang, ZQ; Wagner, EF; Stark, GR			Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase	ONCOGENE			English	Article						growth arrest; DNA damage; N-(phosphonacetyl)-L-aspartate; spindle checkpoint; mouse embryo fibroblasts	WILD-TYPE P53; DNA-BINDING FUNCTION; ANTISENSE RNA EXPRESSION; TUMOR-SUPPRESSOR PROTEIN; POLY(ADP-RIBOSE) POLYMERASE; GENE AMPLIFICATION; CYCLE CHECKPOINT; ATAXIA-TELANGIECTASIA; CELLULAR-RESPONSE; GENOMIC STABILITY	Poly-ADP-ribose polymerase (PARP) and p53 are bath induced by DNA damage and each has been proposed to mediate the normal cellular response to damage, We find that embryo fibroblasts from PARP-null mice have a similar to twofold lower basal level of p53 and that the induction of p53 in response to DNA damage or nucleotide depletion is more than twofold less than in normal mouse cells, These factors combine to decrease the induced level of the p53 protein in PARP-deficient cells by 4-5-fold, compared to normal cells, However, there is virtually no decrease in the induction of p53 activity in PARP-deficient cells, as assayed with a p53-responsive promoter, Furthermore, cells lacking PARP arrest normally in G(1) after DNA damage, in contrast to cells lacking p53, where this checkpoint is absent, Other p53-dependent properties, such as the mitotic spindle checkpoint and permissivity for gene amplification, are also normal in PARP-deficient cells, We conclude that the induced level of the p53 protein is governed by a combination of PARP-dependent and PARP-independent pathways and that the activation of p53 is largely PARP-independent, The results are consistent with a model in which the regulation of gene expression by p53 involves both increases in the amount of the protein and activation of p53 as a transcription factor.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195; INT AGCY RES CANC,F-69372 LYON 08,FRANCE; RES INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Cleveland Clinic Foundation; World Health Organization; International Agency for Research on Cancer (IARC); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Wagner, Erwin F/0000-0001-7872-0196	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DURKACZ BW, 1980, NATURE, V283, P595; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Harlow E., 1988, ANTIBODIES LAB MANUA; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; JUAREZSALINAS H, 1979, NATURE, V282, P740, DOI 10.1038/282740a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kupper JH, 1996, CANCER RES, V56, P2715; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PERRY ME, 1992, P NATL ACAD SCI USA, V89, P8112, DOI 10.1073/pnas.89.17.8112; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; STEWART N, 1995, ONCOGENE, V10, P109; STRAIN AJ, 1985, EXP CELL RES, V159, P531, DOI 10.1016/S0014-4827(85)80026-4; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TSENG A, 1987, P NATL ACAD SCI USA, V84, P1107, DOI 10.1073/pnas.84.4.1107; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WHITACRE CM, 1995, CANCER RES, V55, P3697; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	54	84	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1035	1041		10.1038/sj.onc.1201274	http://dx.doi.org/10.1038/sj.onc.1201274			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285557				2022-12-28	WOS:A1997XT16100004
J	Leung, HY; Mehta, P; Gray, LB; Collins, AT; Robson, CN; Neal, DE				Leung, HY; Mehta, P; Gray, LB; Collins, AT; Robson, CN; Neal, DE			Keratinocyte growth factor expression in hormone insensitive prostate cancer	ONCOGENE			English	Article						kGF; FGF; FGFR isoform; alternative splicing; prostate cancer; paracrine loop	FACTOR RECEPTOR-1; FGF-RECEPTOR; CELLS; BINDING; ACTIVATION; ANDROGEN; CLONING	Cellular interactions between stroma and epithelium are important in the growth and proliferation of prostate cancer, Peptide growth factors may facilitate the progression of prostate cancer as autocrine and/or paracrine factors, Keratinocyte Growth Factor (KGF or FGF7) has a differentiative and proliferative effect on the epithelium of the developing rat prostate, We investigated if KGF may act as a paracrine agent in human prostate cancer and examined the expression of KGF and Fibroblast Growth Factor Receptors (FGFRs) (IIIb and IIIc isoforms of the FGFR1 and FGFR2 genes), Sixty-five percent (11 out of 17 informative cases) of prostate cancers (CaP) expressed KGF mRNA by RT-PCR, while KGF expression was not detected in benign prostatic hyperplasia (BPH) (n = 6), Upregulation of KGF expression was related to hormone insensitive tumours (P<0.05), Tumour grade and stage were not associated with KGF expression, The source of KGF expression was further characterised using an in vitro primary culture model, showing its restriction to the prostatic stroma, The FGFR1IIIb isoform was expressed in all cases of prostate cancer (n = 17), and FGFR1IIIc mRNA was not detected, In the BPH group, FGFR1IIIb transcripts were detected in four out of six cases, FGFR2IIIb expression was detected in five of six cases of BPH and twelve out of seventeen (71%) cases of prostate cancer, In CaP, though not reaching statistical significance, the persistence of FGFR2IIIb expression appeared to be associated with hormone insensitive tumours (P=0.052), FGFR2IIIc expression was present in eleven of seventeen tumours but was absent in all six cases of BPH. Functional assessment of recombinant KGF in a proliferation assay demonstrated a mitogenic effect of up to 100% on cultured prostatic epithelial cells.			Leung, HY (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT SURG,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.		Collins, Anne/A-8243-2008	Leung, Hing Y./0000-0002-3933-3975; Neal, David/0000-0002-6033-5086; Collins, Anne/0000-0002-2991-2703				Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; COLLINS AT, 1994, J ENDOCRINOL, V143, P269, DOI 10.1677/joe.0.1430269; CRUMLEY G, 1991, ONCOGENE, V6, P2255; CUNHA GR, 1983, RECENT PROG HORM RES, V39, P559; EISEMANN A, 1991, ONCOGENE, V6, P2379; EISEMANN A, 1991, ONCOGENE, V6, P1195; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HAMAGUCHI A, 1995, PROSTATE, V27, P141, DOI 10.1002/pros.2990270304; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LEUNG HY, 1994, INT J ONCOL, V4, P1219; McGarvey TW, 1995, EXP MOL PATHOL, V63, P52, DOI 10.1006/exmp.1995.1030; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; Peehl DM, 1996, GROWTH REGULAT, V6, P22; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; STORY MT, 1994, GROWTH FACTORS, V10, P269, DOI 10.3109/08977199409010993; Sugimura Y, 1996, INT J DEV BIOL, V40, P941; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAN GC, 1992, BIOCHEM BIOPH RES CO, V183, P423, DOI 10.1016/0006-291X(92)90498-A; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	26	70	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1115	1120		10.1038/sj.onc.1201256	http://dx.doi.org/10.1038/sj.onc.1201256			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285567				2022-12-28	WOS:A1997XT16100014
J	Burke, TF; Cocke, KS; Lemke, SJ; Angleton, E; Becker, GW; Beckmann, RP				Burke, TF; Cocke, KS; Lemke, SJ; Angleton, E; Becker, GW; Beckmann, RP			Identification of a BRCA1-associated kinase with potential biological relevance	ONCOGENE			English	Article						breast cancer; BRCA1; phosphorylation	CANCER SUSCEPTIBILITY GENE; OVARIAN-CANCER; BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; BRCA1 EXPRESSION; MUTATIONS; TUMOR; FAMILIES; CELLS	A biochemical approach was used to identify proteins which interact with human BRCA1, Through this work, a kinase activity which co-purifies with BRCA1 has been identified, This kinase activity, which phosphorylates BRCA1 in vitro, was originally identified in Sf9 insect cells but is also present in cells of human origin including breast and ovarian carcinoma cell lines, The BRCA1 kinase activity in vitro is associated with a fragment of BRCA1 encompassing amino acids 329-435, This peptide is also phosphorylated in various human cell lines, A computer-assisted sequence analysis revealed that this peptide was a potential substrate for phosphorylation by PKA, PKC, or CKII, However, phosphorylation by these kinases could not be demonstrated in vitro indicating the presence of another kinase activity, Phosphorylation in vitro requires a minimal domain of BRCA1 encompassing amino acids 379-408, Notably, deletion of this minimal domain abolishes growth suppression by BRCA1 indicating that this domain, as well as phosphorylation within this domain, may be important for BRCA1 function.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Canc Res Div, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Div Biotechnol, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly	Beckmann, RP (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Canc Res Div, Indianapolis, IN 46285 USA.							Bienstock RJ, 1996, CANCER RES, V56, P2539; BOYD J, 1995, NAT GENET, V9, P335, DOI 10.1038/ng0495-335; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; OBrien K, 1997, GENE, V184, P115, DOI 10.1016/S0378-1119(96)00583-5; Rao VN, 1996, ONCOGENE, V12, P523; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMAS JE, 1997, IN PRESS CELL GROWTH; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X	32	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	1998	16	8					1031	1040		10.1038/sj.onc.1201623	http://dx.doi.org/10.1038/sj.onc.1201623			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519877				2022-12-28	WOS:000072335900009
J	Rodriguez-Villanueva, J; Greenhalgh, D; Wang, XJ; Bundman, D; Cho, S; Delehedde, M; Roop, D; McDonnell, TJ				Rodriguez-Villanueva, J; Greenhalgh, D; Wang, XJ; Bundman, D; Cho, S; Delehedde, M; Roop, D; McDonnell, TJ			Human keratin-1,bcl-2 transgenic mice aberrantly express keratin 6, exhibit reduced sensitivity to keratinocyte cell death induction, and are susceptible to skin tumor formation	ONCOGENE			English	Article						bcl-2; apoptosis; keratinocyte; skin cancer	IN-VIVO PATTERNS; WILD-TYPE P53; IMMUNOHISTOCHEMICAL ANALYSIS; EPIDERMAL DIFFERENTIATION; BCL-2 PROTEIN; HAIR FOLLICLE; APOPTOSIS; GENE; CARCINOGENESIS; LYMPHOMA	Nonmelanoma skin cancers (NMSC) are among the most common malignancies in the world. Typically, these neoplasms grow slowly and are comparatively indolent in their clinical behavior. The most frequent molecular alterations implicated in the pathogenesis of these neoplasms involve genes known to be regulators of cell death including p53, Ha-ras and bcl-2. In order to evaluate the significance cell death deregulation during skin carcinogenesis, we generated a transgenic mouse model (HK1.bcl-2) using the human keratin 1 promoter to target the expression of a human bcl-2 minigene to the epidermis. Transgenic HK1.bcl-2 protein was expressed at high levels specifically in the epidermis extending from the stratum basale through the stratum granulosum. The epidermis of HK1.bcl-2 mice exhibited multifocal hyperplasia without associated hyperkeratosis and aberrant expression of keratin 6. The rate of proliferation was similar in HK1.bcl-2 and control epidermis although suprabasal BrdUrd incorporating cells were present only in HK1.bcl-2 skin, Keratinocytes from the HK1.bcl-2 mice mere significantly more resistant to cell death induction by U.V.-B, DMBA, and TPA, compared to central keratinocytes. Furthermore, papillomas developed at a significantly greater frequency and shorter latency in the HK1.bcl-2 mice compared to control littermates following initiation with DMBA and promotion with TPA. Together these results support a role for bcl-2 in the pathogenesis of NMSC.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77077 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77077 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 89, Houston, TX 77077 USA.			DELEHEDDE, Maryse/0000-0003-2724-143X	NATIONAL CANCER INSTITUTE [R01CA052607, P01CA068233] Funding Source: NIH RePORTER; NCI NIH HHS [CA52607, CA68233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARBEIT JM, 1996, SKIN CANC, P7; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; BURNS PA, 1991, ONCOGENE, V6, P2363; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENHALG DA, 1995, SKIN CANC MECHANISMS, P317; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KANJILAL S, 1993, CANCER RES, V53, P2961; Krajewski S, 1996, CANCER RES, V56, P2849; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MARIN MC, 1994, ONCOGENE, V9, P3107; MARTHINUSS J, 1995, CELL GROWTH DIFFER, V6, P239; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V9, P701; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; QUILAN RA, 1985, ANN NY ACAD, V455, P282; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RADY P, 1992, CANCER RES, V52, P3804; RODRIGUEZVILLANUEVA J, 1995, PATHOL RES PRACT, V191, P391, DOI 10.1016/S0344-0338(11)80724-7; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTHNAGEL JA, 1990, J INVEST DERMATOL, V94, P573; ROTHNAGEL JA, 1991, CELL GROWTH DIFFER, V2, P107; SCHWEIZER J, 1982, CANCER RES, V42, P1517; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STARK HJ, 1987, DIFFERENTIATION, V35, P236, DOI 10.1111/j.1432-0436.1987.tb00174.x; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WANG YS, 1993, ONCOGENE, V8, P3427; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; ZINKEL S, 1994, SEMIN CANCER BIOL, V5, P77	49	74	75	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					853	863		10.1038/sj.onc.1201610	http://dx.doi.org/10.1038/sj.onc.1201610			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484776				2022-12-28	WOS:000072053200004
J	Hadman, M; Lin, W; Bush, L; Bos, TJ				Hadman, M; Lin, W; Bush, L; Bos, TJ			Apolipoprotein A-1 is a negative target of v-Jun overexpression	ONCOGENE			English	Article						Jun; apolipoprotein A-1; regulation	A-I-GENE; HIGH-DENSITY LIPOPROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; C-JUN; GLUCOCORTICOID RECEPTOR; DNA-BINDING; TRANSCRIPTIONAL REGULATION; FUNCTIONAL ANTAGONISM; EMBRYO FIBROBLASTS; COLLAGENASE GENE	The product of the Jun oncogene influences a variety of processes including cell proliferation and differentiation. Jun exerts its influence by binding to the promoter and enhancer regions of a number of different target genes resulting in their activation or repression. We describe here the isolation and characterization of a gene differentially downregulated upon overexpression of v-Jun but not c-Jun. DNA and amino acid homology search analysis revealed this gene to be identical to chicken apolipoprotein A-1, the major component of high density lipoprotein (HDL). The half life of apolipoprotein A-1 RNA remains constant in the presence or absence of v-Jun overexpression suggesting downregulation by v-Jun is at the level of promoter-activity. Consistent with this hypothesis, apolipoprotein A-1 upstream promoter fragments active in normal and c-Jun expressing CEF are inactive in v-Jun transformed CEF. Analysis of expression of apolipoprotein A-1 in CEF overexpressing other oncogenes revealed a similar downregulation by Myc and v-Src but not c-Fos, v-Ha-Ras, c-Src or c-Ski. Our findings point to a potential regulatory affect on cholesterol metabolism by v-Jun, as a result of altered levels of apolipoprotein A-1 message expression.	Eastern Virginia Med Sch, Dept Microbiol & Immunol, Norfolk, VA 23501 USA	Eastern Virginia Medical School	Bos, TJ (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Immunol, POB 1980, Norfolk, VA 23501 USA.				NCI NIH HHS [R01 CA 51982, R29 CA 51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051982, R01CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BARONI S, 1994, LEUKEMIA RES, V18, P643, DOI 10.1016/0145-2126(94)90047-7; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BHATTACHARYYA N, 1993, DNA CELL BIOL, V12, P597, DOI 10.1089/dna.1993.12.597; BHATTACHARYYA N, 1991, GENE, V104, P163, DOI 10.1016/0378-1119(91)90246-8; BHATTACHARYYA N, 1993, GENE, V137, P315, DOI 10.1016/0378-1119(93)90027-Z; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; EISENBERG S, 1984, J LIPID RES, V25, P1017; FOLIN M, 1993, HAEMATOLOGICA, V78, P277; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GAUDET F, 1995, J BIOL CHEM, V270, P29916; GE RW, 1994, J BIOL CHEM, V269, P13185; GIZANGGINSBERG E, 1990, GENE DEV, V4, P447; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KILBOURNE EJ, 1995, J BIOL CHEM, V270, P7004, DOI 10.1074/jbc.270.12.7004; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAMONFAVA S, 1992, J LIPID RES, V33, P831; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MILNER JN, 1992, GENE DEV, V6, P2491; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; RONNEMAA T, 1989, AM J EPIDEMIOL, V130, P632, DOI 10.1093/oxfordjournals.aje.a115385; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Scribano D, 1996, HAEMATOLOGICA, V81, P343; SPIEGEL RJ, 1982, AM J MED, V72, P775, DOI 10.1016/0002-9343(82)90543-5; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Taylor AH, 1996, J LIPID RES, V37, P2232; TOURAY M, 1991, ONCOGENE, V6, P1227; VARMA VK, 1992, METABOLISM, V41, P1075, DOI 10.1016/0026-0495(92)90288-L; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; VOGT PK, 1990, CANCER BIOL, V1, P27; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WONG WY, 1992, ONCOGENE, V7, P2077; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	55	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					655	660		10.1038/sj.onc.1201574	http://dx.doi.org/10.1038/sj.onc.1201574			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482111				2022-12-28	WOS:000071816600010
J	Mahony, D; Parry, DA; Lees, E				Mahony, D; Parry, DA; Lees, E			Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells	ONCOGENE			English	Article						Cdk6; cell-cycle	CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA-PROTEIN; GENE-EXPRESSION; G1 PHASE; G(1); INHIBITION; D1; PROGRESSION; IDENTIFICATION; OVEREXPRESSION	We have performed biochemical analyses of cdk6 complexes in T cells. By gel filtration chromatography we observed at least three cdk6 containing complexes in the cell, the most abundant eluting at 450 kDa and 50-70 kDa and a minor complex eluting at 170 kDa. Cyclin D was present in the minor 170 kDa complex which coeluted with the peak of cdk associated in vitro Rb kinase activity, Analysis of proteins that co-immunoprecipitated with cdk6 showed that the 450 kDa complex contained both Hsp90 and CDC37. The 50-70 kDa complex was made up of two moieties, a 66 kDa complex containing cdk6 bound to p19(INK4d) and monomeric cdk6. The subcellular localisation of the cdk6 complexes was analysed by preparing cytoplasmic and nuclear extracts. The 450 kDa complex was shown to be predominantly cytoplasmic, whereas the 170 kDa cyclin D/cdk6 and the 50-70 kDa complexes were present in both nuclear and cytoplasmic compartments. When these same extracts were assayed for cdk6 associated kinase activity, only the nuclear cdk6 complexes were active. These data suggest that even though there are cdk6/cyclin D complexes detectable in both the cytoplasm and nucleus, only the cdk6 that is in the nucleus is active.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Mahony, D (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, 901 Calif Ave, Palo Alto, CA 94304 USA.							AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BATES S, 1994, ONCOGENE, V9, P71; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hirai H, 1996, MOL CELL BIOL, V16, P6457; HORI T, 1987, BLOOD, V70, P1069; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, ONCOGENE, V10, P2125; Lukas J, 1996, MOL CELL BIOL, V16, P6917; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEVINS JR, 1992, SCIENCE, V258, P424; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	42	80	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	1998	16	5					603	611		10.1038/sj.onc.1201570	http://dx.doi.org/10.1038/sj.onc.1201570			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482106				2022-12-28	WOS:000071816600005
J	Mandal, M; Bandyopadhyay, D; Goepfert, TM; Kumar, R				Mandal, M; Bandyopadhyay, D; Goepfert, TM; Kumar, R			Interferon-induces expression of cyclin-dependent kinase-inhibitors p21(WAF1) and p27(Kip1) that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK)	ONCOGENE			English	Article						interferons; cell cycle; CDK; CDK-inhibitors; CDK-activating kinase	SENSITIVE HEMATOPOIETIC-CELLS; DAUDI CELLS; RETINOBLASTOMA PROTEIN; ALPHA-INTERFERON; INTERLEUKIN-6 SUPPRESS; GROWTH ARREST; 3T3 CELLS; GENES; P21; G1	To understand the mechanism of interferon (IFN)-mediated suppression of cell cycle progression, we have earlier shown that IFN-alpha enhances the expression of underphosphorylated retinoblastoma protein by inhibiting the cyclin-dependent kinase-2 (CDK-2) activity (Kumar and Atlas, Proc. Natl, Acad, Sci. 89, 6599-6603, 1992; Zhang and Kumar, Biochem. Biophysi. Res. Comm., 200, 522-528, 1994), In the studies presented here, we investigated the mechanism of inhibition of CDKs in IFN-treated cells by delineating the potential role(s) of CDK-inhibitors (CKIs) and CDK-activating kinase (CAK). We report that IFN-alpha inhibits the H-1 kinase activity associated with CDK-4 or CDK-2 due to induction of expression of CDK-inhibitor p21(WAF1) (but not p27(Kip1)) as its immunodepletion from IFN-treated extracts restored the CDK-associated H-1 kinase activity, In addition, we also show that IFN-gamma induces expression of CDK-inhibitors p21(WAF1) and p27(Kip1) and inhibited the H-1 kinase activity associated with CDK-2 or CDK-4, The observed IFN-gamma-mediated inhibition of CDK-2 and CDK-4 kinase activity was due to enhanced interactions with p21(WAF1) and p27(Kip1), respectively, We also demonstrated that IFN-induced CKIs prevent CAK from activating the CDK-2 as immunodepletion of induced CKIs from the inhibitory extracts resulted in the restoration of CAK-mediated activation of CDK-2.	Univ Texas, Md Anderson Canc Ctr, Dept Clin Invest, Cell Growth Regulat Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Clin Invest, Cell Growth Regulat Lab, Cell Growth Regulat Lab, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323	NCI NIH HHS [CA56564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; BURKE LC, 1992, ONCOGENE, V7, P783; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; CLARKE PR, 1995, CURR BIOL, V5, P40, DOI 10.1016/S0960-9822(95)00013-3; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1993, CELL, V75, P805; Harvat BL, 1996, CELL GROWTH DIFFER, V7, P289; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Korutla L, 1996, ANTICANCER RES, V16, P2789; KUMAR R, 1994, J BIOL CHEM, V269, P25437; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR R, 1989, CANCER RES, V49, P5180; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MOORE RN, 1984, SCIENCE, V223, P178, DOI 10.1126/science.6606850; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Peng D, 1996, CANCER RES, V56, P3666; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SEROZ T, 1995, CURR OPIN GENET DEV, V5, P217, DOI 10.1016/0959-437X(95)80011-5; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOKAWA Y, 1977, NATURE, V268, P236, DOI 10.1038/268236a0; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMADA H, 1994, MOL CELL BIOCHEM, V136, P117, DOI 10.1007/BF00926071; Yamada H, 1995, MOL CELL BIOCHEM, V152, P149, DOI 10.1007/BF01076077; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	42	86	89	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					217	225		10.1038/sj.onc.1201529	http://dx.doi.org/10.1038/sj.onc.1201529			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464540				2022-12-28	WOS:000071427100009
J	Veldhoen, N; Stewart, J; Brown, R; Milner, J				Veldhoen, N; Stewart, J; Brown, R; Milner, J			Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog	ONCOGENE			English	Article						therapy-induced p53 mutation; canine p53 germ line mutation; canine lymphoma	CHRONIC MYELOCYTIC-LEUKEMIA; P-GLYCOPROTEIN EXPRESSION; BREAST-CANCER; DNA DAMAGE; CLONAL EVOLUTION; FREE-RADICALS; MUTANT-CELLS; THERAPY; DOXORUBICIN; RESISTANCE	Mutations of the p53 gene are associated with a number of non-lymphoid cancers of the dog. The present study investigates the p53 gene status within canine patients treated for primary and secondary lymphoma. Three out of eight patients exhibited p53 gene mutations, These included one patient with a germ line mutation and two patients with de novo p53 mutations associated with the secondary lymphoma. Allelic loss of the p53 gene was also observed within primary and secondary tumours of the three canine patients. The results indicate that germ line p53 mutations exist in dogs and may be involved in the known predisposition of some breeds to cancer, The presence of therapy-related p53 point mutations was found to be associated with chemoresistant secondary lymphomas. A causative role for DNA-damaging chemotherapy in de novo mutation of the p53 gene is discussed, Characterization of p53 inactivation in canine tumorigenesis may provide a valuable clinical model for assessing the efficacy and optimal therapeutic regimens of anti-cancer agents.	Univ York, Dept Biol, YCRC Res Grp P53, York YO1 5DD, N Yorkshire, England; Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland	University of York - UK; Beatson Institute; University of Glasgow	Veldhoen, N (corresponding author), Univ York, Dept Biol, YCRC Res Grp P53, York YO1 5DD, N Yorkshire, England.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AKMAN SA, 1992, BIOCHEMISTRY-US, V31, P3500, DOI 10.1021/bi00128a026; BARTKOWIAK D, 1992, CANCER CHEMOTH PHARM, V30, P189, DOI 10.1007/BF00686310; CARTER RF, 1986, CAN J VET RES, V50, P154; CERVANTES A, 1988, CANCER LETT, V41, P169, DOI 10.1016/0304-3835(88)90113-9; CHANG H, 1994, BLOOD, V83, P452; DEVILEE P, 1994, ANTICANCER RES, V14, P2039; Doroshaw J., 1996, CANC CHEMOTHERAPY BI, P409; ELROUBY S, 1993, BLOOD, V82, P3452; Felix CA, 1996, BLOOD, V87, P4376, DOI 10.1182/blood.V87.10.4376.bloodjournal87104376; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; FULTON R, 1987, NATURE, V326, P190, DOI 10.1038/326190a0; GREENLEE PG, 1990, CANCER-AM CANCER SOC, V66, P480, DOI 10.1002/1097-0142(19900801)66:3&lt;480::AID-CNCR2820660314&gt;3.0.CO;2-X; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hoffmann L, 1995, ANN ONCOL, V6, P781, DOI 10.1093/oxfordjournals.annonc.a059316; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; KAPPUS H, 1986, BIOCHEM PHARMACOL, V35, P1, DOI 10.1016/0006-2952(86)90544-7; KATZ JP, 1990, J VIROL, V64, P4288, DOI 10.1128/JVI.64.9.4288-4295.1990; KEIZER HG, 1990, PHARMACOL THERAPEUT, V47, P219, DOI 10.1016/0163-7258(90)90088-J; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAEGEL SA, 1995, CANCER LETT, V92, P181, DOI 10.1016/0304-3835(95)03779-V; KUROSAWA M, 1994, BLOOD, V83, P2750; Lee JJ, 1996, CANCER, V77, P1892, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1892::AID-CNCR20>3.0.CO;2-U; Liu PK, 1996, ONCOGENE, V12, P2267; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MACVEAN DW, 1978, VET PATHOL, V15, P700, DOI 10.1177/030098587801500602; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MAYR B, 1994, BRIT VET J, V150, P81, DOI 10.1016/S0007-1935(05)80099-5; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; MUINDI J, 1985, MOL PHARMACOL, V27, P356; ONIONS DE, 1984, JNCI-J NATL CANCER I, V72, P909; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; PEDERSENBJERGAARD J, 1992, J CLIN ONCOL, V10, P1444, DOI 10.1200/JCO.1992.10.9.1444; PREUDHOMME C, 1993, LEUKEMIA, V7, P1888; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SQUIRE RA, 1973, JNCI-J NATL CANCER I, V51, P565; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TURNER MJ, 1990, FREE RADICAL BIO MED, V9, P415, DOI 10.1016/0891-5849(90)90018-E; vanLeeuwen IS, 1997, CANCER LETT, V111, P173, DOI 10.1016/S0304-3835(96)04529-6; vanLeeuwen IS, 1996, ANTICANCER RES, V16, P3737; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; WADA H, 1994, LEUKEMIA, V8, P53; WISHART GC, 1990, BRIT J CANCER, V62, P758, DOI 10.1038/bjc.1990.373	49	55	56	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					249	255		10.1038/sj.onc.1201489	http://dx.doi.org/10.1038/sj.onc.1201489			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464543				2022-12-28	WOS:000071427100012
J	Shaulian, E; Resnitzky, D; Shifman, O; Blandino, G; Amsterdam, A; Yayon, A; Oren, M				Shaulian, E; Resnitzky, D; Shifman, O; Blandino, G; Amsterdam, A; Yayon, A; Oren, M			Induction of Mdm2 and enhancement of cell survival by bFGF	ONCOGENE			English	Article						Mdm2; bFGF; p53; apoptosis; cisplatin	WILD-TYPE P53; FIBROBLAST GROWTH-FACTOR; AUTOREGULATORY FEEDBACK LOOP; CYCLE CHECKPOINT PATHWAY; TUMOR-SUPPRESSOR PROTEIN; TYROSINE KINASE-ACTIVITY; MYC-INDUCED APOPTOSIS; DNA-DAMAGING AGENTS; HEMATOPOIETIC-CELLS; FACTORS STIMULATE	Basic fibroblast growth factor (bFGF) can exert mitogenic and viability-promoting effects in a wide range of biological systems. The biochemical activities mediating the cell survival function of bFGF are largely unknown. We report here that exposure of fibroblasts to bFGF, which confers upon them increased survival, also causes at the same time an increase in cellular levels of the Mdm2 oncoprotein. Cells constitutively exposed to a bFGF autocrine loop are more refractory to killing by cisplatin. This increased chemoresistance coincides with elevated Mdm2 and reduced activation of the endogenous p53, resulting in inefficient transcriptional activation of the bar gene promoter. Importantly, unlike Mdm2 accumulation in fibroblasts exposed to DNA damage, induction of Mdm2 by bFGF does not occur through a p53-mediated pathway. The role of p53 in DNA damage-induced apoptosis and the ability of Mdm2 to block p53-mediated cell death are well established. These findings therefore suggest that induction of Mdm2 and the subsequent inhibition of p53 function may contribute, at least partially, to the anti-apoptotic effects of bFGF and possibly some other survival factors.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHARONI D, 1995, EXP CELL RES, V218, P271, DOI 10.1006/excr.1995.1156; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BLANDINO G, 1995, ONCOGENE, V10, P731; BLOTTNER D, 1992, EXP NEUROL, V118, P35, DOI 10.1016/0014-4886(92)90020-Q; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORDONCARDO C, 1994, CANCER RES, V54, P794; CORVI R, 1995, ONCOGENE, V10, P1081; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Fox JC, 1996, J BIOL CHEM, V271, P12578, DOI 10.1074/jbc.271.21.12578; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUKS Z, 1994, CANCER RES, V54, P2582; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERENTAL I, 1995, EXP CELL RES, V218, P283, DOI 10.1006/excr.1995.1157; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KONDO S, 1995, ONCOGENE, V10, P2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LADANYI M, 1993, CANCER RES, V53, P16; LANDGREN E, 1995, ONCOGENE, V10, P2027; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1995, CELL, V80, P293; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; Momand J, 1997, J CELL BIOCHEM, V64, P343; MOSNER J, 1994, ONCOGENE, V9, P3321; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11653; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PRICE BD, 1994, CANCER RES, V54, P896; REIFENBERGER G, 1993, CANCER RES, V53, P2736; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SoferLevi Y, 1996, ONCOGENE, V13, P2431; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xiang H, 1996, J NEUROSCI, V16, P6753; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zawada WM, 1996, EXP NEUROL, V140, P60, DOI 10.1006/exnr.1996.0115; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHU YM, 1994, BRIT J CANCER, V69, P468, DOI 10.1038/bjc.1994.85	96	92	95	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2717	2725		10.1038/sj.onc.1201453	http://dx.doi.org/10.1038/sj.onc.1201453			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400998				2022-12-28	WOS:A1997YH46800009
J	Xie, SH; Price, JE; Luca, M; Jean, D; Ronai, Z; BarEli, M				Xie, SH; Price, JE; Luca, M; Jean, D; Ronai, Z; BarEli, M			Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells	ONCOGENE			English	Article						CREB; dominant negative; malignant melanoma; metastasis; collagenase	HUMAN MELANOCYTES; MEDIATED INDUCTION; CYCLIC-AMP; BINDING; GENE; EXPRESSION; TRANSCRIPTION; PROTEINS; PHOSPHORYLATION; TYROSINASE	The ATF/CREB family of eukaryotic transcription factors contain the bZIP structural motif and mediate their transcriptional activities via heterodimerization with ATF and AP-1 family members, Quenching of CREB-associated proteins by a dominant-negative CREB that is mutated within its DNA-binding domain decreases radiation resistance of human melanoma cells, The purpose of this study was to determine the role of CREB in tumor growth and metastasis of human melanoma using KCREB. Highly metastatic MeWo were transfected with the and subsequently analysed for changes in their tumorigenic and metastatic potential, Expression of KCREB in MeWo human cells decreased their tumorigenic and metastatic potential in nude mice compared with parental and control transfected cells, The KCREB-transfected cells displayed downregulation of 72kDa collagenase type IV (MMP-2) mRNA expression and activity and decreased invasiveness through Matrigel-coated filters, Moreover, transcriptional activities mediated by the CAT gene driven by the MMP-2 promoter were decreased by 14-45-fold in KCREB-transfected cells, In addition, the cell-surface adhesion molecule MCAM/MUC18 that is involved in metastasis of human melanoma was downregulated in the KCREB-transfected cells, These data indicate that, through their transcriptional activities, CREB and its associated proteins play an important role in the acquisition of the metastatic phenotype of human melanoma cells.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,HOUSTON,TX 77030; MT SINAI SCH MED,RUTTENBERG CANC CTR,NEW YORK,NY 10029	University of Texas System; UTMD Anderson Cancer Center; Icahn School of Medicine at Mount Sinai			Jean, Didier/A-1615-2009	Jean, Didier/0000-0001-5823-7404; RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R21CA064137, R29CA051995, R01CA051995, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 64137, CA 51995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; Bernstein Lori R., 1994, Current Opinion in Oncology, V6, P106, DOI 10.1097/00001622-199401000-00015; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FIDLER IJ, 1990, CANCER RES, V50, P6130; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALABAN R, 1993, SEMIN CANCER BIOL, V4, P171; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Huang SY, 1996, ONCOGENE, V13, P2339; Huang SY, 1996, CLIN CANCER RES, V2, P1969; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LANSCHULZ WH, 1988, SCIENCE, V240, P1759; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LESTER BR, 1992, CURR OPIN ONCOL, V6, P106; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; LUCA M, 1995, ONCOGENE, V11, P1399; MOHLER JL, 1991, CANCER RES, V50, P6580; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; PATRIN AW, 1991, P NATL ACAD SCI USA, V86, P1254; RADINSKY R, 1994, ONCOGENE, V9, P1977; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; SINGH RK, 1995, CANCER RES, V55, P3669; VANLEEUWEN RL, 1994, INT J CANCER, V57, P894, DOI 10.1002/ijc.2910570620; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WANDA T, 1991, J VIROL, V65, P557; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WOLOSHIN PI, 1992, MOL ENDOCRINOL, V6, P1725, DOI 10.1210/me.6.10.1725; Xie SH, 1997, CANCER RES, V57, P2295; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Yang YM, 1996, ONCOGENE, V12, P2223	46	109	113	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2069	2075		10.1038/sj.onc.1201358	http://dx.doi.org/10.1038/sj.onc.1201358			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366524				2022-12-28	WOS:A1997YC28400008
J	Karasaki, H; Obata, M; Ogawa, K; Lee, GH				Karasaki, H; Obata, M; Ogawa, K; Lee, GH			Roles of the Pas1 and Par2 genes in determination of the unique, intermediate susceptibility of BALB/cByJ mice to urethane-induction of lung carcinogenesis: Differential effects on tumor multiplicity, size and Kras2 mutations	ONCOGENE			English	Article						lung tumor; susceptibility gene; interactions; urethane; mouse	HEPATOCARCINOGEN SENSITIVITY LOCI; ADENOMA RESISTANCE LOCUS; HA-RAS GENE; PULMONARY ADENOMA; LIVER-TUMORS; SINGLE-GENE; A/J MICE; MOUSE; ACTIVATION; PROTOONCOGENE	The C3H/HeJ (C3H), A/J and BALB/cByJ (BALB) mouse strains are respectively resistant, sensitive and intermediate regarding the induction of lung tumors by urethane. The phenotypic difference between C3H and A/J is largely determined by the Pas1 (Pulmonary adenoma susceptibility 1) gene an chromosome 6, the A/J allele of which dominantly increases the tumor burden. We recently found Chat BALB mice possess a unique lung tumor resistance gene on chromosome 18, designated Par2 (Pulmonary adenoma resistance 2), which partially, but dominantly suppresses the sensitive phenotype of A/J mice (Oncogene 13: 1599-1604, 1996). It has, however, remained unclear why BALB mice carrying the Par2 gene are significantly more sensitive to urethane-induced lung carcinogenesis than C3H mice that have no dominant lung tumor resistance genes. In the present study, using (C3H x BALB)F-1 x C3H backcross mice treated with urethane, we demonstrated that BALB mice possess the disease allele of the Pas1 gene despite their 15-fold more resistance relative to A/J mice (LOD = 22.6). The BALB Par2 allele only significantly reduced the mean lung tumor multiplicity (LOD=4.4) in the backcross population carrying the BALB allele of Pas1, indicating that the intermediate BALB phenotype may at least in part be the result of interactions between these two dominant genes. While the BALB Pas1 allele increased both the mean multiplicity and size of lung tumors, the BALB Par2 allele affected only the mean tumor multiplicity, implying that they are involved in different stages of multi-step lung carcinogenesis. In addition, we found that 68% of lung tumors from the BALB Pas1-positive backcross mice contained activating point mutations of the KRas2 oncogene, tightly linked to the Pas1 locus, whereas these genetic alterations were absent in tumors from BALB Pas1-negative mice. The Pal2 genotype exhibited no effect on this parameter. Since the activating point mutations mere observed exclusively in the BALB allele as already reported with lung tumors in (C57BL/6J x BALB/cJ)F-1 mice, BALB Pas1 or possibly Kras2 itself may confer selective growth advantage on the affected urethane-initiated lung lesions.	ASAHIKAWA MED COLL,DEPT PATHOL,ASAHIKAWA,HOKKAIDO 078,JAPAN	Asahikawa Medical College								BELINSKY SA, 1989, CANCER RES, V49, P5305; BITTNER J. J., 1938, Public Health Reports, V53, P2197, DOI 10.2307/4582733; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; CHEN B, 1993, CARCINOGENESIS, V14, P1603, DOI 10.1093/carcin/14.8.1603; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DEVEREUX TR, 1991, CARCINOGENESIS, V12, P299, DOI 10.1093/carcin/12.2.299; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; DRAGANI TA, 1991, CANCER RES, V51, P6299; Dragani TA, 1996, FASEB J, V10, P865, DOI 10.1096/fasebj.10.8.8666163; DRAGANI TA, 1991, ONCOGENE, V6, P333; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; FIJNEMAN RJA, 1994, ONCOGENE, V9, P1417; Fijneman RJA, 1996, NAT GENET, V14, P465, DOI 10.1038/ng1296-465; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; LEE GH, 1995, GENETICS, V139, P387; LEE GH, 1995, MOL CARCINOGEN, V14, P190, DOI 10.1002/mc.2940140308; LEE GH, 1995, CARCINOGENESIS, V16, P1993, DOI 10.1093/carcin/16.8.1993; MALKINSON AM, 1994, MOL CARCINOGEN, V10, P61, DOI 10.1002/mc.2940100202; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; MASSEY TE, 1995, CARCINOGENESIS, V16, P1065, DOI 10.1093/carcin/16.5.1065; MATZINGER SA, 1994, MOL CARCINOGEN, V11, P42, DOI 10.1002/mc.2940110108; Obata M, 1996, ONCOGENE, V13, P1599; OHMORI H, 1992, CARCINOGENESIS, V13, P851, DOI 10.1093/carcin/13.5.851; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; Snedecor G.W., 1989, AMES IOWA STATE U PR; Strong LC, 1936, J HERED, V27, P21, DOI 10.1093/oxfordjournals.jhered.a104133; SUZUKI Y, 1990, ONCOGENE, V5, P1037; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	38	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1833	1840		10.1038/sj.onc.1201357	http://dx.doi.org/10.1038/sj.onc.1201357			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362450				2022-12-28	WOS:A1997XZ72500010
J	Li, TJ; Rawlings, DJ; Park, H; Kato, RM; Witte, ON; Satterthwaite, AB				Li, TJ; Rawlings, DJ; Park, H; Kato, RM; Witte, ON; Satterthwaite, AB			Constitutive membrane association potentiates activation of Bruton tyrosine kinase	ONCOGENE			English	Article						Btk; pleckstrin homology domain; membrane targeting; transformation	X-LINKED AGAMMAGLOBULINEMIA; PLECKSTRIN HOMOLOGY DOMAIN; BETA-GAMMA-SUBUNITS; SIGMA-II SPECTRIN; SRC FAMILY; SIGNAL-TRANSDUCTION; PH DOMAIN; B-CELLS; PLASMA-MEMBRANE; POINT MUTATION	Mutations in the nonreceptor tyrosine kinase Btk result in the B cell, immunodeficiencies X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (xid) in mice. Genetic and biochemical evidence implicates Btk as a key component of several B cell signaling pathways. Activation of Btk by a point mutation (E41K) within the PH domain (Btk*) results in fibroblast transformation and is correlated with increased membrane localization of Btk. When wild type Btk is activated by coexpression with Lyn, the tyrosine phosphorylated pool of Btk is highly enriched in the membrane fraction. To determine whether membrane association is sufficient to activate Btk, we targeted Btk to the plasma membrane using a series of fusion proteins including GagBtk, CD16Btk and CD4Btk. Constitutive membrane association greatly enhanced the ability of Btk to transform Rat2 fibroblasts in the presence of high levels of Src activity. All membrane targeted forms of Btk were highly tyrosine phosphorylated. Transformation required membrane localization, Btk kinase activity, transphosphorylation by Src family kinases, and an intact SH2 domain but not the PH or SH3 domains. These data suggest that membrane localization is a critical early step in Btk activation.	UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV IMMUNOL RHEUMATOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOL GENET,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NCI NIH HHS [CA-12800, CA-09056] Funding Source: Medline; NIAMS NIH HHS [AR01912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA012800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K11AR001912] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Afar DEH, 1996, MOL CELL BIOL, V16, P3465; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P475; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHU KT, 1994, J BIOL CHEM, V269, P24095; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HINSHELWOOD S, 1995, EUR J IMMUNOL, V25, P1113, DOI 10.1002/eji.1830250439; HITOSHI Y, 1993, INT IMMUNOL, V5, P1183, DOI 10.1093/intimm/5.9.1183; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JASIN M, 1991, J VIROL, V65, P440, DOI 10.1128/JVI.65.1.440-444.1991; JONES TA, 1990, J VIROL, V64, P2265, DOI 10.1128/JVI.64.5.2265-2279.1990; KASLAUSKAS A, 1989, CELL, V58, P1121; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOIKE M, 1995, INT IMMUNOL, V7, P21, DOI 10.1093/intimm/7.1.21; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Ochs HD, 1996, MEDICINE, V75, P287, DOI 10.1097/00005792-199611000-00001; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8521; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SANTOSARGUMEDO L, 1995, IMMUNOLOGY, V85, P248; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, P NATL ACAD SCI USA, V91, P11256; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang DS, 1996, BIOCHEM BIOPH RES CO, V225, P420, DOI 10.1006/bbrc.1996.1189; Wang DS, 1995, BIOCHEM BIOPH RES CO, V217, P608, DOI 10.1006/bbrc.1995.2818; WICKER LS, 1986, CURR TOP MICROBIOL, V124, P87; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	71	67	68	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1375	1383		10.1038/sj.onc.1201308	http://dx.doi.org/10.1038/sj.onc.1201308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333013	Bronze			2022-12-28	WOS:A1997XW41100001
J	Keeling, SL; Gad, JM; Cooper, HM				Keeling, SL; Gad, JM; Cooper, HM			Mouse Neogenin, a DCC-like molecule, has four splice variants and is expressed widely in the adult mouse and during embryogenesis	ONCOGENE			English	Article						neogenin; sequence; tumorigenesis; cell adhesion molecule; embryogenesis	TUMOR-SUPPRESSOR GENE; MESSENGER-RNA; FREQUENT LOSS; COLORECTAL-CARCINOMA; N-CAM; HETEROZYGOSITY; CANCERS; NCAM; DIFFERENTIATION; CADHERIN	Neogenin is a member of the N-CAM family of cell adhesion molecules and is closely related to the DCC tumor suppressor gene product, Recently, it has been demonstrated that the DCC/Neogenin subfamily plays a key role in axonal guidance within the embryonic nervous system, however little is known about the function of DCC or Neogenin in non-neuronal tissues in vertebrates. To gain an understanding of Neogenin function outside of the nervous system we have cloned and sequenced the mouse homologue of Neogenin. We describe three alternatively spliced exons within the extracellular domain of Neogenin and a fourth alternatively spliced exon within the cytoplasmic domain, We further demonstrate that three of these alternatively spliced exons are developmentally regulated, Analysis of Neogenin mRNA expression showed that two distinct Neogenin transcripts are expressed at significant levels in a broad spectrum of adult mouse tissues and throughout the mid to late stages of embryogenesis. In situ hybridization studies on day 15.5 mouse embryos revealed that Neogenin is expressed widely throughout the developing mouse embryo, in both neuronal and nonneuronal tissues, These observations suggests that Neogenin may play an integral role in regulating differentiation programmes and/or cell migration events within many embryonic and adult tissues.			Keeling, SL (corresponding author), ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, POB 2008, PARKVILLE, VIC 3050, AUSTRALIA.		Cooper, Helen/G-3505-2010; Cooper, Helen M/AAA-2182-2019	Cooper, Helen M/0000-0001-9838-5743				Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BOLAM JP, 1992, EXPT NEUROANATOMY PR, P6; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHOWCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; Cooper HM, 1995, ONCOGENE, V11, P2243; DEVILEE P, 1991, ONCOGENE, V6, P311; ENOMOTO T, 1995, BRIT J CANCER, V71, P462, DOI 10.1038/bjc.1995.94; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAO X, 1993, CANCER RES, V53, P2723; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; HUANG Y, 1992, CANCER RES, V52, P6525; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; Kaufman M.H., 1992, ATLAS MOUSE DEV; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MIYAKE K, 1993, BLOOD, V82, P927; OLEARY DDM, 1993, NEURON, V10, P991, DOI 10.1016/0896-6273(93)90049-W; PORFIRI E, 1993, BLOOD, V81, P2696; REALE MA, 1994, CANCER RES, V54, P4493; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAFFELL JL, 1994, J CELL BIOL, V125, P427, DOI 10.1083/jcb.125.2.427; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECK AC, 1993, CANCER RES, V53, P5605; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; UCHINO S, 1992, CANCER RES, V52, P3099; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Walsh FS, 1996, CURR OPIN CELL BIOL, V8, P707, DOI 10.1016/S0955-0674(96)80113-X; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; ZORN AM, 1992, DEV BIOL, V149, P197, DOI 10.1016/0012-1606(92)90276-M	46	78	83	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					691	700		10.1038/sj.onc.1201225	http://dx.doi.org/10.1038/sj.onc.1201225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264410	Bronze			2022-12-28	WOS:A1997XP68300009
J	Cai, ZZ; Capoulade, C; MoyretLalle, C; AmorGueret, M; Feunteun, J; Larsen, AK; BressacdePaillerets, B; Chouaib, S				Cai, ZZ; Capoulade, C; MoyretLalle, C; AmorGueret, M; Feunteun, J; Larsen, AK; BressacdePaillerets, B; Chouaib, S			Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function	ONCOGENE			English	Article						cell death; p53; resistance; TNF	TUMOR-NECROSIS-FACTOR; WILD-TYPE P53; FACTOR-ALPHA; C-MYC; ADRIAMYCIN-RESISTANT; SUPEROXIDE-DISMUTASE; FACTOR CYTOTOXICITY; HUMAN FIBROBLASTS; INDUCED APOPTOSIS; GENE-EXPRESSION	We have investigated the relationship between the development of tumor resistance towards the cytotoxic action of tumor necrosis factor-alpha (TNF) and p53 function, using the TNF-sensitive MCF7 human breast adenocarcinoma cell line and two TNF-resistant sublines, MCF7/R-A1 and MCF7/Adr, Use of single-strand conformation polymorphism (SSCP) analysis and DNA sequencing shows that MCF7 has a wild-type p53 gene, whereas both TNF-resistant sublines exhibit mutant p53, This includes a point mutation R280K in MCF7/R-A1 cells, and a point mutation at the splicing acceptor site on the upstream border of exon 5 resulting in a 21 pb deletion in MCF7/Adr cells, These mutations result in loss of p53 capacity to transactivate FASAY (functional assay in yeast), In contrast to what is observed for parental MCF7 cells, treatment of resistant sublines with TNF or gamma-irradiation fails neither to induce the expression of the p53-regulated gene products p21(waf1/CIP1) and MDM2, nor to arrest the cells in the G(1) phase of the cell cycle, Disruption of p53 wild-type function in MCF7 cells by transfection with human papillomavirus type-16 E6 gene, leads to abrogation of the cytotoxic, but not the cytostatic activity of TNF, Altogether, our results strongly suggest that wild-type p53 is involved in cytotoxic action of TNF, and point out that loss of p53 function contributes to resistance of tumor cell to TNF-induced killing.	INST GUSTAVE ROUSSY,INSERM,CJF 9411,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 1156,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,UNITE MARQUEURS GENET CANC,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 147,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 1967,F-94805 VILLEJUIF,FRANCE; CTR LEON BERARD,INSERM,U453,F-69373 LYON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard			Chouaib, Salem/F-7939-2016; Moyret-Lalle, Caroline/G-2742-2013; Feunteun, Jean/AAZ-1267-2020; Paillerets, Brigitte Bressac-de/D-8954-2018	Moyret-Lalle, Caroline/0000-0002-8359-2018; Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; Feunteun, Jean/0000-0003-1212-9189				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Cai ZZ, 1996, INT J CANCER, V68, P535, DOI 10.1002/(SICI)1097-0215(19961115)68:4<535::AID-IJC21>3.0.CO;2-2; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; CAIGNARD A, 1997, IN PRESS ONCOLOGY RE, V4; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU SK, 1994, MOL CELL BIOL, V14, P2556; CHOUAIB S, 1992, B CANCER, V79, P935; CHOUAIB S, 1991, IMMUNOL TODAY, V12, P141, DOI 10.1016/0167-5699(91)90076-6; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DARZYNKIEWICZ Z, 1984, CANCER RES, V44, P83; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FAN SJ, 1995, CANCER RES, V55, P1649; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Gallardo D, 1996, CANCER RES, V56, P4891; HARRISON DJ, 1995, J PATHOL, V175, P7, DOI 10.1002/path.1711750103; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAATTELA M, 1995, ONCOGENE, V10, P2297; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEJEUNE F, 1994, CIRC SHOCK, V43, P191; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNOR PM, 1993, CANCER RES, V53, P4776; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PAGLIACCI MC, 1993, LYMPHOKINE CYTOK RES, V12, P439; PUSZTAI L, 1993, BRIT J CANCER, V67, P290, DOI 10.1038/bjc.1993.55; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WU H, 1993, GENE DEV, V7, P1126; Yang B, 1996, CLIN CANCER RES, V2, P1649; YIN D, 1995, NEUROSURGERY, V27, P762; ZYAD A, 1994, CANCER RES, V54, P825	63	82	83	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2817	2826		10.1038/sj.onc.1201445	http://dx.doi.org/10.1038/sj.onc.1201445			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419972				2022-12-28	WOS:A1997YJ80300007
J	Porfiri, E; Rubinfeld, B; Albert, I; Hovanes, K; Waterman, M; Polakis, P				Porfiri, E; Rubinfeld, B; Albert, I; Hovanes, K; Waterman, M; Polakis, P			Induction of a beta-catenin-LEF-1 complex by wnt-1 and transforming mutants of beta-catenin	ONCOGENE			English	Article						beta-catenin; LEF1; wnt-1; cancer	TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTION FACTOR LEF-1; APC GENE-PRODUCT; ALPHA-ENHANCER; SIGNAL-TRANSDUCTION; ACTIVATION DOMAIN; XENOPUS EMBRYOS; CELL-ADHESION; E-CADHERIN; IN-VIVO	Signal transduction by beta-catenin involves its posttranslational stabilization and import to the nucleus where it interacts with transcription factors, Recent implications for beta-catenin signaling in cancer prompted us to examine colon cancer cell lines for the expression of LEF-1, a transcription factor that binds to beta-catenin, The analysis of several cell lines revealed the expression of LEF1 mRNA and a constitutive association of the LEF-1 protein with beta-catenin, In contrast to the colon cells, PC12 and 293 cells did not contain a beta-catenin-LEF-1 complex, even though both proteins were detected in cell lysates, In these cells, the association of endogenous LEF1 and beta-catenin was induced by stimulation with the wnt-1 proto-oncogene. The complex formed following transient stimulation with wnt-1 and also persisted in cells stably expressing wnt-1. Ectopic overexpression of beta-catenin in 293 cells also induced the assembly of the beta-catenin-LEF-1 complex and activated gene transcription from a LEF-1-dependent promotor, Expression of mutant oncogenic forms of beta-catenin identified in cancer cells resulted in higher levels of transcriptional activity, The results suggest that a cancer pathway driven by wnt-1, or mutant forms of beta-catenin, may involve the formation of a persistent transcriptionally active complex of beta-catenin and LEF1.	ONYX PHARMACEUT,RICHMOND,CA 94806; UNIV CALIF IRVINE,DEPT MICROBIOL,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT MOL GENET,IRVINE,CA 92697	University of California System; University of California Irvine; University of California System; University of California Irvine				Rubinfeld, Bonnee/0000-0001-9861-6775				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Inomata M, 1996, CANCER RES, V56, P2213; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LOEB DM, 1993, J NEUROSCI, V13, P2919; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Pai LM, 1997, DEVELOPMENT, V124, P2255; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	37	129	131	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2833	2839		10.1038/sj.onc.1201462	http://dx.doi.org/10.1038/sj.onc.1201462			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419974				2022-12-28	WOS:A1997YJ80300009
J	Chintala, SK; Fueyo, J; GomezManzano, C; Venkaiah, B; Bjerkvig, R; Yung, WKA; Sawaya, R; Kyritsis, AP; Rao, JS				Chintala, SK; Fueyo, J; GomezManzano, C; Venkaiah, B; Bjerkvig, R; Yung, WKA; Sawaya, R; Kyritsis, AP; Rao, JS			Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro	ONCOGENE			English	Article						p16; glioma; invasion; MMP-2; tumor-suppressor	IN-VITRO; CELL-CYCLE; IV COLLAGENASE; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; GLIOBLASTOMA CELLS; TUMOR PROGRESSION; MALIGNANT GLIOMAS; RAT BRAIN; EXPRESSION	Malignant gliomas extensively infiltrate the surrounding normal brain, and their diffuse invasion is one of the most important barriers to successful therapy, Recent studies indicate that the progression of gliomas from low-grade to high-grade may depend on the acquisition of a new phenotype and the subsequent addition of genetic defects, One of the most frequent abnormalities in the progression of gliomas is the inactivation of tumor-suppressor gene p16, suggesting that loss of p16 is associated with acquisition of malignant characteristics. Consistent with this hypothesis, our previous studies showed that restoring wild-type p16 activity into p16-null malignant glioma cells modified their phenotype, In order to understand whether the biological consequences of p16 inactivation in high-grade gliomas included facilitating invasiveness, we used a recombinant replication-deficient adenovirus carrying the cDNA of the p16/CDKN2 gene to infect and express high levels of p16 protein in p16-null SNB19 glioma cells, Invasion of SNB19 glioma cells was tested into two models: invasion of glioma cells through Matrigel-coated transwell inserts and invasion of tumor-cell spheroids into fetal rat-brain aggregates in a co-culture system, Matrigel invasion assays showed that the SNB19 cells expressing exogenous p16 exhibited significantly reduced invasion, Similarly, invasion of p16-treated SNB19 cells into fetal rat-brain aggregates was reduced during a 72 h time period compared to invasion of the adenovirus-control and mock-infected cells, Expression of matrix metalloproteinase-2 (MMP-2), an enzyme involved in tumor-cell invasion, in SNB19 cells expressing p16 was significantly reduced compared to that of parental SNB19 and vector-infected cells, Our results show that restoring wild-type p16 activity into p16-null SNB19 glioma cells significantly inhibits tumor-cell invasion, thus suggesting a novel function of the p16 gene.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROSURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030; UNIV BERGEN,DEPT ANAT & CELL BIOL,BERGEN,NORWAY	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Bergen				Fueyo, Juan/0000-0001-6941-2335; Gomez-Manzano, Candelaria/0000-0002-1259-2133	NATIONAL CANCER INSTITUTE [R01CA056792] Funding Source: NIH RePORTER; NCI NIH HHS [CA56792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; ALBELDA SM, 1993, LAB INVEST, V68, P4; ARAP W, 1995, CANCER RES, V55, P1351; BJERKVIG R, 1986, CANCER RES, V46, P4071; Chintala S.K., 1996, FRONT BIOSCI, V1, pd324, DOI 10.2741/a135; CHINTALA SK, 1996, CANC LETT, V103, P102; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; EASTHAM JA, 1995, CANCER RES, V55, P5151; Fueyo J, 1996, ONCOGENE, V12, P103; Fueyo J, 1996, ONCOGENE, V13, P1615; GIANI C, 1994, CANCER RES, V54, P6338; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; Go Y, 1996, CANCER LETT, V110, P225, DOI 10.1016/S0304-3835(96)04515-6; GOMEZMANZANO C, 1996, CANCER RES, V54, P6353; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRVONEN HE, 1994, BRIT J CANCER, V69, P16, DOI 10.1038/bjc.1994.3; Hsu SC, 1996, CANCER RES, V56, P5684; IWASAKI T, 1995, INT J CANCER, V63, P282, DOI 10.1002/ijc.2910630223; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; Li J, 1996, ONCOGENE, V13, P2379; LI Y, 1994, CANCER RES, V54, P6078; Liotta L A, 1990, Semin Cancer Biol, V1, P99; MASUYAMA JI, 1992, J IMMUNOL, V148, P1367; MERZAK A, 1994, BRIT J CANCER, V70, P199, DOI 10.1038/bjc.1994.280; Miele ME, 1996, MOL CARCINOGEN, V15, P284, DOI 10.1002/(SICI)1098-2744(199604)15:4<284::AID-MC6>3.0.CO;2-G; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; MOHANAM S, 1993, CANCER RES, V53, P4143; Nakagawa T, 1996, J NEURO-ONCOL, V28, P13, DOI 10.1007/BF00300442; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Nygaard SJT, 1995, INVAS METAST, V15, P179; PEDERSEN PH, 1993, CANCER RES, V53, P5158; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; RATNER S, 1988, J IMMUNOL, V140, P583; REED JA, 1995, CANCER RES, V55, P2713; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Uhm JH, 1996, CLIN EXP METASTAS, V14, P421, DOI 10.1007/BF00128958; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WELCH DR, 1994, ONCOGENE, V9, P255; WILKINSON PC, 1986, IMMUNOLOGY, V57, P281; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	50	83	86	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2049	2057		10.1038/sj.onc.1201382	http://dx.doi.org/10.1038/sj.onc.1201382			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366522				2022-12-28	WOS:A1997YC28400006
J	Simonian, PL; Grillot, DAM; Nunez, G				Simonian, PL; Grillot, DAM; Nunez, G			Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-X-L and Bcl-2	ONCOGENE			English	Article						Bak; Bcl-X-L; Ecl-2; apoptosis; chemotherapy; cell death	HOMOLOG BAK; APOPTOSIS; EXPRESSION; CISPLATIN; SURVIVAL; BCL-X(L); DOMAIN; BH1	Bak has been shown to both promote apoptosis and to inhibit cell death while two other members of the Bcl-2 family of proteins, Bcl-X-L and Bcl-2 delay apoptosis induced by various stimuli including chemotherapeutic agents. We generated clones with stable expression of Bak wild-type (wt) and Bak with its BH3 (Delta 78-86) domain deleted (Delta BH3) in FL5.12 cells or FL5.12 cells expressing either Bcl-X-L or Bcl-2 to determine if Bak could accelerate apoptosis and antagonize the death repressor activity of Bcl-X-L and Bcl-2 during chemotherapy-induced apoptosis. We found that Bah accelerated cell death in FL5.12 cells treated with etoposide, fluorouracil or taxol. In FL5.12 cells expressing Bcl-X-L and Bak wt or Bak Delta BH3, both Bak wt or Bak Delta BH3 were able to antagonize the protective effect of Bcl-X-L when treated with etoposide or fluorouracil. Bak wt or Bak Delta BH3 were also able to abrogate the protective effect of Bcl-2 in cells expressing Bcl-2 and Bak wt or Bak Delta BH3 when challenged by etoposide or fluorouracil. Immunoprecipitation studies revealed that deletion of BH3 disrupted heterodimerization between Bak and Bcl-X-L and that both Bak wt and Bak Delta BH3 failed to interact with Bcl-2. These results demonstrate that Bak does not require its BH3 domain to promote apoptosis in stably transfected cells. Furthermore, Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-X-L and Bcl-2.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Nuñez, Gabriel/A-7160-2014		NCI NIH HHS [CA-64556, CA-64421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556, K04CA064421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Krajewska M, 1996, CANCER RES, V56, P2422; Middleton G, 1996, DEVELOPMENT, V122, P695; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MIYASHITA T, 1993, BLOOD, V81, P151; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	18	46	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1871	1875		10.1038/sj.onc.1201350	http://dx.doi.org/10.1038/sj.onc.1201350			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362454				2022-12-28	WOS:A1997XZ72500014
J	Chung, YJ; Park, SW; Song, JM; Lee, KY; Seo, EJ; Choi, SW; Rhyu, MG				Chung, YJ; Park, SW; Song, JM; Lee, KY; Seo, EJ; Choi, SW; Rhyu, MG			Evidence of genetic progression in human gastric carcinomas with microsatellite instability	ONCOGENE			English	Article						gastric carcinoma; mutator phenotype; transforming growth factor beta receptor type II; BAX; insulin-like growth factor II receptor	NONPOLYPOSIS COLON-CANCER; CELL LUNG-CANCER; II RECEPTOR GENE; COLORECTAL-CANCER; MISMATCH REPAIR; MUTATOR PHENOTYPE; BETA RECEPTOR; MUTATIONS; HOMOLOG; CARCINOGENESIS	Mutator phenotype tumors provide unique opportunities to unravel malignant progression because of various gene alterations acquired during clonal tumor evolution, Gastric carcinomas, which have been known to show frequent genetic instability, would be composed of initial gene alterations shared by most tumor areas and subsequent alterations restricted to particular tumor sites, To analyse the timing of genetic events, we examined separate sites of tumor tissue obtained from a given gastric carcinoma patient with microsatellite instability (MSI), Our study included 95 normal/tumor area pairs from 25 patients, Six of the 25 patients (24%) demonstrated various levels of MSI ranging from 7% (two of 30) to 97% (28 of 29) of markers tested in multiple tumor sites. Of the six patients, five manifested frameshift mutations in a tract of ten deoxyadenosines within transforming growth factor beta receptor type II and four demonstrated frameshift mutations in a tract of eight deoxyguanosines within BAX. These mutations were common to all tumor sites regardless of the various level of MSI phenotype, indicating initial events, Two of the six patients exhibited frameshift mutations in mononucleotide repeats of mismatch repair genes, hMSH3 and hMSH6, and the insulin-like growth factor II receptor in restricted tumor areas, indicating additional alterations. Insulin-like growth factor II receptor mutations appear to be caused by hMSH3 and hMSH6 mutations because the former mutations were confined to tumor portions with the latter two mismatch repair lesions, These results provide genetic progression evidence for gastric carcinomas of the mutator pathway, In this pathway, mismatch repair insufficiency initially targets mononucleotide tracts of transforming growth factor beta receptor type II and BAX. During tumorigenesis, primary mismatch repair failure may give rise to the secondary mismatch repair lesions, frameshift mutations of hMSH3 and hMSH6, which result in another tumorigenic mutation in the insulin-like growth factor II receptor.	CATHOLIC UNIV,COLL MED,DEPT MICROBIOL,SOCHO GU,SEOUL 137701,SOUTH KOREA; CATHOLIC UNIV,COLL MED,DEPT CLIN PATHOL,SEOUL 137701,SOUTH KOREA; CATHOLIC UNIV,COLL MED,DEPT INTERNAL MED,SEOUL 137701,SOUTH KOREA	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1996, JPN J CANCER RES, V87, P595, DOI 10.1111/j.1349-7006.1996.tb00265.x; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHONG JM, 1994, CANCER RES, V54, P4595; Chung YJ, 1996, CANCER RES, V56, P4662; CORREA P, 1994, CANCER RES, V54, pS1941; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; EYFJORD JE, 1995, CANCER RES, V55, P646; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FONG KM, 1995, CANCER RES, V55, P28; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HAN HJ, 1993, CANCER RES, V53, P5087; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KARRAN P, 1990, MUTAT RES, V236, P269, DOI 10.1016/0921-8777(90)90010-3; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Larson AA, 1996, CANCER RES, V56, P1426; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOEB LA, 1991, CANCER RES, V51, P3075; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MERLO A, 1994, CANCER RES, V54, P2098; MYEROFF LL, 1995, CANCER RES, V55, P5545; OKA Y, 1985, J BIOL CHEM, V260, P9435; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OOTA K, 1977, INT HIST CLASSIFICAT, V18; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1995, CANCER RES, V55, P5548; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reitmair AH, 1996, CANCER RES, V56, P2922; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; RHYU MG, 1994, ONCOGENE, V9, P29; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zhu JG, 1996, ONCOGENE, V12, P1417	39	70	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1719	1726		10.1038/sj.onc.1201343	http://dx.doi.org/10.1038/sj.onc.1201343			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349506				2022-12-28	WOS:A1997XY63100012
J	Petrenko, O; Ischenko, I; Enrietto, PJ				Petrenko, O; Ischenko, I; Enrietto, PJ			Characterization of changes in gene expression associated with malignant transformation by the NF-kappa B family member, v-Rel	ONCOGENE			English	Article						v-Rel; NF-kappa B; oncogene; transformation	RECEPTOR FUSION PROTEIN; BONE-MARROW CELLS; C-REL; TRANSCRIPTIONAL REGULATION; HEMATOPOIETIC-CELLS; TARGETED DISRUPTION; HOMOLOGY DOMAIN; LYMPHOID-CELLS; GROWTH-FACTOR; MICE LACKING	In this study, alterations in gene expression patterns have been examined in v-Rel-transformed avian bone marrow cells, Using a conditional v-Rel estrogen receptor chimera (v-RelER) which transforms cells in an estrogen-dependent manner, we constructed subtraction cDNA libraries from v-RelER-transformed bone marrow cells, Several different sequences were identified whose expression was altered upon hormone activation of v-RelER. These include two genes related to the MIP-I chemokine family (mip-1 beta and a tca3 homologue), a cell surface antigen sca-2 and the transcription factor nfkb1. The expression of each gene was assayed in a number of wild-type and mutant v-Rel-expressing fibroblast and hematopoietic cells, All v-Rel-transformed hematopoietic cells tested express high levels of nfkb1 and sca-2. In fibroblasts, wild-type v-Rel induced expression of mip-1 beta and nfkb1, while nontransforming mutants of v-Rel failed to do so, suggesting a role for these two genes in v-Rel mediated transformation, Finally, these genes are expressed at high levels in cells overexpressing wild-type and truncated forms of c-Rel, implying that v-Rel transforms, in part, by induction of c-Rel target genes.			Petrenko, O (corresponding author), SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794, USA.				NCI NIH HHS [CA51792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; ADAMS DH, 1994, P NATL ACAD SCI USA, V91, P7144, DOI 10.1073/pnas.91.15.7144; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BURD PR, 1987, J IMMUNOL, V139, P3126; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ERNST H, 1987, J BIOL CHEM, V262, P1206; FRANKEL S, 1994, J MOL BIOL, V235, P1351, DOI 10.1006/jmbi.1994.1090; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; Gilmore TD, 1996, ONCOGENE, V13, P1367; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HODGSON J, 1995, J VIROL, V69, P1971, DOI 10.1128/JVI.69.3.1971-1979.1995; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1994, J VIROL, V68, P2371; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LARSEN J, 1993, ONCOGENE, V8, P3221; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; Lloyd AR, 1996, J IMMUNOL, V156, P932; LU D, 1991, ONCOGENE, V6, P1235; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Noda S, 1996, J EXP MED, V183, P2355, DOI 10.1084/jem.183.5.2355; OHNO H, 1993, LEUKEMIA, V7, P2057; SAITOH SI, 1995, J IMMUNOL, V155, P5574; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMARDOVA J, 1995, ONCOGENE, V10, P2017; SPRANGRUDE GJ, 1989, J IMMUNOL, V142, P425; TAUB DD, 1995, J IMMUNOL, V155, P3877; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Walker AK, 1996, ONCOGENE, V12, P2515; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; White DW, 1996, MOL CELL BIOL, V16, P1169; WIDMER F, 1990, J CELL BIOL, V111, P3035, DOI 10.1083/jcb.111.6.3035; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	65	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1671	1680		10.1038/sj.onc.1201334	http://dx.doi.org/10.1038/sj.onc.1201334			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349500				2022-12-28	WOS:A1997XY63100006
J	Mancini, A; Niedenthal, R; Joos, H; Koch, A; Trouliaris, S; Niemann, H; Tamura, T				Mancini, A; Niedenthal, R; Joos, H; Koch, A; Trouliaris, S; Niemann, H; Tamura, T			Identification of a second Grb2 binding site in the v-Fms tyrosine kinase	ONCOGENE			English	Article						M-CSF receptor; v-Fms tyrosine kinase; Grb2; tyrosine phosphorylation; SH2 domain	FACTOR-I RECEPTOR; GREEN FLUORESCENT PROTEIN; FELINE SARCOMA-VIRUS; ONCOGENE PRODUCT; CSF-1 RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; POINT MUTATION; GROWTH-FACTOR; SH2 DOMAINS	Tyrosine autophosphorylation of the v-Fms oncogene product results in the formation of high-affinity binding sites for cellular proteins containing Src homology 2 (SH2) domains. These proteins transduce various mitogenic and morphogenic signals. As reported previously, (YKNI)-K-696 in the kinase insert domain of v-Fms binds to the growth factor receptor bound protein 2 (Grb2), a stimulator of the Ras/Raf1 pathway. Here, we mapped (YTNL)-T-921 within the C-terminal domain of Fms as a novel autophosphorylation site. We demonstrate that this site constitutes a second Grb2 binding site: a recombinant fusion protein (residues 904-944) containing phosphorylated Y921 bound Grb2 from FDCP-1Mac11 cell extracts significantly more efficiently than a corresponding protein (residues 617-759) containing Y696. A yeast two-hybrid system which allowed the formation of a functional Fms tyrosine kinase was employed to quantify binding of Grb2. Fms-protein containing either one of the two phosphorylation sites bound Grb2 equally well, binding was increased for proteins carrying both sites. In contrast, the simultaneous substitution of Y696 and Y921 by phenylalanines abolished Grb2 binding. Mouse NIH3T3 cells expressing the Y921F mutant Fms-protein showed a substantially higher content of fibronectin network than wild-type transformed cells and had largely lost their serum independent growth phenotype.	HANNOVER MED SCH,INST PHYSIOL CHEM,OE 4310,D-30623 HANNOVER,GERMANY	Hannover Medical School								BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P15337; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; Husson H, 1997, ONCOGENE, V14, P2331, DOI 10.1038/sj.onc.1201074; Joos H, 1996, J BIOL CHEM, V271, P24476, DOI 10.1074/jbc.271.40.24476; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Novak U, 1996, ONCOGENE, V13, P2607; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMOLA U, 1991, J VIROL, V65, P6181, DOI 10.1128/JVI.65.11.6181-6187.1991; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TAYOR GR, 1989, EMBO J, V8, P2029; TROULIARIS S, 1995, ARCH VIROL, V140, P179, DOI 10.1007/BF01309733; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5	36	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1565	1572		10.1038/sj.onc.1201518	http://dx.doi.org/10.1038/sj.onc.1201518			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380408				2022-12-28	WOS:A1997XX36900007
J	Crusius, K; Auvinen, E; Alonso, A				Crusius, K; Auvinen, E; Alonso, A			Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein	ONCOGENE			English	Article						EGFR; TGF-alpha; PMA; TPA; fos; raf	EPIDERMAL GROWTH-FACTOR; SIGNAL-REGULATED KINASE; TYROSINE KINASE; BOVINE PAPILLOMAVIRUS; FACTOR RECEPTOR; C-FOS; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL ACTIVATION; TRANSFORMING ACTIVITY; GENE-PRODUCT	In this report we demonstrate that cells expressing the human papillomavirus type 16 E5 open reading frame (HPV16-E5) show a greatly enhanced transcription of the immediate early genes after EGF or PMA treatment compared to control cells. This enhancement is due to amplification of the signal transduction pathways in response to growth factors or phorbol esters. Upon short-time EGF treatment of the E5-expressing cells we observed an increase in the activation of EGF receptors, resulting in a stronger activation of MAP kinases ERK1/2 compared to control-transfected cells. We also observed that in E5-expressing cells, treatment with PMA results in an increase in membrane-associated PKC activity, and a superactivation of the ERK1/2 MAP kinases. This superactivation is PKC-dependent, since pretreatment of the cells with the PKC inhibitor Ro 31-8220 inhibits MAP kinase activation and early gene transcription almost completely. Furthermore, treatment with genistein strongly reduces the PMA-mediated superactivation of ERK1/2 kinases, demonstrating a PKC-mediated, tyrosine kinase-dependent pathway in the superinduction of MAP kinase activation. Thus, HPV16-E5 effects superactivation of MAP kinases over at least two different pathways, a PKC-mediated, and another, receptor tyrosine-kinase mediated, PKC-independent one.	DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CONRAD M, 1994, VIROLOGY, V200, P796, DOI 10.1006/viro.1994.1244; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DANESCH U, 1994, J BIOL CHEM, V269, P27258; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIMAIO D, 1991, ADV CANCER RES, V56, P133; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; HARVAT BL, 1995, CELL GROWTH DIFFER, V6, P955; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PIM D, 1992, ONCOGENE, V7, P27; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Sambrook J, 1989, MOL CLONING; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHILLER JT, 1986, J VIROL, V57, P1; SEGER R, 1995, J BIOL CHEM, V270, P28325; STONE RL, 1994, J BIOL CHEM, V269, P31323; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	48	81	88	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	1997	15	12					1437	1444		10.1038/sj.onc.1201312	http://dx.doi.org/10.1038/sj.onc.1201312			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333019	Bronze			2022-12-28	WOS:A1997XW41100007
J	Cao, WS; BritosBray, M; Claxton, DF; Kelley, CA; Speck, NA; Liu, PP; Friedman, AD				Cao, WS; BritosBray, M; Claxton, DF; Kelley, CA; Speck, NA; Liu, PP; Friedman, AD			CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells	ONCOGENE			English	Article						CBF beta-SMMHC; inv(16); CBF; leukemia; myeloid; cell cycle	MYOSIN HEAVY-CHAIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; ACUTE MYELOMONOCYTIC LEUKEMIA; FACTOR-RECEPTOR PROMOTER; TRANSCRIPTION FACTOR; FUSION TRANSCRIPT; CHIMERIC PROTEIN; NUCLEAR FACTOR	CBF beta-SMMHC is expressed from the inv(16) chromosome in M4Eo AML. Mice lacking CBF subunits or expressing the CBF beta-SMMHC or AML1-ETO onco-proteins failed to develop definitive hematopoiesis. To investigate these effects on hematopoiesis, we expressed CBF beta-SMMHC from the metallothionein promoter, in both 32D c13 myeloid cells and Ba/F3 B-lymphoid cells. Addition of zinc increased CBF beta-SMMHC levels more than tenfold, with higher levels evident in Ba/F3 lines. Levels obtained in 32D c13 cells were similar to those of endogenous CBF beta. Indirect immunofluorescence revealed zinc-inducible speckled, nuclear staining in Ba/F3 cells and diffuse nuclear staining in 32D c13 cells. CBF beta-SMMHC reduced endogenous CBF DNA-binding fivefold in both cell types, increased cell generation time 1.9-fold, on average, in 32D c13 cells and 1.5-fold in Ba/ F3 cells and decreased tritiated thymidine incorporation into DNA correspondingly. CBFP beta-SMMHC increased the proportion of cells in G1 1.7-fold, on average, in 32D c13 and Ba/F3 cells, and decreased the proportion of cells in S phase by a similar degree. CBF beta-SMMHC induced a marked increase in hypophosphorylated Rb, but did not alter IL-3 Receptor alpha or beta subunit levels. Neither apoptosis nor 32D differentiation was induced by zinc in IL-3 in these lines. Induction of CBF beta-SMMHC WC in 32D c13 cells did not inhibit their differentiation to neutrophils or their expression of myeloperoxidase mRNA in GCSF, and did not produce an eosinophilic phenotype. Additional, proliferative genetic changes in M4eo AMLs might potentiate inhibition of differentiation by CBF beta-SMMHC by allowing its increased expression.	JOHNS HOPKINS UNIV, CTR ONCOL, DIV PEDIAT ONCOL, BALTIMORE, MD 21287 USA; UNIV TEXAS, DEPT HEMATOL, HOUSTON, TX 77030 USA; NHLBI, NIH, BETHESDA, MD 20892 USA; DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; NIH, NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Dartmouth College; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Liu, Paul/A-7976-2012	Liu, Paul/0000-0002-6779-025X	NHLBI NIH HHS [R01 HL51388] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051388] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARTHUR DC, 1983, BLOOD, V61, P994; BAE SC, 1993, ONCOGENE, V8, P809; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BritosBray M, 1996, LEUKEMIA, V10, P984; BRITOSBRAY M, 1997, IN PRESS MOL CELL BI; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Claxton D, 1996, LEUKEMIA, V10, P1479; CLAXTON DF, 1994, BLOOD, V83, P1750; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICKSON P, 1992, BLOOD, V80, P1825; Frank R, 1995, ONCOGENE, V11, P2667; Friedman AD, 1996, CANCER RES, V56, P3250; FRIEDMAN AD, 1991, BLOOD, V78, P2426; FRIEDMAN AD, 1994, BLOOD, V84, pA374; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Haferlach T, 1996, BLOOD, V87, P2459, DOI 10.1182/blood.V87.6.2459.bloodjournal8762459; Hiddemann W., 1995, Blood, V86, p267A; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; McLean TW, 1996, BLOOD, V88, P4252; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1996, BLOOD, V88, P1148; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SACCHI N, 1994, GENE CHROMOSOME CANC, V11, P226, DOI 10.1002/gcc.2870110405; Sacchi N, 1996, ONCOGENE, V12, P437; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SCOTT LM, 1992, BLOOD, V80, P1725; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TIGHE JE, 1994, BLOOD, V84, P2115, DOI 10.1182/blood.V84.7.2115.bloodjournal8472115; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	67	71	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1315	1327		10.1038/sj.onc.1201305	http://dx.doi.org/10.1038/sj.onc.1201305			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315100				2022-12-28	WOS:A1997XV84500010
J	Panagopoulos, I; Lassen, C; Isaksson, M; Mitelman, F; Mandahl, N; Aman, P				Panagopoulos, I; Lassen, C; Isaksson, M; Mitelman, F; Mandahl, N; Aman, P			Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia	ONCOGENE			English	Article						chromosome translocations; DNA sequence; breakpoints; tumors	ACUTE PROMYELOCYTIC LEUKEMIA; RNA-BINDING PROTEIN; CHROMOSOMAL TRANSLOCATION; MOLECULAR ANALYSIS; FUSION; ONCOGENE; CHOP; ERG; RECOMBINATION; CELL	We have sequenced the breakpoint regions in one acute myeloid leukemia (AML) with t(16;21)(pll;q22) resulting in the formation of a FUS/ERG hybrid gene and in four myxoid liposarcomas (MLS), three of which had the t(12;16) (q13:p11) and translocation a FUS/CHOP fusion gene and one with t(12;22;20)(q13;q12;q11) and an EWS/CHOP hybrid gene. The breakpoints were localized to intron 7 of FUS, intron 1 of CHOP, an intronic sequence of ERG and intron 7 of EWS. In two MLS cases with t(12;16) and in the AML, the breaks in intron 7 of FUS had occurred close to each other, a few nucleotides downstream from a TG dinucleotide repeat region. The break in the two MLS had occurred in the same ATGGTG hexamer and in the AML 40 nucleotides upstream from the hexamer. The third case of t(12;16) MLS had a break upstream and near a TC-dinucleotide repeat region and a sequence similar to the chi bacterial recombination element was found to flank the breakpoint. In the MLS with the EWS/ CHOP hybrid gene, the break in intron 7 of EWS had occurred close to an Alu sequence. Similarly, in all 4 MLS, the breaks in intron 1 of CHOP mere near an Alu sequence. No Alu or other repetitive sequences were found 250 bp upstream or downstream from the break in the ERG intron involved in the AML case. In the AML, the MLS with ESW/CHOP and in one MLS with FUS/CHOP there were one, two and six, respectively, nucleotide identity between the contributing germline sequences in the breakpoint. In the other two MLS cases, two and three extra nucleotides of unknown origin were inserted between the FUS and CHOP sequences. At the junction and/or in its close vicinity, identical oligomers, frequently containing a trinucleotide TGG, were found in both partner genes. Our data thus show that all four genes-PUS, EWS, CHOP and ERG-contain characteristic motifs in the breakpoint regions which may serve as specific recognition sites for DNA-binding proteins and have functional importance in the recombination events taking place between the chromosomes. Different sequence motifs may, however, play a role in each individual case.			Panagopoulos, I (corresponding author), UNIV LUND HOSP,DEPT CLIN GENET,S-22185 LUND,SWEDEN.			Mitelman, Felix/0000-0002-3757-7212; Aman, Pierre/0000-0002-1482-8875; Panagopoulos, Ioannis/0000-0003-2159-5341				ADACHI M, 1990, ONCOGENE, V5, P1653; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BHAGIRATH T, 1995, GENE CHROMOSOME CANC, V13, P126, DOI 10.1002/gcc.2870130209; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DOMER PH, 1995, LEUKEMIA, V9, P1305; DONG S, 1993, GENE CHROMOSOME CANC, V6, P133, DOI 10.1002/gcc.2870060302; FELIX CA, 1995, CANCER RES, V55, P4287; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JAEGER U, 1993, BLOOD, V81, P1833; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KAGAN J, 1993, HEMATOL PATHOL, V7, P159; KASAI M, 1992, MOL CELL BIOL, V12, P4751, DOI 10.1128/MCB.12.10.4751; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHOWE LC, 1987, ANNU REV IMMUNOL, V5, P253, DOI 10.1146/annurev.iy.05.040187.001345; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; SPITZNER JR, 1989, NUCLEIC ACIDS RES, V18, P1; YOSHIDA H, 1995, GENE CHROMOSOME CANC, V12, P37, DOI 10.1002/gcc.2870120107	33	51	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1357	1362		10.1038/sj.onc.1201281	http://dx.doi.org/10.1038/sj.onc.1201281			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315104				2022-12-28	WOS:A1997XV84500014
J	Guo, WT; Baluda, MA; Park, NH				Guo, WT; Baluda, MA; Park, NH			Ethanol upregulates the expression of p21(WAF1/CIP1) and prolongs G(1) transition via a p53-independent pathway in human epithelial cells	ONCOGENE			English	Article						ethanol; p53; p21(WAF1/CIP1); cell cycle	HUMAN ORAL KERATINOCYTES; WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; ALCOHOL-CONSUMPTION; HUMAN PAPILLOMAVIRUS; SIGNAL-TRANSDUCTION; HUMAN-LYMPHOCYTES; LEUKEMIC-CELLS; DNA-DAMAGE; APOPTOSIS	The control of cell cycle progression is necessary for accuracy in the replication of DNA and the distribution of genetic information to daughter cells, Disturbances in progression of the cell cycle may result in the loss of genomic integrity, a 'hallmark' of cancer cells, Extensive consumption of alcoholic beverages is a risk with the development of various associated epidermoid cancer including oral and pharyngeal squamous cell carcinomas, However, effects of ethanol on cell cycle progression and on the expression of genes associated with the cell cycle have not been studied. We report here that exposure of human epithelial cells to ethanol, at concentrations (100-200 mM) that do not cause cell death, (a) does not affect or only reduces slightly the cellular level of p53 protein, (b) upregulates the transcription of the WAF1/CIP1 gene, (c) inhibits the Cdk2 activity, and (d) reduces the rate of cellular proliferation by inducing a delay in G(1) phase transition, The results also indicate that, at these non-cytotoxic concentrations, ethanol exhibits its effects through a p53-independent mechanism.	UNIV CALIF LOS ANGELES, DENT RES INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH DENT, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P20DE010598, P50DE010598] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10598] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AHLUWALIA BS, 1995, ALCOHOL, V12, P589, DOI 10.1016/0741-8329(95)02008-X; ANDERSON LM, 1995, ALCOHOL, V12, P97, DOI 10.1016/0741-8329(94)00089-1; BAEK JH, 1994, INT J ONCOL, V5, P1023; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BLOT WJ, 1994, CANCER SURV, V20, P23; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Deleyiannis FWB, 1996, JNCI-J NATL CANCER I, V88, P542, DOI 10.1093/jnci/88.8.542; DEPETRILLO PB, 1993, ALCOHOL CLIN EXP RES, V17, P351, DOI 10.1111/j.1530-0277.1993.tb00774.x; DIAMOND I, 1994, EXS, V71, P175; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELMORE JG, 1995, OTOLARYNG HEAD NECK, V113, P253, DOI 10.1016/S0194-5998(95)70114-1; EWALD SJ, 1993, ALCOHOL CLIN EXP RES, V17, P359, DOI 10.1111/j.1530-0277.1993.tb00776.x; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HARPER JW, 1993, CELL, V75, P805; Hsieh KP, 1996, J BIOL CHEM, V271, P2709, DOI 10.1074/jbc.271.5.2709; KASTAN MB, 1991, CANCER RES, V51, P6304; KO YC, 1995, J ORAL PATHOL MED, V24, P450, DOI 10.1111/j.1600-0714.1995.tb01132.x; Kobayashi T, 1995, ONCOGENE, V11, P2311; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LONGNECKER MP, 1995, ALCOHOL, V12, P87, DOI 10.1016/0741-8329(94)00088-3; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAIER H, 1994, ALCOHOL CLIN EXP RES, V18, P387, DOI 10.1111/j.1530-0277.1994.tb00030.x; MILES MF, 1991, J BIOL CHEM, V266, P2409; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUFTI SI, 1992, CANCER DETECT PREV, V16, P157; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; RABIN RA, 1983, J PHARMACOL EXP THER, V227, P551; Seitz H K, 1992, Eur J Cancer Prev, V1 Suppl 3, P5, DOI 10.1097/00008469-199210003-00002; SHAO H, 1995, CELL IMMUNOL, V164, P11, DOI 10.1006/cimm.1995.1137; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SPINOZZI F, 1993, GASTROENTEROLOGY, V105, P1490, DOI 10.1016/0016-5085(93)90156-7; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILKE N, 1994, EXS, V71, P49; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1995, CANCER RES, V55, P668	43	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1143	1149		10.1038/sj.onc.1201287	http://dx.doi.org/10.1038/sj.onc.1201287			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294607				2022-12-28	WOS:A1997XU99100003
J	Piette, J; Neel, H; Marechal, V				Piette, J; Neel, H; Marechal, V			Mdm2: Keeping p53 under control	ONCOGENE			English	Review						Mdm2; p53; cancer; oncogene	WILD-TYPE P53; AUTOREGULATORY FEEDBACK LOOP; NUCLEAR POLYHEDROSIS-VIRUS; SOFT-TISSUE SARCOMAS; 5S RIBOSOMAL-RNA; TRANSCRIPTIONAL ACTIVATION; GENE AMPLIFICATION; TUMOR-SUPPRESSOR; DNA-DAMAGE; P53-ASSOCIATED PROTEIN	The Mdm2 gene is overexpressed in several human tumors, The oncogenic potential of Mdm2 is partially explained by the inhibition of the activity of the tumor suppressor protein p53, Determination of the three-dimensional structure of complexes between Mdm2 and the N-terminal p53 peptide provided a molecular basis for the inhibition of the transcriptional function of p53 by Mdm2. More dramatically, p53 is targeted by Mdm2 for rapid degradation, The Mdm2 gene itself is activated by p53, which gives the opportunity for feed-back control of p53 activity, Keeping p53 under control is most likely the major task of Mdm2 during early development, Recently, evidence was provided for an alternative, p53-independent function of Mdm2.	HOP ROTHSCHILD, MICROBIOL SERV, F-75571 PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite	Piette, J (corresponding author), CNRS, INST GENET MOL MONTPELLIER, BP5051, 1919 ROUTE MENDE, F-34033 MONTPELLIER 01, FRANCE.		marechal, vincent/P-7719-2017					Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; AYRES MD, 1994, VIROLOGY, V202, P586, DOI 10.1006/viro.1994.1380; BAE IS, 1995, CANCER RES, V55, P2387; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BERBERICH S, 1994, ONCOGENE, V9, P1469; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Bottger V, 1996, ONCOGENE, V13, P2141; BOULIANNE GL, 1991, EMBO J, V10, P2975, DOI 10.1002/j.1460-2075.1991.tb07848.x; BUESORAMOS CE, 1993, BLOOD, V82, P2617; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Carrier F, 1996, MUTAT RES-FUND MOL M, V352, P79, DOI 10.1016/0027-5107(95)00255-3; Chang KW, 1996, CARCINOGENESIS, V17, P595, DOI 10.1093/carcin/17.3.595; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; COX LS, 1994, ONCOGENE, V9, P2951; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Dazard JE, 1997, ONCOGENE, V14, P1123, DOI 10.1038/sj.onc.1200922; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FISCELLA M, 1993, ONCOGENE, V8, P1519; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jones SN, 1996, GENE, V175, P209, DOI 10.1016/0378-1119(96)00151-5; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1991, CANCER RES, V51, P6304; Kastan MB, 1996, BIOESSAYS, V18, P617, DOI 10.1002/bies.950180804; KHATIB ZA, 1993, CANCER RES, V53, P5535; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KONDO S, 1995, ONCOGENE, V10, P2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LACONI S, 1995, CANCER RES, V55, P2560; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; LENG P, 1995, ONCOGENE, V10, P1275; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lohrum M, 1996, ONCOGENE, V13, P2527; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu X, 1996, ONCOGENE, V13, P413; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MacCallum DE, 1996, ONCOGENE, V13, P2575; MARCHETTI A, 1995, DIAGN MOL PATHOL, V4, P93, DOI 10.1097/00019606-199506000-00004; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MAXWELL SA, 1994, ANTICANCER RES, V14, P2541; Mayo LD, 1996, ONCOGENE, V13, P2315; MCCANN AH, 1995, BRIT J CANCER, V71, P981, DOI 10.1038/bjc.1995.189; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; Momand J, 1997, J CELL BIOCHEM, V64, P343; Murdoch KJ, 1996, EXP CELL RES, V227, P332, DOI 10.1006/excr.1996.0282; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; NILBERT M, 1995, CANCER GENET CYTOGEN, V83, P32, DOI 10.1016/S0165-4608(95)00016-X; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PERRY ME, 1994, MT SINAI J MED, V61, P291; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PRICE BD, 1994, CANCER RES, V54, P896; QUESNEL B, 1994, BRIT J HAEMATOL, V88, P415, DOI 10.1111/j.1365-2141.1994.tb05044.x; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Rudt F, 1996, EMBO J, V15, P1383, DOI 10.1002/j.1460-2075.1996.tb00480.x; SCHOTTELIUS A, 1994, LEUKEMIA, V8, P1673; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; SHVARTS A, IN PRESS GENOMICS; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; WANG Y, 1995, ONCOGENE, V10, P779; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608	111	227	234	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1001	1010		10.1038/sj.onc.1201432	http://dx.doi.org/10.1038/sj.onc.1201432			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285554				2022-12-28	WOS:A1997XT16100001
J	Alimandi, M; Heidaran, MA; Gutkind, JS; Zhang, JC; Ellmore, N; Valius, M; Kazlauskas, A; Pierce, JH; Li, WQ				Alimandi, M; Heidaran, MA; Gutkind, JS; Zhang, JC; Ellmore, N; Valius, M; Kazlauskas, A; Pierce, JH; Li, WQ			PLC-gamma activation is required for PDGF-beta R-mediated mitogenesis and monocytic differentiation of myeloid progenitor cells	ONCOGENE			English	Article						PLC-gamma; PDGF-beta R; monocytic differentiation	PROTEIN-KINASE-C; GROWTH-FACTOR; PHOSPHOLIPASE-C; MONOCLONAL-ANTIBODY; RECEPTOR; DELTA; ALPHA; AUTOPHOSPHORYLATION; PHOSPHORYLATION; INVOLVEMENT	To investigate the molecular mechanisms mediating hematopoietic cell differentiation and mitogenesis by activation of the platelet-derived growth factor beta receptor (PDGF-beta R), the mild type PDGF-beta R (PDGF-beta RWT) and tyrosine to phenylalanine mutants of the PDGF-beta R, including F751, F966, F970, F1009, F1021 and F1009/F1021 were overexpressed in FDC-P2 myeloid progenitor cells by retroviral-mediated gene transfer. Stimulation of PDGF-beta RWT and F966, F970 and F1009 infectants with PDGF-BB led to the increased expression of monocytic differentiation markers, In contrast, activation of PDGF-beta R in the parental line or the F1021 or F1009/F1021 mutant infectants failed to induce monocytic differentiation, PDGF-BB stimulation of PDGF-beta RWT, F751, F966, F970 and F1009 infectants led to pronounced DNA synthesis, whereas F1021 and F1009/F1021 infectants did not reveal any increase in mitogenesis when compared to that of the FDC-P2 line, While PDGF stimulation of FDC-2 cells overexpressing PDGF-beta RWT led to a pronounced increase in inositol phosphate formation due to phospholipase C-gamma (PLC-gamma) activation, PDGF-BB induced phosphoinositol hydrolysis was completely abolished in the F1021 and F1009/F1021 infectants, GF 109203X, a specific inhibitor of protein kinase C (PKC) activation, fully blocked PDGF-beta R-mediated monocytic differentiation and mitogenesis, Taken together, these results suggest that stimulation of the PDGF-beta R signaling pathway can mediate monocytic differentiation when PDGF-beta R is expressed at sufficient levels and that activation of PLC-gamma and PKC plays a pivotal role in PDGF-beta R-mediated differentiation and mitogenesis in FDC-P2 cell system.	NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892; NIDR,MOL SIGNALING UNIT,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892; LITHUANIA ACAD SCI,INST BIOCHEM,LT-2600 VILNIUS,LITHUANIA; HARVARD UNIV,SCH MED,SCHEPENS EYE RES INST,BOSTON,MA 02114	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Vilnius University; Harvard University; Harvard Medical School; Schepens Eye Research Institute			Alimandi, Maurizio/AAG-9246-2019; Gutkind, J. Silvio/J-1201-2016; Valius, Mindaugas/N-1220-2019; Valius, Mindaugas/F-2734-2012; Gutkind, J. Silvio/A-1053-2009	Alimandi, Maurizio/0000-0002-1409-6803; Gutkind, J. Silvio/0000-0002-5150-4482; Valius, Mindaugas/0000-0001-8478-8517; 	NATIONAL CANCER INSTITUTE [R29CA055063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER; NCI NIH HHS [CA55063] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Aprikian A., 1996, Blood, V88, p633A; ASHCROFT M, 1996, 1996 M TYR PHOSPH CE; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HO MK, 1982, J IMMUNOL, V128, P1221; INABA T, 1993, J BIOL CHEM, V268, P24353; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LEE SH, 1985, J EXP MED, V161, P475, DOI 10.1084/jem.161.3.475; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; MARTINYBARON G, 1993, J BIOL CHEM, V268, P1749; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UKELESS JC, 1979, J EXP MED, V150, P580; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Uren A, 1996, J BIOL CHEM, V271, P11051, DOI 10.1074/jbc.271.19.11051; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479	31	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					585	593		10.1038/sj.onc.1201221	http://dx.doi.org/10.1038/sj.onc.1201221			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247312	Bronze			2022-12-28	WOS:A1997XN25500010
J	Andrew, SE; Reitmair, AH; Fox, J; Hsiao, L; Francis, A; McKinnon, M; Mak, TW; Jirik, FR				Andrew, SE; Reitmair, AH; Fox, J; Hsiao, L; Francis, A; McKinnon, M; Mak, TW; Jirik, FR			Base transitions dominate the mutational spectrum of a transgenic reporter gene in MSH2 deficient mice	ONCOGENE			English	Article						mismatch repair; MSH2; lacI transgenic; mutation	NONPOLYPOSIS COLON-CANCER; MISMATCH REPAIR PROTEINS; CARCINOMA CELL-LINES; ESCHERICHIA-COLI; MICROSATELLITE INSTABILITY; COLORECTAL TUMORIGENESIS; MUTATOR PHENOTYPES; LACI GENE; DNA; INACTIVATION	Tumors derived from individuals with hereditary nonpolyposis colorectal cancer syndrome frequently demonstrate mutations in both alleles of hMSH2, a key gene in DNA mismatch repair (MMR). Sporadic tumors also frequently exhibit MMR deficiency. In keeping with the role of MMR in the maintenance of genome integrity, mice deficient in MSH2 via gene targeting demonstrate a high incidence of thymic lymphomas and small intestinal adenocarcinomas. To investigate the effects of MSH2 deficiency in normal tissues, mice containing a retrievable transgenic lad reporter gene for mutation detection were crossed with MSH2(-/-) mice, Mice homozygous for MSH2 deficiency revealed 4.8, 11.0 and 15.2-fold elevations in spontaneous mutation frequency in DNA obtained from brain, small intestine, and thymus, respectively, as compared to heterozygous or wild-type mice. Mutations most frequently recovered from MSH2(-/-) mice were single base substitutions (77%), particularly base transitions (64%), Frameshifts occurred less frequently (19%) and fell within very short (3-5 bp) mononucleotide runs. Thus the number of key growth control genes potentially impacted by MMR deficiency extends beyond those containing repetitive sequences. These results highlight the capacity for MSH2 deficiency to serve as a potent driving force during the multi-step evolution of tumors.	UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,CTR MOL MED & THERAPEUT,VANCOUVER,BC V6T 1Z3,CANADA; UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,AMGEN INST,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL,AMGEN INST,TORONTO,ON M5G 2M9,CANADA	University of British Columbia; University of British Columbia; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto				McKinnon, Margaret/0000-0002-3161-414X				Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Beroud C, 1996, NUCLEIC ACIDS RES, V24, P147, DOI 10.1093/nar/24.1.147; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, CANCER RES, V55, P2304; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COX EC, 1976, ANNU REV GENET, V10, P135, DOI 10.1146/annurev.ge.10.120176.001031; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DOHET C, 1985, P NATL ACAD SCI USA, V82, P503, DOI 10.1073/pnas.82.2.503; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUJII H, 1989, J BIOL CHEM, V264, P10057; GLAZER PM, 1986, P NATL ACAD SCI USA, V83, P1041, DOI 10.1073/pnas.83.4.1041; GU M, 1994, MUTAT RES, V307, P533, DOI 10.1016/0027-5107(94)90264-X; HAWN MT, 1995, CANCER RES, V55, P3721; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; KOHLER SW, 1990, GENET ANAL-BIOMOL E, V7, P212, DOI 10.1016/0735-0651(90)90003-X; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEONG PM, 1986, J BACTERIOL, V168, P412, DOI 10.1128/jb.168.1.412-416.1986; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MIRSALIS JC, 1995, ANNU REV PHARMACOL, V35, P145; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; REENAN RAG, 1992, GENETICS, V132, P963; Reitmair AH, 1996, CANCER RES, V56, P2922; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	45	58	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					123	129		10.1038/sj.onc.1201180	http://dx.doi.org/10.1038/sj.onc.1201180			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244348				2022-12-28	WOS:A1997XK37200001
J	Chaffanet, M; Popovici, C; Leroux, D; Jacrot, M; Adelaide, J; Dastugue, N; Gregoire, MJ; Hagemeijer, A; Lafage-Pochitaloff, M; Birnbaum, D; Pebusque, MJ				Chaffanet, M; Popovici, C; Leroux, D; Jacrot, M; Adelaide, J; Dastugue, N; Gregoire, MJ; Hagemeijer, A; Lafage-Pochitaloff, M; Birnbaum, D; Pebusque, MJ			t(6;8), t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosome region 8p11-12	ONCOGENE			English	Article						FGFR1 gene; leukemia; lymphoma; human chromosome pairs 6, 8, 9, 13; translocation; fluorescence in situ hybridization; stem cell; hematopoiesis	ACUTE MONOCYTIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE MONOBLASTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; T-CELL; CLINICOPATHOLOGICAL ENTITY; RECIPROCAL TRANSLOCATION; MYELOMONOCYTIC LEUKEMIA; RECEPTOR GENES; SHORT ARM	A stem-cell myeloproliferative disorder involving T- and B-cell, and myeloid lineages, is associated with three different translocations with a breakpoint in region p11-12 of chromosome 8: t(6;8)(q27;p11), t(8;9)(p11;q33), and t(8;13)(p12;q12), respectively. Using fluorescence in situ hybridization (FISH), we have analysed blood cells from a series of five patients carrying these different translocations. We have identified cosmids from chromosome region 8p11-12 that span the breakpoint in all the cases. They are specific for the FGFR1 gene that encodes a receptor for members of the FGF family. The breakpoint was further detected by Southern and pulsed-field gel electrophoresis analyses with probes from the FGFR1 locus.	Inst Cancerol & Immunol Marseille, INSERM, U119, Oncol Mol Lab, F-13009 Marseille, France; Inst J Paoli I Calmettes, Lab Biol Tumeurs, F-13009 Marseille, France; Univ Grenoble 1, Inst Albert Bonniot, Grp Rech Lymphomes, Grenoble, France; Hop Purpan, Lab Hematol Genet Hemopathies, Toulouse, France; Ctr Hosp Univ, Genet Lab, Nancy, France; Univ Leuven, Ctr Human Genet, Louvain, Belgium; IPC, Dept Hematol, Lab Cytogenet, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU de Toulouse; CHU de Nancy; KU Leuven; UNICANCER; Institut Paoli-Calmette (IPC)	Pebusque, MJ (corresponding author), Inst Cancerol & Immunol Marseille, INSERM, U119, Oncol Mol Lab, 27 Bd Roure, F-13009 Marseille, France.		CHAFFANET, Max/AAU-5743-2020; POPOVICI, Cornel/A-2027-2009; Leroux, Dominique/G-7309-2014; ADELAIDE, José JA/O-4390-2017	POPOVICI, Cornel/0000-0001-8226-3127; ADELAIDE, José JA/0000-0003-4364-9857; CHAFFANET, Max/0000-0002-2344-1488				AGUIAR RCT, 1995, BLOOD, V86, P834, DOI 10.1182/blood.V86.2.834.bloodjournal862834; BEHRINGER D, 1995, LEUKEMIA, V9, P988; BELLOMO MJ, 1992, BRIT J HAEMATOL, V81, P307, DOI 10.1111/j.1365-2141.1992.tb08225.x; BERNSTEIN R, 1987, CANCER GENET CYTOGEN, V24, P213, DOI 10.1016/0165-4608(87)90101-4; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chaffanet M, 1996, CYTOGENET CELL GENET, V72, P63, DOI 10.1159/000134164; DIB A, 1995, ONCOGENE, V10, P995; DREXLER HG, 1995, LEUKEMIA, V9, P480; Elsner S., 1994, British Journal of Haematology, V87, P124; FAGAN K, 1993, CANCER GENET CYTOGEN, V65, P71, DOI 10.1016/0165-4608(93)90062-Q; FRIEDHOFF F, 1983, CANCER GENET CYTOGEN, V9, P391, DOI 10.1016/0165-4608(83)90088-2; HEIM S, 1987, BRIT J HAEMATOL, V66, P323, DOI 10.1111/j.1365-2141.1987.tb06917.x; INHORN RC, 1995, BLOOD, V85, P1881, DOI 10.1182/blood.V85.7.1881.bloodjournal8571881; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEMPSKI H, 1995, GENE CHROMOSOME CANC, V12, P283, DOI 10.1002/gcc.2870120408; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LAI JL, 1992, CANCER GENET CYTOGEN, V60, P180, DOI 10.1016/0165-4608(92)90013-X; LAI JL, 1987, CANCER GENET CYTOGEN, V27, P101, DOI 10.1016/0165-4608(87)90265-2; LESLIE J, 1994, BRIT J HAEMATOL, V86, P876, DOI 10.1111/j.1365-2141.1994.tb04847.x; LEWIS JP, 1983, AM J PEDIAT HEMATOL, V5, P265; MACDONALD D, 1995, LEUKEMIA, V9, P1628; MACDONALD D, 1994, BRIT J HAEMATOL, V86, P879, DOI 10.1111/j.1365-2141.1994.tb04848.x; Michaux L, 1996, BLOOD, V87, P1658, DOI 10.1182/blood.V87.4.1658.bloodjournal8741658; MITELMAN F, 1992, GENE CHROMOSOME CANC, V5, P57, DOI 10.1002/gcc.2870050109; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; NAEEM R, 1995, GENE CHROMOSOME CANC, V12, P148, DOI 10.1002/gcc.2870120210; Nakayama H, 1996, BRIT J HAEMATOL, V92, P692, DOI 10.1046/j.1365-2141.1996.00386.x; OSCIER DG, 1985, J MED GENET, V22, P398, DOI 10.1136/jmg.22.5.398; PEBUSQUE MJ, 1993, GENE CHROMOSOME CANC, V8, P119, DOI 10.1002/gcc.2870080209; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RUTA M, 1988, ONCOGENE, V3, P9; Sainati L, 1996, PEDIATR HEMAT ONCOL, V13, P151, DOI 10.3109/08880019609030805; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SLOVAK ML, 1991, CANCER GENET CYTOGEN, V56, P237, DOI 10.1016/0165-4608(91)90176-U; Soenen V, 1996, GENE CHROMOSOME CANC, V15, P191, DOI 10.1002/(SICI)1098-2264(199603)15:3<191::AID-GCC9>3.0.CO;2-Y; STARK B, 1995, LEUKEMIA RES, V19, P367, DOI 10.1016/0145-2126(94)00150-9; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; vandenBerg H, 1996, LEUKEMIA, V10, P1252; VANNIER JP, 1984, LEUKEMIA RES, V8, P647, DOI 10.1016/0145-2126(84)90013-4; Velloso ERP, 1996, LEUKEMIA LYMPHOMA, V21, P137, DOI 10.3109/10428199609067591; ZELEZNIKLE NJ, 1995, SEMIN HEMATOL, V32, P201	42	55	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					945	949		10.1038/sj.onc.1201601	http://dx.doi.org/10.1038/sj.onc.1201601			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484786				2022-12-28	WOS:000072053200014
J	Valgeirsdottir, S; Paukku, K; Silvennoinen, O; Heldin, CH; Claesson-Welsh, L				Valgeirsdottir, S; Paukku, K; Silvennoinen, O; Heldin, CH; Claesson-Welsh, L			Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains	ONCOGENE			English	Article						PDGF; receptor; Stat; JAK; phosphorylation, binding sites	SIGNAL-TRANSDUCTION PATHWAYS; COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASES; DNA-BINDING ACTIVITY; PHOSPHOLIPASE-C-GAMMA; AUTOPHOSPHORYLATION SITES; TARGETED DISRUPTION; MOUSE-LIVER; IDENTIFICATION; GENE	Signal transducers and activators of transcription (Stats) are known to transduce signals from the cell surface to the nucleus in cytokine receptor signaling. We examined the capacity of platelet-derived gron th factor (PDGF) receptor to interact with and activate Stat molecules. Activation of the PDGF beta-receptor led to tyrosine phosphorylation of Stat1, Stat3 and Stat5, which was accompanied by specific DNA-binding activities, These events were only weakly stimulated by the activated PDGF alpha-receptor. In cells expressing PDGF beta-receptors mutated at Tyr579, Tyr581 or Tyr775, tyrosine phosphorylation as well as DNA-binding activity of Stat5 was reduced. Immobilized peptides containing phosphorylated Tyr579, Tyr581 or Tyr775 bound Stat5, suggesting direct binding of Stat5 to these tyrosine residues of the PDGF beta-receptor. Members of the Janus kinase family were also shown to interact with the PDGF beta-receptor, and to a lesser extent with the alpha-receptor, but their importance for PDGF-induced Stat activation remains to be determined.	Biomed Ctr, Dept Med & Physiol Chem, S-75123 Uppsala, Sweden; Biomed Ctr, Ludwig Inst Canc Res, Uppsala, Sweden; Univ Helsinki, Dept Virol, Haartman Inst, Helsinki, Finland; Tampere Univ, Inst Med Technol, FIN-33101 Tampere, Finland	Ludwig Institute for Cancer Research; University of Helsinki; Tampere University	Claesson-Welsh, L (corresponding author), Biomed Ctr, Dept Med & Physiol Chem, Box 575, S-75123 Uppsala, Sweden.							ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Heldin CH., 1996, MOL CELLULAR BIOL WO, P249; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Raines E.W., 1990, PEPTIDE GROWTH FACTO, DOI [10.1007/978-3-642-49295-2_5, DOI 10.1007/978-3-642-49295-2_5]; RAZ R, 1994, J BIOL CHEM, V269, P24391; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; VALGEIRSDOTTIR S, 1995, J BIOL CHEM, V270, P10161, DOI 10.1074/jbc.270.17.10161; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEIMA SM, 1990, EXP CELL RES, V186, P324, DOI 10.1016/0014-4827(90)90312-X; WENNSTROM S, 1994, ONCOGENE, V9, P651; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	54	63	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					505	515		10.1038/sj.onc.1201555	http://dx.doi.org/10.1038/sj.onc.1201555			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484840				2022-12-28	WOS:000071739400009
J	Harris, TM; Rogler, LE; Rogler, CE				Harris, TM; Rogler, LE; Rogler, CE			Reactivation of the maternally imprinted IGF2 allele in TGF alpha induced hepatocellular carcinomas in mice	ONCOGENE			English	Article						IGF2; imprinting; DEN; hepatocellular carcinoma; transgenic mice	GROWTH-FACTOR-II; INSULIN-RECEPTOR SUBSTRATE-1; HEPATITIS-VIRUS CARRIERS; TRANSGENIC MICE; DIFFERENTIAL EXPRESSION; MESSENGER-RNA; GENE-EXPRESSION; LIVER-TUMORS; OVEREXPRESSION; APOPTOSIS	The Insulin like growth factor 2 (IGF2) gene is expressed in several types of tumors in humans and mice and has been implicated as an important growth factor in tumor progression. IGF2 expression in the TGF alpha transgenic mice was analysed in liver and tumors from animals which also contained one or two functional IGF2 alleles. In a two by two mating experiment using transgenic mice containing either a TGF alpha transgene or a IGF2 gene knockout, we have investigated whether IGF2 imprinting is reversed during hepatocarcinogenesis and the consequences of IGF2 expression for tumor growth. We observed that: (1) 100% of the hepatocellular carcinomas expressed IGF2 (2) the normally imprinted maternal allele is active in the tumors in which the paternal allele is knocked out and (3) all three of the murine IGF2 promoters upstream of the reactivated maternal alleles are transcriptionally active in tumors. We also observed that the total tumor burden of animals with two wild type IGF-2 alleles (paternal and maternal) was the same as the tumor burden in animals which contained only a single reactivated maternal allele. The 100% incidence of reactivation of the imprinted maternal allele suggests that IGF2 expression is selected during murine hepatocarcinogenesis and can substitute for the paternal allele when it is inactivated.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rogler, LE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Marion Bessin Liver Res Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [CA56076] Funding Source: Medline; NIDDK NIH HHS [T32 DK 07218] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007218] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; CARIANI E, 1988, CANCER RES, V48, P6844; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COLLIER JD, 1993, LIVER, V13, P151; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DEMOOR CH, 1994, EUR J BIOCHEM, V226, P1039; DEMOOR CH, 1995, BIOCHEM J, V307, P225, DOI 10.1042/bj3070225; DEPAGTERHOLTHUIZEN P, 1988, BIOCHIM BIOPHYS ACTA, V950, P282, DOI 10.1016/0167-4781(88)90124-8; FLORINI JR, 1993, ADV EXP MED BIOL, V343, P319; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; FURUSAKA A, 1994, CANCER LETT, V84, P85, DOI 10.1016/0304-3835(94)90361-1; GREENBLATT MS, 1994, CANCER RES, V54, P4855; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JIRTLE R, 1995, LIVER REGENERATION C, P199; KAUFMANN WK, 1992, CARCINOGENESIS, V13, P1481, DOI 10.1093/carcin/13.8.1481; KIESS W, 1994, HORM RES, V41, P66, DOI 10.1159/000183963; LAUTERIO TJ, 1992, ADV EXP MED BIOL, V321, P31; LEE GH, 1992, CANCER RES, V52, P5162; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OHLSSON R, 1989, DEVELOPMENT, V106, P555; Pimentel E., 1994, HDB GROWTH FACTORS, VII, P55; PINTAR JE, 1991, ADV EXP MED BIOL, V293, P325; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Rossetti L, 1996, J BIOL CHEM, V271, P203, DOI 10.1074/jbc.271.1.203; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; SHINAR DM, 1993, ENDOCRINOLOGY, V132, P1158, DOI 10.1210/en.132.3.1158; SINGER C, 1995, CANCER RES, V55, P2448; Steinmetz KL, 1996, TOXICOL APPL PHARM, V140, P131, DOI 10.1006/taap.1996.0206; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TAKAGI H, 1992, CANCER RES, V52, P5171; Tanaka S, 1996, J CLIN INVEST, V98, P2100, DOI 10.1172/JCI119016; Tanaka S, 1996, CANCER RES, V56, P3391; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WAKIYAMA M, 1992, NUCL ACIDS S SERIES, V27, P159; YANG D, 1993, CANCER RES, V53, P2020; Yang DY, 1996, J VIROL, V70, P6260, DOI 10.1128/JVI.70.9.6260-6268.1996; YANG DY, 1991, CARCINOGENESIS, V12, P1893, DOI 10.1093/carcin/12.10.1893; Yun K, 1996, AM J PATHOL, V148, P1081; Zhang N, 1997, HEPATOLOGY, V25, P900, DOI 10.1002/hep.510250419	45	36	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					203	209		10.1038/sj.onc.1201519	http://dx.doi.org/10.1038/sj.onc.1201519			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464538				2022-12-28	WOS:000071427100007
J	Maguer-Satta, V; Burl, S; Liu, L; Damen, J; Chahine, H; Krystal, G; Eaves, A; Eaves, C				Maguer-Satta, V; Burl, S; Liu, L; Damen, J; Chahine, H; Krystal, G; Eaves, A; Eaves, C			BCR-ABL accelerates C2-ceramide-induced apoptosis	ONCOGENE			English	Article						CML; BCR-ABL; ceramide; apoptosis; tyrosine phosphorylation	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; HUMAN HEMATOPOIETIC-CELLS; ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE-ACTIVITY; RAS SIGNALING PATHWAY; LONG-TERM CULTURE; HUMAN BONE-MARROW	In patients with chronic myeloid leukemia (CML), the neoplastic (BCR-ABL(+)) progenitor cells are characterized by an increased proliferative activity, Whether these cells are also resistant to apoptosis and if so, under what conditions remains controversial, We now show that highly purified populations of very primitive neoplastic progenitor cells obtained directly from CML patients survive and proliferate in vitro for several weeks in the absence of any added growth factors (except insulin), In contrast, purified primary normal progenitors maintained under the same conditions die rapidly, Nevertheless, both primary CML cells and BCR-ABL(+) BAF3 cells show the same dose-dependent sensitivity to TNF-alpha or ceramide-induced apoptosis as their respective normal counterparts, In fact, time course studies demonstrated an even faster onset of apoptosis in ceramide-treated BCR-ABL(+) BAF3 cells as compared to normal controls, BCR-ABL(+) cells treated with ceramide also showed a rapid and sequential increase in the tyrosine phosphorylation of p210(BCR-ABL), p46-56(SHC) and p120(Cbl), These findings suggest growth factor deprivation and treatment with TNF-alpha or ceramide trigger different initial events both of which can lead to apoptosis in factor-dependent hematopoietic cells, However, in the first case, activation of apoptosis is blocked by the basal activity of p210(BCR-ABL), whereas in the second, the presence of p210(BCR-ABL) appears to accelerate the onset of apoptosis by a mechanism that may involve an activation of its kinase function.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Expt Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; Univ Victor Segalen, Lab Greffe de Moelle, CNRS, UMR 5540, Bordeaux, France; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of British Columbia; University of British Columbia	Eaves, C (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.		Maguer-Satta, Veronique/U-8857-2019	Maguer-Satta, Veronique/0000-0002-1556-068X; Krystal, Gerald/0000-0002-1961-6281				AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Albrecht T, 1996, BRIT J HAEMATOL, V95, P501, DOI 10.1046/j.1365-2141.1996.d01-1934.x; AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CARLESSO N, 1994, ONCOGENE, V9, P149; CASHMAN JD, 1992, LEUKEMIA, V6, P886; Chacko GW, 1996, J IMMUNOL, V157, P2234; CHEN M, 1995, CANCER RES, V55, P991; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; Eaves C J, 1987, Baillieres Clin Haematol, V1, P931, DOI 10.1016/S0950-3536(87)80033-1; EAVES CJ, 1993, P NATL ACAD SCI USA, V90, P12015, DOI 10.1073/pnas.90.24.12015; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hariharan I K, 1988, Oncogene Res, V3, P387; HAWLEY RG, 1994, GENE THER, V1, P136; Hogge DE, 1996, BLOOD, V88, P3765, DOI 10.1182/blood.V88.10.3765.bloodjournal88103765; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIM MY, 1991, J BIOL CHEM, V266, P484; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kitanaka A, 1996, BLOOD, V88, P590, DOI 10.1182/blood.V88.2.590.bloodjournal882590; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LANSDORP PM, 1992, J EXP MED, V175, P1501, DOI 10.1084/jem.175.6.1501; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MaguerSatta V, 1996, BLOOD, V88, P1796; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishii K, 1996, ONCOGENE, V13, P2225; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Petzer AL, 1996, J EXP MED, V183, P2551, DOI 10.1084/jem.183.6.2551; Petzer AL, 1996, BLOOD, V88, P2162, DOI 10.1182/blood.V88.6.2162.bloodjournal8862162; Petzer AL, 1997, BLOOD, V90, P64; PONCHIO L, 1995, BLOOD, V86, P3314, DOI 10.1182/blood.V86.9.3314.bloodjournal8693314; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SANTUCCI MA, 1993, INT J RADIAT ONCOL, V26, P831, DOI 10.1016/0360-3016(93)90498-K; Sattler M, 1996, ONCOGENE, V12, P839; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Selleri C, 1997, BLOOD, V89, P957, DOI 10.1182/blood.V89.3.957; SIRARD C, 1994, BLOOD, V83, P1575; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; STRIFE A, 1988, CANCER RES, V48, P1035; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUTHERLAND HJ, 1991, BLOOD, V78, P666, DOI 10.1182/blood.V78.3.666.bloodjournal783666; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TOKER A, 1994, J BIOL CHEM, V269, P32358; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; UDOMSAKDI C, 1992, P NATL ACAD SCI USA, V89, P6192, DOI 10.1073/pnas.89.13.6192; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WIEDEMANN LM, 1988, BLOOD, V71, P349; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	85	41	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	1998	16	2					237	248		10.1038/sj.onc.1201533	http://dx.doi.org/10.1038/sj.onc.1201533			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464542				2022-12-28	WOS:000071427100011
J	Wang, QJ; Acs, P; Goodnight, JA; Blumberg, PM; Mischak, H; Mushinski, JF				Wang, QJ; Acs, P; Goodnight, JA; Blumberg, PM; Mischak, H; Mushinski, JF			The catalytic domain of PKC-epsilon, in reciprocal PKC-delta and -epsilon chimeras, is responsible for conferring tumorgenicity to NIH3T3 cells, whereas both regulatory and catalytic domains of PKC-epsilon contribute to in vitro transformation	ONCOGENE			English	Article						chimeric PKC; PKC-epsilon; PKC-delta; transformation; tumorgenicity; NIH3T3	PROTEIN-KINASE-C; FIBROBLASTS; NUCLEAR; ISOFORM; RAS	Protein kinase C-epsilon (PKC-epsilon) has been shown to increase growth and cause malignant transformation when overexpressed in NIH3T3 cells, whereas PKC-delta reduced fibroblast growth, Two reciprocal chimeric proteins (PKC-epsilon delta and PKC-delta epsilon were constructed by exchanging the regulatory and catalytic domains of PKC-delta and -epsilon and were stably overexpressed in NIH3T3 cells, Fibroblasts that overexpressed either chimera showed maximum cell density and morphology that were intermediate between cells overexpressing PKC-delta and those that overexpressed PKC-epsilon, Moreover, all lines that expressed chimeras were capable of anchorage-independent growth in the presence of TPA, which indicated that both the regulatory and catalytic domains of PKC-epsilon could independently induce NIH3T3 transformation, although the combination of both domains, as found in PKC-epsilon, was the most active form, In contrast, the translocation pattern and ability to induce tumors in nude mice was attributable to the catalytic domains exclusively, In particular, cells that expressed PKC-delta epsilon retained PKC-epsilon's full potency of tumorgenicity when injected into nude mice, In sum, our findings not only reinforce the concept that only certain PKC isozymes contribute to carcinogenesis but also show that different domains of PKCs mediate the physiologically distinguishable events of transformation and tumorgenesis.	NCI, Genet Lab, Bethesda, MD 20892 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mushinski, JF (corresponding author), NCI, Genet Lab, Bethesda, MD 20892 USA.		Wang, Qiming Jane/B-6064-2012; Mischak, Harald/E-8685-2011	Wang, Qiming Jane/0000-0002-9502-4851; Mischak, Harald/0000-0003-0323-0306				Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; CACACE AM, 1993, ONCOGENE, V8, P2095; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Wang WJ, 1997, J BIOL CHEM, V272, P76; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; ZUALI G, 1996, BRIT J HAEMATOL, V92, P530	15	18	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	1998	16	1					53	60		10.1038/sj.onc.1201507	http://dx.doi.org/10.1038/sj.onc.1201507			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467942				2022-12-28	WOS:000071236800006
J	Wu, Y; Liu, JX; Arlinghaus, RB				Wu, Y; Liu, JX; Arlinghaus, RB			Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase	ONCOGENE			English	Article						Bcr serine/threonine kinase; Bcr tyrosine residues; tyrosine phosphorylation of Bcr; inhibition of Bcr serine kinase by Bcr-Ab1; kinase role of Bcr tyrosines 328 and 360	MUSCLE PYRUVATE-KINASE; ABL ONCOPROTEINS; GENE ENCODES; P160 BCR; PHOSPHORYLATION; LEUKEMIA; CELLS	Bcr is a novel serine/threonine protein kinase that is believed to require two cysteine pairs for activity (Maru and Witte, Cell, 67, 459, 1991), Tyrosine phosphorylated Bcr has dramatically reduced kinase activity, and tyrosine 360 of Bcr, which is one of the sites of phosphorylation by the Bcr - Abl oncoprotein, is required for transkinase activity (Liu et al., Mel. Cell Biol,, 16, 998, 1996), Results presented here indicate that Bcr tyrosine 328 is also phosphorylated within Bcr-Abl expressing cells and is required for Bcr's serine/threonine kinase activity, Bcr Y328F, like Bcr Y360F, had defective transkinase activity but can autophosphorylate. However, the Y328F/Y360F double mutant of Bcr is defective in both trans-and autokinase activities, Taken together with the kinase inhibitory effects of tyrosine phosphorylation of Bcr by Bcr-Abl, our studies with tyrosine to phenylalanine Bcr mutants indicate that the hydroxyl residues of tyrosines 328 and 360 play crucial roles in Bcr's kinase activity.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA65611, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065611, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNAMALAI AE, 1981, J BIOL CHEM, V256, P276; CAMPBELL ML, 1991, ADV CANCER RES, V57, P227; CAMPBELL ML, 1990, ONCOGENE, V5, P773; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; LI WJ, 1989, ONCOGENE, V4, P127; LIFSHITZ B, 1988, ONCOGENE, V2, P113; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TOMICH JM, 1981, BIOCHEMISTRY-US, V20, P6711, DOI 10.1021/bi00526a029	18	18	18	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	1998	16	1					141	146		10.1038/sj.onc.1201524	http://dx.doi.org/10.1038/sj.onc.1201524			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467953				2022-12-28	WOS:000071236800017
J	Kishida, S; Koyama, S; Matsubara, K; Kishida, M; Matsuura, Y; Kikuchi, A				Kishida, S; Koyama, S; Matsubara, K; Kishida, M; Matsuura, Y; Kikuchi, A			Colocalization of Ras and Ral on the membrane is required for Ras-dependent Ral activation through Ral GDP dissociation stimulator	ONCOGENE			English	Article						RalGDS; Ras; Ral; Rap; posttranslational modification	GUANINE-NUCLEOTIDE EXCHANGE; H-RAS; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; POSTTRANSLATIONAL MODIFICATION; PROTEIN-KINASE; R-RAS; B-RAF; P21; TRANSFORMATION	Ral GDP dissociation stimulator (RalGDS), a putative effector protein of Ras, stimulated the GDP/GTP exchange reaction of the post-tanslationally lipid-modified but not the unmodified form of Ral in response to epidermal growth factor in COS cells, The RalGDS action on Ral was enhanced by an active form of Res but not a Ras mutant which was not post-translationally modified in the cells, The RalGDS activity was inhibited by acidic membrane phospholipids such as phosphatidylinositol and phosphatidylserine but not by phosphatidylcholine or phosphatidylethanolamines in vitro. The posttranslationally modified form but not unmodified form of Ras, Ral, and Rap were incorporated in liposomes consisting of these phospholipids. When Ral was incorporated alone in the liposomes, RalGDS did not stimulate the dissociation of GDP from Ral, When Rat was incorporated with the GTP-bound form of Ras in the liposomes, RalGDS stimulated the dissociation of GDP from Ral, while the GDP-bound form of Ras did not affect the RalGDS action, The Ras-dependent Ral activation through RalGDS required the Ras-binding domain of RalGDS, Rap, which shared the same effector loop as Ras, also stimulated the dissociation of GDP from Ral through RalGDS in the liposomes, although Rap did not enhance the RalGDS action in COS cells, Taken together with our previous observations that Ras recruits RalGDS to the membrane, these results indicate that the post-translational modifications of Ras and Ral are important for Ras-dependent Ral activation through RalGDS and that colocalization of Ras and Ral on the membrane is necessary for Ral activation in intact cells.	HIROSHIMA UNIV,SCH MED,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; NATL INST INFECT DIS,DEPT VIROL 2,SHINJYUKU KU,TOKYO 162,JAPAN	Hiroshima University; National Institute of Infectious Diseases (NIID)				kishida, shosei/0000-0003-0405-851X				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BERGER G, 1994, BRIT J HAEMATOL, V88, P372, DOI 10.1111/j.1365-2141.1994.tb05033.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GORMAN CM, 1985, HIGH EFFICIENCY GENE; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; KAWAMURA S, 1991, JPN J CANCER RES, V82, P758, DOI 10.1111/j.1349-7006.1991.tb02699.x; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LopezBarahona M, 1996, ONCOGENE, V12, P463; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALY FE, 1994, J BIOL CHEM, V269, P18743; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; McCormick F, 1996, NAT STRUCT BIOL, V3, P653, DOI 10.1038/nsb0896-653; Murai H, 1997, J BIOL CHEM, V272, P10483; Okada T, 1996, J BIOL CHEM, V271, P4671; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	43	61	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2899	2907		10.1038/sj.onc.1201473	http://dx.doi.org/10.1038/sj.onc.1201473			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416833				2022-12-28	WOS:A1997YK37700002
J	Bocciardi, R; Mograbi, B; Pasini, B; Borrello, MG; Pierotti, MA; Bourget, I; Fischer, S; Romeo, G; Rossi, B				Bocciardi, R; Mograbi, B; Pasini, B; Borrello, MG; Pierotti, MA; Bourget, I; Fischer, S; Romeo, G; Rossi, B			The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck	ONCOGENE			English	Article						RET; multiple endocrine neoplasia type 2B; Crk; Nck; paxillin	PHOSPHORYLATION-DEPENDENT MANNER; GROWTH-FACTOR RECEPTOR; COMPLEXES IN-VIVO; V-CRK; PROTO-ONCOGENE; HIGH-AFFINITY; MOLECULAR CHARACTERIZATION; TRANSFORMING ACTIVITY; ADAPTER PROTEINS; ENDOGENOUS CRK	The RET proto-oncogene encodes a Tyrosine Kinase Receptor (RTK) which plays an important function in the proliferation and/or differentiation of neuroectodermic cells, Germline mutation of a methionine to a threonine within the RET TK domain predisposes to the Multiple Endocrine Neoplasia type 2B (MEN 2B), It has been demonstrated that, unlike c-Ret, the MEN 2B mutated Ret displays constitutive TK activity, tyrosine autophosphorylation and transforms fibroblasts, However, this oncoprotein is more than a fully activated wildtype (WT) Ret TK since it also displays modified substrate specificity, Change in substrate specificity leads to the tyrosine autophosphorylation of MEN 2B Ret on new sites as well as the phosphorylation of several novel downstream targets, But, none of these substrates have been identified and the ability of MEN 2B Ret phosphoprotein to interact with Src Homology 2 (SH2) domain containing molecules has been poorly investigated, In this report, using a constitutively activated Ret TK form, Ret-ptc 2, we demonstrate that the MEN 2B as the activated WT Ret TK binds to several SH, signalling proteins such as Shc, Grb-2, Phospholipase C gamma, Crk and Nck, However, in contrast to the activated WT form, expression of the MEN 2B mutated Ret-ptc 2 results in the tyrosine phosphorylation of a panel of proteins which interestingly interact with Crk and Nck, We identified Paxillin, a cytoskeletal protein as one of the Crk associated proteins that is dramatically phosphorylated in MEN 2B but WT expressing cells, These data suggest that MEN 2B mutated Ret triggers distinct signalling pathways that might be related to its transforming power.	INSERM U364, FAC MED PASTEUR, NICE, FRANCE; IST GIANNINA GASLINI, GENET MOL LAB, I-16148 GENOA, ITALY; IST NAZL TUMORI, DIV ONCOL SPERIMENTALE A, I-20133 MILAN, ITALY; HOP COCHIN, INSERM U363, INST COCHIN GENET MOL, F-75674 PARIS, FRANCE; INT AGCY RES CANC, F-69372 LYON, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Genoa; IRCCS Istituto Giannina Gaslini; Fondazione IRCCS Istituto Nazionale Tumori Milan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; World Health Organization; International Agency for Research on Cancer (IARC)			Pierotti, Marco Alessandro/AAC-4728-2022; Bocciardi, Renata/J-8577-2016; Mograbi, Baharia/N-5531-2018; Mograbi, Baharia/Q-7953-2019; Borrello, Maria Grazia/C-3161-2017; Pasini, Barbara/AHI-2004-2022	Pierotti, Marco Alessandro/0000-0002-7431-8332; Bocciardi, Renata/0000-0001-8415-3802; Borrello, Maria Grazia/0000-0002-6854-2848; Pasini, Barbara/0000-0002-4373-1212; Mograbi, Baharia/0000-0002-1025-3429; BOURGET, Isabelle/0000-0001-6369-8176				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Fugazzola L, 1996, ONCOGENE, V13, P1093; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Iwashita T, 1996, ONCOGENE, V12, P481; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Pandit SD, 1996, J BIOL CHEM, V271, P5850, DOI 10.1074/jbc.271.10.5850; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; Ribon V, 1996, MOL CELL BIOL, V16, P45; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROMANO A, 1994, ONCOGENE, V9, P2923; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SANTORO M, 1994, ONCOGENE, V9, P509; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Torres M, 1996, ONCOGENE, V12, P77; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Vuori K, 1996, MOL CELL BIOL, V16, P2606; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	61	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2257	2265		10.1038/sj.onc.1201413	http://dx.doi.org/10.1038/sj.onc.1201413			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393871				2022-12-28	WOS:A1997YE15700001
J	Gayther, SA; Barski, P; Batley, SJ; Li, LM; deFoy, KAF; Cohen, SN; Ponder, BAJ; Caldas, C				Gayther, SA; Barski, P; Batley, SJ; Li, LM; deFoy, KAF; Cohen, SN; Ponder, BAJ; Caldas, C			Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours	ONCOGENE			English	Article						TSG101; FHIT; splicing; tumour	BREAKPOINT; CANCER; 3P14.2; CELLS	Intragenic deletions of TSG101, the human homolog of a mouse gene (tsg101) that acts to suppress malignant cell growth, were reported in human breast tumours, We screened TSG101 for somatic mutations in DNA and RNA samples isolated from a variety of common human malignancies, EBV-immortalised B-cells, and normal lung parenchyma, Intragenic TSG101 deletions in RNA transcripts were frequently found in all types of samples, Analysis of DNA failed to show genomic rearrangements corresponding to transcripts containing deletions in the same samples, The breakpoints of most transcript deletions coincide with genuine or cryptic splice site sequences, suggesting that they result from alternative or aberrant splicing, A similar spectrum of transcript deletions has previously been described in the putative tumour suppressor gene FHIT. We analysed FHIT in the same series of RNA samples and detected truncated FHIT transcripts frequently in both tumour and normal tissues, In addition, transcripts from TSG101, FHIT and seven other genes were analysed in RNA isolated from normal peripheral blood lymphocytes, Large TSC101 and FHIT intragenic transcript deletions were detected and these appeared to be the predominant transcript in 'aged' lymphocytes. Similar alterations were not detected in transcripts of the other genes which were analysed, Our findings demonstrate that truncated TSG101 and FHIT transcripts are commonly detected in both normal and malignant tissues and that a significant fraction of these are likely to be the result of aberrant splicing, While we cannot exclude that alterations in TSG101 and FHIT occur during cancer development, our data indicate that in this context the commonly observed transcript abnormalities are misleading.	ADDENBROOKES HOSP,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,ACAD DEPT ONCOL,CRC,CAMBRIDGE CB2 2QQ,ENGLAND; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA 94305	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Stanford University; Stanford University			Caldas, Carlos/A-7543-2008; Caldas, Carlos/U-7250-2019	Caldas, Carlos/0000-0003-3547-1489; BARSKI, PIOTR/0000-0002-2002-6748				Druck T, 1997, CANCER RES, V57, P504; Flaman JM, 1996, ONCOGENE, V12, P813; Fong KM, 1997, CANCER RES, V57, P2256; Foster KA, 1996, CANCER RES, V56, P3622; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; Hayashi S, 1997, CANCER RES, V57, P1981; Huebner K, 1997, BBA-REV CANCER, V1332, pM65, DOI 10.1016/S0304-419X(97)00009-7; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lochner K, 1996, CANCER RES, V56, P2171; Luan XD, 1997, ONCOGENE, V15, P79, DOI 10.1038/sj.onc.1201164; Nam DK, 1996, GENE, V178, P169, DOI 10.1016/0378-1119(96)00364-2; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770	17	84	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2119	2126		10.1038/sj.onc.1201591	http://dx.doi.org/10.1038/sj.onc.1201591			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366528				2022-12-28	WOS:A1997YC28400012
J	Hande, MP; Balajee, AS; Natarajan, AT				Hande, MP; Balajee, AS; Natarajan, AT			Induction of telomerase activity by UV-irradiation in Chinese hamster cells	ONCOGENE			English	Article						telomeres; telomerase; UV radiation; hamster cells	HUMAN-CHROMOSOMES; CANCER; ACQUISITION; ASSOCIATION; ACTIVATION; SEQUENCES; (TTAGGG)N; TISSUES; REPEATS; ENZYME	Telomerase is a ribonucleoprotein whose activity has been detected in germline cells and in neoplastic and immortal cells. Telomerase compensates the telomere loss arising by the end replication problem by synthesizing telomeric repeats at the 3' end of the eukaryotic chromosomes, Telomerase is reactivated during cancer progression in human and mice. In order to determine whether the telomerase activity can be upregulated in vitro in response to DNA damaging agents, we examined the telomerase activity in five Chinese hamster cell lines following exposure to 5 J/m(2) or 40 J/m(2) UV-C radiation, All the cell lines tested showed an increase in telomerase activity in the PCR-based telomeric repeat amplification protocol (TRAP) in a dose dependent manner, This increase in telomerase activity correlated well with the number of cells being in the S and G(2)/M phase after UV exposure, However, in unirradiated control cells, similar levels of telomerase activity were observed in different phases of the cell cycle, Furthermore, telomeric signals were clustered in one or more parts of the disintegrating nuclear particles of the apoptotic cell as detected by fluorescence in situ hybridization (FISH), This is the first study to demonstrate the induction of telomerase activity following exposure to DNA-damaging agents like UV radiation in Chinese hamster cells in vitro.	LEIDEN STATE UNIV,DEPT RADIAT GENET & CHEM MUTAGENESIS,MGC,NL-2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Hande, M. Prakash/B-1645-2008	Hande, M. Prakash/0000-0002-4511-6256				ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Bacchetti S, 1996, SEMIN CELL DEV BIOL, V7, P31, DOI 10.1006/scdb.1996.0006; Balajee AS, 1996, MUTAT RES-FUND MOL M, V372, P163, DOI 10.1016/S0027-5107(96)00136-4; BARNETT MA, 1993, NUCLEIC ACIDS RES, V21, P27, DOI 10.1093/nar/21.1.27; BERTONI L, 1994, GENOMICS, V24, P53, DOI 10.1006/geno.1994.1581; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; CHADENEAU C, 1995, ONCOGENE, V11, P893; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; Duchaud E, 1996, CANCER RES, V56, P1400; FLINT J, 1994, AM J HUM GENET, V55, P505; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1996, MOL CELL BIOL, V16, P2932; IJDO JW, 1991, NUCLEIC ACIDS RES, V19, P4780, DOI 10.1093/nar/19.17.4780; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1995, NAT GENET, V9, P104, DOI 10.1038/ng0295-104; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MURNANE JP, 1993, MOL CELL BIOL, V13, P977, DOI 10.1128/MCB.13.2.977; OH HJ, 1997, UNPUB BR J CANC; Pandita TK, 1996, ONCOGENE, V13, P1423; SABATIER L, 1995, RADIAT ENVIRON BIOPH, V34, P229, DOI 10.1007/BF01209747; Slijepcevic P, 1996, CHROMOSOMA, V104, P596, DOI 10.1007/s004120050152; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Ueda M, 1997, CANCER RES, V57, P370; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wright WE, 1996, DEV GENET, V18, P173; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	34	41	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1747	1752		10.1038/sj.onc.1201327	http://dx.doi.org/10.1038/sj.onc.1201327			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349510				2022-12-28	WOS:A1997XY63100016
J	Reinke, V; Lozano, G				Reinke, V; Lozano, G			The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo	ONCOGENE			English	Article						apoptosis; p53; targets; ionizing radiation; mice	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL ACTIVATION; GROWTH-CHARACTERISTICS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; DNA-REPLICATION; CELL-GROWTH; BAX GENE	The tumor suppressor p53 can exert its anti-oncogenic activity in part by inducing apoptosis in cells that have sustained damage to their DNA. It is likely that p53 activates the transcription of target genes that mediate this response. Known p53 targets with potential roles in cell cycle control and apoptosis induction include: p21(WAF1/CIP1), mdm2, cyclin G, bax and Fas. We examined the p53 pathway in the thymus of the mouse after irradiation, FACS analysis demonstrated that the thymocytes of mice with wild-type p53, but not those lacking p53, underwent apoptosis after irradiation. Expression analysis of the target genes revealed that all tested genes underwent p53-dependent induction, although the extent and timing varied. The target genes implicated in cell cycle (p21, mdm2 and cyclin G) were induced 2 h after irradiation, in contrast to targets with a possible role in apoptosis (bax and Fas), which were induced at 4 h. This analysis is the first demonstration that Fas is a p53-responsive gene in vivo. Since p21 and bax expression are not required for p53-dependent apoptosis, we tested whether other target genes affected apoptosis in vivo. We discovered that mdm2 has no role in preventing apoptosis independently of p53 inactivation, and that Fas, like p21 and bax, is not necessary for p53-mediated induction of apoptosis. Therefore, no p53 target identified and tested to date is singly responsible for p53-dependent apoptosis in response to DNA damage in vivo.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA047296, R29CA047296] Funding Source: NIH RePORTER; NCI NIH HHS [CA47296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McMasters KM, 1996, ONCOGENE, V13, P1731; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TAMURA T, 1995, ONCOGENE, V11, P1939; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	49	59	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1527	1534		10.1038/sj.onc.1201316	http://dx.doi.org/10.1038/sj.onc.1201316			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380404				2022-12-28	WOS:A1997XX36900003
J	Fesquet, D; Morin, N; Doree, M; Devault, A				Fesquet, D; Morin, N; Doree, M; Devault, A			Is Cdk7 cyclin H MAT1 the genuine cdk activating kinase in cycling xenopus egg extracts?	ONCOGENE			English	Article						cdk; cdk7; CAK; phosphorylation; cell cycle; Xenopus	MATURATION-PROMOTING FACTOR; RING FINGER PROTEIN; CELL-CYCLE; DEPENDENT KINASES; DNA-REPLICATION; BUDDING YEAST; CAK; PHOSPHORYLATION; P34CDC2; CDC2	Formation of active cdk (cyclin dependent kinase)/ cyclin kinases involves phosphorylation of a conserved threonine residue in the T loop of the cdk catalytic subunit by CAK (Cdk Activating Kinase). CAK was first purified biochemically from higher eukaryotes and identified as a trimeric complex containing a cdk7 catalytic subunit, cyclin H and MAT1 (Menage a trois), a member of the RING finger family. The same trimeric complex is also part of basal transcription factor TFIIH. In budding yeast, the closest homologs of cdk7 and cyclin H, KIN28 and CCL1, respectively, also associate with TFIIH. However, the KIN28/CCL1 complex does not display CAK activity and a distinct protein kinase able to phosphorylate monomeric CDC28 and GST-cdk2 was recently identified, challenging the identification of cdk7 as the physiological CAK in higher eukaryotes. Here we demonstrate that immunodepletion of cdk7 suppresses CAK activity from cycling Xenopus egg extracts, and arrest them before M-phase. We also show that specific translation of mRNAs encoding Xenopus cdk7 and its associated subunits restores CAK activity in cdk7-immunodepleted Xenopus egg extracts. Hence, the cdk7 complex is necessary and sufficient for activation of cdk-cyclin complexes in cycling Xenopus egg extracts.	CTR RECH BIOCHIM MACROMOL,CNRS ERS 155,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Fesquet, didier/M-9750-2019; Fesquet, Didier/A-1490-2009	Fesquet, didier/0000-0001-5657-9689; Morin, Nathalie/0000-0001-8677-1401				Buck V, 1995, EMBO J, V14, P6173, DOI 10.1002/j.1460-2075.1995.tb00308.x; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KREK W, 1992, NEW BIOL, V4, P323; LOHKA MJ, 1984, DEV BIOL, V103, P434, DOI 10.1016/0012-1606(84)90331-2; MATTHEWS G, 1994, CELL BIOL LAB HDB, P131; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; POON RYC, 1995, CURR BIOL, V5, P1243; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Wagner M, 1997, EMBO J, V16, P1305, DOI 10.1093/emboj/16.6.1305	29	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1303	1307		10.1038/sj.onc.1201300	http://dx.doi.org/10.1038/sj.onc.1201300			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315098				2022-12-28	WOS:A1997XV84500008
J	Hurd, C; Khattree, N; Dinda, S; Alban, P; Moudgil, VK				Hurd, C; Khattree, N; Dinda, S; Alban, P; Moudgil, VK			Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells	ONCOGENE			English	Article						breast cancer; tumor suppressors; p53; retinoblastoma; estrogens; antiestrogens	GENE-MUTATIONS; RECEPTOR; PHOSPHORYLATION; PROGRESSION; PROLIFERATION; INHIBITION; TAMOXIFEN; PRODUCT; TAXOL; LINES	We have utilized the estrogen receptor (ER)-positive human breast carcinoma cell line, T47D, to determine the role of ER in regulating cell proliferation, the level of expression of p53 and the state of phosphorylation of retinoblastoma protein (pRB) by 17 beta-estradiol (E-2) and antiestrogens. T47D cells cultured for 7 days proliferated rapidly expressing maximal levels of p53 in medium containing 5% fetal bovine (whole) serum, Exogenously added E-2 had no effect on either of the above parameters, The antiestrogen, ICI 164,384 (ICI, 1 mu M), decreased cell number and p53 level to nearly 20% of the control, Comparatively, a treatment of the tells with 100 nM 4OH-tamoxifen (OHT) decreased cell number to 40% of the control without a concomitant decrease in the p53 levels suggesting a differential ability of these antiestrogens to regulate p53 levels in cells cultured in whole serum, When cells were cultured in medium containing serum depleted of endogenous steroids (charcoal stripped serum), cell number and p53 levels declined, Treatment with exogenous E-2 (1 nM) increased cell proliferation, p53 expression and phosphorylation of pRB. The antiestrogens ICI and OHT blocked these E-2 effects, demonstrating a direct antagonism of ER by ICI and OHT, These results indicate an ER-mediated mechanism for coordinate expression of p53 and hyperphosphorylation of pRB during E-2-induced proliferation of T47D cells.	OAKLAND UNIV,DEPT BIOL SCI,ROCHESTER,MI 48309; OAKLAND UNIV,INST BIOCHEM & BIOTECHNOL,ROCHESTER,MI 48309	Oakland University; Oakland University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARDON S, 1987, CANCER RES, V47, P1441; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; CALEFFI M, 1994, CANCER, V73, P2147, DOI 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Guillot C, 1996, CLIN CANCER RES, V2, P1439; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; KASTAN MB, 1991, CANCER RES, V51, P6304; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; KUSHNER PJ, 1990, MOL ENDOCRINOL, V4, P1465, DOI 10.1210/mend-4-10-1465; LEVENSON AS, 1994, J STEROID BIOCHEM, V51, P229, DOI 10.1016/0960-0760(94)90035-3; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAITOH S, 1994, ONCOGENE, V9, P2869; SCHUCHARD M, 1993, ENDOCR REV, V14, P659, DOI 10.1210/er.14.6.659; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; THOMPSON EW, 1989, CANCER RES, V49, P6929; WAFIK S, 1994, CANCER RES, V54, P1169; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	30	69	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					991	995		10.1038/sj.onc.1201233	http://dx.doi.org/10.1038/sj.onc.1201233			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285694				2022-12-28	WOS:A1997XR76700012
J	Corbeil, HB; Branton, PE				Corbeil, HB; Branton, PE			Characterization of an E2F-p130 complex formed during growth arrest	ONCOGENE			English	Review						E2F; p130; growth arrest; cell cycle	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ADENOVIRUS E1A PROTEINS; CELL-CYCLE ARREST; LARGE T-ANTIGENS; SUSCEPTIBILITY GENE; IN-VIVO; FUNCTIONAL INTERACTIONS; ONCOGENIC ACTIVITY; BINDING PROTEIN	Electrophoretic mobility shift assays were used to analyse the pattern of E2F transcription factor complexes containing pRB and related 'pocket' proteins associated with changes in growth of monkey CV-1 cells. Little change was noted in pRB/E2F complexes following growth arrest or serum stimulation. Serum starvation induced the formation of a novel slowly-migrating p130/E2F complex, termed C7, which was comparable to one reported previously in terminally differentiated C2C12 mouse cells (Corbeil et al., 1995, Oncogene 11, 909-920) and thought to contain one or more additional unidentified proteins. After serum stimulation, C7 complex disappeared in S-phase but returned during mitosis. A major E2F complex containing p107 appeared during S-phase but was undetectable at other times. It appeared likely that regulation of pRB, p107 and p130 occurs by several mechanisms. First, phosphorylation has previously been proposed to be involved. All pRB-related proteins were found to be highly phosphorylated during S-phase when E2F activity was highest, and hypophosphorylated in arrested cells when E2F activity was low. Second, the absolute levels of some members of the RE family varied during the cell cycle. Levels of pRB protein and pRB/E2F complexes changed little; however, the amounts of both p107/E2F and p130/E2F complexes varied according to the overall levels of p107 and p130 proteins. Formation of the novel C7 complex in serum arrested cells suggested a third regulatory mechanism mediated by interactions with additional proteins. Our studies indicated that binding of such proteins with p130/E2F occurred via a site in the 'pocket' similar to that utilized by adenovirus E1A proteins. Such proteins could function as additional regulators of E2F-driven transcription.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University								ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BARBEAU D, 1994, ONCOGENE, V9, P359; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCK V, 1995, ONCOGENE, V11, P31; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; CORBEIL HB, 1994, J VIROL, V68, P6697, DOI 10.1128/JVI.68.10.6697-6709.1994; DAVIES R, 1993, BIOTECHNIQUES, V14, P630; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DYNLACHT BD, 1994, GENE DEV, V8, P2008; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1992, SCIENCE, V255, P87; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FATTAEY AR, 1993, ONCOGENE, V8, P3149; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P65; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7183; JOHNSON DG, 1994, GENE DEV, V8, P1759; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAYOL X, 1993, ONCOGENE, V8, P2561; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4009; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, TRENDS BIOCHEM SCI, V17, P312; NEVINS JR, 1992, MOL CELL BIOL, V12, P5363; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OTTERSON GA, 1993, ONCOGENE, V8, P949; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sambrook J., 2002, MOL CLONING LAB MANU; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHIMIZU M, 1995, MOL CELL BIOL, V15, P882; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Strober BE, 1996, MOL CELL BIOL, V16, P1576; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; XU M, 1994, MOL CELL BIOL, V14, P420; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	107	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					657	668		10.1038/sj.onc.1201224	http://dx.doi.org/10.1038/sj.onc.1201224			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264406				2022-12-28	WOS:A1997XP68300005
J	Pusch, O; Bernaschek, G; Eilers, M; Hengstschlager, M				Pusch, O; Bernaschek, G; Eilers, M; Hengstschlager, M			Activation of c-myc uncouples DNA replication from activation of G1-cyclin-dependent kinases	ONCOGENE			English	Article						c-Myc; G1-cyclins; cell cycle; initiation of replication	CYCLIN-DEPENDENT KINASES; S-PHASE ENTRY; CELL-CYCLE; TRANSCRIPTION FACTOR; THYMIDINE KINASE; PROTEIN-KINASE; RESTRICTION POINT; GROWTH-REGULATION; EXPRESSION; BINDING	Proto-oncogenes like c-myc are thought to control exit from the cell cycle rather than progression through the cell cycle itself, We now present a different view of Myc function, Exponentially growing Rat1-MycER(TM) fibroblasts were size-fractionated by centrifugal elutriation, In these cells, activation of cyclin E- and cyclin A- dependent kinases, degradation of p27, hyperphosphorylation of retinoblastoma protein and activation of E2F occur sequentially at specific cell sizes, Upon activation of Myc, however, these transitions all occur simultaneously in small cells immediately after exit from mitosis. In contrast, Myc has no discernible effect on the cell size at which DNA replication is initiated, These data show first that Myc centrals the activity of G1 cyclin-dependent kinases independently from the transition between quiescence and proliferation and from any effect on cell growth in size, These data also provide evidence of at least one dominant mechanism besides activation of E2F and of cyclin E/cdk2 kinase, which prevents DNA replication unless a critical cell size has been reached.	UNIV VIENNA,DEPT PRENATAL DIAG & THERAPY,A-1090 VIENNA,AUSTRIA; ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY	University of Vienna; Ruprecht Karls University Heidelberg				Pusch, Oliver/0000-0001-7166-2800; Eilers, Martin/0000-0002-0376-6533				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DOU QP, 1994, J BIOL CHEM, V269, P1306; DOU QP, 1993, CANCER RES, V53, P1493; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GIUNTA M, 1995, CELL CYCLE, P46; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; HENGSTSCHLAGER M, 1994, CELL GROWTH DIFFER, V5, P1389; Hengstschlager M, 1996, ONCOGENE, V12, P1635; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JANSENDURR P, 1995, CELL CYCLE, P243; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELHAM MJ, 1990, ONCOGENE, V5, P161; Winston JT, 1996, ONCOGENE, V12, P127; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	62	55	55	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					649	656		10.1038/sj.onc.1201236	http://dx.doi.org/10.1038/sj.onc.1201236			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264405	Bronze			2022-12-28	WOS:A1997XP68300004
J	Sugiyama, H; Papst, P; Fujita, M; Gelfand, EW; Terada, N				Sugiyama, H; Papst, P; Fujita, M; Gelfand, EW; Terada, N			Overexpression of wild type p70 S6 kinase interferes with cytokinesis	ONCOGENE			English	Article						p70 S6 kinase; overexpression; cytokinesis; rapamycin; cell cycle	PROTEIN-KINASE; CYTOCHALASIN-B; MAP2 KINASE; RAPAMYCIN; ACTIVATION; PHOSPHORYLATION; CELLS; INACTIVATION; STIMULATION; TRANSLATION	p70 S6 kinase (p70(s6k)) is a serine/threonine kinase which is activated through an unidentified pathway by mitogenic stimuli, Here we demonstrate that stable- and transient-overexpression of wild type (WT)-p70(s6k) results in perturbation of cytokinesis in NIH3T3 cells. Cells overexpressing WT-p70(s6k) demonstrated a slow growth rate and lower viability, whereas cells overexpressing a mutant T229A-p70(s6k) had a similar growth rate and viability as those of parental NIH3T3 cells. Moreover, WT-p70(s6k) cells demonstrated several abnormalities in cellular morphology; both the cytoplasm and the nuclei were large and a proportion of the cells was multinucleated. Flow cytometric analysis of propidium iodide-stained cells demonstrated that about 50% of the cells had 4N or greater content of DNA, When cell division in WT-p70(s6k) cells was monitored by time-lapse video microscopy, cytokines was often incomplete after mitosis, producing binucleated cells, Addition of rapamycin to WT-p70(s6k) cells, which inactivates endogenous and transfected p70(s6k), failed to reverse any of the morphological abnormalities. These indicate that overexpression of p70(s6k) but not increases in activity of p70(s6k), is responsible for the phenotype. A molecule which interacts with p70(s6k) may be involved in this regulation of cytokinesis.	NATL JEWISH MED & RES CTR,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT DERMATOL,DENVER,CO 80206	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [CA-64685] Funding Source: Medline; NIAID NIH HHS [AI-26940, AI-29704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026940, R01AI026940, R01AI029704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANDI HR, 1993, J BIOL CHEM, V268, P4530; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KRISHAN A, 1972, J CELL BIOL, V54, P657, DOI 10.1083/jcb.54.3.657; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; MORELLI JG, 1992, J INVEST DERMATOL, V98, P290, DOI 10.1111/1523-1747.ep12497951; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SANGER JW, 1972, AM J ANAT, V135, P293, DOI 10.1002/aja.1001350214; Sugiyama H, 1996, J IMMUNOL, V157, P656; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TERADA N, 1993, J BIOL CHEM, V268, P12062; TERADA N, 1995, J IMMUNOL, V155, P3418; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	36	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					443	452		10.1038/sj.onc.1201207	http://dx.doi.org/10.1038/sj.onc.1201207			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242381				2022-12-28	WOS:A1997XM23800009
J	Zheng, GX; Teumer, J; Colmenares, C; Richmond, C; Stavnezer, E				Zheng, GX; Teumer, J; Colmenares, C; Richmond, C; Stavnezer, E			Identification of a core functional and structural domain of the v-Ski oncoprotein responsible for both transformation and myogenesis	ONCOGENE			English	Article						oncogene; v-Ski; mutagenesis; proteolysis	CDNA CLONES; ONCOGENE; GENE; PROTEINS; CELLS; DNA; ACTIVATION; SEQUENCE; VECTORS; VIRUSES	The v-ski oncogene promotes cellular transformation and myogenic differentiation. In quail embryo fibroblasts the two properties are displayed simultaneously and terminal muscle differentiation occurs only among cells already transformed by v-ski. To understand how the two phenotypes are derived from a single gene, we have undertaken to identify functionally important regions in v-ski and to test whether these regions can promote one phenotype without the other. We have generated both random and targeted mutations in v-ski and evaluated the effects of these mutations on expression, intracellular location, transformation, and myogenesis. Among a total of 26 mutants analysed, we have not found complete separation of the myogenic and transforming properties. Mutations in the region of v-Ski encoded by exon 1 of c-ski frequently abolish both its transformation and muscle differentiation activities, whereas mutations outside of this region are always tolerated. When expressed in cells from a minigene containing only the exon 1 sequence, the protein displays the transforming and myogenic activities similar to v-Ski. These results argue that the amino acid sequence encoded by exon 1 contains the core functional domain of the oncoprotein. To determine whether this functional domain has a structural counterpart, we have fragmented the v-Ski protein by limited proteolysis and found a single proteolytically stable domain spanning the entire exon 1-encoded region. Physical studies of the polypeptide encoded by exon 1 confirms that it folds into a compact, globular protein. The finding that both the transforming and myogenic properties of v-ski are inseparable by mutation and are contained in a single domain suggests that they are derived from the same function.	CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106; ORGANOGENESIS INC,CANTON,MA; CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195; UNIV CINCINNATI,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH	Case Western Reserve University; Cleveland Clinic Foundation; University System of Ohio; University of Cincinnati					NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER; NCI NIH HHS [CA43600] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; BOTFIELD MC, 1992, BIOCHEMISTRY-US, V31, P5841, DOI 10.1021/bi00140a020; BOYER PL, 1993, ONCOGENE, V8, P457; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P552; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; COLMENARES C, 1990, CANC BIOL, V1, P383; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; FOSTER DA, 1983, J VIROL, V48, P744, DOI 10.1128/JVI.48.3.744-751.1983; GRIMES HL, 1992, NUCLEIC ACIDS RES, V20, P1511, DOI 10.1093/nar/20.7.1511; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Institutionen B Universitet Uppsala S, 1963, PURE APPL CHEM, V233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P40446	29	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					459	471		10.1038/sj.onc.1201205	http://dx.doi.org/10.1038/sj.onc.1201205			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242383				2022-12-28	WOS:A1997XM23800011
J	Crook, T; Parker, GA; Rozycka, M; Crossland, S; Allday, MJ				Crook, T; Parker, GA; Rozycka, M; Crossland, S; Allday, MJ			A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear : cytoplasmic shuttling defect	ONCOGENE			English	Article						nuclear; cytoplasmic shuttling; mutant p53; transformation	CELL-CYCLE ARREST; WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; HUMAN B-CELLS; TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; MONOCLONAL-ANTIBODIES; BREAST-CANCER; PROTEIN; LOCALIZATION	The DG75 Burkitt lymphoma-derived human B cell line is heterozygous for p53, carrying wild type (WT) and mutant (Arg283His) alleles, The cells constitutively express high levels of both p53 proteins and also Mdm2, Arg283His transactivates the p21(Waf1), Mdm2, bar, cyclin G and IGF-BP3 promoters in transient transfection assays equally as well as, if not better than WT p53. It also suppresses the outgrowth of SAOS-2 cells and specifically binds DNA like wild type protein, However, in primary rodent fibroblasts Arg283His fails to suppress transformation by HPV16-E7 and (Ha-)ras and even has modest transforming activity when transfected alone with (Ha-)ras, When Arg283His is transiently transfected into SAOS-2 cells it efficiently induces apoptosis, so - unlike mutants such as Arg175Pro - its behaviour in transformation assays does not clearly correlate with loss of the apoptosis function, Immunofluorescence staining of both REF transformants and transiently transfected SAOS-2 revealed that this unusual mutant becomes excluded from the nucleus and produces striking cytoplasmic fluorescence, The best correlation with transformation, therefore, appears to be the lack of nuclear retention of Arg283His, Since this mutation does not map to any known nuclear localization signal and its presence seems to result in aberrant exclusion from the nucleus, then it may prove very useful in exploring mechanisms involved in the nuclear:cytoplasmic shuttling of p53.	St Marys Hosp, Imperial Coll, Sch Med, Dept Virol, London W2 1PG, England; St Marys Hosp, Imperial Coll, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Inst Canc Res, Haddow Labs, Surrey SM2 5NG, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; University of London; Institute of Cancer Research - UK	Allday, MJ (corresponding author), St Marys Hosp, Imperial Coll, Sch Med, Dept Virol, Praed St, London W2 1PG, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHO Y, 1994, SCIENCE, V265, P246; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DANG CV, 1989, J BIOL CHEM, V264, P18019; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DUTHU A, 1992, ONCOGENE, V7, P2161; EDWARDS RH, 1994, J VIROL, V68, P1309, DOI 10.1128/JVI.68.3.1309-1315.1994; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Flamini G, 1996, EUR J CANCER, V32A, P802, DOI 10.1016/0959-8049(95)00625-7; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GANNON JV, 1991, NATURE, V349, P802; GIADANO G, 1991, P NATL ACAD SCI USA, V88, P5413; Goldman SC, 1996, AM J PATHOL, V148, P1381; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HORAK E, 1991, ONCOGENE, V6, P2277; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; Lenoir GM, 1987, ADV VIRAL ONCOL, V7, P173; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OCONNOR PM, 1993, CANCER RES, V53, P4776; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTAVI ZN, 1993, CELL, V74, P609; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Parker GA, 1996, ONCOGENE, V13, P2541; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; ROVINSKI B, 1988, ONCOGENE, V2, P445; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Runnebaum IB, 1996, GYNECOL ONCOL, V61, P266, DOI 10.1006/gyno.1996.0137; Sambrook J., 2002, MOL CLONING LAB MANU; SEPEHRNIA B, 1996, J BIOL CHEM, V271, P15081; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	75	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1429	1441		10.1038/sj.onc.1201699	http://dx.doi.org/10.1038/sj.onc.1201699			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525742	Bronze			2022-12-28	WOS:000072572400007
J	Braspenning, J; Marchini, A; Albarani, V; Levy, L; Ciccolini, F; Cremonesi, C; Ralston, R; Gissmann, L; Tommasino, M				Braspenning, J; Marchini, A; Albarani, V; Levy, L; Ciccolini, F; Cremonesi, C; Ralston, R; Gissmann, L; Tommasino, M			The CXXC Zn binding motifs of the human papillomavirus type 16 E7 oncoprotein are not required for its in vitro transforming activity in rodent cells	ONCOGENE			English	Article						human papillomavirus type 16 E7 protein; E7-E1A243 chimeric protein; CXXC motifs; cellular transformation; E7 homodimerization	RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; CERVICAL-CARCINOMA; ZINC-BINDING; IN-VIVO; IDENTIFICATION; DIMERIZATION; COMPLEXES; DOMAINS; REGION	The conserved region 3 (CR3) of the E7 protein of human papillomaviruses contains two CXXC motifs involved in zinc binding and in the homodimerization of the molecule, Studies have suggested that the intact CXXC motifs in the CR3 of HPV16 and HPV18 E7 are required for the in vitro transforming activity of these proteins, CR3 also contains a low affinity pRb binding site and is involved in the disruption of the E2F/Rb1 complex, E7 is structurally and functionally related to Adenovirus E1A protein, which also has two CXXC motifs in CR3. However, the Ad E1A transforming activity appears to be independent of the presence of such domains, In fact, this viral protein exists in vivo as two different forms of 289 and 243 amino acids, The shorter Ad E1A form (Ad E1A243), where both CXXC motifs are deleted by internal splicing, retains its in vitro transforming activity, We have investigated if the HPV16 E7 CR3 can be functionally replaced by the Ad E1A243 CR3, which lacks both CXXC motifs, A chimeric protein (E7/E1A243) containing the CR1 and CR2 of HPV16 E7 fused to the CR3 of Ad E1A 243 was constructed. The E7/E1A243 while not able to homodimerize in the S. cerevisiae two-hybrid system retains several of the properties of the parental proteins, HPV16 E7 and Ad E1A, It associates with the 'pocket' proteins, induces growth in soft agar of NIH3T3 cells and immortalizes rat embryo fibroblasts, These data suggest that the CXXC motifs in CR3 of E7 do not play a direct role in the transforming properties of this viral protein but probably are important for maintaining the correct protein configuration.	Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany; Chiron Corp, Dept Virol, Emeryville, CA 94608 USA; GeneMed Inc, The Woodlands, TX USA	Helmholtz Association; German Cancer Research Center (DKFZ); Novartis	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany.		Gissmann, Lutz/H-4688-2011; Marchini, Antonio/ABD-3328-2020; Ralston, Robert O/A-6924-2009; Marchini, Antonio/AAG-7151-2019	Marchini, Antonio/0000-0003-3157-4552; Ciccolini, Francesca/0000-0002-7276-7361				BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; CLEMENS KE, 1995, VIROLOGY, V214, P289, DOI 10.1006/viro.1995.9926; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HU TH, 1995, INT J ONCOL, V6, P167; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; VOUSDEN KH, 1989, ONCOGENE, V4, P153; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; ZERFASS K, 1995, J GEN VIROL, V76, P1815, DOI 10.1099/0022-1317-76-7-1815; Zwerschke W, 1996, ONCOGENE, V12, P213	26	12	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	1998	16	8					1085	1089		10.1038/sj.onc.1201617	http://dx.doi.org/10.1038/sj.onc.1201617			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519882	Bronze			2022-12-28	WOS:000072335900014
J	Kim, J; Lee, K; Pelletier, J				Kim, J; Lee, K; Pelletier, J			The DNA binding domains of the WT1 tumor suppressor gene product and chimeric EWS/WT1 oncoprotein are functionally distinct	ONCOGENE			English	Article						EWS/WT1; DSRCT; oncogene; cancer genetics; transcription factor	ROUND-CELL TUMOR; EWINGS-SARCOMA TRANSLOCATION; EWS GENE; TRANSCRIPTIONAL ACTIVATOR; MALIGNANT-MELANOMA; FUSION PROTEIN; SOFT PARTS; RNA; APOPTOSIS; SEQUENCE	The t(11; 22)(p13; q12) translocation associated with desmosplastic small round cell tumor results in a chimeric molecule fusing the amino terminal domain (NTD) of the EWS1 gene to three of the four carboxyterminal zinc fingers of the WT1 tumor suppressor gene. Since the DNA binding domains of WT1 and EWS/WT1 are structurally different, we have assessed the functional consequences of the EWS/WT1 fusion. We find that the EWS/WT1 protein has a higher binding affinity for a given recognition target than the WT1 product. This is unlike other fusion products involving translocation of the NTD of EWS to DNA binding domains in which DNA binding specificity and affinity is not changed. We demonstrate that EWS/WT1 is a nuclear protein and that the NTD of EWS contains (a) nuclear localization signal(s). We also find that the integrity of a domain within the WT1 zinc fingers, responsible for mediating interaction between WT1 and the transcriptional repressor par-4, is disrupted in the EWS/WT1 fusion product. Deletion analysis of the NTD of EWS indicated that integrity of the entire domain was necessary to achieve full transactivation potential.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong	McGill University; McGill University; Hong Kong University of Science & Technology	Pelletier, J (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BREUNING W, 1992, NAT GENET, V1, P144; BROWN AD, 1995, ONCOGENE, V10, P1749; Bruening W, 1996, FEBS LETT, V393, P41, DOI 10.1016/0014-5793(96)00853-8; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CLARKSON T, 1992, PCR A PRCTICAL APPRO, P187; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; JEON IS, 1995, ONCOGENE, V10, P1229; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LADANYI M, 1994, CANCER RES, V54, P2837; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	41	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1021	1030		10.1038/sj.onc.1201616	http://dx.doi.org/10.1038/sj.onc.1201616			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519876				2022-12-28	WOS:000072335900008
J	Kolesnikova, TV; Lau, LF				Kolesnikova, TV; Lau, LF			Human CYR61-mediated enhancement of bFGF-induced DNA synthesis in human umbilical vein endothelial cells	ONCOGENE			English	Article						extracellular matrix; heparin-binding protein; connective tissue growth factor; Nov	FIBROBLAST-GROWTH-FACTOR; IMMEDIATE-EARLY GENE; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; NOV PROTOONCOGENE; INDUCIBLE GENE; EXPRESSION; CYR61; IDENTIFICATION; PRODUCT; FAMILY	CYR61 is a member of an emerging family of growth regulators that includes the human connective tissue growth factor and the chicken protooncoprotein Nov, Encoded by a growth factor-inducible immediate-early gene, CYR61 is a secreted, cysteine-rich heparin-binding protein that associates with the extracellular matrix and cell surface. In this report, we describe the cloning of the human hCYR61 cDNA and expression and purification of the hCYR61 protein. The hCYR61 mRNA is abundant in the heart, lung, pancreas and placenta, is present at a low level in skeletal muscle and brain and is not detectable in liver and kidney, Purified recombinant hCYR61 protein does not induce thymidine incorporation in human umbilical vein endothelial cells by itself, but enhances bFGF-induced DNA synthesis. We show that hCYR61 acts in this cell system in part by displacement of bFGF bound to the extracellular matrix. thus increasing the effective concentration of bFGF, Possible biological implications of these observations are discussed.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.			Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA46565] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENEZRA M, 1993, BLOOD, V81, P3324; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BROWN KJ, 1994, BIOCHEMISTRY-US, V33, P13918, DOI 10.1021/bi00250a047; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; ISHIGAKI M, 1997, RINSHO BYORI, V44, P439; Jay P, 1997, ONCOGENE, V14, P1753, DOI 10.1038/sj.onc.1200986; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; LATINKIC BV, 1994, THESIS U ILLINOIS CH; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; MARTINERIE C, 1994, ONCOGENE, V9, P2729; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; Niu DM, 1996, HUM GENET, V98, P65, DOI 10.1007/s004390050161; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WATSON JB, 1994, J CLIN INVEST, V94, P261, DOI 10.1172/JCI117316; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P115; WONG M, 1998, IN PRESS DEV BIOL; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	36	63	71	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	1998	16	6					747	754		10.1038/sj.onc.1201572	http://dx.doi.org/10.1038/sj.onc.1201572			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488038				2022-12-28	WOS:000071931800006
J	Kao, MC; Liu, GY; Chuang, TC; Lin, YS; Wuu, JA; Law, SL				Kao, MC; Liu, GY; Chuang, TC; Lin, YS; Wuu, JA; Law, SL			The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene	ONCOGENE			English	Article						HER-2/neu; SV30 large T antigen; p185; cancer gene therapy	E1A GENE-PRODUCTS; LARGE TUMOR-ANTIGEN; VIRUS-40 LARGE-T; NEU ONCOGENE; OVARIAN-CANCER; PROTO-ONCOGENE; EGF RECEPTOR; TRANSCRIPTIONAL REPRESSION; C-ERBB-2 GENE; BREAST-CANCER	The deregulation of the HER-2/neu protooncogene was demonstrated in a wide variety of human cancers and shown to be correlated with the progress of malignancy and metastasis in animal models. Repression of HER-2/neu overexpression suppressed the malignant phenotypes of HER-2/neu-overexpressing cancer cells. This suggested that HER-2/neu may be a good target for developing anti-cancer drugs, We found a deletion mutant of simian virus 40 (SV40) large T antigen (LT) suppresses the Her-2/neu oncogene expression at the transcriptional level, PCR clones of this mutant SV40LT, named LT425, which contains the N-terminal region of amino acid residues 1-178 of SV40LT, were subcloned and stably transfected into the HER-2/neu-overexpressing human ovarian cancer SKOV3.ip1 cells. These LT425 clones were found to be able to down-regulate the endogenous production of p185(HER-2/neu). In addition, the LT425-expressing stable transfectants showed reduced growth rate, low soft agarose colony forming ability, and low tumorigenic potential as compared with the parental line. These data suggested that the N-terminal 178 amino acids domain only of SV40LT may act as a transforming repressor of HER-2/neu oncogene.	Natl Def Med Ctr, Dept Biochem, Taipei 10764, Taiwan; Cheng Hsin Phys Med & Rehabil Ctr, Taipei, Taiwan; Vet Gen Hosp, Dept Med Res, Taipei 11217, Taiwan	National Defense Medical Center	Kao, MC (corresponding author), Natl Def Med Ctr, Dept Biochem, Taipei 10764, Taiwan.		Liu, Gary/A-6200-2009					Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERCHUCK A, 1990, CANCER RES, V50, P4087; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; CHUANG TC, 1996, THESIS NATL DEFENSE; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Cozen SD, 1995, ONCOGENE, V11, P2295; DEMILIA J, 1989, ONCOGENE, V4, P1233; Eckner R, 1996, MOL CELL BIOL, V16, P3454; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GANNON JV, 1991, NATURE, V349, P802; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gu KF, 1996, CANCER LETT, V99, P185, DOI 10.1016/0304-3835(95)04061-7; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; HUNG MC, 1986, BIOCH MOL EPIDEMIOL, V40, P391; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MATIN A, 1993, CELL GROWTH DIFFER, V4, P1; MILLER SJ, 1994, INT J ONCOL, V4, P965; MITRA AB, 1994, CANCER RES, V54, P637; Monier R., 1986, PAPOVAVIRIDAE, V1, P247; Mymryk JS, 1996, ONCOGENE, V13, P1581; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; REDDY VB, 1978, SCIENCE, V200, P494, DOI 10.1126/science.205947; ROBB JA, 1972, J VIROL, V9, P562, DOI 10.1128/JVI.9.3.562-563.1972; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SALZMAN NP, 1986, PAPOVAVIRIDAE, P27; SAWAI ET, 1994, VIROLOGY, V189, P782; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINER DB, 1990, CANCER RES, V50, P421; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHANG X, 1989, ONCOGENE, V4, P985; ZHAU HE, 1990, MOL CARCINOGEN, V3, P254, DOI 10.1002/mc.2940030503	63	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					547	554		10.1038/sj.onc.1201513	http://dx.doi.org/10.1038/sj.onc.1201513			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484845				2022-12-28	WOS:000071739400014
J	Li, CD; Larsson, C; Futreal, A; Lancaster, J; Phelan, C; Aspenblad, U; Sundelin, B; Liu, Y; Ekman, P; Auer, G; Bergerheim, USR				Li, CD; Larsson, C; Futreal, A; Lancaster, J; Phelan, C; Aspenblad, U; Sundelin, B; Liu, Y; Ekman, P; Auer, G; Bergerheim, USR			Identification of two distinct deleted regions on chromosome 13 in prostate cancer	ONCOGENE			English	Article						prostate cancer; chromosome 13; BRCA2; Rb1; pRb; DBM	RETINOBLASTOMA SUSCEPTIBILITY GENE; COMPARATIVE GENOMIC HYBRIDIZATION; ALLELIC LOSS; IN-SITU; BREAST; BRCA2; HETEROZYGOSITY; CARCINOMA; MUTATIONS; PROTEIN	Aberrations of 13q occur frequently in prostate cancer and this chromosome contains two known tumor suppressor genes, BRCA2 and Rb1. This study analysed 13q LOH, DNA ploidy, BRCA2 mutation and pRb expression in prostate cancers, In total, 13q deletions were found in 18 of 36 tumors but did not correlate with histological grade, stage or DNA ploidy. Two smallest regions of overlapping deletions were defined: one flanked by D13S218 and D13S153; the other flanked by D13S31 and D13S137. BRCA2 was less frequently deleted ,whereas Rb1 did have a high frequency of deletion. None of the two genes was located in any of these two regions, Furthermore, BRCA2 mutation was not found in the five tumors where deletions had involved the BRCA2 locus, Neither did the Rb1 deletion correlate with absent pRb expression. In addition, tetraploidy was found in 14 out of 25 tumors analysed and correlated with aberrant pRb expression. Our results indicate that 13q deletion is an early non-random event, Tumor suppressor genes other than BRCA2 or Rb1 may be the target of 13q deletions. Aberrant pRb expression was not reflect the tyro-hit Rb1 inactivation but may be involved in the tetraploidization of prostate cancer cells.	Karolinska Hosp, Dept Urol, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Mol Med, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Pathol, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Oncol, S-17176 Stockholm, Sweden; Duke Univ, Med Ctr, Dept Surg, Div Gynecol Oncol, Durham, NC 27710 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Duke University	Li, CD (corresponding author), Karolinska Hosp, Dept Urol, S-17176 Stockholm, Sweden.			Auer, Gert/0000-0003-3911-0285; Li, Chunde/0000-0003-4331-079X	NCI NIH HHS [P50-CA68438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA068438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; Cher ML, 1996, CANCER RES, V56, P3091; CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; Cooney KA, 1996, CANCER RES, V56, P1142; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Herzog H, 1996, GENOME RES, V6, P858, DOI 10.1101/gr.6.9.858; HSIEH CL, 1990, SOMAT CELL MOLEC GEN, V16, P567, DOI 10.1007/BF01233097; JEWITT HJ, 1975, UROL CLIN N AM, V2, P105; Kubota Y, 1995, PROSTATE, V27, P314, DOI 10.1002/pros.2990270604; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEONARDO AD, 1997, CANCER RES, V57, P1013; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; Maestro R, 1996, CANCER RES, V56, P1146; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MOSTOFI FK, 1980, 10 WHO INT HIST CLAS; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Pearce SHS, 1996, CLIN ENDOCRINOL, V45, P195, DOI 10.1046/j.1365-2265.1996.d01-1561.x; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; PHILLIPS SMA, 1994, BRIT J CANCER, V70, P1252, DOI 10.1038/bjc.1994.482; RADFORD DM, 1995, CANCER RES, V55, P3399; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; STEINBECK RG, 1994, ANAL QUANT CYTOL, V16, P196; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Tricoli JV, 1996, GENE CHROMOSOME CANC, V15, P108, DOI 10.1002/(SICI)1098-2264(199602)15:2<108::AID-GCC5>3.0.CO;2-7; VISAKORPI T, 1995, CANCER RES, V55, P342; Whitmore Jr WF, 1956, AM J MED, V21, P697; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414; ZHANG X, 1994, CANCER RES, V54, P4177	34	71	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					481	487		10.1038/sj.onc.1201554	http://dx.doi.org/10.1038/sj.onc.1201554			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484837				2022-12-28	WOS:000071739400006
J	Pyles, RB; Santoro, IM; Groden, J; Parysek, LM				Pyles, RB; Santoro, IM; Groden, J; Parysek, LM			Novel protein isoforms of the APC tumor suppressor in neural tissue	ONCOGENE			English	Article						APC; tumor suppressor; neural tissue; protein isoforms	MULTIPLE INTESTINAL NEOPLASIA; COLORECTAL-CANCER; BRAIN-TUMORS; GENE-PRODUCT; WILD-TYPE; ASSOCIATION; COLI; IDENTIFICATION; EXPRESSION; MUTATIONS	The conventional protein isoform of the APC tumor suppressor is 310 kD and is encoded by exons 1-15 of the APC gene, Other RNAs are expressed from the APC gene and include one form that contains an exon upstream of exon 1, designated BS, but this transcript does not include exon 1, This transcript recently has been shown to be enriched in non-dividing, terminally-differentiated cells (Santoro and Groden, 1997). To determine if the BS-containing transcript encoded an alternate APC protein isoform, we generated and affinity-purified a polyclonal antibody directed to protein sequence predicted by exon BS, The BS antibody labeled a band of similar to 300 kD on immunoblots of cerebral and cerebellar tissue from adult human, baboon, rat and mouse, These same tissue lysates also contained prominent BS-reactive proteins of 290 kD, 200 kD and 150 kD, Lysates from mitotically active cells did not contain these APC isoforms, To verify that BS-reactive proteins were APC isoforms, BS-immunoprecipitates were blotted and labeled with commercially available APC antibodies, All four high molecular weight BS-antibody-precipitated proteins were recognized by antibodies directed against epitopes encoded by APC exons 2 and 15. BS isoforms were not, however, labeled with antibodies to an epitope encoded by APC exon 1, consistent with the prediction that BS-APC isoforms lack the domain encoded by these sequences, Like conventional APC, at least one of the four BS-APC protein isoforms also interacts with beta-catenin. BS-APC isoforms that lack exon 1-encoded sequences are incapable of dimerization with the conventional form of APC, yet retain the ability to bind beta-catenin, Such isoforms are likely to be functionally distinct from the conventional APC protein.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Neurobiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Anat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Pyles, RB (corresponding author), Childrens Hosp Res Fdn, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NCI NIH HHS [CA-63507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063507, R01CA063507] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHAT RV, 1994, J NEUROSCI, V14, P3059; CARRARO U, 1983, BIOCHEM BIOPH RES CO, V116, P793, DOI 10.1016/S0006-291X(83)80212-5; GRODEN J, 1995, CANCER RES, V55, P1531; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRODEN J, 1995, NEW ENGL J MED, V332, P884, DOI 10.1056/NEJM199503303321310; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Harlow E., 1988, ANTIBODIES LAB MANUA; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kraus C, 1996, INT J CANCER, V65, P383, DOI 10.1002/(SICI)1097-0215(19960126)65:3<383::AID-IJC18>3.3.CO;2-U; LUONGO C, 1994, CANCER RES, V54, P5947; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MIYASHIRO I, 1995, ONCOGENE, V11, P89; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Santoro IM, 1997, CANCER RES, V57, P488; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1993, CANCER RES, V53, P2728; SULEKOVA Z, 1995, INT J CANCER, V63, P435, DOI 10.1002/ijc.2910630323; TAINER JA, 1984, NATURE, V312, P127, DOI 10.1038/312127a0; THLIVERIS A, 1994, CANCER RES, V54, P2991; Yamamoto H, 1996, CANCER RES, V56, P3605	31	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					77	82		10.1038/sj.onc.1201505	http://dx.doi.org/10.1038/sj.onc.1201505			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467945				2022-12-28	WOS:000071236800009
J	del Peso, L; Hernandez-Alcoceba, R; Embade, N; Carnero, A; Esteve, P; Paje, C; Lacal, JC				del Peso, L; Hernandez-Alcoceba, R; Embade, N; Carnero, A; Esteve, P; Paje, C; Lacal, JC			Rho proteins induce metastatic properties in vivo	ONCOGENE			English	Article						Rho proteins; metastasis; dbl; ost; vav	GTP-BINDING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; JNK/SAPK SIGNALING PATHWAY; TUMOR-CELL INVASION; ACTIN STRESS FIBERS; PHOSPHOLIPASE-D; RAS TRANSFORMATION; 3T3 CELLS; LYSOPHOSPHATIDIC ACID; ADP-RIBOSYLATION	Rho proteins have been implicated in the regulation of multiple signal transduction processes, Some of the members of this family, including the rho gene from Aplysia californica and the human genes (rhoA, rhoB and rac-1), are proto-oncogenes since when properly mutated they can induce cell transformation, and the generated rho-transformed cells are tumorigenic when inoculated into mice, In addition to their tumorigenic activity, there is evidence suggesting that Rho proteins mag contribute to the metastatic phenotype, However, all the experiments implicating Rho proteins or Rho-regulating proteins in the induction of metastatic potential are either indirect or have been performed in vitro. In this study, we investigated whether cells transformed by rho oncogenes do have metastatic potential in vivo. We present evidence that cells transformed by the Aplysia californica rho gene, when injected directly into the blood stream are able to efficiently colonize lungs and secondary organs, consistent with the acquisition of the metastatic potential, Moreover, tumors derived from subcutaneous injections of these rho-transformed cells are also able to metastasize in distant organs, a strong support to the hypothesis that Rho proteins play a role in the metastatic phenotype. Finally, cells transformed by the human oncogenes dbl, vav and ost, three well-known guanine exchange factors for members of the Rho family, or cells transformed by the activated human rac-1 or rhoA genes do also have metastatic potential when injected into the blood stream, These results demonstrate that signaling pathways regulated by Rho proteins play an important role in the acquisition of the metastatic phenotype in vivo.	CSIC, Inst Invest Biomed, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid, Spain.		del Peso, Luis/K-9391-2014; embade, Nieves/K-5190-2014; Lacal, Juan Carlos/AAL-2235-2020; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/N-9064-2015	del Peso, Luis/0000-0003-4014-5688; embade, Nieves/0000-0001-9878-3290; Lacal, Juan Carlos/0000-0002-1908-2777; Carnero, Amancio/0000-0003-4357-3979				AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1993, RAS SUPERFAMILY GTPA, P203; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN LP, 1993, P NATL ACAD SCI USA, V90, P6523, DOI 10.1073/pnas.90.14.6523; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; DAVIES BR, 1993, ONCOGENE, V8, P999; Esteve P, 1995, ONCOGENE, V11, P2657; ESTEVE P, UNPUB; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirai A, 1997, J BIOL CHEM, V272, P13; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JIMENEZ B, 1995, ONCOGENE, V10, P811; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; LEEUWEN FN, 1995, ONCOGENE, V11, P2215; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miele ME, 1996, MOL CARCINOGEN, V15, P284, DOI 10.1002/(SICI)1098-2744(199604)15:4<284::AID-MC6>3.0.CO;2-G; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAI JK, 1994, ANTI-CANCER DRUG DES, V9, P363; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PERONA R, 1997, GENE DEV, V15, P463; PERONA R, 1993, RAS SUPERFAMILY GTPA; PESO L, 1996, BIOCHEM J, V322, P519; PONTA H, 1994, EUR J CANCER, V30A, P1995, DOI 10.1016/0959-8049(94)00393-J; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WIELENGA VJM, 1993, CANCER RES, V53, P4754; WILLIGER BT, 1995, J BIOL CHEM, V270, P29656; ZHANG J, 1993, J BIOL CHEM, V268, P22251	61	154	159	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3047	3057						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444953				2022-12-28	WOS:000070968000005
J	Drane, P; Barel, M; Balbo, M; Frade, R				Drane, P; Barel, M; Balbo, M; Frade, R			Identification of RB18A, a 205 kDa new p53 regulatory protein which shares antigenic and functional properties with p53	ONCOGENE			English	Article						p53; antigen related	WILD-TYPE P53; DNA-BINDING FUNCTION; LARGE T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODY; GROWTH SUPPRESSION; CELLULAR PROTEIN; TUMOR-ANTIGEN; IN-VITRO; KINASE-C	Immunological screening with the anti-p53 moAb, PAb1801 of a cDNA expression library, prepared from human B lymphoma cells, led us to identify a new human 205 kDa protein called RB18A for 'Recognized By PAb1801 moAntibody'. Immunoblotting or immunoprecipitation of fusion protein or in vitro translated protein, respectively, demonstrated that RB18A protein was recognized by several anti-p53 moAb reacting with the N or C-terminal domains of p53. Full length sequence of RB18B cDNA and computer analysis demonstrated that despite common antigenic determinants between RB18A and p53 proteins, nucleotide and deduced protein sequences did not reveal any significant homologies. RB18A mRNA was detected in all tissues tested except in kidney. In addition, RB18A protein shared identical functions with p53 protein: binding to DNA or to p53 and self-oligomerization. Furthermore, RB18A regulated p53 specific binding on his DNA consensus binding site. These functions were associated to the C-terminal domain of RB18A protein and more specifically to the PAb421 binding site present in this domain. The activation by RB18A of p53 binding on DNA was induced through an unstable interaction between both proteins. Altogether, our data demonstrated that RB18A protein shares antigenic and functional properties with p53 and regulated p53 functions.	Hop St Antoine, Ctr INSERM, INSERM U354, Immunochim Regulat Cellulaires & Interact Virales, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Frade, R (corresponding author), Hop St Antoine, Ctr INSERM, INSERM U354, Immunochim Regulat Cellulaires & Interact Virales, F-75012 Paris, France.			BAREL, Monique/0000-0001-8171-7027				Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAREL M, 1991, J IMMUNOL, V147, P1286; BAREL M, 1989, P NATL ACAD SCI USA, V86, P10054, DOI 10.1073/pnas.86.24.10054; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DAUD AI, 1993, AM J PHYSIOL, V264, pH1693, DOI 10.1152/ajpheart.1993.264.5.H1693; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; Kim KK, 1996, J BIOL CHEM, V271, P29255, DOI 10.1074/jbc.271.46.29255; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEGROS Y, 1994, ONCOGENE, V9, P2071; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; Milne DM, 1996, ONCOGENE, V13, P205; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Simons A, 1997, ONCOGENE, V14, P145, DOI 10.1038/sj.onc.1200825; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	63	48	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3013	3024		10.1038/sj.onc.1201492	http://dx.doi.org/10.1038/sj.onc.1201492			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444950				2022-12-28	WOS:000070968000002
J	Weyman, CM; Wolfman, A				Weyman, CM; Wolfman, A			Oncogenic Ras-induced secretion of a novel inhibitor of skeletal myoblast differentiation	ONCOGENE			English	Article						myoblast; differentiation; inhibition; oncogenic Ras	FIBROBLAST GROWTH-FACTOR; PROTEIN-KINASE KINASE; MYOGENIC DIFFERENTIATION; CELL-CYCLE; MUSCLE DIFFERENTIATION; EPITHELIAL-CELLS; G1 PHASE; N-RAS; EXPRESSION; INDUCTION	Expression of oncogenic H-Ras in 23A2 myoblasts (A2:H-Ras cells) is sufficient to induce both a transformed phenotype and a differentiation-defective phenotype, Because oncogenic Pas is known to induce the secretion of several different growth factors involved in maintaining the transformed phenotype of both fibroblast and epithelial cells, we explored the possibility that expression of oncogenic Ras in 23A2 myoblasts might lead to the secretion of a factor which inhibits differentiation, The differentiation of 23A2 myoblasts was inhibited (i) by coculture with an equal number of A2:H-Ras cells, (ii) by culture with an equal number of A2:H-Ras cells in the same tissue culture medium on an insert which allowed equilibration of molecules smaller than I micron, and (iii) by culture in media previously conditioned by A2:H-Ras cells, Similar results were obtained when 23A2 myoblasts expressing oncogenic N-Ras were substituted for A2:H-Ras cells in each assay, No inhibition of differentiation was observed, however, when differentiation-defective E1A-expressing 23A2 cells or C3H10T1/2 fibroblasts were substituted for A2:H-Ras cells, The differentiation inhibitor(s) in media conditioned by A2:K-Ras cells is heat stable, larger than 3 kD, and sensitive to the non-specific growth factor antagonist, suramin, Western analyses failed to detect either FGF-2 or TGF beta (the known inhibitors of myoblast differentiation) in media conditioned by A2:H-Ras cells, Furthermore, while FGF-2 is a potent activator of MAP kinase and TGF beta is a potent inhibitor of mink lung epithelial cell (CCL64) growth, conditioned media from A2:H-Ras cells does not activate MAP kinase and does not inhibit the growth of CCL64 cells. These results indicate that expression of oncogenic Pas induces the secretion of a novel inhibitor of skeletal myoblast differentiation, Furthermore, these results are the first to implicate an autocrine/paracrine mechanism in the inhibition of differentiation by oncogenic Ras.			Weyman, CM (corresponding author), CLEVELAND CLIN FDN,DEPT CELL BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049652, R55GM049652] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 49652] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Berkowitz EA, 1996, ONCOGENE, V12, P1991; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; DAWSON TP, 1995, CANCER RES, V55, P915; ENKEMANN SA, 1990, CELL GROWTH DIFFER, V1, P375; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GIOVANNI C, 1995, BRIT J CANCER, V72, P1224; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LATHROP B, 1985, J CELL BIOL, V101, P2194, DOI 10.1083/jcb.101.6.2194; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; PIRONIN M, 1992, INT J CANCER, V51, P908; RAK J, 1995, CANCER RES, V55, P4575; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; SCHRELL UMH, 1995, J NEUROSURG, V82, P600, DOI 10.3171/jns.1995.82.4.0600; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VISSCHER DA, 1996, ADV ONCOBIOLOGY; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; WEYMAN CM, 1996, ADV ONCOBIOLOGY	37	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2521	2528		10.1038/sj.onc.1201423	http://dx.doi.org/10.1038/sj.onc.1201423			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399640	Bronze			2022-12-28	WOS:A1997YG73200002
J	Gritti, C; Choukroun, V; Soulier, J; Madani, A; Dastot, H; Leblond, V; RadfordWeiss, I; Valensi, F; Varet, B; Sigaux, F; Stern, MH				Gritti, C; Choukroun, V; Soulier, J; Madani, A; Dastot, H; Leblond, V; RadfordWeiss, I; Valensi, F; Varet, B; Sigaux, F; Stern, MH			Alternative origin of p13(MTCP1)-encoding transcripts in mature T-cell proliferations with t(X;14) translocations	ONCOGENE			English	Article						MTCP1; TCL1; alternative promoter T-cell prolymphocytic leukemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; ATAXIA-TELANGIECTASIA; PROLYMPHOCYTIC LEUKEMIA; GENE; CHROMOSOME; EXPRESSION; ONCOGENE; MTCP-1; ABNORMALITIES; MALIGNANCIES	The MTCP1 gene is involved in the t(X;14)(q28;q11) translocation associated with T-cell prolymphocytic leukemia and related conditions. This gene is unusual in that it codes for two distinct proteins: a small mitochondrial protein, p8(MTCP1), putative oncogenic protein, p13(MTCP1). Scarcity of material from t(X;14)-associated proliferations and very low levels of mRNA expression have so far prevented a thorough description of p13(MTCP1)-encoding transcripts. Here, we characterize two additional t(X;14) bearing leukemias allowing this analysis. In one case, with a breakpoint located 5' to the MTCP1 gene, the level of transcription of previously described p13(MTCP1)-encoding transcripts is enhanced. In the second case, with a breakpoint within the MTCP1 intron I, an alternative transcription initiation site is demonstrated in the tumor cells at 229 bp upstream to exon II. The identification of this internal promoter, together with the similarity between TCL1 and MTCP1 genomic structures, allow us to propose a model in which the duplication of an ancestral gene was followed by the insertion of one copy within the intron of a p8-encoding gene, accounting for the unusual feature of the MTCP1 gene.	HOP ST LOUIS, INSERM U462, CTR HAYEM, F-75475 PARIS 10, FRANCE; HOP LA PITIE SALPETRIERE, DEPT HEMATOL, F-75631 PARIS 13, FRANCE; HOP NECKER ENFANTS MALAD, DEPT HEMATOL, F-75743 PARIS 15, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite			Stern, Marc-Henri/A-2728-2011	Stern, Marc-Henri/0000-0002-8100-2272				AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; BEATTY DW, 1986, S AFR MED J, V69, P115; CANKI N, 1983, ZDRAV VESTN, V52, P567; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALLAPICCOLA B, 1984, INT J CANCER, V34, P171, DOI 10.1002/ijc.2910340206; DURO D, 1995, ONCOGENE, V11, P21; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FISCH P, 1993, ONCOGENE, V8, P3271; FU TB, 1994, CANCER RES, V54, P6297; GOYNS MH, 1993, LEUKEMIA, V7, P848; LABARRIERE N, 1995, J BIOL CHEM, V270, P19205, DOI 10.1074/jbc.270.33.19205; MADANI A, 1995, ONCOGENE, V10, P2259; Madani A, 1996, BLOOD, V87, P1923; QUELLE DE, 1995, CELL, V83, P993; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOULIER J, 1994, ONCOGENE, V9, P3565; STERN MH, 1993, ONCOGENE, V8, P2475; TAYLOR AMR, 1981, INT J CANCER, V27, P311, DOI 10.1002/ijc.2910270309; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; THICK J, 1994, LEUKEMIA, V8, P564; Thick J, 1996, ONCOGENE, V12, P379; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; WITZIG TE, 1986, AM J HEMATOL, V21, P139, DOI 10.1002/ajh.2830210204	26	6	6	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1329	1335		10.1038/sj.onc.1201303	http://dx.doi.org/10.1038/sj.onc.1201303			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315101				2022-12-28	WOS:A1997XV84500011
J	Alkema, MJ; Jacobs, H; vanLohuizen, M; Berns, A				Alkema, MJ; Jacobs, H; vanLohuizen, M; Berns, A			Perturbation of B and T cell development and predisposition to lymphomagenesis in E mu Bmi1 transgenic mice require the Bmi1 RING finger	ONCOGENE			English	Article						Bmi1; lymphoid development; lymphomagenesis; provirus tagging	E-MU-MYC; POLYCOMB GROUP GENES; C-MYC; ZINC-FINGER; LEUKEMIA-VIRUS; HOMEOBOX GENE; PROVIRAL INSERTION; AXIAL SKELETON; DROSOPHILA; EXPRESSION	Proviral activation of the Bmi1 gene has implicated Bmi1 as a collaborator of c-Myc in lymphomagenesis. To determine the effect of Bmi1 overexpression on hematopoiesis and lymphomagenesis transgenic mice were generated that overexpress different forms of the Bmi1 protein in their lymphoid compartment. E mu Bmi1 transgenic mice, overexpressing the wild type Bmi1 protein showed a perturbed lymphoid development and were highly susceptible to B and T cell lymphomagenesis. Mutational analysis of the Bmi1 protein demonstrated that the conserved N-terminal RING finger and central part of Bmi1 are essential for its oncogenic potential whereas the C-terminal Pro-Ser rich region is not required. We have used provirus tagging in the E mu Bmi1 mice to identify genes that cooperate with Bmi1 in lymphomagenesis. MoMLV infection in E mu Bmi1 transgenic mice accelerated Lymphoma development. Proviral activation of the Pim and Myc genes but not the Gfi1 gene were frequently observed in these tumors. These results demonstrate that Bmi1 is a potent oncogene and suggest that it plays an important role in early lymphoid development.	NETHERLANDS CANC INST, DIV MOL GENET, NL-1066 CX AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DIV MOL CARCINOGENESIS, NL-1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; Netherlands Cancer Institute				Jacobs, Heinz/0000-0001-6227-9850				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Akasaka T, 1996, DEVELOPMENT, V122, P1513; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; DUBE ID, 1991, BLOOD, V78, P2996; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVERETT R, 1995, J VIROL, V69, P7339, DOI 10.1128/JVI.69.11.7339-7344.1995; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEVY LS, 1993, VIROLOGY, V196, P892, DOI 10.1006/viro.1993.1553; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; MCKEON J, 1994, MOL GEN GENET, V244, P474, DOI 10.1007/BF00583898; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NOMURA M, 1994, DIFFERENTIATION, V57, P39, DOI 10.1046/j.1432-0436.1994.5710039.x; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; PELEGRI F, 1994, GENETICS, V136, P1341; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; vanderLugt NMT, 1996, MECH DEVELOP, V58, P153, DOI 10.1016/S0925-4773(96)00570-9; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zornig M, 1996, ONCOGENE, V12, P1789	56	109	114	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	1997	15	8					899	910		10.1038/sj.onc.1201262	http://dx.doi.org/10.1038/sj.onc.1201262			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285685				2022-12-28	WOS:A1997XR76700003
J	Kinoshita, T; Shirouzu, M; Kamiya, A; Hashimoto, K; Yokoyama, S; Miyajima, A				Kinoshita, T; Shirouzu, M; Kamiya, A; Hashimoto, K; Yokoyama, S; Miyajima, A			Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL3-dependent hematopoietic cells	ONCOGENE			English	Article						cell survival; anti-apoptosis; ras; rapamycin	COLONY-STIMULATING FACTOR; ACTIVATED PROTEIN-KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; COMMON BETA-SUBUNIT; P70 S6 KINASE; SIGNAL-TRANSDUCTION; RAS TRANSFORMATION; ONCOGENIC RAS; NEURITE OUTGROWTH; GROWTH-FACTOR	The Ras signal transduction pathway is activated by a number of hematopoietic cytokines and is implicated in the prevention of apoptotic death in hematopoietic cells, Recent studies have provided evidence that the downstream of Ras is highly divergent and several independent pathways appear to mediate distinct biological functions of Ras, In the present study, we investigated the downstream pathway(s) of Ras responsible for the maintenance of hematopoietic cell survival by using various mutants of signaling molecules, Activation of the Raf/MAPK pathway in interleukin (IL) 3-dependent cells by expression of an oncogenic Raf or a Ras mutant (G12V/T35S) prevented apoptosis following IL-3 deprivation, In contrast, another Ras mutant (G12V/V45E), which is apparently incapable of activating MAPK, efficiently blocked apoptosis as well, It is therefore likely that the activation of the Raf/MAPK pathway is not an absolute requirement for the prevention of apoptosis, and there appears to be a Raf/MAPK-independent pathway that contributes to hematopoietic cell survival, Since Ras(G12V/V45E) was able to cause the phosphorylation of p70/S6 kinase, we inhibited the S6 kinase pathway by rapamycin and by wortmannin, and found that the anti-apoptotic function of Ras(G12V/V45E), but not of Ras(G12V), was critically influenced by both inhibitors, These results indicate that the Raf/MAPK and a rapamycin/wortmannin-sensitive pathways mediate Ras function to prevent apoptotic death in hematopoietic cells.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,DEPT CELLULAR BIOSYNTH,BUNKYO KU,TOKYO 113,JAPAN; RIKEN,INST PHYS & CHEM RES,CELLULAR SIGNALING LAB,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOCHEM & BIOPHYS,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; RIKEN; University of Tokyo			Shirouzu, Mikako/A-6521-2016; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ANDERSON MW, 1992, ENVIRON HEALTH PERSP, V98, P13, DOI 10.2307/3431243; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN CY, 1995, ONCOGENE, V11, P1487; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Hara T, 1996, STEM CELLS, V14, P605, DOI 10.1002/stem.140605; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUTHUKKUMAR S, 1995, TRANSPLANTATION, V60, P264, DOI 10.1097/00007890-199508000-00010; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SCHWAB M, 1990, Critical Reviews in Oncogenesis, V2, P35; SHI YF, 1995, CANCER RES, V55, P1982; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SHIROUZU M, 1992, ONCOGENE, V7, P475; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHETTON AD, 1983, NATURE, V303, P629, DOI 10.1038/303629a0; WHETTON AD, 1984, EMBO J, V3, P409, DOI 10.1002/j.1460-2075.1984.tb01821.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	73	103	104	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					619	627		10.1038/sj.onc.1201234	http://dx.doi.org/10.1038/sj.onc.1201234			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264402				2022-12-28	WOS:A1997XP68300001
J	Canman, CE; Kastan, MB				Canman, CE; Kastan, MB			Small contribution of G1 checkpoint control manipulation to modulation of p53-mediated apoptosis	ONCOGENE			English	Article						apoptosis; p53; p21; E2F	CELL-CYCLE ARREST; S-PHASE ENTRY; GROWTH ARREST; G(1) ARREST; TRANSCRIPTION FACTOR; P53-DEPENDENT APOPTOSIS; RETINOBLASTOMA PROTEIN; P53-INDUCED APOPTOSIS; HEMATOPOIETIC-CELLS; DEPENDENT KINASES	Deregulation of the S-phase promoting E2F-1 transcription factor has been shown to cooperate with p53 to induce apoptosis, BaF3 cells undergo rapid, p53-dependent apoptosis when irradiated in the absence of IL-3, Rapid apoptosis induced by ionizing radiation (IR) coincides with attenuated p21(WAF1/Cip1) induction, Failure to adequately induce p21 could result in inappropriate release of E2F from Rb which may then cooperate with p53 to induce apoptosis in cells deprived of growth factor, We engineered BaF3 cells to express exogenous p21 and tested whether overexpressing p21 in cells irradiated in the absence of IL-3 protects from IR-induced apoptosis. Enforced p21 expression resulted in a consistent, but partial, protection of cells from undergoing IR-induced apoptosis. However, deregulating E2F activity through expression of HPV E7 failed to sensitize cells to IR-induced apoptosis in the presence of IL-3. Together, these data strongly suggest that the IL-3-responsive factors which modulate p53-mediated apoptosis in BaF3 cells are largely independent of G1 cell cycle checkpoint control mediated by p21.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Canman, CE (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, 345 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.			, Christine/0000-0001-8892-7430	NATIONAL CANCER INSTITUTE [R01CA061949, T32CA060441] Funding Source: NIH RePORTER; NCI NIH HHS [CA61949, CA60441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DULLIC V, 1994, CELL, V76, P1013; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GORCZYCA W, 1993, CANCER RES, V54, P2591; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HARPER JW, 1993, CELL, V75, P805; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Liu Y, 1996, CANCER RES, V56, P31; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Minshall C, 1996, J IMMUNOL, V156, P939; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHAUNG H, 1995, J BIOL CHEM, V270, P14500	75	23	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					957	966		10.1038/sj.onc.1201612	http://dx.doi.org/10.1038/sj.onc.1201612			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519869				2022-12-28	WOS:000072335900001
J	Gemma, A; Hagiwara, K; Vincent, F; Ke, Y; Hancock, AR; Nagashima, M; Bennett, WP; Harris, CC				Gemma, A; Hagiwara, K; Vincent, F; Ke, Y; Hancock, AR; Nagashima, M; Bennett, WP; Harris, CC			hSmad5 gene, a human hSmad family member: its full length cDNA, genomic structure, promoter region and mutation analysis in human tumors	ONCOGENE			English	Article						transforming growth factor-beta; cDNA; genomic structure; PCR-SSCP	GROWTH-FACTOR-BETA; MAD-RELATED PROTEIN; II RECEPTOR GENE; TGF-BETA; SIGNALING PATHWAYS; CELL-GROWTH; CLONING; CANCER; INHIBITION; KINASE	hSmad (mothers against decapentaplegic)-related proteins are important messengers within the Transforming Growth Factor-beta(1) (TGF-beta(1)) superfamily signal transduction pathways. To further characterize a member of this family, we obtained a full length cDNA of the human hSmad5 (hSmad5) gene by rapid amplification of cDNA ends (RACE) and then determined the genomic structure of the gene. There are eight exons and two alternative transcripts; the shorter transcript lacks exon 2. We identified the hSmad5 promoter region from a human genomic YAC clone by obtaining the nucleotide sequence extending 1235 base pairs upstream of the 5' end of the cDNA. We found a CpG island consistent with a promoter region, and we demonstrated promoter activity in a 1232 bp fragment located upstream of the transcription initiation site. To investigate the frequency of somatic hSmad5 mutations in human cancers, we designed intron-based primers to examine coding regions by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis. Neither homozygous deletions or point mutations were found in 40 primary gastric tumors and 51 cell lines derived from diverse types of human cancer including 20 cell lines resistant to the growth inhibitory effects of TGF-beta(1). These results suggest that the hSmad5 gene is not commonly mutated and that other genetic alterations mediate the loss of TGF-beta(1) responsiveness in human cancers.	NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; IFREMER, Lab Ecotoxicol, F-44311 Nantes 03, France; Beijing Med Univ, Sch Oncol, Beijing 100034, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ifremer; Peking University	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA.			VINCENT-HUBERT, Francoise/0000-0002-2266-9237				ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gemma A, 1997, CANCER RES, V57, P1435; Gemma A, 1996, INT J CANCER, V68, P605, DOI 10.1002/(SICI)1097-0215(19961127)68:5<605::AID-IJC9>3.0.CO;2-2; Hagiwara K, 1996, NUCLEIC ACIDS RES, V24, P2460, DOI 10.1093/nar/24.12.2460; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LECHNER JF, 1983, CANCER RES, V43, P5915; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Riggins GJ, 1997, CANCER RES, V57, P2578; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; Tamura G, 1996, CANCER RES, V56, P612; VINCENT F, 1997, IN PRESS ONCOGENE; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	30	35	38	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					951	956		10.1038/sj.onc.1201614	http://dx.doi.org/10.1038/sj.onc.1201614			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484787				2022-12-28	WOS:000072053200015
J	Kagan, J; Liu, JH; Stein, JD; Wagner, SS; Babkowski, R; Grossman, BH; Katz, RL				Kagan, J; Liu, JH; Stein, JD; Wagner, SS; Babkowski, R; Grossman, BH; Katz, RL			Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer	ONCOGENE			English	Article						chromosome 10; LOH; microsatellite; bladder cancer; tumor suppressor gene (TSG)	TUMOR-SUPPRESSOR GENES; TRANSITIONAL CELL-CARCINOMA; HUMAN PROSTATE-CANCER; LONG ARM; HETEROZYGOSITY; DELETIONS; GLIOMAS; MARKERS	A limited number of previous studies have indicated a low frequency of chromosome 10 allele losses and deletions in bladder cancers. We investigated the involvement of chromosome 10 in advanced bladder cancers. Loss of heterozygosity (LOH) was analysed in 19 microsatellite loci in 20 grade III invasive transitional cell carcinomas. Nine (45%) of the 20 tumors had at least one allele loss on the long arm of chromosome 10. The short arm of chromosome 10 was not affected, The most frequent LOH occurred at D10S215, where four (29%) of 14 of the informative cases had an allele loss. The minimal region with allele losses was located between the centromeric marker D10S1644 and the telomeric marker D10S541, which are separated by 2.52 cM. The results strongly suggest the existence within that region of a tumor suppressor gene or genes for advanced bladder cancer.	Univ Texas, MD Anderson Cancer Ctr, Div Lab Med, Sect Expt Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kagan, J (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Div Lab Med, Sect Expt Lab Med, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [U01CA056973] Funding Source: NIH RePORTER; NCI NIH HHS [UO1 CA-56973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; BABU VR, 1987, CANCER RES, V47, P6800; Beahrs O. H., 1992, MANUAL STAGING CANC, V4th; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GIBAS Z, 1984, CANCER RES, V44, P1257; GRAY IC, 1995, CANCER RES, V55, P4800; ISSHIKI K, 1993, GENE CHROMOSOME CANC, V8, P178, DOI 10.1002/gcc.2870080307; Ittmann MM, 1996, PROSTATE, V28, P275; KAGAN J, 1995, ONCOGENE, V11, P2121; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KNOWLES MA, 1994, CANCER RES, V54, P531; Lacombe L, 1996, INT J CANCER, V69, P110, DOI 10.1002/(SICI)1097-0215(19960422)69:2<110::AID-IJC7>3.0.CO;2-3; LEVINE AJ, 1992, CANCER SURV, V12, P1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Nagase S, 1996, BRIT J CANCER, V74, P1979, DOI 10.1038/bjc.1996.663; PARKER SL, 1997, J CLIN, V47, P5; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Raskind WH, 1996, GENE CHROMOSOME CANC, V16, P138, DOI 10.1002/(SICI)1098-2264(199606)16:2<138::AID-GCC8>3.0.CO;2-0; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA, P805; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Trybus TM, 1996, CANCER RES, V56, P2263; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; WANG MR, 1994, CANCER GENET CYTOGEN, V73, P8, DOI 10.1016/0165-4608(94)90175-9; Zedenius J, 1996, HUM GENET, V97, P299, DOI 10.1007/BF02185758	27	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					909	913		10.1038/sj.onc.1201606	http://dx.doi.org/10.1038/sj.onc.1201606			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484782				2022-12-28	WOS:000072053200010
J	Cha, HJ; Park, MT; Chung, HY; Kim, ND; Sato, H; Seiki, M; Kim, KW				Cha, HJ; Park, MT; Chung, HY; Kim, ND; Sato, H; Seiki, M; Kim, KW			Ursolic acid-induced down-regulation of MMP-9 gene is mediated through the nuclear translocation of glucocorticoid receptor in HT1080 human fibrosarcoma cells	ONCOGENE			English	Article						ursolic acid; matrix metalloproteinase; glucocorticoid receptor	PROTEIN-PROTEIN-INTERACTION; BASEMENT-MEMBRANE COLLAGEN; NF-KAPPA-B; NEGATIVE REGULATION; IV COLLAGENASE; FUNCTIONAL INTERFERENCE; OLEANOLIC ACID; DNA-BINDING; TUMOR-CELLS; C-JUN	We have previously reported that ursolic acid, a pentacyclic triterpene acid, inhibited the invasion of human fibrosarcoma cells by reducing: the of matrix metalloproteinase-9. Since the chemical structure of ursolic acid is very similar to that of dexamethasone, a synthetic glucocorticoid, we investigated whether ursolic acid acts through the glucocorticoid receptor, The expression of matrix metalloproteinase-9 is thought to be regulated similarly with matrix metalloproteinase-l and matrix metalloproteinase-3 as containing common 2-O-tetradecanoylphorbol-acetate responsible region, where AP-1 proteins can bind, Dexamethasone has been studied to repress the 2-O-tetradecanoylphorbol-acetate-induced expression of matrix metalloproteinase-l and matrix metalloproteinase-3 through a glucocorticoid receptor-mediated manner, In Northern blot analysis, we found that ursolic acid reduced the expression of matrix metalloproteinase-l and matrix metalloproteinase-3 induced by 2-O-tetradecanoylphorbol-acetate, Similarly, ursolic acid down-regulated 2-O-tetradecanoylphorbol-acetate-induction of matrix metalloproteinase-9 gene in the same manner of dexamethasone. RU486, a potent glucocorticoid receptor antagonist, was used for identifying that ursolic acid-indnced down-regulation of matrix metalloproteinase-9 expression is mediated by its binding to glucocorticoid receptor, The effect of ursolic acid on the matrix metalloproteinase-9 expression was blocked by RU486, suggesting that ursolic acid acts via a glucocorticoid receptor in the regulation of matrix metalloproteinase-9, Western blot analysis and immunocytochemistry showed that ursolic acid increased glucocorticoid receptor fraction in the nucleus, although it decreased the synthesis of glucocorticoid receptor mRNA., In addition, ursolic acid did not decrease the expression of c-jun and DNA-binding activity of AP-1 to its cognate sequences, Taken together, we suggest that ursolic acid may induce the repression of matrix metalloproteinase-9 by stimulating the nuclear translocation of glucocorticoid receptor, and the translocated glucocorticoid receptor probably down-modulating the trans-activating function of AP-1 to 2-O-tetradecanoylphorbol-acetate responsible element of matrix metalloproteinase-9 promoter region.	Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Pusan Natl Univ, Res Inst Basic Sci, Pusan 609735, South Korea; Pusan Natl Univ, Pusan Canc Res Ctr, Pusan 609735, South Korea; Pusan Natl Univ, Dept Pharm, Pusan 609735, South Korea; Kanazawa Univ, Canc Res Inst, Dept Mol Virol & Oncol, Kanazawa, Ishikawa 920, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 108, Japan	Pusan National University; Pusan National University; Pusan National University; Pusan National University; Kanazawa University; University of Tokyo	Kim, KW (corresponding author), Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea.		Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015; Cha, Hee-Jae/AFO-8772-2022					ADCOCK IM, 1995, J IMMUNOL, V154, P3500; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALEXANDROVA M, 1992, J STEROID BIOCHEM, V41, P723, DOI 10.1016/0960-0760(92)90412-C; BROWN PD, 1990, CANCER RES, V50, P6184; CELADA A, 1993, J EXP MED, V177, P691, DOI 10.1084/jem.177.3.691; Cha HJ, 1996, CANCER RES, V56, P2281; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GUO DF, 1995, CIRC RES, V77, P249, DOI 10.1161/01.RES.77.2.249; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HIRANO M, 1995, BIOCHEM BIOPH RES CO, V206, P429, DOI 10.1006/bbrc.1995.1059; HUANG MT, 1994, CANCER RES, V54, P701; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LEE HY, 1994, J CANCER RES CLIN, V120, P513, DOI 10.1007/BF01221027; Li JJ, 1997, CANCER RES, V57, P3569; LIOTTA LA, 1979, P NATL ACAD SCI USA, V76, P2268, DOI 10.1073/pnas.76.5.2268; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIU W, 1995, MOL CELL BIOL, V15, P1005; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MCRAE AC, 1994, J REPROD FERTIL, V100, P307, DOI 10.1530/jrf.0.1000307; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OHIGASHI H, 1986, CANCER LETT, V30, P143, DOI 10.1016/0304-3835(86)90082-0; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; SATO H, 1992, ONCOGENE, V7, P77; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHON KH, 1995, CANCER LETT, V94, P213, DOI 10.1016/0304-3835(95)03856-R; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; TEMPLETON NS, 1990, CANCER RES, V50, P5413; TOKUDA H, 1986, CANCER LETT, V33, P279, DOI 10.1016/0304-3835(86)90067-4; TOURAY M, 1991, ONCOGENE, V6, P1227; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TVERBERG LA, 1992, J BIOL CHEM, V267, P17567; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; Young Han-Suk, 1995, Natural Medicines, V49, P190	47	84	91	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	1998	16	6					771	778		10.1038/sj.onc.1201587	http://dx.doi.org/10.1038/sj.onc.1201587			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488041				2022-12-28	WOS:000071931800009
J	Ohtsubo, M; Gamou, S; Shimizu, N				Ohtsubo, M; Gamou, S; Shimizu, N			Antisense oligonucleotide of WAF1 gene prevents EGF-induced cell-cycle arrest in A431 cells	ONCOGENE			English	Article						antisense oligonucleotide; EGF receptor; cell cycle; cyclin-dependent kinase inhibitor; tyrosine phosphorylation	EPIDERMAL GROWTH-FACTOR; SQUAMOUS CARCINOMA-CELLS; HUMAN-TUMOR CELLS; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; P53-INDEPENDENT PATHWAY; EXPRESSION; INHIBITION; ACTIVATION; INDUCTION	A431 cells hyperproduce EGF receptors and possess inactive p53 proteins, It has been suggested that a cyclin-dependent kinase (CDK) inhibitor p21/WAF1 plays a crucial role in the EGF-induced cell-cycle arrest of A431 cells, Here, we investigated the role of WAF1 gene transcription in the EGF-induced cell-cycle arrest by transfecting the 18-mer antisense oligonucleotide which corresponds to the 5' region of WAF1 gene (AS/WAF1). When A431 cells were treated with EGF, a cascade of responses were observed, including immediate hyperphosphorylation of EGF receptor on tyrosine residues, accumulation of WAF1 mRNA and p21/WAF1 protein, dephosphorylation of RE protein which is a substrate of CDK-cyclin, and cell-cycle arrest, In the presence of ASI WAF1, EGF induced the tyrosine-phosphorylation of EGF receptor, but WAF1 mRNA was reduced to a half; accumulation of p21/WAF1 protein and its downstream responses were no longer observed; A431 cells grew continuously, Thus, the transfection of antisense efficiently prevented A431 cells from the EGF-induced arrest, These observations suggest that p21/WAF1 protein is a major effector molecule of the EGF-mediated cell-cycle arrest of A431 cells.	Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo 160, Japan	Keio University	Shimizu, N (corresponding author), Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, 35 Shinanomachi, Tokyo 160, Japan.							BARLOGIE B, 1976, CANCER RES, V36, P1176; BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; BEHZADIAN MA, 1985, CELL STRUCT FUNCT, V10, P219, DOI 10.1247/csf.10.219; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FAN Z, 1994, J BIOL CHEM, V269, P27595; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GAMOU S, 1988, CELL STRUCT FUNCT, V13, P25, DOI 10.1247/csf.13.25; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GAMOU S, 1984, MOL CELL ENDOCRINOL, V37, P205; GILL GN, 1985, SOMAT CELL MOLEC GEN, V11, P309, DOI 10.1007/BF01534689; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; Gulli LF, 1996, CELL GROWTH DIFFER, V7, P173; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HARPER JW, 1993, CELL, V75, P805; HIRAI M, 1990, CELL SIGNAL, V2, P245, DOI 10.1016/0898-6568(90)90052-C; HIRAI M, 1990, CELL STRUCT FUNCT, V15, P191, DOI 10.1247/csf.15.191; HIRAI M, 1988, J CELL BIOL, V107, P791, DOI 10.1083/jcb.107.2.791; HUNTERS J, 1986, FEBS LETT, V206, P319, DOI 10.1016/0014-5793(86)81004-3; Jakus J, 1996, ONCOGENE, V12, P2369; KWOK TT, 1994, CANCER RES, V54, P2834; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; YAMADA H, 1989, EXP CELL RES, V184, P90, DOI 10.1016/0014-4827(89)90367-4; YAMAMOTO T, 1986, CANCER RES, V46, P414	33	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					797	802		10.1038/sj.onc.1201588	http://dx.doi.org/10.1038/sj.onc.1201588			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488044				2022-12-28	WOS:000071931800012
J	Englaro, W; Derijard, B; Ortonne, JP; Ballotti, R				Englaro, W; Derijard, B; Ortonne, JP; Ballotti, R			Solar ultraviolet light activates extracellular signal-regulated kinases and the ternary complex factor in human normal keratinocytes	ONCOGENE			English	Article						ultraviolets A and B; ERKs; SAPKs; TCF/SRF; AP1	SERUM RESPONSE ELEMENT; GROWTH-FACTOR; TYROSINE KINASES; PHOSPHORYLATION; RADIATION; ERK; MECHANISMS; INDUCTION; RECEPTORS; PATHWAYS	Exposure to ultraviolet radiation of solar light is responsible for inflammation, premature skin aging and is the main cause of human skin carcinogenesis. While the noxious consequences of U.V. exposure are known, the molecular events triggered by this radiation are poorly understood. We observed that U.V.-A and U.V.-B irradiation of human keratinocytes induces the activation of tyrosine kinase pathways leading to the tyrosine phosphorylation of several cellular proteins. We also observed a stimulation of the Stress Activated Protein kinases (SAPKs), p38 and JNK, and an activation of the transcription factors AP-1 in response to U.V.-A and U.V.-B radiation. Furthermore, we clearly demonstrated that physiological U.V. doses are able to activate the Extracellular signal-Regulated Kinases, ERK1 and ERK2, which could explain the activation of the Ternary Complex Factor. Thus, in human keratinocytes, solar U.V. light activates multiple signalling pathways that could be involved in skin inflammation following U.V. induced skin injury or in U.V.-induced skin carcinogenesis.	Fac Med Nice, INSERM, U385, F-06107 Nice 2, France; Univ Nice, CNRS, Ctr Biochim, F-06018 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Ballotti, R (corresponding author), Fac Med Nice, INSERM, U385, Ave Valombrose, F-06107 Nice 2, France.		BALLOTTI, Robert/F-8825-2013	BALLOTTI, Robert/0000-0002-7322-4908				ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; DELUCA HF, 1982, BIOCHEM SOC T, V10, P147, DOI 10.1042/bst0100147; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DHANWADA KR, 1995, ONCOGENE, V11, P1947; DjavaheriMergny M, 1996, FEBS LETT, V384, P92, DOI 10.1016/0014-5793(96)00294-3; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HOLICK MF, 1980, SCIENCE, V210, P203, DOI 10.1126/science.6251551; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; JEANMOUGIN M, 1983, PHOTODERMATOSES PHOT, P11; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	28	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					661	664		10.1038/sj.onc.1201536	http://dx.doi.org/10.1038/sj.onc.1201536			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482112				2022-12-28	WOS:000071816600011
J	Medema, RH; Klompmaker, R; Smits, VAJ; Rijksen, G				Medema, RH; Klompmaker, R; Smits, VAJ; Rijksen, G			p21(waf1) can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases	ONCOGENE			English	Article						p21; cyclin B; PCNA; growth inhibition; tetracycline	WILD-TYPE P53; DEPENDENT KINASES; TERMINAL DIFFERENTIATION; RETINOBLASTOMA PROTEIN; GROWTH SUPPRESSION; GENE AMPLIFICATION; CDK INHIBITORS; P21; EXPRESSION; ARREST	p21(waf1) has been shown to mediate the p53-dependent growth arrest induced by DNA-damaging agents, Several functions have been ascribed to p21(waf1) that could be involved in this growth arrest, For one, p21(waf1) is an efficient inhibitor of cyclin-dependent kinases (CDKs). Also, p21(waf1) can interact with proliferating cell nuclear antigen (PCNA), and as such inhibit in vitro DNA-replication. Finally, p21(waf1) has been reported to inhibit stress-activated protein kinases (SAPKs). In order to study these multiple functions of p21(waf1) we have established U2OS-derived cell lines, in which the expression of p21(waf1) can be regulated by the concentration of tetracycline in the culture medium, We observed a virtually complete, but reversible inhibition of cell growth upon induction of p21(waf1)-expression. Both [H-3]thymidine-incorporation and CDK2-activity were strongly inhibited by p21(waf1). Upon induction of p21(waf1) cells accumulated with a 2N or 4N DNA content suggesting events in G1 and G2 can be inhibited by p21(waf1). Indeed, kinase activity associated with cyclin B was reduced dramatically upon induction of p21(waf1), although cyclin B continues to be expressed, In contrast, p21(waf1) does not seem to inhibit the function of PCNA in ongoing DNA replication, since cells expressing high levels of p21(waf1) apparently progressed normally through S-phase. Also, the activity of SAPKs was not substantially affected by the high levels of p21(waf1). We conclude that, at least in these U2OS-derived cells, p21(waf1) functions as an inhibitor of CDK-activity in G1 and G2, but not as an inhibitor of PCNA or SAPKs.	Univ Utrecht Hosp, Dept Haematol, Jordan Lab, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Univ Utrecht Hosp, Dept Haematol, Jordan Lab, POB 85500, NL-3508 GA Utrecht, Netherlands.		Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011; Smits, Veronique A.J./R-2302-2019	Smits, Veronique A.J./0000-0002-9160-4525; Medema, Rene/0000-0002-6754-0381	NCI NIH HHS [CA39826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Savio M, 1996, ONCOGENE, V13, P1591; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wyllie FS, 1996, ONCOGENE, V12, P1077; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	57	151	154	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					431	441		10.1038/sj.onc.1201558	http://dx.doi.org/10.1038/sj.onc.1201558			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484832				2022-12-28	WOS:000071739400001
J	Fang, XJ; Jin, XM; Xu, HJ; Liu, L; Peng, HQ; Hogg, D; Roth, JA; Yu, YH; Xu, FJ; Bast, RC; Mills, GB				Fang, XJ; Jin, XM; Xu, HJ; Liu, L; Peng, HQ; Hogg, D; Roth, JA; Yu, YH; Xu, FJ; Bast, RC; Mills, GB			Expression of p16 induces transcriptional downregulation of the RB gene	ONCOGENE			English	Article						p16; RB; expression; ovarian cancer	TUMOR-SUPPRESSOR GENE; CANCER CELL-LINES; KINASE-4 INHIBITOR GENE; RETINOBLASTOMA-PROTEIN; CDK4 AMPLIFICATION; SQUAMOUS-CELL; CYCLE CONTROL; MTS1 GENE; P16(INK4); INACTIVATION	The RE and p16(INK4A) tumor suppressor genes function in the same pathway of cell cycle control. Previous evidence indicates that the p16(INK4A) gene is transcriptionally repressed by the RE gene product, pRB. In this study using human ovarian cancer cell lines, we found that RE protein and mRNA were expressed at higher levels in cell lines lacking p16 than in those with normal p16. Since this suggests a potential role of p16 in regulating the cellular level of pRB, we studied the effect of wild-type p16(INK4A) on expression of the RE gene. Introduction of p16(INK4A), carried by an adenovirus vector,;into p16-negative cell lines dramatically decreased expression of RE protein and mRNA. Nuclei run-off assays demonstrated that p16 expression induced transcriptional downregulation of the RE gene. These results indicate that expression of RE is inversely regulated by p16. The findings reveal a new dimension of pRB-p16 interaction and should have implications for p16(INK4A)-mediated gene therapy.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Div Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Toronto, Dept Med, Toronto, ON M5G 1L7, Canada; Toronto Gen Hosp, Toronto, ON M5G 1L7, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Mills, GB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Div Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAST RC, 1983, CANCER RES, V43, P1395; BERCHUCK A, 1992, AM J OBSTET GYNECOL, V166, P676, DOI 10.1016/0002-9378(92)91697-9; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BUICK RN, 1985, CANCER RES, V45, P3668; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DODSON MK, 1994, CANCER RES, V54, P610; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GREENBERG ME, 1992, SHORT PROTOCOLS MOL; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; Hengstschlager M, 1996, ONCOGENE, V12, P1635; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JEN J, 1994, CANCER RES, V54, P6353; JIANG W, 1992, CANCER RES, V52, P2980; JIN XM, 1995, CANCER RES, V55, P3250; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P430; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAMMIE GA, 1991, ONCOGENE, V6, P439; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MORI T, 1994, CANCER RES, V54, P3396; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OSWALD F, 1994, ONCOGENE, V9, P2029; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PALES E, 1993, EMBO J, V12, P961; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PENG HQ, 1993, CANCER RES, V53, P3574; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHULZE A, 1994, ONCOGENE, V9, P3475; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SHAPIRO GI, 1995, CANCER RES, V55, P505; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Ueki K, 1996, CANCER RES, V56, P150; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, ONCOGENE, V6, P1139; XU L, 1994, CANCER RES, V54, P5262; ZHOU XL, 1994, ONCOGENE, V9, P3737	52	73	87	1	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					1	8		10.1038/sj.onc.1201525	http://dx.doi.org/10.1038/sj.onc.1201525			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467937				2022-12-28	WOS:000071236800001
J	He, LM; Cui, HM; Walsh, C; Mattsson, R; Lin, WL; Anneren, G; Pfeifer-Ohlsson, S; Ohlsson, R				He, LM; Cui, HM; Walsh, C; Mattsson, R; Lin, WL; Anneren, G; Pfeifer-Ohlsson, S; Ohlsson, R			Hypervariable allelic expression patterns of the imprinted IGF2 gene in tumor cells	ONCOGENE			English	Article						genomic imprinting; epigenetic; choriocarcinoma; activation; silencing	GROWTH FACTOR-II; H19 GENE; CHORIOCARCINOMA	The IGF2 gene, which encodes a growth factor, is subject to genomic imprinting, The frequently observed loss of IGF2 imprinting in a variety of tumors has been suggested to contribute to neoplasia, Since these reports have not documented the imprinting status of IGF2 at the cellular level, it cannot be excluded that the imprinting status might vary within the tumor, The possibility that loss of IGF2 imprinting in neoplastic cells reflects random imprinting patterns, was therefore addressed, We show here that individual cell populations of the JEG-3 choriocarcinoma cell line display heterogenous imprinting patterns of both IGF2 and H19, In addition, a lack of correlation between IGF2 and H19 imprinting status suggests that any regional parental imprint has been functionally lost, This notion is reinforced by the observation that JEG-3 cell subclones display a range of promoter-specific IGF2 allele usage, Moreover, we observed that the imprinting status of H19 and IGF2 were differentially modulated in JEG-3-derived tumors generated in nude mice, The results suggest that allele-specific expression of IGF2 operates in the absence of a parental imprint, Finally, our observations urge caution with respect to the general interpretation of biallelic expression as 'loss of imprinting'.	Uppsala Univ, Dept Anim Dev & Genet, S-75236 Uppsala, Sweden; Columbia Univ, Dept Genet & Dev, New York, NY USA; Univ Uppsala Hosp, Dept Paediat, S-75185 Uppsala, Sweden	Uppsala University; Columbia University; Uppsala University; Uppsala University Hospital	Ohlsson, R (corresponding author), Uppsala Univ, Dept Anim Dev & Genet, Norbyvagen 18A, S-75236 Uppsala, Sweden.		Walsh, Colum/ABD-7013-2020; Cui, Hengmi/A-2598-2008	Walsh, Colum/0000-0001-9921-7506; 				Adam GIR, 1996, DEVELOPMENT, V122, P839; Barletta JM, 1997, CANCER RES, V57, P48; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; DOUCRASY S, 1996, ONCOGENE, V12, P324; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; FEINBERG AP, 1994, COLD SPRING HARB SYM, V59, P357, DOI 10.1101/SQB.1994.059.01.040; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LYON MF, 1995, GENOMIC IMPRINTING C, P129; Mannens M, 1997, NAT GENET, V15, P113, DOI 10.1038/ng0297-113; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1989, EMBO J, V8, P1993, DOI 10.1002/j.1460-2075.1989.tb03606.x; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; OHLSSON R, 1995, GENOMIC IMPRINTING C, P1; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; TYCKO B, 1994, AM J PATHOL, V144, P431; ZHANG YH, 1993, AM J HUM GENET, V53, P113	20	18	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					113	119		10.1038/sj.onc.1201501	http://dx.doi.org/10.1038/sj.onc.1201501			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467950				2022-12-28	WOS:000071236800014
J	PinkasKramarski, R; Eilam, R; Alroy, I; Levkowitz, G; Lonai, P; Yarden, Y				PinkasKramarski, R; Eilam, R; Alroy, I; Levkowitz, G; Lonai, P; Yarden, Y			Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation	ONCOGENE			English	Article						EGF family; signal transduction; tyrosine kinase; NDF/neuregulin; nervous system	EPIDERMAL GROWTH-FACTOR; EMBRYONAL CARCINOMA-CELLS; FACTOR HEREGULIN; NERVOUS-SYSTEM; NEUREGULIN RECEPTORS; CARDIAC DEVELOPMENT; CELLULAR-RESPONSE; NEU; SURVIVAL; ISOFORMS	Two receptor tyrosine kinases, ErB-3 and ErbB-4, mediate signaling by Neu differentiation factors (NDFs, also called neuregulins), while ErbB-1 and ErbB-2 serve as co-receptors, We show that the two NDF/neuregulin differ in spatial and temporal expression The kinase-defective receptor, ErbB-3, is expressed primarily in epithelial layers of various organs, in the peripheral nervous system, and in adult brain, whereas ErbB-4 is restricted to the developing central nervous system and to the embryonic heart, An example of alternating expression of the two receptors is provided by the developing cerebellum: During postnatal cerebellar development, ErbB-4 expression slightly decreases along with a decline in NDF transcription, whereas ErbB-3 expression commences after the peak of neurogenesis, To study functional differences, we established primary brain cultures and found that ErbB-3 was expressed only in oligodendrocytes, whereas ErbB-4 expression was shared by oligodendrocytes, astrocytes and neurons, Blocking the action of endogenous NDF in vitro, by using a soluble form of ErbB-4, accelerated neurite outgrowth in both primary cultures and in neuronal-type cultures of the P19 teratocarcinoma, suggesting an inhibitory effect of NDF on neural differentiation, Apparently, ErbB-3 is associated with proliferation of P19 cells, whereas ErbB-4 correlates with a differentiated phenotype, We conclude that the two NDF receptors play distinct, rather than redundant, developmental and physiological roles.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science			Levkowitz, Gil/AAB-9441-2019; YARDEN, YOSEF/K-1467-2012	Levkowitz, Gil/0000-0002-3896-1881; Pinkas-Kramarski, Ronit/0000-0002-1000-369X				ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACUS SS, 1993, CANCER RES, V53, P5251; BAIN G, 1993, MOL BRAIN RES, V17, P23, DOI 10.1016/0169-328X(93)90068-Z; BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; Baulida J, 1996, J BIOL CHEM, V271, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; BENBARUCH N, 1997, HORMONES GROWTH FACT; BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427; CANNOLL PD, 1996, NEURON, V17, P229; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CHEN MS, 1994, J COMP NEUROL, V349, P389, DOI 10.1002/cne.903490306; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; DANILENKO DM, 1995, J CLIN INVEST, V95, P842, DOI 10.1172/JCI117734; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Grinspan JB, 1996, J NEUROSCI, V16, P6107; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOGAN B, 1986, COLD SPRING HARBOR; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LANOIX J, 1991, CELL GROWTH DIFFER, V2, P391; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; LEVI ADO, 1995, J NEUROSCI, V15, P1329; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1992, ONCOGENE, V7, P1273; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; RODRIGUEZ ER, 1994, BIOCHEM BIOPH RES CO, V205, P652, DOI 10.1006/bbrc.1994.2715; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Syroid DE, 1996, P NATL ACAD SCI USA, V93, P9229, DOI 10.1073/pnas.93.17.9229; Trachtenberg JT, 1996, NATURE, V379, P174, DOI 10.1038/379174a0; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VARTANIAN T, 1994, P NATL ACAD SCI USA, V91, P11626, DOI 10.1073/pnas.91.24.11626; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Verdi JM, 1996, NEURON, V16, P515, DOI 10.1016/S0896-6273(00)80071-9; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	67	108	117	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2803	2815		10.1038/sj.onc.1201466	http://dx.doi.org/10.1038/sj.onc.1201466			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419971				2022-12-28	WOS:A1997YJ80300006
J	Kashiwazaki, H; Tonoki, H; Tada, M; Chiba, I; Shindoh, M; Totsuka, Y; Iggo, R; Moriuchi, T				Kashiwazaki, H; Tonoki, H; Tada, M; Chiba, I; Shindoh, M; Totsuka, Y; Iggo, R; Moriuchi, T			High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay	ONCOGENE			English	Article						p53 mutations; oral squamous cell carcinoma; premalignant lesions; ethnic origin; yeast functional assay	POLYMERASE CHAIN-REACTION; TUMOR-SUPPRESSOR GENE; LUNG-CANCER; PROTEIN EXPRESSION; BREAST-CANCER; CAVITY; IMMUNOHISTOCHEMISTRY; OVEREXPRESSION; TRANSFORMATION; ONCOGENE	To determine the timing and actual incidence of p53 mutations in oral epithelial lesions, we examined 33 primary squamous cell carcinomas (SCCs), 14 dysplasias and six hyperplasias from Japanese patients by a combination of yeast functional assay and DNA sequencing, The assay detects mutations of p53 mRNA between codons 67 and 347 on the basis of the DNA-binding activity of the protein, Twenty-six SCCs (79%) and five dysplasias (36%) were positive for p53 mutation, while all six hyperplasias were negative for the mutation, Human papillomavirus type 16 E6 mRNA was detected in one of seven p53 mutation-negative SCCs by reverse transcription polymerase chain reaction (RT-PCR), We further examined p53 mutations in 17 Sri Lankan oral SCCs using the yeast functional assay and the single-strand conformation polymorphism analysis of PCR-amplified DNA fragments (PCR-SSCP) of exon 5-8. The mutations were confirmed by DNA sequencing and the detection sensitivity was compared between the two methods, Six samples (35%) were positive for p53 mutation in PCR-SSCP analysis, while nine samples (53%) were positive in yeast functional assay, This suggests that the incidence of p53 mutations has been considerably underestimated in the conventional SSCP analysis, The present data indicate that p53 mutations are extremely frequent in oral cancers in the Japanese, and suggest that the timing and significance of p53 mutation in oral tumor progression vary in different ethnic populations and areas.	HOKKAIDO UNIV,SCH MED,INST CANC,DIV CELL BIOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT NEUROSURG,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH DENT,DEPT ORAL SURG 1,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH DENT,DEPT ORAL SURG 2,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH DENT,DEPT ORAL PATHOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; SWISS INST EXPT CANC RES,ONCOGENE GRP,CH-1066 EPALINGES,SWITZERLAND	Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University; Swiss Institute Experimental Cancer Research			Iggo, Richard/G-3546-2014; Shindoh, Masanobu/A-4799-2012	Shindoh, Masanobu/0000-0002-7782-5823				BENNETT WP, 1992, CANCER RES, V52, P6092; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CASSON AG, 1991, CANCER RES, V51, P4495; CESARMAN E, 1993, AM J PATHOL, V143, P845; Chiba I, 1996, ONCOGENE, V12, P1663; CHIBA I, 1990, ONCOGENE, V5, P1603; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELD JK, 1991, BRIT J CANCER, V64, P573, DOI 10.1038/bjc.1991.352; FIELD JK, 1993, ARCH OTOLARYNGOL, V119, P1118; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FUJINAGA Y, 1991, J GEN VIROL, V72, P1039, DOI 10.1099/0022-1317-72-5-1039; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HERMANEK P, 1987, TNM CLASSIFICATION M, P1; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Kusama K, 1996, J PATHOL, V178, P415; LAZARUS P, 1995, INT J CANCER, V60, P458, DOI 10.1002/ijc.2910600406; Lazarus P, 1996, CARCINOGENESIS, V17, P733, DOI 10.1093/carcin/17.4.733; MAESTRO R, 1992, ONCOGENE, V7, P1159; MAITLAND NJ, 1989, BRIT J CANCER, V59, P698, DOI 10.1038/bjc.1989.146; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOYRET C, 1994, ONCOGENE, V9, P1739; Munirajan AK, 1996, INT J CANCER, V66, P297; OGDEN GR, 1992, J PATHOL, V166, P389, DOI 10.1002/path.1711660411; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; Paterson IC, 1996, ORAL ONCOL, V32B, P150, DOI 10.1016/0964-1955(95)00065-8; SAKAI E, 1992, INT J CANCER, V52, P867, DOI 10.1002/ijc.2910520606; SARANATH D, 1993, ORAL ONCOL, V29B, P107, DOI 10.1016/0964-1955(93)90031-9; SAUTER ER, 1992, AM J SURG, V164, P651, DOI 10.1016/S0002-9610(05)80727-5; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SILVERMAN S, 1984, CANCER, V53, P563; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; SOZZI G, 1992, CANCER RES, V52, P6079; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; Tada M, 1996, INT J CANCER, V67, P447, DOI 10.1002/(SICI)1097-0215(19960729)67:3<447::AID-IJC22>3.0.CO;2-3; Tada M, 1997, MOL CARCINOGEN, V18, P171, DOI 10.1002/(SICI)1098-2744(199703)18:3<171::AID-MC6>3.3.CO;2-2; WAHI PN, 1971, INT HISTOLOGICAL CLA, P15; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812	43	77	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2667	2674		10.1038/sj.onc.1201438	http://dx.doi.org/10.1038/sj.onc.1201438			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400993				2022-12-28	WOS:A1997YH46800004
J	HernandezAlcoceba, R; Saniger, L; Campos, J; Nunez, MC; Khaless, F; Gallo, MA; Espinosa, A; Lacal, JC				HernandezAlcoceba, R; Saniger, L; Campos, J; Nunez, MC; Khaless, F; Gallo, MA; Espinosa, A; Lacal, JC			Choline kinase inhibitors as a novel approach for antiproliferative drug design	ONCOGENE			English	Article						oncogenes; choline kinase; antiproliferative drugs; growth factors; phosphorylcholine; ras; src; fos; hemicholinium-3	XENOPUS-LAEVIS OOCYTES; ETHANOLAMINE UPTAKE; LIPID-METABOLISM; GROWTH-FACTORS; RAS PROTEINS; IN-VITRO; ACTIVATION; CELLS; HEMICHOLINIUM-3; RAF-1	Recent progress in deciphering the molecular basis of carcinogenesis is of utmost importance to the development of new anticancer strategies, To this end, it is essential to understand the regulation of both normal cell proliferation and its alterations in cancer cells, We have previously demonstrated that in ras-transformed cells there is an increased level of phosphorylcholine (PCho) resulting from a constitutive activation on choiline kinase (ChoK), The importance of ChoK for the regulation of cell proliferation has also been proposed since an inhibitior for this enzyme, hemicholinium-3 (HC-3), drastically reduces entry into S phase after stimulation with growth factors, Here we report synthesis of several new compounds which are highly specific inhibitors for ChoK, with up to 1000-fold or 600-fold increased inhibitory activity, compared to HC-3 under ex vivo or in vitro conditions respectively, These novel compounds also drastically reduce entry into the S phase after stimulation with specific growth factors, A more profound inhibition of cell proliferation was observed in ras-, src- and mos-transformed cells in the presence of ChoK inhibitors, compared to their parental, untransformed NIH3T3 cells, By contrast, this effect was not observed in fos-transformed cells, While ras, src and mos transformation is associated with elevated levels of ChoK activity, fos-induced transformation does not affect ChoK activity, The inhibitory effect on proliferation of the new compounds correlates with their ability to inhibit the production of phosphorylcholine in whole cells, a proposed novel second messenger for cell proliferation. These results strongly support a critical role of choline kinase in the regulation of cell growth and makes this enzyme a novel target for the design of new antiproliferative and anticancer drugs.	CSIC,INST INVEST BIOMED,MADRID,SPAIN; UNIV GRANADA,DEPT QUIM ORGAN,FAC FARM,GRANADA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Granada			Ubeda, Antonio Espinosa/L-8504-2014; Rosa, Joaquín/L-8436-2014; del Carmen Nuñez-Carretero, M/L-7150-2014; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Ubeda, Antonio Espinosa/0000-0001-9542-564X; Rosa, Joaquín/0000-0002-9035-8123; Lacal, Juan Carlos/0000-0002-1908-2777				BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Bhakoo KK, 1996, CANCER RES, V56, P4630; CANNON JG, 1990, J MED CHEM, V33, P577, DOI 10.1021/jm00164a017; CANNON JG, 1994, MED RES REV, V14, P505, DOI 10.1002/med.2610140503; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; CUADRADO A, 1993, ONCOGENE, V8, P2959; delPeso L, 1997, BIOCHEM J, V322, P519; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DEVITA VT, 1993, CANCER PRINCIPLES PR; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GUYENET P, 1973, MOL PHARMACOL, V9, P630; HAMZA M, 1983, BIOCHEM PHARMACOL, V32, P1893, DOI 10.1016/0006-2952(83)90055-2; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Kerr DJ, 1994, NEW MOL TARGETS CANC; LACAL JC, 1994, ONCOL REP, V1, P677; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; MACARA I, 1989, MOL CELL BIOL, V10, P325; MACDONALD JS, 1995, MANUAL ONCOLOGIC THE; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; POLAK RL, 1977, J NEUROCHEM, V29, P477, DOI 10.1111/j.1471-4159.1977.tb10696.x; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; RONEN SM, 1992, BIOCHIM BIOPHYS ACTA, V1138, P203, DOI 10.1016/0925-4439(92)90039-P; RONEN SM, 1991, BIOCHIM BIOPHYS ACTA, V1095, P5, DOI 10.1016/0167-4889(91)90038-Y; Rosa JC, 1996, J MED CHEM, V39, P4247, DOI 10.1021/jm950884a; TEEGARDEN D, 1990, J BIOL CHEM, V265, P16638; TUCEK S, 1985, J NEUROCHEM, V4, P12; VICIANA PR, 1994, NATURE, V370, P527; VOJTEK AB, 1993, CELL, V74, P204; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZLATKINE P, 1993, BIOCHIM BIOPHYS ACTA, V1153, P237, DOI 10.1016/0005-2736(93)90410-2	35	141	147	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2289	2301		10.1038/sj.onc.1201414	http://dx.doi.org/10.1038/sj.onc.1201414			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393874				2022-12-28	WOS:A1997YE15700004
J	Amariglio, F; Tchang, F; Prioleau, MN; Soussi, T; Cibert, C; Mechali, M				Amariglio, F; Tchang, F; Prioleau, MN; Soussi, T; Cibert, C; Mechali, M			A functional analysis of p53 during early development of Xenopus laevis	ONCOGENE			English	Article						replication; transcription; egg; oocyte	WILD-TYPE P53; TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION DOMAIN; DNA-REPLICATION INVITRO; T-ANTIGEN; GENE AMPLIFICATION; NUCLEAR EXCLUSION; TUMOR-ANTIGEN; EGG EXTRACTS; HOST PROTEIN	p53 is a nuclear protein that acts like a tumor suppressor and is involved in regulation of cellular growth, In Xenopus, the p53 protein is highly expressed during oogenesis and is strictly cytoplasmic in the oocyte, We have analysed its participation in DNA replication and transcription during early development, using the egg and oocyte as model-systems. The injection of sperm nuclei into Xenopus eggs is followed by DNA replication and mitotic events, We show that the endogenous p53 enters the nuclei and moves through a series of discrete subnuclear loci whose distribution is S-phase specific, A specific peripheral nuclear localization of p53 is observed before entry into S-phase, followed by an internal localization which is strictly dependent on ongoing DNA synthesis, At no stage in the cell cycle, however, did we observe any co-localization with RPA or PCNA, which were used as initiation or elongation markers for DNA replication, We also show that injection into the nucleus of the oocyte of small amounts of either Xenopus or human p53 - less than 10% of the cytoplasmic storage - is sufficient to block RNA polymerase II-dependent transcription from a coinjected TATA-box-containing reporter plasmid. Transcription is rescued by microinjection of the TATA-box binding protein (TBP), suggesting that nuclear exclusion of p53 during oogenesis may be necessary for transcription of maternal genes, These characteristics are discussed in relation to the regulation of nuclear activities during early embryogenesis.	CNRS, INST JACQUES MONOD, F-7251 PARID 05, FRANCE; INST CURIE, UMR 218, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)			Prioleau, Marie-Noelle/G-9824-2014; , prioleau/S-6007-2019	, prioleau/0000-0003-2585-4005; soussi, thierry/0000-0001-8184-3293				ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BRAIN R, 1994, ONCOGENE, V9, P1775; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GURDON JB, 1986, J CELL SCI, P287; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; JACKSON P, 1993, ONCOGENE, V8, P589; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIENZLE H, 1989, EUR J BIOCHEM, V184, P181, DOI 10.1111/j.1432-1033.1989.tb15005.x; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAY E, 1991, ONCOGENE, V6, P1363; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; MIYAMOTO N, 1990, BIOCHEM BIOPH RES CO, V168, P604, DOI 10.1016/0006-291X(90)92363-5; MODAK SP, 1993, ONCOGENE, V8, P645; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; PRIOLEAU MN, 1995, EMBO J, V14, P5073, DOI 10.1002/j.1460-2075.1995.tb00189.x; PRIOLEAU MN, 1994, CELL, V77, P439, DOI 10.1016/0092-8674(94)90158-9; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	67	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2191	2199		10.1038/sj.onc.1201395	http://dx.doi.org/10.1038/sj.onc.1201395			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393977				2022-12-28	WOS:A1997YD01900007
J	Carbone, M; Rizzo, P; Pass, HI				Carbone, M; Rizzo, P; Pass, HI			Simian virus 40, poliovaccines and human tumors: a review of recent developments	ONCOGENE			English	Review						SV40; poliovaccines; human tumors	LARGE-T-ANTIGEN; HUMAN-BRAIN-TUMORS; HUMAN PLEURAL MESOTHELIOMA; SIMIAN-VIRUS-40 LARGE-T; DELETION MUTANTS; HUMAN FIBROBLASTS; MONKEY CELLS; SV40; DNA; TRANSFORMATION	Recently, wild-type SV40 and/or DNA sequences indistinguishable from SV40 have been detected in specific types of human tumors: ependymoma and choroid plexus tumors, mesothelioma, osteosarcoma and sarcoma. The same tumor types will develop in hamsters after injection with SV40. These findings are interesting in themselves for they could shed light on the pathogenesis of these tumors. These findings also have public health implications. SV40 was found to have contaminated the poliovaccines and the adenovaccines from 1955 until 1963, therefore resulting in the inadvertent injection of millions of people with this tumor virus. Moreover, our society pays a high cost for asbestos causality, a carcinogen associated with the development of mesothelioma. In addition to asbestos, the potential impact of finding another possible cause for mesothelioma (i.e., SV40), as well as the possible pathogenic role of the contaminated poliovaccines, has generated considerable public interest and concern. To discuss these recent findings, the NM (National Institutes of Health) and the FDA (Food and Drug Administration), organized an International Conference at the NM, Bethesda, MD, January 27-28, 1997. The association of SV40 with human mesothelioma was also discussed in a special session at the IV International Mesothelioma Conference that was held at the University of Pennsylvania, Philadelphia, PA, May 13-16, 1997. The purpose of this review is to summarize data, from the discovery of the contaminated poliovaccines, to the most recent findings presented at the meetings in Bethesda and Philadelphia, to discuss technical and other problems associated with this research, and the potential for using these findings to develop new diagnostic and therapeutic approaches for SV40-associated malignancies.	WAYNE STATE UNIV, KARMANOS CANC INST, DETROIT, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Carbone, M (corresponding author), LOYOLA UNIV, DEPT PATHOL, CANC IMMUNOL PROGRAM, CARDINAL BERNARDIN CANC CTR, MAYWOOD, IL 60153 USA.			Pass, Harvey/0000-0003-3222-3471; rizzo, paola/0000-0001-7174-9674	NCI NIH HHS [CA-74283-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPEL JD, 1988, P NATL ACAD SCI USA, V85, P7670, DOI 10.1073/pnas.85.20.7670; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; BELL DW, 1997, P 4 INT MES C U PENN, P27; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BRIGHT RK, 1994, CLIN EXP IMMUNOL, V96, P491; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1996, ONCOGENE, V13, P527; CARBONE M, 1989, CANCER RES, V49, P1565; CARBONE M, 1991, MOL BASIS HUMAN CANC, P191; CARBONE M, IN PRESS NATURE MED; CICALA C, 1994, J VIROL, V68, P3138, DOI 10.1128/JVI.68.5.3138-3144.1994; CICALA C, 1993, AM J PATHOL, V142, P1524; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; COLE NC, 1996, VIROLOGY, V2, P1997; *COMM DIS CTR, 1961, 248 COMM DIS CTR; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; DELUCA A, IN PRESS NATURE MED; DEVILLERS E, 1997, SV40 POSS HUM POL WO, V1, P176; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DIXON K, 1982, NATURE, V296, P672, DOI 10.1038/296672a0; Dubes G. R., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P185; EDDY BE, 1961, P SOC EXP BIOL MED, V107, P191; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713, DOI 10.1001/jama.1963.03060090045016; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GALATEAUSALLE F, 1997, SV40 POSS HUM POL WO, V1, P186; GEISSLER E, 1990, PROG MED VIROL, V37, P211; GRIFFITHS D, 1997, SV40 POSS HUM POLL W, V1, P171; ILYINSKII PO, 1992, J VIROL, V66, P6353, DOI 10.1128/JVI.66.11.6353-6360.1992; JENSEN F, 1964, J NATL CANCER I, V32, P917; KIRSCHSTEIN RL, 1962, NATURE, V195, P299, DOI 10.1038/195299b0; KRIEG P, 1981, P NATL ACAD SCI-BIOL, V78, P6446, DOI 10.1073/pnas.78.10.6446; LABELLA F, 1985, VIRUS RES, V2, P329, DOI 10.1016/0168-1702(85)90029-2; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; LEDNICKY JA, 1995, VIRUS RES, V35, P143, DOI 10.1016/0168-1702(94)00093-R; LEDNICKY JA, IN PRESS INT J CANC; LEWIS AM, 1979, P NATL ACAD SCI USA, V76, P4299, DOI 10.1073/pnas.76.9.4299; LEWIS AM, 1973, BIOHAZARDS BIOL RES, P96; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LINNAINMAA K, 1997, P 4 INT MES C U PENN, P30; MARK EJ, 1991, ANN NY ACAD SCI, V643, P196, DOI 10.1111/j.1749-6632.1991.tb24463.x; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MARSELLA JM, IN PRESS ENV HLTH PE; MARSHALL J, 1991, ONCOGENE, V6, P1673; Martini F, 1996, CANCER RES, V56, P4820; MELNICK JL, 1962, P SOC EXP BIOL MED, V109, P965, DOI 10.3181/00379727-109-27392; MELNICK JL, 1996, VIROLOGY, V1, P655; MONINI P, 1995, DNA TUMOR VIRUSES ON, P51; Moorwood K, 1996, EXP CELL RES, V223, P308, DOI 10.1006/excr.1996.0086; MORRIS JA, 1961, P SOC EXP BIOL MED, V108, P56, DOI 10.3181/00379727-108-26843; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; OLIN P, 1997, SV40 POSS HUM POL WO, V1, P315; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; Pass Harvey I., 1996, P89; PASS HI, 1997, SV40 POSS HUM POL WO, V1, P180; Pepper C, 1996, THORAX, V51, P1074, DOI 10.1136/thx.51.11.1074; PETO J, 1995, LANCET, V345, P535, DOI 10.1016/S0140-6736(95)90462-X; Price B, 1997, AM J EPIDEMIOL, V145, P211, DOI 10.1093/oxfordjournals.aje.a009093; RABSON AS, 1962, J NATL CANCER I, V29, P765; RAY AR, 1994, J NEUROONCOLOGY, V20, P55; Ray F.A., 1995, DNA TUMOR VIRUSES ON, P15; REDDEL RR, 1989, J NATL CANCER I, V81, P945, DOI 10.1093/jnci/81.12.945; RHIM JS, 1986, SCIENCE, V232, P385, DOI 10.1126/science.2421406; ROGGLI VL, 1992, PATHOLOGY ASBESTOS A, P383; RULEY EH, 1996, IMPORTANT ADV ONCOLO, P89; SHAH KV, 1971, AM J EPIDEMIOL, V93, P291, DOI 10.1093/oxfordjournals.aje.a121260; SHEIN HM, 1962, P NATL ACAD SCI USA, V48, P1164, DOI 10.1073/pnas.48.7.1164; SIMMONS DT, 1995, DNA TUMOR VIRUSES ON, P27; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; STOIAN M, 1984, REV ROUM MED VIROL, V35, P127; Strickler HD, 1996, CANCER EPIDEM BIOMAR, V5, P473; STRICKLER HD, 1997, SV40 POSS HUM POL WO, V1, P323; SWEET BH, 1960, P SOC EXP BIOL MED, V105, P420, DOI 10.3181/00379727-105-26128; TEVETHIA SS, 1990, MOL BIOL MED, V7, P83; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; VONDERWETH A, 1992, VIROLOGY, V189, P334, DOI 10.1016/0042-6822(92)90711-W; WALSH JW, 1982, NEUROSURGERY, V10, P643, DOI 10.1227/00006123-198205000-00018; WEINER LP, 1972, NEW ENGL J MED, V305, P1517; WEISS AF, 1975, P NATL ACAD SCI USA, V72, P609, DOI 10.1073/pnas.72.2.609	83	171	174	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	1997	15	16					1877	1888		10.1038/sj.onc.1201375	http://dx.doi.org/10.1038/sj.onc.1201375			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365233				2022-12-28	WOS:A1997YA87200001
J	Huang, YY; Yuan, ZM; Ishiko, T; Nakada, S; Utsugisawa, T; Kato, T; Kharbanda, S; Kufe, DW				Huang, YY; Yuan, ZM; Ishiko, T; Nakada, S; Utsugisawa, T; Kato, T; Kharbanda, S; Kufe, DW			Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1-beta-D-arabinofuranosylcytosine	ONCOGENE			English	Article						ara-C; c-Abl kinase; apoptosis; p53	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; INDEPENDENT MECHANISMS; DNA-DAMAGE; P53; STRESS; CYCLE; GROWTH; DEATH; LOCALIZATION	Treatment of cells with the antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C) and other genotoxic agents is associated with activation of the c-Abl protein tyrosine kinase. The functional role of c-Abl in the response to DNA damage, however, remains unclear. The present studies demonstrate that cells expressing a dominant negative, kinase-inactive c-Abl (K-R) are resistant to killing by ara-C. The expression of c-Abl (K-R) blocked ara-C-induced apoptosis by a mechanism that is at least in part independent of the p53 tumor suppressor. Cells null for c-Abl also exhibited resistance to induction of apoptosis. These findings provide support for a pro-apoptotic function of c-Abl in the response to certain genotoxic drugs.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Utsugisawa, Taiju/ABD-7059-2021	Kato, Tomohisa/0000-0002-3047-9847	NCI NIH HHS [CA66996, CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066996, R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; GOGA A, 1995, ONCOGENE, V11, P791; GUNJI H, 1991, CANCER RES, V51, P741; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATTIONI T, 1995, ONCOGENE, V10, P1325; OHNO Y, 1988, CANCER RES, V48, P1494; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	34	42	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	1997	15	16					1947	1952		10.1038/sj.onc.1201376	http://dx.doi.org/10.1038/sj.onc.1201376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365241				2022-12-28	WOS:A1997YA87200009
J	Lerner, EC; Zhang, TT; Knowles, DB; Qian, YM; Hamilton, AD; Sebti, SM				Lerner, EC; Zhang, TT; Knowles, DB; Qian, YM; Hamilton, AD; Sebti, SM			Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines	ONCOGENE			English	Article						Ras; prenylation; human tumors; FTase inhibitors	PROTEIN GERANYLGERANYLATION; FARNESYL; GROWTH; BLOCKS	The farnesyltransferase (FTase) inhibitor FTI-277 is highly effective at blocking oncogenic H-Ras but not K-Ras4B processing and signaling. While inhibition of processing and signaling of oncogenic K-Ras4B is more sensitive to the geranylgeranyltransferase I (GGTase I) inhibitor GGTI-286 than it is to FTI-277 in K-Ras4B-transformed NIH3T3 cells, the sensitivity of K-Ras as well as H-and N-Ras to the CAAX peptidomimetics in human tumor cell lines is not known. Here, we report that a panel of five human carcinoma cell lines from pancreatic, pulmonary, and bladder origins all express H-, N-, and K-Ras, and their respective prenylation sensitivities to the FTase and GGTase I inhibitors is variable. In all of the cell lines investigated, the prenylation of N-Ras was highly sensitive to FTI-277, and in two of the cell lines, N-Ras showed slight sensitivity to GGTI-298, an analog of GGTI-286. Although the prenylation of H-Ras was also sensitive to FTI-277, complete inhibition of H-Ras processing even at high concentrations of FTI-277 and/or GGTI-298 was never achieved. The prenylation of K-Ras, on the other hand, was highly resistant to FTI-277 and GGTI-298. Most significantly, treatment of human tumor cell lines with both inhibitors inhibition of K-Ras prenylation. In human lung adenocarcinoma A-549, prenylation of K-Ras was highly resistant even when co-treated with both inhibitors. Furthermore, soft agar experiments demonstrated that in all the human tumor cell lines tested inhibition of K-Ras prenylation was not necessary for inhibition of anchorage-independent growth. In addition, although GGTI-298 had very little effect on soft agar growth, the combination of FTI-277 and GGTI-298 resulted in significant growth inhibition. Therefore, the results demonstrate that while FTI-277 inhibits N-Ras and H-Ras processing in the human tumor cell lines evaluated, inhibition of K-Ras processing requires both an FTase inhibitor as well as a GGTase I inhibitor, and that inhibition of human tumor growth in soft agar does not require inhibition of oncogenic K-Ras processing.	UNIV PITTSBURGH,DEPT PHARMACOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,DEPT CHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [U19-CA67771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; NAGASU T, 1995, CANCER RES, V55, P5310; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SATTLER I, 1996, REGULATION RAS SIGNA, P95; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	17	202	214	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1283	1288		10.1038/sj.onc.1201296	http://dx.doi.org/10.1038/sj.onc.1201296			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315095				2022-12-28	WOS:A1997XV84500005
J	Oda, T; Kujovich, J; Reis, M; Newman, B; Druker, BJ				Oda, T; Kujovich, J; Reis, M; Newman, B; Druker, BJ			Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase	ONCOGENE			English	Article						c-Abl; tyrosine kinase; SH2 domains; yeast two hybrid screen	CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; RNA-POLYMERASE-II; MIDDLE-T-ANTIGEN; C-ABL; SIGNAL-TRANSDUCTION; SRC HOMOLOGY-2; BCR-ABL; PHILADELPHIA-CHROMOSOME; BINDING DOMAINS	To further our understanding of the molecular mechanism of Bcr-Abl mediated transformation, a yeast two hybrid screen was used to identify proteins binding to the Abl tyrosine kinase. Two partial cDNAs encoding novel SH2 domain-containing proteins were cloned and designated Shd and She. Both have homology to Shb, a previously reported SH2 domain-containing protein. Northern blot analysis showed that She is expressed in heart, lung, brain, and skeletal muscle, while expression of Shd is restricted to the brain. The deduced amino acid sequence of the full length mouse Shd cDNA contains an amino-terminal proline-rich region, and a carboxy-terminal SH2 domain. A bacterially expressed Shd domain bound multiple tyrosine-phosphorylated proteins with relative molecular weights of 200, 170, 130, 100, 90, 78, 72 and 32 kDa from K562 cell lysates. Shd contains five YXXP motifs, a substrate sequence preferred by Abl tyrosine kinases. Shd was tyrosine phosphorylated in COS-7 cells co-transfected with Shd and c-Abl or Bcr-Abl. These results suggest that Shd may be a physiological substrate of c-Abl and may function as an adapter protein in the central nervous system.	OREGON HLTH SCI UNIV,DIV HEMATOL & MED ONCOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University			Oda, Tsukasa/ABI-1855-2020	Oda, Tsukasa/0000-0002-8941-161X; Druker, Brian/0000-0001-8331-8206	NCI NIH HHS [CA65823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BURNS LA, 1993, J BIOL CHEM, V268, P17659; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DRUKER BJ, 1991, NUCLEIC ACIDS RES, V19, P6855, DOI 10.1093/nar/19.24.6855; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GOGA A, 1995, ONCOGENE, V11, P791; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harlow E., 1988, ANTIBODIES LAB MANUA; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KANAKURA Y, 1990, BLOOD, V76, P706; KARLSSON T, 1995, ONCOGENE, V10, P1475; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Nakamura T, 1996, ONCOGENE, V13, P1111; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; ODA T, 1994, J BIOL CHEM, V269, P22925; ODA T, 1995, LEUKEMIA, V9, P295; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P174; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WELSH M, 1994, ONCOGENE, V9, P19; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	61	20	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1255	1262		10.1038/sj.onc.1201299	http://dx.doi.org/10.1038/sj.onc.1201299			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315092				2022-12-28	WOS:A1997XV84500002
J	LustigYariv, O; Schulze, E; Komitowski, D; Erdmann, V; Schneider, T; deGroot, N; Hochberg, A				LustigYariv, O; Schulze, E; Komitowski, D; Erdmann, V; Schneider, T; deGroot, N; Hochberg, A			The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene?	ONCOGENE			English	Article						H19; IGF2; choriocarcinoma cell lines	GROWTH FACTOR-II; HUMAN EMBRYOGENESIS; MOUSE; RNA; RELAXATION	H19 is a paternally imprinted gene with unknown function, It is located in close proximity to the maternally imprinted IGF-2 gene on chromosome 11p15,5, In this study no consistent relationship between the expression of these two genes in clones derived from JEG-3 and JAr cell lines could be detected, Nor could a consistent relationship be detected between the expression levels of these two genes and between certain characteristic tumorigenic properties of these clones, We included in this study clones, expressing low H19 levels, which after transfection with an H19 expression construct highly expressed the H19 gene, In tumors, formed by the injection of cells of JAr or JEG-3 clones into nude mice, the H19 expression was high and irrelevant to the expression level in the cells before the injection, The same phenomenon was found for IGF-2 expression during tumorigenesis caused by cells of different JEG-3 clones and in some but not all JAr derived clones, Both H19 and IGF-2 are biallelicly expressed in all the JAr and JEG-3 clones, In summary, our observations point to the conclusion that H19 is not a tumor suppressor gene, However, its high expression in all the tumors formed after injection of cells of the JAr and JEG-3 clones, leaves its role, if any, in choriocarcinogenesis an open question.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; UNIV GOTTINGEN,ZOOL INST ENTWICKLUNGS BIOL,D-3400 GOTTINGEN,GERMANY; DKFZ,DEPT HISTODIAGNOST & PATHOMORPHOL,HEIDELBERG,GERMANY; FREE UNIV BERLIN,INST BIOCHEM,DEPT CHEM,D-1000 BERLIN,GERMANY	Hebrew University of Jerusalem; University of Gottingen; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin								Adam GIR, 1996, DEVELOPMENT, V122, P839; ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; AUSUBEL FM, 1993, CURRRENT PROTOCOLS M, V1; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper MJ, 1996, J UROLOGY, V155, P2120, DOI 10.1016/S0022-5347(01)66120-2; DEGROOT N, 1994, TROPH RES, V8, P285; DoucRasy S, 1996, ONCOGENE, V12, P423; DUGIMONT T, 1995, MOL CELL, V85, P117; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; FRESHNEY RI, 1990, CULTURE ANIMAL CELLS, P142; GOSHEN R, 1993, MOL REPROD DEV, V34, P374, DOI 10.1002/mrd.1080340405; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; Hibi K, 1996, CANCER RES, V56, P480; HOLTHUIZEN PE, 1993, REGUL PEPTIDES, V48, P77, DOI 10.1016/0167-0115(93)90337-8; JINNO Y, 1995, NAT GENET, V10, P318, DOI 10.1038/ng0795-318; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KONDO M, 1995, ONCOGENE, V10, P1193; Kondo M, 1996, ONCOGENE, V12, P1365; LUSTIG O, 1994, MOL REPROD DEV, V38, P239, DOI 10.1002/mrd.1080380302; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MCDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAPPOLEE DA, 1992, GENE DEV, V6, P939, DOI 10.1101/gad.6.6.939; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; RECHLER MM, 1990, PEPTIDE GROWTH FACTO, V1, P263; ROBERTSON EJ, 1995, DEV BIOL, V6, P293; Sambrook J., 2002, MOL CLONING LAB MANU; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Scrable H J, 1990, Adv Cancer Res, V54, P25, DOI 10.1016/S0065-230X(08)60807-6; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; Verkerk AJMH, 1997, ONCOGENE, V14, P95, DOI 10.1038/sj.onc.1200802; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	45	50	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					169	177		10.1038/sj.onc.1201175	http://dx.doi.org/10.1038/sj.onc.1201175			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244352				2022-12-28	WOS:A1997XK37200005
J	Qian, M; Kralova, J; Yu, WP; Bose, HR; Dvorak, M; Sanders, BG; Kline, K				Qian, M; Kralova, J; Yu, WP; Bose, HR; Dvorak, M; Sanders, BG; Kline, K			c-Jun involvement in vitamin E succinate induced apoptosis of reticuloendotheliosis virus transformed avian lymphoid cells	ONCOGENE			English	Article						AP-1; dominant negative c-Jun; c-Jun; vitamin E succinate; apoptosis; avian retrovirus transformed lymphoid cells	EXPRESSION; GROWTH; AP-1; FOS; PROTEINS; INVITRO; GENES	Previous studies have shown that treatment of avian reticuloendotheliosis virus-transformed RECC-UTC4-1 (C4-1) lymphoblastoid cells with 10 mu g/ml (18.8 mu M) of RRR-alpha-tocopheryl succinate (vitamin E succinate, VES) for 3 days induced approximately 50% of the cells to undergo apoptosis, Elevated and prolonged expression of c-jun mRNA and protein was temporally correlated with VES-induced cell death, Data presented in this paper show that the elevated and prolonged expression of c-jun message and protein are not accounted for by enhanced stability, and show the involvement of c-Jun in VES-induced apoptosis in this lymphoblastoid cell type, C4-1 cells infected with a virus carrying a dominant, negatively acting mutant form of c-Jun, supjun-1, exhibited: (i) 71% reduction in VES-induced apoptosis, (ii) a 2.0-2.5-fold decrease in wildtype, endogenous c-Jun expression, and (iii) a 2.4-2.6-fold reduction in AP-1 binding activity, Additionally, cells co-treated with VES plus RRR-alpha-tocopherol, exhibited a 70% reduction in apoptosis, a marked reduction in c-Jun expression and a 1.6-fold reduction in AP-1 binding activity, These studies suggest that c-Jun plays a crucial role in VES-induced apoptosis in C4-1 cells, and add to understanding of mechanisms of action involved VES-mediated tumor cell growth inhibition.	ACAD SCI CZECH REPUBL, GENET INST, PRAGUE, CZECH REPUBLIC; ACAD SCI CZECH REPUBL, INST MOL GENET, PRAGUE, CZECH REPUBLIC; UNIV TEXAS, DEPT MICROBIOL, AUSTIN, TX 78712 USA; UNIV TEXAS, DIV NUTR, AUSTIN, TX 78712 USA	Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin			Dvořák, Michal/I-9939-2014; Dvorak, Michal/G-5861-2014; Kralova, Jarmila/G-3834-2014	Kralova, Jarmila/0000-0002-4735-8857	NCI NIH HHS [CA33192, CA45422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033192, R01CA045422, R29CA045422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; CHEN YR, 1996, BIOL CHEM J, V271, P31929; COLLOTTA F, 1992, BIOL CHEM J, V267, P18278; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; KLINE K, 1991, VITAMINS AND MINERALS IN THE PREVENTION AND TREATMENT OF CANCER, P189; KLINE K, 1990, NUTR CANCER, V14, P27, DOI 10.1080/01635589009514075; KLINE K, 1995, NUTR CANC PREVENTION, P39; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; NISHIMURA T, 1988, ONCOGENE, V3, P659; OFFORD EA, 1993, CARCINOGENESIS, V14, P2447, DOI 10.1093/carcin/14.12.2447; OKUNO H, 1991, ONCOGENE, V6, P1491; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PRASAD KN, 1992, J AM COLL NUTR, V11, P487; Qian M, 1996, NUTR CANCER, V25, P9, DOI 10.1080/01635589609514424; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWARTZ J, 1993, ADJUVANT NUTRITION C, P173; SLACK R, 1989, NUTR CANCER, V12, P75, DOI 10.1080/01635588909514004; Sutterluety H, 1996, J MOL BIOL, V259, P383, DOI 10.1006/jmbi.1996.0327; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TRABER MG, 1988, AM J CLIN NUTR, V48, P605, DOI 10.1093/ajcn/48.3.605; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VANDEWERKEN R, 1993, EUR J BIOCHEM, V217, P781; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu WP, 1997, NUTR CANCER, V27, P267, DOI 10.1080/01635589709514537; Yu WP, 1997, NUTR CANCER, V27, P92, DOI 10.1080/01635589709514508	37	56	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	1997	15	2					223	230		10.1038/sj.onc.1201181	http://dx.doi.org/10.1038/sj.onc.1201181			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244357				2022-12-28	WOS:A1997XK37200010
J	Zhou, Q; StetlerStevenson, M; Steeg, PS				Zhou, Q; StetlerStevenson, M; Steeg, PS			Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro	ONCOGENE			English	Article						cyclin D; 9-cis retinoic acid; all trans retinoic acid; Cdk2; Cdk4; breast cancer	DEPENDENT KINASE-ACTIVITY; CANCER-CELLS; RETINOBLASTOMA PROTEIN; 9-CIS-RETINOIC ACID; GENE-EXPRESSION; S-PHASE; GROWTH; OVEREXPRESSION; PROGRESSION; AMPLIFICATION	Transfection and transgenic mouse experiments supported an oncogenic role for cyclin D1 in breast cancer, We recently reported that noninvasive carcinoma ill situ lesions of the human breast overexpress cyclin D, suggesting that this molecular event may represent a valuable target for chemoprevention, The purpose of the present series of investigations vr as to identify agents which could reduce the cyclin D expression of breast cells, We report that 9-cis retinoic acid (9-cis RA) and all trans retinoic acid (tRA) inhibited the cyclin D1 and D3 expression levels of human MCF-7, ZR-75 and T-47D breast carcinoma cells in vitro. Where detectable, similar trends were observed in the immortalized, HBL-100 and MCF-10A breast cell lines, Cyclin D2 was undetectable, The effect of retinoids was both dose- and time-dependent, and correlated with altered cell cycle kinetics and proliferative status, Retinoids were also found to inhibit the expression levels of other cell cycle related proteins, including Cdk2 and Cdk4, resulting in lower kinase activities, In contrast to other breast prevention studies? no synergistic effect was observed with retinoids and tamoxifen. The data indicate that retinoids can potently reduce ca clin D expression levels in a variety of breast cell Lines in vitro, and suggest further consideration of this mechanism for the chemoprevention of breast cancer.	NCI,DIV CLIN SCI,PATHOL LAB,FLOW CYTOMETRY UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhou, Q (corresponding author), NCI,WOMENS CANC SECT,BETHESDA,MD 20892, USA.		zhou, qun/AAU-7592-2020	zhou, qun/0000-0001-6271-3143				ANZANO MA, 1994, CANCER RES, V54, P4614; Asano K, 1995, BIOCHEM BIOPH RES CO, V217, P1169, DOI 10.1006/bbrc.1995.2892; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; COSTA A, 1994, CANCER RES, V54, pS2032; Courjal F, 1996, INT J CANCER, V69, P247; DHINGRA K, 1995, J CELL BIOCH S, V23, P19; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; GILLETT C, 1994, CANCER RES, V54, P1812; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GORSPE M, 1996, MOL CELL BIOL, V14, P762; HAN EKH, 1995, ONCOGENE, V10, P953; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; JIANG W, 1993, ONCOGENE, V8, P3447; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Lama G, 1996, CANCER LETT, V100, P181, DOI 10.1016/0304-3835(95)04099-4; LATAN R, 1996, FASEB J, V10, P1031; LOVE R, 1994, MONOGR NATL CANC I, P61; LOVEC H, 1994, ONCOGENE, V9, P323; MAN T, 1994, LEUKEMIA, V8, P1785; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Noguchi M, 1996, ONCOLOGY-BASEL, V53, P175; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAGE DL, 1993, BREAST CANCER RES TR, V28, P157, DOI 10.1007/BF00666428; RUBIN M, 1994, CANCER RES, V54, P6549; SAVATIER P, 1995, ONCOGENE, V12, P309; SHAO ZM, 1995, ONCOGENE, V11, P493; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SIMPSON JF, IN PRESS AM J PATHOL; SPORN MB, 1983, CANCER RES, V43, P3034; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TAM SW, 1994, ONCOGENE, V9, P2663; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; WERSTO RP, 1995, CYTOMETRY, V20, P43, DOI 10.1002/cyto.990200108; WETHERALL NT, 1986, EUR J CANCER CLIN ON, V22, P53, DOI 10.1016/0277-5379(86)90342-1; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG SY, 1994, AM J CLIN PATHOL, V102, P695, DOI 10.1093/ajcp/102.5.695; ZHAO ZR, 1995, EXP CELL RES, V219, P555, DOI 10.1006/excr.1995.1264; Zhou P, 1996, CANCER RES, V56, P36; ZUCKERBERG L, 1995, MODERN PATHOL, V8, P560; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	53	88	88	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					107	115		10.1038/sj.onc.1201142	http://dx.doi.org/10.1038/sj.onc.1201142			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233783				2022-12-28	WOS:A1997XH58600012
J	Nakamura, H; Yoshida, M; Tsuiki, H; Ito, K; Ueno, M; Nakao, M; Oka, K; Tada, M; Kochi, M; Kuratsu, J; Ushio, Y; Saya, H				Nakamura, H; Yoshida, M; Tsuiki, H; Ito, K; Ueno, M; Nakao, M; Oka, K; Tada, M; Kochi, M; Kuratsu, J; Ushio, Y; Saya, H			Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region	ONCOGENE			English	Article						glioma; chromosome 10q25; tumor suppressor gene; neuralized; h-neu gene	GROWTH-FACTOR RECEPTOR; HUMAN GLIOMAS; NEUROGENIC GENES; ZINC-FINGER; HETEROZYGOSITY; AMPLIFICATION; ENCODES; CHROMOSOME-10; INHIBITORS; CANDIDATE	The loss of chromosome 10 is the most frequent genetic alteration found in malignant astrocytomas, In particular, the long arm of chromosome 10 was previously reported to have two or more common deletion regions where tumor suppressor genes may be located, In this study, we performed deletion mapping of 44 malignant astrocytomas using 12 microsatellite markers on chromosome 10q and demonstrated that the minimal common region of loss of heterozygosity (LOH) was present between D10S192 and D10S566 localized at 10q25.1. Subsequently, we have identified a novel gene, termed h-neu, within the region frequently deleted and found that h-neu encodes a protein with strong homology to the Drosophila neuralized (D-neu) protein, Northern blot and RT-PCR analyses revealed that h-neu mRNA was expressed at very low levels in human malignant astrocytoma tissues and the majority of glioma cell lines examined, while normal brains expressed h-neu transcript, Furthermore, DNA sequencing analysis of the h-neu transcript revealed one of the glioma cell lines, U251MG, had a single nucleotide substitution which resulted in an amino acid change from glycine (GGC) to serine (AGC) at codon 253, The D-neu gene is known to serve a critical function in neurogenesis in Drosophila, and loss-of-function mutations produce hyperplasia of primitive neuronal cells, These observations led us to hypothesize that h-neu gene plays a role in determination of cell fate in the human central nervous system and may act as a tumor suppressor whose inactivation could be associated with malignant progression of astrocytic tumors.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 860, Japan; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 860, Japan; Nakamura Mem Hosp, Dept Neurosurg, Sapporo, Hokkaido 060, Japan; Hokkaido Univ, Sch Med, Dept Neurosurg, Sapporo, Hokkaido 060, Japan	Kumamoto University; Kumamoto University; Hokkaido University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 860, Japan.		Saya, Hideyuki/J-4325-2013					Albarosa R, 1996, AM J HUM GENET, V58, P1260; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BOULIANNE GL, 1991, EMBO J, V10, P2975, DOI 10.1002/j.1460-2075.1991.tb07848.x; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; FLEMING TP, 1992, CANCER RES, V52, P4550; Frank S, 1997, CANCER RES, V57, P2638; FULTS D, 1990, CANCER RES, V50, P5784; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; KARLBOM AE, 1993, HUM GENET, V92, P169; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI YJ, 1995, ONCOGENE, V11, P597; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; PREISS A, 1988, EMBO J, V7, P3917, DOI 10.1002/j.1460-2075.1988.tb03278.x; PRICE BD, 1993, EMBO J, V12, P2411, DOI 10.1002/j.1460-2075.1993.tb05895.x; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1994, CANCER RES, V54, P1324; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; Reifenberger J, 1996, J NEUROPATH EXP NEUR, V55, P822, DOI 10.1097/00005072-199607000-00007; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; SONODA Y, 1995, ONCOGENE, V11, P2145; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TAKAHASHI M, 1988, ONCOGENE, V3, P571; USHIO Y, 1991, Current Opinion in Oncology, V3, P467, DOI 10.1097/00001622-199106000-00005	33	64	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1009	1019		10.1038/sj.onc.1201618	http://dx.doi.org/10.1038/sj.onc.1201618			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519875	Bronze			2022-12-28	WOS:000072335900007
J	Wang, Q; Driouch, K; Courtois, S; Champeme, MH; Bieche, I; Treilleux, I; Briffod, M; Rimokh, R; Magaud, JP; Curmi, P; Lidereau, R; Puisieux, A				Wang, Q; Driouch, K; Courtois, S; Champeme, MH; Bieche, I; Treilleux, I; Briffod, M; Rimokh, R; Magaud, JP; Curmi, P; Lidereau, R; Puisieux, A			Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers	ONCOGENE			English	Article						human breast cancer; TSG101/CC2; rearrangement; mutation	HETEROZYGOSITY; CHROMOSOME-11; PHOSPHORYLATION; ADENOCARCINOMA; PHOSPHOPROTEIN; ONCOPROTEIN-18; INSTABILITY; PROGRESSION; EXPRESSION; STATHMIN	Large intragenic deletions of the TSG101/CC2 gene were recently reported in seven of 15 primary metastatic breast cancers. Although the number of samples was small, this observation suggested that TSG101/CC2 alterations were a major event in breast carcinogenesis. To study the frequency of these deletions in invasive breast cancers we analysed 189 primary invasive breast tumours and 59 breast cancer metastases. We detected intragenic rearrangements in only three samples (two primary tumours and one metastasis). Northern blot analysis of 43 tumours without rearrangements failed to detect any abnormalities. Furthermore, we studied TSG101/CC2 in 11 human breast adenocarcinoma cell lines by Southern blot, RT-PCR and sequencing of the entire coding region of the gene, and detected no abnormalities. These results show that genetic alteration of TSG101/CC2 is a rare event in breast cancer.	Ctr Leon Berard, Unite Oncol Mol, INSERM, U453, F-69373 Lyon 08, France; Ctr Rene Huguenin, Lab Oncogenet, F-92210 St Cloud, France; Ctr Leon Berard, Dept Anat & Cytol Pathol, F-69373 Lyon 08, France; Ctr Rene Huguenin, Lab Anatomocytopathol, F-92210 St Cloud, France; INSERM, U440, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Rene Huguenin Hospital; UNICANCER; Centre Leon Berard; Rene Huguenin Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm)	Puisieux, A (corresponding author), Ctr Leon Berard, Unite Oncol Mol, INSERM, U453, F-69373 Lyon 08, France.		Bièche, Ivan/O-7399-2017; CURMI, Patrick/G-4036-2013; Rimokh, Ruth/G-7506-2014	Bièche, Ivan/0000-0002-2430-5429; CURMI, Patrick A./0000-0001-5045-8501; PUISIEUX, Alain/0000-0002-9938-3798				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Baffa R, 1996, CANCER RES, V56, P268; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BRATTSAND G, 1993, LEUKEMIA, V7, P569; CHENG KC, 1993, ADV CANCER RES, V60, P121; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HANASH SM, 1988, J BIOL CHEM, V263, P12813; KARNIK P, 1995, HUM MOL GENET, V4, P1889, DOI 10.1093/hmg/4.10.1889; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lu KH, 1997, CANCER RES, V57, P387; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; Tran YK, 1996, CANCER RES, V56, P2916; WEBER JL, 1989, AM J HUM GENET, V44, P388; WINQVIST R, 1995, CANCER RES, V55, P2660	24	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					677	679		10.1038/sj.onc.1201563	http://dx.doi.org/10.1038/sj.onc.1201563			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482115				2022-12-28	WOS:000071816600014
J	Kangas, AL; Nicholson, DW; Holtta, E				Kangas, AL; Nicholson, DW; Holtta, E			Involvement of CPP32/Caspase-3 in c-Myc-induced apoptosis	ONCOGENE			English	Article						apoptosis; CPP32/Caspase-3; c-Myc; ODC	PROGRAMMED CELL-DEATH; WILD-TYPE P53; ORNITHINE DECARBOXYLASE ACTIVITY; CRMA-INHIBITABLE PROTEASE; TUMOR-SUPPRESSOR P53; POLY(ADP-RIBOSE) POLYMERASE; GRANZYME-B; CYCLE ARREST; CONVERTING-ENZYME; GENE-EXPRESSION	c-Myc is a transcriptional activator implicated in the control of cell proliferation, differentiation and transformation, but is also involved in the regulation of programmed cell death, apoptosis. Despite intensive research, the molecular mechanisms by which c-Myc triggers and executes cell death remain still elusive. Here, we made use of Rat 1A MycER cells expressing a conditionally active c-Myc protein and tested first the hypothesis that ornithine decarboxylase (ODC), which is a transcriptional target of c-Myc, were a mediator of c-Myc-induced apoptosis. However, our results show that the activity of ODC is not required for the c-Myc-mediated apoptosis to occur in these cells. We also found that the expression of p53, p21(waf1/cip1), Bcl-2, Bax, Bcl-x(L), Bad and cyclins D1, E, A and B did not show any significant changes following c-Myc induction. But, our studies revealed that the c-Myc induced apoptosis is associated with a specific cleavage of poly(ADPribose) polymerase (PARP), suggesting that a cysteine protease of the ICE/CED-3 family is involved. Moreover, we found that the cysteine protease CPP32/Caspase-3, which is known to cleave PARR, is processed from its inactive form to an active protease composed of 17 and 12 kDa subunits; whilst Ich-1/Caspase-2 belonging to another subset of this protease family was not processed/activated following c-Myc activation. The activation of CPP32 and apoptotic cell death were inhibited by addition of Z-VAD-fmk, a universal inhibitor of ICE-like proteases. Further, a selective inhibitor of CPP32-like proteases (Z-DEVD-fmk) partly inhibited apoptosis. These results provide evidence that the ICE/CED3-family proteases, CPP32 and likely others, play a critical role in the execution of a nuclear proto-oncogene, c-Myc-induced apoptosis.	Univ Helsinki, Dept Pathol, Haartman Inst, FIN-00014 Helsinki, Finland; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Dorval, PQ H9R 4P8, Canada	University of Helsinki; Merck & Company	Holtta, E (corresponding author), Univ Helsinki, Dept Pathol, Haartman Inst, POB 21 Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLIFFORD A, 1995, CANCER RES, V55, P1680; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DESIDERIO MA, 1995, CELL GROWTH DIFFER, V6, P505; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERNANDESALNEMR.F, 1996, P NATL ACAD SCI USA, V93, P7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MEGOSH L, 1995, CANCER RES, V55, P4205; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOSHIER JA, 1993, CANCER RES, V53, P2618; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; POHJANPELTO P, 1985, MOL CELL BIOL, V5, P1385, DOI 10.1128/MCB.5.6.1385; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; POULIN R, 1995, BIOCHEM J, V311, P723, DOI 10.1042/bj3110723; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sakamuro D, 1995, ONCOGENE, V11, P2411; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOBIAS KE, 1995, CELL GROWTH DIFFER, V6, P1279; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	89	60	64	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					387	398		10.1038/sj.onc.1201779	http://dx.doi.org/10.1038/sj.onc.1201779			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467964				2022-12-28	WOS:000071582100011
J	O'Hagan, RC; Hassell, JA				O'Hagan, RC; Hassell, JA			The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase	ONCOGENE			English	Article						PEA3; Ets; breast cancer; c-ErbB-2/HER2/Neu; tumorigenesis; metastasis	HUMAN-BREAST-CANCER; ACTIVATED PROTEIN-KINASE; MAP KINASE; NEU ONCOGENE; POINT MUTATION; EWINGS-SARCOMA; DNA-BINDING; CHROMOSOME-TRANSLOCATION; SIGNALING PATHWAY; MOLECULAR-CLONING	The HER2/neu gene, which is overexpressed in 20-30% of human breast tumors, encodes a receptor tyrosine kinase that functions through multiple signaling pathways to regulate the activity of nuclear transcription factors. We have reported that PEAS, an Ets family transcription factor, is overexpressed in HER2/Neu-induced breast tumors and their metastases. To account for the increased levels of PEA3 in these turners we have suggested that HER2/Neu enhances PEAS transcriptional activity, which then acts to stimulate expression of the PEAS gene. This hypothesis is consistent with the occurrence of PEAS binding sites in the PEAS promoter and with the ability of PEA3 to transactivate this promoter. To learn whether HER2/Neu indeed regulates PEAS activity we measured the capacity of constitutively-activated HER2/Neu to affect PEAS-dependent reporter gene expression. Coexpression of PEA3 and HER2/Neu stimulated PEA3-dependent reporter gene expression to a much greater extent than did either protein alone suggesting that HER2/Neu upregulates the transcriptional activity of PEAS. To define the pathway whereby HER2/Neu functions we employed dominant-negative mutants of signaling proteins known to be downstream of HER2/Neu. Overexpression of Rap1a, a Pas-related protein capable of antagonizing Pas function, completely inhibited the ability of HER2/Neu to stimulate PEAS-dependent gene expression. Pas is known to stimulate at least two mitogen-activated protein kinase (MAPK) cascades, the extracellular-regulated kinase (ERK) cascade and the stress-activated kinase (SAPK) or Jun kinase (JNK) cascade. Similarly, HER2/Neu activated both ERKs and SAPKs/JNKs in a Pas-dependent fashion. Dominant-inhibitory mutants in either the ERK or SAPK/JNK cascades partially inhibited HER2/Neu activation of PEAS-dependent gene expression. These findings suggest that HER2/Neu regulates PEA3 activity through two different Ras-dependent MAPK pathways.	McMaster Univ, Inst Mol Biol & Biotechnol, Canc Res Grp, Hamilton, ON L8S 4K1, Canada	McMaster University	Hassell, JA (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, Canc Res Grp, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.							BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENZ CC, 1997, IN PRESS ONCOGENE; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IGLEHART JD, 1990, CANCER RES, V50, P6701; JANES PW, 1994, ONCOGENE, V9, P3601; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Kaya M, 1996, ONCOGENE, V12, P221; KING CR, 1989, CANCER RES, V49, P4185; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU E, 1992, ONCOGENE, V7, P1027; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATRISIAN LM, 1994, ANN NY ACAD SCI, V91, P10129; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONTE D, 1994, ONCOGENE, V9, P1397; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; OHagan RC, 1996, ONCOGENE, V13, P1323; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RICCI A, 1995, ONCOGENE, V11, P1519; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITE MRA, 1992, ONCOGENE, V7, P677; XIE YM, 1995, ONCOGENE, V10, P2409; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAN MH, 1994, NATURE, V372, P798; ZHANG S, 1995, MOL CELL BIOL, V15, P4623	69	64	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					301	310		10.1038/sj.onc.1201547	http://dx.doi.org/10.1038/sj.onc.1201547			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467955				2022-12-28	WOS:000071582100002
J	Kerkhoff, E; Houben, R; Loffler, S; Troppmair, J; Rapp, UR				Kerkhoff, E; Houben, R; Loffler, S; Troppmair, J; Rapp, UR			Regulation of c-myc expression by Ras/Raf signalling	ONCOGENE			English	Article						raf; signal transduction; myc	NIH 3T3 CELLS; RAF; ACTIVATION; PROTEIN; GROWTH; FOS; TRANSFORMATION; ONCOGENES; KINASE; GENE	The c-myc gene is induced upon growth factor stimulation of arrested cells, The interaction of a mitogen with a transmembrane receptor triggers a variety of parallel signal transduction cascades. In order to analyse the role of the Ras/Raf cascade in the regulation of c-myc expression we have established fibroblast cell lines harboring conditional systems activating or inhibiting this pathway, Fusion of the c-Raf-1 kinase domain with the hormone binding domain of the estrogen receptor (c-Raf-1-BxB-ER(TM)) provides a 4-hydroxytamoxifen regulated form of the oncogenic c-Raf-1 kinase, We have generated NIH3T3 cells stably expressing the chimeric Raf protein (N-BxB-ER(TM)). 4-hydroxytamoxifen mediated activation of the fusion protein in serum starved N-BxB-ER(TM) induces the expression of the c-myc gene within 2-6 h, Deletion of the c-Raf-1 kinase domain generates a mutant c-Raf-1 protein (c-Raf-1-C4B), which can directly interact with the effector domain of the Ras protein and thereby block Ras mediated signalling, We have established a NIH3T3 based cell line expressing the c-Raf-1-C4B protein under the control of a tetracycline responsive promoter (N-C4B-tet), Serum starved cells expressing the c-Raf-1-C4B protein exhibit a significantly reduced induction of c-myc expression following serum stimulation compared to the same cells not expressing the Ras inhibitor, The induction of c-myc mRNA following the activation of the isolated Raf/Mek/Erk cascade in addition to the partial inhibition of serum mediated induction of c-myc expression in the presence of the Ras inactivating c-Raf-1-C4B mutant strongly indicates an involvement of the Ras/Raf pathway in the regulation of c-myc expression.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Verbacher Str 5, D-97078 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837; Houben, Roland/0000-0003-4538-2324				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BORTNER DM, 1992, INT J ONCOL, V1, P221; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cooper G.M., 1995, ONCOGENES; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Markowitz D G, 1988, Trans Assoc Am Physicians, V101, P212; MCCHARTY SA, 1997, MOL CELL BIOL, V17, P2401; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORSE HC, 1988, CELLULAR ONCOGENE AC, P335; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; RAPP UR, 1994, ONCOGENE, V9, P3493; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WATERS CM, 1991, ONCOGENE, V6, P797; Yang BS, 1996, MOL CELL BIOL, V16, P538	34	113	115	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					211	216		10.1038/sj.onc.1201520	http://dx.doi.org/10.1038/sj.onc.1201520			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464539				2022-12-28	WOS:000071427100008
J	Feldman, BJ; Reid, TR; Cleary, ML				Feldman, BJ; Reid, TR; Cleary, ML			Pim1 cooperates with E2a-Pbx1 to facilitate the progression of thymic lymphomas in transgenic mice	ONCOGENE			English	Article						E2a-Pbx1; Pim1; lymphomagenesis; retroviral mutagenesis; progression	E-MU-MYC; PRE-B; DNA-BINDING; BONE-MARROW; C-MYC; LEUKEMIA; E2A; FUSION; PROTEINS; PBX1	Mice transgenic for the leukemia oncogene E2A-PBX1 invariably develop lethal, high-grade T-cell lymphomas by 5 months of age. In this study, retroviral insertional mutagenesis was employed to identify oncogenes that cooperate with the E2A-PBX1 transgene in lymphomagenesis. Neonatal retroviral infection substantially reduced length of survival due to accelerated development of lymphomas (81 versus 130 days). The Pim1 gene was targeted by retroviral insertions in 48% of accelerated lymphomas whereas less than 5% contained activated c-Myc and none contained activated Pim2. However, Pim1 DNA rearrangements were frequently sub-stoichiometric and not present at all sites of involvement in an otherwise monoclonal lymphoma indicating that Pim1 activation occurred late in the course of lymphomagenesis. Tumor subpopulations containing activated Pim1 alleles displayed a substantial growth advantage over Pim1 negative cells following serial transfer to secondary, syngeneic recipients. Cooperative interactions were observed in intercrossed Pim1 and E2A-PBX1 transgenic mice in which all double transgenic progeny developed lethal, diffuse T lineage lymphomas by 3 months of age, whereas only 13% of E2A-PBX1 and none of Pim1 single transgenic intercross progeny developed lymphomas by 1 year, Tumors from double transgenic mice were monoclonal providing evidence that additional genetic events were required for transformation, Therefore, Pim1 and E2a-Pbx1 cooperate in T lineage lymphomagenesis but they are not sufficient and the role of Pim1 is more likely to be associated with tumor progression.	STANFORD UNIV,MED CTR,DEPT PATHOL,STANFORD,CA 94305	Stanford University					NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971] Funding Source: NIH RePORTER; NCI NIH HHS [CA42971] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; ADAMS JM, 1992, CANCER SURV, V15, P119; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BREUER M, 1991, CANCER RES, V51, P958; Buckley AR, 1996, CELL GROWTH DIFFER, V7, P1713; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CUYPERS HT, 1984, CELL, V37, P141; CUYPERS HTM, 1986, J VIROL, V60, P230, DOI 10.1128/JVI.60.1.230-241.1986; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DOMEN J, 1993, LEUKEMIA, V7, pS108; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Giordano V, 1997, J IMMUNOL, V158, P4097; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HOOVER D, 1991, J BIOL CHEM, V266, P14018; HUNGER SP, 1991, BLOOD, V77, P687; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1994, ONCOGENE, V9, P3159; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Liang H, 1996, ARCH BIOCHEM BIOPHYS, V330, P259, DOI 10.1006/abbi.1996.0251; LILLY M, 1992, ONCOGENE, V7, P727; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MULI AL, 1996, EMBO J, V15, P2425; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OFarrell AM, 1996, BLOOD, V87, P3655, DOI 10.1182/blood.V87.9.3655.bloodjournal8793655; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; SORENSEN IK, 1966, CARCINOGENESIS, V17, P2221; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERPUTTEN H, 1981, CELL, V24, P729, DOI 10.1016/0092-8674(81)90099-4; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	45	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2735	2742		10.1038/sj.onc.1201670	http://dx.doi.org/10.1038/sj.onc.1201670			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9401000				2022-12-28	WOS:A1997YH46800011
J	Shridhar, V; Sun, QC; Miller, OJ; Kalemkerian, GP; Petros, J; Smith, DI				Shridhar, V; Sun, QC; Miller, OJ; Kalemkerian, GP; Petros, J; Smith, DI			Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas	ONCOGENE			English	Article						7q31.2 loss; renal cell carcinoma; fragile sites	TUMOR-SUPPRESSOR GENE; PRIMARY BREAST-CANCER; SQUAMOUS-CELL; FREQUENT LOSS; FRAGILE SITE; HOMOZYGOUS DELETION; ALLELIC LOSSES; LUNG-CANCER; 7Q31.1; LOCUS	Cytogenetic and molecular analysis of DNA sequences with highly polymorphic microsatellite markers have implicated allele loss in several chromosomal regions including 3p, 6p, 6q, 8p, 9p, 9q, 11p and 14q in the pathogenesis of sporadic renal cell carcinomas (RCCs), Deletions involving the long arm of chromosome 7 have not been described in RCCs although they have been seen in several other tumor types, However, there have been no detailed analysis of loss of heterozygosity (LOH) of 7q sequences in sporadic RCCs, We therefore studied LOH for DNA sequences on 7q with 10 highly polymorphic markers in 92 matched normal/tumor samples representing sporadic RCCs including papillary, nonpapillary, and oncocytomas in order to determine whether allelic loss could be detected in a tumor type with no visible 7q rearrangements at the cytogenetic level, We found chromosome 7q allele loss in 59 of 92 cases (64%) involving one, two, or more microsatellite markers, The most common allele loss included loci D7S522 (24%) and D7S649 (30%) at 7q31.1-31.2, a region that contains one of the common fragile sites, FRA7G. By comparative multiplex PCR analysis, we detected a homozygous deletion of one marker in the 7q 31.1-31.2 region in one tumor, RC21. These results support the idea that a tumor suppressor gene in 7q31 is involved in the pathogenesis of sporadic renal cell carcinomas.	MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,DIV EXPT PATHOL,ROCHESTER,MN 55905; WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,KARMANOS CANC INST,DETROIT,MI 48201; EMORY UNIV,SCH MED,DEPT UROL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,WINSHIP CANC CTR,ATLANTA,GA 30322; WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48201	Mayo Clinic; Barbara Ann Karmanos Cancer Institute; Wayne State University; Emory University; Emory University; Wayne State University					NCI NIH HHS [CA48031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achille A, 1996, CANCER RES, V56, P3808; ANGLARD P, 1994, CANCER RES, V51, P1073; BARBI G, 1984, HUM GENET, V68, P290, DOI 10.1007/BF00292586; BERGER R, 1985, CYTOGENET CELL GENET, V40, P490, DOI 10.1159/000132181; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; COLLARD JG, 1987, CANCER RES, V47, P6666; COQUELLE A, 1997, CELL, V89, P219; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; KOVACS G, 1989, CANCER RES, V49, P651; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; MILES J, 1988, CANCER GENET CYTOGEN, V34, P135, DOI 10.1016/0165-4608(88)90180-X; MORITA R, 1991, CANCER RES, V51, P820; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OGAWA O, 1991, CANCER RES, V51, P949; PARADEE W, 1995, GENOMICS, V27, P358, DOI 10.1006/geno.1995.1057; PRESTI JC, 1993, CANCER RES, V53, P5780; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Shridhar R, 1996, CANCER RES, V56, P4347; Shridhar V, 1997, ONCOGENE, V14, P1269, DOI 10.1038/sj.onc.1201100; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; TAKAHASHI S, 1995, CANCER RES, V55, P4114; THONES W, 1986, PATHOL RES PRACT, V181, P125; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; TSAI YC, 1990, CANCER RES, V50, P44; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WANG ND, 1993, GENOMICS, V17, P341, DOI 10.1006/geno.1993.1330; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WIELAND I, 1992, P NATL ACAD SCI USA, V89, P9705, DOI 10.1073/pnas.89.20.9705; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	45	69	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2727	2733		10.1038/sj.onc.1201448	http://dx.doi.org/10.1038/sj.onc.1201448			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400999				2022-12-28	WOS:A1997YH46800010
J	Allay, E; Reese, JS; McGuire, EA; Koc, ON; Sedransk, N; Gerson, SL				Allay, E; Reese, JS; McGuire, EA; Koc, ON; Sedransk, N; Gerson, SL			Potentiation of lymphomagenesis by methylnitrosourea in mice transgenic for LMO1 is blocked by O-6-alkylguanine DNA-alkyltransferase	ONCOGENE			English	Article						DNA repair; LMO1; lymphomagenesis; O-6-alkylguanine; DNA-alkyltransferase; carcinogenesis	INDUCED THYMIC LYMPHOMAS; N-METHYLNITROSOUREA; ESCHERICHIA-COLI; EXPRESSION; GENE; RAS; METHYLTRANSFERASE; PROTECTS; REPAIR; LEUKEMIA	We evaluated induction of lymphomas by the methylating carcinogen, N-methylnitrosourea [MNU], in transgenic mice expressing both LMO1 and the DNA repair gene, MGMT, in the thymus, The goal was to determine whether environmental mutagens shorten the latency or increase the incidence of LMO1+lymphomas and whether mice transgenic for both LMO1 and MGMT, and thereby able to repair O-6-methylguanine DNA adducts induced by MNU, would be protected, Mice heterozygous for LMO1 or MGMT were crossed and offspring treated with MNU at 6 weeks of age, MNU induced lymphoma incidence was highest in the LMO1 mice, 91% and lowest in the hMGMT+mice, 15%, MNU induced K-ras mutations in codon 12 in non-MGMT transgenics resulted in a shorter latency of tumors and accounting for half of the early lymphomas in LMO1 mice, The effect of MNU was abrogated in the LMO1/hMGMT transgenic mice, indicating the ability of MGMT expression to block the carcinogenic effect of MNU even in cancer prone mice, Thus, methylating agents potentiate lymphomagenesis of LMO1, in part through activation of K-ras and the MAPK pathway, a process which appear to synergize with LMO1 mediated transcription activation, O-6-alkylguanine DNA-alkyltransferase mediated DNA repair effectively blocks chemical carcinogenesis in mice carrying the LMO1 oncogene.	CASE WESTERN RESERVE UNIV,SCH MED,DIV HEMATOL ONCOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CWRU IRELAND CANC CTR,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CLEVELAND,OH 44106; UNIV PITTSBURGH,DIV HEMATOL,INST CANC,PITTSBURGH,PA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA063193, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA43703, R01CA63193] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL JM, 1993, MOL CARCINOGEN, V7, P151, DOI 10.1002/mc.2940070305; Becker K, 1996, CANCER RES, V56, P3244; BOEHM T, 1990, ONCOGENE, V5, P1103; BREUER M, 1991, CANCER RES, V51, P958; COROMINAS M, 1991, CANCER RES, V51, P5129; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; ELSON A, 1995, ONCOGENE, V11, P181; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; Gerson Stanton L., 1993, Current Opinion in Oncology, V5, P136; HAQQI TM, 1992, P NATL ACAD SCI USA, V89, P1253, DOI 10.1073/pnas.89.4.1253; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; KANEKO Y, 1989, LEUKEMIA, V3, P886; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Knudson AG, 1995, ADV CANCER RES, V67, P1, DOI 10.1016/S0065-230X(08)60708-3; LINDEMAN G, 1994, ONCOGENE, V10, P1013; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; LIU LL, 1994, CANCER RES, V54, P4648; MACKAY WJ, 1994, J BACTERIOL, V176, P3224, DOI 10.1128/jb.176.11.3224-3230.1994; MANGUES R, 1994, CANCER RES, V54, P6395; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; NEALE GAM, 1995, BLOOD, V86, P3060; NEWCOMB EW, 1988, CANCER RES, V48, P5514; PAULY GT, 1994, BIOCHEMISTRY-US, V33, P9169, DOI 10.1021/bi00197a020; REBECK GW, 1991, J BACTERIOL, V173, P2068, DOI 10.1128/jb.173.6.2068-2076.1991; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; XIAO W, 1995, MUTAT RES-DNA REPAIR, V336, P133, DOI 10.1016/0921-8777(94)00048-B; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; ZAIDI NH, 1995, CARCINOGENESIS, V16, P1047, DOI 10.1093/carcin/16.5.1047	31	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2127	2132		10.1038/sj.onc.1201384	http://dx.doi.org/10.1038/sj.onc.1201384			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366529	Bronze			2022-12-28	WOS:A1997YC28400013
J	Janson, W; Brandner, G; Siegel, J				Janson, W; Brandner, G; Siegel, J			Butyrate modulates DNA-damage-induced p53 response by induction of p53-independent differentiation and apoptosis	ONCOGENE			English	Article						p53; butyrate; DNA damage; differentiation; apoptosis	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; TUMOR-SUPPRESSOR GENE; BREAST-CANCER CELLS; LARGE-T-ANTIGEN; SODIUM-BUTYRATE; IN-VIVO; MONOCLONAL-ANTIBODIES; P53-DEPENDENT APOPTOSIS; P53-DEFICIENT MICE	Butyrate, a physiologically occurring agent, has been reported to decrease constitutively high expressed p53 levels in transformed cells. To elucidate,whether butyrate also inhibits DNA-damage-induced p53 response we investigated the effects of butyrate and the anticancer drug mitomycin C in normal C3H10T1/2 cells harbouring wild-type p53. In comparison with p53-deficient fibroblasts we examined p53 protein level, cell cycle arrest, differentiation, and apoptosis. Butyrate induced G1 phase arrest, differentiation, and p53-independent increase in p21(waf1/cip1) protein. Moreover, butyrate induced p53-independent apoptosis, which was, as well as p53-mediated apoptosis, associated with a dose-dependent increase in Bax and c-Myc protein. Pretreatment with butyrate repressed dose-dependently mitomycin-C-induced p53 accumulation and interfered with p53-dependent cell cycle arrest. Butyrate further partially inhibited p53-mediated apoptosis, but low doses of butyrate were more effective than higher concentrations. This was reflected in an enhanced decrease in c-Myc and Bax protein in response to mitomycin C with low concentrations of butyrate. Our data indicate that the differentiation stimulus of butyrate, in association with p21(waf1/cip1) induction, and apoptosis, may explain antineoplastic effects of butyrate. Co-carcinogenic features of butyrate may result from inhibition of p53-mediated DNA damage response.	UNIV FREIBURG,INST MED MICROBIOL & HYG,DEPT VIROL,D-79104 FREIBURG,GERMANY	University of Freiburg								ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BERRY RD, 1988, CARCINOGENESIS, V9, P447, DOI 10.1093/carcin/9.3.447; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CALABRESSE C, 1993, BIOCHEM BIOPH RES CO, V195, P31, DOI 10.1006/bbrc.1993.2005; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CHEN YQ, 1995, CANCER RES, V55, P4536; COLEMAN WB, 1994, CARCINOGENESIS, V15, P145, DOI 10.1093/carcin/15.2.145; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FORBES IJ, 1992, EXP CELL RES, V198, P367, DOI 10.1016/0014-4827(92)90393-M; FRITSCHE M, 1993, ONCOGENE, V8, P307; FRITSCHE M, 1991, THESIS FREIBURG GERM; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAZITT Y, 1994, CANCER RES, V54, P950; GOETZ C, 1995, INT J ONCOL, V6, P1129; GOLDBERG YP, 1992, J CELL BIOCHEM, V49, P74, DOI 10.1002/jcb.240490113; GOPE R, 1993, CELL MOL BIOL, V39, P589; GORCZYCA W, 1993, CANCER RES, V53, P3186; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HALDAR S, 1994, CANCER RES, V54, P2095; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; HOJO ETS, 1994, MUTAT RES-FUND MOL M, V309, P165, DOI 10.1016/0027-5107(94)90089-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; JANSON W, 1996, THESIS FREIBURG GERM; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KITAMURA N, 1993, P ELECTROCHEM SOC, V12, P187; KRUH J, 1982, MOL CELL BIOCHEM, V42, P5; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERRITT AJ, 1994, CANCER RES, V54, P614; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOLINARI M, 1995, ONCOGENE, V10, P1849; MOLLINEDO F, 1993, BIOCHEM J, V294, P137, DOI 10.1042/bj2940137; MONDAL S, 1976, NATURE, V260, P710, DOI 10.1038/260710a0; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OLTAVI ZN, 1993, CELL, V74, P609; RAGIMOV N, 1993, ONCOGENE, V8, P1183; ROBB JA, 1973, EXP CELL RES, V81, P120, DOI 10.1016/0014-4827(73)90118-3; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SAITO Y, 1995, ONCOGENE, V11, P1013; SANKARANARAYANA.K, 1984, GENET RES, V56, P267; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAO ZM, 1995, ONCOGENE, V11, P493; SIEGEL J, 1995, ONCOGENE, V11, P1363; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOBALLE PW, 1994, MELANOMA RES, V4, P213, DOI 10.1097/00008390-199408000-00003; SOLARY E, 1993, BLOOD, V81, P1359; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STEINMEYER JE, 1988, ONCOGENE, V5, P1691; STEMMERMANN GN, 1973, CANCER-AM CANCER SOC, V31, P1260, DOI 10.1002/1097-0142(197305)31:5<1260::AID-CNCR2820310535>3.0.CO;2-N; STEWART N, 1995, ONCOGENE, V7, P1513; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TOSCANI A, 1988, ONCOGENE RES, V3, P223; UTESCH D, 1993, CARCINOGENESIS, V14, P457, DOI 10.1093/carcin/14.3.457; WAGA S, 1994, NATURE, V369, P578; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WARELL RP, 1993, NEW ENGL J MED, V329, P177; WINTERSBERGER E, 1984, FEBS LETT, V166, P326, DOI 10.1016/0014-5793(84)80105-2; WINTERSBERGER E, 1983, J CELL BIOCHEM, V21, P239, DOI 10.1002/jcb.240210306; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052	89	59	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1395	1406		10.1038/sj.onc.1201304	http://dx.doi.org/10.1038/sj.onc.1201304			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333015				2022-12-28	WOS:A1997XW41100003
J	Kornmann, M; Ishiwata, T; Beger, HG; Korc, M				Kornmann, M; Ishiwata, T; Beger, HG; Korc, M			Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions	ONCOGENE			English	Article						fibroblast growth factor-5; fibroblast growth factor receptor splice variant; in situ hybridization; mitogenic signaling; pancreatic cancer; protein kinases	FGF RECEPTORS; CELL-LINES; EXPRESSION; TRANSDUCTION; FAMILY; SPECIFICITY; ACTIVATION; MECHANISMS; INDUCTION; ONCOGENES	Fibroblast growth factor (FGF)-1 and -2 are overexpressed in human pancreatic cancer. In this study the role of FGF-5 in human pancreatic cancer was investigated, as FGF-5 has a classical signal sequence for secretion not found in FGF-1 or -2. Northern blot analysis with a 306 bp FGF-5 cDNA revealed the presence of 4.0 kb and 1.6 kb FGF-5 mRNA transcripts in both normal and cancerous pancreatic tissues. Densitometric analysis indicated that 4.0 kb and 1.6 kb FGF-5 mRNA transcripts levels were increased 2.4- and 2.7-fold in the cancers by comparison with normal tissues, respectively (P<0.002, P<0.0001). Immunohistochemistry and in situ hybridization demonstrated that FGF-5 localized in the cancer cells, stromal fibroblast and inflitrating macrophages. FGF-5 mRNA was also detected in COLO-357 human pancreatic cancer cells. Furthermore, secreted FGF-5 protein was present in conditioned medium of COLO-357 cells. Exogeneous FGF-5 (0.37 nM) increased the growth of COLO-357 cells by 48% (P<0.0001) and increased mitogen-activated protein kinase activity. COLO-357 cells expressed the IIIc isoform of the type I FGF receptor, the preferred FGF receptor for FGF-5. These observations suggest that FGF-5 may participate in autocrine and paracrine pathways promoting pancreatic cancer cell growth in vivo.	UNIV CALIF IRVINE,MED SCI INST C240,DEPT MED BIOL CHEM & PHARMACOL,IRVINE,CA 92697; UNIV ULM,DEPT GEN SURG,D-89075 ULM,GERMANY	University of California System; University of California Irvine; Ulm University			Ishiwata, Toshiyuki/H-1151-2014	Ishiwata, Toshiyuki/0000-0002-4180-0069	NIDDK NIH HHS [DK-44948] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044948] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; ALTORKI N, 1993, CANCER-AM CANCER SOC, V72, P649, DOI 10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO;2-L; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; Burgess W. H., 1996, P154; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EBERT M, 1995, INT J CANCER, V62, P529, DOI 10.1002/ijc.2910620507; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GAMBARINI AG, 1993, MOL CELL BIOCHEM, V124, P121, DOI 10.1007/BF00929204; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GILBERT E, 1993, MOL CELL BIOL, V13, P5441; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOLDFARB M, 1991, ANN NY ACAD SCI, V638, P38, DOI 10.1111/j.1749-6632.1991.tb49016.x; Hannon K, 1996, J CELL BIOL, V132, P1151, DOI 10.1083/jcb.132.6.1151; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; HERBERT JM, 1991, DEVELOPMENT, V112, P407; HUGHES RA, 1993, NEURON, V10, P369, DOI 10.1016/0896-6273(93)90327-N; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KITAOKA T, 1994, INVEST OPHTH VIS SCI, V35, P3189; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NGUYEN C, 1988, ONCOGENE, V3, P703; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; SIDDIQI I, 1995, BIOCHEM BIOPH RES CO, V215, P309, DOI 10.1006/bbrc.1995.2467; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WERNER S, 1991, ONCOGENE, V6, P2137; YAMANAKA Y, 1993, CANCER RES, V53, P5289; YAMASAKI M, 1996, J BIOL CHEM, V271, P15919; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yoshimura K, 1996, CANCER LETT, V103, P91, DOI 10.1016/0304-3835(96)04198-5; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	41	91	93	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1417	1424		10.1038/sj.onc.1201307	http://dx.doi.org/10.1038/sj.onc.1201307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333017				2022-12-28	WOS:A1997XW41100005
J	Smith, DP; Houghton, C; Ponder, BAJ				Smith, DP; Houghton, C; Ponder, BAJ			Germline mutation of RET codon 883 in two cases of de novo MEN 2B	ONCOGENE			English	Article						multiple endocrine neoplasia type 2B; RET protooncogene; germline mutation	MULTIPLE ENDOCRINE NEOPLASIA; MEDULLARY-THYROID CARCINOMA; RECEPTOR TYROSINE KINASE; AUTOPHOSPHORYLATION SITES; PROTOONCOGENE MUTATIONS; HIRSCHSPRUNG DISEASE; POINT MUTATION; ACTIVATION; DOMAIN; IDENTIFICATION	Germline mutations in the RET proto-oncogene are seen in the majority of patients with the dominantly inherited cancer syndromes multiple endocrine neoplasia type 2 (MEN 2). The clinical subtypes of MEN 2 (MEN 2A, MEN 2B and familial MTC) all have medullary thyroid carcinoma, but vary in the involvement of pheochromocytoma, parathyroid adenoma/hyperplasia and developmental abnormalities. A single RET mutation, resulting in the substitution M918T, has been identified in 94% of cases of MEN 2B (which consists of MTC, pheochromocytoma and developmental abnormalities). Here we report the identification of a new germline RET mutation (A883F) in two de novo cases of MEN 2B. Identification of this new mutation will contribute to understanding the molecular basis of MEN 2B, and will assist in the clinical management of families harbouring this mutation.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT PATHOL,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge								ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Iwashita T, 1996, ONCOGENE, V12, P481; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P213, DOI 10.1046/j.1365-2265.1996.505292.x; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Pignon JM, 1997, BRIT J HAEMATOL, V96, P374, DOI 10.1046/j.1365-2141.1997.d01-2042.x; Ponder BAJ, 1996, ADV CANCER RES, V70, P179, DOI 10.1016/S0065-230X(08)60875-1; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Toogood AA, 1995, CLIN ENDOCRINOL, V43, P759, DOI 10.1111/j.1365-2265.1995.tb00547.x; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Webster MK, 1996, MOL CELL BIOL, V16, P4081; ZHANG B, 1991, J BIOL CHEM, V266, P990	40	129	138	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1213	1217		10.1038/sj.onc.1201481	http://dx.doi.org/10.1038/sj.onc.1201481			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294615				2022-12-28	WOS:A1997XU99100011
J	Yuan, B; Oechsli, N; Hendler, FJ				Yuan, B; Oechsli, N; Hendler, FJ			A region within murine chromosome 7F4, syntenic to the human 11q13 amplicon, is frequently amplified in 4NQO-induced oral cavity tumors	ONCOGENE			English	Article						head and neck neoplasia; chemical carcinogenesis; gene amplification; cyclin D1; chromosome 7	SQUAMOUS-CELL CARCINOMAS; MOUSE SKIN CARCINOGENESIS; HA-RAS GENE; CYCLIN D1; GENOMIC ORGANIZATION; ONCOGENE ACTIVATION; BREAST-CANCER; INT-2 GENE; HETEROZYGOSITY; AMPLIFICATION	Our previous reports have shown that two thirds of 4-nitroquinoline-1-oxide (4NQO)-induced murine oral squamous cell carcinomas (SCC) have Hras1 mutations, Loss of heterozygosity (LOH) involving the distal portion of chromosome (Chr) 7 occurred in half of the tumors with Hras1 mutations, Here, we demonstrate that five of six tumors with LOH have 4-8-fold amplification involving the distal portion of Chr 7 (7F4). Ccnd1, Fgf4 and Fgf3, within the most telomeric region of Chr 7 (70.5 cM), are co-amplified, The region is syntenic to a previously identified human amplicon at 11q13. Only one out of eight tumors without LOH at Chr 7 had twofold amplification; the other seven had no detectable amplification, Significant amplification is restricted to the chromosome with the Hras1 mutation, Gene amplification occurred without overexpression since only one of five tumors with amplification and one of six tumors without Ccnd1 amplification expressed increased protein, Although amplification of 11q13 occurs rather frequently in human tumors, 4NQO-induced oral, cavity tumors in inbred mice are the first example of a murine tumor with consistent amplification, Our observations are strikingly similar to human head and neck SCC where overexpression of genes within the 11q13 amplicon is inconsistently detected, The amplification of genes localized to human 11q13 and the syntenic region on murine Chr 7 during tumorigenesis suggests that similar structural elements are present which predispose these regions to amplification during malignant transformation.	UNIV LOUISVILLE, JAMES GRAHAM BROWN CANC CTR, DEPT BIOCHEM & MOL BIOL, LOUISVILLE, KY 40292 USA; UNIV LOUISVILLE, JAMES GRAHAM BROWN CANC CTR, DEPT MED, LOUISVILLE, KY 40292 USA; UNIV LOUISVILLE, JAMES GRAHAM BROWN CANC CTR, HENRY VOGT CANC RES INST, LOUISVILLE, KY 40292 USA; UNIV LOUISVILLE, CTR GENET & MOL MED, LOUISVILLE, KY 40292 USA; UNIV LOUISVILLE, CTR ENVIRONM HLTH SCI, LOUISVILLE, KY 40292 USA; LOUISVILLE VA MED CTR, LOUISVILLE, KY USA	University of Louisville; University of Louisville; University of Louisville; University of Louisville; University of Louisville					OAPP OPHS HHS [PG94-3, PG95-5] Funding Source: Medline	OAPP OPHS HHS		AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO;2-6; ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIANCHI AB, 1993, MAMM GENOME, V4, P220, DOI 10.1007/BF00417566; BREMNER R, 1994, MOL CARCINOGEN, V11, P90, DOI 10.1002/mc.2940110206; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; Bringuier PP, 1996, ONCOGENE, V12, P1747; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; BUCHBERG AM, 1992, MAMM GENOME, V3, pS162, DOI 10.1007/BF00648429; BUCHMANN A, 1991, CANCER RES, V51, P4097; CARTER SL, 1994, CANCER RES, V54, P6270; Cha R S, 1992, PCR Methods Appl, V2, P14; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FILMUS J, 1994, ONCOGENE, V9, P3627; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; GAFFEY MJ, 1995, HUM PATHOL, V26, P1221, DOI 10.1016/0046-8177(95)90197-3; GILLETT C, 1994, CANCER RES, V54, P1812; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GUSTAFSON CE, 1994, BRIT J CANCER, V70, P395, DOI 10.1038/bjc.1994.315; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAWKINS BL, 1994, HEAD NECK-J SCI SPEC, V16, P424, DOI 10.1002/hed.2880160506; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HOWELL RE, 1989, J ORAL PATHOL MED, V18, P79, DOI 10.1111/j.1600-0714.1989.tb00741.x; HU LH, 1995, AACR, V36, P542; Huber JL, 1996, INT CONGR SER, V1114, P89; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KEMP CJ, 1993, MOL CARCINOGEN, V7, P147, DOI 10.1002/mc.2940070304; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MICHALIDES R, 1995, CANCER RES, V55, P975; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RINCHIK EM, 1992, MAMM GENOME, V3, pS104, DOI 10.1007/BF00648425; RIOU G, 1988, ONCOGENE, V3, P329; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; RUBIN JS, 1995, J LARYNGOL OTOL, V109, P72, DOI 10.1017/S0022215100129305; RUMSBY G, 1990, BRIT J CANCER, V61, P365, DOI 10.1038/bjc.1990.80; SARANATH D, 1991, BRIT J CANCER, V63, P573, DOI 10.1038/bjc.1991.133; SARANATH D, 1991, J CANCER RES CLIN, V117, P484, DOI 10.1007/BF01612771; SOMERS KD, 1990, ONCOGENE, V5, P915; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; TSUDA T, 1989, CANCER RES, V49, P5505; VIEL A, 1991, TUMORI, V77, P16, DOI 10.1177/030089169107700104; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WANI MA, 1994, CANCER RES, V54, P2504; WINQVIST R, 1993, CANCER RES, V53, P4486; Winston JT, 1996, ONCOGENE, V12, P127; Yuan B, 1997, MOL CARCINOGEN, V19, P8, DOI 10.1002/(SICI)1098-2744(199705)19:1<8::AID-MC2>3.0.CO;2-D; YUAN B, 1994, CANCER RES, V54, P5310; Yuan B, 1996, GENOMICS, V38, P58, DOI 10.1006/geno.1996.0592	62	20	20	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1161	1170		10.1038/sj.onc.1201269	http://dx.doi.org/10.1038/sj.onc.1201269			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294609				2022-12-28	WOS:A1997XU99100005
J	Porcellini, A; Ruggiano, G; Pannain, S; Ciullo, I; Amabile, G; Fenzi, G; Avvedimento, EV				Porcellini, A; Ruggiano, G; Pannain, S; Ciullo, I; Amabile, G; Fenzi, G; Avvedimento, EV			Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells	ONCOGENE			English	Article						thyrotropin receptor; mutations; cAMP signaling; neoplasm, genetics	SOMATIC MUTATIONS; THYROGLOBULIN GENE; FRTL5 CELLS; EXPRESSION; ADENOSINE-3',5'-MONOPHOSPHATE; ACTIVATION; TRANSFORMATION; IDENTIFICATION; CLONING; HORMONE	TSH receptor mutants in the VI transmembrane segment, found in thyroid autonomously functioning adeonomas, have been expressed in differentiated thyroid cells, All mutant receptors constitutively stimulated adenylyl cyclase, The biological activity, measured as cAMP production relative to the wild type receptor, was specific for each mutant in transient and stable transfection assays. Cells expressing these mutants proliferated in the absence of TSH, The rate of growth in the absence of TSH paralleled basal cAMP production for each mutant receptor, Low TSH concentrations stimulated of mutant receptor-expressing growth of the cells expressing the wild type receptor, Also, the entry in the cell cycle and the plating efficiency were markedly stimulated by the expression of the mutant receptors, These data provide a molecular link between the occurrence of TSH receptor mutations and thyroid autonomously functioning adenomas.	UNIV REGGIO CALABRIA,FAC MED,DIPARTIMENTO MED SPERIMENTALE,I-88100 CATANZARO,ITALY; FDN G PASCALE,SERV ONCOL SPERIMENTALE E,IST NAZL TUMORI,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED,DIPARTIMENTO BIOL & PATOL MOL & CELLULARE L CALIF,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED,DEPT ENDOCRINOL,I-80131 NAPLES,ITALY	Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II			Porcellini, Antonio/AAC-6097-2019; Porcellini, Antonio/E-1900-2011	Porcellini, Antonio/0000-0001-6882-9518				AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AVVEDIMENTO EV, 1989, CELL, V58, P1135, DOI 10.1016/0092-8674(89)90511-4; AVVEDIMENTO VE, 1984, BIOCHEM BIOPH RES CO, V122, P472; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; AVVEDIMENTO VE, 1988, P NATL ACAD SCI USA, V85, P1744, DOI 10.1073/pnas.85.6.1744; BIDEY SP, 1988, J ENDOCRINOL, V119, P365, DOI 10.1677/joe.0.1190365; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; JIN S, 1986, ENDOCRINOLOGY, V119, P802, DOI 10.1210/endo-119-2-802; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1991, BIOCHIMIE, V73, P29, DOI 10.1016/0300-9084(91)90070-H; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; PORCELLINI A, 1995, ONCOGENE, V11, P1089; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P567; SAJI M, 1992, ENDOCRINOLOGY, V130, P520, DOI 10.1210/en.130.1.520; Sambrook J., 2002, MOL CLONING LAB MANU; SETTE C, 1994, J BIOL CHEM, V269, P9245; SUAREZ HG, 1991, ONCOGENE, V6, P677; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; TRAMONTANO D, 1986, ENDOCRINOLOGY, V118, P1945, DOI 10.1210/endo-118-5-1945; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099	32	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					781	789		10.1038/sj.onc.1201240	http://dx.doi.org/10.1038/sj.onc.1201240			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266964				2022-12-28	WOS:A1997XQ11700004
J	Pegram, MD; Finn, RS; Arzoo, K; Beryt, M; Pietras, RJ; Slamon, DJ				Pegram, MD; Finn, RS; Arzoo, K; Beryt, M; Pietras, RJ; Slamon, DJ			The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells	ONCOGENE			English	Article						HER-2/neu (c-erbB-2); breast cancer; ovarian cancer; drug resistance; chemotherapy	GROWTH-FACTOR-RECEPTOR; RESISTANT CHINESE-HAMSTER; C-HA-RAS; C-ERBB-2 EXPRESSION; CARCINOMA-CELLS; ENDOMETRIAL CANCER; ONCOGENE AMPLIFICATION; MONOCLONAL-ANTIBODY; PROTEIN EXPRESSION; PROGNOSTIC VALUE	Recent studies indicate that oncogenes may be involved in determining the sensitivity of human cancers to chemotherapeutic agents. To define the effect of HER-2/neu oncogene overexpression on sensitivity to chemotherapeutic drugs, a full-length, human HER-2/neu cDNA was introduced into human breast and ovarian cancer cells. In vitro dose-response curves following exposure to 7 different classes of chemotherapeutic agents were compared for HER-2- and control-transfected cells. Chemosensitivity was also tested in vivo for HER-2- and control-transfected human breast and ovarian cancer xenografts in athymic mice. These studies indicate that HER-2/neu overexpression was not sufficient to induce intrinsic, pleomorphic drug resistance. Furthermore, changes in chemosensitivity profiles resulting from HER-2/neu transfection observed in vitro were cell line specific. In vivo, HER-2/neu-overexpressing breast and ovarian cancer xenografts were responsive to different classes of chemotherapeutic drugs compared to control-treated xenografts with no statistically significant differences between HER-2/neu-overexpressing and non-overexpressing xenografts. We found no instance in which HER-2/neu-overexpressing xenografts were rendered more sensitive to chemotherapeutic drugs in vivo. HER-2/neu-overexpressing xenografts consistently exhibited more rapid regrowth than control xenografts following initial response to chemotherapy suggesting that a high rate of tumor cell proliferation rather than drug resistance may be responsible for the prognosis associated with HER-2/neu overexpression in human cancers.	UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Pietras, Richard/0000-0002-2846-3192	NCI NIH HHS [1K12 CA01714, R01 CA36827] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001714, R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; ALLRED DC, 1992, J CLIN ONCOL, V10, P599, DOI 10.1200/JCO.1992.10.4.599; ANBAZHAGAN R, 1991, ANN ONCOL, V2, P47, DOI 10.1093/oxfordjournals.annonc.a057824; ARTEAGA CL, 1994, CANCER RES, V54, P3758; BARBARESCHI M, 1992, AM J CLIN PATHOL, V98, P408, DOI 10.1093/ajcp/98.4.408; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P15, DOI 10.1016/0002-9378(91)90615-X; BERGER MS, 1988, CANCER RES, V48, P1238; BERNS EMJJ, 1995, GENE, V159, P11, DOI 10.1016/0378-1119(94)00534-Y; BORG A, 1991, ONCOGENE, V6, P137; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; CASCIARI JJ, 1994, J NATL CANCER I, V86, P1846, DOI 10.1093/jnci/86.24.1846; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHRISTEN RD, 1990, J CLIN INVEST, V86, P1632, DOI 10.1172/JCI114885; COHEN BE, 1986, CANCER TREAT REP, V70, P859; DICKSTEIN B, 1993, J CELL PHYSIOL, V157, P110, DOI 10.1002/jcp.1041570115; DICKSTEIN BM, 1995, MOL CELL ENDOCRINOL, V110, P205, DOI 10.1016/0303-7207(95)03535-F; DINCALCI M, 1982, CANCER CHEMOTH PHARM, V7, P141; DISAIA PJ, 1972, AM J OBSTET GYNECOL, V114, P979, DOI 10.1016/0002-9378(72)90109-3; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FELIP E, 1995, CANCER, V75, P2147, DOI 10.1002/1097-0142(19950415)75:8<2147::AID-CNCR2820750818>3.0.CO;2-8; FLICK DA, 1984, J IMMUNOL METHODS, V68, P167, DOI 10.1016/0022-1759(84)90147-9; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GORMLEY PE, 1979, CLIN PHARMACOL THER, V25, P351; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARLAND SJ, 1984, CANCER RES, V44, P1693; HETZEL DJ, 1992, GYNECOL ONCOL, V47, P179, DOI 10.1016/0090-8258(92)90103-P; ISONISHI S, 1991, CANCER RES, V51, P5903; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KERBEL RS, 1994, COLD SPRING HARB SYM, V59, P661, DOI 10.1101/SQB.1994.059.01.076; KERBEL RS, 1995, INVAS METAST, V14, P50; KLIJN JGM, 1993, CANCER SURV, V18, P165; KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294; LEE AKC, 1992, MODERN PATHOL, V5, P61; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LUKES AS, 1994, CANCER, V73, P2380, DOI 10.1002/1097-0142(19940501)73:9<2380::AID-CNCR2820730922>3.0.CO;2-G; MACMILLAN WE, 1978, CANCER RES, V38, P3479; MEYERS MB, 1986, P NATL ACAD SCI USA, V83, P5521, DOI 10.1073/pnas.83.15.5521; MEYERS MB, 1993, BIOCHEM PHARMACOL, V46, P1841, DOI 10.1016/0006-2952(93)90591-J; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NELSON RL, 1980, CANCER TREAT REV, V7, P17, DOI 10.1016/S0305-7372(80)80003-X; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; NUTI M, 1991, ANTICANCER RES, V11, P1225; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; Pauletti G, 1996, ONCOGENE, V13, P63; PETERS GJ, 1993, INT J CANCER, V54, P450, DOI 10.1002/ijc.2910540316; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POLLER DN, 1991, BREAST CANCER RES TR, V20, P3, DOI 10.1007/BF01833351; PRESS MF, 1994, CANCER RES, V54, P5675; QUENEL N, 1995, BREAST CANCER RES TR, V35, P283, DOI 10.1007/BF00665980; QUERZOLI P, 1990, TUMORI, V76, P461, DOI 10.1177/030089169007600508; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; REILE H, 1990, ANAL BIOCHEM, V187, P262, DOI 10.1016/0003-2697(90)90454-H; ROBERT J, 1982, EUR J CANCER CLIN ON, V18, P739, DOI 10.1016/0277-5379(82)90072-4; SABBATINI ARM, 1994, INT J CANCER, V59, P208, DOI 10.1002/ijc.2910590212; SAFFARI B, 1995, CANCER RES, V55, P5693; SCANLON KJ, 1989, ANTICANCER RES, V9, P1301; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SKLAR MD, 1991, CANCER RES, V51, P2118; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SMITH K, 1993, ONCOGENE, V8, P933; STAL O, 1994, CYTOMETRY, V16, P160, DOI 10.1002/cyto.990160210; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; WIERNIK PH, 1987, CANCER RES, V47, P2486; WRIGHT C, 1992, BRIT J CANCER, V65, P271, DOI 10.1038/bjc.1992.54; YONEMURA Y, 1991, CANCER RES, V51, P1034; Yu DH, 1996, ONCOGENE, V13, P1359	73	269	285	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					537	547		10.1038/sj.onc.1201222	http://dx.doi.org/10.1038/sj.onc.1201222			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247307				2022-12-28	WOS:A1997XN25500005
J	Aniskovitch, LP; Jacob, ST				Aniskovitch, LP; Jacob, ST			Distinct rat proteins can recognize CCAAT-homologous sequences of the metallothionein promoter and trans-activate this promoter	ONCOGENE			English	Article						metallothionein-I promoter activation; hepatoma protein; liver protein	ENRICHED TRANSCRIPTIONAL ACTIVATOR; C/EBP-RELATED PROTEINS; BINDING-PROTEIN; GENE FAMILY; CYCLIC-AMP; POU-DOMAIN; FACTOR CP2; I GENE; EXPRESSION; LIVER	We have previously purified and characterized a rat liver protein C'BP-1 that is either identical or closely related to C/EBP delta (Aniskovitch and Jacob, 1997), The mouse metallothionein-I (MT-I) promoter contains two C'BP-1 binding sites, one of which includes the MRE-c' region (-135 to -110). The C'BP-1 binding activity was detected by EMSA as a major activity for MRE-c' in nonproliferating adult liver cells but not in rat hepatoma cells, In this study, we purified and characterized a factor, C'BP-2, which had a dominant binding activity for MRE-c' in Morris hepatoma 3924A, a poorly differentiated, fast-growing tissue, C'BP-2 is a 28 kDa protein which exists in solution as a monomer, As observed for C'BP-1, affinity-purified C'BP-2 stimulated transcription from the mMT-I gene promoter, DNase I footprinting revealed two C'BP-2 binding sites in the regions that overlap with the CCAAT homologies of the C'BP-1 binding sites on the mMT-I promoter, C'BP-2 made essential contacts with the CCAAT homology and in the region upstream of this sequence, Competition electrophoretic mobility shift assay and methylation interference analysis revealed that C'BP-2 is a protein closely related, but not identical, to CP2, These data suggest that C'BP-1 and C'BP-2 may play a role in hepatocyte proliferation and/or differentiation.	Ohio State Univ, Coll Med, Dept Biochem Med, Columbus, OH 43210 USA; Chicago Med Sch, Dept Mol Biol & Pharmacol, N Chicago, IL 60064 USA	Ohio State University; Chicago Medical School	Jacob, ST (corresponding author), Ohio State Univ, Coll Med, Dept Biochem Med, Columbus, OH 43210 USA.		Jacob, Samson/H-3135-2011		NCI NIH HHS [CA 61321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aniskovitch LP, 1997, ARCH BIOCHEM BIOPHYS, V341, P337, DOI 10.1006/abbi.1997.9976; BALDWIN AS, 1988, CURRENT PROTOCOLS MO; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CARTER AD, 1984, P NATL ACAD SCI-BIOL, V81, P7392, DOI 10.1073/pnas.81.23.7392; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DATTA PK, 1993, CELL MOL BIOL RES, V39, P439; Datta PK, 1997, BIOCHEM BIOPH RES CO, V230, P159, DOI 10.1006/bbrc.1996.5655; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DOOLEY S, 1992, BIOTECHNIQUES, V13, P540; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KIM CG, 1988, MOL CELL BIOL, V8, P4270, DOI 10.1128/MCB.8.10.4270; KURL RN, 1985, P NATL ACAD SCI USA, V82, P1059, DOI 10.1073/pnas.82.4.1059; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLFI NF, 1987, P NATL ACAD SCI USA, V84, P3851, DOI 10.1073/pnas.84.11.3851; LIM LC, 1993, J BIOL CHEM, V268, P18008; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; ROSE KM, 1981, ISOZYMES-CURR T BIOL, V5, P115; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SWENDEMAN SL, 1994, J BIOL CHEM, V269, P11663; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	33	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1475	1486		10.1038/sj.onc.1201659	http://dx.doi.org/10.1038/sj.onc.1201659			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525746				2022-12-28	WOS:000072572400011
J	Geurts, JMW; Schoenmakers, EFPM; Roijer, E; Astrom, AK; Stenman, G; van de Ven, WJM				Geurts, JMW; Schoenmakers, EFPM; Roijer, E; Astrom, AK; Stenman, G; van de Ven, WJM			Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas	ONCOGENE			English	Article						NFIB; pleomorphic adenoma of the salivary glands; HMGIC	NUCLEAR FACTOR-I; SALIVARY-GLAND TUMORS; DNA-BINDING; PROTEINS; TRANSCRIPTION; PROMOTER; BREAKPOINT; CARCINOMA; CLONING; LIPOMAS	Approximately 12% of all pleomorphic adenomas of the salivary glands are characterized by chromosome aberrations involving the chromosome segment 12q13-15. Several chromosomes have been found as translocation partners of chromosome 12, and some of these recurrently. Recently, the HMGIC gene was identified as the target gene affected by the 12q13-15 aberrations. Here, me report the identification and characterization of a new translocation partner gene of HMGIC in pleomorphic adenomas, 3'-RACE analysis of a primary adenoma with an apparently normal karyotype revealed an HMGIC fusion transcript containing ectopic sequences derived from the human NFIB gene, previously mapped to chromosome band 9p24.1. The HMGIC NFIB fusion transcript was also confirmed by RT-PCR, Since the chromosome segment 9p12-24 is repeatedly involved as translocation partner of chromosome 12q13-15 in pleomorphic adenomas, we tested whether NFIB might be a recurrent partner of HMGIC, RT-PCR analysis of a second adenoma with an ins(9;12)(p23;q12q15) as the sole anomaly, revealed that also in this tumor an HMGIC/NFIB hybrid transcript was present, The reciprocal NFIB/HMGIC fusion transcript, however, could not be detected in any of these tumors, Nucleotide sequence analysis of the fusion transcripts indicated that the genetic aberration in both tumors resulted in the replacement of a carboxy-terminal segment of HMGIC by the last five amino acids of NFIB. In conclusion, our results reveal the recurrent involvement of the NFIB gene as translocation partner gene of HMGIC in pleomorphic adenomas.	Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, Mol Oncol Lab, B-3000 Louvain, Belgium; Gothenburg Univ, Sahlgrens Hosp, Canc Genet Lab, S-41345 Gothenburg, Sweden	KU Leuven; Sahlgrenska University Hospital; University of Gothenburg	van de Ven, WJM (corresponding author), Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium.							APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; ASHAR HR, 1995, CELL, V82, P57; BULLERDIEK J, 1993, CANCER GENET CYTOGEN, V65, P27, DOI 10.1016/0165-4608(93)90054-P; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Fejzo MS, 1996, GENE CHROMOSOME CANC, V17, P1, DOI 10.1002/(SICI)1098-2264(199609)17:1<1::AID-GCC1>3.0.CO;2-0; Geurts JMW, 1997, CANCER RES, V57, P13; Geurts JMW, 1997, CANCER GENET CYTOGEN, V95, P198, DOI 10.1016/S0165-4608(96)00411-6; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; INOUE T, 1990, J BIOL CHEM, V265, P19065; KAZMIERCZAK B, 1995, CANCER RES, V55, P6038; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NORDKVIST A, 1994, GENE CHROMOSOME CANC, V10, P115, DOI 10.1002/gcc.2870100206; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; QIAN F, 1995, GENOMICS, V28, P66, DOI 10.1006/geno.1995.1107; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; Roijer E, 1996, GENE CHROMOSOME CANC, V17, P166; ROULET E, 1995, MOL CELL BIOL, V15, P5552; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENMAKERS EFPM, 1995, GENOMICS, V29, P665, DOI 10.1006/geno.1995.9952; SCHOENMAKERS EFPM, 1994, GENOMICS, V20, P210, DOI 10.1006/geno.1994.1155; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SHAH JP, 1990, CURR PROB SURG, V27, P779, DOI 10.1016/0011-3840(90)90032-Z; STENMAN G, 1994, CHROMOSOME 12 ABERRA, P3; TIJAN R, 1994, CELL, V77, P5; Tkachenko A, 1997, CANCER RES, V57, P2276; Waldron CA., 1991, SURG PATHOLOGY SALIV, P165; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0; ZORBAS H, 1992, J BIOL CHEM, V267, P8478	36	115	118	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					865	872		10.1038/sj.onc.1201609	http://dx.doi.org/10.1038/sj.onc.1201609			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484777				2022-12-28	WOS:000072053200005
J	Meili, R; Cron, P; Hemmings, BA; Ballmer-Hofer, K				Meili, R; Cron, P; Hemmings, BA; Ballmer-Hofer, K			Protein kinase B/Akt is activated by polyomavirus middle-T antigen via a phosphatidylinositol 3-kinase-dependent mechanism	ONCOGENE			English	Article						middle-T; PI 3-kinase; protein kinase B/Akt; polyomavirus	TUMOR-ANTIGEN; PHOSPHOINOSITIDE 3-KINASE; PHOSPHORYLATION; TRANSFORMATION; ASSOCIATION; PP60C-SRC; BINDING; AKT; PHOSPHATASE-2A; INTERACTS	The middle tumor antigen (middle-T) of mouse polyomavirus is responsible for the transforming potential of this virus, Middle-T has been shown to interact with a variety of cellular proteins known to mediate mitogenic signaling, like phosphatase-2A, Src family kinases, phosphatidylinositol 3-kinase (PI3-kinase), the adapter protein SHC, phospholipase C gamma-1 and 14-3-3 family proteins, Association with SHC and PI 3-kinase, respectively, stimulates two independent signaling pathways that are indispensible for viral oncogenicity. SHC activates the Ras/MAPK pathway via Grb2/SOS resulting in changes in early gene expression, The downstream targets of PI 3-kinase are less well studied but seem to impinge on serum response factor (SRF) which is also involved in regulating early gene expression, Recently, the protein kinase B/Akt (PKB/Akt) has been identified as a target of PI 3-kinase in receptor tyrosine kinase signaling, Here we show that PKB/Akt is a target of wild type middle-T, but not of mutants unable to activate PI 3-kinase, These data were confirmed using inhibitors of PI 3-kinase as well as dominant-negative alleles of the catalytic subunit of this lipid kinase, In addition, mutants of PKB/Akt lacking a pleckstrin homology domain and therefore unable to bind to D3 phospatidylinositides were not activated by middle-T, Taken together these data suggest that middle-T activates PKB/Akt in a PI 3-kinase-dependent manner, Furthermore, direct association with D3 phosphatidylinositides seems to be essential for activation of PKB/Akt.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Ballmer-Hofer, K (corresponding author), Inst Med Radiobiol, CH-5232 Villigen, Switzerland.			Ballmer-Hofer, Kurt/0000-0002-3800-9129				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; COURTNEIDGE SA, 1989, ONCOGENE RES, V4, P75; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dahl J, 1996, MOL CELL BIOL, V16, P2728; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	37	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					903	907		10.1038/sj.onc.1201605	http://dx.doi.org/10.1038/sj.onc.1201605			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484781				2022-12-28	WOS:000072053200009
J	Ulrich, E; Duwel, A; Kauffmann-Zeh, A; Gilbert, C; Lyon, D; Rudkin, B; Evan, G; Martin-Zanca, D				Ulrich, E; Duwel, A; Kauffmann-Zeh, A; Gilbert, C; Lyon, D; Rudkin, B; Evan, G; Martin-Zanca, D			Specific TrkA survival signals interfere with different apoptotic pathways	ONCOGENE			English	Article						survival signals; signal transduction; Akt; TrK	NERVE-GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; PC12 CELLS; ACTIVATION; FIBROBLASTS; RECEPTORS; PROTOONCOGENE; TRANSDUCTION; REQUIREMENT	Survival signalling by ligand-activated tyrosine kinase receptors plays a crucial role in maintaining the balance between cell viability and apoptosis in multicellular organisms. To identify receptor domains and pathways involved in survival signalling, the nerve growth factor receptor TrkA was expressed in Rat-1/MycER(TM) fibroblasts. We demonstrate that wt-TrkA receptor delays c-Myc-, U.V.- and Cycloheximide-induced apoptosis and activates targets such as the mitogen-activated protein kinase (MAPK) Erk2 and the serine/threonine kinase Akt/PKB, both of which have been implicated in survival signalling. TrkA mutated within its SHC binding site (Y490F) delays c-Myc-induced apoptosis without activating endogenous Akt/PKB. In contrast, the TrkA Y490F mutant receptor does not delay U.V.-induced apoptosis whilst TrkA mutated at its PLC-gamma binding site (Y785F) is capable of protecting from apoptosis induced by c-Myc or U.V. treatment. The double mutant TrkA YY490/785FF fails to block either of these two apoptotic stimuli. While PI3-kinase inhibitors LY294002 and Wortmannin competely block survival signalling following U.V. treatment, neither drug affects the ability of TrkA to block c-Myc-induced apoptosis. We show that the Akt/PKB pathway is essential for NGF stimulated TrkA survival signalling in the case of U.V.-induced apoptosis, but that apoptosis induced by c-Myc is also blocked by a novel, Akt/PKB-independent, pathway. These observations suggest that TrkA can activate different survival signalling pathways, which can interfere with specific apoptotic pathways.	Imperial Canc Res Fund Labs, London WC2A 3PX, England; Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain; Ecole Normale Super Lyon, Lab Cell & Mol Biol, Lyon, France	Cancer Research UK; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; Ecole Normale Superieure de Lyon (ENS de LYON)	Evan, G (corresponding author), Imperial Canc Res Fund Labs, 44 Lincolns Inn Fields, London WC2A 3PX, England.			RUDKIN, Brian B./0000-0003-3700-1982				BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CARTER AN, 1992, J BIOL CHEM, V267, P14563; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; D'Mello SR, 1997, J NEUROSCI, V17, P1548; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P4086, DOI 10.1073/pnas.94.8.4086; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Minshall C, 1996, J IMMUNOL, V156, P939; MITRA G, 1991, ONCOGENE, V6, P2237; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; Parrizas M, 1997, J BIOL CHEM, V272, P154; Price BD, 1996, CANCER RES, V56, P246; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SMEYNE RJ, 1994, NATURE, V368, P245; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; Spear N, 1997, J NEUROCHEM, V69, P53; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Virdee K, 1996, J NEUROCHEM, V67, P1801; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127; Zhai S, 1996, EXP CELL RES, V224, P335, DOI 10.1006/excr.1996.0143	44	56	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					825	832		10.1038/sj.onc.1201842	http://dx.doi.org/10.1038/sj.onc.1201842			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484773				2022-12-28	WOS:000072053200001
J	Kleymenova, EV; Yuan, XQ; LaBate, ME; Walker, CL				Kleymenova, EV; Yuan, XQ; LaBate, ME; Walker, CL			Identification of a tumor-specific methylation site in the Wilms tumor suppressor gene	ONCOGENE			English	Article						EcoRI restriction enzyme; rat model; mesothelioma; renal cell carcinoma; leiomyoma/leiomyosarcoma	DNA METHYLATION; MALIGNANT MESOTHELIOMA; HUMAN NEOPLASIA; GROWTH-FACTOR; WT1 GENE; EXPRESSION; CANCER; CELLS; DELETION; RAT	Malignant mesothelioma is one of the very few extrarenal neoplasms in which the Wilms tumor suppressor gene (wt1) is expressed. We examined wt1 for alterations in rat mesotheliomas, a well characterized animal model for the human disease. Southern analysis revealed a 3.5 kb EcoRI wt1 fragment readily detectable in majority of mesothelioma cell lines and primary mesotheliomas but not in normal rat tissues. Cloning and sequencing of this fragment revealed that the presence of this EcoRI fragment resulted from an inability of this enzyme to cut at a EcoRI site in intron 1 of wt1. This site contains potential motifs for cytosine methylation and treatment of mesothelioma cells with 5-azadeoxycytosine restored the normal EcoRI digestion pattern of wt1 in these cells indicating that cleavage was inhibited by methylation at this site. Southern analysis using HpaII/MspI digestion revealed no differences in methylation between mesothelioma cell lines and normal mesothelium at other CpG sites in wt1 5' region. Renal cell carcinoma lines which did not express wt1 were also methylated at this EcoRI site. Our identification of a site frequently methylated in malignant cells, independent of gene expression, provides a new model system to study determinants of site-specific methylation in tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Kleymenova, EV (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA.				NCI NIH HHS [CA63613] Funding Source: Medline; NIEHS NIH HHS [ES06658] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006658] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANTMAN KH, 1993, CANC PRINCIPLES PRAC, P1489; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; BERMUDEZ E, 1990, EXP CELL RES, V190, P91, DOI 10.1016/0014-4827(90)90148-4; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHENG JQ, 1994, CANCER RES, V54, P5547; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWELL JK, 1991, ONCOGENE, V6, P595; CRAIGHEAD JE, 1987, AM J PATHOL, V129, P448; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FREED J, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P317; FUNAKI K, 1991, CANCER RES, V51, P4059; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOWE SR, 1995, AM J PATHOL, V146, P1568; Jones PA, 1996, CANCER RES, V56, P2463; KIKUCHI H, 1992, AM J PATHOL, V140, P781; Kleymenova EV, 1997, MOL CARCINOGEN, V18, P54, DOI 10.1002/(SICI)1098-2744(199701)18:1<54::AID-MC7>3.3.CO;2-U; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIYAGI T, 1993, LEUKEMIA, V7, P970; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; PALEKAR LD, 1988, BIOL INTERACTION INH, P355; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; RAINIER S, 1994, JNCI-J NATL CANCER I, V86, P753, DOI 10.1093/jnci/86.10.753; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; SEKIDO Y, 1995, CANCER RES, V55, P1227; SHARMA PM, 1992, CANCER RES, V52, P6407; SMITH SS, 1991, J MOL BIOL, V217, P39, DOI 10.1016/0022-2836(91)90609-A; WAGNER J C, 1960, Br J Ind Med, V17, P260; WALKER C, 1994, CANCER RES, V54, P3101; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; XIAO S, 1995, ONCOGENE, V11, P511	44	18	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					713	720		10.1038/sj.onc.1201583	http://dx.doi.org/10.1038/sj.onc.1201583			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488035				2022-12-28	WOS:000071931800003
J	Johnston, D; Hatzis, D; Sunday, ME				Johnston, D; Hatzis, D; Sunday, ME			Expression of v-Ha-ras driven by the calcitonin/calcitonin gene-related peptide promoter: a novel transgenic murine model for medullary thyroid carcinoma	ONCOGENE			English	Article						C-cells; RT-PCR; immunohistochemistry; thyroglobulin; cell lineage; dense-core granules	ONCOGENE INDUCES DIFFERENTIATION; CELL LUNG-CANCER; THYROGLOBULIN IMMUNOREACTIVITY; C-CELLS; MICE; PROTEIN; PHEOCHROMOCYTOMAS; TUMORS; ORIGIN; ENTITY	v-Ha-ras has been demonstrated previously to induce neuroendocrine differentiation of medullary thyroid carcinoma (MTC, malignant C cell tumor) cell lines. The potential role of ras mediated signaling in neuroendocrine cells in vivo has been investigated by expressing v-Ha-ras under control of the neural/neuroendocrine specific calcitonin/calcitonin gene-related peptide (CGRP) promoter. Five independent mouse lineages were derived following germ line insertion of the transgene. Four of the five lineages consistently express the transgene; neuroendocrine expression is found in three of the five lineages as both spliced and full length messages. Phenotypically, the mice expressing rascal have shortened lifespans primarily due to the high incidence of MTCs between 6 months to a year of age. C-cell hyperplasia is demonstrated in several mice in the absence of gross evidence of tumor formation. Histopathological and ultrastructural analyses demonstrate typical features of MTCs including prominent immunohistochemical staining for calcitonin and dense-core neurosecretory-type granules. In addition, four of 22 tumors co-express thyroglobulin (a non-neuroendocrine follicular epithelial cell marker) and calcitonin (a neuroendocrine marker) in a subset of the tumor cells. The rascal transgenic mouse provides a unique model for investigating the sequential pathogenesis of MTC and possibly also for elucidating the relationship between MTC and mixed medullary-follicular carcinomas.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Sunday, ME (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.			Sunday, Mary E./0000-0002-6788-1469	NHLBI NIH HHS [R01-HL44984, R01-HL50045] Funding Source: Medline; NICHD NIH HHS [N01-HD02911] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044984, R01HL050045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; BAETSCHER M, 1991, ONCOGENE, V6, P1133; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENNETT MM, 1992, ANN NY ACAD SCI, V657, P36, DOI 10.1111/j.1749-6632.1992.tb22755.x; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BOS JL, 1989, CANCER RES, V49, P4682; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; CUTHBERTSON RA, 1988, LAB INVEST, V58, P484; DAVIS LG, 1986, BASIC METHODS MOL BI, P1; DeLellis RA, 1994, PATHOBIOLOGY AGING R, P285; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; GLASSER SW, 1994, AM J PHYSIOL-LUNG C, V267, pL489, DOI 10.1152/ajplung.1994.267.5.L489; HARVEY M, 1995, CANCER RES, V55, P1146; HOLM R, 1987, LAB INVEST, V57, P258; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KOSTROUCH Z, 1991, ENDOCRINOLOGY, V129, P2202, DOI 10.1210/endo-129-4-2202; KOVACS CS, 1994, CANCER-AM CANCER SOC, V74, P928, DOI 10.1002/1097-0142(19940801)74:3<928::AID-CNCR2820740321>3.0.CO;2-E; LEBLANC B, 1990, VET PATHOL, V27, P445, DOI 10.1177/030098589902700610; LJUNGBERG O, 1985, VET PATHOL, V22, P95, DOI 10.1177/030098588502200201; LJUNGBERG O, 1983, CANCER, V52, P1053, DOI 10.1002/1097-0142(19830915)52:6<1053::AID-CNCR2820520621>3.0.CO;2-Q; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MABRY M, 1989, J CLIN INVEST, V84, P194, DOI 10.1172/JCI114140; MANENTI G, 1994, EUR J CANCER, V30A, P987, DOI 10.1016/0959-8049(94)90130-9; MANGUES R, 1990, ONCOGENE, V5, P1491; MOLEY JF, 1991, CANCER RES, V51, P1596; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; POLAK JM, 1974, HISTOCHEMISTRY, V40, P209, DOI 10.1007/BF00501955; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; SANTELLI G, 1993, CANCER RES, V53, P5523; SCHULZ N, 1992, CANCER RES, V52, P450; SOBRINHOSIMOES M, 1985, ULTRASTRUCT PATHOL, V8, pR3; SUNDAY ME, 1988, ENDOCRINOLOGY, V122, P1551, DOI 10.1210/endo-122-4-1551; SUNDAY ME, 1994, LAB INVEST, V70, P875; SUNDAY ME, 1991, METHODS NEUROSCI, V5, P123; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WILLIAMS ED, 1989, J PATHOL, V159, P135, DOI 10.1002/path.1711590208	39	29	29	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	1998	16	2					167	177		10.1038/sj.onc.1201478	http://dx.doi.org/10.1038/sj.onc.1201478			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464534				2022-12-28	WOS:000071427100003
J	Antelman, D; Perry, S; Hollingsworth, R; Gregory, RJ; Driscoll, B; Fung, YK; Bookstein, R				Antelman, D; Perry, S; Hollingsworth, R; Gregory, RJ; Driscoll, B; Fung, YK; Bookstein, R			Engineered mutants of pRB with improved growth suppression potential	ONCOGENE			English	Article						retinoblastoma; E2F; promoter repression	RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; BLADDER-CARCINOMA CELLS; DNA-BINDING ACTIVITY; SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR; TERMINAL REGION; T-ANTIGEN; RB GENE; DEPENDENT KINASE	We have constructed a panel of substitution mutants which affect one or more of the putative cdk target sites of the RB protein. We have examined the activity of these mutants relative to wild-type RB by both a transcriptional repression assay and by measuring growth suppression in vitro. We find that some phosphorylation site mutants of pRB can repress E2 transcription more strongly than wild-type RB. These mutants are partially resistant to phosphorylation by cdks and can arrest tumor cells in G1 in vitro. Our results indicate a functional correlation between the ability to repress E2F-dependent transcription and the ability to suppress tumor cell growth in vitro. In addition, we describe two classes of RB mutants: N-terminal truncated p56(RB) and a novel mutant of RB containing multiple substitutions near its nuclear localization signal. Both classes of RB mutants have greater activity than the mild-type protein. Because RB is a key regulator of cell cycle progression, expression of a more potent, phosphorylation resistant RB may have utility in both RB(-/-) and RB(+/+) tumors as well as in hyperproliferative disorders.	PHARMACIA & UPJOHN INC,KALAMAZOO,MI 49001; GENZYME INC,FRAMINGHAM,MA; CHILDRENS HOSP LOS ANGELES,DIV OPTHAMOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033	Pfizer; Sanofi-Aventis; Children's Hospital Los Angeles; University of Southern California	Antelman, D (corresponding author), CANJI INC,3030 SCI PK RD,SAN DIEGO,CA 92121, USA.							AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; INOUE A, 1995, J BIOL CHEM, V270, P22571, DOI 10.1074/jbc.270.38.22571; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KITAGAWA M, 1995, ONCOGENE, V10, P229; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MITTNACHT S, 1991, COLD SPRING HARB SYM, V56, P197; OOKAWA K, 1993, ONCOGENE, V8, P2175; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEN SF, 1994, J IMMUNOL METHODS, V169, P231, DOI 10.1016/0022-1759(94)90267-4; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1994, P NATL ACAD SCI USA, V91, P9837, DOI 10.1073/pnas.91.21.9837; Xu HJ, 1996, CANCER RES, V56, P2245; ZHU L, 1994, COLD SPRING HARB SYM, V59, P75, DOI 10.1101/SQB.1994.059.01.011; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	64	8	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2855	2866		10.1038/sj.onc.1201465	http://dx.doi.org/10.1038/sj.onc.1201465			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419977				2022-12-28	WOS:A1997YJ80300012
J	Hu, MCT; Qiu, WR; Wang, YP				Hu, MCT; Qiu, WR; Wang, YP			JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases	ONCOGENE			English	Article						p53; c-Jun kinase; phosphorylation; tumor suppressor protein	TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; JUN ACTIVATION DOMAIN; MAP KINASE; IN-VIVO; PHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; INDUCED APOPTOSIS; CELLS	The function of the tumor suppressor protein p53 is modulated by post-translational events, primarily by phosphorylation. p53 is phosphorylated at multiple sites by a variety of protein kinases depending on the cellular environment. It has been suggested that serine 34 of mouse p53 is specifically phosphorylated by a stress-activated protein kinase in response to ultraviolet radiation. Since serine 34 is a major site of phosphorylation of mouse p53 in vivo and its specific protein kinase is still not definitively identified yet, we have examined the c-Jun N-terminal kinase 1 (JNK1) activity on p53 by expressing JNK1 in 293T cells. We show here that activated JNK1 phosphorylates mouse p53 specifically at serine 34 in vitro, while a dominanant-negative JNK1 mutant does not phosphorylate p53. More importantly, JNK1 associates with p53 in vivo, with or without activation, confirming that JNK1 is indeed a p53 kinase. Interestingly, activated JNK2 and JNK3 also phosphorylate serine 34 of mouse p53. Furthermore, JNK2 and JNK3 also associate with p53 in vivo, indicating that not only JNK1, but also JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Phosphorylation of p53 by JNKs may play an important role in nuclear signal transduction in response to environmental stress or tumorigenic agents.			Hu, MCT (corresponding author), AMGEN INC, DEPT CELL BIOL, THOUSAND OAKS, CA 91320 USA.							ALESSI DR, 1993, ONCOGENE, V8, P2015; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hecker D, 1996, ONCOGENE, V12, P953; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JAMAL S, 1995, ONCOGENE, V10, P2095; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLER E, 1995, ONCOGENE, V10, P1175; MULLER E, 1993, ONCOGENE, V8, P2193; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YANG CL, 1995, CANCER RES, V55, P4210	55	107	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2277	2287		10.1038/sj.onc.1201401	http://dx.doi.org/10.1038/sj.onc.1201401			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393873				2022-12-28	WOS:A1997YE15700003
J	Clark, J; Lu, YJ; Sidhar, SK; Parker, C; Gill, S; Smedley, D; Hamoudi, R; Linehan, WM; Shipley, J; Cooper, CS				Clark, J; Lu, YJ; Sidhar, SK; Parker, C; Gill, S; Smedley, D; Hamoudi, R; Linehan, WM; Shipley, J; Cooper, CS			Fusion of splicing factor genes PSF and NonO (p54(nrb)) to the TFE3 gene in papillary renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; PSF splicing factor; NonO (p54(nrb)) splicing factor; chromosome translocations; TFE3 transcription factor	TUMOR-SUPPRESSOR GENE; ALVEOLAR RHABDOMYOSARCOMA; TRANSLOCATION X-1; BINDING PROTEIN; TRANSCRIPTION; CYTOGENETICS; RNA; BREAKPOINT; SARCOMA; ADENOCARCINOMA	We demonstrate that the cytogenetically defined translocation t(X;1)(p11.2;p34) observed in papillary renal cell carcinomas results in the fusion of the splicing factor gene PSF located at 1p34 to the TFE3 helix-loop-helix transcription factor gene at Xp11.2. In addition we define an X chromosome inversion inv(X)(p11.2;q12) that results in the fusion of the NonO (p54(nrb)) gene to TFE3. NonO (p54(nrb)), the human homologue of the Drosophila gene NonA(diss) which controls the male courtship song, is closely related to PSF and also believed to be involved in RNA splicing. In each case the rearrangement results in the fusion of almost the entire splicing factor protein to the TFE3 DIVA-binding domain. These observations suggest the possibility of intriguing links between the processes of RNA splicing, DNA transcription and oncogenesis.	INST CANC RES, HADDOW LABS, SECT CELL BIOL & EXPT PATHOL, SUTTON SM2 5NG, SURREY, ENGLAND; INST CANC RES, HADDOW LABS, CANC GENE CLONING LAB, SUTTON SM2 5NG, SURREY, ENGLAND; NCI, UROL ONCOL SECT, BETHESDA, MD 20892 USA	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Clark, J (corresponding author), INST CANC RES, HADDOW LABS, SECT MOL CARCINOGENESIS, SUTTON SM2 5NG, SURREY, ENGLAND.			Lu, Yong-Jie/0000-0001-6174-6621; Hamoudi, Rifat/0000-0002-1402-0868; Shipley, Janet/0000-0001-6748-8678				ANGLARD P, 1992, CANCER RES, V52, P348; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; DAVIS RJ, 1994, CANCER RES, V54, P2869; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; DIJKHUIZEN T, 1995, GENE CHROMOSOME CANC, V14, P43, DOI 10.1002/gcc.2870140108; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; ELFVING P, 1995, CYTOGENET CELL GENET, V69, P90, DOI 10.1159/000133945; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; JEON IS, 1995, ONCOGENE, V10, P1229; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P249, DOI 10.1002/gcc.2870030403; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; Mitelman F., 1994, CATALOG CHROMOSOME A; Murphy W, 1994, ATLAS TUMOUR PATHOLO; OHJIMI Y, 1993, CANCER GENET CYTOGEN, V70, P77, DOI 10.1016/0165-4608(93)90136-A; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Savage Paul D., 1994, Current Opinion in Oncology, V6, P301, DOI 10.1097/00001622-199405000-00013; SHIPLEY JM, 1995, CYTOGENET CELL GENET, V71, P280, DOI 10.1159/000134127; SHIPLEY JM, 1993, CYTOGENET CELL GENET, V64, P233, DOI 10.1159/000133585; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; TOMLINSON GE, 1991, CANCER GENET CYTOGEN, V57, P11, DOI 10.1016/0165-4608(91)90184-V; TONK V, 1995, CANCER GENET CYTOGEN, V81, P72, DOI 10.1016/S0165-4608(94)00195-2; VANDENBERG E, 1993, INT J CANCER, V55, P223, DOI 10.1002/ijc.2910550210; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 1996, CYTOGENET CELL GENET, V75, P2, DOI 10.1159/000134444; YANG YS, 1993, MOL CELL BIOL, V13, P5593, DOI 10.1128/MCB.13.9.5593; YOSHIDA AA, 1995, P ANN ASS CANC RES, V26, P31; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	37	242	259	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2233	2239		10.1038/sj.onc.1201394	http://dx.doi.org/10.1038/sj.onc.1201394			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393982	Green Published			2022-12-28	WOS:A1997YD01900012
J	Dirks, PB; Patel, K; Hubbard, SL; Ackerley, C; Hamel, PA; Rutka, JT				Dirks, PB; Patel, K; Hubbard, SL; Ackerley, C; Hamel, PA; Rutka, JT			Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells	ONCOGENE			English	Article						astrocytoma; cyclins; cyclin-dependent kinases; GFAP; retinoic acid; p16; p21	RETINOBLASTOMA PROTEIN; POTENTIAL MEDIATOR; TUMOR SUPPRESSION; GENE-EXPRESSION; MAMMALIAN-CELLS; CDK INHIBITOR; MICE LACKING; P27(KIP1); ARREST; GROWTH	We have characterized the expression and activity of the cell cycle regulatory machinery and the organization of the cytoskeleton of the p16(ink4a)-deficient astrocytoma cell line, U343 MG-a (U343), following retinoic acid (RA) treatment, RA causes cell cycle arrest at low cell density and significant morphological changes in U343 cells, reflected by reorganization of the intermediate filament, GFAP, and actin, RA-induced cell cycle arrest is also associated with induction of p27(Kip1) expression, inhibition of cdk2-associated kinase activity and alteration of the phosphorylation state of the pRB-family proteins, We next determined the effect of inducing expression of the cyclin dependent kinase inhibitors (CKI's), p16(Ink4a), p21(Cip1/Waf1) or p27(Kip1) on the proliferation and morphology of these malignant astrocytoma cells in the absence and presence of RA, Induction of p16, p21 or p27, using the tetracycline repressor system, potently inhibits proliferation of U343 cells, However, rather than resembling RA-treated cells, CKI-induced U343 cells become flat with abundant cytoplasm and perinuclear vacuolization, CKI-induced morphological alterations are accompanied by a significant reorganization of glial filaments within the cytoplasm, Interestingly, when U343 cells are arrested by p16, p21 or p27 induction and with RA, a dramatic morphological cells acquiring multiple long, tapering processes reminiscent of primary astrocytes, This rearrangement is accompanied by reorganization of GFAP, vimentin and actin, Vimentin specifically relocalizes to the tips of the long processes which form, The arrangement of intermediate filaments in these cells is, in fact, indistinguishable from their arrangement in primary human astrocytes, These data demonstrate that when a strong proliferative block, produced by CKI expression, occurs in conjunction with the morphogenic signals generated by RA, these p16-deficient malignant astrocytoma cells are induced to phenotypically resemble normal astrocytes.	HOSP SICK CHILDREN,DIV NEUROSURG,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Ichimura K, 1996, ONCOGENE, V13, P1065; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LIU L, 1995, ONCOGENE, V11, P405; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGLIARO LC, 1995, CELL GROWTH DIFFER, V6, P673; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RUTKA JT, 1988, INT J CANCER, V53, P3634; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WALDMAN T, 1995, CANCER RES, V55, P5187; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6	41	53	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2037	2048		10.1038/sj.onc.1201392	http://dx.doi.org/10.1038/sj.onc.1201392			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366521				2022-12-28	WOS:A1997YC28400005
J	Sakamoto, Y; Yoshida, M; Semba, K; Hunter, T				Sakamoto, Y; Yoshida, M; Semba, K; Hunter, T			Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain	ONCOGENE			English	Article						tumor suppressor gene; phosphorylation; transcription factor; DNA binding	FACTOR-A-CHAIN; GROWTH-FACTOR; SUPPRESSOR GENE; KIDNEY DEVELOPMENT; MOLECULAR-CLONING; UROGENITAL SYSTEM; MAMMALIAN-CELLS; EXPRESSION; SITE; RECOGNITION	The Wilms' tumor suppressor gene, WT1, encodes a transcription factor in the zinc finger family, which binds to GC-rich sequences and functions as a transcriptional activator or repressor, The WT1 protein plays a crucial role in urogenital development in mammals and its function is thought to be conserved during vertebrate evolution, Although accumulating evidence suggests that WT1 regulates a subset of genes including growth factor and growth factor receptor genes, little is known about regulators or signal cascades that could modulate the function of WT1, In this study, we show that the WT1 protein expressed exogenously in fibroblasts was phosphorylated in vivo, and that treatment with forskolin, which activates the cAMP-dependent protein kinase (PKA) in vivo, induced phosphorylation of additional sites in WT1, We identified the forskolin-induced phosphorylation sites as Ser-365 and Ser-393, which lie in the zinc finger domain in zinc fingers 2 and 3, respectively, PKA phosphorylated WT1 at Ser-365 and Ser-393 in vitro, as well as at additional sites, and this phosphorylation abolished the DNA-binding activity of WT1 in vitro. Using WT1 mutants in which Ser-365 and Ser-393 were mutated to Ala individually and in combination, we showed that phosphorylation of these sites was critical for inhibition of DNA binding in vivo, Thus, coexpression of the PKA catalytic subunit with wild type WT1 reduced the level of WT1 DNA-binding activity detected in nuclear extracts, and decreased transcriptional repression activity in vivo, In contrast to wild type WT1, all of the phosphorylation site mutants retained significant DNA-binding activity and repression activity in the presence of PKA, Analysis of the mutants showed that phosphorylation of Ser-365 and Ser-395 had additive inhibitory effects on WT1 DNA-binding in vivo and that phosphorylation at both sites was required for neutralization of repression activity, Therefore, we conclude that PKA modulates the activity of WT1 in vivo through phosphorylation of Ser-365 and Ser-393, which inhibits DNA binding, This in turn results in a decrease in WT1 transcriptional repression, Our findings provide the first evidence that the function of WT1 can be modulated by its phosphorylation in vivo.	SALK INST BIOL STUDIES, MOL BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV TOKYO, INST MED SCI, DEPT CELLULAR & MOL BIOL, MINATO KU, TOKYO 108, JAPAN	Salk Institute; University of Tokyo					NCI NIH HHS [CA39760, CA14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Algar EM, 1996, ONCOGENE, V12, P1005; ALOI JA, 1995, ENDOCRINOLOGY, V136, P1227, DOI 10.1210/en.136.3.1227; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1985, DNA CLONING PRACTICA; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HEWITT SM, 1995, CANCER RES, V55, P5386; HSU SY, 1995, MOL ENDOCRINOL, V9, P1356, DOI 10.1210/me.9.10.1356; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kennedy D, 1996, NAT GENET, V12, P329, DOI 10.1038/ng0396-329; KENT J, 1995, ONCOGENE, V11, P1781; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Menke AL, 1996, ONCOGENE, V12, P537; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P29976; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; Semba K, 1996, GENE, V175, P167, DOI 10.1016/0378-1119(96)00143-6; SHARMA PM, 1994, P NATL ACAD SCI USA, V91, P9931, DOI 10.1073/pnas.91.21.9931; SHARMA PM, 1992, CANCER RES, V52, P6407; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1994, J BIOL CHEM, V269, P12577; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x	59	48	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	1997	15	17					2001	2012		10.1038/sj.onc.1201391	http://dx.doi.org/10.1038/sj.onc.1201391			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366517				2022-12-28	WOS:A1997YC28400001
J	Shiohara, M; Gombart, AF; Berman, JD; Koike, K; Komiyama, A; Koeffler, HP				Shiohara, M; Gombart, AF; Berman, JD; Koike, K; Komiyama, A; Koeffler, HP			Cytostatic effect of TNF alpha on cancer cells is independent of p21(WAF1)	ONCOGENE			English	Article						ME180; p21(WAF1); TNF alpha; antisense	TUMOR-NECROSIS-FACTOR; CYCLIN-DEPENDENT KINASES; NF-KAPPA-B; MANGANOUS SUPEROXIDE-DISMUTASE; HUMAN LEUKEMIC-CELLS; POSTTRANSCRIPTIONAL STABILIZATION; P53-INDEPENDENT INDUCTION; TERMINAL DIFFERENTIATION; INHIBITOR P21; G(1) ARREST	Tumor necrosis factor alpha (TNF alpha) is a cytotoxic/cgtostatic compound for a variety of human cancer cells. The p21(WAF1) protein is a cyclin-dependent kinase inhibitor (CDKI) that binds to cyclin/cyclin-dependent kinase (CDK) complexes and inhibits their kinase activities, thereby leading to cell cycle arrest. We found that the cytostatic effect of TNF alpha on the cervical cancer cell line, ME180, was concomitant with an arrest of these cells in the G0/G1 phase of the cell-cycle. This corresponded with an increase in both p21(WAF1) mRNA and protein levels which likely occurred via a p53-independent pathway since ME180 is infected with the human papilloma virus. To elucidate the role of p21(WAF1) in the TNF alpha-mediated growth and cell cycle arrest, we stably transformed ME180 cells with an antisense p21(WAF1)- expression vector. Two clones with reduced levels of p21(WAF1) both in their basal state as well as after their exposure to TNF alpha were selected. The growth of these cells was still inhibited by TNF alpha and they arrested in G0/G1 similar to wildtype or empty vector transfected cells. These results indicate that although p21(WAF1) expression increases dramatically with TNF alpha treatment, it may not play a critical role in the cytostatic effect of TNF alpha on ME180 cervical cancer cells.	SHINSHU UNIV, SCH MED, DEPT PEDIAT, MATSUMOTO, NAGANO 390, JAPAN	Shinshu University	Shiohara, M (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, CEDARS SINAI RES INST, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90048 USA.				NCI NIH HHS [CA26038, CA42710] Funding Source: Medline; NIDDK NIH HHS [DK42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710, R01CA026038, P30CA042710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elstner E, 1997, J CLIN INVEST, V99, P349, DOI 10.1172/JCI119164; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; Gorospe M, 1996, CANCER RES, V56, P475; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUO K, 1995, MOL CELL BIOL, V15, P3823; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HERZOG TJ, 1992, CYTOKINE, V4, P214, DOI 10.1016/1043-4666(92)90058-Y; HIRAMA T, 1995, BLOOD, V86, P841; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LI Y, 1994, ONCOGENE, V9, P2261; MANCHESTER KM, 1993, BIOCHEM J, V290, P185, DOI 10.1042/bj2900185; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; ROSENBLUM MG, 1989, CRIT REV IMMUNOL, V9, P21; Sambrook J, 1989, MOL CLONING; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SRIVASTAVA S, 1992, CARCINOGENESIS, V13, P1273, DOI 10.1093/carcin/13.7.1273; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang QM, 1996, CANCER RES, V56, P264; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG W, 1995, CANCER RES, V55, P668	50	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1605	1609		10.1038/sj.onc.1201315	http://dx.doi.org/10.1038/sj.onc.1201315			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380413				2022-12-28	WOS:A1997XX36900012
J	Berns, K; Hijmans, EM; Bernards, R				Berns, K; Hijmans, EM; Bernards, R			Repression of c-Myc responsive genes in cycling cells causes G(1) arrest through reduction of cyclin E CDK2 kinase activity	ONCOGENE			English	Article						c-Myc; cell cycle; cyclin; CDK	ORNITHINE DECARBOXYLASE GENE; RETINOBLASTOMA-PROTEIN; DEPENDENT KINASES; EPIDERMAL DIFFERENTIATION; TRANSCRIPTIONAL REPRESSOR; ONCOGENIC ACTIVITY; MESSENGER-RNA; IN-VIVO; S-PHASE; MAX	The c-myc gene encodes a sequence-specific DNA binding protein involved in proliferation and oncogenesis. Activation of c-myc expression in quiescent cells is sufficient to mediate cell cycle entry, whereas inhibition of c-myc expression causes cycling cells to withdraw from the cell cycle. To search for components of the cell cycle machinery that are targets of c-Myc, we have made a mutant c-Myc protein, named MadMyc, that actively represses c-myc target genes. Expression of MadMyc in cycling NIH3T3 cells causes a significant accumulation of cells in G(1). The MadMyc-induced G(1) arrest is rescued by ectopic expression of cyclin E/CDK2 and cyclin D1/ CDK4, but not by Cdc25A, a known cell cycle target of c-Myc. The MadMyc G(1) arrest does not require the presence of a functional retinoblastoma protein and is associated with a strong reduction in cyclin E/CDK2 kinase activity in arrested cells. MadMyc does not cause alterations in the expression levels of cyclin E, CDK2, p27(kip1), cyclin DI or CDK4 in G(1)-arrested cells. These data indicate that inhibition of c-Myc activity in exponentially growing cells leads to G(1) arrest through loss of cyclin E-associated kinase activity.	NETHERLANDS CANC INST,DIV MOL CARCINOGENESIS,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Bernards, Rene/0000-0001-8677-3423				ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CERNI C, 1995, ONCOGENE, V11, P587; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GORUPPI S, 1994, ONCOGENE, V9, P1537; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1995, ONCOGENE, V11, P1409; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KELLY K, 1983, CELL, V35, P600; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Marhin WW, 1996, ONCOGENE, V12, P43; Mayol X, 1996, ONCOGENE, V13, P237; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; THOMPSON CR, 1986, NATURE, V314, P363; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wu SJ, 1996, ONCOGENE, V12, P621; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	67	95	97	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1347	1356		10.1038/sj.onc.1201280	http://dx.doi.org/10.1038/sj.onc.1201280			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315103	Green Published			2022-12-28	WOS:A1997XV84500013
J	Kondo, T; Minamino, N; NagamuraInoue, T; Matsumoto, M; Taniguchi, T; Tanaka, N				Kondo, T; Minamino, N; NagamuraInoue, T; Matsumoto, M; Taniguchi, T; Tanaka, N			Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity	ONCOGENE			English	Article						IRF-1; NPM; tumor suppressor; human cancers	REGULATORY FACTOR-I; IFN-BETA-GENE; NUCLEAR FACTOR; DNA-DAMAGE; EXPRESSION; PROTEINS; LEUKEMIA; GROWTH; P53; TRANSFORMATION	Interferon regulatory factor-1 (IRF-1) acts as a transcriptional activator in the interferon system and as a tumor suppressor. The loss of functional IRF-1 has been observed in a significant number of patients with myelodysplastic syndrome (MDS) and leukemia, suggesting a potentially critical role of IRF-1 in human oncostasis. Here we report an alternative mechanism by which IRF-1 may be inactivated. We purified an IRF-1 association molecule which was revealed to be identical to a nuclear factor nucleophosmin (NPM)/B23/numatrin. Functional analysis showed that NPM inhibited the DNA-binding and transcriptional activity of IRF-1. Moreover, NPM was overexpressed in several clinical leukemia samples and human-derived leukemia cell lines. Finally, overexpression of NPM in NIH3T3 cells resulted in malignant transformation. These results suggest the possible involvement of NPM in inactivating IRF-1-dependent anti-oncogenic surveillance in human cancer development.	UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; NATL CARDIOVASC CTR,RES INST,SUITA,OSAKA 565,JAPAN	University of Tokyo; National Cerebral & Cardiovascular Center - Japan			Kondo, Takeshi/G-2103-2012	Kondo, Takeshi/0000-0001-7455-5824; Tanaka, Nobuyuki/0000-0002-6373-2220				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BENETT JM, 1985, ANN INTERN MED, V103, P626; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; LEBEAU MM, 1989, CANCER CEL, V7, P53; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NAKANO H, 1994, NUCLEIC ACIDS RES, V22, P543, DOI 10.1093/nar/22.3.543; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PETRICOIN E, 1994, MOL CELL BIOL, V14, P1477, DOI 10.1128/MCB.14.2.1477; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tan RSP, 1996, CANCER RES, V56, P2417; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIEBEL F, 1969, J CELL PHYSIOL, V74, P191, DOI 10.1002/jcp.1040740211; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	39	152	159	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1275	1281		10.1038/sj.onc.1201286	http://dx.doi.org/10.1038/sj.onc.1201286			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315094				2022-12-28	WOS:A1997XV84500004
J	Hamilton, M; Wolfman, A				Hamilton, M; Wolfman, A			Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo	ONCOGENE			English	Article						Ras; Raf-1; MAPK; cell proliferation	ACTIVATED PROTEIN-KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; SIGNAL-TRANSDUCTION PATHWAY; GROWTH-FACTOR; MAMMALIAN-CELLS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; V-RAF; B-RAF; K-RAS	The Ras GTPases function as molecular switches, regulating a multiplicity of biological events, However the contribution, if any, of a specific c-Ras isoform (Ha-, N-, or Ki-ras A or B) in the regulation of a given biological or biochemical process, is unknown, Murine C3H10T1/2 fibroblasts transformed with activated (G12V)Ha-ras or (Q61K)N-ras proliferate in serum-free media and have constitutive MAPK activity, The growth factor antagonist, suramin, inhibited the serum-independent proliferation of Ha-ras transformed fibroblasts, but not the serum-independent proliferation of N-ras transformed cells. The inhibition of cell proliferation was concomitant with the abrogation of the constitutive MAPK activity in the Ha-ras transformed fibroblasts, Analysis of the Ras-signalling complexes in immunoprecipitates from Ha-ras transformed cells revealed that Raf-1 co-immunoprecipitated with endogenous c-N-ras but not (G12V)Ha-ras. Pretreatment with suramin resulted in the loss of Raf-1 from c-N-ras immunoprecipitates, A c-N-ras antisense oligonucleotide, which down-regulated c-N-ras protein levels, abrogated the constitutive MAPK activity and serum-independent proliferation of (G12V)Ha-ras transformed cells, The data suggest that Raf-1 has a higher affinity for N-ras then Ha-ras in vivo, and c-N-ras function is required for the serum-independent proliferation of Ha-ras transformed cells.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hamilton, M (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM049652, R01GM049652] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49652] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berkowitz EA, 1996, ONCOGENE, V12, P1991; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; CARBONE A, 1991, ONCOGENE, V6, P731; CASTELLI C, 1994, CANCER RES, V54, P4785; COX AD, 1995, METHOD ENZYMOL, V255, P195; CREWS CM, 1993, CELL, V55, P915; DAWSON TP, 1995, CANCER RES, V55, P915; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; DIBATTISTE D, 1993, ONCOGENE, V8, P637; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KEHINDE EO, 1995, CANCER SURV, V23, P217; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1990, ONCOGENE, V5, P713; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MAHER J, 1995, ONCOGENE, V11, P1639; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MOODIE SA, 1995, ONCOGENE, V11, P447; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OKUDA K, 1994, J BIOL CHEM, V269, P24602; OLDHAM SM, 1996, P NATL ACAD SCI USA, V93, P6294; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PIRONIN M, 1992, INT J CANCER, V51, P980, DOI 10.1002/ijc.2910510624; RAK J, 1995, CANCER RES, V55, P4575; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	58	61	62	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1417	1428		10.1038/sj.onc.1201653	http://dx.doi.org/10.1038/sj.onc.1201653			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525741				2022-12-28	WOS:000072572400006
J	Sanchez-Perez, I; Murguia, JR; Perona, R				Sanchez-Perez, I; Murguia, JR; Perona, R			Cisplatin induces a persistent activation of JNK that is related to cell death	ONCOGENE			English	Article						cisplatin; JNK1; phosphatases; DNA damage	TERNARY COMPLEX-FORMATION; C-JUN; PROTEIN-KINASE; PLATINUM(II) COMPOUNDS; OXIDATIVE STRESS; GAMMA-RADIATION; MAP-KINASES; DNA; PHOSPHORYLATION; APOPTOSIS	Genotoxic stress triggers signalling pathways that either mediate cell killing or protection of affected cells. While induction of p53 is observed for most of the genotoxins, activation of MAPK/SAPK cascades is not a general response. The role of MAPK/SAPK activation on cell fate, seems to be dependent, in some systems, on the balanced response among both cascades. We have here examined the effect of cis and trans-DDP on the activation of ERK and JNK activities. While no significant induction of ERK was observed with the compounds, both of them are able to strongly activate JNK. Trans-DDP response is rapid and transient while the cis-DDP one is slow and persistent. In contrast with the observed nuclear translocation of JNK in response to U.V. light, none of the platinum compounds induces translocation, on the contrary, activation of JNK occurs in both the nuclear and cytoplasmic compartments, Inhibition of tyrosine phosphatases by orthovanadate pretreatment prolongs the time of JNK induction in response to both platinum compounds, The positive modulation of JNK activation correlates with an increase in toxicity that, for cis-DDP corresponds to a tenfold decrease in the IC50. A strong increase in MKP-1 levels was observed only in response to trans-DDP suggesting the involvement of this activity in the downregulation of JNK activity in response to this compound, Altogether the results suggest that the prolonged activation of JNK in response to cis-DDP contributes to cell death induction.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Perona, R (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Sánchez-Pérez, Isabel/R-4107-2016; Murguia, Jose R./H-4419-2015	Sánchez-Pérez, Isabel/0000-0002-4829-201X; Murguia, Jose R./0000-0001-9364-4603				ALAZARD R, 1982, MUTAT RES, V93, P327, DOI 10.1016/0027-5107(82)90148-8; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P6058; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KASTAN MB, 1991, CANCER RES, V51, P6304; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; PASCOE JM, 1974, BIOCHEM PHARMACOL, V23, P1345, DOI 10.1016/0006-2952(74)90354-2; PINTO AL, 1985, P NATL ACAD SCI USA, V82, P4616, DOI 10.1073/pnas.82.14.4616; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; WANG HG, 1994, ONCOGENE, V9, P2751; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	52	216	222	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	1998	16	4					533	540		10.1038/sj.onc.1201578	http://dx.doi.org/10.1038/sj.onc.1201578			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484843				2022-12-28	WOS:000071739400012
J	Vande Pol, SB; Brown, MC; Turner, CE				Vande Pol, SB; Brown, MC; Turner, CE			Association of Bovine Papillomavirus Type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif	ONCOGENE			English	Article						integrin; transformation; cytoskeleton; phosphotyrosine	TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; BINDING PROTEIN; CELLS; IDENTIFICATION; KINASE; EXPRESSION; VINCULIN; SYSTEM; GENE	We have found that the E6 oncoprotein of Bovine Papillomavirus Type 1 (BE6) as well as the E6 protein of the cancer associated HPV-16 (16E6) interact with the focal adhesion protein paxillin. Mutational analysis of paxillin revealed that BE6 binds paxillin through small protein interaction motifs called LD motifs that have been previously identified as important in regulating association of paxillin with vinculin and focal adhesion kinase (FAK), and that BE6 can interact with at least two separate binding sites on paxillin. The LD motifs of paxillin that bind BE6 share homology with the E6 binding site of E6-AP, a ubiquitin ligase that together with 16E6 targets the degradation of the p53 tumor suppressor. Paxillin binding to BE6 excludes simultaneous binding to E6-AP. Mutational analysis of BE6 can distinguish the interaction of BE6 with E6-AP compared to paxillin and revealed that the interaction of BE6 with paxillin may be necessary for the induction of anchorage independent growth of cells by BE6.	Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; SUNY Syracuse, Dept Anat & Cell Biol, Syracuse, NY USA	Case Western Reserve University; State University of New York (SUNY) System	Vande Pol, SB (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA.		Pol, Scott Vande/AAO-1068-2020	Pol, Scott Vande/0000-0002-0587-4802	NATIONAL CANCER INSTITUTE [R29CA069292, R01CA069292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607, R29GM047607] Funding Source: NIH RePORTER; NCI NIH HHS [CA69292, R29 CA069292] Funding Source: Medline; NIGMS NIH HHS [GM47607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HARLOW E, 1990, CIBA F SYMP, V150, P262; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Howley P M, 1991, Princess Takamatsu Symp, V22, P239; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; MEYERS C, 1992, J VIROL, V66, P1655, DOI 10.1128/JVI.66.3.1655-1664.1992; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Moore DD, 1995, GLOB MOB SURV; Ned R, 1997, J VIROL, V71, P4866, DOI 10.1128/JVI.71.6.4866-4870.1997; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SIKORSKI RS, 1989, GENETICS, V122, P19; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Trujillo JM, 1996, VIROLOGY, V220, P1, DOI 10.1006/viro.1996.0279; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VANDEPOL SB, 1995, J VIROL, V69, P395, DOI 10.1128/JVI.69.1.395-402.1995; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOOD CK, 1994, J CELL SCI, V107, P709; YAN MH, 1994, J BIOL CHEM, V269, P19067; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030	54	114	117	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	1998	16	1					43	52		10.1038/sj.onc.1201504	http://dx.doi.org/10.1038/sj.onc.1201504			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467941				2022-12-28	WOS:000071236800005
J	Huguet, C; Crepieux, P; Laudet, V				Huguet, C; Crepieux, P; Laudet, V			Rel/NF-kappa B transcription factors and I kappa B inhibitors: Evolution from a unique common ancestor	ONCOGENE			English	Article						ankyrin repeat protein; rel homology domain; NF-AT; molecular phylogeny	CANDIDATE PROTOONCOGENE BCL-3; CHICKEN SPLEEN-CELLS; DNA-BINDING SUBUNIT; C-REL; PROTO-ONCOGENE; GENE FAMILY; V-REL; FUNCTIONAL-CHARACTERIZATION; SIGNAL-TRANSDUCTION; PRECURSOR P105	From the sequences of Rel/NF-kappa B and I kappa B proteins, we constructed an alignment of their Rel Homology Domain (RHD) and ankyrin repeat domain, Using this alignment, we performed tree reconstruction with both distance matrix and parsimony analysis and estimated the branching robustness using bootstrap resampling methods, We defined four subfamilies of Rel/NF-kappa B transcription factors: (i) cRel, RelA, ReLB, Dorsal and Dif; (ii) NF-kappa B1 and NF-kappa B2; (iii) Relish and (iv) NF-AT factors, the most divergent members, Subfamilies I and II are clustered together whereas Relish diverged earlier than other Rel/NF-kappa B proteins, Three subfamilies of I kappa B inhibitors were also defined: (i) NF-kappa B1 and NF-kappa B2; (ii) close to subfamily I, the short I kappa B proteins I kappa B alpha. I kappa B beta and Bcl-3; (iii) Relish that diverged earlier than other I kappa B inhibitors, Our definition of groups and subfamilies fits to structural and functional features of the Rel/NF-kappa B and I kappa B proteins, We also showed that ankyrin repeats of NF-kappa B1, NF-kappa B2 and Relish are short I kappa B-specific ankyrin motifs. These proteins defining a link between Rel/NF-kappa B and I kappa B families, we propose that all these factors evolved from a common ancestral RHD-ankyrin structure within a unique superfamily, explaining the specificities of interaction between the different Rel/NF-kappa B dimers and the various I kappa B inhibitors.	INST BIOL LILLE,IFR3,UMR319,LAB MECANISMES DEV & CANCERISAT,F-59021 LILLE,FRANCE; INST BIOL LILLE,IFR3,LAB REGULAT PROC INVAS ANGIOGENESE & APOPTOSE,EP560,F-59021 LILLE,FRANCE				Crepieux, Pascale/X-3217-2019					ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BIRKENMEIER CS, 1993, J BIOL CHEM, V268, P9533; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWNELL E, 1989, ONCOGENE, V4, P935; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; Chytil M, 1996, CURR OPIN STRUC BIOL, V6, P91, DOI 10.1016/S0959-440X(96)80100-X; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DUBREUIL RR, 1994, P NATL ACAD SCI USA, V91, P10285, DOI 10.1073/pnas.91.22.10285; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Fryxell KJ, 1996, TRENDS GENET, V12, P364, DOI 10.1016/S0168-9525(96)80020-5; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Gilmore TD, 1996, ONCOGENE, V13, P1367; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; Heron E, 1995, GENOMICS, V30, P493, DOI 10.1006/geno.1995.1270; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HILLIS DM, 1992, J HERED, V83, P189, DOI 10.1093/oxfordjournals.jhered.a111190; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Huguet C, 1994, Cell Death Differ, V1, P71; IKEDA T, 1993, GENE, V133, P237, DOI 10.1016/0378-1119(93)90645-J; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; ITO CY, 1995, GENOMICS, V29, P490, DOI 10.1006/geno.1995.9977; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; Kumar S., 1993, MEGA MOL EVOLUTIONAR; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; MULLER CW, 1996, NATURE STRUCTURE BIO, V3, P244; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1993, ONCOGENE, V8, P2275; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Suyang H, 1996, MOL CELL BIOL, V16, P5444; SUZUKI K, 1995, NUCLEIC ACIDS RES, V23, P4664, DOI 10.1093/nar/23.22.4664; SWOFFORD DL, 1991, PHYLOGENETICAL ANAL; TANNAHILL D, 1995, INT J DEV BIOL, V39, P549; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	81	47	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2965	2974		10.1038/sj.onc.1201471	http://dx.doi.org/10.1038/sj.onc.1201471			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416840				2022-12-28	WOS:A1997YK37700009
J	Palecek, E; Vlk, D; Stankova, V; Brazda, V; Vojtesek, B; Hupp, TR; Schaper, A; Jovin, TM				Palecek, E; Vlk, D; Stankova, V; Brazda, V; Vojtesek, B; Hupp, TR; Schaper, A; Jovin, TM			Tumor suppressor protein p53 binds preferentially to supercoiled DNA	ONCOGENE			English	Article						DNA-protein interaction; scanning force microscopy; SFM; p53 protein-DNA complexes; supercoiled DNA; wild type human and rat p53 proteins	C-TERMINAL DOMAIN; WILD-TYPE; COMPLEXES; DAMAGE; SITE	Wild type human tumor suppressor protein p53 (expressed in insect cells) binds strongly to negatively supercoiled (sc) plasmid DNA at a native superhelix density, as evidenced by electrophoretic retardation of scDNA in agarose gels and imaging by scanning force microscopy (SFM), The binding occurs both in the presence and absence of the p53 consensus sequence, At relatively low p53/DNA ratios, binding of p53 to scDNA results in the appearance of several retarded DNA bands on the gels, similar to a conventional topoisomer ladder generated enzymatically, :However, after removal of p53 by deproteination, the original mobility of the scDNA is recovered, indicating that the reduction of torsional stress accompanying p53 binding does not reflect changes in linking number, In DNA samples partially relaxed by topoisomerase I p53 binds preferentially to the scDNA molecules with the largest negative superhelix density, SFM imaging of the p53/scDNA complex reveals a partial or total relaxation of the compact scDNA, the degree of which increases with the number of bound p53 molecules, Competition assays with linear DNA reveal a preference of p53 for scDNA, In addition, scDNA induces dissociation of p53 from a preformed complex with a DNA fragment (474 bp) containing the consensus sequence, We conclude that the affinity of p53 for negatively supercoiled DNA is greater than that for the consensus sequence in linear fragments, However, thermally denatured linearized plasmid DNA is efficient in competing for the binding of p53 to scDNA, although the first retarded band (presumed to contain one bound p53 molecule) is retained in the case of the plasmid containing the consensus sequence, Thus, it appears that interactions involving both the core domain and the C-terminal domain regulate the binding of p53 to scDNA, The above results are not restricted to human p53; the wild type rat p53 protein also results in the retardation of scDNA on agarose gels, The biological implications of the novel DNA binding activities of p53 are discussed.	MASARYK MEM CANC INST, CR-65653 BRNO, CZECH REPUBLIC; UNIV DUNDEE, DEPT PATHOL, DUNDEE DD1 4HN, SCOTLAND; MAX PLANCK INST BIOPHYS CHEM, DEPT MOL BIOL, D-37070 GOTTINGEN, GERMANY	Masaryk Memorial Cancer Institute; University of Dundee; Max Planck Society	Palecek, E (corresponding author), ACAD SCI CZECH REPUBL, INST BIOPHYS, KRALOVOPOLSKA 135, CR-61265 BRNO, CZECH REPUBLIC.		Palecek, Emil/C-1075-2013; Brazda, Vaclav/ABH-9460-2020; Vlk, Daniel/A-1413-2014; Václav, Brázda/F-9582-2011	Palecek, Emil/0000-0003-2561-8336; Brazda, Vaclav/0000-0003-2837-4226; Václav, Brázda/0000-0003-2837-4226				ANDERSON ME, 1995, BIOESSAYS, V17, P3, DOI 10.1002/bies.950170103; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; CHEN D, 1994, NUCL ACIDS MOL BIOL, V8, P147; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK DN, 1994, NUCL ACIDS MOL BIOL, V8, P133; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; HALL AR, 1995, ONCOGENE, V10, P561; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Muller BF, 1996, ONCOGENE, V12, P1941; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; Pfannschmidt C, 1996, NUCLEIC ACIDS RES, V24, P1702, DOI 10.1093/nar/24.9.1702; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAPER A, 1994, FEBS LETT, V355, P91, DOI 10.1016/0014-5793(94)01166-4; SCHAPER A, 1996, PROCEDURES SCANNING; SCHAPER A, 1997, UNPUB; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	34	76	76	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2201	2209		10.1038/sj.onc.1201398	http://dx.doi.org/10.1038/sj.onc.1201398			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393978				2022-12-28	WOS:A1997YD01900008
J	Yasuhara, N; Sahara, S; Kamada, S; Eguchi, Y; Tsujimoto, Y				Yasuhara, N; Sahara, S; Kamada, S; Eguchi, Y; Tsujimoto, Y			Evidence against a functional site for Bcl-2 downstream of caspase cascade in preventing apoptosis	ONCOGENE			English	Article						apoptosis; bcl-2; bcl-x; caspase; ICE; CPP32; Fas; signal transduction	FAS-MEDIATED APOPTOSIS; PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; MITOCHONDRIAL-MEMBRANES; CYSTEINE PROTEASE; ACTIVATION; EXPRESSION; NUCLEAR; LOCALIZATION; ONCOPROTEIN	Apoptotic cell death is driven by ICE family proteases (caspases) and negatively regulated by Bcl-2 family proteins. Although it has been shown that Bcl-2 exerts anti-apoptotic activity by blocking a step(s) leading to the activation of caspases, a role for Bcl-2 and Bcl-x(L) downstream of the caspase cascade has remained unclear. Here, we show that purified active caspase-3 (CPP32/Yama/apopain) and caspase-1 (ICE) induces apoptosis when microinjected into the cytoplasm of cells, confirming our recent observations, and that the apoptosis is not at all prevented by Bcl-2 and Bcl-x(L), which are overexpressed more than sufficiently to prevent Fas-mediated and overexpressed procaspase-1-mediated apoptosis. Thus, Bcl-2 and Bcl-x(L) do not act downstream of the caspase cascade.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT MED GENET,SUITA,OSAKA 565,JAPAN	Osaka University								AKAO Y, 1994, CANCER RES, V54, P2468; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Boulakia CA, 1996, ONCOGENE, V12, P529; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CLEM RJ, 1994, APOPTOSIS, V2, P89; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Hasegawa J, 1996, CANCER RES, V56, P1713; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Kamada S, 1997, CELL DEATH DIFFER, V4, P473, DOI 10.1038/sj.cdd.4400268; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Marin MC, 1996, ONCOGENE, V12, P2259; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATSUOKA Y, 1994, J CELL SCI, V107, P693; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2251; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUSIN SA, 1996, J EXP MED, V184, P1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	41	26	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1921	1928		10.1038/sj.onc.1201370	http://dx.doi.org/10.1038/sj.onc.1201370			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365238				2022-12-28	WOS:A1997YA87200006
J	Kitanaka, C; Namiki, T; Noguchi, K; Mochizuki, T; Kagaya, S; Chi, S; Hayashi, A; Asai, A; Tsujimoto, Y; Kuchino, Y				Kitanaka, C; Namiki, T; Noguchi, K; Mochizuki, T; Kagaya, S; Chi, S; Hayashi, A; Asai, A; Tsujimoto, Y; Kuchino, Y			Caspase-dependent apoptosis of COS-7 cells induced by Bax overexpression: differential effects of Bcl-2 and Bcl-x(L) on Bax-induced caspase activation and apoptosis	ONCOGENE			English	Article						Bax; Bcl-2; Bcl-x(L); apoptosis; caspase; CPP32	CRMA-INHIBITABLE PROTEASE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; DEATH; FAMILY; HETERODIMERIZATION; CPP32; GENE; CHEMOTHERAPY; MITOCHONDRIA	Bcl-2 family proteins and ICE/CED-3 family proteases (caspases) are regarded as the basic regulators of apoptotic cell death. They are evolutionarily conserved and implicated in a variety of apoptosis. However, the precise mechanism by which these two families interact to regulate cell death is not yet known. In this study, we found that the overexpression of the Bcl-2 family member Bax induced apoptotic cell death in COS-7 cells through the activation of CPP32 (caspase-3)-like proteases that cleaved the DEVD tetrapeptide. This apoptotic cell death was suppressed by the viral proteins CrmA and p35, as well as by the chemically synthesized caspase inhibitors Z-Asp-CH2-DCB and zVAD-fmk. We also found that the Bax-induced apoptosis of COS-7 cells was suppressed by Bcl-x(L) and Bcl-2, though both Bcl-x(L) and Bcl-2 similarly prevented etoposide-induced apoptosis in COS-7 cells, In addition, Bcl-x(L) inhibited the activation of caspase-3-like proteases accompanying Bax-induced COS-7 cell death but Bcl-2 did not. These results indicate that the caspase activation is essential for Bax-induced apoptosis, and that the ability of Bcl-2 and Bcl-x, to prevent the Bax-induced caspase activation and apoptosis in COS-7 cells could be differentially regulated. Our results also suggest that Bcl-2 family proteins function upstream of caspase activation and control apoptosis through the regulation of caspase activity.	NATL CANC CTR, RES INST, DIV BIOPHYS, CHUO KU, TOKYO 104, JAPAN; UNIV TOKYO, SCH MED, DEPT NEUROSURG, BUNKYO KU, TOKYO 113, JAPAN; OSAKA UNIV, SCH MED, CTR BIOMED RES, DEPT MED GENET, SUITA, OSAKA 565, JAPAN	National Cancer Center - Japan; University of Tokyo; Osaka University								Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boulakia CA, 1996, ONCOGENE, V12, P529; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Cosulich SC, 1996, CURR BIOL, V6, P997, DOI 10.1016/S0960-9822(02)00644-9; DOLE M, 1994, CANCER RES, V54, P3253; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Estoppey S, 1997, CELL DEATH DIFFER, V4, P34, DOI 10.1038/sj.cdd.4400205; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Gottschalk AR, 1996, CELL DEATH DIFFER, V3, P113; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Ibrado AM, 1996, CANCER RES, V56, P4743; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jung YK, 1996, J BIOL CHEM, V271, P5112; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KONDO S, 1994, BRIT J CANCER, V70, P421, DOI 10.1038/bjc.1994.321; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perry DK, 1997, CELL DEATH DIFFER, V4, P29, DOI 10.1038/sj.cdd.4400200; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SAMBROOK J, 1989, EXPRESSION CLONED GE; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Shimizu S, 1996, ONCOGENE, V12, P2251; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	51	56	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1763	1772		10.1038/sj.onc.1201349	http://dx.doi.org/10.1038/sj.onc.1201349			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362442				2022-12-28	WOS:A1997XZ72500002
J	Knippschild, U; Milne, DM; Campbell, LE; DeMaggio, AJ; Christenson, E; Hoekstra, MF; Meek, DW				Knippschild, U; Milne, DM; Campbell, LE; DeMaggio, AJ; Christenson, E; Hoekstra, MF; Meek, DW			p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs	ONCOGENE			English	Article						CK1 delta; CK1 epsilon; DNA damage; p53; phosphorylation; protein kinase	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; CELLS; CHECKPOINT; EXPRESSION; GENE; IRRADIATION; APOPTOSIS; MUTATION	The p53 tumour suppressor protein plays a key role in the integration of stress signals, Multi-site phosphorylation of p53 may play an integral part in the transmission of these signals and is catalysed by many different protein kinases including an unidentified p53-N-terminus-targeted protein kinase (p53NK) which phosphorylates a group of sites at the N-terminus of the protein. In this paper, we present evidence that the delta and epsilon isoforms of casein kinase 1 (CK1 delta and CK1 epsilon) show identical features to p53NK and can phosphorylate p53 both in vitro and in vivo. Recombinant, purified glutathione S-transferase (GST)-CK1 delta and GST-CK1 epsilon fusion proteins each phosphorylate p53 in vitro at serines 4, 6 and 9, the sites recognised by p53NK. Furthermore, p53NK (i) co-purifies with CK1 delta/epsilon, (ii) shares identical kinetic properties to CK1 delta/epsilon, and (iii) is inhibited by a CK1 delta/epsilon-specific inhibitor (IC261). In addition, CK1 delta is also present in purified preparations of p53NK as judged by immunoanalysis using a CK1 delta-specific monoclonal antibody. Treatment of murine SV3T3 cells with IC261 specifically blocked phosphorylation in vivo of the CK1 delta/epsilon phosphorylation sites in p53, indicating that p53 interacts physiologically with CK1 delta and/or CK1 epsilon. Similarly, over-expression of a green fluorescent protein (GFP)-CK1 delta fusion protein led to hyper-phosphorylation of p53 at its N-terminus. Treatment of MethAp53ts cells with the topoisomerase-directed drugs etoposide or camptothecin led to increases in both CK1 delta-mRNA and -protein levels in a manner dependent on the integrity of p53, These data suggest that p53 is phosphorylated by CK1 delta and CK1 epsilon and additionally that there may be a regulatory feedback loop involving p53 and CK1 delta.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, DUNDEE DD1 9SY, SCOTLAND; ICOS CORP, BOTHELL, WA 98021 USA	University of Dundee; Icos Corporation								ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; Christenson E, 1997, Recent Results Cancer Res, V143, P263; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FERRELL JE, 1991, METHOD ENZYMOL, V200, P430; FISCELLA M, 1993, ONCOGENE, V8, P1519; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Hall PA, 1996, J PATHOL, V180, P1; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Knippschild U, 1996, ONCOGENE, V13, P1387; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lohrum M, 1996, ONCOGENE, V13, P2527; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; OTTO A, 1993, ONCOGENE, V8, P2591; PAULES RS, 1995, CANCER RES, V55, P1763; PINTEL D, 1981, J VIROL, V38, P518, DOI 10.1128/JVI.38.2.518-528.1981; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santos JA, 1996, J CELL SCI, V109, P1847; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	43	146	146	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1727	1736		10.1038/sj.onc.1201541	http://dx.doi.org/10.1038/sj.onc.1201541			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349507				2022-12-28	WOS:A1997XY63100013
J	Waber, P; Dlugosz, S; Cheng, QC; Truelson, J; Nisen, PD				Waber, P; Dlugosz, S; Cheng, QC; Truelson, J; Nisen, PD			Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16(INK4a)	ONCOGENE			English	Article						p16(INK4a); cyclin-dependent kinase inhibitors; chromosome 9; loss of heterozygosity; squamous cell carcinoma of the head and neck	SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; ALLELIC LOSS; HOMOZYGOUS DELETIONS; LUNG-CANCER; P16 GENE; CDKN2; MUTATIONS; FREQUENCY; LINES	Although genetic alterations of chromosome band 9p21-22 occur frequently in head and neck squamous cell carcinoma (HNSCC) cell lines, alterations of the cyclin-dependent kinase inhibitor p16(INK4a) located in this region are less common in corresponding primary tumors. To further investigate genetic alterations at 9p21-22 and p16(INK4a) in primary HNSCC, a paired set of 21 tumors and blood specimens that were shown previously to exhibit allelic loss at 3p and elsewhere, were tested for LOH at 9p21-22 using eight different highly polymorphic marker. Sixteen of the samples (81%) exhibited LOH for at least one marker. Frequent LOH was found surrounding p16(INK4a) and at three additional noncontiguous regions of 9p21-22. No homozygous deletions were identified. SSCP screening and direct sequence analysis led to the identification of mutations the p16(INK4a) gene in two tumors. p16(INK4a) was not hypermethylated in any of the samples studied. Furthermore, there was no correlation between LOH at 9p21-22 and the RB1 tumor suppressor gene. These findings indicate that in the set of tumors that we tested, LOH at 9p21-22 is common in primary HNSCC but that genetic alterations of p16(INK4a) located in this region are unusual. Additional tumor suppressor genes at 9p21-22 may therefore be involved in the pathogenesis of this tumor.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OTOLARYNGOL HEAD & NECK SURG,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,ACAD COMP SERV,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BARTKOVA J, 1995, CANCER RES, V55, P949; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CAIRNS P, 1995, CANCER RES, V55, P224; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CALLENDER T, 1994, CANCER-AM CANCER SOC, V74, P152, DOI 10.1002/1097-0142(19940701)74:1<152::AID-CNCR2820740124>3.0.CO;2-K; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1385; HERMAN JG, 1995, CANCER RES, V55, P4525; HUANG DP, 1994, CANCER RES, V54, P4003; HUSSUSSIAN C, 1997, NAT GENET, V8, P15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIRKPATRIC H, 1997, IN PRESS ONCOGENE; LEE NK, 1994, INT J ONCOL, V5, P205; LEE NK, 1994, ONCOL REP, V1, P637; LEE NK, 1993, ARCH OTOLARYNGOL, V119, P1125; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Liggett WH, 1996, CANCER RES, V56, P4119; LIU Q, 1995, ONCOGENE, V10, P1061; LO E, 1995, CANCER RES, V55, P2039; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MUSCAT JE, 1992, CANCER, V69, P2244, DOI 10.1002/1097-0142(19920501)69:9&lt;2244::AID-CNCR2820690906&gt;3.0.CO;2-O; NAWROZ H, 1994, CANCER RES, V54, P1152; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Reed AL, 1996, CANCER RES, V56, P3630; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SUN Y, 1995, ONCOGENE, V10, P785; UCHIDA T, 1995, BLOOD, V86, P2724, DOI 10.1182/blood.V86.7.2724.bloodjournal8672724; VANDERRIET P, 1994, CANCER RES, V54, P1156; Waber PG, 1996, ONCOGENE, V12, P365; WABER PG, 1993, CANCER RES, V53, P6028; WEBER JL, 1989, AM J HUM GENET, V44, P388; ZHANG SY, 1994, CANCER RES, V54, P5050	42	42	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1699	1704		10.1038/sj.onc.1201336	http://dx.doi.org/10.1038/sj.onc.1201336			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349503				2022-12-28	WOS:A1997XY63100009
J	deBoer, CJ; Vaandrager, JW; vanKrieken, JHJM; Holmes, Z; Kluin, PM; Schuuring, E				deBoer, CJ; Vaandrager, JW; vanKrieken, JHJM; Holmes, Z; Kluin, PM; Schuuring, E			Visualization of mono-allelic chromosomal aberrations 3' and 5' of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization	ONCOGENE			English	Article						11q13; t(11;14); NHL; translocation	MESSENGER-RNA DEGRADATION; HUMAN BREAST-CANCER; UNTRANSLATED REGION; SQUAMOUS-CELL; BCL-1 GENE; OVEREXPRESSION; TRANSLOCATION; AMPLIFICATION; EXPRESSION; PRAD1	In mantle cell lymphoma (MCL), in addition to the characteristic t(11;14)(q13;q32), rearrangements on the 3' side of the cyclin D1 gene have been described. In a series of 32 MCL we found three cases with 3'-rearrangements by Southern blot analysis with a probe representing the 3' untranslated region of the cyclin D1 gene. All three were characterized by the absence of the 4.5 kb transcript, and instead, two cases showed overexpression of the 1.7 kb and a third case (MCLp14) an aberrant 2.5 kb transcript. At the genomic level, fine mapping experiments showed in the 3' untranslated region a 2 kb deletion in MCLp14 and a breakpoint in the other two cases. Fiber FISH analysis showed that in all three cases the 3' aberration co-exists with a regular t(11;14) breakpoint 5' of cyclin D1 on a single allele. Fiber FISH analysis of 16 additional MCL revealed two other such cases with breakpoints 5' and 3' of cyclin D1. These mono-allelic aberrations affecting the cyclin D1 gene suggest that the t(11;14) as a first step switches on transcription, and then sequences in the untranslated region of cyclin D1 are affected to stabilize the message.	LEIDEN UNIV, MED CTR, DEPT PATHOL, NL-2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV, MED CTR, DEPT HEMATOL, NL-2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC			van Krieken, Joannes H J M/D-4138-2009	van Krieken, Joannes H J M/0000-0001-6544-1040				AKIYAMA N, 1994, CANCER RES, V54, P377; Bigoni R, 1996, ONCOGENE, V13, P797; BOSCH F, 1995, BRIT J HAEMATOL, V91, P1025, DOI 10.1111/j.1365-2141.1995.tb05429.x; BOSCH F, 1994, BLOOD, V84, P2726; BROOKES S, 1992, GENE CHROMOSOME CANC, V4, P290, DOI 10.1002/gcc.2870040404; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Courjal F, 1996, INT J CANCER, V69, P247; DEBOER CJ, 1995, BLOOD, V86, P2715, DOI 10.1182/blood.V86.7.2715.bloodjournal8672715; DEBOER CJ, 1995, ONCOGENE, V10, P1833; deBoer CJ, 1997, ANN ONCOL, V8, P109, DOI 10.1023/A:1008207005567; DEBOER CJ, 1993, CANCER RES, V53, P4148; deBoer CJ, 1996, ANN ONCOL, V7, P251; FLORIJN RJ, 1995, HUM MOL GENET, V4, P831, DOI 10.1093/hmg/4.5.831; GILLETT C, 1994, CANCER RES, V54, P1812; HAYASHI T, 1994, INT J HEMATOL, V59, P281; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KLUIN PM, 1996, CURR DIAGN PATHOL, V3, P187; KOMATSU H, 1994, BLOOD, V84, P1226; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; RIMOKH R, 1994, BLOOD, V83, P3689; RIMOKH R, 1993, BLOOD, V81, P3063; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Vaandrager JW, 1997, BLOOD, V89, P349, DOI 10.1182/blood.V89.1.349.349_349_349; WILLIAMS ME, 1994, ANN ONCOL, V5, pS71, DOI 10.1093/annonc/5.suppl_1.S71; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	34	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1599	1603		10.1038/sj.onc.1201320	http://dx.doi.org/10.1038/sj.onc.1201320			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380412				2022-12-28	WOS:A1997XX36900011
J	Nguyen, H; Lin, RT; Hiscott, J				Nguyen, H; Lin, RT; Hiscott, J			Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins	ONCOGENE			English	Article						interferon regulatory factor (IRF)-1; STAT1 (p91); apoptosis; transcription	TRANSCRIPTION FACTOR IRF-1; IFN-BETA; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; INTERFERON GENE; VIRUS INDUCTION; NUCLEAR FACTOR; FACTOR-I; KINASE; TRANSFORMATION	Interferon Regulatory Factor (IRF)-1 has been characterized as an important growth regulatory and immunomodulatory transcription factor. To further characterize the potential targets of IRF-1 antiproliferative activity, IRF-1 was expressed under the control of the tetracycline-inducible system in murine NIH3T3 cells. Due to their ability to mimic IRF-1 transactivator function, the regulatory potential of IRF-1/RelA and IRF-2/RelA fusion proteins consisting of the DNA binding domains of IRF-1 or IRF-2 fused to the transactivation domain of NF-kappa B RelA(p65) was also examined. Cells inducibly expressing IRF-1 or IRF/RelA in response to doxycycline treatment displayed significantly reduced growth rates compared to control cells, and inhibition of cell growth correlated directly with the level of transgene expression. Interestingly, IRF-1 and IRF/RelA expression also induced a low level of apoptosis, as detected by microscopic analyses. Furthermore, expression of the interferon inducible, double stranded RNA dependent kinase PKR was increased following IRF-1 or IRF/RelA induction. Most strikingly, induction of IRF-1 and IRF/RelA expression resulted in a significant increase in STAT1 (p91) protein and increased ISGF3 DNA binding activity, suggesting that IRF-1 tumor suppressor activity may involve a novel mechanism which activates the JAK-STAT pathway through STAT1. WAF1 levels were also constitutively elevated in IRF-1 and IRF-1/RelA cells. These studies demonstrate that inducible expression of the transactivation function of IRF-1 or IRF/RelA mediates tumor suppressor activity by inducing cell growth arrest, apoptosis and the differential activation of growth regulatory genes such as PKR, STAT1 and WAF1.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,TERRY FOX MOL ONCOL GRP,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University			Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				BARBER GN, 1993, GENOMICS, V16, P765, DOI 10.1006/geno.1993.1262; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HANASH SM, 1995, GENES CHROM CANC, V8, P34; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEHTONEN A, IN PRESS J IMMUNOL; LIN RT, 1994, J BIOL CHEM, V269, P17542; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NGUYEN H, 1995, ONCOGENE, V11, P537; OZAWA H, 1996, NATURE, V382, P816; PENNINGER JM, 1994, IMMUNOL REV, V142, P231, DOI 10.1111/j.1600-065X.1994.tb00892.x; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SQUIRE J, 1993, GENOMICS, V16, P768, DOI 10.1006/geno.1993.1263; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; UEGAKI K, 1993, PROTEIN ENG, V6, P195, DOI 10.1093/protein/6.2.195; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; XANTHOUDAKIS S, 1989, J BIOL CHEM, V264, P1139; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; [No title captured]	44	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1425	1435		10.1038/sj.onc.1201318	http://dx.doi.org/10.1038/sj.onc.1201318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333018				2022-12-28	WOS:A1997XW41100006
J	Schaefer, G; Fitzpatrick, VD; Sliwkowski, MX				Schaefer, G; Fitzpatrick, VD; Sliwkowski, MX			gamma-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175	ONCOGENE			English	Article						neuregulin; receptor tyrosine kinase; autocrine growth stimulation	NEU-DIFFERENTIATION FACTOR; FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; CARCINOMA CELLS; GENE-PRODUCT; FACTOR-ALPHA; TUMOR-CELLS; ERBB2; FAMILY; EGF	A novel neuregulin isoform, termed gamma-HRG, was cloned and characterized from the human breast cancer cell line, MDA-MB-175. As observed with other neuregulins, gamma-HRG, is a product of alternative mRNA splicing of the neuregulin gene, gamma-HRG contains the EGF-like and immunoglobulin-like domains that are commonly found in other family members, but lacks a transmembrane and cytoplasmic region. The new isoform possesses a unique N-terminal region that includes a hydrophobic domain that may function as a secretion signal. A purified recombinant version of gamma-HRG competes for binding to soluble ErbB3- and ErbB4-IgG fusion proteins with affinities similar to those observed for rHRG beta 1(177-244). gamma-HRG has a wide distribution in mesenchymal or neuronal tissues but in contrast to other neuregulins, it is not present in breast, lung, liver and small intestine. Expression of gamma-HRG with its cognate receptors, ErbB3 and ErbB2 suggested that the growth of the MDA-MB-175 cell line might be a result of the stimulation of a growth factor signaling pathway. Treatment of MDA-MB-175 cells with an anti-ErbB2 monoclonal antibody that interferes with the ligand-dependent formation of ErbB2-ErbB3 heterodimer complexes shows a strong growth inhibitory effect on this cell line. Moreover, incubation with a receptor-IgG fusion protein that neutralizes secreted gamma-HRG, also inhibits cell growth. These data suggest that the secretion of gamma-HRG by MDA-MB-175 cells leads to the formation of a constitutively active receptor complex and stimulates the growth of these cells in an autocrine manner.	GENENTECH INC,S SAN FRANCISCO,CA 94080; UNIV FREIBURG,DEPT BIOL,D-7800 FREIBURG,GERMANY	Roche Holding; Genentech; University of Freiburg				Schaefer, Gabriele/0000-0001-9727-3555				ALIMANDI M, 1995, ONCOGENE, V10, P1813; AVILA MA, 1995, ONCOGENE, V10, P963; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BURDEN S, 1997, IN PRESS NEURON; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE R, 1993, BREAST CANCER RES TR, V24, P227, DOI 10.1007/BF01833263; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Ethier SP, 1996, MOL CARCINOGEN, V15, P134; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; FENDLY BM, 1990, CANCER RES, V50, P1550; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVI ADO, 1995, J NEUROSCI, V15, P1329; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Lewis GD, 1996, CANCER RES, V56, P1457; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MODJTAHEDI H, 1994, INT J ONCOL, V4, P277; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; PARK JW, 1993, P AM ASSOC CANC RES, V84, P3107; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Sadick MD, 1996, ANAL BIOCHEM, V235, P207, DOI 10.1006/abio.1996.0114; Sambrook J., 2002, MOL CLONING LAB MANU; Scher HI, 1995, CLIN CANCER RES, V1, P545; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; Tang CK, 1996, CANCER RES, V56, P3350; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; ZHANG D, 1997, IN PRESS P NATL AC S; Zhang K, 1996, J BIOL CHEM, V271, P3884	50	88	111	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1385	1394		10.1038/sj.onc.1201317	http://dx.doi.org/10.1038/sj.onc.1201317			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333014				2022-12-28	WOS:A1997XW41100002
J	Ponten, F; Berg, C; Ahmadian, A; Ren, ZP; Nister, M; Lundeberg, J; Uhlen, M; Ponten, J				Ponten, F; Berg, C; Ahmadian, A; Ren, ZP; Nister, M; Lundeberg, J; Uhlen, M; Ponten, J			Molecular pathology in basal cell cancer with p53 as a genetic marker	ONCOGENE			English	Article						p53; BCC; mutation; LOH; heterogeneity; clonality	SKIN-CANCER; MUTATIONS; CARCINOMA; SUNLIGHT; EXPOSURE; PATTERN	Human basal cell cancer (BCC) has unique growth characteristics with virtual inability to metastasize, We investigated clonality and genetic progression using p53 mutations as marker. Sampling was done through microdissection of frozen immunohistochemically stained 16 mu m slices of tumors. From 11 BCC tumors 78 samples were analysed. Direct DIVA sequencing of exons 5-8 was performed, haplotypes were determined after cloning of p53 exons and loss of heterozygosity (LOH) ascertained by microsatellite analysis, All tumors had p53 mutations and in a majority both p53 alleles were affected, commonly through missense mutations. Microdissection of small parts (50-100 cells) of individual tumors showed BCC to be composed of a dominant cell clone and prone to genetic progression with appearance of subclones with a second and even third p53 mutation, Samples from normal immunohistochemically negative epidermis always showed wild type sequence, except for a case of previously unknown germline p53 mutation. Our analysis also included p53 immunoreactive patches i.e. morphologically normal epidermis with a compact pattern of p53 immunoreactivity. Mutations within those were never the same as in the adjacent BCC. This detailed study of only one gene thus uncovered a remarkable heterogeneity within a tumor category famous for its benign clinical behavior.	ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,KTH,S-10044 STOCKHOLM,SWEDEN	Royal Institute of Technology	Ponten, F (corresponding author), UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN.		Uhlen, Mathias/AAV-8746-2021; Uhlen, Mathias/B-3262-2016; Williams, Cecilia/A-6677-2009	Uhlen, Mathias/0000-0002-4858-8056; Williams, Cecilia/0000-0002-0602-2062				BERG C, 1995, CLIN CHEM, V41, P1461; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DIFFEY BL, 1979, PHYS MED BIOL, V24, P931, DOI 10.1088/0031-9155/24/5/006; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUTREAL PA, 1992, CANCER RES, V52, P2624; GALLAGHER RP, 1995, ARCH DERMATOL, V131, P157, DOI 10.1001/archderm.131.2.157; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HARRIS CC, 1995, ANN S BIOL SKIN, V1, P115; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; IMAYAMA S, 1987, AM J PATHOL, V128, P497; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KANJILAL S, 1995, CANCER RES, V55, P3604; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KRESS S, 1992, CANCER RES, V52, P6400; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; KUBO Y, 1994, J INVEST DERMATOL, V102, P440, DOI 10.1111/1523-1747.ep12373002; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MADSEN A, 1965, ACTA PATHOL MICROB S, V177, P9; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; PONTEN F, 1994, J INVEST DERMATOL, V102, P304, DOI 10.1111/1523-1747.ep12371787; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; RADY P, 1992, CANCER RES, V52, P3804; Ren ZP, 1996, ONCOGENE, V12, P765; REN ZP, 1996, INT J CANCER, V66, P174; REN ZP, 1996, ROLE MUTATIONS P52 G; RUTHER U, 1982, NUCLEIC ACIDS RES, V10, P5765, DOI 10.1093/nar/10.19.5765; VANSCOTT EJV, 1982, J INVEST DERMATOL, V36, P109; VONDOMARUS H, 1984, J AM ACAD DERMATOL, V10, P1043; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	36	83	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1059	1067		10.1038/sj.onc.1201435	http://dx.doi.org/10.1038/sj.onc.1201435			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285560				2022-12-28	WOS:A1997XT16100007
J	Haas, K; Staller, P; Geisen, C; Bartek, J; Eilers, M; Moroy, T				Haas, K; Staller, P; Geisen, C; Bartek, J; Eilers, M; Moroy, T			Mutual requirement of CDK4 and Myc in malignant transformation: Evidence for cyclin D1/CDK4 and p16(INK4A) as upstream regulators of Myc	ONCOGENE			English	Article						oncogene cooperation; REF assay; cell cycle regulation; Myc function; CDK4	CELL-CYCLE; C-MYC; RETINOBLASTOMA-PROTEIN; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC ACTIVITY; RAS COTRANSFORMATION; HOMOZYGOUS DELETION; NUCLEAR-PROTEIN; KINASE-ACTIVITY	We demonstrate in this paper that CDK4 which is a G1 phase specific cell cycle regulator and catalytic subunit of D-type cyclins has oncogenic activity similar to D-type cyclins themselves and is able to provoke focus formation when cotransfected with activated Ha-ras into primary rat embryo fibroblasts. Surprisingly, using two different mutants we show that CDK4's ability to bind to p16(INK4a) and not its kinase activity is important for its transforming potential. In addition, p16(INK4a) but not a mutant form that is found in human tumours can completely abrogate focus formation by CDK4 suggesting that CDK4 can malignantly transform cells by sequestering p16(INK4a) Or other CKIs. We demonstrate that both cyclin D1 and CDK4 functionally depend on active Myc to exert their potential as oncogenes and vice versa that the transforming ability of Myc requires functional cyclin D/CDK complexes. Moreover, we find that p16(INK4a) and the Rb related protein p107 which releases Myc after phosphorylation by cyclin D1/CDK4 efficiently block Myc's activity as a transcriptional transactivator and as an oncogene. We conclude that both p16(INK4a) and cyclin D/CDK4 complexes are upstream regulators of Myc and directly govern Myc function in transcriptional transactivation and transformation via the pocket protein p107.	UNIV ESSEN GESAMTHSCH KLINIKUM,INST ZELLBIOL TUMORFORSCH,D-45122 ESSEN,GERMANY; ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY; DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN,DENMARK	University of Duisburg Essen; Ruprecht Karls University Heidelberg; Danish Cancer Society			Bartek, Jiri/G-5870-2014; Moroy, Tarik/D-9923-2011	Eilers, Martin/0000-0002-0376-6533				AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BOTZ J, 1996, JOURNAL, V16, P3401; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CERNI C, 1995, ONCOGENE, V11, P587; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Geng Y, 1996, ONCOGENE, V12, P1173; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HALL M, 1995, ONCOGENE, V11, P1581; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HU J, 1992, MOL CELL BIOL, V12, P971; JIANG W, 1993, ONCOGENE, V8, P3447; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KHATIB ZA, 1993, CANCER RES, V53, P5535; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOBORI T, 1994, NATURE, V368, P53; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYMOND A, 1995, ONCOGENE, V11, P1173; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1994, J CELL SCI, V107, P581; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SONODA Y, 1995, ONCOGENE, V11, P2145; Starostik P, 1996, MOL CELL BIOL, V16, P3606; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	88	73	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					179	192		10.1038/sj.onc.1201171	http://dx.doi.org/10.1038/sj.onc.1201171			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244353				2022-12-28	WOS:A1997XK37200006
J	Gagnebin, J; Kovar, H; Kajava, AV; Estreicher, A; Jug, G; Monnier, P; Iggo, R				Gagnebin, J; Kovar, H; Kajava, AV; Estreicher, A; Jug, G; Monnier, P; Iggo, R			Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity	ONCOGENE			English	Article						p53; gene therapy; transcription	DNA-BINDING; PROTEIN; MUTATIONS; GENE	p53 triple mutants (120N/121G/277H, 120H/121G/277H, 120S/121G/277H and 120H/121G/277Y) have altered sequence specificity in bandshift assays in vitro and transcription assays in vivo. These mutants activate transcription from the site TTT CATG AAA but not from wild type sites. The triple mutants activate more strongly than p53 with a single 277Y mutation. The TTT site matches the wild type p53 consensus at only 4/10 positions and is not recognised by wild type p53. 277Y mutations have been described in human tumours, and Ewing tumour cells expressing this mutant from the endogenous p53 locus selectively activate transcription from transfected luciferase reporters regulated by TTT-mutant p53 binding sites. p53 mutants with altered sequence specificity have potential advantages for cancer gene therapy: if used to activate transcription of conditionally toxic genes they would allow tumour-targeting by p53, which acts as a sensor for the malignant state, but place control over cell killing in the hands of the clinician. Rare tumours expressing such mutants from the endogenous p53 locus could be targeted directly with p53-regulated suicide vectors, but for most tumours both the p53 mutant and the reporter would need to be encoded by the virus.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; CHU Vaudois, Univ Hosp, Serv Otorhinolaryngol, CH-1011 Lausanne, Switzerland; St Anna Kinderspital, CCRI, A-1090 Vienna, Austria	Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Saint Anna Children's Hospital	Iggo, R (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		Kajava, Andrey V/E-1107-2014; Iggo, Richard/G-3546-2014	Kajava, Andrey V/0000-0002-2342-6886; Kovar, Heinrich/0000-0001-6873-9109; Estreicher, Anne/0000-0001-6828-2508				ABARZUA P, 1996, ONCOGENE, V13, P2447; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CULVER KW, 1992, SCIENCE, V256, P1500; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; FREIDLANDER P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KOVAR H, 1993, ONCOGENE, V8, P2683; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196	22	17	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					685	690		10.1038/sj.onc.1201568	http://dx.doi.org/10.1038/sj.onc.1201568			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482117				2022-12-28	WOS:000071816600016
J	Madamanchi, NR; Bukoski, RD; Runge, MS; Rao, GN				Madamanchi, NR; Bukoski, RD; Runge, MS; Rao, GN			Arachidonic acid activates Jun N-terminal kinase in vascular smooth muscle cells	ONCOGENE			English	Article						arachidonic acid; cytokines; growth factors; JNK1; signaling	CYTOSOLIC PHOSPHOLIPASE A(2); JNK/SAPK SIGNALING PATHWAY; BINDING PROTEINS RAC1; RAT MESANGIAL CELLS; C-JUN; MASTOCYTOMA-CELLS; GROWTH; LIPOXYGENASE; METABOLITES; EXPRESSION	We have previously demonstrated that arachidonic acid activates extracellular signal-regulated protein kinases (ERKs) group of mitogen-activated protein kinases (MAPKs) in vascular smooth muscle cells (VSMC). To understand the role of arachidonic acid in cellular signaling events, we have now studied its effect on jun N-terminal kinases (JNKs) group of MAPKs in VSMC. Arachidonic acid activated JNK1 in a time-and concentration-dependent manner with maximum effects at 10 min and 50 mu M. Induced activation of JNK1 by arachidonic acid is specific as other fatty acids such as linoleic and stearic acids had no such effect. Indomethacin and nordihydroguaiaretic acid (NDGA), potent inhibitors of the cyclooxygenase (COX) and the lipoxygenase (LOX)/monooxygenase (MOX) pathways, respectively, had no effect on arachidonic acid activation of JNK1 suggesting that the observed phenomenon is independent of its metabolism through either pathway. 12-hydroperoxyeicosatetraenoic acid (12-HpETE), the LOX metabolite of arachidonic acid significantly induced JNK1 activity. Protein kinase C (PKC) depletion by prolonged treatment of VSMC with phorbol 12-myristate 13-acetate (PMA) resulted in partial decrease in the responsiveness of JNK1 to arachidonic acid suggesting a role for both PKC-dependent and -independent mechanisms in the activation of JNK1 by this important fatty acid. On the other hand, the responsiveness of JNK1 to 12-HpETE was completely abolished in PKC-depleted cells, suggesting a major role for PKC in l2-HpETE-induced JNK1 activation. IL-1 beta and TNF-alpha activated JNK1 in a time-dependent manner with maximum effect at 10 min. Desensitization of JNK1 by arachidonic acid significantly reduced its responsiveness to both the cytokines. In addition, 4-bromophenacyl bromide (4-BPB), a potent and selective inhibitor of phospholipase A(2) (PLA(2)), significantly attenuated the cytokine-induced activation of JNK1. Together, these results show that (1) arachidonic acid and its LOX metabolite, 12-HpETE, activate JNK1 in VSMC, (2) PKC-dependent and -independent mechanisms play a role in the activation of JNK1 by arachidonic acid and 12-HpETE, and (3) arachidonic acid mediates, at least partially, the cytokine-induced activation of JNK1.	Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sect Hypertens & Vasc Res, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Rao, GN (corresponding author), Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA.			Madamanchi, Nageswara/0000-0003-0590-0908				ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P4917, DOI 10.1073/pnas.90.11.4917; BUTCHER RD, 1993, CANCER RES, V53, P3405; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HANSSON A, 1986, BIOCHEM BIOPH RES CO, V134, P1215, DOI 10.1016/0006-291X(86)90380-3; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; JAATTELA M, 1995, ONCOGENE, V10, P2297; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIKKAWA U, 1988, PHILOS T ROY SOC B, V320, P313, DOI 10.1098/rstb.1988.0079; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; Knoepp SM, 1996, J BIOL CHEM, V271, P1678, DOI 10.1074/jbc.271.3.1678; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIN L, 1994, CIRC RES, V74, P197, DOI 10.1161/01.RES.74.2.197; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIU B, 1995, P NATL ACAD SCI USA, V92, P9323, DOI 10.1073/pnas.92.20.9323; Lu G, 1996, CIRC RES, V79, P611, DOI 10.1161/01.RES.79.3.611; MA YH, 1993, CIRC RES, V72, P126, DOI 10.1161/01.RES.72.1.126; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; NAKAO J, 1982, ATHEROSCLEROSIS, V44, P339, DOI 10.1016/0021-9150(82)90008-9; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RALPH RK, 1990, CANCER LETT, V49, P181, DOI 10.1016/0304-3835(90)90156-R; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; SAKATA A, 1987, J IMMUNOL, V138, P4353; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; SCHWARTZMAN ML, 1994, J BIOL CHEM, V269, P24321; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	62	36	40	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					417	422		10.1038/sj.onc.1201551	http://dx.doi.org/10.1038/sj.onc.1201551			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467967				2022-12-28	WOS:000071582100014
J	Frederick, A; Rolfe, M; Chiu, MI				Frederick, A; Rolfe, M; Chiu, MI			The human UNP locus at 3p21.31 encodes two tissue-selective, cytoplasmic isoforms with deubiquitinating activity that have reduced expression in small cell lung carcinoma cell lines	ONCOGENE			English	Article						ubiquitin protease; small cell lung cancer; 3p21	FAT-FACETS GENE; PROTEIN-DEGRADATION; TRE ONCOGENE; ENZYME; CANCER; UBIQUITIN; PROTOONCOGENE; RECEPTORS; SUBUNIT; KINASE	The human Unp gene at 3p21.3 has sequence similarity to ubiquitin proteases and has been suggested to play a role in carcinogenesis of the lung (Gray et al., 1995). To investigate this possibility, we isolated cDNAs from several human tissue libraries and found evidence for two major isoforms, encoding proteins predicted to either contain an internal 47 amino acid segment or not. Both are functional in deubiquitination assays, and mutation of a critical conserved cysteine residue to alanine abolished activity. Unp specifies two closely-migrating transcripts whose relative abundance varies among human adult tissues. Antibodies specific to UNP confirm the presence of at least two endogenous protein isoforms of approximately 105-110 kDa in cell lysates, as predicted from the cDNA sequences. Cellular fractionation and immunocytochemistry revealed UNP expression localized primarily in the cytoplasm. When we examined a panel of lung-derived cell lines for both UNP mRNA and protein expression, we found reduced levels of UNP protein in all four small cell lung carcinoma cell lines tested. These findings directly contradict and offer alternative interpretations to a number of previously published observations on Unp.	Mitotix Inc, Cambridge, MA 02139 USA		Chiu, MI (corresponding author), Mitotix Inc, 1 Kendall Sq,Bldg 600, Cambridge, MA 02139 USA.							BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1994, ONCOGENE, V9, P611; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Jackers P, 1996, ONCOGENE, V13, P495; Kalderon D, 1996, CURR BIOL, V6, P662, DOI 10.1016/S0960-9822(09)00443-6; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NAKAMURA T, 1992, ONCOGENE, V7, P733; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Roche J, 1996, ONCOGENE, V12, P1289; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; TAM SW, 1994, CANCER RES, V54, P5816; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu YA, 1997, J BIOL CHEM, V272, P51	37	47	50	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					153	165		10.1038/sj.onc.1201537	http://dx.doi.org/10.1038/sj.onc.1201537			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464533				2022-12-28	WOS:000071427100002
J	Iravani, M; Dhat, R; Price, CM				Iravani, M; Dhat, R; Price, CM			Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15(INK4B)) in childhood acute lymphoblastic leukemia	ONCOGENE			English	Article						MTS1; p16(INK4A); MTS2; p15(INK4B); methylation; childhood leukemia	DEPENDENT KINASE INHIBITORS; CELL-CYCLE ARREST; DNA METHYLATION; HUMAN CANCERS; TGF-BETA; P16; INACTIVATION; HYPERMETHYLATION; EXPRESSION; FREQUENCY	The multi tumor suppressor genes MTS1 (CDKN2 p16(INK4A)) and MTS2 (CDKN1, p15(INK4B)) located at 9p21-22 are inactivated in some human cancers via several mechanisms including deletion and hypermethylation, We have investigated the deletion and methylation status of MTS1 and MTS2 in childhood acute lymphoblastic leukemia (ALL) of both T-cell (17 cases) and B-cell phenotypes (29 cases), and p16(INK4A) and p15(INK4B) mRNA expression in 36 of these cases, Biallelic or monoallelic loss of both MTS1 and MTS2 was observed in 12 cases of B-ALL and nine cases of T-ALL. Two cases of T-ALL showed deletion of MTS1 but not MTS2 The 5' CpG region of MTS2 was hypermethylated in 12 cases of precursor B-ALL and eight cases of T-ALL but no hypermethylation was found in the 5' CPG region of MTS1, All cases with homozygous deletion of MTS1 or MTS2 had no or low levels of mRNA expression and similar low levels of expression were found in cases in which MTS2 was present but fully methylated, Thus hypermethylation of MTS2, in contrast to MTS1, is frequent in childhood ALL, Furthermore our data show that although inactivation of MTS1 by deletion is common, inactivation of MTS2 by a combination of deletion and hypermethylation is more frequent in both B-ALL (20/29, 69%) and T-ALL (17/17, 100%), This suggests that both MTS1 and MTS2 are important targets of the 9p21-22 deletion.	INST CANC RES,CHESTER BEATTY LABS,LEUKAEMIA RES FUND CTR,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costello JF, 1996, CANCER RES, V56, P2405; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; GREGER V, 1994, HUM GENET, V94, P491; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAIDAR MA, 1995, BLOOD, V86, P311, DOI 10.1182/blood.V86.1.311.bloodjournal861311; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; HIRAMA T, 1995, BLOOD, V86, P841; Jamal R, 1996, LEUKEMIA, V10, P629; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LI Y, 1994, CANCER RES, V54, P6078; Lo KW, 1996, CANCER RES, V56, P2721; MARCO JAG, 1996, BLOOD, V88, P1568; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nagatake M, 1996, CANCER RES, V56, P1886; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; PRICE CM, 1992, BLOOD, V80, P1033; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; Reed AL, 1996, CANCER RES, V56, P3630; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sambrook J., 2002, MOL CLONING LAB MANU; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; ZULUETA MG, 1995, CANCER RES, V55, P4531	39	53	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2609	2614		10.1038/sj.onc.1201428	http://dx.doi.org/10.1038/sj.onc.1201428			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399648				2022-12-28	WOS:A1997YG73200010
J	Hamdane, M; DavidCordonnier, MH; DHalluin, JC				Hamdane, M; DavidCordonnier, MH; DHalluin, JC			Activation of p65 NF-kappa B protein by p210(BCR-ABL) in myeloid cell line (p210(BCR-ABL) activates p65 NF-kappa B)	ONCOGENE			English	Article						p210(BCR-ABL); tyrosine kinase; signal transduction; NF-kappa B activity; p65 NF-kappa B (RelA); myeloid cells	CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; TYROSINE KINASE-ACTIVITY; CHRONIC MYELOCYTIC-LEUKEMIA; C-ABL; TRANSCRIPTIONAL ACTIVATION; PHILADELPHIA-CHROMOSOME; V-ABL; ANTISENSE INHIBITION; IMMUNOGLOBULIN GENES	The chimeric tyrosine kinase p210(BCR-ABL) is involved in the pathogenesis of chronic myelogenous leukemia. It transforms immature hematopoietic cells in vitro and abrogates IL-3-dependent growth. The mechanisms by which p210(BCR-ABL) mediates its oncogenicity are not well elucidated. Identifying transcription factors targeted by the chimeric protein may help to clarify these mechanisms. We have analysed the effect of p210(BCR-ABL) expression on NF-kappa B activity in DA1 cells (an IL-3-dependent murine myeloid progenitor cell line). A specific stimulation of NF-kappa B activity by kinase-active wild-type p210(BCR-ABL) has been evidenced by transcriptional activation assays. Electrophoretic mobility supershift assays revealed the presence of p65 protein (RelA) DNA binding activity in p210(BCR-ABL) transformed DA1 cells but not in parental DA1 cells. Activation of RelA in transformed DA1 cells may occur by protein stabilization. Experiments using oligonucleotides antisense to RelA showed that p210(BCR-ABL) transfected cells failed to survive after IL-3 removal. Moreover, inhibition of cellular growth was shown following treatment of p210(BCR-ABL) transformed DA1 cells by p65 antisense oligonucleotides. This study suggests that p65 NF-kappa B may be an effector for p210(BCR-ABL) and probably contributes to its induced transformation process.	INSERM U124,INST RECH CANC LILLE,F-59045 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			DAVID-CORDONNIER, Marie-Helene/P-9909-2019; David-Cordonnier, Marie-Helene/M-3725-2018	DAVID-CORDONNIER, Marie-Helene/0000-0001-9831-5577; David-Cordonnier, Marie-Helene/0000-0001-9831-5577; Hamdane, Malika/0000-0001-7971-8696				AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; CARLESSO N, 1994, ONCOGENE, V9, P149; COOK WD, 1982, P NATL ACAD SCI USA, V72, P2917; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; Gilmore TD, 1996, ONCOGENE, V13, P1367; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IHLE JN, 1985, CONTEMP TOP MOLEC IM, V10, P93; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KERR LD, 1994, BIOESSAYS, V16, P453, DOI 10.1002/bies.950160702; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LI WJ, 1988, ONCOGENE, V2, P559; LIFSHITZ B, 1988, ONCOGENE, V2, P113; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MANDANAS RA, 1993, BLOOD, V82, P1838; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; NARAYANAN R, 1992, ONCOGENE, V7, P553; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1992, ONCOGENE, V7, P2095; Neumann M, 1996, ANTICANCER RES, V16, P1075; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PEREZ JR, 1994, MOL CELL BIOL, V14, P5326, DOI 10.1128/MCB.14.8.5326; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1996, ONCOGENE, V12, P839; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHMITZ ML, 1995, IMMUNOBIOLOGY, V193, P116, DOI 10.1016/S0171-2985(11)80534-6; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; Shuai K, 1996, ONCOGENE, V13, P247; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SOKOLOSKI JA, 1993, BLOOD, V82, P625; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107	75	66	69	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2267	2275		10.1038/sj.onc.1201411	http://dx.doi.org/10.1038/sj.onc.1201411			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393872				2022-12-28	WOS:A1997YE15700002
J	Mishra, L; Tully, RE; Monga, SPS; Yu, P; Cai, T; Makalowski, W; Mezey, E; Pavan, WJ; Mishra, B				Mishra, L; Tully, RE; Monga, SPS; Yu, P; Cai, T; Makalowski, W; Mezey, E; Pavan, WJ; Mishra, B			Praja1, a novel gene encoding a RING-H2 motif in mouse development	ONCOGENE			English	Article						Praja1 gene; PRAJA1 protein; RING-H2 domain; molecular cloning; liver development; chromosome localization; explant cultures	ZINC-FINGER; PROTEIN; DOMAIN; FAMILY; GRANIN	As part of a cloning strategy to identify genes involved in early mouse liver development we have isolated Praja1, a gene with similar sequences to the Drosophila melanogaster gene goliath (gl) which is involved in the fate of mesodermal cells ultimately forming gut musculatures, fat body, and the heart, Praja1 is a 2.1 kb gene encoding a putative 396 amino acid ORF and includes a COOH-terminal RING-H2 domain, Using the Jackson Laboratory BSS panel, we have localized Praja1 on chromosome X at 36 cM, which may be a candidate gene for mouse sla (sex linked sideroblastic anemia), near the X inactivation center gene, Xist, Northern blot analysis demonstrated three transcripts (3.1, 2.6 and 2.1 kb) in mRNA from adult mouse tissues brain, liver, and kidney as well as in mRNA from developing mouse embryos (days 7, 11, 15 and 17 post coitus, p.c.). In vitro transcription/translation yielded a product with an M-r of 59 kD, Immunohistochemical staining of in vitro liver explant cultures using a heterologous antibody against praja1 demonstrated cytoplasmic staining of cuboidal cells that have hepatocyte morphology and organization, The presence of the RING-H2 domain, a proline-rich region at the COOH-end, and regions rich in acidic amino acids, leads to the hypothesis that the Praja1 product is possibly involved in mediating protein-protein interactions, possibly as part of a protein sorting or transport pathway, This is strengthened by the similarity of Praja1 to rat Neurodap1, whose product has been shown to localize to the endoplasmic reticulum and golgi in brain.	NATL HUMAN GENOME RES INST, LAB GENET DIS RES, CLIN GENE THERAPY BRANCH, NIH, BETHESDA, MD USA; NATL CTR BIOTECHNOL INFORMAT, NIH, BETHESDA, MD USA; JOHNS HOPKINS SCH MED, BALTIMORE, MD USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; Johns Hopkins University; Johns Hopkins Medicine	Mishra, L (corresponding author), VET ADM MED CTR, LAB DEV MOL BIOL, WASHINGTON, DC 20422 USA.		Makalowski, Wojciech/I-2843-2016; Mezey, Eva/A-8105-2008	Mezey, Eva/0000-0002-5907-4691; Pavan, William/0000-0001-8281-5120; Mishra, Lopa/0000-0002-6850-0808; Cai, Tao/0000-0002-2877-8637; Makalowski, Wojciech/0000-0003-2303-9541; Monga, Satdarshan/0000-0002-8437-3378				BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BOUCHARD ML, 1993, GENE, V125, P205, DOI 10.1016/0378-1119(93)90330-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FALCONER DS, 1962, GENET RES, V3, P248, DOI 10.1017/S0016672300035035; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Herman GE, 1996, MAMM GENOME, V6, pS317; HOUSSAINT E, 1980, CELL DIFFER DEV, V9, P269, DOI 10.1016/0045-6039(80)90026-3; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Konat Gregory W., 1994, P37; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN NM, 1975, MED BIOL, V53, P427; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAYAMA M, 1995, J NEUROSCI, V15, P5238; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHEVACH E, 1991, CURRENT PROTOCOLS IM; Silhavy T. J., 1984, EXPT GENE FUSIONS	23	40	41	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2361	2368		10.1038/sj.onc.1201405	http://dx.doi.org/10.1038/sj.onc.1201405			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393880				2022-12-28	WOS:A1997YE15700010
J	Pelicano, L; Li, FS; Schindler, C; ChelbiAlix, MK				Pelicano, L; Li, FS; Schindler, C; ChelbiAlix, MK			Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action	ONCOGENE			English	Article						interferon; retinoic acid; STAT; IRF-1; signalisation pathways	2'5' OLIGOADENYLATE SYNTHETASE; PML GROWTH-SUPPRESSOR; CONSTITUTIVE EXPRESSION; GENE-EXPRESSION; IFN-ALPHA; TRANSCRIPTIONAL ACTIVATOR; PROMYELOCYTIC LEUKEMIA; VIRUS-INFECTION; CELL-LINES; INDUCTION	Retinoic acid (RA) and interferons (IFNs) are negative regulators of cell proliferation, In vitro and in vivo, their combination leads to a more potent growth inhibition, However, the molecular mechanisms by which RA and IFNs potentiate each other are not fully understood. As some IFN-induced gene products regulate cell growth and/or antiviral activity, we analysed the effects of RA on their expressions. RA increases the level of 2'5'oligoadenylate synthetase, p68 kinase, the promyelocytic leukemia protein (PML) and Sp100 in both HL-60 and WISH cells. Moreover, RA and IFN act cooperatively to increase the expression of these proteins, RA also inhibits vesicular stomatitis virus replication and induces a higher antiviral state and growth inhibition when combined with IFN. RA stimulates the IFN regulatory factor 1 (IRF-1) gene expression directly through the GAS motif and causes the induction and secretion of IFN alpha. Additional mechanisms could he involved as RA increases the level of signal transducing activators of transcription (STAT) proteins, and enhances the IFN-induced STAT activation, suggesting that cooperative effects by RA and IFN are mediated through multiple pathways.	HOP ST LOUIS,CNRS,UPR 9051,F-75010 PARIS,FRANCE; COLUMBIA UNIV COLL PHYS & SURG,DIV MOL MED,NEW YORK,NY 10032	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Columbia University								Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOURGEADE MF, 1984, CANCER RES, V44, P5355; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHELBIALIX MK, 1986, BIOCHEM BIOPH RES CO, V141, P1042, DOI 10.1016/S0006-291X(86)80149-8; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CHELBIALIX MK, 1994, J CELL PHYSIOL, V158, P47, DOI 10.1002/jcp.1041580107; CHELBIALIX MK, 1996, TUMOR BIOL REGULATIO, P17; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FERBUS D, 1985, MOL CELL BIOCHEM, V67, P125, DOI 10.1007/BF02370171; FREY JR, 1991, CANCER LETT, V57, P223, DOI 10.1016/0304-3835(91)90161-A; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; JUSTESEN J, 1980, NUCLEIC ACIDS RES, V8, P3073, DOI 10.1093/nar/8.14.3073; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LANCILLOTTI F, 1995, CANCER RES, V55, P3158; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Mangelsdorf David J., 1994, P319; Matikainen S, 1996, BLOOD, V88, P114; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROMEO G, 1989, TRENDS GENET, V5, P19, DOI 10.1016/0168-9525(89)90007-3; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1995, RECEPTOR, V5, P81; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Stadler M, 1995, ONCOGENE, V11, P2565; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9	50	89	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2349	2359		10.1038/sj.onc.1201410	http://dx.doi.org/10.1038/sj.onc.1201410			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393879				2022-12-28	WOS:A1997YE15700009
J	Hayashi, K; Metzger, R; Salonga, D; Danenberg, K; Leichman, LP; Fink, U; Sendler, A; Kelsen, D; Schwartz, GK; Groshen, S; Lenz, HJ; Danenberg, PV				Hayashi, K; Metzger, R; Salonga, D; Danenberg, K; Leichman, LP; Fink, U; Sendler, A; Kelsen, D; Schwartz, GK; Groshen, S; Lenz, HJ; Danenberg, PV			High frequency of simultaneous loss of p16 and p16 beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach	ONCOGENE			English	Article						p16; p16 beta; gene expression; esophageal tumors	TUMOR-SUPPRESSOR GENE; POLYMERASE CHAIN-REACTION; THYMIDYLATE SYNTHASE; RETINOBLASTOMA PROTEIN; HOMOZYGOUS DELETION; P16/CDKN2 GENE; MESSENGER-RNA; CYCLE ARREST; CDKN2 GENE; MUTATION	Quantitative reverse transcription PCR (RT-PCR) was used to measure gene expressions (relative mRNA levels) of p16 and the alternate transcript p16 beta in esophageal and gastric tumors, p16 gene expression was undetectable in 13 of 25 esophageal squamous cell carcinomas. In 11 of these tumors, p16 beta was simultaneously missing whereas two of the p16-deficient tumors still expressed p16 beta. Among 34 esophageal adenocarcinomas and 11 gastric adenocarcinomas, only one tumor lacked p16 expression and all tumors expressed p16 beta. p16 sequences were not detectable by PCR in genomic DNA from tumors lacking both p16 and p16 beta mRNA, suggesting that the simultaneous loss of both gene expressions resulted from homozygous genomic deletion of the p16 gene. However, DNA from tumors that lacked p16 mRNA but expressed p16 beta did contain the p16 gene, consistent with loss of p16 expression in these tumors by transcriptional suppression. No point mutations in p16 cDNA were detected among 12 that were sequenced, but one p16 cDNA from a squamous cell carcinoma had a 19-base deletion, possibly indicating a splice-site mutation. Among those tumors that expressed p16 mRNA, the gene expression values of both p16 and p16 beta varied over a wide range. In some cases, p16 expression was detectable but low, suggesting that down-regulation of p16 expression may be used in some cases to achieve the funtional equivalent of gene deletion or transcriptional silencing. These results demonstrate that p16 expression patterns differ based on tumor histology and origin. Homozygous deletion of p16 appears to be common in esophageal squamous cell carcinomas but in adenocarcinomas, both gene deletion and transcriptional silencing of p16 were infrequent.	UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,LOS ANGELES,CA 90033; TOKYO WOMENS MED COLL,TOKYO 162,JAPAN; TECH UNIV MUNICH,D-8000 MUNICH,GERMANY; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	University of Southern California; Tokyo Women's Medical University; Technical University of Munich; Memorial Sloan Kettering Cancer Center					PHS HHS [R01-56111] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ATTWOOD SEA, 1992, SURGERY, V111, P503; Bartsch D, 1996, J NATL CANCER I, V88, P680, DOI 10.1093/jnci/88.10.680; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOT WJ, 1993, JAMA-J AM MED ASSOC, V270, P1320, DOI 10.1001/jama.270.11.1320; BLOT WJ, 1994, SEMIN ONCOL, V21, P403; BROWN LM, 1995, J NATL CANCER I, V87, P104, DOI 10.1093/jnci/87.2.104; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Galiana C, 1995, MOL CARCINOGEN, V14, P286, DOI 10.1002/mc.2940140409; GERADTS J, 1995, CANCER RES, V55, P6006; Gonzalez MV, 1995, CLIN CANCER RES, V1, P1043; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1383, DOI 10.1093/jnci/87.18.1383; Herman J. G., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P595; Heyman M, 1996, J CLIN ONCOL, V14, P1512, DOI 10.1200/JCO.1996.14.5.1512; HORIKOSHI T, 1992, CANCER RES, V52, P108; HUANG Y, 1993, CANCER RES, V53, P1889; Ichimura K, 1996, ONCOGENE, V13, P1065; IGAKI H, 1995, CANCER RES, V55, P3421; IGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090, DOI 10.1006/bbrc.1994.2294; ILSON DH, 1995, CANCER, V75, P2197, DOI 10.1002/1097-0142(19950501)75:9<2197::AID-CNCR2820750902>3.0.CO;2-S; JEN J, 1994, CANCER RES, V54, P6353; JIN XM, 1995, CANCER RES, V55, P3250; JOHNSTON PG, 1995, CANCER RES, V55, P1407; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; Kratzke RA, 1996, CANCER RES, V56, P3415; Kuo DYS, 1996, CLIN CANCER RES, V2, P1981; LARRICK PD, 1995, REVERSE TRANSCRIPTAS, P1; Lenz HJ, 1996, J CLIN ONCOL, V14, P176, DOI 10.1200/JCO.1996.14.1.176; LENZ HJ, 1995, REVERSE TRANSCRIPTAS, P166; Liggett WH, 1996, CANCER RES, V56, P4119; LIU QY, 1995, ONCOGENE, V10, P619; Maesawa C, 1996, CANCER RES, V56, P3875; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; Reed AL, 1996, CANCER RES, V56, P3630; REED JA, 1995, CANCER RES, V55, P2713; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAPIRO GI, 1995, CANCER RES, V55, P505; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; SUN Y, 1995, ONCOGENE, V10, P785; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VIGNESWARAN WT, 1993, ANN THORAC SURG, V56, P838, DOI 10.1016/0003-4975(93)90341-E; WYNER EL, 1994, CANCER RES, V54, P5284; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737	51	27	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1481	1488		10.1038/sj.onc.1201295	http://dx.doi.org/10.1038/sj.onc.1201295			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333024				2022-12-28	WOS:A1997XW41100012
J	Bates, NP; Hurst, HC				Bates, NP; Hurst, HC			An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression	ONCOGENE			English	Article						ERBB2; oestrogen repression; ERBB3; DNase I hypersensitive sites	HUMAN-BREAST-CANCER; GROWTH-FACTOR-RECEPTOR; NEGATIVE REGULATORY ELEMENTS; HER-2 NEU ONCOGENE; CELL-LINE MCF-7; ESTROGEN-RECEPTOR; C-ERBB-2 ONCOPROTEIN; PROTEIN EXPRESSION; POOR SURVIVAL; GENE	Overexpression of the ERBB2 gene in human breast cancer is associated with a poor prognosis and resistance to hormonal treatment and chemotherapy. Oestrogen receptor (ER) positive tumour-derived cell lines are known to express relatively low levels of ERBB2 protein under oestrogenic conditions, but markedly higher levels following withdrawal of oestrogens or administration of tamoxifen. Expression of the closely related ERBB3 gene, which co-operates with ERBB2 in cellular transformation, is now shown to respond to oestrogenic manipulation in a similar way, both responses being mediated largely by transcriptional changes. Six previously undescribed DNase I hypersensitive sites occur within the first intron of ERBB2 in cells that overexpress the gene. A 409 base pair DNA fragment containing one of these sites conferred ER dependent oestrogen inhibition on the ERBB2 promoter in two types of transient transfection assay. DNase I footprinting revealed four separate transcription factor binding sites within this fragment consistent with a role as a transcriptional enhancer. These findings implicate intron 1 sequences in the control of ERBB2 expression for the first time and demonstrate that one site within this region is involved in mediating the transcriptional response to oestrogens. Additionally, there is likely to be synergism between ERBB2 and ERBB3 signalling when both are overexpressed in response to oestrogen inhibition, thereby driving transformed cell behaviour.	HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,MOL ONCOL UNIT,LONDON W12 0NN,ENGLAND	Cancer Research UK; Imperial College London								ADNANE J, 1989, ONCOGENE, V4, P1389; ALIMANDI M, 1995, ONCOGENE, V10, P1813; ANTONIOTTI S, 1994, BRIT J CANCER, V70, P1095, DOI 10.1038/bjc.1994.454; BATES NP, 1996, CLIN GENE ANAL MANIP, P332; BERCHUCK A, 1990, CANCER RES, V50, P4087; BORG A, 1990, CANCER RES, V50, P4332; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN YY, 1994, ONCOGENE, V9, P2269; CHRYSOGELOS SA, 1993, NUCLEIC ACIDS RES, V21, P5736, DOI 10.1093/nar/21.24.5736; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DARBRE P, 1983, CANCER RES, V43, P349; DATI C, 1990, ONCOGENE, V5, P1001; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; DSOUZA B, 1993, ONCOGENE, V8, P1797; *EARL BREAST CANC, 1992, LANCET, V339, P1; *EARL BREAST CANC, 1992, LANCET, V339, P71; GASPARINI G, 1992, J CLIN ONCOL, V10, P686, DOI 10.1200/JCO.1992.10.5.686; GASPARINI G, 1994, EUR J CANCER, V30A, P16, DOI 10.1016/S0959-8049(05)80010-3; GROOTECLAES M, 1994, CANCER RES, V54, P4193; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; HAYWARD JL, 1977, EUR J CANCER, V13, P89, DOI 10.1016/0014-2964(77)90234-1; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; JAKOWLEW SB, 1984, NUCLEIC ACIDS RES, V12, P2861, DOI 10.1093/nar/12.6.2861; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MILLER SJ, 1994, INT J ONCOL, V4, P599; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; PRESS MF, 1993, CANCER RES, V53, P4960; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; READ LD, 1990, CANCER RES, V50, P3947; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; RUSSELL KS, 1992, CANCER RES, V52, P6624; SARKAR FH, 1994, J BIOL CHEM, V269, P12285; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SKINNER A, 1993, ONCOGENE, V8, P3393; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TSU JY, 1985, NUCLEIC ACIDS RES, V13, P2485; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WARRI AM, 1991, INT J CANCER, V49, P616, DOI 10.1002/ijc.2910490425; WRIGHT C, 1989, CANCER RES, V49, P2087; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765; YONEMURA Y, 1991, CANCER, V67, P2914, DOI 10.1002/1097-0142(19910601)67:11<2914::AID-CNCR2820671134>3.0.CO;2-G	63	49	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					473	481		10.1038/sj.onc.1201368	http://dx.doi.org/10.1038/sj.onc.1201368			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242384				2022-12-28	WOS:A1997XM23800012
J	Shao, ZH; Siegert, JL; Ruppert, S; Robbins, PD				Shao, ZH; Siegert, JL; Ruppert, S; Robbins, PD			Rb interacts with TAF(II)250/TFIID through multiple domains	ONCOGENE			English	Article						retinoblastoma protein; transcription factor TFIID; protein-protein interaction	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; TFIID COMPLEX; T-ANTIGEN; PROTEIN; BINDING; EXPRESSION; IDENTIFICATION; ACTIVATION	The retinoblastoma tumor suppressor gene product (Rb) binds directly to the largest TFIID subunit, TATA-binding protein associated factor TAF(II)250, first identified as the cell cycle regulatory protein CCG1. Here we map the domains in Rb and TAF(II)250 important for their interaction in vitro and in vivo. Both the amino terminus and the large pocket of Rb are able to associate independently with TAF(II)250. The binding domain(s) within the large pocket are distinct from the viral oncoprotein and E2F binding region since certain pocket mutations, which abolish E1A binding, do not abolish TAF(II)250 binding. Consistent with the large pocket of Rb binding to TAF(II)250, the large pocket domains of both p107 and p130 are able to bind to TAF(II)250 in vivo. We also demonstrate that at least two regions of TAF(II)250 are able to bind to the large pocket of Rb independently whereas the amino terminus of Rb binds to a distinct domain in TAF(II)250. We further demonstrate that Rb can bind to TFIID in vitro, presumably in part through an interaction with TAF(II)250. Our results suggest a complex interaction between Rb and TAF(II)250 and imply that TAF(II)250, TFIID, and potentially other basal transcription factors are targets for regulation by Rb and Rb-related proteins.	UNIV PITTSBURGH, SCH MED, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA 15261 USA; GENENTECH INC, DEPT MOL BIOL, San Francisco, CA 94080 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Roche Holding; Genentech					PHS HHS [55227] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Carrozza MJ, 1996, MOL CELL BIOL, V16, P3085; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HAYASHIDA T, 1994, GENE, V141, P267; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAYOL X, 1993, ONCOGENE, V8, P2561; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAO Z, 1995, REGULATION TRANSCRIP; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	24	24	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	1997	15	4					385	392		10.1038/sj.onc.1201204	http://dx.doi.org/10.1038/sj.onc.1201204			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242374				2022-12-28	WOS:A1997XM23800002
J	Ganter, B; Lipsick, JS				Ganter, B; Lipsick, JS			Myb binding sites within the N-ras promoter repress transcription	ONCOGENE			English	Article						Myb; N-ras; promoter; transcription	AVIAN-MYELOBLASTOSIS VIRUS; AMINO-TERMINAL REGION; C-MYB; DNA-BINDING; V-MYB; MAMMALIAN-CELLS; TRANSFORMING GENES; SARCOMA-VIRUSES; RECEPTOR GENE; HUMAN BLADDER	In vitro and in vivo methods were combined to determine the function of the three Myb binding sites (NrasI, NrasII and NrasIII) within the promoter region of the mouse N-ras gene. We found that the c-Myb DNA-binding domain can bind with high affinity to NrasI and NrasII, but with a reduced affinity to NrasIII: In contrast, the full length v-Myb protein from BM2 cells only bound to the middle one of the three sites, NrasII. Both c-Myb and v-Myb functioned as repressors and reduce the basal activity of the N-ras promoter by 60%, as determined by transient transfection experiments using different regions of the N-ras promoter. This repression required a functional Myb DNA-binding domain and could not be overcome by fusion to the potent VP16 activation domain. In electrophoretic mobility shift assays, the v-Myb protein is shown to be present in different conformations depending on its binding to the NrasII or the mim-1A site. The v-Myb conformation is thus suggested to play a critical role in the regulation of v-Myb activity.	STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305	Stanford University					NCI NIH HHS [R01 CA43592] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043592] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUSUBEL FM, 1987, CURR PROTO MOL BIOL; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOHRMANN D, 1987, NATURE, V325, P268; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GARCIA A, 1991, ONCOGENE, V6, P265; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INOUE T, 1994, J BIOL CHEM, V269, P32451; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; JEFFERS M, 1994, BBA-GENE STRUCT EXPR, V1219, P623, DOI 10.1016/0167-4781(94)90221-6; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KU DH, 1993, J BIOL CHEM, V268, P2255; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lipsick JS, 1996, ONCOGENE, V13, P223; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P325; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; PACIUCCI R, 1991, MOL CELL BIOL, V11, P1334, DOI 10.1128/MCB.11.3.1334; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, J SAMBROOK MOL CLONI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; THORN JT, 1991, ONCOGENE, V6, P1843; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; YAMAMOTO K, 1993, JPN J CANCER RES, V84, P1136, DOI 10.1111/j.1349-7006.1993.tb02813.x	56	16	18	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					193	202		10.1038/sj.onc.1201173	http://dx.doi.org/10.1038/sj.onc.1201173			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244354				2022-12-28	WOS:A1997XK37200007
J	Zou, TT; Lei, JY; Shi, YQ; Yin, J; Wang, S; Souza, RF; Kong, D; Shimada, Y; Smolinski, KN; Greenwald, BD; Abraham, JM; Harpaz, N; Meltzer, SJ				Zou, TT; Lei, JY; Shi, YQ; Yin, J; Wang, S; Souza, RF; Kong, D; Shimada, Y; Smolinski, KN; Greenwald, BD; Abraham, JM; Harpaz, N; Meltzer, SJ			FHIT gene alterations in esophageal cancer and ulcerative colitis (UC)	ONCOGENE			English	Article						FHIT; mutation; tumor suppressor gene; esophageal carcinoma; UC-associated neoplasms (UCANs)	CELL LUNG-CANCER; SHORT ARM; ADENOMATOUS POLYPOSIS; FRAGILE SITES; CHROMOSOME-3; HETEROZYGOSITY; CARCINOMA; DYSPLASIAS; TUMORS; LINES	FHIT (fragile histidine triad gene), a candidate tumor suppressor gene, was recently identified and cloned at chromosome 3p14.2. Alterations of this gene have been reported in a number of primary human tumors, including colorectal, esophageal, gastric and lung carcinomas, However, some reports have found no abnormalities in this gene, We investigated a total of 63 primary esophageal tumors, nine esophageal cancer cell lines and 17 ulcerative colitis-associated neoplasms (UCANs) for alterations of FHIT, In 13 esophageal tumors, we employed overlapping reverse transcriptase-PCRs (RT-PCRs) to amplify and sequence the complete open reading frame of FHIT, One of 13 primary esophageal tumors analysed by RT-PCR expressed no detectable FHIT transcript; the remaining 12 expressed normal-sized transcripts with wild-type open reading frame sequences, Tn an additional 50 esophageal tumors, the polymorphic microsatellite loci D3S1300 and D3S1313 mere used to evaluate loss of heterozygosity (LOH) at 3p14.2. Eleven of these 50 tumors shelved LOH at one or both loci, Tn all these 11 tumors, genomic PCR and direct sequencing of FHIT exons 5-9 was performed, This analysis revealed that none of these 11 primary esophageal tumors contained any alterations in the FHIT open reading frame or adjacent intron sequences, Finally, among 17 UCANs, the in vitro synthesized protein (IVSP) assay detected no truncated protein products, nor were there any abnormalities in size or DNA sequence of FHIT RT-PCR products, However, in six of nine esophageal carcinoma cell lines, no FHIT RT-PCR product was detectable using either of the overlapping primer sets, Genomic PCR and direct sequencing of exons 5-9, also performed in these nine cell Lines, revealed wild-type sequence in eight cell lines; however, one cell Line contained no exon 5 PCR product, This cell Line also lacked detectable FHIT transcript. These data suggest that the open reading frame of FHIT is not important in the development or progression of most primary esophageal carcinomas or UCANs, although lack of expression of the FHIT transcript may be common in esophageal cancer-derived cell Lines, The possibility of an additional tumor suppressor gene at chromosome 3p14.2 remains to be evaluated.	UNIV MARYLAND,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21201; VET AFFAIRS HOSP,BALTIMORE,MD 21201; KYOTO UNIV,DEPT SURG 1,KYOTO 606,JAPAN; MT SINAI MED CTR,DEPT PATHOL,NEW YORK,NY 10029	University System of Maryland; University of Maryland Baltimore; Kyoto University; Icahn School of Medicine at Mount Sinai			Harpaz, Noam/L-3411-2017	Harpaz, Noam/0000-0003-4923-2200				BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; Druck T, 1997, CANCER RES, V57, P504; Kastury K, 1996, CANCER RES, V56, P978; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LISITSYN NA, 1994, COLD SPRING HARB SYM, V59, P585, DOI 10.1101/SQB.1994.059.01.066; Mao L, 1996, CANCER RES, V56, P5128; MELTZER SJ, 1990, CANCER RES, V50, P3627; MOOIBROEK H, 1987, CANCER GENET CYTOGEN, V27, P361, DOI 10.1016/0165-4608(87)90020-3; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUTHERLAND GR, 1991, GENET ANAL-BIOMOL E, V8, P161, DOI 10.1016/1050-3862(91)90056-W; TARMIN L, 1995, CANCER RES, V55, P2035; Thiagalingam S, 1996, CANCER RES, V56, P2936; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Yanagisawa K, 1996, CANCER RES, V56, P5579; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZEIGER MA, 1995, GENE CHROMOSOME CANC, V13, P151, DOI 10.1002/gcc.2870130303; ZEIGER MA, 1994, GENE CHROMOSOME CANC, V11, P15, DOI 10.1002/gcc.2870110104; ZHOU XL, 1995, GENE CHROMOSOME CANC, V13, P285, DOI 10.1002/gcc.2870130409	23	40	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					101	105		10.1038/sj.onc.1201169	http://dx.doi.org/10.1038/sj.onc.1201169			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233782				2022-12-28	WOS:A1997XH58600011
